<SEC-DOCUMENT>0001140361-22-041399.txt : 20221114
<SEC-HEADER>0001140361-22-041399.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114163250
ACCESSION NUMBER:		0001140361-22-041399
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		221386473

	BUSINESS ADDRESS:	
		STREET 1:		10355 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10355 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>brhc10043851_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:erna="http://eternatx.com/20220930" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_c22ccf8961c24411a4dc3128a2a7bde8" contextRef="c20220101to20220930" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_a942b6f54f4e4ec5859321d3fdad4855" contextRef="c20220101to20220930" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_abb101a7ebd449109dd1e62fdde53300" contextRef="c20220101to20220930">2022</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_39b484f2dcd947b2bb3afcb659813a82" contextRef="c20220101to20220930">Q3</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_4a6e57997870416c838e962abca99627" contextRef="c20220101to20220930">0000748592</ix:nonNumeric><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_a01fe878e0064f3999e272199bd42d2c" contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF">0.05</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_7ee35f032c0c4b188f3eb65a7a37136f" contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF">0.05</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_c63bc29191b04902b61f2975f98f0e21" contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF">0.05</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_f5174a00983f4b74a313cc26b70a9518" contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF">0.05</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_b943329114c841ec8b57e15e6be15da4" contextRef="c20220921to20220921" unitRef="U004" decimals="2">0.05</ix:nonFraction><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_5b09bcc1ce7d4736a68839d07677b3d8" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">P5Y6M</ix:nonNumeric><ix:nonNumeric name="erna:AggregateCalendarDays" id="Fact_35a0d29cf6104e00b3095ed13c7f4044" contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember">P15D</ix:nonNumeric><ix:nonNumeric name="erna:TermToPaySecurityDeposit" id="Fact_8744bc3fa0f34851947cbc5afae0d9dc" contextRef="c20221018to20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember">P2D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="erna-20220930.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220101to20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-17</xbrli:startDate><xbrli:endDate>2022-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220921to20220921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-21</xbrli:startDate><xbrli:endDate>2022-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221018_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221018_PledgingPurposeAxis_LetterOfCreditMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:PurchasePriceAllocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:PurchasePriceAllocationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:PurchasePriceAllocationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AssetAcquisitionAxis_NovellusIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716_OwnershipAxis_CitiusPharmaceuticalsIncMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">erna:CitiusPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220309_ClassOfWarrantOrRightAxis_CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220309_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220714_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:MilestoneOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220524to20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:MilestoneOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-09</xbrli:startDate><xbrli:endDate>2022-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221001to20221031_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:DheshGovenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-15</xbrli:startDate><xbrli:endDate>2021-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:DheshGovenderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-15</xbrli:startDate><xbrli:endDate>2021-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220805to20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-05</xbrli:startDate><xbrli:endDate>2022-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_LegalEntityAxis_UniversityOfSouthFloridaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">erna:UniversityOfSouthFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-15</xbrli:startDate><xbrli:endDate>2021-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NoveCiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">erna:InvestorRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">erna:CollaboratorRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-22</xbrli:startDate><xbrli:endDate>2018-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">erna:InvestorRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-05-01</xbrli:startDate><xbrli:endDate>2012-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AwardTypeAxis_TimeBasedStockOptionGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:TimeBasedStockOptionGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:PerformanceBasedStockOptionGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:TimeBasedStockOptionGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:TimeBasedStockOptionGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:PerformanceBasedStockOptionGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_EmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220930_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220306_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220712_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220930_InvestmentTypeAxis_PIPEInvestorMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220601to20220630_InvestmentTypeAxis_PIPEInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementClassOfStockAxis_CommonClassCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementClassOfStockAxis_CommonClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementClassOfStockAxis_CommonClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ERSquibbSonsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221018to20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ERSquibbSonsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-18</xbrli:startDate><xbrli:endDate>2022-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221018_PledgingPurposeAxis_LetterOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ERSquibbSonsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221008to20221008_RelatedPartyTransactionsByRelatedPartyAxis_ExacisBiotherapeuticsIncMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ExacisBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-08</xbrli:startDate><xbrli:endDate>2022-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>erna:BoardMember</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>erna:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>erna:Goals</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div style="text-align: center; font-weight: bold;">
          <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" />
          <div style="color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION<br />
          </div>

          <div style="font-size: 12pt; font-weight: bold;">Washington, D.C. 20549<br />
          </div>

          <div>&#160;</div>

          <div style="font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_65a5bd1dc56e4e9fa76fe4c159364cb1" contextRef="c20220101to20220930">10-Q</ix:nonNumeric></div>

          <div>&#160;</div>

          <div>
            <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: normal;">(Mark One)</div>

          </div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_f5695269fd9849b1ad3e287311e756db" contextRef="c20220101to20220930" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
                </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
                </td>

  </tr>


</table>
          <div>
            <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"> <br />
            </div>

            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_1a5e02a723a44803911ce76215333228" contextRef="c20220101to20220930" format="ixt:date-monthname-day-year-en">September 30, 2022</ix:nonNumeric></div>

          </div>

          <div>
            <div style="color: rgb(0, 0, 0);">or</div>

          </div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_8f0bb10d72d14a57a69b5a993fd689db" contextRef="c20220101to20220930" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
                </td>

  </tr>


</table>
          <div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br />
            </div>

            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the transition period from _________ to _____________</div>

          </div>

          <div>&#160;</div>

          <div style="font-weight: bold;">Commission file number: <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_90945eedff1d43ccb6b9f2cf10eb4255" contextRef="c20220101to20220930">001-11460</ix:nonNumeric></div>

          <div><img src="image00001.jpg" alt="graphic" />&#160; </div>

          <div style="font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_667a4cb77c0e4f97a5f98867d5da68f7" contextRef="c20220101to20220930">Eterna Therapeutics Inc.</ix:nonNumeric><br />
          </div>

          <div style="font-style: italic; font-weight: normal;">(Exact name of registrant as specified in its charter)</div>

          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_365d4ddc9f38423e9711b8d4963edc92" contextRef="c20220101to20220930" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
                  </div>
                </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_97b5b2e4b47d404f9034ad5fbfd3ff25" contextRef="c20220101to20220930">31-1103425</ix:nonNumeric><br />
                  </div>
                </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-style: italic;">(State of incorporation)</div>
                </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-style: italic;">(I.R.S. Employer Identification No.)</div>
                </td>

  </tr>


</table>
          <div><br />
          </div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_24198666a6e1424db0ed06e7967ad2a3" contextRef="c20220101to20220930">10355 Science Center Drive, Suite 150</ix:nonNumeric></div>
                  <div style="text-align: center; font-weight: bold;"> <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_7ddd7994e15149029c9b495d3f55e217" contextRef="c20220101to20220930">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_d6a7dfe18d2540d191c1187b4d1f1189" contextRef="c20220101to20220930" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></div>
                </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; text-align: center;">
                  <div style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_0e555dd5288741d7b9cd4cb57dbe1c83" contextRef="c20220101to20220930">92121</ix:nonNumeric><br />
                  </div>
                </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-style: italic;">(Address of principal executive offices)</div>
                </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-style: italic;">(Zip Code)</div>
                </td>

  </tr>


</table>
          <div style="font-weight: bold;"> <br />
          </div>

          <div style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_aec6d7905fe745589eba585f16b05baa" contextRef="c20220101to20220930">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_3140b70708c34c3b9a68858bc300e443" contextRef="c20220101to20220930">582-1199</ix:nonNumeric></div>

          <div style="font-style: italic; font-weight: normal;">(Registrant&#8217;s telephone number, including area code)</div>

          <div><br />
          </div>

          <div>
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityInformationFormerLegalOrRegisteredName" id="Fact_6074edd9bee54855854a1942219ed966" contextRef="c20220101to20220930">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><br />
            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; font-style: italic;">(Former name, former address and former fiscal year, if changed since last
              report)</div>

          </div>

          <div><br />
          </div>

          <div style="color: rgb(0, 0, 0); font-weight: normal;">Securities registered pursuant to Section 12(b) of the Act:</div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>
                    <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
                  </div>
                </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>
                    <div style="text-align: center; color: rgb(0, 0, 0);">Trading symbol</div>
                  </div>
                </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>
                    <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_784fd6f68af849e29a263038edce410e" contextRef="c20220101to20220930">Common stock, $0.005 par value per share</ix:nonNumeric><br />
                  </div>
                </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_e013b520c9f44ff789c9f63b9dd0b8af" contextRef="c20220101to20220930">ERNA</ix:nonNumeric><br />
                  </div>
                </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_62cb464167ec4dbf90e91b7d4085fc8e" contextRef="c20220101to20220930" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
                  </div>
                </td>

  </tr>


</table>
          <div style="text-align: justify; font-weight: normal;"> <br />
          </div>

          <div style="text-align: justify; font-weight: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
            for such shorter period that the registrant <span style="color: rgb(0, 0, 0);">was required to file </span>such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_76afc7460ee64ea68778bff5cb3053c1" contextRef="c20220101to20220930">Yes</ix:nonNumeric> &#9746; No &#9744;</div>

          <div style="font-weight: normal;">&#160;</div>

          <div style="text-align: justify;"><span style="color: rgb(0, 0, 0); font-weight: normal;">Indicate by check mark whether the registrant has submitted electronically every interactive data file required to be submitted pursuant to Rule 405 of
              Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_bd444aff6e7b4585aa924e220d53ef0e" contextRef="c20220101to20220930">Yes</ix:nonNumeric> </span><span style="font-weight: normal;">&#9746;</span><span style="color: rgb(0, 0, 0); font-weight: normal;">&#160; No &#9744;</span></div>

          <div style="font-weight: normal;">&#160;</div>

          <div style="text-align: justify; font-weight: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See
            definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

          <table cellspacing="0" cellpadding="0" border="0" style="border-collapse: collapse; width: 90%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="width: 20%; vertical-align: top; font-weight: normal;">
                  <div style="text-align: justify;">Large accelerated filer</div>
                </td>

    <td style="width: 45%; vertical-align: bottom; font-weight: normal;">&#9744;</td>

    <td style="width: 20%; vertical-align: bottom; font-weight: normal;">
                  <div style="text-align: justify;">Accelerated filer</div>
                </td>

    <td style="width: 5%; vertical-align: bottom; font-weight: normal;">
                  <div style="text-align: justify;">&#9744;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top; font-weight: normal;">
                  <div style="text-align: justify;"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_6ad38af2f2c743f7a2915bc8443fc032" contextRef="c20220101to20220930" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric><br />
                  </div>
                </td>

    <td style="width: 45%; vertical-align: bottom; font-weight: normal;">&#9746;</td>

    <td style="width: 20%; vertical-align: bottom; font-weight: normal;">
                  <div style="text-align: justify;">Smaller reporting company</div>
                </td>

    <td style="width: 5%; vertical-align: bottom; font-weight: normal;"><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_ccf1d8e8266345448d6fdca3a5cd7b08" contextRef="c20220101to20220930" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
                </td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top; font-weight: normal;">&#160;</td>

    <td style="width: 45%; vertical-align: bottom; font-weight: normal;">&#160;</td>

    <td style="width: 20%; vertical-align: bottom; font-weight: normal;">
                  <div style="text-align: justify;">Emerging growth company</div>
                </td>

    <td style="width: 5%; vertical-align: bottom; font-weight: normal;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b9f91141568345a09bf6e35e6d05b327" contextRef="c20220101to20220930" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                </td>

  </tr>


</table>
          <div style="text-align: justify; font-weight: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
            standards provided <span style="color: rgb(0, 0, 0);">pursuant to </span>Section 13(a) of the Exchange Act. &#9744;</div>

          <div style="font-weight: normal;">&#160;</div>

          <div style="text-align: justify; font-weight: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_95af04fbd2c948c29a2cb7458163301a" contextRef="c20220101to20220930" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; No &#9746;</div>

          <div style="font-weight: normal; text-align: left;">&#160; <br />
          </div>

          <div style="text-align: justify; font-weight: normal;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As of November 11, 2022, the registrant had outstanding <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_bc957f6268e2465a826577b07f033e50" contextRef="c20221111" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,942,120</ix:nonFraction> shares of common stock, $0.005 par value per share.</div>

          </div>

          <div style="text-align: justify;">
            <p style="font: 10pt 'Times New Roman'; margin: 0px; text-indent: 24.5pt;">&#160;</p>
          </div>

          <div style="text-align: justify;">
            <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after:always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          </div>

          <!--PROfilePageNumberReset%LCR%1%%%--> </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <a id="TABLEOFCONTENTS"><!--Anchor--></a>
    <div style="text-align: center;"> <span style="font-weight: bold;">TABLE OF CONTENTS</span><br />
    </div>

    <div style="text-align: center;"><span style="font-weight: bold;"> <br />
      </span></div>

    <div><span style="font-weight: bold;"> <br />
    </span></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 4.96%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Page</div>
          </td>

  </tr>

  <tr>

    <td style="width: 95.04%; vertical-align: top;" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">PART I &#8211; FINANCIAL INFORMATION</div>
          </td>

    <td style="width: 4.96%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Financial Statements (unaudited)</div>
          </td>

    <td style="width: 4.96%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CONDENSEDCONSOLIDATEDBALA">Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">1</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CONDENSEDCONSOLIDATEDSTAT">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#STOCKHOLDERSANDMEMBERSEQU">Condensed Consolidated Statements of Changes in Stockholders&#8217; and Members&#8217; Equity for the three and nine months ended
                September 30, 2022 and 2021</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">3</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#OFCASHFLOWS">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">5<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#NOTESTOCONDENSEDCONSOLIDA">Notes to Condensed Consolidated Financial Statements</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">6</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ManagementsDiscussionandA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">29</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#QuantitativeandQualitativ">Quantitative and Qualitative Disclosures About Market Risk</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">42<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ControlsandProcedures.">Controls and Procedures</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; text-align: right;"> 42<br />
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

  </tr>

  <tr>

    <td style="width: 95.04%; vertical-align: top;" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">PART II &#8211; OTHER INFORMATION</div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item1.">Legal Proceedings</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"> 44<br />
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 1A.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item1A.">Risk Factors</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">44<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item2.">Unregistered Sales of Equity Securities and Use of Proceeds</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">44<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item3.">Defaults Upon Senior Securities</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">44<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item4.">Mine Safety Disclosures</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">44<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 5.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item5.">Other Information</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">44<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Item 6.</div>
          </td>

    <td style="width: 88.36%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Item6.">Exhibits</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">44<br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 95.04%; vertical-align: top;" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#SIGNATURE">Signatures</a></div>
          </td>

    <td style="width: 4.96%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">46<br />
            </div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">i</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
            Contents</a><br />
        </div>

      </div>

    </div>

    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; as that term is defined under the Private Securities Litigation Reform
          Act of 1995 (&#8220;PSLRA&#8221;), Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements include statements related to
          future events, results, performance, prospects and opportunities, including statements related to our strategic plans and targets, revenue generation, product availability and offerings, capital needs, capital expenditures, industry trends and
          our financial position. Forward-looking statements are based on information currently available to us, on our current expectations, estimates, forecasts, and projections about the industries in which we operate and on the beliefs and assumptions
          of management. Forward looking statements often contain words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions. In addition,
          any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, and other characterizations of future events or circumstances, are forward-looking statements. Forward-looking
          statements by their nature address matters that are, to different degrees, subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. For us,
          particular factors that might cause or contribute to such differences include those risks and uncertainties described in Part I, Item 1A &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K/A for the year ended December 31, 2021 and described in
          other documents we file from time to time with the Securities and Exchange Commission, which we refer to as the SEC.</div>

      </div>

      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Readers are urged not to place undue reliance on the forward-looking statements in this Quarterly Report on Form 10-Q, which speak only as of
          the date of this Quarterly Report on Form 10-Q. We are including this cautionary note to make applicable, and take advantage of, the safe harbor provisions of the PSLRA. Except as required by law, we do not undertake, and expressly disclaim any
          obligation, to disseminate, after the date hereof, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.</div>

      </div>

      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We believe that the expectations reflected in forward-looking statements in this Quarterly Report on Form 10-Q are based upon reasonable
          assumptions at the time made. However, given the risks and uncertainties, you should not rely on any forward- looking statements as a prediction of actual results, developments or other outcomes. You should read these forward-looking statements
          with the understanding that we may be unable to achieve projected results, developments or other outcomes and that actual results, developments or other outcomes may be materially different from what we expect.</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On October 17, 2022 we changed our name from Brooklyn ImmunoTherapeutics, Inc. to Eterna Therapeutics Inc. Unless stated otherwise or the context otherwise requires,
        all references in this Quarterly Report on Form 10-Q to &#8220;Eterna&#8221; refer to Eterna Therapeutics Inc., references to &#8220;Brooklyn LLC&#8221; refer to Brooklyn ImmunoTherapeutics LLC, a wholly owned subsidiary of Eterna, and references to the &#8220;Company,&#8221; &#8220;we,&#8221;
        &#8220;us&#8221; or &#8220;our&#8221; refer to Eterna and its subsidiaries, including Brooklyn LLC, Novellus, Inc. and Novellus Therapeutics Limited.</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">ii</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
              Contents</a><br />
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%1%%%--> </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div style="text-align: center; font-weight: bold;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">PART I. FINANCIAL
            INFORMATION</div>

          <div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Item

















                  1.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Financial Statements</div>
                </td>

  </tr>


</table>
        </div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>

        </div>

        <!--Anchor--> <a id="CONDENSEDCONSOLIDATEDBALA"><!--Anchor--></a>
        <div style="text-align: center; font-weight: bold;">&#160;<!--Anchor-->CONDENSED CONSOLIDATED
          <!--Anchor--><!--Anchor-->BALANCE SHEETS<!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;"> (In thousands, except par value amount)<br />
        </div>

        <div style="text-align: center; font-weight: bold;"> <span style="font-weight: bold;">(unaudited)</span></div>

        <div style="text-align: center; font-weight: bold;"><span style="font-weight: bold;"> <br />
          </span></div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" rowspan="1" colspan="2">September 30,
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-weight: bold; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" rowspan="1" colspan="2">December 31,
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;" colspan="1"></td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">2022</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; text-indent: -9pt; margin-left: 9pt;">ASSETS</div>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; text-align: center;" colspan="2"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Current assets:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Cash</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Cash" id="Fact_95dda23c92d847678e06bd2488a77e2c" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,254</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Cash" id="Fact_00fbac43fe3841daa4f9f17da38d8a8c" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,985</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Other receivable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" id="Fact_eb3475879c984b229da0795b69991627" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">926</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" id="Fact_ee182beb80e7427a8e44921a96eb5c21" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">684</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_924d072972a64dd2b93231a29a239d7a" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,672</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_633ad162eaa44dc4a84145c32d193f57" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,097</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 27pt;">Total current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_b1a7b6ef9531485da0a1aaaacd639959" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,852</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_5ad64840ea984061bb9d10cc8681d789" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,766</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Property and equipment, net</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_95132a85f15144539816df2bb02a1d59" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">231</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_616e4d8489d14af6aed2f9d5c53fce4f" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">670</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Right-of-use assets - operating leases</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_2d6c8bfbafe64faeb5325d376d987e88" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,912</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_d3cbf3d126324979a3925bafe52a7e54" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,567</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Goodwill</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_8c5567a64f284563936e2406a212f5be" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,044</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_a91021e738a643ea81d1a3e80a79f3b8" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,044</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">In-process research and development</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_2563293303b0443184d81479b5fd26fe" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_305c31e3e34e447498e6f4e82b5a4c36" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,990</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt;">Investment in non-controlling interest</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EquityMethodInvestments" id="Fact_f765a194746c48209deb2d7ac37174bf" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EquityMethodInvestments" id="Fact_e1f3e4ff044e4d9596113337af2cbe4a" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="margin-left: 9pt;">Other assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_61ebf41ddf65449da4bbbaf14da5eec2" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">819</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_c031daa388624efd81b9d901e8502cfd" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">488</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 27pt;">Total assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Assets" id="Fact_c7903c4571694ce9b1482fe730890507" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,926</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Assets" id="Fact_ee512d5e84194a08af027857dfe049d1" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,525</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; text-indent: -9pt; margin-left: 9pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Current liabilities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Accounts payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_ddf230f2796345b395bd34589bc38b79" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,150</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_33a32138c0854027ad3522b61cc19cfa" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,755</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_b61db524492d4b58bfb731f1120e6aff" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,230</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_d831c2cccf664f6d8fc457e89d5ba8c0" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,249</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Operating lease liabilities, current</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_b94f6793cab6457eb78f7e1832ba896a" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">436</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_ef94ba6be7944a3c824a289d1e306ede" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">426</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt;">Finance lease liabilities, current</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_4ab857f59f684ab7b4112fcaaba43176" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_ffa5412b98704597b7f7a281764b4787" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">Other current liabilities</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_8dd64977a66549d6920b51ec5a568387" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,648</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_f9fd8dad044942f499343933f2acd4fb" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">247</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 27pt;">Total current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_6be829a26ca64ba286ba625da0ea7b54" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,467</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_9b27efcee29f42e691e5c5ab0193ece9" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,677</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Warrant liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_81c39921f8f1494584e9b0e0df2f3e0d" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Fact_3d35589e2cd049a4b429279cfc9bb764" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Operating lease liabilities, non-current</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_abf2a7f4593748bdb9998514f383eb09" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,317</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_b71b9a9e7c01476da652aa1645264aa9" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,297</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt;">Finance lease liabilities, non-current</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_7d1d456de236466c812db0aeddf79a74" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_51cf461ba5c24747bc7e12d6b0ba9df1" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;" rowspan="1">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Other liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_993b24efd49d450d9d4bd629f60f4d81" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_12693b77fb904038aee287c909bdd16b" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 27pt;">Total liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_47d0c88d67d143fd882dbfd3c41ba003" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,113</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_c4685ad725a0456896a4daaea179f7cc" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,022</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Stockholders&#8217; equity:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 18pt;">Preferred stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_c0ea5613ea6d40f0b9dffe14abd1edc5" contextRef="c20220930" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_bcd8709d033f428e8173ed7775036d5c" contextRef="c20211231" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.005</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_4ac7253f1c734f6ea97099ac1ba020da" contextRef="c20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_4a03470ef4d44c388f86bc6c1a210cb6" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_f02586de8d224caaadf31d214af57aa9" contextRef="c20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_cf2c9722e4d248b3800a3c6265700290" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_9249699cab6b4d61b305f727f21d5fb3" contextRef="c20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_62790db89ed1415c8007a230ba3678a0" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span>
                  designated and outstanding of Series A convertible preferred stock at <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2022</span> and <span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2021</span>, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" id="Fact_ebb9e8aebf25456688cf39b98102f735" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" id="Fact_6d87828446cb4966bfa8abfdc0b31371" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></ix:nonFraction></span> liquidation
                  preference</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_bf15d0c11c1f4cf69948bff8bdbae6bb" contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_45395650bc8540d6bb8258ab24654d4f" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_bff4899c7a4c455b8db15fdbcecbf908" contextRef="c20220930" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_257c1ec62cdd4252b18550449dd232ac" contextRef="c20211231" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.005</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_7119e67f1a7d414fbf6f3bffc85e9a59" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_3e6a98d480254a9d85432242ebb4f684" contextRef="c20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction></ix:nonFraction></span> shares authorized at September 30, 2022 and December 31, 2021; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_f601d269d9c04248b625a64786b12601" contextRef="c20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_2e2aaa0c1032417d9bb0449e4aa7a77f" contextRef="c20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,942</ix:nonFraction></ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_7915b2a904804cc7a5afe329e97d0616" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_697836017c014cf592042b99e699dc22" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,601</ix:nonFraction></ix:nonFraction></span> issued and outstanding at <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2022</span> and <span style="text-indent: 0pt;">December 31</span>, <span style="text-indent: 0pt;">2021</span>,
                  respectively</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_2b231a38168d4d269f9df29f7d542e8a" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_ca85d9de920342b1b645849103698793" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Additional paid-in capital</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_67dbf3fddadd48278c72fff99da58c09" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,596</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_0f4c94f4fa8e4d368768b6209f607800" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">166,190</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;">Accumulated deficit</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_1e9c34acc7db4ab88c524eb84650e8ca" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160,799</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_05e0332d63fc428795de517bc62f82c3" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">140,701</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 27pt;">Total stockholders&#8217; equity</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_25a6999c8d124f7399563b7bb55bef01" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,813</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_7598124631174cfd8973ed650ad791d0" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,503</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 27pt;">Total liabilities and stockholders&#8217;&#160; equity</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_cf6023ac81b54e04b6ab6b340a1e0533" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,926</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_9ffeeb1208514f12a9d7a2f5890fbd93" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,525</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -216.2px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span></span></div>

        <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

        <div style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: -216.2px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Share and per share data have been adjusted for all periods
            presented to reflect a <span style="-sec-ix-hidden:Fact_f5174a00983f4b74a313cc26b70a9518">1-for-20</span> reverse stock split effective October 17, 2022.</span> </div>

        <div style="text-align: center;"> <br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div style="text-align: center;"><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 8pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</span></div>

          <div class="BRPFPageBreak" style="page-break-after:always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%1%%%--> </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>

      <!--Anchor--> <a id="CONDENSEDCONSOLIDATEDSTAT"><!--Anchor--></a>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CONDENSED CONSOLIDATED
        <!--Anchor--><!--Anchor-->STATEMENTS OF OPERATIONS</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> (In thousands, except per share amounts)<br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
<div>(unaudited)
        </div>
<div><br />
        </div>

      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Three months ended <span style="text-indent: 0pt;">September 30</span>,</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Nine months ended <span style="text-indent: 0pt;">September 30</span>,</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;"><span style="font-weight: bold;">2022</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px;">2021</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px;">2022</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px;">2021</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Operating expenses:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_fcb8f0cde1114c07b550fe04507d8d18" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,963</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_4baba3fedfaa46a5b44db1c0124b5198" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_840636f9220643929a58cb20b249e345" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,430</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_efa411487c7443d29e55f55e87d5d015" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,456</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">In-process research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" id="Fact_382a802f7726496388367cc0debdf509" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" id="Fact_9b0a112c6c794a4e93e1d33ce49087b0" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" id="Fact_9ad72ade040a4b049b70fbb4d86b37e5" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,990</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" id="Fact_71bc332108c244b9b954c382194c95fd" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 52%; background-color: #CCEEFF;">
              <div style="margin-left: 9pt;">General and administrative</div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_a52d436b986e479da3662e6dc4297aa6" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,341</ix:nonFraction><br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_f8204a263ca04f61a729589f0d936e76" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,247</ix:nonFraction><br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_fd15a7fd2684495fb7d50e75cdb9117d" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,060</ix:nonFraction><br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_7645bfe81afb45acad87078dec96eafc" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,451</ix:nonFraction><br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Transaction costs</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_14386ef69dd1497dbb51a88bb6d0c53d" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_f8a575a4b02e43fdbd4ba3d9b3546157" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_d881b244f47947a8b160e83a1efa1174" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_5f4f246c7004423686bd87e095dbd87c" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,765</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Total operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_48719b92a24c4ac5b2752149e44e1201" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,304</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_4a0f638652f34b16ba1639fb8bbc6055" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,276</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_39c253dbb5124f45971363183669fe36" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,480</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_24377a5b3c9b43b1848b682ef0a833b2" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">105,210</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Loss from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_2d897a233ebb4ad0be4ade512ee55fa6" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,304</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_f179c2fd71e547b0aa066aa61e5535d0" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">86,276</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_1418c70c8e0f435f865efb9432688699" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,480</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_6efb307c97c54042bf83014798879f7d" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">105,210</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 52%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Other income (expense), net:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Loss on sale of NTN assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_30173ad10791464cb91b3418ca4a142f" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_6a74ee0f9a064b45b437a3a4273a4417" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_6855e694e42144c7b1e331b1e40854b9" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_3ce596e5f1b14ed8bb5ffe5706ac2a4c" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,648</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 52%;">
              <div style="margin: 0px 0px 0px 9pt; text-indent: -9pt;">Change in fair value of warrant liabilities</div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="erna:WarrantLiabilitiesExpense" id="Fact_09993d5225204b7caa6ca7d4f40c6c92" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,024</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="erna:WarrantLiabilitiesExpense" id="Fact_e7b4de36b2c3466b8050a0a431426175" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="erna:WarrantLiabilitiesExpense" id="Fact_950d79fa9d0449eea6c47ce7e73aa85e" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,493</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="erna:WarrantLiabilitiesExpense" id="Fact_457867c777044514a66cfe9c09fc092e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 52%; background-color: #CCEEFF;">
              <div style="margin: 0px 0px 0px 9pt; text-indent: -9pt;">Loss on non-controlling investment</div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="erna:LossOnNonControllingInvestment" id="Fact_3f038166563149a4b083bd752f644e9c" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="erna:LossOnNonControllingInvestment" id="Fact_ff416c1f37d94c02887a46fab3796636" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="erna:LossOnNonControllingInvestment" id="Fact_1e724508381b4cb58c9bf82a1a02ef1d" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">932</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="erna:LossOnNonControllingInvestment" id="Fact_f739b0840a1947a89a84d0ff18a851e8" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other (expense) income, net</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_ee661a9bed9d491b9df675ac429fb866" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_199635d1118e4377867adddf06737e38" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">290</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_ac6ed153c95941a09af234023c7d9448" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,166</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_dbe81c3a14c2421aabf1a11d26ed5c98" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">265</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Total other income (expense), net<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_a59c4e37d799493a8bb5aedd6001fd20" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">993</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_7c0d2eab914c4a1487c58810e0911177" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">290</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_8823257c2d30437c9572d21385e75ab6" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,395</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_cf4114f4f3c84db8bb9c94125102779c" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,383</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 52%;">Loss before income taxes<br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_f47bf0eadbfa4111a27aa9d511c15bc5" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,311</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_fdcecb32554d4bc4b992eaf96dcee39b" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,986</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_3e4f3e101c7141cf82f2b57b70fd0a2e" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,085</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_3b5cc27450944f468a1f738d5f3f8590" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114,593</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">Provision for income taxes<br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_fc6f21bd0e78406b811157f565b27b8a" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_02deff61da1a4f9c884053ac6c784e0f" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_e88ac563e8de48ce962a6e8c736d439a" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_e99828cc53da4df892f67bb5c75db10e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_68213818e5ac47a097dfde7f03c1e393" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,316</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_438c5c00826b4c08836c403e9cade373" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,986</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cd0915f19365455195d370c781cc246b" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,090</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a97d3e8b54b34845b74ae6c11feb13f2" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114,593</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="margin: 0px 0px 0px 9pt; text-indent: -9pt;">Series A preferred stock dividend<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_05c6e75ae7bb463ba96c2871b7032d49" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_0305675da2e5442589390b4539a1aafb" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_bd5dc0b6c5b54b8caa9510ca37735228" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_9a99306c5734409895f7d86828cfb424" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 52%; padding-bottom: 4px;">
              <div style="margin: 0px 0px 0px 9pt; text-indent: -9pt;">Net loss attributable to common stockholders<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_4e1e088824dd44ad923a8e25ceb358b6" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,316</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_f2597401e7e44824a30433ffe906adfe" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,986</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_4b0ff00d58bd4918b7bb38e7b1fb271e" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,098</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_22922fe6a31b430cbd66cbf73ae129dc" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114,601</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss per common share - basic and diluted</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_433df7f7277f4b94946da8bad192474e" contextRef="c20220701to20220930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_34e303eedf6d4022a679cd466dff4c2d" contextRef="c20220701to20220930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">2.49</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_1c308bf4448f4774b40f898bb89aae72" contextRef="c20210701to20210930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_0cef766e9b09437393e9a0d493fc9b6c" contextRef="c20210701to20210930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">34.03</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_e9f58143840a447f9b4067028d43e66e" contextRef="c20220101to20220930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_cc5a8df7b9b1487a9cfd802b3997d0c2" contextRef="c20220101to20220930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">7.04</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_7d74759038d44725b24221fed9ba6b8f" contextRef="c20210101to20210930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_18faedef211946f2b18e747aeb2aa275" contextRef="c20210101to20210930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">56.79</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Weighted average shares outstanding - basic and diluted</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_81ee7bb08d264453a916fcb311c108d6" contextRef="c20220701to20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_4f9541bb27cc4aa086bff8336f667a4d" contextRef="c20220701to20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,941</ix:nonFraction></ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_dbe8c3fc5a704a71977e6e252771729f" contextRef="c20210701to20210930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_453bc034a8e241cca5854de8eef0bfe3" contextRef="c20210701to20210930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,527</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_9c2e2607e7e3449bb03e99107b4c46e2" contextRef="c20220101to20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_0ee05e117a8e4df5a41747e7d6f2d59e" contextRef="c20220101to20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,855</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_c77751be56f0491fb9fe96fca6793fe4" contextRef="c20210101to20210930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b198cc0dac9646a59e6c1831bdc2c158" contextRef="c20210101to20210930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,018</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: -216.2px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Share and per share data have been adjusted for all periods
          presented to reflect a <span style="-sec-ix-hidden:Fact_c63bc29191b04902b61f2975f98f0e21">1-for-20</span> reverse stock split effective October 17, 2022.</span> </div>

      <div><br />
      </div>

      <div>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.<br />
        </div>

        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div style="text-align: center; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>

        <div style="text-align: center; font-weight: bold;">
          <div>CONDENSED <a id="STOCKHOLDERSANDMEMBERSEQU"><!--Anchor--></a><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; AND <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">MEMBERS&#8217; </span>EQUITY<!--Anchor--> </span></div>

          <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">For the three and nine months ended September 30, 2022 and 2021 </span>(unaudited)</div>

          <div> (in thousands)<br />
          </div>

          <div> <div><br class="Apple-interchange-newline" /></div>

            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Common Stock</div>
                  </td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Series A Preferred</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Stock</div>
                  </td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"> Additional Paid-</div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">in</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Accumulated</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Shares</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Amount</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Shares</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Amount</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Capital</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Deficit</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Total</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at July 1, 2022</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;<br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e2b1e5f6e3d2472fbbd4cda74b830d74" contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,873</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_fc9acbe443a1488780602ce81f7349ca" contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_1abe70d599eb44ad9cfdf0acf3574c2c" contextRef="c20220630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_09d5ea9090d7494c87c3f4fecb574035" contextRef="c20220630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">$<br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_bc34b4dc0d464b8c920054614e603e7b" contextRef="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,246</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_df9f4f5a8fa741a1b0762e5ebf23f58a" contextRef="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">153,483</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_279677985b3547f185016ec45a37feaa" contextRef="c20220630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,778</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Issuance of common stock from vested restricted stock units</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_bfe7ab6d1e244dababe0f4d5714061ab" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_cb90bc8369544e52896037b629152fd6" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_802db65fb4724881885a6daa89cb236c" contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_b9d3a5a4b7a74715bff705c786e0d180" contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_3ce7f26849c3495fb70bae6f0e283562" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_829ec489744944e4bae388cd62901837" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_7ad4943a698d4e4a9aded186114bfa5a" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Issuance of common stock from exercise of pre-funded warrants</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="Fact_71a5d6ae75e840fe80eae9a376637987" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_00ba747d7bdb40318b5d188fcd41098c" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="Fact_8527890a79b94939b2722840ae1e876d" contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_e4eda11271d7443a99a8c71897768c6a" contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_0797c6283a124f8699f97e0fd7a9459b" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">874</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_57843c145ebe43ecb9a95d2b3d090b37" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_99866d58b49049a492d4c2f018a02ba3" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">875</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Stock-based compensation</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_d41fb057fef04a6cb11a505c379c395f" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_f63c26ff66794367bd399cb3cb2af238" contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_09f61981b16842c98bab19bf84baf6a0" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">476</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_228dadd8388e4ad3a37bb31a83d06af1" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_34705c2d36f7498aaa185c95b67dd7b2" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">476</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Net loss</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f8ab1ff8b1ad49e4a79b311ca2b91210" contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e92d5f1679d1432eae5422942281791e" contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ffad54830ae94350bc63edb60d383888" contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_759776caf8294e9e957be32e5dab1d73" contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,316</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3a37c7633df043bbb0924a16f5b9d1ca" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,316</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 4px;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2022</span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_957b736207134eb284af677a59e42abd" contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,942</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8a23c7aacc6949d2bfb703c4e5621e7a" contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_0f7b80578ed9492887835f7c332c4d0f" contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">$<br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6790578beb244af4a57129bb124da7fe" contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e96858a7c6614da6b8c9513a4b75428e" contextRef="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,596</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ed7fae5e76004e9bba2d9f8c0550ce26" contextRef="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160,799</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_368df00270254ce79f07eea8e0a1f3ee" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,813</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at January 1, 2022</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f5f9105b14224cbb99dc01361ad5a86f" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,601</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$<br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_f3020c1167794977a8ec9aab3cad9453" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_06640b73e15143adb300a75a082567bc" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_032f7ac9b6a14b3cb09b5396c4978ca4" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b468a57b7cd940469e928beb550b4056" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">166,190</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_496eb1d627c4412aa0d7feab8a913352" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">140,701</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$<br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e94ead561ba6471e9c4486a14e484324" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,503</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Issuance of common stock in connection with private offering</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesPrivateOffering" id="Fact_775b46324ef146c3aab941aa9d6d56df" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValuePrivateOffering" id="Fact_16ae3ef190da4e819e2bddb844e3d817" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesPrivateOffering" id="Fact_cf7a97b07ff74c58a2838ebe60865789" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValuePrivateOffering" id="Fact_e00e81f6ad414ac1b6e217dc3ea88293" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">(<ix:nonFraction name="erna:StockIssuedDuringPeriodValuePrivateOffering" id="Fact_3a5ba8366af64d7497386891f28bb51b" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValuePrivateOffering" id="Fact_84f81fee9a19453782f26a048608e324" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValuePrivateOffering" id="Fact_1d03d2d3cba84b6e8005167621e2c573" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Forfeiture of unvested restricted stock</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_1487d7b9183541209d2f916beea0a2f8" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_caef22008f2c471593e80d953e32ccd3" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_6c74f3e541cf4d95adf6c0b5409e6621" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_50b6ff46684b4b8b8ba61b759fba71a3" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_52a75ef092af4e688d32ef5430b8f2af" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_51976fa252a44bf2878bbf9ad1cfc4dc" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_873f314b9d304f4aba6355eb40a0c975" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Issuance of common stock from vested restricted stock units</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_d07f5d53000047e4b11c6e0b31f354cb" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_791faa4608d84a088d844f0f7171cddf" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_4a7eb9c1e4254b4cbba19779aa2be98e" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_391f9f83e3df40bebeffd7b357cbc9be" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_ad9ca0ea85b541db982ca5e50f17adac" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_97f1714710c740ddb6f2066d2c658f6c" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" id="Fact_a1c70049b98f4f48b4b7c0688a50cdb3" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Issuance of common stock from exercise of pre-funded warrants</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="Fact_3a402bc4253f46d68b589579d2f6e235" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_cbb21e7c482040f29e36923147ada4b0" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="Fact_7d11371e8ed14f72b1c36727888d7102" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_6a534cd711514dfb9454f891ec12e121" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_48de3c17782146bd816307e154c031ae" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">874</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_38ca44441274479bb4e1621a698f2a53" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="Fact_a340242b6d894ff08fef03c92bd8a4a1" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">875</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Stock-based compensation</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_a963576d4ce740baa26783d9ab445984" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_626394d824f84dea9510baee7404b687" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_4f0e3056aeac490d8cf70d7565285aa3" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_cae83c2d87ec4698a7035001fcbcd9ed" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_46f74bceffa14fd9b97e86861356b187" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Cash dividends to Series A preferred stockholders</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:PreferredStockDividendsShares" id="Fact_905c69bc4c3c4e54b1f115b4d1fbcaeb" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_8377295197264ef189ce743c6c5bb9e9" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:PreferredStockDividendsShares" id="Fact_7e1c251c311d4114b6a4688ca6b9b679" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_25aeb79e75104ec78d154dc690d79351" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_b413b18e5d7743c580bc683ccc946add" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_f627b0f7e6d54e02a38259107078849b" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_f0555db154844705b48a8207be11cf86" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt; font-weight: normal;">Net loss</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_366507d07cf7426abc034636c79165a8" contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_efcc057d623b436192469649086280b2" contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_96e843585cc84eafb70d419ff2342f4b" contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_5b7fdb30633f44429260ef83f4db1fa3" contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,090</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_69886567761b46b9b1d7e7b5af856d84" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,090</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-weight: normal; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2022</span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_5fc49a4b09414c61821d57b4ea751d81" contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,942</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_21fcd949d4df4da68eff31520a21e341" contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_ceb5f0f23cf34f79ab9dde7aa308309f" contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c220cb2d33f54dfea8198f98dfb79d11" contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_852f53d65f2244b582031afd4b0e757b" contextRef="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,596</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2d8179ab377e477c89a43a2c99338b6e" contextRef="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">160,799</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-weight: normal; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_efd9853d4a5144589d996fd23eccdf95" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,813</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-weight: normal; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
            <div style="text-align: center;"> <br />
              <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: -216.2px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Share and per share data have been adjusted for all periods presented to
                reflect a <span style="-sec-ix-hidden:Fact_7ee35f032c0c4b188f3eb65a7a37136f">1-for-20</span> reverse stock split effective October 17, 2022.</span><br class="Apple-interchange-newline" />
            </div>

          </div>

          <div> <br />
          </div>

          <div>
            <div><span style="font-weight: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span> </div>

            <div><span style="font-weight: normal;"> <br />
              </span></div>

            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table
                    of Contents</a><br />
                </div>

              </div>

            </div>

          </div>

        </div>

        <div>
          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; margin-left: 5.4pt; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>

          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; margin-left: 5.4pt; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; AND MEMBERS&#8217;
            EQUITY</div>

          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; margin-left: 5.4pt; font-weight: bold;">For the three and nine months ended September 30, 2022 and 2021
            (unaudited)</div>

          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; margin-left: 5.4pt; font-weight: bold;">(in thousands)</div>

        </div>

        <div><br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="6">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Membership Equity</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="6">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Common Stock</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="6">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"><span style="font-weight: bold;">Series A Preferred </span></div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Stock</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"><span style="font-weight: bold;">Additional <span style="font-weight: bold;">Paid</span>-<br />
                    </span>in</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Accumulated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: center; padding-bottom: 2px;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-style: normal; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Class A</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Class B</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Class C</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Common</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Amount</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Amount</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Capital</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Deficit</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Total</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at July 1, 2021</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8dc8b77171a6454785f233ab0e7f8d0f" contextRef="c20210630_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_607f5a87563149f790a67b6335829741" contextRef="c20210630_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e609f0a5c1aa44e09ea3282b523badef" contextRef="c20210630_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_be492d80f1124adabf3acb5f99097df1" contextRef="c20210630_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_dc7efe1fdbaa45e594572509cd350051" contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,235</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0203a8a94a1c4bfd9dad82ccf5cb107f" contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_4a36cbe94d624fcdb6217aeda3121a50" contextRef="c20210630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1222a65f3f2d451391a4ec014ac856e4" contextRef="c20210630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3c612c01955647409c2228395767a45a" contextRef="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,347</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c6cbd6b8233c4f82988d1b97edca8196" contextRef="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,756</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e2c5be7c330e4edca887070804a21b26" contextRef="c20210630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,603</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Common stock to be retained by NTN stockholders</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_375154bfc6ef4649bb5fb096072b1c67" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_fb53af3aac2e4dc0a2b478667fbd9571" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_9f35c422191144aab59292a8780d5f14" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_78b5984c950d4ba8a4d2ca601f4c1af4" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNSharesStockholders" id="Fact_a38f7d6977424c88893830475ac89e81" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_be7e05cd0c984404b805073729237cc0" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNSharesStockholders" id="Fact_65a31d5504e0479c8ecc8e97ca5b3291" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_843456884f7347c183222e85ef32fa57" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_33732403247349289dbf6cedd8882ca7" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_610ea90e95a8474dbe8868cb5cd757bc" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:CommonStockToBeRetainedByNTNValueStockholders" id="Fact_62482dc873ae4cab81009cd948762113" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Issuance of common stock from the exercise of stock options</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_c28cb013ea594a06ad2b45193bd73e2a" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f4bd79d7bc4e43f6b0271f5744e2e5f2" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_6b283c6708d7428fa06a50afade59dd8" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_99cbd41249ab4f079fdce50159d2f8c0" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_48d3d6c06c064a97bceb14835e47003c" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_21a91f6767674dc585a800cf5f09ffd4" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_f9008bc51afa421d80aee222797a748f" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_2425cf5b97b64db893dd701bd31d094b" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_6d998797b62644a2a28bff8e493df581" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_3a8bbea7a80e423683e84f0170224763" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_74c61979281a4ed988c2bc4144d4bcf0" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_2e47249a26a64aa0b237abe0b1d266cd" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_48b7de992f8c4dfaba9fc6424e38bd5b" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_965cb5109f914feab893b8f980adaa8b" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_4bf13b38407c45d8af2cfe29bb93e30b" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_16c3616510964ba0abd4dc80588ee189" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_4417b6ff483a4c118dc6adffe67492cf" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_0011b94e259c4444b6e5946a7ca111ba" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_fa57761f05194bf3a11f9f5468806c54" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_fed103d5a04844c1a8b38fded50c294a" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_4735ab0b7f224e40a93d01dc891d0d86" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_fe69fc5a9b514b1bac7b6978b22ffb52" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_ef8126235c27495887e5eb2ec98d4fb4" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_5a21d0dda16342e99a79e002875b9686" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_7efc3b96ca1b4aa285d0099961f5cec0" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_0e6562d8f995421a8427ae38a79fac94" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesInLieuOfDividends" id="Fact_2a7dc7b8dcfa41829d003bc0d7c1117d" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_91c15ad33e3b40028f9aee66660f8188" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesInLieuOfDividends" id="Fact_01fe53ca68c64c32935acd3af1f16476" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_e502964f919d46218101d2d16063214e" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_1dda143f396f46c2b639aa19a8341657" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_c09a8a1e4a66493093695e9655e5138e" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_50552a220de74c6b85007eacba9aca87" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock in connection with the acquisition of Novellus, Inc.</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_5cbd78cedf0d4fda87bb27c60e36dbbd" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_f445cb83af9f45e9bba160f8db7c7339" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_18f201d1c86f4ae482cfcc04eea90d1c" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_8133a4fd21724debbf20ac629c2d6816" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions2" id="Fact_6b8368626bb64cf180ca18cc9802289a" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">351</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_61a3ce401a514183bc6916be0d2775dd" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions2" id="Fact_bde068c40eff426eb047f803490dc880" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_c5dd7297fdc84b018f2f725e502d6b08" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_3cf4957e271a48caba825755af905628" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,682</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_5f9f6310772f48339141b432fcaddc75" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_bc52b5f836fb4c11ab6a4add19dd503c" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,684</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Forfeiture of unvested restricted stock</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_7003da87a2854562abb7d2507c391660" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_b14d203bb3784570b3107668505baede" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_f8a21cbe86174bdab533e2a04320688e" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_2bfa95f4adde4b789aff180ff0c6646d" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_aac17aa84ea84dc8b4536f6167a06a8b" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_ede89710c5764f6db4716f4c64aac095" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_e98e4050540a4a4b8013afe555171cc6" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_d6c4eaf5140848a7a11a468ee2f4e8a6" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_a23e99bc098b49c7afd26ce7235e922c" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_6a62243a58d546c3a2b96128e782fefe" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_0944ccf925e34afea9abc72d3e78c758" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_c85123e981a14564aa6c86a27e01c328" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_9ba66b814bdd426d8a4431767a3043a5" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_6a91b006071f4059a14007f96f454f3c" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_53349258865f434da80086721b87e3c8" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_4133be16eb334af1b4f2ff743182ce2b" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1a49017f3c2b4a58803af514d1a347c2" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_5f781b2528e54840972a3b3ef5a994df" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,729</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_26dbe3b8dda343e69701c0ee177de157" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_258c6fc46b9f4fa38044ce636130dab1" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,729</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ff08e05589c74fa2b3a6142cd1db3d49" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_737241e6f5114e47bc6ac33daf97443a" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a38c547565c5444da50de466e3fee353" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_27283385bf774b1a9e6a44d932d0ad32" contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f236890827574369a0652b620655102b" contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f7019eab4baa45b7bd2d7fa0d69ad646" contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e2741ac8ed25466e984aebe7342c1d07" contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7c73e49331c3416a96e758999388d3d9" contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,986</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_956d610af0bd4d609273758545bf0474" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,986</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; padding-bottom: 4px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2021</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d0462b8409bf4577824d03a131b363e7" contextRef="c20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6b2e214910f449aa82f94dfff471fb85" contextRef="c20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8c13d5e36a0346e7830da2bbe1c0961f" contextRef="c20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ff97f46517f14b7b8962850a2fb1f863" contextRef="c20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_c2632998ae6542c1b2362fe99d4da764" contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,602</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c01bce97e06c4ae8b15a404e4e738cc9" contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_366177fc8d1b4f968f0694c9accee215" contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_f4230244ce12426598ab5efcc51bb669" contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1f2f2602f23346fca2471ac20e20711d" contextRef="c20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">164,258</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1f9a41097aaa4052884282f0fbc8a4fb" contextRef="c20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">132,742</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_bbcaef06119d454baf65288b9cac08f8" contextRef="c20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,530</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at January 1, 2021</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_7da0d186c5b0472a83f65197d0bb64ee" contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,202</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e0f4c036eac24489bdcdaa9679ec0475" contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,400</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9cdfe422f20342f3a6ab35ace6d0c1f2" contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a9e32a76c88e4b93a5a6a01a3740c2eb" contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">198</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_bf582aaf1e264eee9f73d0d8ebb2a0e4" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4c06c522d2f4469a80ebe91cb9f117cd" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_b230468e82d34c28891689e2818ce30d" contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d0b3e41a40994d3d86273b1f8e2e68b8" contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2a245f649d924d6986e4bbd572d537a0" contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_abbd77055e1948dcb248b249ea42beaa" contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,141</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_67698045274d47f88c4787bdfac95c8b" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,659</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Brooklyn rights offerings membership units</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_3107b14302ab450eac40f7609252e35e" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_862f06c051d2414c96c86c4760b6fe6e" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_733a6dbef1b04db0b7ccf6aaef376bb6" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_c40157a3b3c74cbcac9cc70784ebce02" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_bb4352eadec94980ae6d20ad255466c7" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_3822dc971c9847c481f5ea4e091d36d6" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_0faeaaacc9d54b11bb4c7ea63722d7ad" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_225a021ae6d84b94baad9c112e025c4c" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_1e6722efa71944dfad64b2b36089df53" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Elimination of Brooklyn&#8217;s historical members&#8217; equity</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_ad50f56a73fb431c9194ca80e290bec1" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,702</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_dc51bef44d264b8d884790aee02f247b" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,400</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_37be016efb8849b68723f2b94018e3b8" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_df5cfdb565e04a2dad9d196262e4988e" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_4e4d3db0bbdc4531ad246fe3574ea226" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_bda69ac828c546c89aaee9d890c0a2ca" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_134a9b20677347cabaeee9ab98807ec7" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,300</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_d874a173d2904611b0bdb087eb70942c" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_54dfcb4a01864c08b018e23a84f88eb9" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Issuance of common stock for business combination</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_92abea589ccc4a41a8ff26ea5950fca8" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_d201d1dc92ef47448deadeac4c0260bd" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_d2306f252978493483a094e729590a27" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_0d492f42e45a470aa56e5104f75f4fc6" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions1" id="Fact_edd7a01607a6471f970d0c083731aa1f" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">76</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_ef1ac71eb6fb4c1698fedad4a8322f11" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions1" id="Fact_7b4ba3556dd3480abb56eae1fb9c0e94" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_244c272909724fb49c2c9e8c923dc295" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_ff8198c2ee864c9bb0e99dc20da44303" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,177</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_fec5f54e7bcb4c15ab0ed8d14cbf8177" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_c0f021f7bb804d89b662051edd5192f5" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,177</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Series A preferred stock retained in business combination</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_c970cfd84f594dbcbde8b46567bdf623" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_5e1ab0702abe4fc0a1356d85c6f65883" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_cde930ac85064e7ab9c5d7891906ea26" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_f999413487a8462ea4f964452710ef43" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_e27dbdcd693d47fab1e11b9560e8d1c5" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_dce05b9ec97b41ceaf0f11e7851e87e8" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_fde11040ebaf4892bdd226c40b0738be" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_0759c7688558414faaf737e2bb98cb4d" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_baa990ff1bb74a698984147f8eaea42b" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_9f99788d588f4285808041c30196dbf2" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_34ac98851f68434b8477b32a45797746" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Issuance of common stock to Brooklyn members</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_cee00a579cf74aaf8da4b9fe94d94cc2" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_02178268805c4ec2ace149d10675b108" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_17271e6748e94bd1a48b79d0c29d21cd" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_bfc4fd8edea4486d843ab5d89d0b9d58" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsAcquisitions" id="Fact_6d1a41081c5d4fceb02e39e137edd3f9" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_9714bf5b370646b88c58d47b72c83878" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsAcquisitions" id="Fact_8c6bd22c340c47fab7aa97aa6c4e6be1" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_0cce2bdda7e34101a36d655cef64ee60" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_a502fffd17654797b7be258427333ed0" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_9f29619645974b9fb1a0e18a74734557" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_d0cb7163e49d47238bf81118b960823b" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock to Financial Advisor upon consummation of merger</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_026b204959dc43868348dac36a6137ec" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_4810f269dfd64c848c3f6b38a06800d7" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_95eea29db69a465da50e462e7a26b726" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_fda10bf67c504db3a3ce2a751002dfb7" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_684cb5ceb7e14dc6a0a14086e1e40e02" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">53</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_77c0c8e49f2d4ccf96f3f7d5aeaeef9f" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_020c172cd88d4093b0e2176b4876e8f2" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_ac39652da55f4c0682e6d31039803efd" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_237cb32e8c204018b56a0ad2f4c9ec1f" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,765</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_23276eb99c674a9280fd3321b19387e5" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_ae8666b7ba8e41fab9ec3b68ea1c386a" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,765</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Issuance of common stock from the exercise of stock options</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_c8f12874af2f4a80b0d75362704f35c1" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_506aff40cc2b40d0bfbab6cc43186a87" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a53656f0853f45b18ce0989a8b4e1915" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_da87c9b89bba430bbaa74a3d2e6d4477" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_96f9f855eb114568b747b782e3403fdc" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_88d7a6f047264c88ac1b241faac61c00" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_897ff3ae1e254aa4b80769e641bb2e93" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_034eead3cc5a4b4c961fde8026c52e0e" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_9757270358504de9b5aff351bf1b9715" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f0acd60cc06844f2ada854ed1d04b285" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f96ee1ba8e4a400294dafe79b3be1142" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_d4525aaf3c724341aa52d7ac6d8ff6f5" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_c8248465f48c47d3ba81c2f1544137d0" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_04677b95a8c946c28a39c0ddb4e78f67" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_5dcc093e28ee4a3085ef252781a7d090" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_f765ae98485347299a1c5bbcdb5745b0" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">178</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_cd48f6f836e84141a55daef3d6a353a8" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_d6980199fe5c44f9a395bb52e60ab20b" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_8854add4f3d44983be921dcfb51fb803" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_bd52645c914e4a1e9ce35eae7120becb" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,025</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_8527242625d94b1da428f856483f7464" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_951f81bd8ab94986a56a80cb0052867e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,026</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_ca152f8d69f64b758706e85998a6c184" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_bd0c7de8b56a41eb9d6c3b4f3cb2a631" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_9763421680284f7ebbae19772cec78e5" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_fd03420a8d8d4696a6e0817142a658be" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesInLieuOfDividends" id="Fact_8426e0b6404046f9bce96f990c1e2770" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_f7c05b611b654edca5fb87af78b7ee39" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesInLieuOfDividends" id="Fact_8d2f7134a0bd49d88bd908362bc0cd52" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_84b3cbe0f1de49bea0901dc64e5ea808" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_910d6a7376944c39bf1add620547f5ec" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_9b0c973e6bbf4e9fa0904892663ef8fb" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_7d60e7c383c74d6a842122f179ae42c9" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt;">Issuance of common stock in connection with the acquisition of Novellus, Inc.</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_659350083287482094e00fbc06ac5cf9" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_4b20042ef7ff40ec83915a41ce2f020e" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_d0989d33b8644f8da2d3f4af3fa4a1e3" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_09e4c432746842089c25ebb48ef8b10a" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions2" id="Fact_1d0c305e9640427ba2f6f21f2736f792" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">351</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_c16e4008740b4bda845e5064b553bf98" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions2" id="Fact_3b53e669fffa4be780ef649312102764" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_eabce3f267514a6289e7219bddf825ad" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_dae15234adaf4c5184a285823e18e7f6" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,682</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_5399dbe4779946688b905a026782d75c" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_d03f8e2399bb465a86839290c42a183f" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,684</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Forfeiture of unvested restricted stock</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_7bf2271ea9e74b52a19027e559d0b77b" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_132b6f124c834c5a90f15997d695f841" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_7d09a546d4d54a2286a11557c5669c1b" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_422df02bd91d4e8187a0a6d913a869eb" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_2b42d848d1164d98a247dcd45ea6580b" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_be506cce459b4185b975e825b27fc11d" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_34ba18af2b9e42e98de1bfa9c3adbb47" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_46102578d35648419ec11cba927f88c9" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_5ad35b1ecb54460aa04809ef9ebdb829" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_14e648ce25ef4efaa3b36a4ffb6063e3" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_f0f07fc67ae34b9dae4fa47cd973b903" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b3bc100c53804e1d8c4ebb6026553067" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_7d761ba3de0f4e9f8ae9c48956735534" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_db85315df79947bd858898cad4f13e75" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_ace5de06d1f442f8827900c406902b7d" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_2b57f37fe7824d15b360573b2847acb2" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_8af3bb858be04955bc4c28ba38fc9175" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_918e7ef1dde048d88cd2b1c1ae31356a" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,302</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_bc11676f28bb4dc0896218919723c7a9" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_7574f55f79454c949bb738995a4cf329" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,302</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; padding-bottom: 2px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_74ae1d95dbef49238652c544469cdaf0" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cf1faabe035b4045b8282f107e3ff3ae" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_38ffae36546043e28d65b7eca4edbe55" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d48fc3916b084665aee183c5e197829f" contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4dc6d64f0c1e48ec8a89b9c2b4c0ab5f" contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_49b9d28bd40247b4a62b27cebeebb208" contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cb5c3f9cb6094a6bbbb2b8abeb112b92" contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3bd5d6e96c9c407d80656287617d9363" contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114,593</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_44effd0fb76044d2a093a7715c7cbc6b" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114,593</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balances at <span style="text-indent: 0pt;">September 30</span>, <span style="text-indent: 0pt;">2021</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e6587047fc8d492ba668c185a2bbea93" contextRef="c20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1af030f8dac64b2481bc55c0663a50d2" contextRef="c20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_f6961af204ad4aa9b9a60bbba3221087" contextRef="c20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c5b813d3cbb244fda7cd077d6b6b7d37" contextRef="c20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_b258b2f713fd4ee0aeed2e4334d6c9e1" contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,602</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_089f18010f0941aab348d2afd2cae608" contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_70ac653f536b4ea8a97d3fdbd7379f76" contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">156</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d06447d404ab4c30b6725129651ff064" contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_7a9d8d8616e34b2c9372467199c63817" contextRef="c20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">164,258</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b2d24eb83b9d4d429a14aac023dc63a9" contextRef="c20210930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">132,742</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2b5685515f4348c9a725ce75ead2e0db" contextRef="c20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,530</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br />
          </div>

          <div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; margin-left: 65pt; font-family: 'Times New Roman';">Share and per share data have been adjusted for all periods presented to reflect a <span style="-sec-ix-hidden:Fact_a01fe878e0064f3999e272199bd42d2c">1-for-20</span> reverse stock split effective October 17, 2022.</div>

          <div><br class="Apple-interchange-newline" /></div>

        </div>

        <div style="text-align: center;"><span style="font-weight: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div>

        <div><br /></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 8pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div style="text-align: center; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>

        <div><span style="font-weight: bold;"> </span></div>

        <div style="text-align: center; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF
          <!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor-->CASH FLOWS<a id="OFCASHFLOWS"><!--Anchor--></a><!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;">(in thousands) </div>

        <div style="text-align: center; font-weight: bold; text-indent: -81pt; margin-left: 81pt;"> (unaudited)<br />
        </div>

        <div><br />
        </div>

        <div style="text-align: center;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-weight: bold; text-align: center;" rowspan="1" colspan="6">For the nine
                  months ended</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30, </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">2021</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Cash flows used in operating activities:</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6f4f0938e705409e94ac1b73bb1e3782" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,090</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6f3b8843d08e4ee9a23065b21d921a11" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114,593</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Depreciation and amortization</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_52c3a375a4bc4ef3a35ebac43a7a055b" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">144</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_46233d7668a1445c909bce61aa877bfe" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">93</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Stock-based compensation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_6fb1e37bcaff4d3ea366570481288ecb" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_e9daee9d9c134e3ba876a7acdd3e7f0d" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,302</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Amortization of right-of-use asset</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_e8a57958dfa64ad9af1fda481bbc817a" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">267</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_846320f5f364420baaedabc15565c637" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">243</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">
                      <div style="margin-left: 9pt;">Impairment of right-of-use asset </div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_7d6e1951ffab441fa30136c75211d561" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">772</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_c3f5998dca1f4449a63a37f0b621834e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">
                      <div style="margin-left: 9pt;">Impairment of in-process research and development </div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ImpairmentOfOngoingProject" id="Fact_a9cbbd3606314678adf463b4ed119cbd" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,990</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ImpairmentOfOngoingProject" id="Fact_4d4895a83d2a484bb975e46c5a9d5516" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">
                      <div style="margin-left: 9pt;">In-process R&amp;D acquired in Novellus asset acquisition</div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="erna:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_8949226e2e194f478d957e45a54eacb4" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="erna:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_1e47f412a1a64fdfa2a55ab511512bbe" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,538</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Transaction costs - shares to Financial Advisor</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_845d862a50614f16816355c3df31707e" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_ea2dfa78201241efa117efa36c4e983e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,765</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Loss on sale of NTN assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_fd03224a48344f47b38694ef12fd9665" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_c92af19678294878b3796383c06fbc0d" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,648</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 18pt;">Loss on disposal of fixed assets </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:GainLossOnDisposalOfFixedAssets" id="Fact_66db2d7e57854ec887f6e58344ea87ec" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">431</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:GainLossOnDisposalOfFixedAssets" id="Fact_457e8979737d4828a06529ce29be430c" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Gain on forgiveness of PPP loan<br />
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="erna:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" id="Fact_cb1a3def19df4df8949ba142f62c4521" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="erna:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" id="Fact_be6bb975355049c692cd068da360fa9c" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">310</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 18pt;">Gain on lease termination </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="erna:GainOnTerminationOfLease" id="Fact_d5112a306f0e42298775a537de0108f0" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">85</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:GainOnTerminationOfLease" id="Fact_2aa8db5a59a44247bb110873cb5dfef2" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Gain on lease warrant liabilities</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="erna:WarrantLiabilitiesExpense" id="Fact_3b7eea33734148619b2f90453f98759e" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,493</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="erna:WarrantLiabilitiesExpense" id="Fact_c0a2ab30569d4c15b138ec2457bdbe58" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 18pt;"> Loss on non-controlling investment </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="erna:LossOnNonControllingInvestment" id="Fact_4b1f3da2cc1944009396c13fa39c4ba3" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">932</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;"><ix:nonFraction name="erna:LossOnNonControllingInvestment" id="Fact_68a861101a8c4077a800bd61258f50fa" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Changes in operating assets and liabilities:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 27pt;"> Other receivable </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" id="Fact_321c1973cc5047a891af6441bdf24fb0" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">237</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" id="Fact_c6ef839db990450f8b728fa2ddfbf06e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 27pt;">Prepaid expenses and other current assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_520f5afb31b34c90ae1ef28e60bb64af" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">575</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_e64fdf9e0a804db3a0b4c84741503972" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,109</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">
                      <div style="margin-left: 9pt;">Other non-current assets</div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" id="Fact_bf8dd294cc0b412bb83aa8debd6020d3" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">331</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" id="Fact_cf7683086b6848e5a5e5b5a2bf36f095" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 27pt;">Accounts payable and accrued expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_3d86258584294221bc4a8f1779bf05d1" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,376</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_1017090743054a8b989bdcf7f1f92067" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 27pt;">Operating lease liability</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="erna:IncreaseDecreaseInOperatingLeaseLiabilities" id="Fact_ab893a212ace4afd9248c9af7adde3b7" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">(<ix:nonFraction name="erna:IncreaseDecreaseInOperatingLeaseLiabilities" id="Fact_ec6073fc08e24ab08f7ec95a1eaa1167" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">226</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="color: rgb(0, 0, 0); margin-left: 27pt;">Other liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_6388b59ba02b4c47b13572a9b8368eec" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,043</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_6464b7360e484717bcde3755511ad950" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">202</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal; margin-left: 27pt;">Net cash used in operating activities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6afe89da9d5e4371852a35cd6bcf978a" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,541</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_0d27849903f54936966c012f234980eb" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16,656</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Cash flows used in investing activities:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Purchase of property and equipment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_907da751a9484053bd82995235768cfe" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">276</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_345be2badee34621acc0609312969b97" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">Purchase of Novellus, net of common stock issue and cash acquired<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="erna:PaymentsToAcquireProductiveAssetsNet" id="Fact_c5bd8b3aa4154f859d554c4b6420f111" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="erna:PaymentsToAcquireProductiveAssetsNet" id="Fact_69f206947ce54d29b733c50460c1dd1f" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,854</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Proceeds from the sales of fixed assets </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Fact_4e447ab2f13b4cb1b5a9e8876cd4c63c" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Fact_80ce915fc2a0443bb431089b2edcb2e2" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Purchase of NTN, net of cash acquired</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfAssetsInvestingActivities" id="Fact_8738013835e34e668a0b8d2e26358450" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfAssetsInvestingActivities" id="Fact_5c08b6ebac864f6aa134d216b4f43f95" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">147</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Proceeds from the sale of NTN assets, net of cash disposed</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" id="Fact_8481d30f6c17452cbc0f049374130a54" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" id="Fact_4d634b1023414ddbb6c7b5e13d186617" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal; margin-left: 27pt;">Net cash used in investing activities </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_86c765326cbf4488a9d5ef8f728cac04" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">176</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_dd20e0dd75b346f6a76968736b843588" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,595</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Cash flows provided by financing activities:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;"> Proceeds from issuance of common stock and warrants in connection with private offering </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_8f7ade7b2c2d4d62b6a51617dbace42f" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,993</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_f2fe506cce404ab4bf920a520b6a4b28" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">Issuance of common stock from exercise of pre-funded warrants<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" id="Fact_5859c33254b2495bb38b0f83230d15a1" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" id="Fact_b055e8d842754478b839a675fdf6f1cb" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Payroll tax remitted on net share settlement of equity awards </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_f1e98fc89dd24b2092775070c109ff70" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_8d18602ab28a439582665c4340208d05" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Dividends paid to Series A preferred stockholders </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" id="Fact_2c5e2f636e9f480580f5a893f53b46ed" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" id="Fact_d4181d37f2dd40838e89408f34444526" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Principal payments on finance leases</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_64a0d4d8fdae42c599c8f93babc5abbc" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_734d170b64164bdd9743dcd2765beb9e" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Proceeds from issuance of common stock to Lincoln Park </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:ProceedsFromIssuanceOfCommonStockToLincolnPark" id="Fact_6ce04020486c479b8ad2e96bd5a000f3" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:ProceedsFromIssuanceOfCommonStockToLincolnPark" id="Fact_f73da412b2e04317aa4d6e064ebd4e72" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,106</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" rowspan="1">
                  <div style="margin-left: 18pt;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fees incurred in connection with the common stock issued to Lincoln Park<br />
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="erna:FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" id="Fact_8e4cc7acdd7e4685808343e0ec186918" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="erna:FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" id="Fact_effb9da0837d42a3a1898e6569447588" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,080</ix:nonFraction></td>

    <td valign="bottom" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;">Proceeds from sale of members<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -12px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">&#8217;</span> equity</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" id="Fact_81e0f700f7b24b9da524e4208f788c87" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" id="Fact_9ab7998575c94e0091fea177541ae6c4" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">Proceeds from the exercise of stock options </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_2b77964f2c20484facd57a4d73fa6684" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_5ad45aa45f484cadbf65e6ec4aed9d88" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Repayment of NTN<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -12px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">&#8217;</span>s PPP loan</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="erna:PaymentsOfPaycheckProtectionProgramLoan" id="Fact_bb728a9e854a4dfc85c9053211f0c4fe" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="erna:PaymentsOfPaycheckProtectionProgramLoan" id="Fact_58b3dad94bc641a8b91d06894aa1f4bb" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">532</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal; margin-left: 27pt;">Net cash provided by financing activities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_7ee8c29eaf5d4137bd1dade481e9fe87" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,986</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_a3c0168a36be4dc9b4e6aedd42e190c2" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,004</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">Net (decrease) increase in cash and cash equivalents </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_a7ca9048f87f4fd2a35d9628a1157dbf" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,731</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_d342d4143f6d43069d907c90637f390c" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,753</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Cash and cash equivalents at beginning of period</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_68ddc76da6d24c3ca6d775ad07700aa7" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,985</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_21e1369ba44b4e44af787746f2cb5a06" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Cash and cash equivalents at end of period</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_4e6af96bfd13497f9ce3100a1be4038f" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,254</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_f3250412451646d5979ec858937827e3" contextRef="c20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,383</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Supplemental disclosures of cash flow information:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Cash paid during the period for:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 18pt;">Interest</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_bc7be38cf8dc49669a94ff5a0b1da0a8" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_ab19eca704eb470ca2f10673d71b420b" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; text-indent: -9pt; margin-left: 9pt; width: 76%; padding-bottom: 4px;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">
                      <div style="margin-left: 9pt;">Income taxes </div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_011a88eee4e94cf1b2cd0165df3665a9" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_ed12edf98566485f87fecac4405cebab" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div>&#160;</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="color: rgb(0, 0, 0); font-weight: normal;">Supplemental disclosure of non-cash investing and financing activities:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">Conversion of warrant liability to equity<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:ConversionOfWarrantLiabilityToEquity" id="Fact_c335264b146041fe8398812c77409dfb" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">867</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:ConversionOfWarrantLiabilityToEquity" id="Fact_ebcc6d18d2174f038cce4934d591455f" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;" rowspan="1">
                  <div style="margin-left: 9pt;">Issuance of common stock for Series A preferred stock dividend<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:IssuanceOfCommonStockForSeriesAPreferredStockDividend" id="Fact_838b2f6ec0db4d1e904cf78de38c237c" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:IssuanceOfCommonStockForSeriesAPreferredStockDividend" id="Fact_26c392a725a0446299eda2ef70db1e49" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Issuance of common stock for business combination</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_b605189355444d24a4142fd3e8fad3c5" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_eefa35ba47fd41208551e33ee8ef2db6" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,177</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;" rowspan="1">
                  <div style="margin-left: 9pt;">Issuance of common Stock for Novellus acquisition<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:IssuanceOfCommonStockForAssetAcquisition" id="Fact_ade9a6799da04dcab1bee5f43e524958" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:IssuanceOfCommonStockForAssetAcquisition" id="Fact_1ba3d69336304305a959dd13132b605d" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,684</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">Series A preferred stock retained in business combination </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" id="Fact_f4c255ac08514813bafeb28c359e9af5" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" id="Fact_6125f9343898419088c1928f1d5288aa" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;" rowspan="1">
                  <div>
                    <div style="margin-left: 9pt;">Initial measurement of ROU assets, net of tenant improvement allowance</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfRightOfUseAssetsAndLiabilities" id="Fact_7d564310af0e485d8b60800f6518fbd1" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,706</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfRightOfUseAssetsAndLiabilities" id="Fact_5add340712bc4e5bbaf034afc3e70e55" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">816</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">Initial measurement of operating lease liabilities<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfOperatingLeaseLiabilities" id="Fact_0d903887b38b48d8881b6cf15b8d5f36" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,706</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfOperatingLeaseLiabilities" id="Fact_a698a74a669a4b5bbc36d5446dfecf7b" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">866</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;" rowspan="1">
                  <div style="margin-left: 9pt;">Initial measurement of finance lease liabilities<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfFinanceLeaseLiabilities" id="Fact_2e0cb3aa3c8e4789b4e8f0c5e3ab2a8b" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfFinanceLeaseLiabilities" id="Fact_db97c02767c8401ea8674c834a94ae83" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
        </div>

        <div style="text-align: center;"> <br />
        </div>

        <div style="text-align: center;">
          <div>The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        </div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 8pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

          <div class="BRPFPageBreak" style="page-break-after:always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span>
    <span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>

        </div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><a id="NOTESTOCONDENSEDCONSOLIDA"><!--Anchor--></a><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor-->NOTES TO CONDENSED CONSOLIDATED
          FINANCIAL STATEMENTS</div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Unaudited) </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
<ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_c159c89179e84bc69ae87d8760bbfc7e" contextRef="c20220101to20220930" escape="true" continuedAt="Text_a568e45f177e4b66896e9550d57298931">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
         </div>
</ix:nonNumeric>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d57298931" continuedAt="Text_a568e45f177e4b66896e9550d57298932">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1)</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d57298932" continuedAt="Text_a568e45f177e4b66896e9550d57298933">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d57298933" continuedAt="Text_a568e45f177e4b66896e9550d57298934">
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d57298934" continuedAt="Text_a568e45f177e4b66896e9550d57298935">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Description of Business</div>
</ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d57298935" continuedAt="Text_a568e45f177e4b66896e9550d57298936">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">
          <div>
            <ix:continuation id="Text_a568e45f177e4b66896e9550d57298936" continuedAt="Text_a568e45f177e4b66896e9550d57298937">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On October 11, 2022, Eterna Therapeutics Inc., a Delaware corporation, (&#8220;Eterna&#8221; or the &#8220;Company&#8221;), filed with the Secretary of State of the State of Delaware a Certificate of A<span style="font-size: 10pt;">mendment to its Restated Certificate of Incorporation, as amended (the &#8220;Charter&#8221;), to change its name from Brooklyn ImmunoTherapeutics, Inc. to Eterna Therapeutics Inc., which became effective on October 17, 2022
                  (the &#8220;Name Change&#8221;). The Name Change did not require approval of the Company&#8217;s stockholders and did not affect the rights of the Company&#8217;s security holders. </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In connection with the Name Change, the trading symbol of the Company&#8217;s common stock, par value
                $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_c165c822cd464e0597d4a447d664ec59" contextRef="c20221017" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">0.005</ix:nonFraction> per share (&#8220;common stock&#8221;), on The Nasdaq Global Market changed from &#8220;BTX&#8221; to &#8220;ERNA.&#8221;</span></div>
</ix:continuation>
            <ix:continuation id="Text_a568e45f177e4b66896e9550d57298937" continuedAt="Text_a568e45f177e4b66896e9550d57298938">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_a568e45f177e4b66896e9550d57298938" continuedAt="Text_a568e45f177e4b66896e9550d57298939">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Eterna, together with its subsidiaries including Brooklyn ImmunoTherapeutics LLC (<span style="font-size: 10pt;">&#8220;Brooklyn LLC&#8221;), Novellus,
                Inc. (&#8220;Novellus&#8221;) and Novellus Therapeutics Limited (&#8220;Novellus Ltd.&#8221;), is a biopharmaceutical company using its mRNA technology platform, including mRNA-based cell reprogramming and gene editing technologies, to create next generation mRNA,
                gene editing and cell therapies, including iPSC therapies for multiple therapeutic indications. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company also plans to develop and advance a pipeline of therapeutic products both internally and through strategic partnerships. </span>As used herein, the
                &#8220;Company&#8221; refers collectively to Eterna and its subsidiaries.</span></div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_a568e45f177e4b66896e9550d57298939" continuedAt="Text_a568e45f177e4b66896e9550d572989310">
<div><br /></div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989310" continuedAt="Text_a568e45f177e4b66896e9550d572989311">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div><ix:continuation id="Text_a568e45f177e4b66896e9550d572989311" continuedAt="Text_a568e45f177e4b66896e9550d572989312">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_a568e45f177e4b66896e9550d572989312" continuedAt="Text_a568e45f177e4b66896e9550d572989313">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2020, Eterna (then known as &#8220;NTN Buzztime, Inc.&#8221;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of Eterna
              (the &#8220;Merger Sub&#8221;), entered into an agreement and plan of merger and reorganization (the &#8220;Merger Agreement&#8221;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned
              subsidiary of Eterna and as the surviving company of the merger (the &#8220;Merger&#8221;). The Merger closed on March 25, 2021. In connection with the Merger, the Company changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.,&#8221;
              <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and, as described above, the Company has since changed
                its name to Eterna Therapeutics Inc. </span>The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.</div>
</ix:continuation>
            <ix:continuation id="Text_a568e45f177e4b66896e9550d572989313" continuedAt="Text_a568e45f177e4b66896e9550d572989314">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_a568e45f177e4b66896e9550d572989314" continuedAt="Text_a568e45f177e4b66896e9550d572989315">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Eterna sold its rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN
              Buzztime, Inc.&#8221; (the &#8220;Disposition&#8221;) prior to the Merger to eGames.com Holdings LLC (&#8220;eGames.com&#8221;) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Eterna and eGames.com (the &#8220;Asset
              Purchase Agreement&#8221;). </div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989315" continuedAt="Text_a568e45f177e4b66896e9550d572989316">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989316" continuedAt="Text_a568e45f177e4b66896e9550d572989317">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">On July 16, 2021, Eterna and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an
          agreement and plan of acquisition (the &#8220;Novellus Acquisition Agreement&#8221;) with (a) Novellus LLC, (b) Novellus (the sole equity holder of Novellus Ltd. and, prior to the closing under the Novellus Acquisition Agreement, a subsidiary of Novellus
          LLC), and (c) a seller representative (the &#8220;Novellus Acquisition&#8221;), pursuant to which Eterna acquired Novellus and its subsidiary, Novellus Ltd. As part of the Novellus Acquisition, Eterna also acquired <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_105ff8ca8ce2424a9d1f42d62c416bfc" contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">25.0</ix:nonFraction>% of the total outstanding equity interests of NoveCite, Inc. (&#8220;NoveCite&#8221;), a corporation focused on developing an allogeneic mesenchymal stem cell product for patients
          with acute respiratory distress syndrome, including from COVID-19. </div>
</ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989317" continuedAt="Text_a568e45f177e4b66896e9550d572989318">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><br />
        </div>
</ix:continuation>

        <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_981de089ea644818a2ff1997672bf5df" contextRef="c20220101to20220930" escape="true" continuedAt="Text_232cbdf288fc451d919f2b15d5bf26971"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989318" continuedAt="Text_a568e45f177e4b66896e9550d572989319">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Basis of Presentation</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_232cbdf288fc451d919f2b15d5bf26971" continuedAt="Text_232cbdf288fc451d919f2b15d5bf26972"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989319" continuedAt="Text_a568e45f177e4b66896e9550d572989320">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_232cbdf288fc451d919f2b15d5bf26972" continuedAt="Text_232cbdf288fc451d919f2b15d5bf26973"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989320" continuedAt="Text_a568e45f177e4b66896e9550d572989321">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_232cbdf288fc451d919f2b15d5bf26973" continuedAt="Text_232cbdf288fc451d919f2b15d5bf26974"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989321" continuedAt="Text_a568e45f177e4b66896e9550d572989322">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The


          accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial statements and with the instructions to
          Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited financial statements include all the
          normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented.<br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_232cbdf288fc451d919f2b15d5bf26974" continuedAt="Text_232cbdf288fc451d919f2b15d5bf26975"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989322" continuedAt="Text_a568e45f177e4b66896e9550d572989323">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_232cbdf288fc451d919f2b15d5bf26975"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989323" continuedAt="Text_a568e45f177e4b66896e9550d572989324">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">These































          condensed consolidated financial statements should be read together with the audited consolidated financial statements and notes thereto contained in Eterna&#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2021 filed with the
          Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 30, 2022 (the &#8220;10-K/A&#8221;). The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements contained in the 10-K/A but does
          not include all of the information and footnotes required by GAAP for complete financial statements. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be anticipated
          for the entire year ending December 31, 2022, or any other period.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989324" continuedAt="Text_a568e45f177e4b66896e9550d572989325">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </div>
</ix:continuation>
        <div>
          <ix:nonNumeric name="erna:ReverseStockSplitPolicyTextBlock" id="Text_d304fcff0eb94408ae8685ebfad5aa93" contextRef="c20220101to20220930" escape="true" continuedAt="Text_c2f070411396443a856b905e1fc311621"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989325" continuedAt="Text_a568e45f177e4b66896e9550d572989326">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman'; font-style: italic;">Reverse Stock Split</div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_c2f070411396443a856b905e1fc311621" continuedAt="Text_c2f070411396443a856b905e1fc311622"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989326" continuedAt="Text_a568e45f177e4b66896e9550d572989327">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c2f070411396443a856b905e1fc311622" continuedAt="Text_c2f070411396443a856b905e1fc311623"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989327" continuedAt="Text_a568e45f177e4b66896e9550d572989328">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">A<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">s approved by the Company&#8217;s stockholders at the Company&#8217;s Annual Meeting of Stockholders held
              on September 21, 2022, the Company effected a reverse stock split of its common stock at a ratio of <span style="-sec-ix-hidden:Fact_b943329114c841ec8b57e15e6be15da4">1-for-20</span>, as determined by the
              Company&#8217;s Board of Directors within the parameters approved by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split&#8221;).&#160; The Reverse Stock Split became effective under Delaware law at 11:59 p.m. Eastern time on October 16, 2022.</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c2f070411396443a856b905e1fc311623" continuedAt="Text_c2f070411396443a856b905e1fc311624"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989328" continuedAt="Text_a568e45f177e4b66896e9550d572989329">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c2f070411396443a856b905e1fc311624" continuedAt="Text_c2f070411396443a856b905e1fc311625"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989329" continuedAt="Text_a568e45f177e4b66896e9550d572989330">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common stock were automatically
            combined and reclassified into one issued and outstanding share of common stock. The Reverse Stock Split did not affect any stockholder&#8217;s ownership percentage of the common stock, alter the par value of the common stock or modify any voting
            rights or other terms of the common stock. The number of authorized shares of common stock under the Charter remains unchanged. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares to
            which a stockholder would otherwise be entitled, the Company paid an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the then fair value of a share as determined in good
            faith by the Board. The Company paid an aggregate of $<ix:nonFraction name="erna:CashPaidForFractionalSharesInConnectionWithReverseStockSplit" id="Fact_ae62bc3edff1451f8ad788641e3f8f77" contextRef="c20220921to20220921" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">719</ix:nonFraction> for a total of <ix:nonFraction name="erna:NumberOfSharesConsideredAsFractionalInReverseStock" id="Fact_5ebcf3ac588a4f1d958025c0a02e426a" contextRef="c20220921to20220921" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">175</ix:nonFraction> fractional shares.<br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c2f070411396443a856b905e1fc311625" continuedAt="Text_c2f070411396443a856b905e1fc311626"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989330" continuedAt="Text_a568e45f177e4b66896e9550d572989331">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c2f070411396443a856b905e1fc311626"><ix:continuation id="Text_a568e45f177e4b66896e9550d572989331" continuedAt="Text_a568e45f177e4b66896e9550d572989332">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">All share and per share data in this Quarterly Report on Form 10-Q have been adjusted for all periods presented to reflect the Reverse
            Stock Split.</div>
</ix:continuation></ix:continuation>
          </div>

        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989332" continuedAt="Text_a568e45f177e4b66896e9550d572989333">
<div><br />
        </div>
</ix:continuation><ix:continuation id="Text_a568e45f177e4b66896e9550d572989333" continuedAt="Text_a568e45f177e4b66896e9550d572989334"><ix:nonNumeric name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="Text_71c8f622b17c4c8e9d9a5535cd70cf24" contextRef="c20220101to20220930" escape="true" continuedAt="Text_1079a719188242de9ed7612fd6c1e5541">
<div>
         <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989334" continuedAt="Text_a568e45f177e4b66896e9550d572989335"><ix:continuation id="Text_1079a719188242de9ed7612fd6c1e5541" continuedAt="Text_1079a719188242de9ed7612fd6c1e5542">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-style: italic;">Reclassifications</span><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989335" continuedAt="Text_a568e45f177e4b66896e9550d572989336"><ix:continuation id="Text_1079a719188242de9ed7612fd6c1e5542" continuedAt="Text_1079a719188242de9ed7612fd6c1e5543">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_a568e45f177e4b66896e9550d572989336"><ix:continuation id="Text_1079a719188242de9ed7612fd6c1e5543">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain reclassifications have been made
          to Eterna&#8217;s prior years&#8217; financial statements to conform to the current year presentation. These reclassifications had no effect on Eterna&#8217;s previously reported results of operations or accumulated deficit.</div>
</ix:continuation></ix:continuation>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 57.55pt; margin-left: 24pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; <span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</span> </div>

      </div>

      <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

      <div><ix:nonNumeric name="erna:LiquidityAndCapitalResourcesTextBlock" id="Text_b6fb6892a9904282bc9f5185ebebb1c1" contextRef="c20220101to20220930" escape="true" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8481">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
        <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8481" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8482">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2)</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">LIQUIDITY AND CAPITAL RESOURCES</div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8482" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8483">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8483" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8484">
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8484" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8485">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting clinical trials and providing general and
              administrative support for operations. As of September 30, 2022, the Company had a cash balance of approximately $<ix:nonFraction name="us-gaap:Cash" id="Fact_5b136a25e40941f49b4c632f2ebe786d" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.3</ix:nonFraction> million and
              an accumulated deficit of approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_a67afac2714f4d20b28c20a8bb37b38f" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">160.8</ix:nonFraction> million. For the three and nine months ended September 30, 2022, the Company
              incurred a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c76543e934a44306b2678fc79346c5bd" contextRef="c20220701to20220930" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">7.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0d724342b94c4d91932231988e54d487" contextRef="c20220101to20220930" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">20.1</ix:nonFraction> million, respectively, and for the nine months ended September 30, 2022, the Company used cash in operating activities of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_e6e8d4c3ae5444eba361b6922c288705" contextRef="c20220101to20220930" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">15.5</ix:nonFraction> million.</span><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:continuation>
          <div style="text-indent: 0pt;">
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8485" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8486">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160; <br />
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8486" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8487">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">October 18, 2022, the Company
                entered into a facility sublease agreement (the &#8220;Sublease&#8221;) for approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" id="Fact_ce3defc24d654b8291da69da441d1c4f" contextRef="c20221018_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">45,500</ix:nonFraction> square feet of office and laboratory space
                in Somerville, Massachusetts.&#160; Pursuant to the Sublease, the Company delivered to the sublessor a security deposit in the form of a letter of credit in the amount of $<ix:nonFraction name="us-gaap:LineOfCredit" id="Fact_0ebf21638c7047ffa94928b9284a313b" contextRef="c20221018_PledgingPurposeAxis_LetterOfCreditMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction> million, which will be reduced on an incremental basis throughout the term of the lease.&#160; The letter of credit was issued by the Company&#8217;s commercial bank, which
                required that the Company cash collateralize the letter of credit by depositing $<ix:nonFraction name="us-gaap:RestrictedCash" id="Fact_0336b907ce804b83861b66334d4bdc15" contextRef="c20221018_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction> million in a restricted cash account with
                such bank.&#160; The amount of required restricted cash collateral will decline in parallel with the reduction in the amount of the letter of credit over the term of the sublease.&#160; The Company&#8217;s deposit of this restricted cash reduced the amount
                of working capital the Company has to fund its operations. See Note 15,&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Subsequent

                Events,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;for more information on the
                Subleas</span>e.</div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8487" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8488">
<div><span style="font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8488" continuedAt="Text_0cd6422a863f464fb3cfa155da98a8489">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;"> </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table
                    of Contents</a><br />
                </div>

              </div>

            </div>
<ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a8489" continuedAt="Text_0cd6422a863f464fb3cfa155da98a84810">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
             <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a84810" continuedAt="Text_0cd6422a863f464fb3cfa155da98a84811">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In connection with preparing the accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022, the Company&#8217;s management concluded that there is substantial doubt regarding
              the Company&#8217;s ability to continue as a going concern because it does not expect to have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these financial statements.
              The Company will need to raise additional capital, which could be through the remaining availability under an equity line purchase agreement with Lincoln Park Capital Fund, LLC (the &#8220;Second Purchase Agreement&#8221;) (to the extent the Company is
              permitted to use such agreement) (see Note 12), public or private equity offerings, debt financings, corporate collaborations or other means. The Company may also seek governmental grants to support its clinical trials and preclinical trials.
              The Company currently has no arrangements for such capital and no assurances can be given that it will be able to raise such capital when needed, on acceptable terms, or at all. </div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a84811" continuedAt="Text_0cd6422a863f464fb3cfa155da98a84812">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a84812" continuedAt="Text_0cd6422a863f464fb3cfa155da98a84813">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a84813" continuedAt="Text_0cd6422a863f464fb3cfa155da98a84814">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_0cd6422a863f464fb3cfa155da98a84814">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The
              accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may
              result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</div>
</ix:continuation>

            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br />
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%6%%%--> </div>

    </div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <ix:nonNumeric name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="Text_fbcb17304ce04aa5b619ffb95c920909" contextRef="c20220101to20220930" escape="true" continuedAt="Text_53cbfb752887407e959417674dc9b3321">
<div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3)</div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</div>
                  </td>

  </tr>


</table>
          </div>
</ix:nonNumeric>
        </div>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3321" continuedAt="Text_53cbfb752887407e959417674dc9b3322">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3322" continuedAt="Text_53cbfb752887407e959417674dc9b3323">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 27pt; margin-left: 9pt; font-variant: normal; text-transform: none;">Merger</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3323" continuedAt="Text_53cbfb752887407e959417674dc9b3324">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3324" continuedAt="Text_53cbfb752887407e959417674dc9b3325">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On August 12, 2020, Eterna, Brooklyn LLC and the Merger Sub
          entered into the Merger Agreement, and the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes. Brooklyn LLC, as the accounting
          acquirer, recorded the assets acquired and liabilities assumed of Eterna in the Merger at their fair values as of the acquisition date.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3325" continuedAt="Text_53cbfb752887407e959417674dc9b3326">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3326" continuedAt="Text_53cbfb752887407e959417674dc9b3327">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Brooklyn LLC was determined to be the accounting acquirer
          based upon the terms of the Merger and other factors including that (i) Brooklyn LLC members, received common stock in the Merger that represented <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" id="Fact_6345027e2351441ca473a39a9651c08d" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">96.35</ix:nonFraction>%
          of Eterna&#8217;s outstanding common stock on a fully diluted basis, (ii) all of the directors of Eterna immediately after the Merger were designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC&#8217;s
          management became the management of Eterna immediately after the Merger.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3327" continuedAt="Text_53cbfb752887407e959417674dc9b3328">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3328" continuedAt="Text_53cbfb752887407e959417674dc9b3329">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">At the closing of the Merger, all the outstanding membership
          interests of Brooklyn LLC converted into the right to receive an aggregate of approximately <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" id="Fact_2789e6cb7042465a9dae17674df934ad" contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,999,000</ix:nonFraction> shares of common stock, of which
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_3c34298cadee403e99c5230aa796c98e" contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">53,000</ix:nonFraction> shares were issued as compensation to Brooklyn LLC&#8217;s financial advisor for its services to Brooklyn LLC in connection with the
          Merger.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b3329" continuedAt="Text_53cbfb752887407e959417674dc9b33210">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33210" continuedAt="Text_53cbfb752887407e959417674dc9b33211">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The purchase price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" id="Fact_227decf93219417199a7605f42a9d98c" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.2</ix:nonFraction> million, which represents the consideration transferred in the Merger to stockholders of Eterna immediately before the Merger, was calculated
          based on the closing price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" id="Fact_fb3b8ad711e04e6a8bf2b6c2b2fb567a" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">108</ix:nonFraction> per share for approximately <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6ee5e4d5ec294648b86e84a862707a97" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">76,000</ix:nonFraction> shares common stock that those stockholders owned on March 25, 2021 immediately prior to the Merger because that represented a more reliable measure of the fair value of
          consideration transferred in the Merger.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33211" continuedAt="Text_53cbfb752887407e959417674dc9b33212">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33212" continuedAt="Text_53cbfb752887407e959417674dc9b33213">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Under the acquisition method of accounting, the total
          purchase price has been allocated to the acquired tangible and intangible assets and assumed liabilities of Eterna based on their estimated fair values as of March 25, 2021, the Merger closing date. Because the consideration paid by Brooklyn LLC
          in the Merger is more than the estimated fair values of Eterna&#8217;s net assets deemed to be acquired, goodwill is equal to the difference of approximately $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_472f7ddf38ab474d8e5329a8f559e9e2" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.6</ix:nonFraction>
          million, which has been calculated using the fair values of the net assets of Eterna as of March 25, 2021.</div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33213" continuedAt="Text_53cbfb752887407e959417674dc9b33214">
<div><br /></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                  Contents</a><br />
              </div>

            </div>

          </div>

        </div>


        <ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Text_c4998b5fcb854dbda6d5d8398d1e26e9" contextRef="c20220101to20220930" escape="true" continuedAt="Text_caab9df533a04ea7be6633a840a502b11"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33214" continuedAt="Text_53cbfb752887407e959417674dc9b33215">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The allocation of the purchase price to the tangible and
          intangible assets acquired and liabilities deemed to be assumed from Eterna, based on their estimated fair values as of March 25, 2021, is as follows (in thousands):</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_caab9df533a04ea7be6633a840a502b11" continuedAt="Text_caab9df533a04ea7be6633a840a502b12"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33215" continuedAt="Text_53cbfb752887407e959417674dc9b33216">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_caab9df533a04ea7be6633a840a502b12"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33216" continuedAt="Text_53cbfb752887407e959417674dc9b33217">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Historical</div>
                <div style="text-align: center; font-weight: bold;"> Balance</div>
                <div style="text-align: center; font-weight: bold;"> Sheet of</div>
                <div style="text-align: center; font-weight: bold;"> Eterna at</div>
                <div style="text-align: center; font-weight: bold;"> March 25, 2021</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Fair Value</div>
                <div style="text-align: center; font-weight: bold;">Adjustment </div>
                <div style="text-align: center; font-weight: bold;">to</div>
                <div style="text-align: center; font-weight: bold;"> Eterna</div>
                <div style="text-align: center; font-weight: bold;">Pre-Merger</div>
                <div style="text-align: center; font-weight: bold;"> Assets</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;" colspan="2">
                <div><span style="font-weight: bold;">Purchase </span></div>
                <div><span style="font-weight: bold;">Price</span></div>
                <div><span style="font-weight: bold;"> Allocation</span></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" id="Fact_2725424f41d8481391d5d9b74743798c" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">148</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" id="Fact_7d87050ae9ec4f008c9c341fa74d0ff9" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" id="Fact_d8ace7599d8747adb96381429da64b93" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">148</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Accounts receivable</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" id="Fact_cb87f6125c9941798faca3b91b0fc241" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">103</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" id="Fact_6150027b5c354d98927eaacab5da5e26" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" id="Fact_f156f9133848407b9a71d0ce72a589a6" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">103</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Prepaid expense and other current assets</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" id="Fact_a2366e9700d343e0a60acbffb1de278e" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">329</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" id="Fact_ed3daa1edecb49d0aac9d037e3372471" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" id="Fact_fc45bfd49d5e4f2ab447d164788dd284" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">329</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Property and equipment, net</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" id="Fact_de133348dc744b73943b32d78de0ba45" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" id="Fact_68e80322ecf64c28accbe07905b466c9" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" id="Fact_61e8e74da9d24dc3873dd9b556f4e377" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Software development costs</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="Fact_be407ced63244e4f9eec7e6feea2e91e" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,296</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div>(<ix:nonFraction name="erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="Fact_e7c09bf992d04167997ac7570b800df2" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">368</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="Fact_c2b4633c0f4b49baa15fd1028e20578d" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">928</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Customers</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_4997f04d55164c74b3a474032d24a260" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_d791bf9a81764ef382af7ac319a41fdd" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">548</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_d5bc4102ca1c4c9c867ea007d3bea130" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">548</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Trade name</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_e2be2ae057604e9fadda2f32cc4e0d62" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_1a52d912e8cc4886aa3f303fd7f9205e" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">299</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_b6fbd1b00a084964be550dfe7081dafc" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">299</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;">
                <div style="text-align: left;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Accounts payable, accrued liabilities and other current liabilities</div>
                </div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" id="Fact_718b1a37aeb24eb6b75c9c6f255edfad" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,781</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" id="Fact_43fa4f28ccda4ac4a7bf9580517ed159" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" id="Fact_c3c635779da24d1f96c46f9f49fc3eeb" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,781</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Net assets acquired, excluding goodwill</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_5561988841f0434e91fa9cd6ea091477" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">890</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_e2e9aeb6a23b4862b5d360b16f12cffb" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">479</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_1ef02e1de8154d69b9c4cf16a893a519" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">411</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; text-indent: -9pt; margin-left: 9pt;" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Total consideration</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" id="Fact_83d8cd6575d64b17bc310467ccdd17ff" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,178</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Net assets acquired, excluding goodwill</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_dbeb92621a8e4652bbb1dd829640641f" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">411</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Goodwill</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_5765c3c9d34d498db67fb96ed0b497e3" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,589</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33217" continuedAt="Text_53cbfb752887407e959417674dc9b33218">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33218" continuedAt="Text_53cbfb752887407e959417674dc9b33219">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Brooklyn LLC was obligated under the Merger Agreement to have
          $<ix:nonFraction name="erna:ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" id="Fact_079ee68d81994e8c8e4ff9536be82f4a" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction> million in cash and cash equivalents on its balance sheet at the effective time of the Merger. To ensure Brooklyn LLC had the
          required funds, certain beneficial holders of Brooklyn LLC&#8217;s Class A membership interests entered into contractual commitments to invest $<ix:nonFraction name="erna:BeneficialHoldersContractualCommitmentsToInvest" id="Fact_50ca5d73004241d4ad356fb1b98dc32d" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>
          million into Brooklyn LLC immediately prior to the closing of the Merger. During March 2021, Eterna offered its Class A unit holders an additional <ix:nonFraction name="erna:PercentageOfAdditionalRightsOffering" id="Fact_84250eda626c4b77909aabf344a072a5" contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>%
          rights offering for an additional $<ix:nonFraction name="erna:ProceedsFromSaleOfRights" id="Fact_7e2bb9bbdaba40fc8633535d11d2d4d1" contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million to be raised by a rights offering. Eterna received funds from the rights offering
          between February 17, 2021 and April 5, 2021.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33219" continuedAt="Text_53cbfb752887407e959417674dc9b33220">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33220" continuedAt="Text_53cbfb752887407e959417674dc9b33221">
<div style="display:none;"><br /></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-indent: 36pt;">Disposition</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33221" continuedAt="Text_53cbfb752887407e959417674dc9b33222">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>

        <ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Text_a08043633ac149379ad703bbb3529414" contextRef="c20220101to20220930" escape="true" continuedAt="Text_7c1fb5a6148b4d10823bda9f0f2f94871"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33222" continuedAt="Text_53cbfb752887407e959417674dc9b33223">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 26, 2021, Eterna sold its rights, title and interest
          in and to the assets relating to the business it operated (under the name NTN Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" id="Fact_47491901f1a9498ba4d04cf776788f7c" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction> million and assumption of specified liabilities relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the
          Disposition are as follows (in thousands):</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_7c1fb5a6148b4d10823bda9f0f2f94871" continuedAt="Text_7c1fb5a6148b4d10823bda9f0f2f94872"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33223" continuedAt="Text_53cbfb752887407e959417674dc9b33224">
<div><br /></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_7c1fb5a6148b4d10823bda9f0f2f94872"><ix:continuation id="Text_53cbfb752887407e959417674dc9b33224" continuedAt="Text_53cbfb752887407e959417674dc9b33225">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" rowspan="1">
                <div style="text-align: left; font-weight: bold;">Proceeds from sale:</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" rowspan="1">Cash</td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" id="Fact_88a767ade9e645dc83886066da5f0482" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">132</ix:nonFraction></td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Escrow</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" id="Fact_34581ffa0b6e455db516d2995b411d8d" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div style="text-align: left;">Assume advance/loans</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" id="Fact_e71c580f0205445cbb1f08715ca869a4" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,700</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Interest on advance/loans</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" id="Fact_3381c21b5e27475784ce770dd86d2d94" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">68</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left; font-weight: bold;">Carrying value of assets sold:</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" id="Fact_277461b5b71e49b597d4bcdd00717feb" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Accounts receivable</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" id="Fact_b0585c4c9fe4403bad8be1df2492ac88" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Prepaids and other current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" id="Fact_01983c2f9ca34e15ac9a456d0cae9626" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">124</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Property and equipment, net</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" id="Fact_4980ab42739144b0ba3c3f1b645a3eda" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Software development costs</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div>(<ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" id="Fact_005630643b6249838ae2371476146b35" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">927</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Customers</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" id="Fact_6559ccae4cb54d7997cc7388bbf83b06" contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">548</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Trade name</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" id="Fact_7d71ce070dd5465397fc0ead5b2b99a7" contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">299</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Goodwill</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" id="Fact_350a220a8bb642adbec96a132ea49a90" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,589</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Other assets</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" id="Fact_8c77542dadd448819c547cbb6bbd7f0d" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">103</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; font-weight: bold;">Liabilities transferred upon sale:</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Accounts payable and accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" id="Fact_9ea3916e259340e7b08b17cb2c926493" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">113</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Obligations under finance leases</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div><ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" id="Fact_bb4bfb60be4547d4a711c58a3db1356b" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Lease liability</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationLeaseLiability" id="Fact_8375b3b4fa174987a6f2576877447acc" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);">
                <div style="text-align: left;">Deferred revenue</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                <div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" id="Fact_3ff7f60b33764ef9812e88a611c48cea" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Other current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" id="Fact_387823009c274495afc867a527cf1353" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">149</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Transaction costs</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>(<ix:nonFraction name="erna:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" id="Fact_55727fceace444cb84fec2fb6a354748" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">265</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;">
                <div style="text-align: left; font-weight: bold;">Total loss on sale of assets</div>
              </td>

    <td valign="bottom" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                <div style="font-weight: bold;">$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                <div style="font-weight: bold;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" id="Fact_5463a573ebb34ea4b9c50321772b8189" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,648</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                <div style="font-weight: bold;">)</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33225" continuedAt="Text_53cbfb752887407e959417674dc9b33226">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33226" continuedAt="Text_53cbfb752887407e959417674dc9b33227">
<div style="display:none;"><br /></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 36pt; font-variant: normal; text-transform: none;">Acquisition</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33227" continuedAt="Text_53cbfb752887407e959417674dc9b33228">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33228" continuedAt="Text_53cbfb752887407e959417674dc9b33229">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On July 16, 2021, Eterna and Brooklyn Acquisition Sub, Inc.
          entered into the Novellus Acquisition Agreement. The Novellus Acquisition closed contemporaneously with the execution and delivery of the Novellus Acquisition Agreement. At the closing:</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33229" continuedAt="Text_53cbfb752887407e959417674dc9b33230">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_53cbfb752887407e959417674dc9b33230" continuedAt="Text_53cbfb752887407e959417674dc9b33231">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: left;"><span style="font-family: 'Times New Roman';">&#9679;</span></div>
                </td>

    <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: justify;">Eterna acquired all of the outstanding equity interests of Novellus as the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, following which, Novellus, as the surviving
                    corporation, became Eterna&#8217;s wholly owned subsidiary and Novellus Ltd. became Eterna&#8217;s indirectly owned subsidiary; and</div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_53cbfb752887407e959417674dc9b33231" continuedAt="Text_53cbfb752887407e959417674dc9b33232">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_53cbfb752887407e959417674dc9b33232" continuedAt="Text_53cbfb752887407e959417674dc9b33233">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: left;"><span style="font-family: 'Times New Roman';">&#9679;</span></div>
                </td>

    <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: justify;">Eterna acquired <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_892449318ec8491c962c8b233e7c96cd" contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">25.0</ix:nonFraction>% of the total outstanding equity interests of NoveCite.</div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_53cbfb752887407e959417674dc9b33233" continuedAt="Text_53cbfb752887407e959417674dc9b33234">
<div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33234" continuedAt="Text_53cbfb752887407e959417674dc9b33235">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As consideration for the Novellus Acquisition, Eterna paid $<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" id="Fact_26070e6aebdf42f2bf71a638922e9461" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.9</ix:nonFraction> million in cash and delivered approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_3a4cf21299214a1ebe070f6a006e26b8" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">351,000</ix:nonFraction>
          shares of common stock, which under the terms of the Novellus Acquisition Agreement, were valued at a total of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_c22eeb85867440d6acb5db7260e5f064" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">102.0</ix:nonFraction> million based on
          an agreed upon price of $<ix:nonFraction name="erna:AssetAcquisitionSharePrice" id="Fact_ef938c72808843b79e912311d6d3228f" contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">290.5060</ix:nonFraction> per share. At the date of issuance, the fair value of the shares was approximately $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_43ba5e42f91647aca67d9faf1eca5a0f" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">58.7</ix:nonFraction> million.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33235" continuedAt="Text_53cbfb752887407e959417674dc9b33236">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33236" continuedAt="Text_53cbfb752887407e959417674dc9b33237">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Novellus Acquisition Agreement contained customary
          representations, warranties and certain indemnification provisions. Approximately <ix:nonFraction name="erna:EscrowShares" id="Fact_1b708c91213540b49d0fce2431ab4382" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">37,000</ix:nonFraction> of the shares issued as consideration were
          placed in escrow to secure indemnification obligations to Eterna under the Novellus Acquisition Agreement, and all such shares were released to the sellers in July 2022. The Novellus Acquisition Agreement also contains certain non-competition and
          non-solicitation provisions pursuant to which Novellus LLC agreed not to engage in certain competitive activities for a period of <ix:nonNumeric name="erna:AcquisitionAgreementNonCompetitivePeriod" id="Fact_856c31a82a424c75b8ff755e89079e0d" contextRef="c20220101to20220930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric>
          following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus prior to the Novellus Acquisition continued their employment, or were otherwise engaged by Eterna, immediately following the
          Novellus Acquisition.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33237" continuedAt="Text_53cbfb752887407e959417674dc9b33238">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33238" continuedAt="Text_53cbfb752887407e959417674dc9b33239">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with the Novellus Acquisition, the co-founders
          of Novellus entered into lock-up agreements with respect to approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_ac69959d13704697a9f8023d9b488a0b" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">169,000</ix:nonFraction> of the shares of common stock received in the
          Novellus Acquisition, and Eterna&#8217;s Chairman of the Board and its former Chief Executive Officer and President entered into identical lock-up agreements with respect to their current holdings of Eterna stock. Each lock-up agreement extends for a
          period of <ix:nonNumeric name="erna:EachLockUpAgreementExtendsTerm" id="Fact_11c9737e255a45cb8aaf7cbfbdb5e373" contextRef="c20220101to20220930_AssetAcquisitionAxis_NovellusIncMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, provided that up to <ix:nonFraction name="erna:PercentageOfCommonStockSubjectToLockUpAgreement" id="Fact_120ef8a092474508bdbe9d2be124c02d" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RangeAxis_MaximumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% of the shares of common stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on the Nasdaq exceeds specified
          thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period. </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33239" continuedAt="Text_53cbfb752887407e959417674dc9b33240">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33240" continuedAt="Text_53cbfb752887407e959417674dc9b33241">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal;">The


          Company expects the Novellus Acquisition will advance its evolution into a platform company with a pipeline of next generation mRNA cellular and gene editing programs. In addition, the acquisition of Novellus Ltd. builds on the License Agreement
          (as defined in Note 10). As a result of the Novellus Acquisition, in accordance with the terms of the Novellus-Factor License Agreement, the rights and obligations of Novellus Ltd. thereunder pertaining to any and all licensed products have
          inured to Eterna. The License Agreement with Factor Bioscience Limited (&#8220;Factor Limited&#8221;) under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene editing and cell therapy products,
          remained unchanged after the completion of the Novellus Acquisition.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33241" continuedAt="Text_53cbfb752887407e959417674dc9b33242">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33242" continuedAt="Text_53cbfb752887407e959417674dc9b33243">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Although Eterna acquired all of the outstanding equity
          interests of Novellus, the Company accounted for the Novellus Acquisition as an asset acquisition (as the assets acquired did not constitute a business as defined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805,&#160;<span style="font-style: italic;">Business Combinations</span>),&#160;and was measured by the amount of cash paid and by the fair value of the shares of common stock issued. As a result, substantially all of the value acquired was attributed to in-process research and
          development (IPR&amp;D), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities, as discussed further below.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33243" continuedAt="Text_53cbfb752887407e959417674dc9b33244">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33244" continuedAt="Text_53cbfb752887407e959417674dc9b33245">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Eterna paid $<ix:nonFraction name="erna:PaymentsToAcquireProductiveAssetsNet" id="Fact_5a9188ce4591487dadbe10257a893eed" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.9</ix:nonFraction> million in cash, net of cash acquired, as part of the consideration for the Novellus Acquisition, of which $<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" id="Fact_0ca4da8c64e543339a2f15785854dd48" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million was paid in cash for the investment in NoveCite. Eterna also issued approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_03b74eba589c4e048b544874baca8be5" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">351,000</ix:nonFraction>
          shares of the Company&#8217;s common stock, of which approximately <ix:nonFraction name="erna:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" id="Fact_52178f86039e4c23a86344d6f2039da8" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">182,000</ix:nonFraction> shares are unrestricted and <ix:nonFraction name="erna:StockIssuedDuringPeriodRestrictedSharesAcquisitions" id="Fact_6ed03e4e86754f72abce63a4d4b2cedd" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">169,000</ix:nonFraction> shares are subject to the <ix:nonNumeric name="erna:LockUpPeriodForRestrictedShares" id="Fact_d161f43c1fdd40ddaab5fe2c7385cec3" contextRef="c20220101to20220930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" format="ixt-sec:durwordsen">three-year</ix:nonNumeric>
          lockup. The unrestricted shares were valued at $<ix:nonFraction name="erna:AssetAcquisitionUnrestrictedSharesSharePrice" id="Fact_c13cc18bd21c4a1c881cbe9b27a09baa" contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">201</ix:nonFraction> per share, which was the closing price of Eterna&#8217;s common stock on July 16, 2021.
          The fair value of the restricted shares was discounted by approximately <ix:nonFraction name="erna:PercentageOfDiscountOnFairValueOfRestrictedShares" id="Fact_eafb3ed229e246b189d184a53cdee839" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">35</ix:nonFraction>% to $<ix:nonFraction name="erna:AssetAcquisitionRestrictedSharesSharePrice" id="Fact_855122ce93544dd79afc6107b219be54" contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">130.60</ix:nonFraction> per restricted share, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models. <ix:nonNumeric name="us-gaap:AssetAcquisitionTableTextBlock" id="Text_3ac8744c64734e319bb6f2f33b766498" contextRef="c20220101to20220930" escape="true" continuedAt="Text_62dc1eb3a6294a80b59f864392d38f8a1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">The resulting fair value of the asset acquired is as follows
          (in thousands):</span></ix:nonNumeric></div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33245" continuedAt="Text_53cbfb752887407e959417674dc9b33246"><ix:continuation id="Text_62dc1eb3a6294a80b59f864392d38f8a1" continuedAt="Text_62dc1eb3a6294a80b59f864392d38f8a2">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33246" continuedAt="Text_53cbfb752887407e959417674dc9b33247"><ix:continuation id="Text_62dc1eb3a6294a80b59f864392d38f8a2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Fair Value of</div>
                <div style="text-align: center; font-weight: bold;">Consideration</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div style="text-align: left;">Cash paid</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" id="Fact_39d4421ba124482f93efb8141e0cd044" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,882</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div style="text-align: left;">Cash acquired</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" id="Fact_1deb707b9c76427c914e5172d23a51f7" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div style="text-align: left;">Unrestricted shares</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="erna:StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" id="Fact_b7e5bb60c51547b2afb424ae5fdaba62" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,628</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;">
                <div style="text-align: left;">Restricted shares</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div><ix:nonFraction name="erna:StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" id="Fact_7f9eb42232a84fb08c455d4684062dd7" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,056</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div style="text-align: left;">Total fair value of consideration paid</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="erna:AssetAcquisitionFairValueOfConsiderationPaid" id="Fact_8e9c44cef3514ff1b96e7d73aae78726" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,538</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;">
                <div style="text-align: left;">Less amount of cash paid for NoveCite investment</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" id="Fact_4ed1ea680cb4479e8214e6ec50da0d35" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-align: left;">Fair value of IPR&amp;D acquired</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="erna:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_23117f13e1fe4d1a96e201957179c496" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,538</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33247" continuedAt="Text_53cbfb752887407e959417674dc9b33248">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33248" continuedAt="Text_53cbfb752887407e959417674dc9b33249">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">IPR&amp;D that is acquired through an asset purchase that has
          no alternative future uses and no separate economic values from its original intended purpose is expensed in the period the cost is incurred. Accordingly, the Company expensed the fair value of the IPR&amp;D during the third quarter of 2021 in
          the amount of $<ix:nonFraction name="erna:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_cac07234c12240be99feec51269f3e5d" contextRef="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="1" scale="0" format="ixt:num-dot-decimal">80.5</ix:nonFraction> million.</div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33249" continuedAt="Text_53cbfb752887407e959417674dc9b33250">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33250" continuedAt="Text_53cbfb752887407e959417674dc9b33251">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Investment in NoveCite</span></div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33251" continuedAt="Text_53cbfb752887407e959417674dc9b33252">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33252" continuedAt="Text_53cbfb752887407e959417674dc9b33253">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33253" continuedAt="Text_53cbfb752887407e959417674dc9b33254">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_53cbfb752887407e959417674dc9b33254">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal;">As
          a result of the Novellus Acquisition,&#160; Eterna acquired and currently owns <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_d42ea9b878dc4aac9d4ef08746cd8aef" contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of NoveCite and Citius Pharmaceuticals, Inc. (&#8220;Citius&#8221;)
          owns the remaining <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_f559aec610414c84bd46a92ee1b45b3e" contextRef="c20210716_OwnershipAxis_CitiusPharmaceuticalsIncMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>%. A member of the Company&#8217;s management is entitled to hold one of <ix:nonFraction name="erna:NumberOfBoardSeats" id="Fact_1137f9de8edf4ecd8923f916a9335174" contextRef="c20210716to20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> board seats on NoveCite&#8217;s board of directors. Citius&#8217; s officers and directors hold the other two board seats. The Company is accounting for its interest in NoveCite
          under ASC Topic 323, <span style="font-style: italic;">Investments &#8211; Equity<span style="font-style: italic;"> Meth</span>od and Joint&#160;Ventures</span>.&#160;The investment was recorded at cost, which was $<ix:nonFraction name="us-gaap:EquityMethodInvestments" id="Fact_9c811628c39e4b80bbfe51bb9eabbb0b" contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million&#160;and is adjusted for the Company&#8217;s share of&#160;NoveCite&#8217;s earnings or losses, which are reflected in the accompanying condensed consolidated statement of operations.
          The investment may also reflect an equity loss in the event that circumstances indicate an other-than-temporary impairment. For the three and nine months ended September 30, 2022, the Company recorded approximately $<ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" id="Fact_2d83d625ad174229a87f583420cd2ce3" contextRef="c20220701to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" id="Fact_2e86197a27514fd8ace4e4fe2779776d" contextRef="c20220101to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million, respectively,
          in losses from its investment in NoveCite, and of the $<ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" id="Fact_57406785178349fb9526f30d188ea46c" contextRef="c20220101to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million loss for the nine months ended September 30, 2022, $<ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" id="Fact_ad83c074931e47cb927ef69380d01fc1" contextRef="c20210101to20211231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million related to NoveCite&#8217;s year ended December 31, 2021. The Company does not guarantee obligations of NoveCite nor is it otherwise committed
          to providing further financial support for NoveCite. Therefore, the Company will record losses only up to its investment carrying amount.</div>
</ix:continuation>

        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

      </div>

    </div>

    <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_e7c69bb7250f40eca795c907e47ea32c" contextRef="c20220101to20220930" escape="true" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold;">4)<br />
              </td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">FAIR VALUE OF FINANCIAL INSTRUMENTS</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed1" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed2">
<div>&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed2" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Fair


















          value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest
          priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed3" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed4">
<div>&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed4" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed5">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div>
          <div>
            <div>
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed5" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed6">
<div>
                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';">&#9679;</span></span></div>
                      </td>

    <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Level
                          1 Inputs &#8211; Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</div>
                      </td>

  </tr>


</table>
              </div>
</ix:continuation>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed6" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed7">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed7" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed8">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed8" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed9">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div>
          <div>
            <div>
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed9" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed10">
<div>
                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';">&#9679;</span></span></div>
                      </td>

    <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Level
                          2 Inputs &#8211; Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in
                          active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities,
                          prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</div>
                      </td>

  </tr>


</table>
              </div>
</ix:continuation>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed10" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed11">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed11" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed12">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed12" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed13">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div>
          <div>
            <div>
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed13" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed14">
<div>
                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';">&#9679;</span></span></div>
                      </td>

    <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Level
                          3 Inputs &#8211; Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.</div>
                      </td>

  </tr>


</table>
              </div>
</ix:continuation>
            </div>

          </div>

        </div>

        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed14" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed15">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed15" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed16">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation><ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed16" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed17"><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Text_4d476c48d31d495f848d9bf273e04d58" contextRef="c20220101to20220930" escape="true" continuedAt="Text_7a70d86516f04785982f06ff12d627411">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
        <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
        <div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed17" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed18"><ix:continuation id="Text_7a70d86516f04785982f06ff12d627411" continuedAt="Text_7a70d86516f04785982f06ff12d627412">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div><ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed18" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed19"><ix:continuation id="Text_7a70d86516f04785982f06ff12d627412" continuedAt="Text_7a70d86516f04785982f06ff12d627413">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed19" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed20"><ix:continuation id="Text_7a70d86516f04785982f06ff12d627413" continuedAt="Text_7a70d86516f04785982f06ff12d627414">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">T<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">here were <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_be73ba9fe1ef4009b8922f2e798b4c8a" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> liabilities measured at fair value as of Decem</span>ber 31, 2021.
                The following tables summarize the liabilities that are measured at fair value as of September 30, 2022 (in thousands)</span>:</div>
</ix:continuation></ix:continuation>
          </div>

          <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed20" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed21"><ix:continuation id="Text_7a70d86516f04785982f06ff12d627414" continuedAt="Text_7a70d86516f04785982f06ff12d627415">
<div> <br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed21" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed22"><ix:continuation id="Text_7a70d86516f04785982f06ff12d627415">
<div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of September 30,
                      2022</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 1</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 2</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 3</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Liabilities:</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Warrant liabilities - Common Warrants</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_d1a523ec4a4e482ba0195400255fd3b9" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_8dc070b8189c44e790209fe7de6f8987" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$ <br />
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_6465159755f94fbbb2f941689a53515b" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_7b60d649e06143abbb254b9a56b428d7" contextRef="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_9c2dff582b314261a508b2761ef72bb1" contextRef="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_04bd0d10e6fb485ea572fbc9394ed578" contextRef="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          </div>
</ix:continuation></ix:continuation>
        </div>

        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed22" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed23">
<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">  <br /></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed23" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed24">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed24" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed25">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed25" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed26">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed26" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed27">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">On
          March 9, 2022, the Company issued pre-funded warrants exercisable for approximately <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_7febd74da57d41e88e430b64cee83bb1" contextRef="c20220309_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded
          Warrants&#8221;) and warrants exercisable for approximately <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_14c68fcd29a4420ebc7c89a5c2459458" contextRef="c20220309_ClassOfWarrantOrRightAxis_CommonWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">343,000</ix:nonFraction> shares of common stock (the &#8220;Common Warrants&#8221;) to the PIPE Investor in
          connection with the PIPE Transaction (as each such term is defined in Note 12). On July 12, 2022, the PIPE Investor exercised its <ix:nonFraction name="erna:ClassOfWarrantOrRightExercised" id="Fact_bc5d557a32e2411092e001a56283a7ad" contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction>
          Pre-Funded Warrants at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_9b5b993e313e430da3692628ef65bf43" contextRef="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per share for an aggregate exercise price of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_2a72c58017d54564a8e2df846aa8f6f9" contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction>,000 in cash. The Company issued <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_e169b551d58d48d1953972ef4aacf72e" contextRef="c20220714_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction>
          shares of common stock to the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds. Following the exercise, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_9ecaf7255e1e48c49281bfb2117198de" contextRef="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> Pre-Funded
          Warrants remained outstanding. See Note 12 for more information related to the PIPE Transaction.</div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed27" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed28">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </div>
</ix:continuation>
        <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">
            <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed28" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed29">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC
              815-40,&#160;Derivatives and Hedging, Contracts in Entity&#8217;s Own Equity&#160;(&#8220;ASC 815-40&#8221;), as these warrants provide for a cashless settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40.&#160; These warrant
              liabilities were measured at fair value at inception and are then subsequently measured on a recurring basis, with changes in fair value presented within the Company&#8217;s statements of operations.</div>
</ix:continuation>
            <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed29" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed30">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed30" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed31">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common
              Warrants, which is considered a Level 3 fair value measurement.&#160; Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the Company&#8217;s control.&#160; A significant change in
              one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company&#8217;s warrant liabilities, which could also result in material non-cash gains or losses being reported in the
              Company&#8217;s consolidated statement of operations.</div>
</ix:continuation>
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed31" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed32">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
                </span> </div>
</ix:continuation>
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed32" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed33">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed33" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed34">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The estimated fair value of the Pre-Funded Warrants was deemed a Level 2 measurement as all significant inputs to the valuation model used to estimate the fair value of the Pre-Funded Warrants were directly
                  observable from the Company&#8217;s publicly-traded common stock. Upon exercise of the Pre-Funded Warrants on July 12, 2022, the Company reclassified the fair value of the Pre-Funded Warrants<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> to equity</span> as of such date.</span> </div>
</ix:continuation>
              <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed34" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed35">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
                </span></div>
</ix:continuation>
            </div>

          </div>

          <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed35" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed36">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="Fact_d22c0402d7b745a4a8919b05cf5ee11a" contextRef="c20220101to20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million in the aggregate, which was $<ix:nonFraction name="erna:OverSubscriptionAmountReceived" id="Fact_8fb0ab5891924572a86da5b8218008fd" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million more
            than the $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" id="Fact_79c91c8bd9b844a0be69a016a037fd21" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction> million proceeds received in the PIPE Transaction.&#160; The excess $<ix:nonFraction name="erna:OverSubscriptionAmountReceived" id="Fact_c7da8a8adf694f20a2c8008740fd3f97" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million represents an inducement to the purchaser to enter into the PIPE Transaction and was recorded in warrant liabilities expense in the accompanying consolidated
            statement of operations.&#160; Given the Company&#8217;s capital requirements and market conditions, the Company consummated this financing on market terms available at the time of the transaction. </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed36" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed37">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed37" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed38">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br />
        </div>
</ix:continuation>
        <div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                  Contents</a><br />
              </div>

            </div>

          </div>

          <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed38" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed39">
<div><br /></div>
</ix:continuation>
        </div>

        <div style="clear: both;">
          <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="Text_55fe4c73466947d584f99fad7ef80692" contextRef="c20220101to20220930" escape="true" continuedAt="Text_f78fd2e1a7ba4cc59c478f7fb3116b6f1"><ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed39" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed40">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company remeasured the fair value of the Common Warrants as of September 30, 2022. The following table presents the changes in the warrant
            liabilities from the issuance date (in thousands): </div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_f78fd2e1a7ba4cc59c478f7fb3116b6f1" continuedAt="Text_f78fd2e1a7ba4cc59c478f7fb3116b6f2"><ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed40" continuedAt="Text_78f7cdc4d9814bfb8c925eec5657cbed41">
<div>&#160;</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_78f7cdc4d9814bfb8c925eec5657cbed41"><ix:continuation id="Text_f78fd2e1a7ba4cc59c478f7fb3116b6f2">
<div>
            <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pre-Funded <span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrants</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> (Level 2)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> Common Warrants</span></div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>(Level 3)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>Total Warrant</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Liabilities</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at January 1, 2022</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_30b638baa60d43d79b2af54cce00f786" contextRef="c20211231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_f418af7b0e2b4fc9973f4e0f6b4a4c68" contextRef="c20211231_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_404d563b3b2a4c1da82a610120608e6f" contextRef="c20211231" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at March 9, 2022 (issuance date)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="Fact_ec2633eb628f4633b8cc9f6a5b1dac73" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,646</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="Fact_94561e180bf04fd1939eb47c70e2dc11" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,943</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="Fact_53040150b278457fb7bf494e3680fa29" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,589</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" id="Fact_abe8c62a25734b91a388d8fbaa2f247f" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,779</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" id="Fact_7d17e02c193e435d9c18950f155c6110" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,310</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" id="Fact_78e212dc44e14c6ca0f49ac85beb8a6e" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,089</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">Exercise of pre-funded warrants</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_de5e5a43efcb42d4b67c57998b562d5a" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">867</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_7e4afd05ae75432693a06064548a421f" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" id="Fact_447738d40cb64d72a27a7cee33ce652b" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">867</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at September 30, 2022</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_5e58f01f1ac4426c865aae1afbddfa13" contextRef="c20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_6662b61d084f464ab24fc829e86c5dcf" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_de0dfd48bff2411abb177b215eaa2ca5" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
            </div>
</ix:continuation></ix:continuation>
        </div>

        <div style="clear: both;">
        </div>

        <div style="font-family: 'Times New Roman';">&#160; </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
      <ix:nonNumeric name="erna:LesseeOperatingAndFinanceLeasesTextBlock" id="Text_841b46bb9bed4714a4243e1b8297e997" contextRef="c20220101to20220930" escape="true" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb991">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">LEASES</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb991" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb992">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb992" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb993">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <span style="font-style: italic; font-weight: bold;">Operating Leases</span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb993" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb994">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <br />
      </div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb994" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb995">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has operating leases for office and laboratory space in the borough of Manhattan in New York, New York and in Cambridge, Massachusetts, which expire in 2026 and 2028, respectively. On March 31, 2022, the
            Company entered into a facility lease in San Diego, California (the &#8220;San Diego Lease&#8221;) with Torrey Pines Science Center Limited Partnership for approximately <ix:nonFraction name="erna:OperatingLeaseArea" id="Fact_cc221559d9394aee8dc245cbcc43e53c" contextRef="c20220930" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">5,200</ix:nonFraction> square feet of laboratory and office space. The term of the San Diego Lease is <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_1c504f90a1ca4d46b648063076c9f9a1" contextRef="c20220930" format="ixt-sec:durmonth">62</ix:nonNumeric> months and
            the lease commencement date was April 19, 2022. The San Diego Lease will expire in June 2027. See Note 15 for information regarding an additional lease the Company entered into in October 2022.</span> </div>
</ix:continuation>
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb995" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb996">
<div>&#160;</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb996" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb997">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Base rent for the San Diego Lease is $<ix:nonFraction name="erna:BaseRentPerSquareFoot" id="Fact_2383c150bf3e4a74b3075e653085441d" contextRef="c20220101to20220930" unitRef="U005" decimals="2" scale="0" format="ixt:num-dot-decimal">6.35</ix:nonFraction>
          per square foot in the first year of the San Diego Lease, with a rent abatement for the second and third full months of the first year. The base rent will increase by approximately <ix:nonFraction name="erna:PercentageBaseRentIncreaseOnEachAnniversary" id="Fact_f0d8f2a36a8546c2a81042c0ec6b7615" contextRef="c20220930" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% on each anniversary of the lease commencement date. The Company is also required to pay its share of operating expenses and property taxes. The San Diego Lease provides for a one-time
          option to extend the lease term for an additional <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_6adf8f8a631f400d97ff793609aa0a5b" contextRef="c20220930" format="ixt-sec:durwordsen">five years</ix:nonNumeric> at the then fair rental value. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recorded a $<ix:nonFraction name="erna:InitialMeasurementOfOperatingLeaseROUAssets" id="Fact_45a6e57c4e64417abce233ad33368250" contextRef="c20220101to20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million right-of-use (&#8220;ROU&#8221;) asset and $<ix:nonFraction name="erna:InitialMeasurementOfOperatingLeaseLiabilities" id="Fact_d486aeff4a4e4740a68cefaf1d64cddd" contextRef="c20220101to20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million lease liabilities
            for the San Diego Lease.</span></div>
</ix:continuation>
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb997" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb998">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span></span></div>
</ix:continuation>
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb998" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb999">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb999" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9910">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the second quarter of 2022, the Company decided to
            consolidate its research and development efforts in Cambridge, Massachusetts, and the Company intends to sublease the San Diego laboratory and office space.&#160; As a result, the Company recognized an impairment charge of approximately $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_12b268002bcc457cbe993ceb8d82dfcd" contextRef="c20220101to20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction> million on the San Diego Lease ROU asset </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">during the nine months ended September 30, 2022, which is recorded in general and administrative expense on the condensed
            consolidated statements of operations. There was <ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_387bdeb3c4564fd58a8e657cc515ce28" contextRef="c20220701to20220930" unitRef="U002" decimals="-6" scale="6" sign="-" format="ixt-sec:numwordsen">no</ix:nonFraction> impairment charge recognized for the three months ended September 30, 2022.&#160;</span></div>
</ix:continuation>
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9910" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9911">
<div><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9911" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9912">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On March 5, 2022, the Company entered into an Agreement to Assign Space Lease with Regen Lab USA LLC (&#8220;Regen&#8221;) pursuant to which the Company
          agreed to assign its Brooklyn, New York lease (the &#8220;Brooklyn Lease&#8221;) to Regen. The effective date of the assignment was contingent upon, among other things, a consent from BioBat, Inc. (the &#8220;Landlord&#8221;). Additionally, Regen agreed to purchase
          certain equipment from the Company for $<ix:nonFraction name="erna:LesseeCommitmentToPurchaseProperty" id="Fact_ae3fce1988b6424f8c997a6220ce8ab8" contextRef="c20220305" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>, partly reimburse the Company $<ix:nonFraction name="erna:UnamortizedLeaseholdImprovements" id="Fact_ada214d8ff1a48718efa2b514b5fcad7" contextRef="c20220305" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> toward certain existing unamortized leasehold improvements, and to reimburse the Company for the existing security deposit the Company had under the Brooklyn Lease of approximately
          $<ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" id="Fact_71f7ff82f6d84c718d162cc3a6abd2dd" contextRef="c20220305" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,000</ix:nonFraction>.</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;">
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9912" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9913">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;"> <br />
        </div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;">
          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">
            <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9913" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9914">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">O<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">n March 25, 2022, the Company entered into an Assignment and Assumption of Lease Agreement (the &#8220;Assignment Agreement&#8221;) with Regen,
                which included the Landlord&#8217;s consent to the assignment. The effective date of the assignment was March 28, 2022.&#160; Under the Assignment Agreement, Regen (i) accepted the assignment of the Brooklyn Lease; (ii) assumed all of the obligations,
                liabilities, covenants and conditions of the Company&#8217;s as tenant under the Brooklyn Lease; (iii) assumed and agreed to perform and observe all of the obligations, terms, requirements, covenants and conditions to be performed or observed by
                the Company under the Brooklyn Lease; and (iv) made all of the representations and warranties under the Brooklyn Lease with the same force and effect as if Regen had executed the Brooklyn Lease originally as the tenant.</span></div>
</ix:continuation>
            <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9914" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9915">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br />
            </div>
</ix:continuation>
            <a style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;" id="z_Hlk100163005"></a><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9915" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9916">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">N<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">otwithstanding Regen&#8217;s assumption of the Brooklyn Lease, the Company remains liable and responsible for the due keeping, and full
                performance and observance, of all the provisions of the Brooklyn Lease applicable to the tenant thereunder.&#160;&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As a result of the Assignment Agreement, the Company wrote off the remaining ROU asset balance and the corresponding lease liability</span>.</div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9916" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9917">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;"> <br />
        </div>
</ix:continuation>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
              Contents</a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9917" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9918">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company accounts for leases under ASC 842,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: normal;">&#160;Leases</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. Operating leases are included in
          &#8220;Right-of use assets - operating leases&#8221; within the Company&#8217;s balance sheets and represent the Company&#8217;s right to use an underlying asset for the lease term. The Company&#8217;s related obligation to make lease payments are included in &#8220;Operating lease
          liabilities, non-current&#8221; and &#8220;Operating lease liabilities, current&#8221; within the Company&#8217;s balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Because the
          rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense for lease
          payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet and are recognized as lease expense on a straight-line basis over the lease term.</span></div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9918" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9919">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9919" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9920">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as
        payments for insurance, tax payments and other miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are
        expensed when the obligation for those payments is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9920" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9921">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9921" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9922"><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" id="Text_61c9f6b734834163875eb001b9438a4f" contextRef="c20220101to20220930" escape="true" continuedAt="Text_f14d20fcf9334cfda3355d6ec2014ed01">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the net operating lease expenses were as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9922" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9923"><ix:continuation id="Text_f14d20fcf9334cfda3355d6ec2014ed01" continuedAt="Text_f14d20fcf9334cfda3355d6ec2014ed02">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9923" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9924"><ix:continuation id="Text_f14d20fcf9334cfda3355d6ec2014ed02" continuedAt="Text_f14d20fcf9334cfda3355d6ec2014ed03">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" colspan="6"><span style="font-weight: bold;">Three months ended September 30,</span><br />
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br />
              </div>
            </td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" colspan="2"><span style="font-weight: bold;">2021</span> <br />
            </td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating lease expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_f714280b44904704b7f470fdfb458aca" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_59ab5ebce2b44c799ad40e2efa2286c2" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">187</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Sublease income</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_71fb24faa1a44db28d702768bff804e9" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_476656a0b6014c77b747b5dc8c54cd28" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Variable lease expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_8220a5079b844a8790df2dd75f4c7ea0" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">60</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_c7e6c3e8ea52415f866656fab0d54275" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total lease expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LeaseCost" id="Fact_2186821e7d1f4a86b91ab9aec9b77b14" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LeaseCost" id="Fact_94ae51b470784d49b340c8f287fbf35b" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">172</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9924" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9925"><ix:continuation id="Text_f14d20fcf9334cfda3355d6ec2014ed03" continuedAt="Text_f14d20fcf9334cfda3355d6ec2014ed04">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9925" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9926"><ix:continuation id="Text_f14d20fcf9334cfda3355d6ec2014ed04">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;"><span style="font-weight: bold;">Nine months ended September 30,</span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-weight: bold; white-space: nowrap;">2022</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;"><span style="font-weight: bold;">2021<br />
                </span></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating lease expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_1675da0fd8534879b85cbaa44393175d" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">476</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_e8744662352648bda34f17cb13832299" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">501</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Sublease income</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_3230628a26cc4601bac365b26e5f782c" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">63</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_4281c7ad20cf47cdae4155eedab0e216" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Variable lease expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_0d0bf91fc5ba456d96f26eb4c39cc647" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">113</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_30953eecbb0342868deca75ee3950b2b" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total lease expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LeaseCost" id="Fact_240181d4d9ad443d87844394cc362625" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">526</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LeaseCost" id="Fact_b98ef3b955034ecea3679b13afa71434" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">455</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9926" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9927">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation>

      <div>
        <ix:nonNumeric name="erna:OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" id="Text_0117423f6c5d4e8889085a4954592f89" contextRef="c20220101to20220930" escape="true" continuedAt="Text_9ce05cdf8ceb4903a92c545b9632915b1"><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9927" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9928">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The tables below show the beginning
          balances of the operating ROU assets and lease liabilities as of January 1, 2022 and the ending balances as of September, 2022, including the changes during the period (in thousands).</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_9ce05cdf8ceb4903a92c545b9632915b1" continuedAt="Text_9ce05cdf8ceb4903a92c545b9632915b2"><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9928" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9929">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_9ce05cdf8ceb4903a92c545b9632915b2" continuedAt="Text_9ce05cdf8ceb4903a92c545b9632915b3"><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9929" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9930">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br />
          </span></div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_9ce05cdf8ceb4903a92c545b9632915b3" continuedAt="Text_9ce05cdf8ceb4903a92c545b9632915b4"><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9930" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9931">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2"><span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ROU Assets</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease ROU assets at
                January 1, 2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_6f5b31eacfde450ba3ad63a35c3c9b67" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,567</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" rowspan="1"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Initial measurement of operating lease ROU assets</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfOperatingLeaseROUAssets" id="Fact_9c6d01a41f914d1884150a31e619a3a8" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,706</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Amortization of operating lease
                ROU assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_c92d138208584f03b3c3efa9bda66763" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">267</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" rowspan="1"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Impairment of ROU assets</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_7e62267a9ba7400ba8fcf37f0bfed752" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">772</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">Remeasurement of ROU asset<br />
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="erna:RemeasurementOfOperatingLeaseRightOfUseAsset" id="Fact_f552f885b9fd45b49bce7b44e59549f1" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Write off of ROU asset due to lease termination</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="erna:WriteOffOfOperatingLeaseRightOfUseAsset" id="Fact_bf8cc10dfbcc4c8398f529c5a6d83329" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease ROU assets at
                September 30, 2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_fe2834e7ffe54a0dbf8e59e90e4cb210" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,912</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_9ce05cdf8ceb4903a92c545b9632915b4" continuedAt="Text_9ce05cdf8ceb4903a92c545b9632915b5"><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9931" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9932">
<div style="display:none;"><br /></div>
<div style="letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-indent: 0px; text-transform: none;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_9ce05cdf8ceb4903a92c545b9632915b5"><ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9932" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9933">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2"> <span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Liabilities</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease liabilities at
                January 1, 2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_d2531558136b45ff9934795c981343ae" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" rowspan="1"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Initial measurement of operating lease liabilities</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="erna:InitialMeasurementOfOperatingLeaseLiabilities" id="Fact_5365a408e9d34f07925f723025617296" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,706</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Principal payments on operating
                lease liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="erna:PrincipalPaymentsOnOperatingLeaseLiabilities" id="Fact_f51173cd0c0344f2b641d134eefa50cf" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">223</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Write off of operating lease liability due to lease termination</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="erna:WriteOffOfOperatingLeaseLiability" id="Fact_50939fb666e546af8c308f21fd03d55f" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease liabilities at
                September 30, 2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_36bbdf685c2b46c29db293eab4e6e9e0" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,752</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less non-current portion</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_f6cd93ed80b24f31b20d838b3269814c" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,317</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Current portion at September 30,
                2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_377d0ad909d54d5390510c06beefc8d0" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">436</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9933" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9934">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9934" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9935">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">As of September 30, 2022, the Company&#8217;s operating leases had a weighted-average
        remaining life of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_53f1f92662cb4919a08b7a6db4c8de53" contextRef="c20220930" format="ixt-sec:duryear">4.9</ix:nonNumeric> years with a weighted-average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_c1b072234c6c42c9bef4ea6992fb4321" contextRef="c20220930" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">8.97</ix:nonFraction>%.&#160; <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_e2b159b4095a42d88f56aa812e76c0ed" contextRef="c20220101to20220930" escape="true" continuedAt="Text_a1f0cdd7e6a9414c8fb71f8cae10a9b11"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; font-variant: normal;">The maturities of the operating lease liabilities are as follows (in thousands):</span></ix:nonNumeric></div>
</ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9935" continuedAt="Text_1a5972b2bb1d4eebbc25e7047a73fb9936"><ix:continuation id="Text_a1f0cdd7e6a9414c8fb71f8cae10a9b11" continuedAt="Text_a1f0cdd7e6a9414c8fb71f8cae10a9b12">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_1a5972b2bb1d4eebbc25e7047a73fb9936"><ix:continuation id="Text_a1f0cdd7e6a9414c8fb71f8cae10a9b12">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2022</span><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_4f649176fde24c4191ea8d77cf4603f0" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">166</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2023</span><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_c230693a7dec454e87cd3c8816446b8f" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">673</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2024</span><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_3e0000f665374646a40ad4a119f3e568" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">688</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2025</span><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_27d67a99fccd4b9eb0af560af710101b" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">703</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2026</span><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_6b9ec79b6ad34c079beb422dff1ef3b1" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">708</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Thereafter</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="erna:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" id="Fact_2bcfceb944ae4fd691a94b23ad03427c" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">470</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">Total payments</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"> <br />
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_915ec453bc30406aba50958ea851af6b" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,408</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" rowspan="1">Less imputed interest</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_8e9b0d0a8797415c8ad5fc16174b45a1" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">656</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">Total operating lease liabilities</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_72f45571f3204930a9680f7f13856fec" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,752</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <div><br />
      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Text_5afc5ac629e546bdb31169d1b63098b8" contextRef="c20220101to20220930" escape="true" continuedAt="Text_4de4612be10b446f89ffe31d1eab17731">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6)<br />
              </td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL<br />
                </div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17731" continuedAt="Text_4de4612be10b446f89ffe31d1eab17732">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17732" continuedAt="Text_4de4612be10b446f89ffe31d1eab17733">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In 2018, the Company acquired IRX Therapeutics (&#8220;IRX&#8221;), which was accounted for as a business combination. The Company recorded IPR&amp;D in the
          amount of $<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_75e4b0fbb28e4c5cad098fd10b88c43d" contextRef="c20181231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million, which represented the fair value assigned to technologies that were acquired in connection with the IRX
          acquisition and which have not reached technological feasibility and have no alternative future use. IPR&amp;D assets acquired in a business combination are considered to be indefinite lived until the completion or abandonment of the associated
          research and development projects. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;D assets, these assets are then deemed
          definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;D assets,
          calculated as the excess of carrying value of the IPR&amp;D assets over fair value.</div>
</ix:continuation>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17733" continuedAt="Text_4de4612be10b446f89ffe31d1eab17734">
<div><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17734" continuedAt="Text_4de4612be10b446f89ffe31d1eab17735">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company also recorded goodwill in the amount of $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_1f05ffc379ed4ab4ae7bd984e3b41434" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>
          million related to the IRX acquisition. Goodwill and indefinite-lived IPR&amp;D assets are not amortized but are tested for impairment annually, or more frequently if the Company becomes aware of any events occurring or changes in circumstances
          that indicate that the fair value of the entity is less than its carrying values.</div>
</ix:continuation>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17735" continuedAt="Text_4de4612be10b446f89ffe31d1eab17736">
<div><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17736" continuedAt="Text_4de4612be10b446f89ffe31d1eab17737">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In June 2022, the Company received results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III or IVA squamous cell carcinoma of the oral
            cavity. The IRX-2 multi-cytokine biologic immunotherapy represents substantially all the fair value assigned to the technologies of IRX that the Company acquired. Despite outcomes that favored IRX-2 in certain predefined subgroups, the INSPIRE
            trial did not meet the primary endpoint of Event-Free Survival (at two years of follow up). Significant additional clinical development work would be required to advance IRX-2 in the form of additional Phase 2 and 3 studies to further evaluate
            the treatment effect of IRX-2 in patient subgroups and in combination with checkpoint inhibitor therapies. The INSPIRE trial was the only Company-sponsored study of IRX-2. IRX-2 has been studied externally in other clinical settings outside of
            head and neck cancer in the form of investigator sponsored trials, which have either ended or are not currently active. Based on the totality of available information, the Company currently does not have plans to further develop the IRX-2
            product candidate. As such, the Company determined that the carrying value of the IPR&amp;D asset was impaired and recognized a non-cash impairment charge of approximately $<ix:nonFraction name="us-gaap:ImpairmentOfOngoingProject" id="Fact_7f19dda955bd4e8981dd158780bfa56b" contextRef="c20220401to20220630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million on the condensed consolidated statement of operations during the second quarter of 2022, which reduced the value of the asset to <ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_7c4c9dac745d44c7a2e8ffb2e6141058" contextRef="c20220630" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">zero</ix:nonFraction>.</span></div>
</ix:continuation>
        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17737" continuedAt="Text_4de4612be10b446f89ffe31d1eab17738">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_4de4612be10b446f89ffe31d1eab17738">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As of September 30, 2022, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair value of
          the entity is less than its carrying value of goodwill. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the
          decline in the Company&#8217;s stock price from $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_e92534bee4f0498485817d6ece09b9a4" contextRef="c20220630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.40</ix:nonFraction> per share as of June 30, 2022 to $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_2672ebdc756e448bbba54843db8f0278" contextRef="c20220930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.94</ix:nonFraction> per share as of September 30, 2022, the Company determined that there were indications of impairment. Accordingly, the Company proceeded to the first step in the
          quantitative assessment of impairment and determined that the fair value of the reporting unit exceeded the carrying amount of goodwill, and therefore, the goodwill was <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_e0e40dceb9d6474dbe028c8d3891b9f3" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t impaired as of September 30, 2022. </div>
</ix:continuation>

        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-size: 10pt;"> </span></div>

    <div>
      <div>
        <ix:nonNumeric name="erna:ChiefExecutiveOfficerSeparationAgreementTextBlock" id="Text_6ceabdf972514268a0aae5473fc3ec3b" contextRef="c20220101to20220930" escape="true" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e1">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                  <div style="font-weight: bold;">7)</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="font-weight: bold;">CEO SEPARATION AGREEMENT</div>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
      </div>

      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e1" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e2">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e2" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e3">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">On May 24, 2022, Dr. Howard J. Federoff resigned as the Company&#8217;s Chief Executive
        Officer and President effective May 26, 2022. In connection with Dr. Federoff&#8217;s resignation, the Company entered into a&#160;<span style="color: rgb(0, 0, 0);">Separation Agreement and General Release with Dr. Federoff (the &#8220;Separation Agreement&#8221;),
          pursuant to which Dr. Federoff resigned from his positions as Chief Executive Officer and as an officer, director and employee of the Company and all subsidiaries. Dr. Federoff&#8217;s resignation from the Board was not due to any disagreement with the
          Company on any matter relating to the Company&#8217;s operations, policies or practices. In consideration for Dr. Federoff&#8217;s execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Dr. Federoff will
          receive following benefits under the Separation Agreement:</span></div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e3" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e4">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e4" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e5">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $<ix:nonFraction name="us-gaap:PaymentsForPostemploymentBenefits" id="Fact_5780bd48292d4ec98ecf15649e2160de" contextRef="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million, representing Dr. Federoff&#8217;s
                target bonus for 2022;</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e5" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e6">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e6" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e7">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">payment of Dr. Federoff&#8217;s annual base salary for a period of twelve months after the expiration of the applicable revocation period (the &#8220;Separation Period&#8221;), for a total gross amount equal to $<ix:nonFraction name="erna:PaymentToOfficerBaseSalary" id="Fact_3cc98728802448f1ac4f1d69c57baa3e" contextRef="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million;</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e7" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e8">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e8" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e9">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">payment of Dr. Federoff&#8217;s premiums for continued health benefits provided under COBRA for the Separation Period;</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e9" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e10">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e10" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e11">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">full acceleration of the vesting of all outstanding options (with the exception of the Milestone Grant (as defined below) options) that would have vested during the Separation Period, and such options,
                together with outstanding options that vested prior to the separation date, representing collectively approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_b1d534549dad4a8cae8d6bdc40180383" contextRef="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">76,000</ix:nonFraction>
                shares of common stock, may be exercised for a period of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_5e928d07e4ee449d95a4c5ac3948ed01" contextRef="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" format="ixt-sec:durwordsen">thirty-six months</ix:nonNumeric> after the separation date (see Note 11 for
                modification accounting impact);</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e11" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e12">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e12" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e13">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><span style="color: rgb(0, 0, 0); font-size: 10pt;">acceleration and vesting of 25/36</span><span style="font-size: 10pt;"><sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><span style="color: rgb(0, 0, 0);">&#160;of the Milestone Grant options, representing collectively approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_9d63c2593c694653b99329dbbc954272" contextRef="c20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction> shares of
                    common stock, may be exercised for a period of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_7a3b7e327ffc49b7832de9bf64040bf8" contextRef="c20220524to20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" format="ixt-sec:durwordsen">thirty-six months</ix:nonNumeric> after the separation date (see Note 11 for modification
                    accounting impact); and</span></span></div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e13" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e14">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e14" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e15">
<table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $<ix:nonFraction name="erna:SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" id="Fact_98debbbbdec4438689b462743d9060e5" contextRef="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million, representing the value Dr.
                Federoff would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period, assuming the performance metrics were waived and
                assuming a per share value of $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_2be37a5534644febb55222d8ee1be18c" contextRef="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">16.20</ix:nonFraction>.</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e15" continuedAt="Text_164252dfb29e48b08f57ab94c66c2e7e16">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_164252dfb29e48b08f57ab94c66c2e7e16">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Separation Agreement also includes certain other customary representations,
        warranties and covenants of Dr. Federoff, and provides for reimbursement of certain expenses incurred by Dr Federoff. The Separation Agreement supersedes all other agreements or arrangements between Dr. Federoff and the Company regarding the
        subject matter of the agreement, including those with respect to severance payments and benefits.</div>
</ix:continuation>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <br />
      </div>

    </div>

    <div><span style="font-size: 10pt;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Text_126d9fc4c1f1413b8e9ade1b48543c02" contextRef="c20220101to20220930" escape="true" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031021">
<div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-weight: bold;">RELATED PARTY TRANSACTIONS</span></div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

    </div>
</ix:nonNumeric>
    <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031021" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031022">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On September 9, 2022, the Company entered into
        a Master Services Agreement (the &#8220;MSA&#8221;) with Factor Bioscience Inc. (&#8220;Factor&#8221;), pursuan</span>t to which Factor has agreed to provide services to the Company as agreed between the Company and Factor and as set forth in one or more work orders under
      the MSA, including the first work order included in the MSA. Under the first work order, Factor has agreed to provide the Company with mRNA cell engineering research support services, including access to certain facilities, equipment, materials and
      training, and the Company has agreed to pay Factor an initial fee of $<ix:nonFraction name="erna:MasterServiceAgreementInitialFeesPayable" id="Fact_6aa5d70eadda40eca74ba44c34eaa9e5" contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million, payable in <ix:nonFraction name="erna:NumberOfMonthlyInstallmentsForFeesPayable" id="Fact_bb5cebeae4564b3ba4d998927aa212f9" contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">twelve</ix:nonFraction> equal monthly installments of approximately $<ix:nonFraction name="erna:RelatedPartyTransactionPeriodicFeesPaymentAmount" id="Fact_856e99631b5b426aab5e698cea63598f" contextRef="c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million.
      Following the initial 12-month period, the Company has agreed to pay Factor a monthly fee of $<ix:nonFraction name="erna:MonthlyMasterServicesAgreementFeesPayable" id="Fact_045710f0cba54dcf86d345dc8e96da35" contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million until such time as the first work
      order under the MSA is terminated. The Company paid a deposit of $<ix:nonFraction name="erna:DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" id="Fact_59cdd6b5c3674b14b4a8b4838a47e2e5" contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million, which will be applied to the last month of the first work
      order.</div>
</ix:continuation>
    <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031022" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031023">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
    </div>
</ix:continuation>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
            Contents</a><br />
        </div>

      </div>

    </div>

    <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031023" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031024">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The
      Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with <ix:nonNumeric name="erna:NoticePeriodForFirstTerminationOfContract" id="Fact_18e02f788240462ca19c51eded213b52" contextRef="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" format="ixt-sec:durday">120</ix:nonNumeric>
      days&#8217; prior notice. Factor may terminate such work order only on and after the fourth anniversary of the date of the MSA, su<span style="font-family: 'Times New Roman';">bject to providing the Company with <ix:nonNumeric name="erna:NoticePeriodForFirstTerminationOfContract" id="Fact_20242649880d4586b48d2964110340f9" contextRef="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" format="ixt-sec:durday">120</ix:nonNumeric> days&#8217; prior notice. The MSA contains customary confidentiality provisions and representations and warranties of the parties, and the MSA may be terminated by ether party
        upon <ix:nonNumeric name="erna:NoticePeriodForSupersedingTerminationProvisions" id="Fact_4ae61c4572b341828f8f0bcce26f5666" contextRef="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior notice, subject to any superseding termination provisions contained in a particular work order.</span></div>
</ix:continuation>
    <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031024" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031025">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
    </div>
</ix:continuation>
    <div>
      <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031025" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031026">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">In connection with entering into the MSA, on September
          9, 2022, Factor&#8217;s subsidiary, Factor Limited, entered into a waiver agreement (the &#8220;Waiver Agreement&#8221;) with Brooklyn LLC, pursuant to which Factor Limited agreed to waive payment of $<ix:nonFraction name="erna:AgreedWaivePayment" id="Fact_0e4081618fdc4266a0cf9c63f774074e" contextRef="c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million otherwise payable to it (the &#8220;License Fee Obligation&#8221;) in October 2022 by Brooklyn LLC under a license agreement by and among Factor Limited, Novellus Ltd., and
          Brooklyn LLC.&#160; See Note 10, </span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">License Agreements</span><span style="font-size: 10pt; font-family: 'Times New Roman';">, for more information on this
          agreement. </span><span style="font-family: 'Times New Roman';">Under the terms of the Waiver Agreement, the License Fee Obligation is waived conditionally on the Company paying Factor Inc. amounts due under the MSA.</span></div>
</ix:continuation>
    </div>

    <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031026" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031027">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"> </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
      </span></div>
</ix:continuation>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">
      <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031027" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031028">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As a
        result of entering into the Waiver Agreement and the MSA on September 9, 2022, the Company recognized $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_c14eb8eff7594d629fa09fce4722a351" contextRef="c20220701to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million in research and
        development expense, as the license does not have an alternative future use, and a corresponding liability.<br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031028" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d031029">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d031029" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d0310210">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On
        September 1, 2022, Novellus and Eterna entered into a Second Amendment to the Limited Waiver and Assignment Agreement (the &#8220;Waiver and Assignment Agreement&#8221;) with Drs. Matthew Angel and Christopher Rohde (the &#8220;Founders&#8221;) whereby the Company has
        agreed to be responsible for all future, reasonable and substantiated legal fees, costs, settlements and judgments incurred by the Founders, the Company or Novellus for certain claims and actions and any pending or future litigation brought against
        the Founders, Novellus and/or the Company by or on behalf of the Westman and Sowydra legal matters described in Note 10 (the &#8220;Covered Claims&#8221;). The Founders will continue to be solely responsible for any payments made to satisfy a judgement or
        settlement of any pending or future wage act claims. Under the Waiver and Assignment Agreement, the Founders agreed that they are not entitled to, and waived any right to, indemnification or advancement of past, present or future legal fees, costs,
        judgments, settlement or other liabilities they may have been entitled to receive from the Company or Novellus in respect of the Covered Claims. The Company and the Founders will share in any recoveries up to the point at which the parties have
        been fully compensated for legal fees, costs and expenses incurred, with the Company retaining any excess recoveries. The Company has the sole authority to direct and control the prosecution, defense and settlement of the Covered Claims.</div>
</ix:continuation>
      <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d0310210" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d0310211">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span></div>
</ix:continuation>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">
        <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d0310211" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d0310212">
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On Sept<span style="font-size: 10pt;">ember
              6, 2022, the </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company entered into an
              assignment and assumption of contracts agreement (the &#8220;Assignment and Assumption Agreement&#8221;) with Factor, pursuant to which the Company assumed certain contracts with third parties that Factor had previously entered into in anticipation of
              entering into a sublease for premises in Somerville, Massachusetts.&#160; In October 2022, the Company entered into a sublease for the premises (see Note 15).&#160; Under the Assignment and Assumption Agreement, the Company agreed to reimburse Factor
              for costs already incurred or paid by it under the assumed contracts in the amount of approximately $<ix:nonFraction name="erna:ReimburseCostsIncurredOrPaid" id="Fact_42deb91aba4445b8a4b9c6bd11af6700" contextRef="c20221001to20221031_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million, and the Company
              assumed the future obligations under these contracts, which relate to the design and build-out of the subleased space.</span></span></div>
</ix:continuation>
        <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d0310212" continuedAt="Text_dd0d9d609c0942f2b8ae44b1d2d0310213">
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span></div>
</ix:continuation>
        <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0pt; text-transform: none;">
          <ix:continuation id="Text_dd0d9d609c0942f2b8ae44b1d2d0310213">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The
            MSA, any work orders under the MSA, the Waiver Agreement, the Waiver and Assignment Agreement, and the Assignment and Assumption Agreement have been deemed related party transactions, as the Company&#8217;s Interim Chief Executive Officer, Dr.
            Matthew Angel, is also the Chairman and Chief Executive Officer of Factor and the Director of Factor Limited.</div>
</ix:continuation>

          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <br />
          </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                  Contents</a><br />
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_11b1ef32b2cd47caa90778a9d86a8757" contextRef="c20220101to20220930" escape="true" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f1">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                  <div style="text-align: left;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9)</span>
                  </div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold;">ACCRUED EXPENSES AND OTHER LIABILITIES</div>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f1" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f2">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>

        <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_be17dfdfa79a4b779d61a265c3966534" contextRef="c20220101to20220930" escape="true" continuedAt="Text_bb7415670b464417aa6dbd37397e30531"><ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f2" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f3">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following (in thousands):</div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_bb7415670b464417aa6dbd37397e30531" continuedAt="Text_bb7415670b464417aa6dbd37397e30532"><ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f3" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f4">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_bb7415670b464417aa6dbd37397e30532"><ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f4" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f5">
<table cellspacing="0" cellpadding="0" border="0" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold; text-align: center; padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                <div>September 30,</div>
                <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</span></div>
              </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">December 31,<br />
                <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued compensation </div>
              </td>

    <td valign="bottom" style="font-family: &#38;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td valign="bottom" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_8600be0b34324917b8291cab948fe82b" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,701</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="font-family: &#38; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td valign="bottom" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_d52f04c30f5046118bee60c3fdec7bcf" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">656</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="font-family: &#38; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued research and development expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="erna:AccruedResearchAndDevelopmentExpenses" id="Fact_d63d0d3959774aa8b8e2496dd81676f2" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">373</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="erna:AccruedResearchAndDevelopmentExpenses" id="Fact_ac782b051bba45f1ab2385e0580919b7" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued general and administrative expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="erna:AccruedGeneralAndAdministrativeExpenses" id="Fact_d51d691816c84167aae9b5de677f3d94" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,156</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="erna:AccruedGeneralAndAdministrativeExpenses" id="Fact_851bed016c0a4fc7a88e95d567863357" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">371</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_0b4c6b0c0d2a4519beb8a038cc1b039f" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,230</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_1c55af4a38a44652b7aeb6c87bac4965" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,249</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <div><ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f5" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f6"><ix:nonNumeric name="us-gaap:OtherLiabilitiesTableTextBlock" id="Text_30b8ae52d9f0481d8d28fd2e9a1e050f" contextRef="c20220101to20220930" escape="true" continuedAt="Text_b0aad591d6214643807bd9dd9e9058221">
<div><br />
          </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f6" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f7"><ix:continuation id="Text_b0aad591d6214643807bd9dd9e9058221" continuedAt="Text_b0aad591d6214643807bd9dd9e9058222">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other liabilities consisted of the following (in thousands):</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f7" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f8"><ix:continuation id="Text_b0aad591d6214643807bd9dd9e9058222" continuedAt="Text_b0aad591d6214643807bd9dd9e9058223">
<div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f8" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f9"><ix:continuation id="Text_b0aad591d6214643807bd9dd9e9058223" continuedAt="Text_b0aad591d6214643807bd9dd9e9058224">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f9" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f10"><ix:continuation id="Text_b0aad591d6214643807bd9dd9e9058224">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">September 30,</div>
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2021<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Current portion of License Fee Obligation<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="erna:CurrentPortionOfLicenseFeeObligation" id="Fact_4fb7d48e140249f2b86f1a05cee7777e" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,750</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="erna:CurrentPortionOfLicenseFeeObligation" id="Fact_ccb12af633074fa0b20fbd79584c8efb" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Insurance policy premiums</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="erna:InsurancePolicyPremiums" id="Fact_1e77684dc27842b89c1638bb12a489c4" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">898</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="erna:InsurancePolicyPremiums" id="Fact_0d1efd98f995482e84e4f76327a88381" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">247</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1">Total other current liabilities<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_cba88dfea7ea402b82f20dc479313c81" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,648</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_2405aff9adff498ba4c19ea652862b74" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">247</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">Long term portion of License Fee Obligation<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:LongTermPortionOfLicenseFeeObligation" id="Fact_3f458e152a594affa7286afdffd1bfe2" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,642</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="erna:LongTermPortionOfLicenseFeeObligation" id="Fact_f724f89a1c7f44ae99f5d2b6eadb6ce4" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesNoncurrent" id="Fact_b90f90e12386498a9773106cb4ead436" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesNoncurrent" id="Fact_295d76a02a8e46cfbc8648ece8c9b434" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total other liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherLiabilities" id="Fact_ab026b9a99c24a4e820d9211c3f093d6" contextRef="c20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherLiabilities" id="Fact_9af810c7949c48a09b5ff66ca343d640" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f10" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f11">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f11" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f12">
<div><span style="font-family: 'Times New Roman';"> </span><br />
          </div>
</ix:continuation>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f12" continuedAt="Text_f6ffa604b17f42379bae5b66e6fd697f13">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_f6ffa604b17f42379bae5b66e6fd697f13">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued compensation at September 30,
                2022 includes approximately $<ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_d1957ab0e61e4eb6827cbcb9357198a8" contextRef="c20220930_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million of severance, of which, approximately $<ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_d81f07e7ca80455ea1261c948a051898" contextRef="c20220930_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million relates to severance for Dr. Federoff pursuant to the Separation Agreement discussed above.</span> </span>Accrued general and administration expenses at
            September 30, 2022 includes $<ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_cf7d3c8f390e440989e6280c729ceca4" contextRef="c20220930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million for legal-related matters.</span><br />
        </div>
</ix:continuation>

        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_4cf1c0a45d11426480401321d6af121c" contextRef="c20220101to20220930" escape="true" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">10)<br />
              </span> </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">COMMITMENTS AND CONTINGENCIES</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e1" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e2">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e2" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">Legal Matters<br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e3" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e4">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>
</ix:continuation>
      <div style="text-align: justify; text-indent: 28.9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e4" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated
          with such actions are expensed as incurred. In addition, the Company assesses the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
          reasonably estimated.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e5" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e6">
<div><br /></div>
</ix:continuation>
      <div style="text-align: justify;">
        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e6" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e7">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); text-indent: 36pt;"><span style="text-decoration: underline;"><span style="font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dhesh Govender v. Brooklyn
              Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)</span></span></div>
</ix:continuation>
        <div style="text-align: justify;"> <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e7" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e8">
<div><br /></div>
</ix:continuation>
          <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e8" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">On
            or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn LLC and certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh
            Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges that Brooklyn LLC and certain of its officers and directors (&#8220;defendants&#8221;) engaged in unlawful and discriminatory
            conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire
            him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell
            reprogramming technology to Brooklyn LLC, he was promised a $<ix:nonFraction name="erna:LossContingencyDamagesSoughtExpectedSalary" id="Fact_58298f1de2174aadb40d035bfc5d0752" contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million salary and <ix:nonFraction name="erna:LossContingencyDamagesSoughtExpectedEquityPercentage" id="Fact_e6dbb22f5e284e7089a3e9efd5340fbf" contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% of the equity of Brooklyn LLC. Based on these and other allegations, plaintiff seeks damages of not less than $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" id="Fact_ca3bdd3d9be145a6afa3d341ea9d4a3c" contextRef="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction> million<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">. By Order dated November 10,&#160;2021, the Court granted defendants&#8217; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn
              LLC.&#160; Govender thereafter filed his Statement of Claim (the &#8220;Demand&#8221;) with the American Arbitration Association (&#8220;AAA&#8221;), Case No. 01-21-0017-9417, on December 15,&#160;2021 against the same defendants, and served it on defendants&#8217; counsel on
              February 3,&#160;2022. In his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender <ix:nonFraction name="erna:LossContingencyDamagesSoughtExpectedEquityPercentage" id="Fact_d139082c72e446d58a6e9d5f7547a94b" contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% of the equity of Brooklyn LLC and to employ Govender at a $<ix:nonFraction name="erna:LossContingencyDamagesSoughtExpectedSalary" id="Fact_159f31ab295142a1bbf479891465d28c" contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against Brooklyn LLC and Cherington based on the breach of these same promises and a
              claim for quantum meruit against the Brooklyn LLC. In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" id="Fact_4885b66ea7f340dea5bb2236bcb11e18" contextRef="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">100</ix:nonFraction> million and is seeking damages in an amount to be determined at the hearing. Defendants filed an answering statement to the Demand on February 28,&#160;2022 and the
              parties have selected a <ix:nonFraction name="erna:LossContingencyNumberOfArbitrationPanel" id="Fact_db4620d03bad48f5b9928e22d089c5ab" contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-member arbitration panel. The date on which arbitration is
                scheduled to begin has not yet been set. Defendants intend to vigorously defend themselv</span>es against these claims.</span> At this stage in the litigation, the Company is not able to predict the probability of a favorable or unfavorable
            outcome. </div>
</ix:continuation>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: justify;">
                <div>
                  <div style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e9" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e10">
<div><br /></div>
</ix:continuation>
                    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
                      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e10" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e11">
<div style="display:none;"><br /></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: 36pt;"><span style="text-decoration: underline;">Emerald Private Equity Fund, LLC Matter</span></div>
</ix:continuation>
                      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e11" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
                        </span> </div>
</ix:continuation>
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e12" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e13">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#8220;Emerald&#8221;), a stockholder of Eterna, made a demand pursuant to 8
                          Del. C. 220 to inspect certain books and records of Eterna. The stated purpose of the demand was to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock
                          certificates, including investigating whether: (i) Eterna&#8217;s stock certificates were issued in accordance with the Merger Agreement; (ii)&#160;certain restrictions on the sale of Eterna common stock following the Merger were proper and
                          applied without favor; (iii) anyone received priority in post-Merger issuances of Eterna&#8217;s stock certificates that allowed them to benefit from an increase in the trading price of Eterna&#8217;s common stock; and (iv) it<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> should pursue remedial
                            measures and/or report alleged misconduct to the SEC. Eterna responded to the demand letter and produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement
                            entered into among the parties, including certain additional stockholders who subsequently joined as parties to such agreement. In October 2021, Emerald requested that Eterna produce additional information related to the
                            authority, purpose and justification for the restriction imposed on the sale of Eterna common stock following the Merger and the timing of share delivery to Eterna stockholders, following which request Eterna agreed to produce
                            certain additional information and emails relating to these topics.</span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e13" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e14">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
                          </span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e14" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e15">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                          <div class="BRPFPageFooter" style="width: 100%;"></div>

                          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

                          <div class="BRPFPageBreak" style="page-break-after: always;">
                            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

                          <div class="BRPFPageHeader" style="width: 100%;">
                            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of Contents</a><br />
                            </div>

                          </div>

                        </div>

                        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">
                          <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e15" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e16">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On March 30,&#160;2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and former directors of the
                              Company, and the Company&#8217;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims for breach
                              of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty. Emerald&#8217;s counsel expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor on
                              behalf of individual stockholders whom counsel represents in addition to Emerald (collectively, the &#8220;Emerald Plaintiffs&#8221;); and the Company engaged in such discussions in lieu of incurring the legal costs anticipated in respect
                              of litigating </span>the Emerald Plaintiffs&#8217; claims, all of which the Company disputes.&#160; Following such discussions, with no admission of wrongdoing, the Company and the Emerald Plaintiffs entered into a confidential
                            settlement agreement, pursuant to which the Company paid $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" id="Fact_6ae75c5847d844c886f9d1cb29e2b7f4" contextRef="c20220805to20220805" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million in full settlement of all of the Emerald
                            Plaintiffs&#8217; purported claims, including a release by the Emerald Plaintiffs in favor of the Company in respect of any and all such claims<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">. </span><br />
                            </span></div>
</ix:continuation>
                        </div>

                        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e16" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e17">
<div><br /></div>
</ix:continuation>
                          <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e17" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e18">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="text-decoration: underline;">John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949
                              (Middlesex County (Massachusetts) Superior Court)</span></div>
</ix:continuation>
                          <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e18" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e19">
<div><br />
                          </div>
</ix:continuation>
                          <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e19" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e20">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County
                              (Massachusetts) Superior Court against Novellus, Inc. and the company&#8217;s founders and former executives, Dr. Christopher Rohde and Dr. Matthew Angel (collectively, &#8220;Defendants&#8221;). The case includes allegations that Novellus,
                              Inc. violated the Massachusetts Wage Act. Eterna acquired Novellus, Inc. on July 16,&#160;2021. Mr. Westman&#8217;s claims relate to alleged conduct that took place before Eterna acquired Novellus, Inc. Defense and liability in
                              association with any Wage Act claims have been assumed by Dr. Rohde and Dr. Angel. On December 24,&#160;2021, Westman dismissed the case without prejudice so the parties could mediate the matter. The parties&#8217; February 2022
                              mediation was unsuccessful and the dispute is currently pending in arbitration.</span></div>
</ix:continuation>
                          <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e20" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e21">
<div><span style="font-style: italic;"><br />
                            </span></div>
</ix:continuation>
                            <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e21" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e22">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;">Novellus, Inc</span><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">. <span style="font-style: normal;">v. Sowyrda et al</span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;">., C.A. No.
                                  2184CV02436-BLS2</span></span></div>
</ix:continuation>
                            <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e22" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e23">
<div><span style="font-style: normal;"> </span></div>
</ix:continuation>
                            <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e23" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e24">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; background-color: rgb(255, 255, 255);"><br />
                            </div>
</ix:continuation>
                            <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e24" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e25">
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);">On October 25, 2021 Novellus, Inc. filed a complaint in the Superior Court of Massachusetts,
                              Suffolk County, against former Novellus, Inc. employees Paul Sowyrda and John Westman and certain other former investors in Novellus LLC (Novellus, Inc.&#8217;s former parent company prior to the Company&#8217;s acquisition of Novellus,
                              Inc.), alleging breach of fiduciary duty, breach of contract and civil conspiracy. Eterna acquired Novellus, Inc. on July 16, 2021. On May 27, 2022 Novellus, Inc. amended the complaint to withdraw all claims against all
                              defendants except Paul Sowyrda and John Westman. On July 1, 2022, Westman filed a motion to compel arbitration or in the alternative, to stay the litigation pending the disposition of certain litigation in the Court of
                              Chancery for the State of Delaware filed by Mr. Sowyrda against Novellus LLC, Dr. Christopher Rohde, Dr. Matthew Angel, Leonard Mazur and Factor Bioscience, Inc. captioned&#160;<span style="font-style: italic;">Zelickson et al., v.
                                Angel et al.,</span>&#160;C.A. 2021-1014-JRS and by Westman against Novellus LLC captioned&#160;<span style="font-style: italic;">Westman v. Novellus LLC</span>, C.A. No. 2021-0882-NAC (the &#8220;Delaware Actions&#8221;). On July 1, 2022,
                              Sowyrda answered the complaint and asserted counterclaims against Novellus, Inc, and third-party defendants Dr. Matthew Angel and Dr. Christopher Rohde alleging violations of the Massachusetts Wage Act, Massachusetts Minimum
                              Fair Wage Law, the Fair Labor Standards Act, breach of contract, unjust enrichment and quantum meruit. Sowyrda also joined in Westman&#8217;s motion to stay the case pending the Delaware Actions. Novellus, Inc.&#8217;s claims and Mr.
                              Sowyrda&#8217;s counterclaims relate to alleged conduct that took place before Eterna acquired Novellus, Inc. Defense and liability in association with any Wage Act claims have been assumed by Dr. Rohde and Dr. Angel. The Company
                              filed its opposition to Sowyrda and Westman&#8217;s motions on August 19, 2022.&#160; On September 9, 2022, Westman and Sowyrda filed replies in support of their motions and requested to be heard.&#160; The hearing is scheduled for November
                              16, 2022.</div>
</ix:continuation>
                            <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e25" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e26">
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);"> <br />
                            </div>
</ix:continuation>
                            <div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);">
                              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e26" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e27">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Under applicable Delaware law and Novellus Inc.&#8217;s organizational documents, the Company may be required to advance or reimburse certain legal
                                expenses incurred by former officers and directors of Novellus, Inc. in connection with the foregoing Westman and Sowyrda matters. However, a future advance or reimbursement is not currently probable nor can it be reasonably
                                estimated.</div>
</ix:continuation>
                            </div>

                          </div>

                          <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e27" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e28">
<div><br /></div>
</ix:continuation>
                        </div>

                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageFooter" style="width: 100%;"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table
                    of Contents</a><br />
                </div>

              </div>

            </div>

            <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e28" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e29">
<div style="display:none;"><br /></div>
<div style="font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">Licensing Agreements</div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e29" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e30">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e30" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e31">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">USF</span></div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e31" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e32">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e32" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e33">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Brooklyn LLC has license agreements with University of
                South Florida Research Association, Inc. (&#8220;USF&#8221;), granting Brooklyn LLC the right to sell, market, and distribute IRX-2, subject to a <ix:nonFraction name="erna:LossContingencyPercentageOfRoyaltyPayable" id="Fact_8ba6369ce1894a938b0e56cf736e306c" contextRef="c20220101to20220930_LegalEntityAxis_UniversityOfSouthFloridaMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>%
                royalty payable to USF based on a percentage of gross product sales. Under the license agreement with USF, Brooklyn LLC is obligated to repay patent prosecution expenses incurred by USF. To date, Brooklyn LLC has not recorded any product
                sales, or obligations related to USF patent prosecution expenses. The license agreement terminates upon the expiration of the IRX-2 patents.</div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e33" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e34">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e34" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e35">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">Novellus Ltd. and Factor Limited</span> <br />
              </div>
</ix:continuation>
              <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e35" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e36">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"> <br />
              </div>
</ix:continuation>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal;">
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e36" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e37">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">In December 2020, Brooklyn LLC entered into option agreements (the
                  &#8220;Option Agreements&#8221;) with Novellus Ltd. and Factor Limited (together, the &#8220;Licensors&#8221;) to obtain the right to exclusively license the Licensors&#8217; intellectual property and mRNA cell reprogramming and gene editing technology for use in the
                  development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia (the &#8220;Licensed Technology&#8221;). The option was exercisable
                  before February 28, 2021 (or April 30, 2021 if the Merger had not closed by that date) and required Brooklyn LLC to pay a non-refundable option fee of $<ix:nonFraction name="erna:LossContingencyNonRefundableOptionFee" id="Fact_758444352bf447668f3a45799d09a299" contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million and then an initial license fee of $<ix:nonFraction name="erna:InitialLicenseFees" id="Fact_c07af1f7628249b89d6e43ab11ab4bf6" contextRef="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction> million <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(including
                    the non-refundable fee of $<ix:nonFraction name="erna:LossContingencyNonRefundableOptionFee" id="Fact_a26b483077444e52b502d441089069ec" contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million) in order to exercise the option.</span></div>
</ix:continuation>
              </div>

              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e37" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e38">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <br />
                </div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e38" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e39">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"> In April 2021, Brooklyn LLC and the Licensors amended the Option Agreements to extend the exercise period to May 21, 2021 and to require Brooklyn LLC to pay a total $<ix:nonFraction name="erna:AdditionalFeesObligatedToPay" id="Fact_73ecc6e76d104d3baa995965247d5bfc" contextRef="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million of the $<ix:nonFraction name="erna:InitialLicenseFees" id="Fact_82f85b7906d24235854a00cdecf418f6" contextRef="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction> million
                  initial license fees to the Licensors by April 15, 2021.</div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e39" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e40">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br />
                  </span></div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e40" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e41">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In
                    April 2021, Brooklyn LLC and the Licensors entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) pursuant to which Brooklyn LLC acquired an exclusive worldwide license to the Licensed Technology <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for use in the development of certain mRNA,
                      gene-editing, and cellular therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia. </span>Under the terms of the License Agreement, Brooklyn
                    LLC is obligated to pay the Licensors a total of $<ix:nonFraction name="erna:AmountRequireToPayInitialLicenseFees" id="Fact_86729254208342a3bdb207d4e169eee0" contextRef="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction> million in connection with the execution of the License Agreement, all
                    of which was paid as of June 2021.</span></div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e41" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e42">
<div><span style="font-size: 10pt;"><br />
                </span></div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e42" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e43">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As a result of the Novellus Acquisition, in accordance with the terms of the Novellus-Factor License Agreement, the rights and obligations of Novellus Ltd. thereunder pertaining to any and all licensed
                      products have inured to Eterna<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The agreement with Factor Limited under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain
                        next-generation mRNA gene editing and cell therapy products, remained unchanged after the completion of the Novellus Acquisition. Accordingly, under the License Agreement,</span> Brooklyn LLC remained obligated to pay to Factor
                      Limited a fee</span> of $<ix:nonFraction name="erna:AmountObligatedToPayInYearTwo" id="Fact_5efb266fc3434c0ea8afca2b191c2d9e" contextRef="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million in October 2022, which would have been in addition to a fee of $<ix:nonFraction name="erna:AmountObligatedToPayInYearOne" id="Fact_f3929e51def348e6a0a34430e5b147d9" contextRef="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million paid to Factor Limited in October 2021. <span style="letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In connection with the Company entering into the MSA (see Note 8), Factor Limited
                      entered into the Waiver Agreement with Brooklyn LLC, pursuant to which Factor Limited waived payment of the $<ix:nonFraction name="erna:AmountObligatedToPayInYearTwo" id="Fact_af1cb3eab82d4fa7ac29f5e806dade4b" contextRef="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million
                      otherwise payable to it in October 2022 by Brooklyn LLC</span>.</span> </div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e43" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e44">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><br />
                </div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e44" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e45">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Brooklyn LLC is also
                    required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of
                    these milestones, Brooklyn LLC will be obligated to pay, in the case of development and regulatory milestones, milestone payments to the Licensors in specified amounts and, in the case of commercialization milestones, specified
                    royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely achieve certain delineated milestones, the Licensors will have the right to terminate Brooklyn
                    LLC&#8217;s rights under provisions of the License Agreement relating to those milestones.</span> </div>
</ix:continuation>
                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e45" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e46">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </div>
</ix:continuation>
                <div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;">
                  <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e46" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e47">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">Novellus Ltd. also has a license agreement with Factor Limited, which was entered into in February 2015, amended in June
                    2018 and March 2020, and then amended and restated in November 2020 (the &#8220;Novellus-Factor License Agreement&#8221;).&#160; The Novellus-Factor License Agreement grants to Novellus Ltd. an exclusive license to use certain technology owned by Factor
                    Limited for the development of mesenchymal stem cell-based cellular therapies for treating diseases and conditions in humans and animals&#160; (the &#8220;Novellus-Factor Licensed Technology&#8221;). Under the License Agreement, Novellus Ltd. in turn
                    granted a sublicense to Brooklyn LLC to use the Novellus-Factor Licensed Technology to develop up to four mesenchymal stem cell-based therapy products for use in the treatment of cancer in humans.</div>
</ix:continuation>
                </div>

                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e47" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e48">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </div>
</ix:continuation>
                <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div class="BRPFPageFooter" style="width: 100%;"></div>

                  <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

                  <div class="BRPFPageBreak" style="page-break-after: always;">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

                  <div class="BRPFPageHeader" style="width: 100%;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS">
                        Table of Contents</a><br />
                    </div>

                  </div>

                </div>

                <div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;">
                  <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e48" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e49">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">Under the Novellus-Factor License Agreement, Novellus Ltd. is required to use commercially reasonably efforts to achieve
                    certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. The Novellus-Factor License Agreement states that upon its achievement of these milestones,
                    Novellus Ltd. will be obligated to make milestone payments of up to $<ix:nonFraction name="erna:MilestonePayments" id="Fact_9b45c1703837495f91b61de71698475e" contextRef="c20220101to20220930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.0</ix:nonFraction> million in aggregate to Factor Limited as well as
                    specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus Ltd. fails to timely achieve certain delineated milestones under the Novellus-Factor License Agreement,
                    Factor Limited could seek to terminate the license granted thereunder. The Novellus-Factor License Agreement provides that in the event of termination of the Novellus-Factor License Agreement, if Novellus Ltd. requests that its
                    sublicense to Brooklyn LLC under the License Agreement survive such termination, such sublicense shall be considered a direct license from Factor Limited to Brooklyn LLC, provided that Brooklyn LLC agrees in writing that (i) Factor
                    Limited is entitled to enforce all relevant provisions directly against Brooklyn LLC, and (ii) Factor Limited shall not assume, and shall not be responsible to Brooklyn LLC for, any representations, warranties or obligations of Novellus
                    Ltd. to Brooklyn LLC, other than to permit Brooklyn LLC to exercise any rights to the technology sublicensed by Novellus Ltd. to Brooklyn LLC.&#160; Factor Limited also agreed under the License Agreement that upon the termination of the
                    Novellus-Factor License Agreement for any reason other than Brooklyn LLC&#8217;s breach of the License Agreement, the rights and licenses granted to Brooklyn LLC by Novellus Ltd. under the License Agreement shall survive such termination of
                    the Novellus-Factor License Agreement, and Factor Limited grants to Brooklyn LLC such rights and licenses on the same terms and conditions as granted by Novellus Ltd. to Brooklyn LLC under the License Agreement.. Following the
                    expiration of one of the delineated milestone deadlines in the Novellus-Factor License Agreement without Novellus Ltd.&#8217;s achievement of the required regulatory filing on November 1, 2022, Novellus Ltd., Brooklyn LLC and Factor began
                    discussions regarding an amendment to the terms of the License Agreement and the Novellus-Factor License Agreement in order for Brooklyn LLC, among other things, to directly license the Novellus-Factor Licensed Technology from Factor
                    and consolidate and amend the milestone, payment and other terms with respect thereto accordingly. There can be no assurance that such an amendment will be made on the forgoing terms, if at all.</div>
</ix:continuation>
                </div>

                <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e49" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e50">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;">&#160;</div>
</ix:continuation>
              </div>

            </div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 27pt;">
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: justify;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e50" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e51">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e51" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e52">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">NoveCite</span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e52" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e53">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><span style="text-decoration: underline;"> <br />
                          </span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e53" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e54">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;"> </span>In October 2020, Novellus Ltd. (as
                          sublicensor) and NoveCite (as sublicensee) entered into an exclusive license agreement (the &#8220;Sublicense&#8221;) to license novel cellular therapy for acute respiratory distress syndrome, which NoveCite is licensing from Factor Limited.
                          Under the sublicense agreement, NoveCite is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified
                          commercialization milestones. In general, upon its achievement of these milestones, NoveCite will be obligated, in the case of development and regulatory milestones, to make milestone payments to the Novellus Ltd. in specified
                          amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers.</div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e54" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e55">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><span style="text-decoration: underline;"><br />
                          </span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e55" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e56">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">Under the terms of the Sublicense, in the event
                          that Novellus Ltd. receives any revenue involving the original cell line included in the licensed technology, then Novellus Ltd. shall remit to NoveCite <ix:nonFraction name="erna:PercentageOfRevenue" id="Fact_9f3f2d598a1c42d6880fe638c03c7629" contextRef="c20220930_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of such revenue.<span style="text-decoration: underline;"><br />
                          </span></div>
</ix:continuation>
                        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e56" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e57">
<div><br /></div>
</ix:continuation>
                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e57" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e58">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">Royalty Agreements</div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e58" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e59">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e59" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e60">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">Collaborator Royalty Agreement</span></div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e60" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e61">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e61" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e62">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Effective June 22, 2018, IRX terminated its Research,
        Development and Option Facilitation Agreement and its Options Agreement (the &#8220;RDO and Options Agreements&#8221;) with a collaborative partner (the &#8220;Collaborator&#8221;), pursuant to a termination agreement (the &#8220;Termination Agreement&#8221;). <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Termination Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. </span>In connection
        with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and Brooklyn LLC has no obligation to refund any payments received from the Collaborator. As consideration for
        entering into the Termination Agreement, the Collaborator will receive a royalty equal to <ix:nonFraction name="erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" id="Fact_d90f37171e90443789a8853a44211323" contextRef="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">6</ix:nonFraction>% of revenues from the sale of IRX-2, for the
        period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2 or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.</div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e62" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e63">
<div><br /></div>
</ix:continuation>
      <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;">
        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e63" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e64">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"> <span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Royalty Agreement with certain former IRX Therapeutics Investors</span></span> </div>
</ix:continuation>
        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e64" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e65">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e65" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e66">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#8220;IRX Investor Royalty Agreement<span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#8221;</span>)
            with certain investors who participated in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. Pursuant to the IRX Investor Royalty Agreement,
            when Brooklyn LLC becomes obligated to pay royalties to USF under the agreement described above under &#8220;Licensing Agreements-USF,&#8221; it will pay an additional royalty of <ix:nonFraction name="erna:PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" id="Fact_c1789a9d9592455cad7c444a83394701" contextRef="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of gross sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement.
            Brooklyn LLC has not recognized any revenues to date, and no royalties are due pursuant to any of the above-mentioned royalty agreements.</span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e66" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e67">
<div><span style="text-decoration: underline;"> <br />
      </span></div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e67" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e68">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">Investor Royalty Agreement</span></div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e68" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e69">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e69" continuedAt="Text_874b721bf6d84c0e89c030a86146e82e70">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="text-align: justify; text-indent: 28.9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal;">
        <ix:continuation id="Text_874b721bf6d84c0e89c030a86146e82e70">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; text-indent: 36pt;">On
          March 22, 2021, Brooklyn LLC restated its royalty agreement with certain beneficial holders of Brooklyn ImmunoTherapeutics Investors GP LLC and Brooklyn ImmunoTherapeutics Investors LP, whereby such beneficial holders will continue to receive, on
          an annual basis, royalties in an aggregate amount equal to <ix:nonFraction name="erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" id="Fact_d9e55ff9304c42a0b33210bba28c0a44" contextRef="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the net revenues of IRX-2, a cytokine-based therapy being developed
          by Brooklyn LLC to treat patients with cancer.</div>
</ix:continuation>
<div>
         <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</div>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
       <br /></div>

    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
            Contents</a><br />
        </div>

      </div>

    </div>

    <div> <br />
    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_70a2bde5640b4c6fbfb4f07f8c2ae6f1" contextRef="c20220101to20220930" escape="true" continuedAt="Text_a5759648f8804440bbec22f6cb57c8831">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">11)<br />
              </span> </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal; font-variant: normal; text-transform: none;">STOCK-BASED COMPENSATION</div>
              </div>
            </td>

  </tr>


</table>
    </div>
</ix:nonNumeric><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8831" continuedAt="Text_a5759648f8804440bbec22f6cb57c8832">
<div><span style="font-family: 'Times New Roman';">&#160; <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
     <br /></div>
</ix:continuation>
    <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;">
      <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8832" continuedAt="Text_a5759648f8804440bbec22f6cb57c8833">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Stock Options</span></div>
</ix:continuation>
      <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8833" continuedAt="Text_a5759648f8804440bbec22f6cb57c8834">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>

      <ix:nonNumeric name="erna:ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" id="Text_a42af0f817d24c2ebcb0d6af991c7f03" contextRef="c20220101to20220930" escape="true" continuedAt="Text_8a74d57372d14845b11555104172d7571"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8834" continuedAt="Text_a5759648f8804440bbec22f6cb57c8835">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the Company
        granted the following stock options (in thousands):</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_8a74d57372d14845b11555104172d7571" continuedAt="Text_8a74d57372d14845b11555104172d7572"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8835" continuedAt="Text_a5759648f8804440bbec22f6cb57c8836">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_8a74d57372d14845b11555104172d7572"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8836" continuedAt="Text_a5759648f8804440bbec22f6cb57c8837">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">&#160;</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock options granted</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_2faa9d20d3b240cb8eef651f788d93b9" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">188</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_41f54f55f77a4644a6404863740ca254" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_0939cda5a6ea4849bfe37cf51034ac9f" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">287</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_da081a8a08b44025bfdee2ae9529ced2" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8837" continuedAt="Text_a5759648f8804440bbec22f6cb57c8838">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"> <br />
      </div>
</ix:continuation>

      <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_5cceeba9c96e484bac4dec338d0cbe9f" contextRef="c20220101to20220930" escape="true" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a1"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8838" continuedAt="Text_a5759648f8804440bbec22f6cb57c8839">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The following weighted-average assumptions were used for stock options granted during the three and nine months ended
        September 30, 2022 and 2021:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a1" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a2"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c8839" continuedAt="Text_a5759648f8804440bbec22f6cb57c88310">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a2" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a3"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88310" continuedAt="Text_a5759648f8804440bbec22f6cb57c88311">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

    <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a3" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a4"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88311" continuedAt="Text_a5759648f8804440bbec22f6cb57c88312">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a4" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a5"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88312" continuedAt="Text_a5759648f8804440bbec22f6cb57c88313">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" rowspan="1" colspan="6">Three months ended September 30,</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average risk-free rate</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_5976be41533b45e0b8a785027c669fa1" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.64</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_1dc20fc7f86c440783584acbefc37d1e" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.97</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average volatility</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_0608028ed20146c98fd90188e301487a" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">89.80</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_3a09567b3b604a1786c13909dfb9acdf" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">143.29</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_bd778c51ee8d4b6fad1685cb264f5d14" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"> <br />
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_c25598ded7f04fb5bb27dbf832774826" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expected term</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_b7a907c88d1b4d09b17794399918e0fb" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">5.73</ix:nonNumeric> years</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_2392378adfec43b493a5d4d507ea2dd4" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.08</ix:nonNumeric> years</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a5" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a6"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88313" continuedAt="Text_a5759648f8804440bbec22f6cb57c88314">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a6" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a7"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88314" continuedAt="Text_a5759648f8804440bbec22f6cb57c88315">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
      </span> </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a7" continuedAt="Text_fcd75f3da9894a5897b1ace8cfef037a8"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88315" continuedAt="Text_a5759648f8804440bbec22f6cb57c88316">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_fcd75f3da9894a5897b1ace8cfef037a8"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88316" continuedAt="Text_a5759648f8804440bbec22f6cb57c88317">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Nine months ended September 30,</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average risk-free rate</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_ee09fc8516b341fc9d7b0ba637560a46" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.54</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_fd2d84ad9dbf433984f2d8fb8e65414c" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.06</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average volatility</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_f2b7174f083548978784fd40a6e9a334" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">91.20</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_4b46408ed58e464d8c63d3681527e543" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">134.88</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_8450d75f9c1f42dabd9276f584686ec0" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_120d3aacb79f46fca7fea75ff5e79425" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expected term</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_0e3c3126fd2b4bde94fadd4e8c75c4e0" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">5.30</ix:nonNumeric> years</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_60423c9e5abc427d927d2178c0aa07b3" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.08</ix:nonNumeric> years</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88317" continuedAt="Text_a5759648f8804440bbec22f6cb57c88318">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">  </span></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88318" continuedAt="Text_a5759648f8804440bbec22f6cb57c88319">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88319" continuedAt="Text_a5759648f8804440bbec22f6cb57c88320">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the three and nine months ended September 30, 2022, options to purchase approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_e1ab66c85b9449f2b9784cb51a5de845" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_751a332ddb3e4068aad6295a9ecccd17" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">124,000</ix:nonFraction></ix:nonFraction> shares of common stock were granted to Dr. Matthew Angel, the Company&#8217;s Interim Chief Executive Officer. Dr. Angel&#8217;s stock options vest at rate of 1/24 on the grant
        date with the remaining options to vest in <ix:nonFraction name="erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" id="Fact_844fe16f46424abeb43ba4c1df32f207" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember" unitRef="U007" decimals="INF" scale="0" format="ixt:num-dot-decimal">46</ix:nonFraction> substantially equal monthly installments thereafter. For the nine months ended September
        30, 2022,</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> stock options to
        purchase </span>approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_6a62edfe53884f6ba370f09f01f815fd" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction> shares of common stock were granted to Dr. Howard J. Federoff, who served as the Company&#8217;s Chief
      Executive Officer and President until May 26, 2022 (the &#8220;March 2022 Stock Option Grant&#8221;). The March 2022 Stock Option Grant vests in <ix:nonFraction name="erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" id="Fact_44b665ef1db84db188b32f678d778a04" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U007" decimals="0" scale="0" format="ixt:num-dot-decimal">36</ix:nonFraction>
      substantially equal monthly installments from the grant date and had an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88320" continuedAt="Text_a5759648f8804440bbec22f6cb57c88321">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88321" continuedAt="Text_a5759648f8804440bbec22f6cb57c88322">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the nine months ended September 30, 2021</span>, options to purchase approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_9a9b140d72864ecd931ccd106a26af16" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">161,000</ix:nonFraction> shares of common stock were granted to Dr. Federoff upon his appointment as Chief Executive Officer and President in April 2021. Approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_c83705df58e4473a80a12a86bcf2a97b" contextRef="c20210101to20210930_AwardTypeAxis_TimeBasedStockOptionGrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">131,000</ix:nonFraction> stock options were under a time-based grant (the &#8220;Time-Based Grant&#8221;) and approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_82974d9ec2bf470bbcf948647a487caa" contextRef="c20210101to20210930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> stock options were under a performance-based grant (the &#8220;Milestone Grant&#8221;). The Time-Based Grant vests over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_ab40459d5bf743848c18a34120470150" contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric>, with <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact_558d1d3cf9c74090b7c2360a3d34cda9" contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% vesting on the one-year anniversary of the grant date and
      the remaining options vesting in <ix:nonFraction name="erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" id="Fact_12d57ec4feb44c86ac1e2a487706cf56" contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember" unitRef="U007" decimals="0" scale="0" format="ixt:num-dot-decimal">36</ix:nonFraction> substantially equal monthly installments thereafter. The Milestone Grant vests upon the first
      concurrence by the U.S. Food and Drug Administration that a proposed investigation may proceed following review of a Company filed investigational new drug application in connection with that the License Agreement. Both the Time-Based Grant and the
      Milestone Grant had an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date.</div>
</ix:continuation>
    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88322" continuedAt="Text_a5759648f8804440bbec22f6cb57c88323">
<div><br /></div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
              Contents</a><br />
          </div>

        </div>

      </div>

    </div>

    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88323" continuedAt="Text_a5759648f8804440bbec22f6cb57c88324">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">Vesting of all stock options grants is subject to continuous service with the Company
      through such vesting dates.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88324" continuedAt="Text_a5759648f8804440bbec22f6cb57c88325">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88325" continuedAt="Text_a5759648f8804440bbec22f6cb57c88326">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">As discussed above, pursuant to the Separation Agreement with Dr. Federoff, the Company&#160;<span style="color: rgb(0, 0, 0);">accelerated the vesting of approximately <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" id="Fact_8e8a8821e8134af48380122373341df7" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,000</ix:nonFraction> stock options under the March 2022 Stock Option Grant and
        approximately <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" id="Fact_9b633bc64c124c74aa029c1dc4a586f6" contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">33,000</ix:nonFraction> stock options under the Time-Based Grant. The Company also waived the performance condition under the Milestone
        Grant and accelerated the vesting of approximately <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" id="Fact_4e75b15fc4894eeeb8f5d8101527c7f7" contextRef="c20220101to20220930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction> stock options under the Milestone Grant. Lastly, the Company extended the
        post-termination exercise period from <ix:nonNumeric name="erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" id="Fact_c3603e31add344b8b02f5f086fe45931" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:durwordsen">90 days</ix:nonNumeric> to <ix:nonNumeric name="erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" id="Fact_fa4fbc744c5146eea172730e96a1e86a" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">36 months</ix:nonNumeric> immediately following the Separation Date for all options that were vested after such accelerations.</span></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88326" continuedAt="Text_a5759648f8804440bbec22f6cb57c88327">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88327" continuedAt="Text_a5759648f8804440bbec22f6cb57c88328">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-size: 10pt;">The above modifications to Dr. Federoff&#8217;s stock options grants resulted in modification accounting under ASC 718,&#160;</span><span style="font-style: italic; color: rgb(0, 0, 0); font-size: 10pt;">Compensation &#8211; Stock Compensation.&#160;</span><span style="color: rgb(0, 0, 0); font-size: 10pt;">As a result, the Company immediately recognized approximately $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" id="Fact_77591ae9b93f420489cb91f40615ad6f" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million for the incremental fair value of stock options that were vested prior to the modification by calculating the difference&#160;</span><span style="font-size: 10pt;">between the fair
        value of the modified award and the fair value of the original award immediately before it was modified. For stock options that were not vested prior to the modification but then vested as a result of the acceleration, the Company reversed any
        stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_ab38cf7dd1e34e24b2e3471a6624e6c7" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>
        million of stock compensation expense in full since there was no future service period required to be provided.</span></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88328" continuedAt="Text_a5759648f8804440bbec22f6cb57c88329">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88329" continuedAt="Text_a5759648f8804440bbec22f6cb57c88330">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2021, there were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_ddbc9972cbb843b79ad5e06226115479" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_0b854c1403434c3197344cad5830c0c4" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">65</ix:nonFraction></ix:nonFraction> options exercised for total cash proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_822a7ce34d6f479da235e93ef9ca8246" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_766d30aa1f604960968c6350f7d8a576" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,202</ix:nonFraction></ix:nonFraction>.
      The options exercised had a total intrinsic value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_669206ca98d74caa91d9ac56a00f31af" contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_12779a74bea441a38741a8ee045e682b" contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,212</ix:nonFraction></ix:nonFraction>. There were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_57de99d3e4064a55a22fb96eef0c8f89" contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_29db51465b6a4e849f54ee557c86eef6" contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> options exercised during the three and nine months ended September 30, 2022.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88330" continuedAt="Text_a5759648f8804440bbec22f6cb57c88331">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88331" continuedAt="Text_a5759648f8804440bbec22f6cb57c88332">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">As of September 30, 2022, there were approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_ac7ba2c1f4b84da09969c1534bbb57e3" contextRef="c20220930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">362,000</ix:nonFraction> stock options outstanding.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88332" continuedAt="Text_a5759648f8804440bbec22f6cb57c88333">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88333" continuedAt="Text_a5759648f8804440bbec22f6cb57c88334">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Restricted Stock Units</span></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88334" continuedAt="Text_a5759648f8804440bbec22f6cb57c88335">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>

    <ix:nonNumeric name="erna:ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" id="Text_82480ccdbaf14aaa93f1747e868977fa" contextRef="c20220101to20220930" escape="true" continuedAt="Text_09fffcecb67b47648c9f347ae3e0665a1"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88335" continuedAt="Text_a5759648f8804440bbec22f6cb57c88336">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the Company granted
      the following restricted stock units (&#8220;RSUs&#8221;) (in thousands):</div>
</ix:continuation></ix:nonNumeric>
    <ix:continuation id="Text_09fffcecb67b47648c9f347ae3e0665a1" continuedAt="Text_09fffcecb67b47648c9f347ae3e0665a2"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88336" continuedAt="Text_a5759648f8804440bbec22f6cb57c88337">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_09fffcecb67b47648c9f347ae3e0665a2"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88337" continuedAt="Text_a5759648f8804440bbec22f6cb57c88338">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">RSUs Granted</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_e13b0aff84f54f538571af27630ec445" contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_141ff9eda0044601a6bc89d9ff383510" contextRef="c20210701to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_6d03b86aacf543c4bfd6b676c6205a1b" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_1ee1f8fbaaff4384923706bc51416b36" contextRef="c20210101to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88338" continuedAt="Text_a5759648f8804440bbec22f6cb57c88339">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88339" continuedAt="Text_a5759648f8804440bbec22f6cb57c88340">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The Company recognizes the fair value of RSUs granted as expense on
      a straight-line basis over the requisite service period. For performance based RSUs, the Company begins recognizing the expense once the achievement of the related performance goal is determined to be probable.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88340" continuedAt="Text_a5759648f8804440bbec22f6cb57c88341">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88341" continuedAt="Text_a5759648f8804440bbec22f6cb57c88342">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Outstanding RSUs are settled in an equal number of shares of common
      stock on the vesting date of the award. An RSU award is settled only to the extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal
      number of shares of common stock without any offsetting payment by the recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88342" continuedAt="Text_a5759648f8804440bbec22f6cb57c88343">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88343" continuedAt="Text_a5759648f8804440bbec22f6cb57c88344">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">In lieu of paying cash to satisfy withholding taxes due upon the
      settlement of vested RSUs, at the Company&#8217;s discretion, an employee may elect to have shares of common stock withheld that would otherwise be issued at settlement, the value of which is equal to the amount of withholding taxes payable. <ix:nonNumeric name="erna:ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" id="Text_c47d53b3e1244a578725da6cdb8320a8" contextRef="c20220101to20220930" escape="true" continuedAt="Text_c8c4211ddef5416b9232e75aa564e76a1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the number of RSUs that vested and were settled during the three and nine months ended
        September 30, 2022, as well as the number of shares of common stock withheld to cover the withholding taxes and the net shares issued upon settlement (in thousands):</span></span></ix:nonNumeric></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88344" continuedAt="Text_a5759648f8804440bbec22f6cb57c88345"><ix:continuation id="Text_c8c4211ddef5416b9232e75aa564e76a1" continuedAt="Text_c8c4211ddef5416b9232e75aa564e76a2">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
      </span></div>
</ix:continuation></ix:continuation>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
            Contents</a><br />
        </div>

      </div>

    </div>

    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88345" continuedAt="Text_a5759648f8804440bbec22f6cb57c88346"><ix:continuation id="Text_c8c4211ddef5416b9232e75aa564e76a2" continuedAt="Text_c8c4211ddef5416b9232e75aa564e76a3">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88346" continuedAt="Text_a5759648f8804440bbec22f6cb57c88347"><ix:continuation id="Text_c8c4211ddef5416b9232e75aa564e76a3">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Three months ended</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Nine months ended</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2022</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2022</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">RSUs vested</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_8fd8754640044a2abfbb584510499958" contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><br />
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_e3fa79163e4d45fa80f9251d5e505e1f" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Common stock withheld to cover
              taxes</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="erna:CommonStockWithheldToCoverTaxes" id="Fact_2d0965c899eb4a77b236dc1a591fa9bf" contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="erna:CommonStockWithheldToCoverTaxes" id="Fact_e78e32e4f9e049f7816f3edb7e3d00a6" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Common stock issued</div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" id="Fact_009c607122434a5ebc6ae01b0e8c81cb" contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" id="Fact_688f7e6b02eb47428a1a1cdccfc66354" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88347" continuedAt="Text_a5759648f8804440bbec22f6cb57c88348">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88348" continuedAt="Text_a5759648f8804440bbec22f6cb57c88349">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_fa5f82b38b6d43e2a889c499aa10a022" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_EmployeeMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction> RSUs granted during the nine months ended September 30, 2022 are performance-based RSUs (the &#8220;2022 PSUs&#8221;), of which approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_c11de3071a964f718300ed9c868ec368" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction> were awarded to Dr. Federoff. The 2022 PSUs are subject to the achievement of <ix:nonFraction name="erna:NumberOfPerformanceGoalsAreSubjectToAchieve" id="Fact_691678523f4c45a18c779ad711a4c805" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction>
      performance goals, which are weighted equally. Once a performance goal is achieved, the tranche of shares allocated to that performance goal will be earned and will begin to vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_bc47722f805c42afa1c8294b7a1a98c4" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> annual basis beginning on the date the performance goal was achieved. If a performance goal is not achieved, the tranche of shares allocated to that performance goal will be
      unearned and forfeited. As of September 30, 2022, <ix:nonFraction name="erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" id="Fact_a514fe6c452b4a2892ae773fd2bc84b2" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> of the performance goals were not achieved by the due date, and as a result,
      approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_f3b902a3ee8043508d84000fbab6978b" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,000</ix:nonFraction> 2022 PSUs were cancelled and any previously recognized stock compensation expense was reversed.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88349" continuedAt="Text_a5759648f8804440bbec22f6cb57c88350">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88350" continuedAt="Text_a5759648f8804440bbec22f6cb57c88351">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Pursuant to Dr. Federoff&#8217;s Separation Agreement, Dr. Federoff&#8217;s <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_495836093eb5433aa3997ee8b9092673" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction> 2022 PSUs were canceled in full (a portion of which included the PSUs allocated to the performance goal that was not achieved timely), and&#160;<span style="color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $<ix:nonFraction name="us-gaap:PaymentsForPostemploymentBenefits" id="Fact_46d73c3e6d5449edbc93532022ae4607" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million was paid to Dr. Federoff, which represents
        the value Dr. Federoff would have received if he were entitled to receive a settlement of a pro rata portion of his 2022 PSUs through the expiration of the Separation Period, assuming the performance metrics were waived and assuming a per share
        value of $<ix:nonFraction name="us-gaap:SharePrice" id="Fact_1c3c20eb104846f29a907b1eae4079ac" contextRef="c20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">16.20</ix:nonFraction>. Any stock compensation expense previously recognized on Dr. Federoff&#8217;s 2022 PSUs was reversed and approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_6b5aaea1d9a54e639bfd3143505f6ed3" contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million was recognized as compensation expense.</span></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88351" continuedAt="Text_a5759648f8804440bbec22f6cb57c88352">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88352" continuedAt="Text_a5759648f8804440bbec22f6cb57c88353">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">As of September 30, 2022, there were approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_0a0d283f00d944b89bb93a395a4a7adc" contextRef="c20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction> RSUs outstanding.<br />
      <br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88353" continuedAt="Text_a5759648f8804440bbec22f6cb57c88354">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Restricted Stock</span></div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88354" continuedAt="Text_a5759648f8804440bbec22f6cb57c88355">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88355" continuedAt="Text_a5759648f8804440bbec22f6cb57c88356">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Pursuant to the Merger, Brooklyn LLC&#8217;s approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_e201db6ae964420aba4649d8f482680f" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000</ix:nonFraction> outstanding restricted common units were exchanged for approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_61e1b338927f4966b47b6c1925b6ca3e" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">32,000</ix:nonFraction> shares of Eterna&#8217;s restricted common stock. There were no changes to any conditions and requirements of the restricted common stock. The shares vested quarterly beginning on March 31, 2021 and were to continue
      through December 31, 2022, contingent on continued service. Due to the modification of the restricted common units, the fair value of the restricted common stock immediately after the Merger was compared to the fair value of the restricted common
      units immediately prior to the Merger, and the change in fair value of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_1716d1d34eee47c2b646e90540642e5d" contextRef="c20210101to20210930_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million was recognized in the statement of operations during
      the nine months ended September 30, 2021. The Company recognizes the fair value of restricted common stock as an expense on a straight-line basis over the requisite service period.&#160; During the nine months ended September 30, 2022, approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_8396aa2d88d94d9b89a9ed05f99c3e4f" contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,000</ix:nonFraction> shares of unvested restricted common stock were forfeited due to the holders of such shares no longer providing services to the Company.&#160; As of
      September 30, 2022, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_992bfb660892480f9b0a492a2b9d45c1" contextRef="c20220930_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of unvested restricted stock outstanding.</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88356" continuedAt="Text_a5759648f8804440bbec22f6cb57c88357">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88357" continuedAt="Text_a5759648f8804440bbec22f6cb57c88358">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Stock-Based Compensation Expense</div>
</ix:continuation>
    <ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88358" continuedAt="Text_a5759648f8804440bbec22f6cb57c88359">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>

    <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_2a62e4701a9043609da3bdda0440e3d0" contextRef="c20220101to20220930" escape="true" continuedAt="Text_f9dc0e6aad99497fa836fe743a6c0a681"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88359" continuedAt="Text_a5759648f8804440bbec22f6cb57c88360">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt; margin-right: 0.5pt;">For the three and nine months ended September 30, 2022 and 2021,
      the Company recognized stock-based compensation expense as follows, which includes the expense related to Dr. Federoff&#8217;s modified awards discussed above (in thousands):</div>
</ix:continuation></ix:nonNumeric>
    <ix:continuation id="Text_f9dc0e6aad99497fa836fe743a6c0a681" continuedAt="Text_f9dc0e6aad99497fa836fe743a6c0a682"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88360" continuedAt="Text_a5759648f8804440bbec22f6cb57c88361">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br />
    </div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_f9dc0e6aad99497fa836fe743a6c0a682"><ix:continuation id="Text_a5759648f8804440bbec22f6cb57c88361">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">Research and development</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_c8dc470446da4d44b10a08aee8522226" contextRef="c20220701to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">183</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_0622702a8abf482fa375506f5cfb19ba" contextRef="c20210701to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">448</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_b9da6e98aab84db7bb448168b426dc91" contextRef="c20220101to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,075</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_26650292092347f2a43b7c4c967f2b25" contextRef="c20210101to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,018</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">General and administrative</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d15928e35c44426f906575d77c7fa594" contextRef="c20220701to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">293</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_68a8f9b7c9d14fcf9232931f36efb808" contextRef="c20210701to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,281</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_20cdb1a942994265975a14143761efae" contextRef="c20220101to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,463</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d020b2312d5f49fb841bf0ae4063c21a" contextRef="c20210101to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,284</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div style="color: rgb(0, 0, 0);">Total</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f7d1f0019a36420aba658900d71ee22e" contextRef="c20220701to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">476</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d1843381b88448609b7e17600b735120" contextRef="c20210701to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,729</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_cc36e43ce78e4bebabd42218d2879056" contextRef="c20220101to20220930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_c8dc6aff77aa4d6698970759e3aa0508" contextRef="c20210101to20210930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,302</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;"></span></div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
            Contents</a><br />
        </div>

      </div>

    </div>
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
     <span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">
        <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_b2be21af16d24bb093b1de68f296d004" contextRef="c20220101to20220930" escape="true" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f81">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify;">12)</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">STOCKHOLDERS&#8217; EQUITY<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <div>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f81" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f82">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"><span style="font-weight: normal;"> <br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f82" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f83">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Private Placement of
            Equity</div>
</ix:continuation>
          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f83" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f84">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br />
              </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt;">
              <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f84" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f85">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On March 6, 2022, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;PIPE Investor&#8221;)
                providing for the private placement (the &#8220;PIPE Transaction&#8221;) to the PIPE Investor of approximately <ix:nonFraction name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" id="Fact_5e4c53d37caa4a4aa66a76d4e7094cbd" contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">343,000</ix:nonFraction> units (collectively,
                the &#8220;Units&#8221;), each Unit consisting of (i) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_10e7581f6c6c4062b2c40b5b84d0437e" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> share of the Company&#8217;s common stock (or, in lieu thereof, one Pre-Funded Warrant
                to purchase one share of common stock) and (ii) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_933d21ee14154b9db6063bc73f5b47c9" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> warrant (the &#8220;Common Warrants&#8221;) to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_e7420cde835b45f4a526541b70f0aa21" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> share of common stock, for an aggregate gross purchase price of approximately $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" id="Fact_9513ecad95154dfab151abfbeaf38ab6" contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction> million (the &#8220;Subscription Amount&#8221;). The PIPE Transaction closed on March 9, 2022. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Pursuant to the Purchase Agreement, the Company is prohibited from issuing equity in variable
                  rate transactions for a period of <ix:nonNumeric name="erna:VariableRateTransactionsPeriod" id="Fact_cedf2de1f35845f08f54f12af414cb45" contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember" format="ixt-sec:durwordsen">one-year</ix:nonNumeric> following consummation of the PIPE Transaction, including issuing equity under the
                  Second Purchase Agreement.</span></div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f85" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f86">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span>
            </div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f86" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f87">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each Pre-Funded Warrant had an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_57a4de5823584082904ae05cb2b5219e" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per share of common stock, was immediately exercisable, could be
              exercised at any time, had no expiration date and was subject to customary adjustments. The Pre-Funded Warrants could not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed <ix:nonFraction name="erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="Fact_0b7361ebd7fb4053b337ce71488fdaae" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>% immediately after exercise thereof. Upon the closing of the PIPE Transaction, the Company issued <ix:nonFraction name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" id="Fact_b2df6e5f8ecf42c2bf4deae12863cd00" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">275,000</ix:nonFraction> shares of common stock and issued Pre-Funded Warrants representing approximately <ix:nonFraction name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" id="Fact_cb59e80d80764b67b09c1809e70fe3a5" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction> shares of common stock. On July 12, 2022, the PIPE Investor exercised its&#160;<ix:nonFraction name="erna:ClassOfWarrantOrRightExercised" id="Fact_b011b29945d14c63a1680bafed9b2b9f" contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction>
              Pre-Funded Warrants at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_73f551d8b3784387b38e263de40d61cb" contextRef="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per share<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">for an aggregate exercise price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_6d6981101e1246c8a73e99f72fa96651" contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,786</ix:nonFraction>, in cash. The Company issued <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_61c50c0140a440e1938d8a11d081eb5a" contextRef="c20220714_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction> shares of common stock to
                  the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds. Subsequent to the exercise, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_06a92160e6a8419bbe9338a74ee70b93" contextRef="c20220712_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> Pre-Funded Warrants
                  remained outstanding.</span></span></div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f87" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f88">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span>
              <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f88" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f89">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Each Common Warrant has an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_dd3b7ee8cbd74916bcb02824e850d864" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">38.20</ix:nonFraction> per share, becomes exercisable <ix:nonNumeric name="erna:ClassOfWarrantOrRightsExercisableTerm" id="Fact_01af5c0a6f044620ab8e37c4e781677f" contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember" format="ixt-sec:durwordsen">six months</ix:nonNumeric> following the closing of the PIPE Transaction, expires <span style="-sec-ix-hidden:Fact_5b09bcc1ce7d4736a68839d07677b3d8">five-and-one-half </span> years from the date of issuance and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed <ix:nonFraction name="erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="Fact_b9d005106b5449668fc8becbe108d2e2" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.99</ix:nonFraction>% immediately after exercise thereof, subject to increase to <ix:nonFraction name="erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="Fact_04cf1dfcbbee4574887e87561eb101de" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>% at the option of the holder.</div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f89" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f810">
<div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">&#160;</div>
</ix:continuation>
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%21%%%-->
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 28.9pt; text-transform: none;">
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f810" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f811">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As of September 30, 2022, the Company had <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_d8e24589dff5407c9b747866caf33c38" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">343,000</ix:nonFraction>
              Common Warrants outstanding with a weighted average exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_fae5492c2680461f9e3629e3c0f2a2fc" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">38.20</ix:nonFraction> per share and a weighted average contractual life of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_ca8c2dc4094c4749b8861c52af4ec429" contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember" format="ixt-sec:duryear">4.95</ix:nonNumeric> years.</div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f811" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f812">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f812" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f813">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f813" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f814">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f814" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f815">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">The





























































            Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a cashless settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These
            warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the statement of operations. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Upon exercise of the Common Warrants and Pre-Funded Warrants, the fair value on the exercise date is reclassified from warrant
              liabilities to equity</span>.</div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f815" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f816">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f816" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f817">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
          <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;">
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f817" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f818">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" id="Fact_818ba13c72ad40cd92ff0c04a05589bf" contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million in the aggregate, which was $<ix:nonFraction name="erna:OverSubscriptionAmountReceived" id="Fact_c887bc9fd7b14f6980af9118235a87bd" contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million more
              than the Subscription Amount. The excess $<ix:nonFraction name="erna:OverSubscriptionAmountReceived" id="Fact_478bc158fb6e4b6daf583f6b566399cc" contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million represents an inducement to the PIPE Investor to enter into the PIPE
              Transaction and was recorded in warrant liabilities expense in the accompanying consolidated statement of operations. Given the Company&#8217;s capital requirements and market conditions, the Company consummated this financing on market terms
              available at the time of the transaction.</div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f818" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f819">
<div><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f819" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f820">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; margin-right: 2pt;">The Company incurred fees of approximately $<ix:nonFraction name="erna:TransactionFeesPayable" id="Fact_c73826c98f9b423985ebec97be571366" contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million through September 30, 2022 related to the PIPE Transaction, which were allocated to the fair value of the Common Warrants and the Pre-Funded Warrants and recorded in other expense, net on the
              accompanying condensed consolidated statement of operations.</div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f820" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f821">
<div><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f821" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f822">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the PIPE Transaction, the Company and the PIPE Investor also entered into a registration rights agreement, dated March 6,
              2022, pursuant to which the Company agreed to prepare and file a registration statement with the SEC no later than 15 days following the filing date of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021
              Annual Report&#8221;) to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants. The Company agreed to use its best efforts to
              have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed the 2021 Annual Report on April 15, 2022
              and the registration statement on April 29, 2022. The resale registration statement became effective on May 11, 2022.</div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f822" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f823">
<div><br />
            </div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table
                    of Contents</a><br />
                </div>

              </div>

            </div>

            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f823" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f824">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the registration rights agreement, the Company is obligated to pay the PIPE Investor liquidated damages equal to <ix:nonFraction name="erna:ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" id="Fact_ca8f450cf4004a03a96f29f1f8b744fd" contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>% of the Subscription Amount per month, with a maximum aggregate payment of <ix:nonFraction name="erna:ObligationToPayLiquidatedDamagesPercentage" id="Fact_e23d721f8ea84fe5aedb2bc5a2b18526" contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember_RangeAxis_MaximumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">12</ix:nonFraction>% of the Subscription Amount, in the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered for resale
              thereunder for more than <ix:nonNumeric name="erna:ConsecutiveCalendarDays" id="Fact_a5b5e7f58eb5418997b1f417324f39dc" contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember" format="ixt-sec:durday">10</ix:nonNumeric> consecutive calendar days or more than an aggregate of <span style="-sec-ix-hidden:Fact_35a0d29cf6104e00b3095ed13c7f4044">fifteen</span> calendar days (which need not be consecutive calendar days) during any 12-month period.</div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f824" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f825">
<div><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f825" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f826">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On May 24, 2022, the Company provided the PIPE Investor with notice that it was not able to resell the securities registered for resale under
              the registration agreement because the Company had not timely filed its Quarterly Report on Form 10-Q (the &#8220;Q1 2022 10-Q&#8221;) with the SEC, and that the PIPE Investor could not use the registration statement to resell the related securities
              until the Company filed the Q1 2022 10-Q.&#160; Because the PIPE Investor was unable to use the registration statement for at least <ix:nonNumeric name="erna:ConsecutiveCalendarDays" id="Fact_b8be767f29e74a29bb58dfca91799404" contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember" format="ixt-sec:durday">10</ix:nonNumeric>
              consecutive calendar days, the Company accrued $<ix:nonFraction name="us-gaap:LossContingencyEstimateOfPossibleLoss" id="Fact_13148b4372194414b3a7d1fe2b181421" contextRef="c20220331_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million during the first quarter of 2022 for the contingent loss the Company
              incurred as liquidated damages as a result of the late Q1 2022 10Q filing, which is recorded in other expense, net for the nine months ended September 30, 2022 in the accompanying condensed consolidated statements of operations.&#160; The Company
              paid such $<ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" id="Fact_f5d6300dea254c1383a88d873a05ef7c" contextRef="c20220601to20220630_InvestmentTypeAxis_PIPEInvestorMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million liquidated damages payment in June 2022.</div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f826" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f827">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f827" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f828">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> On June 30, 2022, the Company filed its Q1 2022 10-Q along with the 10-K/A, and on July 1, 2022, the Company provided its notice to the PIPE
              Investor that it may resume use of the resale registration statement.</div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f828" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f829">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify; text-indent: 36pt;">&#160;</div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f829" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f830">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify; text-indent: 36pt;"><span style="font-weight: normal;"> <span style="font-style: italic;">Merger</span></span></div>
</ix:continuation>
          <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f830" continuedAt="Text_e319b03e995f4536a06967eff6ebd3f831">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; text-indent: 0px; text-transform: none; background-color: rgb(255, 255, 255);"><span style="font-weight: normal;"> <br />
            </span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_e319b03e995f4536a06967eff6ebd3f831">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">Under the terms of the Merger
              Agreement </span></span>(see Note 3)<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">, on March 25, 2021, Eterna issued shares of common stock to the equity holders of Brooklyn LLC. The <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_3663e2cbc3c24d699eb3559e030e94bd" contextRef="c20210325_StatementClassOfStockAxis_CommonClassAMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">87,000</ix:nonFraction>
              Class A units of Brooklyn LLC were converted into </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_eea066cc77e14d44b3f2a90851f0258b" contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,114,000</ix:nonFraction> shares of common stock; the <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_bf409077e40242dcb0c3b37535429efb" contextRef="c20210325_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction> Class B units were converted into </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_f892f1cf8d3243c796d808dd9dff8bb9" contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">126,000</ix:nonFraction>
              shares of common stock; the <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_15e0508e6cb442ada157199a74f0e02e" contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> Class C units were converted into </span></span>approximately <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_d69f9773d1f84fa8bc8913a70cfea8f8" contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">84,000</ix:nonFraction><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> shares of common stock; </span></span>approximately <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_e78959963c61408f9520dea24cb405df" contextRef="c20210325_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">630,000</ix:nonFraction><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> shares of common units were
              converted into </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_d5f7b1c555304023aeac81080a790e48" contextRef="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">31,000</ix:nonFraction> shares of common stock, and <ix:nonFraction name="erna:ClassOfWarrantOrRightIssued" id="Fact_8eee233b891f4970b9e8cb33c99ac872" contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,500,000</ix:nonFraction> rights options were converted into </span></span>approximately <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_c9744f4bb41f49c9a49f43f71d2755f6" contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">591,000</ix:nonFraction><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> shares of common stock. <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">Eterna</span></span> also
              issued </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> <ix:nonFraction name="erna:StockIssuedDuringPeriodSharesAcquisitions1" id="Fact_f0add22f4d7d4d7ea3de994a62d3b6a5" contextRef="c20210325to20210325" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">53,000</ix:nonFraction> shares of common stock to its financial advisor pursuant to the Merger Agreement</span></span>.</div>
</ix:continuation>
        </div>

      <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 28.9pt; text-transform: none;"><br />
      </div>

    </div>

    <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div>
          <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="Text_8268f62872184c44b547e4e59daca28d" contextRef="c20220101to20220930" escape="true" continuedAt="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a21">
<div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify;">13)</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">EARNINGS PER SHARE</span> </div>
                  </td>

  </tr>


</table>
          </div>
</ix:nonNumeric>
          <ix:continuation id="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a21" continuedAt="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a22">
<div><br /></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a22" continuedAt="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a23">
<div style="display:none;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period
          including the weighted average effect of the Pre-Funded Warrants the Company issued in connection with the PIPE Transaction, the exercise of which requires little or no consideration for the delivery of shares of common stock. The Company
          determined that the exercise of the Pre-Funded Warrants requires nominal consideration for the delivery of shares of common stock, and as such, has considered the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_16ac43b550844f6d8782bd901074b552" contextRef="c20220309_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">68,000</ix:nonFraction> shares underlying the Pre-Funded Warrants to be outstanding effective on March 9, 2022 for the purposes of calculating basic EPS. Diluted net loss per share is calculated by
          dividing net loss by the weighted-average number of common shares outstanding (including the weighted average effect of the Pre-Funded Warrants) plus dilutive securities. Stock options, RSUs, warrants and other convertible securities are
          considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. Diluted net loss per share is the same as basic net loss per share in periods where the
          effect of potentially dilutive shares of common stock are antidilutive. <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_f95b70294eaa41198c37dcff691de5a5" contextRef="c20220101to20220930" escape="true" continuedAt="Text_82970f1f7e5a409082412bac4c10c2781"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table presents the amount of stock options, RSUs, warrants and convertible preferred stock that were excluded from the computation of diluted net loss per
          common share for the three and nine months ended September 30, 2022 and 2021, as their effect was anti-dilutive:</span></ix:nonNumeric></div>
</ix:continuation>
        <ix:continuation id="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a23" continuedAt="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a24"><ix:continuation id="Text_82970f1f7e5a409082412bac4c10c2781" continuedAt="Text_82970f1f7e5a409082412bac4c10c2782">
<div><br />
        </div>
</ix:continuation></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_ecbd8d67a4bd4cdfa77f5dd41f5ad3a24"><ix:continuation id="Text_82970f1f7e5a409082412bac4c10c2782">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Three and Nine months ended September 30,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">2022</div>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; text-align: center;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Stock options</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_5317fd874d4141afbec1f431718c158d" contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_3de5dc1889a04f9fa4616361e042d164" contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">362</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_fd62192fbb8047ab8b2a89e4ce660ff3" contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_df4a468051c04051ae1111bfcd353116" contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">RSUs</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4cfec09352ef49feb6f26e9014dfda4f" contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_1af926a4fb154e6db7664bc6beb83ad1" contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_51600cfa4e2740619ce6d107eedd0d49" contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2e9896fe49814a5fa5204f52f055a91b" contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Warrants</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_3826f425d24349358510e828d60b1a46" contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2327c210992844d5954a701ff8b94677" contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">343</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_37b13f0a9b6a4d359ac064407830cc12" contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_367b4c0b8d644babb8723814461fe48d" contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Preferred stock converted into common stock</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_d830d3c215bf4584842fd59224f6faaa" contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2ac63eb8355a47379d2a2cc4a670d901" contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_a7da759bc54f4bac8331f656d4bb0f76" contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_26e309eb933c4b50bf848602c5455bef" contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Total potential common shares excluded from computation</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_39ea060b135c4a19ab9e06da2fb7a6d3" contextRef="c20220701to20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_1b119c7cd5454ed88f86b2ff0fc33024" contextRef="c20220101to20220930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">722</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_a3022a96399c4a61b4d5447edae7d51a" contextRef="c20210101to20210930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_16711c14f46d4c049261ec27a9734dd4" contextRef="c20210701to20210930" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">193</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
         </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div><br />
    </div>


    <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Text_71749bfdf5ce4d45be3204a3fb4fa9d8" contextRef="c20220101to20220930" escape="true" continuedAt="Text_8b76befb556b4c3481fdbc9710dd43381">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">14)<br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">RECENT ACCOUNTING PRONOUNCEMENTS</div>
          </td>

  </tr>


</table>
</ix:nonNumeric><ix:continuation id="Text_8b76befb556b4c3481fdbc9710dd43381" continuedAt="Text_8b76befb556b4c3481fdbc9710dd43382">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span>
     </div>
</ix:continuation>
    <ix:continuation id="Text_8b76befb556b4c3481fdbc9710dd43382" continuedAt="Text_8b76befb556b4c3481fdbc9710dd43383"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_ded1775e458c4616b485ea8de8a75a66" contextRef="c20220101to20220930" escape="true" continuedAt="Text_18620060341f462b9999969d1a2637e51">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> September 2022, the Financial Accounting Standard Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2022-04,&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Liabilities&#8212;Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier
        Finance Program Obligations&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(&#8220;ASU












        2022-04&#8221;). ASU 2022-04 requires a buyer that uses supplier finance programs to make annual disclosures about the program&#8217;s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and
        associated roll-forward information. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is
        effective for fiscal years beginning after December 15, 2023. The Company does not expect a material impact on its financial statements as a result of adopting this amendment.</span></div>
</ix:nonNumeric></ix:continuation>
    <ix:continuation id="Text_8b76befb556b4c3481fdbc9710dd43383" continuedAt="Text_8b76befb556b4c3481fdbc9710dd43384"><ix:continuation id="Text_18620060341f462b9999969d1a2637e51" continuedAt="Text_18620060341f462b9999969d1a2637e52">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
      </span></div>
</ix:continuation></ix:continuation>
    <ix:continuation id="Text_8b76befb556b4c3481fdbc9710dd43384"><ix:continuation id="Text_18620060341f462b9999969d1a2637e52">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In June 2022, the FASB issued ASU No. 2022-03,&#160;Fair Value Measurement (Topic 820): Fair Value Measurement
        of Equity Securities&#160;Subject to Contractual Sale Restrictions&#160;(&#8220;ASU 2022-03&#8221;). The FASB issued ASU 2022-03 to (1) clarify the&#160;guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual
        restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity related securities subject to contractual sale restrictions that are measured at
        fair value in accordance with Topic 820. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair
        value. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years with early adoption permitted. The Company is evaluating when to adopt the amendments in ASU 2022-02. The Company
        does not expect a material impact as a result of adopting this amendment.</span>  </div>
</ix:continuation></ix:continuation>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;"> <br />
    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

      <div><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_677b4506c14f4d87b7c706a033b5aa24" contextRef="c20220101to20220930" escape="true" continuedAt="Text_23ec6ae273274172a4448590e76257171">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
        <ix:continuation id="Text_23ec6ae273274172a4448590e76257171" continuedAt="Text_23ec6ae273274172a4448590e76257172">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">15)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">SUBSEQUENT EVENTS</div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_23ec6ae273274172a4448590e76257172" continuedAt="Text_23ec6ae273274172a4448590e76257173">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_23ec6ae273274172a4448590e76257173" continuedAt="Text_23ec6ae273274172a4448590e76257174">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_23ec6ae273274172a4448590e76257174" continuedAt="Text_23ec6ae273274172a4448590e76257175">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><ix:continuation id="Text_23ec6ae273274172a4448590e76257175" continuedAt="Text_23ec6ae273274172a4448590e76257176">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e76257176" continuedAt="Text_23ec6ae273274172a4448590e76257177">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Facility Sublease</span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e76257177" continuedAt="Text_23ec6ae273274172a4448590e76257178">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e76257178" continuedAt="Text_23ec6ae273274172a4448590e76257179">
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e76257179" continuedAt="Text_23ec6ae273274172a4448590e762571710">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571710" continuedAt="Text_23ec6ae273274172a4448590e762571711">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On October 18, 2022, the Company entered into the Sublease with E.R. Squibb &amp; Sons, L.L.C., a Delaware
            limited liability company and subsidiary of Bristol-Myers Squibb Company (&#8220;Sublessor&#8221;), for office, laboratory and research and development space (the &#8220;Premises&#8221;). The Premises consists of approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" id="Fact_23939bef93e44a27bbc33c7d6574a975" contextRef="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">45,500</ix:nonFraction> square feet on the ninth floor of the building currently under construction located at 250 Water Street, Somerville, Massachusetts 02141.</div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571711" continuedAt="Text_23ec6ae273274172a4448590e762571712">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571712" continuedAt="Text_23ec6ae273274172a4448590e762571713">
<div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571713" continuedAt="Text_23ec6ae273274172a4448590e762571714">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571714" continuedAt="Text_23ec6ae273274172a4448590e762571715">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal; text-indent: 36pt;">The Sublease rent commences on the date that is the earlier of (i) the date that the Company commences
            business operations from the Premises and (ii) the date that is the one-year anniversary of the later to occur of (A) October 18, 2022 and (B) the date that Sublessor obtains the primary landlord&#8217;s consent for the Sublease (such applicable
            date, the &#8220;Rent Commencement Date&#8221;). The Sublease has a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_f379b196274b4fb88d5b348804b0abe9" contextRef="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember" format="ixt-sec:duryear">10</ix:nonNumeric> years from the Rent Commencement Date (the &#8220;Term&#8221;), subject to a
            <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_9b210ebebc25489b8a5d7c097b7a371f" contextRef="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> extension in accordance with the terms of the Sublease.</div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571715" continuedAt="Text_23ec6ae273274172a4448590e762571716">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571716" continuedAt="Text_23ec6ae273274172a4448590e762571717">
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571717" continuedAt="Text_23ec6ae273274172a4448590e762571718">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571718" continuedAt="Text_23ec6ae273274172a4448590e762571719">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; text-indent: 36pt;">Pursuant to the Sublease, within <span style="-sec-ix-hidden:Fact_8744bc3fa0f34851947cbc5afae0d9dc">two</span> business days following receipt of the primary landlord&#8217;s consent to the Sublease, the Company will pay Sublessor a security deposit in the form of a letter of credit
            in the amount of approximately $<ix:nonFraction name="us-gaap:LineOfCredit" id="Fact_f12b20ca06e3479b899839a43bac4028" contextRef="c20221018_PledgingPurposeAxis_LetterOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction> million. Provided there are no events of default by the Company under the Sublease, the letter of
            credit will be reduced on an incremental basis throughout the Term. Pursuant to the Sublease, the Company has agreed to pay base rent of approximately $<ix:nonFraction name="erna:OperatingLeasesMonthlyBaseRent" id="Fact_44e4cbcadd814bf2a4bcfbfbcddb06dd" contextRef="c20221018to20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>
            million per month during the first year of the Term, increasing on an incremental basis each subsequent year of the Term, as well as traditional lease expenses including, certain taxes, operating expenses and utilities.</div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571719" continuedAt="Text_23ec6ae273274172a4448590e762571720">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571720" continuedAt="Text_23ec6ae273274172a4448590e762571721">
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                  Contents</a><br />
              </div>

            </div>

          </div>

          <ix:continuation id="Text_23ec6ae273274172a4448590e762571721" continuedAt="Text_23ec6ae273274172a4448590e762571722">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571722" continuedAt="Text_23ec6ae273274172a4448590e762571723">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: italic; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; text-indent: 36pt;">Exacis Option Agreement (Related Party Transaction)</div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571723" continuedAt="Text_23ec6ae273274172a4448590e762571724">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571724" continuedAt="Text_23ec6ae273274172a4448590e762571725">
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571725" continuedAt="Text_23ec6ae273274172a4448590e762571726">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571726" continuedAt="Text_23ec6ae273274172a4448590e762571727">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal; text-indent: 36pt;">On October 8, 2022, the Company entered into an option agreement (the &#8220;Option Agreement&#8221;) with Exacis
            Biotherapeutics, Inc., a Delaware corporation (&#8220;Exacis&#8221;), pursuant to which Exacis granted the Company the option to negotiate and enter into an exclusive worldwide license to certain of the technology licensed by Exacis for the treatment of
            cancer in humans (the &#8220;Option&#8221;). The Option Agreement provides that the Company will pay Exacis a fee of $<ix:nonFraction name="erna:OptionFee" id="Fact_0799c2f47f7c404fae5a8fd48c246d1c" contextRef="c20221008to20221008_RelatedPartyTransactionsByRelatedPartyAxis_ExacisBiotherapeuticsIncMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million for the Option,
            which would be creditable against the fees or purchase price payable under any such license if entered into by the Company in accordance with Option Agreement. The Option Agreement provides for certain payments upon the execution of a
            definitive license agreement, which would become payable only upon execution, and in accordance with the terms, of the applicable license agreement, if any.</div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571727" continuedAt="Text_23ec6ae273274172a4448590e762571728">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571728" continuedAt="Text_23ec6ae273274172a4448590e762571729">
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571729" continuedAt="Text_23ec6ae273274172a4448590e762571730">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571730" continuedAt="Text_23ec6ae273274172a4448590e762571731">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; text-indent: 36pt;">The Option Agreement has been deemed a related party transaction, as one of the Company&#8217;s Board members, Dr. Gregory
            Fiore, is the Chief Executive Officer of Exacis.<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> Additionally, the Company&#8217;s Interim Chief Executive Office, Dr. Matthew Angel, is </span><span style="font-size: 10pt; font-family: 'Times New Roman';">Chairman of Exacis&#8217; scientific advisory board. Dr. Angel is also the Chairman and Chief Executive Officer of Factor, which is </span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the majority shareholder</span> of Exacis.</div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571731" continuedAt="Text_23ec6ae273274172a4448590e762571732">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; text-indent: 36pt;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_23ec6ae273274172a4448590e762571732">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation> </div>

        </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <a id="ManagementsDiscussionandA"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 44.4pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-align: justify; font-style: italic;"><span style="color: #000000;">You should read this discussion together with the unaudited interim condensed consolidated financial statements, related notes, and other financial information
            included elsewhere in this Quarterly Report on Form 10-Q together with our audited consolidated financial statements, related notes, and other information contained in </span>our Annual Report on Form 10-K/A filed with the <span style="color: #000000;">Securities and Exchange Commission</span> (the &#8220;SEC&#8221;) on June 30, 2022 (the &#8220;10-K/A&#8221;),<span style="color: #000000;"> as well as the information contained in our Annual Report on Form 10-K for the year ended December 31, 2021 (the
            &#8220;Original 10-K&#8221;), filed with the SEC on April 15, 2022, to the extent the information contained in the Original 10-K was not superseded by the information contained in the 10-K/A. The following discussion contains or is based on assumptions,
            estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under &#8220;Risk Factors,&#8221; in Part I, Item 1A of the 10-K/A and as described from time to time in our other filings with the
            SEC. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Overview</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">We are a biopharmaceutical company using our mRNA technology platform, including mRNA-based cell reprogramming and gene editing
          technologies, to create next generation mRNA, gene-editing and cell therapies, including iPSC therapies for multiple therapeutic indications.&#160; We plan to develop and advance a pipeline of therapeutic products both internally and through strategic
          partnerships.&#160; Our mRNA technology platform, which includes novel lipid nanoparticles (&#8220;LNPs&#8221;) for mRNA delivery and targeted transgene insertion, was acquired through a license with Factor Bioscience Limited (&#8220;Factor Limited&#8221;) and through our
          acquisition of Novellus, Inc. and Novellus, Ltd. in July 2021, which we refer to as the Novellus Acquisition.</div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Name Change and Ticker Symbol Change</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">Effective October 17, 2022, we changed our name from Brooklyn ImmunoTherapeutics, Inc. to Eterna Therapeutics Inc. pursuant to an amendment to our Certificate of Incorporation, as
          amended&#160; (the &#8220;Name Change&#8221;). The Name Change did not require approval of our stockholders and did not affect the rights of our security holders. In connection with the Name Change, the trading symbol of our common stock on The Nasdaq Global
          Market changed from &#8220;BTX&#8221; to &#8220;ERNA.&#8221;</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Merger with NTN Buzztime, Inc.</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">On March 25, 2021, we completed the Merger with NTN Buzztime, Inc., changed our name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; and consummated a one-for-two reverse split
          of our common stock.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">On March 26, 2021, we sold the rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings
          LLC, or eGames.com, in exchange for eGames.com&#8217;s payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business. This transaction, which we refer to as the Disposition, was completed in
          accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between us and eGames.com.</div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The Merger has been accounted for as a reverse acquisition in accordance with U.S. generally accepted accounting principles, or GAAP. Under this method of accounting, Brooklyn LLC was deemed the
          &#8220;acquiring&#8221; company and Eterna (then known as NTN Buzztime, Inc.) was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Operations prior to the Merger are those of Brooklyn ImmunoTherapeutics, LLC (&#8220;Brooklyn LLC&#8221;), and the
          historical financial statements of Brooklyn LLC became the historical financial statements of Eterna with respect to periods prior to the completion of the Merger.</div>

        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">Acquisition of Novellus</span></div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;">On July 16, 2021, we acquired Novellus, Inc. and Novellus, Inc.&#8217;s wholly owned subsidiary, Novellus, Ltd. Eterna also acquired 25.0% of the total outstanding equity interests of NoveCite, Inc.&#160;
            As consideration for the Novellus Acquisition, we paid $22.9 million in cash and delivered 351,000 shares of common stock, which under the terms of the Novellus Acquisition Agreement, were valued at a total of $102.0 million based on an agreed
            upon price of $290.5060 per share.&#160; At the date of issuance, the fair value of the shares was approximately $58.7 million.</div>

        </div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">mRNA, Gene-Editing, and Cellular Medicines</span></div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">We are advancing the technology that we obtained through a license with Factor Limited and through the Novellus Acquisition in
            July 2021 to evaluate and develop mRNA, gene-editing, and cellular medicines, with an initial focus on hematologic and solid tumors. We expect that the first-generation product candidates will include gene-editing mRNA for in vivo cell
            engineering and induced pluripotent stem cell (&#8220;iPSC&#8221;)-derived cytotoxic lymphocytes (&#8220;iCLs&#8221;) and immune-modulating cells (&#8220;iIMCs&#8221;). We expect to begin preclinical development, including manufacturing process development, of iCLs and iIMCs for
            clinical indications including hematologic and solid tumors, as well as other indications that require overcoming molecular cues of the tissue microenvironment. The prior work of Novellus, Inc. and NoveCite shows evidence for preclinical
            efficacy of iPSC-derived cells in inflammatory conditions (for example, acute respiratory distress syndrome, or ARDS). Interactions with the FDA provided guidance on Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;), and manufacturing plans, which
            will be undertaken in a similar manner for additional applications. We expect that second generation products will involve more complex gene editing, for which we anticipate using the stepwise addition of genes provided by the in-licensed
            Factor Limited gene editing machinery, NoveSlice, to efficiently place genes and regulatory sequences into safe harbor locations. Development of processes to advance CMC and manufacturing will follow the experience from first generation
            products. We are also exploring opportunities to advance in vivo mRNA cell engineering therapies for hematologic and solid tumors by combining the NoveSlice gene editing technology with ToRNAdo<sup>TM</sup>, the in-licensed LNP technology.</div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In conjunction with our internal efforts, we are actively seeking strategic partners to license and advance our technology.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">IRX-2</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2, or IL2, and other key cytokines. Together, these cytokines are believed to signal,
          enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells, unlike many existing cancer therapies, which rely on targeting the cancer directly. IRX-2 is prepared from the supernatant of
          pooled allogeneic peripheral blood mononuclear cells, known as PBMCs, that have been stimulated using a proprietary process employing a specific population of cells and a specific mitogen.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Unlike existing recombinant IL2 therapies, IRX-2 is derived from human blood cells. We believe this may promote better tolerance, broader targeting and a natural molecular conformation leading to
          greater activity, and may permit low physiologic dosing, rather than the high doses needed in other existing IL2 therapies.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Results of the Phase 2b INSPIRE trial, or the INSPIRE trial, released in June 2022, showed outcomes favored IRX-2 in certain predefined subgroups but the INSPIRE trial did not meet the primary
          endpoint of Event-Free Survival (&#8220;EFS&#8221;) at two years of follow up. One hundred and fifty patients were enrolled in the study. At two years of follow-up in the intention-to-treat (ITT, n=105) population the median EFS was 48.3 months and was not
          reached in the control arm (Hazard Ratio 1.10 (95% Confidence Interval, 0.6-2.1; p value=0.62)). Subgroups favoring the IRX-2 arm included patients with later stage (III and IV) disease and those that did not receive chemotherapy. Trends in EFS
          rates as defined by the Kaplan-Meier estimate at two years of follow-up in patients with later stage (III and IV) disease were 57.2 (40.3, 70.9) vs 49.4 (28.3, 67.4) in favor of IRX-2. In patients that did not receive chemotherapy (radiation
          only) as part of adjuvant treatment, the EFS Kaplan-Meier estimate at two years of follow-up was 76.4 (52.2, 89.4) vs 60.6 (29.4, 81.4) in favor of IRX-2. There were no new safety signals observed with IRX-2. We currently do not have plans to
          further develop the IRX-2 product candidate.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The INSPIRE trial was the only Company-sponsored study of IRX-2.&#160; IRX-2 has been studied externally in other clinical settings outside of head and neck cancer in the form of investigator
          sponsored trials, which have either ended or are not currently active. Based on the totality of available information, the Company currently does not have plans to further develop the IRX-2 product candidate. As such, the Company determined that
          the carrying value of the IPR&amp;D asset was impaired and recognized a non-cash impairment charge of approximately $6.0 million on the condensed consolidated statement of operations during the second quarter of 2022, which reduced the value of
          the asset to zero. </div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Impact of COVID-19 Pandemic</span></div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The development of our product candidates has been, and could continue to be, disrupted and materially adversely affected by past and continuing impacts of the COVID-19 pandemic. This is largely
          a result of measures imposed by the governments and hospitals in affected regions, businesses and schools were suspended due to quarantines intended to contain this outbreak. The spread of COVID-19 from China to other countries resulted in the
          Director General of the World Health Organization declaring COVID-19 a pandemic in March 2020. Despite progress in vaccination efforts, the longer-term impact of the COVID-19 pandemic on our development plans and on the ability to conduct our
          clinical trials remains uncertain and cannot be predicted with confidence. COVID-19 could continue to disrupt production and cause delays in the supply and delivery of products used in our operations, may affect our operations, including the
          conduct of clinical studies, or the ability of regulatory bodies to grant approvals or supervise our candidates and products, may further divert the attention and efforts of the medical community to coping with the COVID-19 and disrupt the
          marketplace in which we operate and may have a material adverse effects on our operations. COVID-19 may also affect our employees and employees and operations at suppliers that may result in delays or disruptions in supply. In addition, a
          recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. Additionally, if the COVID-19 pandemic has a significant impact on our business and financial results for
          an extended period of time, our liquidity and cash resources could be negatively impacted. The extent to which the COVID-19 pandemic and ongoing global efforts to contain its spread will impact our operations will depend on future developments,
          which are highly uncertain, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic. Further, the specific clinical outcomes, or future pandemic related impacts of emerging
          COVID-19 variants cannot be reliably predicted.</div>

        <div><br />
        </div>

        <div>&#160;<span style="font-weight: bold;">Recent Developments</span></div>

        <div> <br />
        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">Reverse Stock Split</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">Effective at 11:59 p.m. Eastern time on October 16, 2022, we effected a reverse stock split at a ratio of 1-for-20 (the &#8220;Reverse Stock Split&#8221;). Upon the effectiveness of the
          Reverse Stock Split, every twenty shares of the issued and outstanding common stock were automatically combined and reclassified into one issued and outstanding share of common stock. The Reverse Stock Split did not affect any stockholder&#8217;s
          ownership percentage of the common stock, alter the par value of the common stock or modify any voting rights or other terms of the common stock. The number of authorized shares of common stock under our Charter remains unchanged. No fractional
          shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares to which a stockholder would otherwise be entitled, we paid an amount of cash equal to the product of (i) the fractional share to which the holder
          would otherwise be entitled and (ii) the then fair value of a share as determined in good faith by the Board.&#160; We paid an aggregate of $719 for a total of 175 fractional shares.</div>

        <div>
          <div><br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">All share</span> and per share data in this Quarterly Report on Form 10-Q have been adjusted for all periods presented to reflect the Reverse Stock Split.</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">Facility Sublease</span></div>

        <div>
          <div><br />
          </div>

          <div style="color: #000000; text-align: justify; text-indent: 36pt;">On October 18, 2022, we entered into a sublease agreement (the &#8220;Sublease&#8221;) with E.R. Squibb &amp; Sons, L.L.C., a Delaware limited liability company and subsidiary of
            Bristol-Myers Squibb Company (&#8220;Sublessor&#8221;), for office, laboratory and research and development space (the &#8220;Premises&#8221;). The Premises consists of approximately 45,500 square feet on the ninth floor of the building currently under construction
            located at 250 Water Street, Somerville, Massachusetts 02141.</div>

          <div>&#160;</div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div>
          <div style="color: #000000; text-align: justify; text-indent: 36pt;">The Sublease rent commences on the date that is the earlier of (i) the date that the Company commences business operations from the Premises and (ii) the date that is the
            one-year anniversary of the later to occur of (A) October 18, 2022 and (B) the date that Sublessor obtains the primary landlord&#8217;s consent for the Sublease (such applicable date, the &#8220;Rent Commencement Date&#8221;). The Sublease has a term of 10 years
            from the Rent Commencement Date (the &#8220;Term&#8221;), subject to a five-year extension in accordance with the terms of the Sublease.</div>

          <div>&#160;</div>

          <div style="text-align: justify; text-indent: 24.5pt;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">Pursuant to the Sublease, we were required to deliver to the Sublessor a security deposit in the form of a letter of credit in
              the amount of $4.1 million. Provided there are no events of default by us under the Sublease, the letter of credit will be reduced on an incremental basis throughout the Term. The letter of credit was issued by our commercial bank, which
              required that we cash collateralize the letter of credit by depositing $4.1 million of restricted cash in a separate account maintained by such bank.&#160; The amount of restricted cash that we are required to maintain in such account will decline
              during the Term in parallel with the reduction of the amount of the letter of credit.&#160; This restricted cash requirement reduced the amount of working capital we have to fund our operations.</div>

          </div>

          <div>&#160;</div>

          <div style="color: #000000; text-align: justify; text-indent: 36pt;">Pursuant to the Sublease, we have agreed to pay base rent of $0.4 million per month during the first year of the Term, increasing on an incremental basis each subsequent year of
            the Term, as well as traditional lease expenses including, certain taxes, operating expenses and utilities.</div>

          <div>&#160;</div>

        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">Certain Related Party Transactions</span></div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: #000000;">On September 9, 2022, we entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Factor Bioscience Inc. (&#8220;Factor&#8221;), pursuant to which Factor has agreed to provide services to
            us as agreed between us and Factor and set forth in one or more work orders under the MSA, including the first work order included in the MSA. Factor has agreed to provide us with mRNA cell engineering research support services, including
            access to certain facilities, equipment, materials and training, and we have agreed to pay Factor an initial fee of $5.0 million, payable in twelve equal monthly installments of approximately $0.4 million. Following the initial 12-month period,
            we have agreed to pay Factor a monthly fee of $0.4 million until such time as the first work order under the MSA is terminated.</div>

        </div>

        <div>
          <div style="text-indent: 36pt;"><span style="color: #000000;"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: #000000;">We may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with 120 days&#8217; prior notice.&#160; Factor may
            terminate such work order only on and after the fourth anniversary of the date of the MSA, subject to providing us with 120 days&#8217; prior notice.&#160;&#160; In connection with entering into the MSA, on September 9, 2022, Factor&#8217;s subsidiary, Factor
            Limited, entered into a waiver agreement with Brooklyn LLC, pursuant to which Factor Limited agreed to waive payment of $3.5 million otherwise payable to it in October 2022 by Brooklyn LLC under its license agreement with Factor Limited.</div>

        </div>

        <div><br />
        </div>

        <div>
          <div>
            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As a result of entering into the Waiver Agreement and the MSA during third quarter of 2022, we recognized $3.5 million in
              research and development expense and a corresponding liability for the committed obligation in the License Agreement that is being paid through the MSA.</div>

            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">On September 6, 2022, we entered into an assignment and assumption of contracts agreement (the &#8220;Assignment and Assumption Agreement&#8221;) with Factor, pursuant to which we assumed
          certain contracts with third parties that Factor had previously entered into in anticipation of entering into a sublease for premises in Somerville, Massachusetts.&#160; In October 2022, we entered into the sublease for the premises.&#160; See Note 15 to
          our unaudited interim financial statements included in this Quarterly Report on Form 10-Q for more information on this subsequent event.&#160; Under the Assignment and Assumption Agreement, we agreed to reimburse Factor for costs already incurred and
          paid by Factor under the assumed contracts in the amount of approximately $0.1 million, and we assumed the future obligations under these contracts, which relate to the design and build-out of the subleased space.</div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: #000000;">The foregoing have been deemed related party transactions, as our Interim Chief Executive Officer, Dr. Matthew Angel, is also the Chairman and Chief Executive Officer of Factor
            and the Director of Factor Limited.&#160; For more information please see Note 8 and Note 15 to our unaudited interim financial statements included in this Quarterly Report on Form 10-Q.</div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000;"> <br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">Exacis Option Agreement</span></div>

        <div>
          <div><br />
          </div>

          <div style="color: #000000; text-align: justify; text-indent: 36pt;">On October 8, 2022, we entered into an option agreement (the &#8220;Option Agreement&#8221;) with Exacis Biotherapeutics, Inc., a Delaware corporation (&#8220;Exacis&#8221;), pursuant to which Exacis
            granted us the option to negotiate and enter into an exclusive worldwide license to certain of the technology licensed by Exacis for the treatment of cancer in humans (the &#8220;Option&#8221;). The Option Agreement provides that we will pay Exacis a fee
            of $0.3 million for the Option, which would be creditable against the fees or purchase price payable under any such license if entered into by us in accordance with Option Agreement. The Option Agreement provides for certain payments upon the
            execution of a definitive license agreement, which would become payable only upon execution, and in accordance with the terms, of the applicable license agreement, if any.</div>

          <div>&#160;</div>

          <div style="color: #000000; text-align: justify; text-indent: 36pt;">The Option Agreement has been deemed a related party transaction, as one of our Board members, Dr. Gregory Fiore, is the Chief Executive Officer of Exacis.&#160; Additionally, our
            Interim Chief Executive Office, Dr. Matthew Angel, is Chairman of Exacis&#8217; scientific advisory board. Dr. Angel is also the Chairman and Chief Executive Officer of Factor, which is the majority shareholder of Exacis. For more information please
            see Note 15 to our unaudited interim financial statements included in this Quarterly Report on Form 10-Q.</div>

          <div><br />
          </div>

        </div>

        <div style="text-indent: 36pt;"><span style="text-decoration: underline;">PIPE Transaction</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">On March 6, 2022, we entered into a Securities Purchase Agreement with an investor (the &#8220;PIPE Investor&#8221;) providing for the private placement (the &#8220;PIPE Transaction&#8221;) to the PIPE Investor of
          approximately 343,000 units (the &#8220;Units&#8221;), each of&#160; which consisted of (i) one share of our common stock (or, in lieu thereof, one pre-funded warrant (the &#8220;Pre-Funded Warrants&#8221;) to purchase one share of common stock) and (ii) one warrant (the
          &#8220;Common Warrants&#8221;) to purchase one share of common stock, for an aggregate purchase price of approximately $12.0 million (the &#8220;Subscription Amount&#8221;). The PIPE Transaction closed on March 9, 2022. We incurred fees of $1.0 million through September
          30, 2022 related to the PIPE Transaction.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Each Pre-Funded Warrant has an exercise price of $0.10 per share of common stock, was immediately exercisable and may be exercised at any time and has no expiration date and is subject to
          customary adjustments. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">On July 12, 2022, the PIPE Investor exercised its 68,000 Pre-Funded Warrants at an exercise price of $0.10 per share for an aggregate exercise price of $6,786, in cash.&#160; We issued 68,000 shares
          of common stock to the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds.&#160; Following the exercise, no Pre-Funded Warrants remained outstanding.</div>

        <div>
          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt;">Each Common Warrant has an exercise price of $38.20 per share, becomes exercisable six months following the closing of the PIPE Transaction, expires five-and-one-half years from the date of
            issuance, and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof,
            subject to increase to 9.99% at the option of the holder.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC 815-40, <span style="font-style: italic;">Derivatives and Hedging, Contracts in Entity&#8217;s Own Equity,</span>
          as these warrants provide for a cashless settlement provision that fails the requirement of the indexation guidance under ASC 815-40.&#160; The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair
          value presented within the statement of operations. Upon exercise of the Common Warrants and Pre-Funded Warrants, the fair value on the exercise date is reclassified from warrant liabilities to equity.</div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;">The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $12.6 million in the aggregate, which was $0.6 million more than the Subscription Amount.&#160; The
            excess $0.6 million represents an inducement to the PIPE Investor to enter into the PIPE Transaction and was recorded in warrant liabilities expense in the accompanying consolidated statement of operations.</div>

          <div><br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">In connection with the PIPE Transaction, we and the PIPE Investor also entered into a registration rights agreement, dated March 6, 2022, pursuant to which we agreed to prepare and file a
          registration statement with the SEC to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants. We agreed to use our best
          efforts to have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved.&#160; We filed such registration statement on April 29,
          2022, which became effective on May 11, 2022.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Pursuant to the registration rights agreement, we are obligated to pay the PIPE Investor liquidated damages equal to 2% of the Subscription Amount per month, with a maximum
          aggregate payment of 12% of the Subscription Amount, in the event the PIPE Investor is not permitted to use the registration statement to resell the related securities for more than 10 consecutive calendar days or more than an aggregate of
          fifteen calendar days (which need not be consecutive calendar days) during any 12-month period.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">On May 24, 2022, we provided the PIPE Investor with notice that it was not able to resell the securities under the registration agreement because we did not timely file our
          Quarterly Report on Form 10-Q (the &#8220;Q1 2022 10-Q&#8221;) with the SEC, and that the PIPE Investor could not use the registration statement to resell the related securities until we filed the Q1 2022 10-Q.&#160; Because the PIPE Investor was unable to use
          the resale registration statement for at least 10 consecutive calendar days, we accrued $0.2 million during the first quarter of 2022 for the estimated contingent loss we expect to incur as a result of the late Q1 2022 10Q filing, which is
          recorded in other expense, net for the nine months ended September 30, 2022 in the accompanying condensed consolidated statements of operations.&#160; We paid the $0.2 million liquidated damages payment in June 2022.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">On June 30, 2022, we filed the Q1 2022 10-Q along with the 10-K/A, and on July 1, 2022, we provided notice to the PIPE Investor that it may resume use of the resale
          registration statement.</div>

        <div><br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Basis of Presentation</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Reverse Stock Split</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">All<span style="color: #000000;"> share</span> and per share data in <span style="color: #000000;">this Quarterly Report on Form 10-Q</span> have been adjusted for all periods presented to
          reflect the Reverse Stock Split.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Revenues</div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We are a development stage company and have had no revenues from product sales to date. We will not have revenues from product sales until such time as we receive regulatory approval of our
          product candidates, successfully commercialize our products or enter into a licensing agreement which may include up-front licensing fees, of which there can be no assurance.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Research and Development Expenses</div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We expense our research and development costs as incurred. Our research and development expenses consist of costs incurred for company-sponsored research and development activities, as well as
          support for selected investigator-sponsored research. Upfront payments and milestone payments for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to
          have any alternative future uses other than the specific research and development project for which it was intended. In-Process Research and Development (&#8220;IPR&amp;D&#8221;) that is acquired through an asset acquisition and has no alternative future
          uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial expenses, insurance coverage for clinical trials,
          expensed licensed technology, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials and allocations of various overhead costs related to our product
          development efforts. We also have a Master Services Agreement with <span style="color: #000000;">Factor under which Factor provides us with mRNA cell engineering research support services, including access to certain facilities, equipment,
            materials and training.</span></div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;"> <br />
          </span></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">In the normal course of our business, we contract with third parties to perform various clinical study and trial activities in the on-going development and testing of potential products. The
          financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events or milestones, the
          successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar conditions. Preclinical and clinical study and trial associated
          activities such as production and testing of clinical material require significant up-front expenditures. We anticipate paying significant portions of a study&#8217;s or trial&#8217;s cost before such begins and incurring additional expenditures as the study
          or trial progresses and reaches certain milestones.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">General and Administrative Expenses</div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our general and administrative expenses consist primarily of salaries, benefits and other costs, including equity-based compensation, for our executive and administrative personnel, legal and
          other professional fees, travel, insurance, other costs of being a publicly traded company and other corporate costs.</div>

        <div> <br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Results of Operations</div>

        <div> <br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Comparison of the Three and Nine Months Ended September 30, 2022 and 2021</div>

        <div> <br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1"><br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Three months ended September 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="2"><br />
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Change</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(in thousands)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses:</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Research and development</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">4,963</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,491</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,472</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In-process research and development</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">80,538</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(80,538</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">General and administrative</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,341</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">4,247</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(906</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Total operating expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">8,304</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">86,276</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(77,972</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(8,304</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(86,276</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">77,972</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other income, net:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,024</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,024</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss on non-controlling investment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(21</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(21</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other (expense) income, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(10</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">290</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(300</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Total income, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">993</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">290</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">703</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss before income taxes</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(7,311</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(85,986</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">78,675</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Provision for income taxes</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(5</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(5</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(7,316</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(85,986</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">78,670</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        </div>

        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1"><br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Nine months ended September 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="2"><br />
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Change</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(in thousands)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses:</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Research and development</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">8,430</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">8,456</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(26</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In-process research and development</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">5,990</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">80,538</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(74,548</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">General and administrative</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">14,060</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">10,451</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,609</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Transaction costs</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">5,765</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(5,765</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Total operating expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">28,480</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">105,210</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(76,730</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(28,480</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(105,210</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">76,730</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other income (expense), net:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss on sale of NTN assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(9,648</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">9,648</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">10,493</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">10,493</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss on non-controlling investment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(932</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(932</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other (expense) income, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(1,166</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">265</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(1,431</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Total other income (expense), net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">8,395</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(9,383</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">17,778</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Loss before income taxes</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(20,085</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(114,593</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">94,508</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Provision for income taxes</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(5</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(5</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(20,090</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(114,593</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">94,503</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        </div>

        <div> <br />
        </div>

        <div> <span style="font-style: italic;">Research and Development Expenses </span> </div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Three months ended September 30,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">MSA expense</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,699</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,699</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">183</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">448</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(265</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Payroll-related</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">736</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">744</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(8</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other expenses, net</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">345</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">299</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">46</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Total research and development expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">4,963</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,491</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,472</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Nine months ended September 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Change</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(in thousands)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">MSA expense</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,699</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">--</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3,699</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">License fees</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">4,000</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(4,000</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Clinical trials</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">812</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,076</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(264</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Payroll-related</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">2,337</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,797</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">540</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,075</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1,018</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">57</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Other expenses, net</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">507</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">565</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(58</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Total research and development expenses</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">8,430</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">8,456</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(26</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>


</table>
          <div> <br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">For the three months ended September 30, 2022, our total research and development expenses increased compared to the prior year
            period, which was primarily the result MSA expenses recognized during the three months ended September 30, 2022. There were no comparable MSA expense in the prior year period. This increase in expense was offset by a decrease in stock-based
            compensation expense for the three months ended September 30, 2022, resulting from stock option and restricted stock unit forfeitures.</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">36</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">For the nine months ended September 30, 2022, our research and development expenses decreased primarily due to a $4.0 million
            license fee paid in 2021 to Factor Limited and Novellus, Ltd. (the &#8220;Licensors&#8221;) under the License Agreement with the Licensors, as well as due to a decrease in clinical trial and other miscellaneous expense, offset by increased expenses related
            to the MSA, increased payroll due to severance expense and stock compensation expense related to an increase in equity awards granted during 2022 when compared to the same period in 2021.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">In January 2022, we completed a reduction in our workforce involving eight research and development employees.&#160; As a result, we incurred approximately $0.5 million for severance and
          termination-related costs, which we recorded during the first quarter of 2022. In June 2022, we made the decision to consolidate our research and development in Cambridge, Massachusetts, and as a result, we accrued approximately $0.1 million for
          severance and termination-related costs for certain employees in the San Diego, California location.&#160; In August 2022, we recognized approximately $0.3 million in severance expense related to the resignation of a San Diego executive.</div>

        <div><br />
        </div>

        <div style="font-style: italic;">
          <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Impairment of In-Process Research and Development</div>

        </div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Three months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Impairment of in-process research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>80,538</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(80,538</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Nine months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; white-space: nowrap;">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; white-space: nowrap;">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;">
                <div style="font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Impairment of in-process research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>5,990</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>80,538</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(74,548</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">As discussed above, in June 2022, we received the results from the INSPIRE phase 2 trial of IRX-2. The IRX-2 multi-cytokine biologic immunotherapy represents substantially all the fair value
          assigned to the technologies of IRX that we acquired in 2018. Despite outcomes that favored IRX-2 in certain predefined subgroups, the INSPIRE trial did not meet the primary endpoint of Event-Free Survival (EFS) at two years of follow up.
          Significant additional clinical development work will be required to advance IRX-2 in the form of additional Phase 2 and 3 studies to further evaluate the treatment effect of IRX-2 in patient subgroups and in combination with checkpoint inhibitor
          therapies.&#160; The INSPIRE trial is the only company sponsored study of IRX-2.&#160; IRX-2 has been studied externally in other clinical settings outside of head and neck cancer in the form of investigator sponsored trials, which have either ended or are
          not currently active. Based on the totality of available information, we currently do not have plans to further develop the IRX-2 product candidate. As such, we determined that the carrying value of the IPR&amp;D asset was impaired and recognized
          a non-cash impairment charge of approximately $6.0 million for the nine months ended September 30, 2022.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2021, we expensed the $80.5 million fair value of IPR&amp;D acquired in the Novellus Acquisition because there was no future alternative use
          for the IPR&amp;D other than for its intended purpose.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">37</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">General and Administrative Expenses</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Three months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,353</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,708</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(355</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>293</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,280</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(988</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll-related</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>424</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>546</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(121</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Insurance</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>528</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>367</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>161</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Occupancy expense</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>189</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>177</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>12</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Loss on disposal of assets</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>156</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>13</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>143</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other expenses, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>398<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>156</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>242</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total general and administrative expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>3,341</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>4,247</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>(906</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Nine months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll-related</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>2,706</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>720</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,986</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Impairment of ROU asset</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>772</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>772</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Insurance</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,421</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>767</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>654</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Loss on disposal of fixed assets</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>431</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>13</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>418</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Occupancy expense</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>541</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>478</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>63</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>4,776</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>5,748</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(972</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,465</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>2,284</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(821</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other expenses, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>1,950</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>441</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>1,509</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total general and administrative expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>14,060</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>10,451</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>3,609</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our general and administrative expenses decreased for the three months ended September 30, 2022, as compared to the same period in 2021, primarily due to a decrease in professional fees for
          accounting services, decreased stock-based compensation expense from the forfeitures of stock-options and restricted stock units, and decreased payroll-related expense due to a decrease in headcount, which was offset by an increase in severance
          expense when compared to the same period in 2021.&#160; These decreases were further offset by increases for the three months ended September 30, 2022 in insurance premiums, the disposal of certain assets related to consolidating our research and
          development activities in Cambridge, Massachusetts, and other expenses due to legal-related matters, as compared to the same period in 2021.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The increase in general and administrative expense for the nine months ended September 30, 2022 was primarily related to increased headcount as well as severance expense for certain employees,
          including our former Chief Executive Officer, who resigned effective May 26, 2022.&#160; We also recognized a non-cash impairment charge on our San Diego, California right-of-use (&#8220;ROU&#8221;) operating lease asset due to consolidating our research and
          development activities in Cambridge, Massachusetts and our intention to sublease the San Diego, California facility.&#160; Other increases included premiums for public company insurance policies, losses on the disposal of fixed assets and other fees
          primarily due to legal-related matters, as compared to the same period in 2021.&#160; These increases were offset by decreased professional fees for accounting and legal services and decreased stock-based compensation expense due to primarily to
          forfeitures of stock options and restricted stock units when compared to the same periods in 2021.</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Transaction Costs</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The $5.8 million in transaction costs incurred for the nine months ended September 30, 2021 related to the issuance of common stock to Brooklyn LLC&#8217;s financial advisor upon consummation of the
          Merger, and there were no comparable transaction costs for same period in 2022.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">38</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Loss on Sales of NTN Assets</div>

        <div style="text-align: justify;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We incurred a $9.6 million loss on the sale of NTN assets for the nine months ended September 30, 2021 in connection with the Disposition, and there were no comparable transaction costs for
          either the three or nine-month periods ended September 30, 2022.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Warrant Liabilities Expense</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">For the three months ended September 30, 2022, we recognized a credit of $1.0 million for the change in the fair value of warrant liabilities due to a decrease in the market price of our common
          stock during the quarter.&#160; For the nine months ended September 30, 2022, we recognized a credit of&#160; $11.1 million for the change in the fair value of warrant liabilities, which was offset by $0.6 million in expense related to the excess fair
          value of the Common Warrants and Pre-Funded Warrant issued in connection with the PIPE Transaction over the $12.0 million gross proceeds received. There were no comparable expenses for same periods in 2021.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Loss on Non-Controlling Investment</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">We account for our investment in NoveCite under the equity method.&#160; During the three and nine months ended September 30, 2022,
            we recognized approximately $21,000 and $0.9 million of loss, respectively, on our 25% non-controlling investment in NoveCite, respectively.&#160; Of the $0.9 million loss for the nine months ended September 30, 2022, $0.5 million relates to the
            prior year.&#160; We do not have guaranteed obligation of NoveCite nor are we otherwise committed to providing further financial support for NoveCite.&#160; Therefore, we will record losses only up to our investment carrying amount.&#160; There were no
            comparable expenses for same periods in 2021.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Other Expense, Net</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Three months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest expense, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(10</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(20</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>10</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income from PPP loan forgiveness</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>310</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(310</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total other (expense), income net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(10</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>290</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(300</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Six months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">PIPE transaction fees</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(1,007</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(1,007</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Liquidated damages</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(240</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(240</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest expense, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(24</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(56</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>32</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income from PPP loan forgiveness</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>310</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(310</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other income, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>105</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>11</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>94</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total other (expense), income net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>(1,166</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>265</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>(1,431</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We recognized a change from other income, net of $0.3 million for the three months ended September 30, 2021 to other expense, net of $10,000 for the three months ended September 30, 2022.&#160; This
          change was primarily related to income we recognized in 2021 for the forgiveness of Brooklyn LLC&#8217;s loan under the Payment Protection Program (&#8220;PPP&#8221;).&#160; We did not have such income for the same period in 2022.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We recognized a change from other income, net of $0.3 million for the nine months ended September 30, 2021 to other expense, net of approximately $1.2 million for the nine months ended September
          30, 2022.&#160; During the nine months ended September 30, 2022, our increase in other expense, net was primarily due to fees related to the PIPE Transaction, which was allocated to the warrants issued in connection with the transaction. Additionally,
          we recorded a loss related to the liquidated damages we incurred under our registration rights agreement with the PIPE Investor as a result of not timely filing with the SEC our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.&#160;
          During the nine months ended September 30, 2021, we recognized income from the forgiveness of our PPP loan.&#160; We did not have such income for the same period in 2022.&#160; These increases in expense were offset by income from the sale of certain fixed
          assets and a decrease in interest expense when compared to the same period in 2021.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">39</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Provision for Income Taxes</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">During 2022, we expect to incur state income tax liabilities related to our operations. We have established a full valuation allowance for all deferred tax assets, including our
          net operating loss carryforwards, since we could not conclude that we were more likely than not able to generate future taxable income to realize these assets. The effective tax rate differs from the statutory tax rate due primarily to our full
          valuation allowance.</div>

        <div><br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Liquidity and Capital Resources</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">At September 30, 2022, we had cash and cash equivalents of approximately $13.3 million.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">On March 9, 2022, we issued 275,000 shares of common stock and Pre-Funded Warrants representing approximately 68,000 shares of common stock for net proceeds of approximately $11.0 million in
          connection with the PIPE Transaction.&#160; The 68,000 shares Pre-Funded Warrants were exercised on July 12, 2022 at an exercise price of $0.10 per share for total proceeds of approximately $7,000.&#160; Pursuant to the purchase agreement entered into in
          respect of the PIPE Transaction, we are prohibited from issuing equity in variable rate transactions for a period of one-year following consummation of the PIPE Transaction, including issuing equity under the Second Purchase Agreement.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On October 18, 2022, we entered into the Sublease for approximately 45,500 square feet of office and laboratory space in
          Somerville, Massachusetts.&#160; As part of the Sublease, we delivered a security deposit in the form of a letter of credit in the amount of $4.1 million, which will be reduced on an incremental basis throughout the term of the lease.&#160; The letter of
          credit was issued by our commercial bank, which required that we cash collateralize the letter of credit with $4.1 million of cash deposited in a restricted account maintained by such bank.&#160; The amount of required restricted cash collateral will
          decline in parallel with the reduction in the amount of the letter of credit over the term of the sublease.&#160; The required restricted cash reduced the amount of working capital we have to fund our operations.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We have to date incurred operating losses, and we expect these losses to continue in the future as we further develop our product development programs and operate as a publicly traded company.&#160;
          Developing product candidates, conducting clinical trials and commercializing products are expensive, and we will need to raise substantial additional funds to achieve our strategic objectives. It will likely be some years before we obtain the
          necessary regulatory approvals to commercialize one or more of our product candidates. Based on our current financial condition and forecasts of available cash, including as mentioned above, we believe we do not have sufficient funds to fund our
          operations for the next twelve months from the filing of the financial statements contained in this Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the &#8220;Q3 2022 10-Q&#8221;). There can be no assurance that we will ever be in a
          position to commercialize IRX-2 or any other product candidate we may acquire, or that we will obtain any additional financing that we require in the future or, even if such financing is available, that it will be obtainable on terms acceptable
          to us.</div>

        <div style="text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">In that regard, our future funding requirements will depend on many factors, including:</div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the terms and timing of any collaborative, licensing and other agreements that we may establish;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost and timing of regulatory approvals;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">40</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost and timing of establishing sales, marketing and distribution capabilities;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the effect of competition and market developments;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the scope, rate of progress and cost of our clinical trials and other product development activities; and</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>future clinical trial results.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We plan to raise additional funds to support our product development activities and working capital requirements through the remaining availability under the Second Purchase Agreement (to the
          extent we are permitted to use such agreement), public or private equity offerings, debt financings, strategic partnerships, out-license collaborations or other means. We may also seek governmental grants to support our clinical trials and
          preclinical trials. Further, we may seek to raise capital to fund additional product development efforts even if we have sufficient funds for our planned operations. Any sale by us of additional equity or convertible debt securities could result
          in dilution to our stockholders. There can be no assurance that any such required additional funding will be available to us at all or available on terms acceptable to us.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Further, to the extent that we raise additional funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that are
          not favorable to us. If we are not able to secure additional funding when needed, we may have to delay the commercialize of our products, reduce the scope of or eliminate one or more research and development programs, which could have an adverse
          effect on our business.</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt; font-style: italic;">Cash Flows</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt; color: #000000;">Cash flows from operating, investing and financing activities, as reflected in the accompanying consolidated statements of cash flows, are summarized as follows:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: #000000; font-weight: bold;">For the nine months ended<br />
                  September 30,</div>
              </td>

    <td valign="bottom" rowspan="2" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;&#160;</td>

    <td valign="bottom" rowspan="2" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;&#160;</td>

    <td valign="bottom" rowspan="2" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;
                <div style="text-align: center; color: #000000; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" rowspan="2" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-weight: bold;">2021</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cash (used in) provided by:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Operating activities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">(15,541</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">(16,656</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000;">1,115</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Investing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: #000000;">(176</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: #000000;">(22,595</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: #000000;">22,419</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Financing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: #000000;">11,986</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: #000000;">62,004</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: #000000;">(50,018</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net (decrease) increase in cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: #000000;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: #000000;">(3,731</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: #000000;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: #000000;">22,753</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: #000000;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: #000000;">(26,484</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div style="color: #000000;">)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: #000000;"><span style="text-decoration: underline;">Net Cash Used in Operating Activities</span></div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000;">
            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The decrease in cash used in operating activities was due to a decrease in net loss of $4.3 million, after giving effect to
              adjustments made for non-cash transactions, offset by an increase in cash provided by operating assets and liabilities of $5.4 million during the nine months ended September 30, 2022 compared to the same period in 2021.&#160; The increase in cash
              provided by operating assets and liabilities was primarily driven by increased accrued compensation due to higher headcount and severance, accrued costs for litigation matters, increased liabilities related to the MSA and increased insurance
              liabilities.</div>

          </div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000;"><span style="text-decoration: underline;">Net Cash Used in Investing Activities</span></div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt;">The decrease in net cash used in investing activities was primarily due to cash used to purchase Novellus of $22.9 million during the nine months ended September 30, 2022 compared to the same
            period in 2021, which was offset by proceeds of approximately $0.3 million from the Merger and the Disposition transactions.&#160; There were no similar transactions during the nine months ended September 30, 2022.</div>

          <div><br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">41</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;"><span style="text-decoration: underline;">Net Cash Provided by Financing Activities</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">The decrease in net cash provided by financing activities was primarily the result of a decrease in net proceeds from capital raises of approximately $51 million, net, offset by a
          decrease in principal payments made for long-term debt arrangements of $0.5 million during the nine months ended September 30, 2022 compared to the same period in 2021.</div>

        <div><br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Critical Accounting Estimates</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">There were no significant changes in our critical accounting estimates during the three and nine months ended September 30, 2022 from those described in &#8220;Management&#8217;s Discussion and Analysis of
          Financial Condition and Results of Operations&#8221; section of the 10-K/A.</div>

        <div> <br />
        </div>

        <div style="text-align: justify; font-weight: bold;">Recent Accounting Pronouncements</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In September 2022, the Financial Accounting Standard Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2022-04, <span style="font-style: italic;">Liabilities&#8212;Supplier

















            Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations </span>(&#8220;ASU 2022-04&#8221;). ASU 2022-04 requires a buyer that uses supplier finance programs to make annual disclosures about the program&#8217;s key terms, the
          balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and associated roll-forward information. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim
          periods within those fiscal years, except for the requirement to disclose roll-forward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect a material impact on our financial statements as a result
          of adopting this amendment.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">In June 2022, FASB issued ASU No. 2022-03, </span><span style="font-style: italic; color: #000000;">Fair Value Measurement (Topic 820): Fair Value Measurement of
            Equity Securities Subject to Contractual Sale Restrictions </span><span style="color: #000000;">(&#8220;ASU 2022-03&#8221;).</span> The FASB issued ASU 2022-03 to (1) clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value
          of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity related securities subject to
          contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity
          security and, therefore, is not considered in measuring fair value. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years with early adoption permitted. We are evaluating when
          to adopt the amendments in ASU 2022-02. We do not expect a material impact on our financial statements as a result of adopting this amendment.</div>

        <div><br />
        </div>

        <a id="QuantitativeandQualitativ"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top;">&#160;<span style="font-weight: bold;">Item 3.</span></td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Quantitative and Qualitative Disclosures About Market Risk.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Under the rules and regulations of the SEC, as a smaller reporting company we are not required to provide the information otherwise required by this item.</div>

        <div> <br />
        </div>

        <a id="ControlsandProcedures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 48.7pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Controls and Procedures.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-indent: 36pt; font-style: italic;">Disclosure Controls and Procedures</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, designed to ensure that information required to be disclosed in
          our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including
          our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">42</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
          of achieving the desired control objectives, and we were required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of the end of the period covered by this
          Q3 2022 10-Q under the supervision, and with the participation, of our management, including our interim Chief Executive Officer and President (who serves as our principal executive officer) and our Chief Financial Officer (who serves as our
          principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Based on that evaluation, our interim Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of the period
          covered by this Q3 2022 10-Q in providing reasonable assurance of achieving the desired control objectives due primarily to the material weaknesses discussed below.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt; font-style: italic;">Management&#8217;s Plan for Material Weaknesses in Internal Control over Financial Reporting</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Upon completion of the Merger in March 2021 and the resulting change in our business model and strategy, we experienced a complete turnover of our employees, including all of the members of our
          executive management team, which resulted in, among other things, our having insufficient accounting staff available to enable and ensure adequate segregation of duties and our lacking appropriate and complete documentation of policies and
          procedures critical to the accomplishment of financial reporting objectives. The accounting personnel and documentation deficiencies each increase the risk that a material misstatement of our financial statements will not be prevented or detected
          on a timely basis.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Additionally, we were unable to timely file our Q1 2022 10Q with the SEC due to identifying errors in our financial statements reported in the Original 10-K for the years ended December 31, 2021
          and 2020 during our preparation of the financial statements for the quarter ended March 31, 2022.&#160; Management concluded that the errors were the result of accounting personnel&#8217;s&#8217; lack of technical proficiency in complex matters.&#160; We filed an
          amendment to our Annual Report on Form 10-K/A for the years ended December 31, 2021 and 2020 on June 30, 2022 to correct the errors in our financial statements for the years ended December 31, 2021 and 2020 and for the quarters ended June 30,
          2020, September 30, 2020, March 31, 2021, June 30, 2021 and September 30, 2021.&#160; See the Form 10-K/A for further detail on the restatement.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Management is implementing measures designed to ensure that the deficiencies contributing to the ineffectiveness of our internal controls over financial reporting are promptly remediated, such
          that the internal controls are designed, implemented and operating effectively. The remediation actions include:</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>hiring additional accounting personnel in a number, and with experience, to allow for proper segregation of duties and the accurate application of GAAP, including a chief financial officer, whom we hired in May of 2022;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>developing and implementing, and then monitoring the effectiveness of, written policies and procedures required to achieve our financial reporting objectives in a timely manner, including policies and procedures relating to internal
                  control over financial reporting, which;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>providing additional training to accounting personnel; and.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>consulting with an accounting advisor for technical, complex and non-recurring matters, with whom we have engaged and begun consulting.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We are committed to developing a strong internal control environment, and we believe the remediation efforts that we have implemented and will implement will result in significant improvements in
          our control environment. Following indications of internal control deficiencies in early 2021, we hired our Vice President of Finance in the second quarter of 2021 to oversee all accounting and financial reporting matters, including implementing
          a framework for internal controls over financial reporting, a full-time controller at the beginning of 2022, and our chief financial officer in May of 2022. Also, during the fourth quarter of 2021, we engaged a third-party consulting firm with
          expertise in implementing the framework for internal controls over financial reporting, and we are making progress on developing this framework, including identifying key controls, creating process narratives or flowcharts, developing test plans,
          and testing of the key controls to ensure the framework is complete and effective. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over
          financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">43</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt; font-style: italic;">Changes in Internal Control over Financial Reporting</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Other than described above, there was no change in our internal control over financial reporting during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our
          internal control over financial reporting.</div>

        <div> <br />
        </div>

        <div style="text-align: center; font-weight: bold;">PART II &#8212; OTHER INFORMATION</div>

        <div> <br />
        </div>

        <a id="Item1."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 41.3pt; vertical-align: top; font-weight: bold;">Item 1.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Legal Proceedings.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">This information is set forth under &#8220;Note 10&#8212;Commitments and Contingencies&#8212;Legal Matters&#8221; to the condensed consolidated financial statements included in this Q3 2022 10-Q and is incorporated in
          this Item 1 by reference.</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">From time to time we may become involved in legal proceedings arising in the ordinary course of business. Except as described above, we do not believe there is any litigation pending that could
          have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or cash flows.</div>

        <div> <br />
        </div>

        <a id="Item1A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 48.1pt; vertical-align: top; font-weight: bold;">Item 1A.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Risk Factors.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">During the reporting period covered by this Quarterly Report on Form 10-Q, there have been no material changes to our risk
            factors as set forth in the 10-K/A and our subsequently filed Quarterly Reports on Form 10-Q.</div>

        </div>

        <div><br />
        </div>

        <a id="Item2."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 42pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Unregistered Sales of Equity Securities and Use of Proceeds.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-indent: 36pt;">None</div>

        <div><br />
        </div>

        <a id="Item3."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.45pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 3.</td>

    <td style="vertical-align: top; text-align: justify;">
                <div style="color: #000000; font-style: italic; font-weight: bold;">Defaults Upon Senior Securities.</div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: -55.45pt; margin-left: 55.45pt;"><span style="color: #000000;"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 24.5pt; color: #000000;">None.</div>

        <div style="text-align: justify; text-indent: -55.45pt; margin-left: 55.45pt;"><span style="color: #000000;"> </span><br />
        </div>

        <a id="Item4."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.45pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: #000000; font-style: italic; font-weight: bold;">Mine Safety Disclosures.</div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: -55.45pt; margin-left: 55.45pt;"><span style="color: #000000;"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 24.5pt; color: #000000;">Not Applicable.</div>

        <div style="text-align: justify; text-indent: -55.45pt; margin-left: 55.45pt;"><span style="color: #000000;"> </span><br />
        </div>

        <a id="Item5."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.45pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 5.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: #000000; font-weight: bold;"><span style="font-style: italic;">Other Information</span>.</div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: -55.45pt; margin-left: 55.45pt;"><span style="color: #000000;"> </span><br />
        </div>

        <div style="text-indent: 24.5pt; color: #000000;">None.</div>

        <div><br />
        </div>

        <a id="Item6."><!--Anchor--></a>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 48.15pt; vertical-align: top; font-weight: bold;">Item 6.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-style: italic; font-weight: bold;">Exhibits.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">44</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 8.01%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="font-weight: bold;">Exhibit</div>
              </td>

    <td style="width: 0.74%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>

    <td style="width: 66%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-weight: bold;">Description</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="font-weight: bold;">Incorporated By Reference</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: #0000FF;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036122033478/brhc10041894_ex10-1.htm">10.1</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: #000000;">Master Services Agreement, dated September 9, 2022, by and between Factor Bioscience Inc. and the Company.</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit 10.1 to Form 8-K filed on September 15, 2022</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top;">
                <div style="color: #0000FF;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036122031997/brhc10041542_ex10-1.htm">10.2*</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top;">&#160;</td>

    <td style="width: 66%; vertical-align: top;">
                <div style="color: #000000;">Separation Agreement and General Release, dated August 24, 2022, by and between the Company and Kevin D&#8217;Amour.</div>
              </td>

    <td style="width: 0.54%; vertical-align: top;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">
                <div>Exhibit 10.1 to Form 8-K/A filed on September 1, 2022</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10043851_ex10-3.htm">10.3</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Third Amended and Restated Exclusive License Agreement, dated November 1, 2020, by and between Factor Bioscience Limited and Novellus
                  Therapeutics Limited.</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top;">
                <div><a href="brhc10043851_ex31-1.htm">31.1</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top;">&#160;</td>

    <td style="width: 66%; vertical-align: top;">
                <div>Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.54%; vertical-align: top;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="brhc10043851_ex31-2.htm">31.2</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top;">
                <div><a href="brhc10043851_ex32-1.htm">32.1</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top;">&#160;</td>

    <td style="width: 66%; vertical-align: top;">
                <div>Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.54%; vertical-align: top;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">
                <div>Furnished herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="brhc10043851_ex32-2.htm">32.2</a></div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Furnished herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top;">
                <div>101.INS</div>
              </td>

    <td style="width: 0.74%; vertical-align: top;">&#160;</td>

    <td style="width: 66%; vertical-align: top;">
                <div>Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</div>
              </td>

    <td style="width: 0.54%; vertical-align: top;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>101.SCH</div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Inline XBRL Taxonomy Extension Schema Document</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top;">
                <div>101.CAL</div>
              </td>

    <td style="width: 0.74%; vertical-align: top;">&#160;</td>

    <td style="width: 66%; vertical-align: top;">
                <div>Inline XBRL Taxonomy Extension Calculation Linkbase Document</div>
              </td>

    <td style="width: 0.54%; vertical-align: top;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>101.DEF</div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Inline XBRL Taxonomy Extension Definition Linkbase Document</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top;">
                <div>101.LAB</div>
              </td>

    <td style="width: 0.74%; vertical-align: top;">&#160;</td>

    <td style="width: 66%; vertical-align: top;">
                <div>Inline XBRL Taxonomy Extension Label Linkbase Document</div>
              </td>

    <td style="width: 0.54%; vertical-align: top;">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>101.PRE</div>
              </td>

    <td style="width: 0.74%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 66%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Inline XBRL Taxonomy Extension Presentation Linkbase Document</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.01%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>104</div>
              </td>

    <td style="width: 0.74%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 66%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</div>
              </td>

    <td style="width: 0.54%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 24.1%; vertical-align: top;">&#160;</td>

  </tr>


</table>
        <div> <br />
        </div>

        <div>*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management contract or compensation plan or arrangement</div>

        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">45</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: italic;"><a href="#TABLEOFCONTENTS"> Table of
                Contents</a><br />
            </div>

          </div>

        </div>

        <a id="SIGNATURE"><!--Anchor--></a>
        <div style="text-align: center; font-weight: bold;">SIGNATURE</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.95%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="width: 50.05%; vertical-align: bottom;">
                <div style="text-align: justify;">ETERNA THERAPEUTICS INC.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.1%; vertical-align: middle;">&#160;</td>

    <td style="width: 46.96%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top;">
                <div style="text-align: justify;">Date: November 14, 2022</div>
              </td>

    <td style="width: 3.1%; vertical-align: bottom;">
                <div style="text-align: justify;">By:</div>
              </td>

    <td style="width: 46.96%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">/s/ Andrew Jackson</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top;">&#160;</td>

    <td style="width: 3.1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.96%; vertical-align: bottom;">
                <div style="text-align: justify;">Andrew Jackson</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top;">&#160;</td>

    <td style="width: 3.1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.96%; vertical-align: bottom;">
                <div style="text-align: justify;">Chief Financial Officer</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.95%; vertical-align: top;">&#160;</td>

    <td style="width: 3.1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.96%; vertical-align: bottom;">
                <div style="text-align: justify;">(on behalf of the Registrant and as Principal Financial Officer)</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-align: center;"> <br />
          <span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">46</span></div>

        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>


  </div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>brhc10043851_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman,Times,serif; text-align: right;">
  <!--PROfilePageNumberReset%Num%1%- % -%-->
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b> </b></font></p>
  <hr noshade="noshade" style="height: 4px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); margin-left: auto; margin-right: auto; border: medium none;">
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b> </b></font></p>
  <b> </b> <b>Exhibit 10.3<br>
  </b> <b> </b> <b><br>
  </b>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Factor Bioscience Limited</b></font><font style="font-family: Times New Roman,Times,serif;"><br>
      <font style="font-size: 10pt;"><b>Novellus Therapeutics Limited</b></font></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><u>THIRD AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT</u></font></p>
  <p style="margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">THIS THIRD AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this &#8220;<i><u>Agreement</u></i>&#8221;)



      is entered into as of this 1st day of November, 2020 (the &#8220;<i><u>Third Amendment Effective Date</u></i>&#8221;), by and between Factor Bioscience Limited, a company organized and existing under the laws of Ireland (&#8220;<i><u>Licensor</u></i>&#8221;), and Novellus
      Therapeutics Limited, a company organized and existing under the laws of Ireland (&#8220;<i><u>Licensee</u></i>&#8221;), and supersedes and replaces the Second Amended and Restated Exclusive License Agreement (the &#8220;<i><u>Prior Agreement</u></i>&#8221;) entered into as
      of the 16th day of March, 2020 (the &#8220;<i><u>Second Amendment Effective Date</u></i>&#8221;), by and between Licensor and Licensee. Licensor and Licensee may each be referred to in this Agreement individually as a &#8220;<i><u>Party</u>&#8221;</i> and collectively as
      the &#8220;<i><u>Parties</u></i>.&#8221;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">WHEREAS, Licensor and Licensee previously entered into an Exclusive
      License Agreement (the &#8220;<i><u>Original Agreement</u></i>&#8221;) as of the 6th day of February, 2015 (the &#8220;<i><u>Effective Date</u></i>&#8221;), subsequently amended and restated the Original Agreement by entering into an Amended and Restated Exclusive License
      Agreement (the &#8220;<i><u>First Amended and Restated Agreement</u></i>&#8221;) as of the 15th day of June, 2018 (the &#8220;<i><u>Amendment Effective Date</u></i>&#8221;), and subsequently amended and restated the First Amended and Restated Agreement by entering into the
      Prior Agreement;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">WHEREAS, the Parties desire to amend, restate, and replace such Prior
      Agreement to, among other things, amend certain definitions and provisions, terminate certain rights and licenses previously granted to Licensee under the Prior Agreement, and grant Licensee rights to certain Licensed Technology in the Field (as such
      terms are defined herein);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">WHEREAS, Licensor owns or has in-licensed certain Licensed Technology (as
      defined herein) pertaining to technology, processes and products, including, but not limited to, methods and compositions for generating Cell Lines (as such term is defined herein);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">WHEREAS, Licensee desires to develop and commercialize Licensed Products
      (as defined herein), and Licensee desires to receive from Licensor certain rights to the Licensed Technology in order that Licensee may develop and commercialize Licensed Products (as defined herein); and</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">WHEREAS, in furtherance of the foregoing, Licensor agrees to grant such
      rights to Licensee, and Licensee agrees to use Commercially Reasonable Efforts (as defined herein) to diligently proceed to develop and make commercially available Licensed Products in accordance with this Agreement for commercial exploitation in the
      Field (as defined herein) and in the Territory (as defined herein);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-indent: 37pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in
      this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 1</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Definitions</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-indent: 37pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Unless otherwise specifically provided herein, the following terms, when
      used with a capital letter at the beginning, will have the following meanings:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 1 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Affiliate</u></i>&#8221; means, with respect to a Party, a person, corporation,
      partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control
      with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting
      stock of such entity, or by contract or otherwise. For the purposes of this definition and this Agreement, and for the avoidance of doubt, Factor Bioscience Limited. Factor Bioscience Pty Ltd, Factor Bioscience LLC, and Factor Bioscience Inc.
      (collectively, the &#8220;<i><u>Factor Bio Entities</u></i>&#8221;) are each deemed not to be Affiliates of any of Novellus Therapeutics Limited, Novellus LLC, and Novellus, Inc. (collectively, the &#8220;<i><u>Novellus Entities</u></i>&#8221;), and each of the Novellus
      Entities is deemed not to be an Affiliate of any of the Factor Bio Entities.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Agreement</u></i>&#8221; has the meaning set forth in the Preamble.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Amendment Effective Date</u></i>&#8221; has the meaning set forth in the
      Preamble.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Applicable Law</u></i>&#8221; means all statutes, ordinances, regulations,
      rules or orders of any kind whatsoever of any agency, bureau, branch, office, court, commission, authority, department, ministry, official or other instrumentality of, or being vested with public authority under any law of, any country, state or
      local authority or any political subdivision thereof, or any association of countries that may be in effect from time to time and applicable to the activities contemplated by this Agreement.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Auxiliary Technologies</u></i>&#8221; means (a) any one or more of the
      technologies set forth on <u>Exhibit 1.5</u>, and (b) any Improvement.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Auxiliary Technology Patents</u></i>&#8221; means (a) the patents and patent
      applications set forth on <u>Exhibit 1.6</u>, (b) any reissue, divisional, continuation, reexamination, renewal, extension or supplementary protection certificate for each of the patents and patent applications set forth on <u>Exhibit 1.6</u>, (c)
      the Improvement Patents, and (d) any reissue, divisional, continuation, reexamination, renewal, extension or supplementary protection certificate for each of the Improvement Patents, but only to the extent that each of the foregoing in clauses (a),
      (b), (c), and (d) (i) is Controlled by Licensor, (ii) includes at least one claim that is directed to subject matter disclosed in the patents and patent applications described in clause (a) above, and claims priority to such patents and patent
      applications, and (iii) is necessary or useful to Exploit the Licensed Products in the Field, and (c) all foreign patents and patent applications corresponding to the foregoing specific patents and patent applications described in clause (a) and
      clause (b) above. For the avoidance of doubt, the Auxiliary Technology Patents do not include any patents not explicitly described in the preceding sentence.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Cell Line</u></i>&#8221; means a human pluripotent stem cell line that is made
      using the cell reprogramming methods disclosed in the Licensed Patents.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Combination Product</u></i>&#8221; shall mean any product that is comprised of
      a Licensed Product and one or more agents that are not themselves Licensed Product (the &#8220;<i><u>Other Agent(s)</u></i>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Commercially Reasonable Efforts</u></i>&#8221; means, with respect to the
      performance of research, development and/or commercialization activities hereunder, including with respect to the research, development and/or commercialization of any Licensed Product by or on behalf of Licensee, the carrying out of such activities
      using commercial and business efforts and resources comparable to the efforts and resources that a party would typically devote to products of similar market potential at a similar stage in development or product life, taking into account all
      scientific, commercial and other factors that such a party would take into account, including issues of safety, toxicity and efficacy, as well as regulatory requirements of the FDA or similar government agencies.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 2 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.10.&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Confidential Information</u></i>&#8221; means all
      Information disclosed by one Party to the other during the negotiation of or under this Agreement in any manner, whether orally, visually, electronically, in writing or in other tangible or intangible form, that relates to Licensed Technology, the
      Auxiliary Technologies, Cell Lines, Licensed Products, or this Agreement, unless such information is subject to an exception described in <u>Section 8.6</u>.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.11. <i>&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Control</u></i>&#8221; or &#8220;<i><u>Controlled by</u></i>&#8221;
      means, in the context of a license to or ownership of Intellectual Property, the ability on the part of a Party to grant access to or a license or sublicense of such Intellectual Property as provided for herein without violating the terms of any
      agreement or other arrangement between such Party and any third party existing at the time such Party would be required hereunder to grant such access or license or sublicense.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Cover</u>&#8221; </i>or &#8220;<i><u>Covered</u></i>&#8221; means that
      the use, manufacture, sale, offer for sale, research, development, commercialization, importation or other commercial exploitation of the subject matter in question by an unlicensed entity: (a) would infringe an issued or pending claim of a Licensed
      Patent or an Auxiliary Technology Patent, or (b) incorporates, uses, or otherwise relies upon the Licensed Technology or the Auxiliary Technologies.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Effective Date</u></i>&#8221; has the meaning set forth in
      the Preamble.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.14. <i>&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Exploit</u></i>&#8221; and &#8220;<i><u>Exploitation</u></i>&#8221;
      mean to develop, make, have made, manufacture, research, use, sell, have sold, offer for sale, commercialize, distribute, import and export.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>FDA</u>&#8221; </i>means the United States Food and Drug
      Administration or any successor agency thereto.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Field</u>&#8221; </i>means the Exploitation of Licensed
      Products for the treatment of diseases and conditions in humans and animals.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>First Commercial Sale</u></i>&#8221; means the first
      arm&#8217;s-length sale or other transfer for value of a Licensed Product by or on behalf of Licensee, or an Affiliate or sublicensee of Licensee, to an unrelated third party.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Improvement(s)</u></i>&#8221; means any Services Agreement
      Improvement and any other invention, discovery, advancement, development, or creation which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of Licensee or an Affiliate of Licensee (or Licensee&#8217;s or its
      Affiliate&#8217;s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions to) Licensee or its Affiliates): (b) is not an Independent Invention;
      and (c) meets at least one of the following criteria: (i) is an improvement or modification to the Licensed Technology, the Auxiliary Technologies or to the Cell Lines; (ii) utilizes, incorporates, or reads upon any element of the Licensed Technology
      or the Auxiliary Technologies or is invented, developed, authored, created, or reduced to practice using the Licensed Technology or the Auxiliary Technologies; and (iii) is invented, developed, authored, created, or reduced to practice by or on
      behalf of Licensor or an Affiliate of Licensor (or Licensor&#8217;s or its Affiliate&#8217;s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions
      to) Licensor or its Affiliates).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Improvement Patents</u></i>&#8221; means the patents and
      patent applications claiming Improvements, and any reissue, divisional, continuation, continuation-in-part or reexamination certificate thereof. During the Term, all Improvement Patents shall be set forth in <u>Exhibit 1.19</u>.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 3 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>IND</u>&#8221; </i>means an Investigational New Drug Application filed with
      the FDA required for the initiation of clinical trials in humans for the applicable Licensed Product in the United States (or the foreign equivalent thereof).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Independent Invention</u></i>&#8221; means any invention, discovery,
      advancement, development, or creation, which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of Licensee or an Affiliate of Licensee (or the personnel or agents of Licensee or an Affiliate of Licensee, including
      any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign inventions to) Licensee or an Affiliate of Licensee); (b) does not utilize, incorporate, or read upon any element of the
      Licensed Technology, Auxiliary Technology or a Valid Claim and is not invented, developed, authored, created, or reduced to practice using the Licensed Technology or the Auxiliary Technology; and (c) is not invented, developed, authored, created, or
      reduced to practice by Licensor (or Licensor&#8217;s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign inventions to) Licensor).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Information</u></i>&#8221; means all information, know-how, data, results,
      technology, materials, business or financial information of any type whatsoever, in any tangible or intangible form, provided by or on behalf of one Party to the other Party, either in connection with the discussions and negotiations pertaining to
      this Agreement or in the course of performing this Agreement, or that otherwise relates to the Licensed Technology, the Auxiliary Technologies, or Cell Lines, whether disclosed orally, visually, electronically, in writing or in other tangible or
      intangible form, and which may include data, knowledge, practices, processes, ideas, research plans, antibodies, small molecules, compounds, targets, biological and chemical formulations, structures and designs, laboratory notebooks, proof of concept
      and pre-clinical studies, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to the disclosing Party or to its present or future products,
      sales, suppliers, customers, employees, investors or business.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.23.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Intellectual Property</u></i>&#8221; means all (a) patents, patent
      applications, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, reexamination, post-grant proceeding, utility model, certificate of invention and design patents, applications, registrations and applications
      for registration, and any equivalent in any jurisdiction; (b) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications for registration thereof; (c) copyrights and
      registrations and applications for registration thereof, including all moral rights; (d) Information, inventions, trade secrets and confidential information, whether patentable or non-patentable and whether or not reduced to practice, know-how, show
      how, manufacturing and product processes and techniques, research and development information, notebooks, formulae, diagrams, technical and engineering specifications, business and marketing plans and customer and supplier lists and other
      information; (e) other proprietary rights relating to any of the foregoing (including remedies against infringement thereof and rights of protection of interest therein under the laws of all jurisdictions); and (f) copies and tangible embodiments
      thereof.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.24.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Licensed Know-How</u></i>&#8221; means all unpatented inventions, technology,
      methods, materials (including biological and pharmaceutical materials), know-how, studies, pre-clinical and clinical data (including toxicology and safety data), tests and assays, reports, manufacturing processes, regulatory filings (including
      drafts) and approvals and other information Controlled by Licensor as of the Effective Date, in each case that relates to the subject matter disclosed in the Licensed Patents or the Auxiliary Technology Patents and is necessary or useful to make, use
      or sell Licensed Products in the Field in the Territory.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellas Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 4 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.25.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Licensed Patents</u></i>&#8221; means (a) the patents and
      patent applications set forth on <u>Exhibit 1.25</u>, and (b) any reissue, divisional, continuation, reexamination, renewal, extension or supplementary protection certificate for each of the patents and patent applications set forth on <u>Exhibit
        1.25</u>, but only to the extent that each of the foregoing in clauses (a) and (b) (i) is Controlled by Licensor, (ii) includes at least one claim that is directed to subject matter disclosed in the patents and patent applications described in
      clause (a) above, and claims priority to such patents and patent applications, and (iii) is necessary or useful to Exploit the Licensed Products in the Field. For the avoidance of doubt, the Licensed Patents do not include any patents not explicitly
      described in the preceding sentence.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.26.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Licensed Product</u></i>&#8221; means any Covered
      allogeneic cell therapy product comprising MSCs for use in the Field. For the avoidance of doubt, Licensed Products expressly exclude autologous cell therapy products and any product comprising Covered cells that are not MSCs, except where such cells
      are present in inconsequential amounts and do not contribute appreciably to the potency, function, activity, or stability of the product.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.27.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Licensed Technology</u></i>&#8221; means the Licensed
      Patents, Licensed Know-How, Cell-Lines, and Improvement Patents, if any, all to the extent owned or Controlled by Licensor and in each case that are necessary for Licensee to Exploit the Licensed Products in the Field.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.28.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>MSCs</u>&#8221; </i>means a population of mesenchymal stem
      cells derived from a Cell Line, and having a set of specific, defined, and experimentally validated biological attributes.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.29.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Net Sales</u></i>&#8221; means all gross revenue collected
      from or through Licensee, its Affiliates, or sublicensees from any Licensed Product, including sales, licensing, leasing or other commercial exploitation of Licensed Products. Net Sales excludes the following items (but only as they pertain to the
      making, using, importing or selling of the applicable Licensed Product, are included in gross revenue, and are separately billed): (a) import, export, excise and sales taxes, custom duties, value added taxes, tariffs or other fees leveled by
      government authorities, and other consumption taxes similarly incurred or other governmental charges levied to the extent included on the bill or invoice or as a separate item; (b) costs of insurance, packing, and transportation from the place of
      manufacture to the customer&#8217;s premises or point of use; (c) credit for returns, allowances, or trades, including credits or allowances additionally granted upon rejections or recalls, claims returns pursuant to agreements (including, without
      limitation, managed care agreements), warranty claims, or claims allowed under government regulations, to the extent actually allowed and taken; (d) charge-back payments, and rebates actually granted or administrative fees actually booked to trade
      customers, patients (including those in the form of a coupon or voucher), managed health care organizations, pharmaceutical benefit managers, group purchasing organizations and national, state or local governments, and to the agencies, purchasers and
      reimbursers of managed health organizations, pharmaceutical benefit managers, group purchasing organizations, or federal, state or local governments; <i><u>provided, however</u>,</i> that in each case such amounts shall be applied in a normal and
      customary manner with respect to other similarly situated products or services of the selling party and not applied disproportionately to the Licensed Product; and (e) Net Sales at transfer prices to a control person of the Licensee (or any member of
      the consolidated group of such control person), or pricing between subsidiaries of a consolidated group of such control person (including the Licensee as a member of such consolidated group), but shall include the first sale or other commercial
      disposition of the applicable Licensed Product to an unaffiliated third party; all as determined in accordance with the selling party&#8217;s usual and customary accounting methods, which are in accordance with U.S. generally accepted accounting principles
      (GAAP), consistently applied.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.30.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Patent Expenses</u></i>&#8221; shall mean all fees, costs,
      and expenses (including attorneys&#8217; fees) paid or incurred in the preparation, filing, prosecution, issuance, and maintenance of the Licensed Patents and Auxiliary Technology Patents.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 5 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.31. <i>&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Party</u></i>&#8221; or &#8220;<i><u>Parties</u></i>&#8221; has the meaning set forth in
      the Preamble.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.32.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Pediatric Priority Review Voucher</u></i>&#8221; or &#8220;<i><u>PRV</u></i>&#8221; means
      a priority review voucher issued by FDA or otherwise under the authority of the United States Department of Health and Human Services to Licensee or any of its Affiliates or sublicensees as the sponsor of a rare pediatric disease or neglected
      tropical disease product application, that entitles the holder of such voucher to priority review of a single human drug application submitted under Section 505(b)(1) or 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301 et seq.,
      as amended from time to time, together with any rules, regulations and requirements promulgated thereunder or Section 351(a) of the United States Public Health Service Act, as further defined in the Federal Food, Drug, and Cosmetic Act.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.33.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Phase I Clinical Trial</u></i>&#8221; means a clinical trial generally
      consistent with 21 CFR &#167;312.21(a) that is required for receipt of clearance or marketing authorization of a Licensed Product from the applicable Regulatory Authority and which is conducted to evaluate safety of a Licensed Product for a particular
      indication or indications in healthy subjects.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.34.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Phase IIb Clinical Trial</u></i>&#8221; means a clinical trial generally
      consistent with 21 CFR &#167;312.21(b) that is required for receipt of clearance or marketing authorization of a Licensed Product from the applicable Regulatory Authority and which is conducted to assess the optimal manner of use of such a Licensed
      Product (dose and dose regimens) of a Licensed Product for a particular indication or indications in patients with the disease or condition under study. Any clinical trial that is not a Phase III Clinical Trial and which is conducted to evaluate a
      Licensed Product that has already been tested in a Phase I Clinical Trial shall be deemed a Phase IIb Clinical Trial.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.35.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Phase III Clinical Trial</u></i>&#8221; means a clinical trial generally
      consistent with 21 CFR &#167;312.21(c) that is required for receipt of clearance or marketing authorization of a Licensed Product from the applicable Regulatory Authority and which is conducted after preliminary evidence suggesting effectiveness of the
      Licensed Product has been obtained, and is intended to gather additional information to evaluate the overall benefit-risk relationship of the Licensed Product for a particular indication and provide an adequate basis for physician labeling.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.36.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Regulatory Approval</u></i>&#8221; means the approval (including label
      expansions to include additional indications), license, registration, clearance or authorization of the applicable Regulatory Authority necessary for the lawful marketing, commercialization and sale of a Licensed Product in a country or jurisdiction
      of the Territory.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.37.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Regulatory Authority</u></i>&#8221; means the FDA or any similar foreign
      national governmental regulatory authority involved in the granting of authorization to conduct clinical trials or Regulatory Approvals for the manufacture, sale, pricing and/or reimbursement of a Licensed Product in the Field.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.38.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Second Amendment Effective Date</u></i>&#8221; has the meaning set forth in
      the Preamble.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.39.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Services Agreement</u></i>&#8221; means any contract between Licensor or its
      Affiliate and Licensee or its Affiliate pursuant to which Licensor or its Affiliate provides services to Licensee or its Affiliate, which services may include, but are not limited to, the production of MSCs.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.40.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<i><u>Services Agreement Improvement(s)</u></i>&#8221; means any invention,
      discovery, advancement, development, or creation arising out of the services provided by Licensor or its Affiliate to Licensee or its Affiliates under a Service Agreement, unless otherwise mutually agreed upon by the Parties in the applicable
      Services Agreement.</font><font style="font-family: Times New Roman,Times,serif;"><br style="clear: both;">
    </font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 6 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin: 0px;">&#160;</p>
  <p style="margin: 0px;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">1.41.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;"><i>&#8220;<u>Sublicense Fees</u>&#8221;</i> means any
      consideration paid to Licensee or its Affiliates as consideration for or in connection with a sublicense of, or other right, license, option, privilege, or immunity with respect to, any Licensed Product or any of the rights to the Licensed Technology
      or the Auxiliary Technologies granted to Licensee hereunder, including without limitation license fees, technology access fees, equity or debt investments, upfront payments, milestone payments, unearned minimum royalties and royalties payable on
      sales of Licensed Products in excess of the Royalty on Net Sales payable hereunder, payments for materials or services (including research and development services), and other payments, and/or other forms of remuneration of any kind, but specifically
      excluding the Royalty on Net Sales payable hereunder. For the avoidance of doubt, Sublicense Fees shall include any and all payments made by any sublicensee to Licensee that are required by an agreement between Licensee and a sublicensee, wherein
      said agreement includes the granting of any rights in any Licensed Product or the sublicensing of any rights in the Licensed Technology or the Auxiliary Technologies, including, but not limited to. up-front payments, milestone payments, diligence
      payments, royalty payments payable on sales of Licensed Products in excess of the Royalty on Net Sales payable hereunder, payments for materials or services, and any other payments, rights or benefits that are payable by or on behalf of such
      sublicensee to Licensee as consideration for such rights granted to such sublicensee.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">1.42.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;"><i>&#8220;<u>Term</u>&#8221;</i> has the meaning set
      forth in </font><u>Section 7.1</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">1.43.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;"><i>&#8220;<u>Territory</u>&#8221; </i>means Earth.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">1.44. <font style="font-family: Times New Roman,Times,serif; background-color: white;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i>&#8220;<u>Third Amendment Effective Date</u>&#8221;</i>
      has the meaning set forth in the Preamble.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 2pt; text-align: justify; background-color: transparent;">1.45. <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i>&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Valid Claim</u></i>&#8221;
      means: (a) any currently pending claim of a patent application within the Licensed Patents or Improvement Patents, which has not been abandoned; or (b) a claim of a granted and unexpired patent within the Licensed Patents. Auxiliary Technology
      Patents or Improvement Patents that (i) has not been revoked, held invalid, or declared unpatentable or unenforceable by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time
      allowed for appeal; (ii) has not been rendered or admitted to be invalid, abandoned or unenforceable through reissue or disclaimer or otherwise; or (iii) has not been lost through an interference proceeding.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 2pt; text-align: justify; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;"><font style="background-color: white;"><b>Section 2</b></font><br>
    <font style="background-color: white;"><i><u>Licenses</u></i></font></p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>License Grant</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Subject to the terms and
      conditions of this Agreement (including the terms and provisions set forth in </font><u>Section 2.4</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">and </font><u>Section 5.2</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">), Licensor hereby grants to Licensee an exclusive (even as to Licensor), non-transferrable (except in accordance with </font><u>Section 11.2</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">), royalty-bearing license, with the right to grant sublicenses pursuant to </font><u>Section 2.2</u>, <font style="font-family: Times New Roman,Times,serif; background-color: white;">under the Licensed Technology, the
      Auxiliary Technologies, and the Auxiliary Technology Patents to Exploit Licensed Products in the Territory in the Field during the Term.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Sublicensing</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee may sublicense the rights
      granted to it under </font><u>Section 2.1</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">through a single tier (i.e., absent Licensor&#8217;s express prior written consent, no sublicensee will have any further right
      to grant sublicenses) to third party sublicensees, so long as: (a) the sublicense is royalty-bearing and in writing; (b) the terms of the sublicense agreement are consistent with the terms and conditions of this Agreement, including, without
      limitation, </font><u>Section 7.7</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">: (c) the sublicense was negotiated by Licensee in good faith, for a proper commercial purpose and on reasonable arm&#8217;s-length
      commercial terms: (d) the sublicense agreement names Licensor as a third party beneficiary thereof; (e) the sublicensee has, or has the ability to acquire, adequate resources (including scientific, technical and financial) to perform its obligations
      under such sublicense, as reasonably determined by Licensee at the time of entry into the sublicense; and (f) a complete, confidential copy of the sublicense agreement and any amendments thereto are provided to Licensor within thirty (30) days of the
      execution of said sublicense agreement or any such amendments thereto. In each case, Licensee will be responsible for the performance of its sublicensees relevant to this Agreement, including, without limitation, making any payments provided for
      hereunder. Subject to </font><u>Section 8.6</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">. Licensee will provide Licensor with a complete, confidential copy of each such sublicense agreement executed by
      Licensee and any amendments thereto, and will promptly notify Licensor of the termination of any such sublicense.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 7 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">&#160;</font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Rights in Improvements. Improvement Patents and Independent Inventions.</u></i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">2.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: Times New Roman,Times,serif; background-color: white;">Improvements shall
      be automatically included as part of the Auxiliary Technologies, and Improvement Patents shall be automatically included as part of the Auxiliary Technology Patents. Licensee and Licensor agree promptly to update <u>Exhibit 1.19</u></font> <font style="font-family: Times New Roman,Times,serif; background-color: white;">hereto upon written request by either Party from time to time, to reflect the inclusion of such Improvement Patents in the Auxiliary Technology Patents. Each Party will use
      reasonable efforts to disclose to the other Party during the Term any and all Improvements and Improvement Patents and Licensee and Licensor agree promptly to update </font><u>Exhibit 1.19</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">hereto upon written request by either Party from time to time, to reflect the inclusion of any Improvement Patents.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">2.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: Times New Roman,Times,serif; background-color: white;">Subject to the
      rights granted to Licensee in </font><u>Section 2.1</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">and </font><u>Section 2.2</u>, <font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensor shall own, and Licensee shall assign and hereby does assign to Licensor all right, title and interest in and to all Improvements and Improvement Patents, including all related certificates of correction, reissue certificates, and
      supplementary protection certificates, and all other rights granted under 35 U.S.C. &#167; 307, 35 U.S.C. &#167; 318, 35 U.S.C. &#167; 328, and 35 U.S.C. &#167; 254-257. Licensee shall execute and assist with any and all applications, assignments, or other instruments
      which Licensor deems necessary to perfect the foregoing assignment and/or to evidence, apply for, obtain, maintain, defend or enforce patent or other intellectual property protection in any and all countries worldwide with respect to Improvements
      assigned to Licensor as set forth above or to protect otherwise Licensor&#8217;s interest therein.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">2.3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee shall own
      all right, title and interest in and to all Independent Inventions invented, developed, created, or reduced to practice by or on behalf of Licensee.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Retained Rights: Requirements</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;"><font style="font-style: normal;">2.4.1.&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Retained Rights.</u></i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="background-color: white;">Any and all licenses granted hereunder are subject to Licensor&#8217;s right to
      make and use, and to permit academic, government, and not-for-profit institutions or agencies to make and use the Licensed Technology, the Auxiliary Technologies, and the Auxiliary Technology Patents (a) both in the Field and outside of the Field for
      non-commercial research, academic, educational, and all other non-commercial purposes, and for the development of the Licensed Technology and the Auxiliary Technologies, and (b) outside of the Field for all commercial and non-commercial purposes.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 8 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;"><i>&#160;</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: Transparent;"><font style="background-color: white;">2.4.2.<i>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Right to Publish.</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Subject to this </font><u>Section



      2.4.2</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">, any and all licenses granted hereunder are subject to the right of Licensor to review publication of scientific findings related to the Licensed Technology.
      If Licensee desires to submit any publication related to the Licensed Technology or that would otherwise disclose Confidential Information of Licensor or any patentable information related to Licensed Technology (including any Improvement), Licensee
      will provide Licensor with prior written notice of such proposed publication and a copy of such proposed publication. Licensor will use reasonable efforts to complete its review of such proposed publication promptly, and in any event will complete
      its review within thirty (30) days of receipt of the proposed publication. Licensor shall notify Licensee of any Licensor Confidential Information contained in such proposed publication and, in response to such notification, Licensee will promptly
      delete any Licensor Confidential Information from the proposed publication that Licensor has identified during such thirty (30) day review period. Licensor will have the right to delay submission of the proposed publication for up to an additional
      sixty (60) days if Licensor determines, in its sole discretion, that publication of the proposed publication would have negative effects on Licensor&#8217;s patent rights. In the event that Licensor decides to delay submission of the proposed publication,
      Licensor shall inform Licensee of such decision within the initial thirty (30) day review period, and the Parties shall reasonably cooperate in order to resolve any concerns with the proposed publication within such review period (as may be extended
      that it has already been submitted.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: Transparent; text-indent: 73pt;"><font style="font-style: normal;">2.4.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>U.S. Federal Funding.</u></i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Any and all licenses granted
      under patents supported by U.S. federal funding are subject to the rights, conditions, and limitations imposed by U.S. law (see 35 U.S.C. &#167;202 </font><u>et seq</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">. and
      regulations pertaining thereto), including without limitation: (i) the royalty-free, non-exclusive license granted to the U.S. government; and (ii) the requirement that any products covered by an issued claim and sold in the U.S. will be
      substantially manufactured in the United States. Licensee agrees to inform Licensor of those Improvements that are developed, reduced to practice or invented by Licensee&#8217;s personnel and agents or the personnel or agents of Licensee&#8217;s Affiliates (or
      that are Controlled by Licensee or Licensee&#8217;s personnel or agents or the personnel or agents of Licensee&#8217;s Affiliates) during the Term of the Agreement and beyond with the support (either entirely or in part) of U.S. federal funding, and to provide
      all information and documentation to Licensor that Licensor may request to secure patent rights for those inventions, including, but not limited to, grant numbers, contract numbers, and names of granting and contracting institutions and
      organizations.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;"><font style="background-color: white;"><b>Section 3</b></font><br>
    <font style="background-color: white;"><i><u>Reservation of Rights</u></i></font></p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">3.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>No Grant of Other Technology or Patent Rights</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">Each Party understands and acknowledges that the other Party owns its own
      Intellectual Property and all rights therein. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest or license, or be deemed to obtain any
      ownership interest or license, in or to any technology, know-how, patents, patent applications, products, or materials of the other Party, including, but not limited to, items Controlled or developed by the other Party, at any time pursuant to this
      Agreement. This Agreement does not create, and shall under no circumstances be construed or interpreted as creating, an obligation on the part of either Party to grant any license to the other Party other than as expressly set forth herein. Any
      further contract or license agreement between the Parties shall be in writing. No licenses are implied by Licensor to Licensee, except as specifically stated in this Agreement. Except as explicitly set forth in this Agreement, Licensor shall not be
      deemed by estoppel or implication to have granted Licensee any license or other right to any Intellectual Property of Licensor or its Affiliates.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 9 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">3.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Reserved Rights</u></i>.</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">All rights and interests not expressly granted to Licensee under this
      Agreement are reserved by Licensor (the <i>&#8216;&#8216;<u>Reserved Interests</u></i>&#8221;) for itself, its licensors, and other licensees and sublicensees. It shall not be a breach of this Agreement for Licensor, acting directly or indirectly, to exploit its
      Reserved Interests in any manner anywhere in the Territory.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;"><font style="background-color: white;"><b>Section 4</b></font><br>
    <font style="background-color: white;"><i><u>Due Diligence</u></i></font></p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Regulatory Approval</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee will be solely
      responsible, at Licensee&#8217;s expense, for securing any federal, state, or local Regulatory Approval from Regulatory Authorities necessary for commercial sale of Licensed Products, and Licensee shall deliver regular reports to Licensor concerning such
      Regulatory Approvals in accordance with </font><u>Section 5.3.2</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">4.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Licensee Responsibilities</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 71pt; background-color: transparent;">4.2.1&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee shall be solely
      responsible, at its expense, for the commercialization of Licensed Products in the Field in the Territory. Licensee will use Commercially Reasonable Efforts to diligently proceed to develop and make commercially available at least one Licensed
      Product in the Field in the United States or a major market country in Europe or Asia (i.e., the United Kingdom, France, Germany, China, or Japan; each a &#8220;<i><u>Major Market Country</u>&#8221;).</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 71pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 71pt; background-color: transparent;">4.2.2&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee shall provide
      Licensor semi-annual written updates on Licensee&#8217;s Licensed Product development and commercialization activities in the Field in the Territory, which updates shall be provided to Licensor and at least every six (6) months during the Term and upon
      Licensor&#8217;s reasonable request therefor, and Licensor shall have the right to reasonably request additional information regarding Licensee&#8217;s progress in this regard. Such updates will include the activities undertaken by or on behalf of Licensee since
      the last report was delivered; and the activities to be undertaken by or on behalf of Licensee during the next twelve (12)-month period and the expected timing of such activities (including the estimated dates of initiation and completion of such
      activities).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 71pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">4.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Licensee&#8216;s Failure to Develop and/or Commercialize Licensed Products</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 71pt; background-color: transparent;">4.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">In the event that
      Licensor notifies Licensee in writing that Licensor reasonably believes that, during any consecutive twelve (12)-month period during the Term, Licensee has failed to use its Commercially Reasonable Efforts to develop and/or make commercially
      available (as applicable) one or more Licensed Products in the Field in the United States or in a Major Market Country, then Licensee shall deliver to Licensor within sixty (60) days of receipt of such written notice copies of supporting
      documentation evidencing that Licensee has used Commercially Reasonable Efforts to develop such Licensed Product(s) and/or make such Licensed Product(s) commercially available in the Field in the United States or in a Major Market Country during such
      twelve (12)-month period. If Licensee fails to provide such supporting documentation within sixty (60) days after Licensor&#8217;s written request for it, or if. after examination of such supporting documentation provided by Licensee, Licensor continues to
      reasonably believe that Licensee has failed to use its Commercially Reasonable Efforts to develop such Licensed Product(s) and/or make such Licensed Product(s) commercially available in the Field in the United States or a Major Market Country, then
      the Parties shall revolve such dispute in accordance with </font><u>Section 10</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 71pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 10 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;">4.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee shall
      achieve the following milestones (&#8220;<i><u>Milestones</u></i>&#8221;): (a) within two (2) years after the Third Amendment Effective Date. Licensee shall submit an IND for a Licensed Product in the Field; and (b) within twenty four (24) months after
      submission of the IND, Licensee shall have dosed the first patient with a Licensed Product in a Phase I Clinical Trial in the United States or in a Major Market Country. It shall be deemed a material breach of this Agreement and Licensor may elect to
      terminate this Agreement in its entirety if any of the following occur: (y) Licensee has not submitted an IND for any Licensed Product in the Field on or before the date that is two (2) years after the Third Amendment Effective Date; or (z) Licensee
      has not dosed a patient with any Licensed Product in a Phase I Clinical Trial in the United States or in a Major Market Country on or before the date that is twenty four (24) months after submission of the IND.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;"><font style="background-color: white;"><b>Section 5</b></font><br>
    <font style="background-color: white;"><i><u>Consideration; Records &amp; Reports</u></i></font></p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">5.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Upfront Consideration</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">In consideration for the rights
      granted by Licensor to Licensee under this Agreement, Licensee shall pay to Licensor a fee in the amount set forth in </font><u>Section 5.1</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">of </font><u>Exhibit A</u>
    <font style="font-family: Times New Roman,Times,serif; background-color: white;">(&#8220;<i><u>Upfront Fee</u></i>&#8221;), and which First Installment has been fully paid as of the Third Amendment Effective Date.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">5.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Continuing Payments</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;"><font style="font-style: normal;">5.2.1.&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Milestone Payments.</u></i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">For each Licensed Product, each
      time a Milestone set forth in </font><u>Section 5.2.1</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">of </font><u>Exhibit A</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">is



      achieved by Licensee (or an Affiliate of Licensee) (and such Milestone is not otherwise achieved through a sublicense as provided in </font><u>Section 2.2</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">),
      Licensee shall pay to Licensor the corresponding milestone payment set forth <font style="font-size: 10pt;">in </font></font><u>Section 5.2.1</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">of </font><u>Exhibit



      A</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">(each, a <font style="font-size: 10pt;">&#8220;</font><i><u>Milestone Payment</u></i>&#8221;), such Milestone Payment to be made within thirty (30) days of the achievement
      of the applicable Milestone. For the avoidance of doubt, with respect to a Licensed Product, in the event that Licensee (or, as applicable Licensee&#8217;s sublicensee) skips or avoids one or more Milestones (<i>e.g.</i>, by obtaining approval for a
      Licensed Product in the United States before initiating a Phase IIb Clinical Trial or a Phase III Clinical Trial for such Licensed Product), then with respect to such Licensed Product. Licensee shall make the Milestone Payments associated with all
      such skipped or avoided Milestones upon the earlier of (a) achieving the next Milestone for such Licensed Product, or (b) the First Commercial Sale of such Licensed Product.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;"><font style="font-style: normal;">5.2.2.&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Royalties on Net Sales.</u></i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Commencing upon the First
      Commercial Sale of a Licensed Product in any country in the Territory, on a calendar quarter basis, Licensee shall pay to Licensor a royalty equal to the percentage of Net Sales set forth in </font><u>Section 5.2.2</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">of </font><u>Exhibit A</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">(&#8220;<i><u>Royalty on Net Sales</u></i>&#8221;). On a country-by-country basis, upon
      expiration of the last to expire of a Valid Claim in the subject country, Licensee shall have a nonexclusive license to Exploit the Licensed Know-How for the development and commercialization of Licensed Products in the applicable country in the
      Field, and the Royalty on Net Sales due thereafter under this </font><u>Section 5.2.2</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">shall be reduced by fifty percent (50%) in the applicable country.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;"><font style="font-style: normal;">5.2.3&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Royalties on Sublicense Fees.</u></i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 1in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee shall, within thirty
      (30) days of receipt of any Sublicense Fees, pay to Licensor an amount equal to the percentage of said Sublicense Fees set forth in </font><u>Section 5.2.3</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">of </font><u>Exhibit



      A</u><font style="font-family: Times New Roman,Times,serif; background-color: white;">.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 11 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i><u>No Multiple Royalties</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">For the avoidance of doubt, no multiple Royalties on Net Sales will be
      required to be paid because a Licensed Product or its manufacture, use, sale or importation is covered by more than one (1) Valid Claim.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font: 10pt Times New Roman,Times,serif;">5.2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i><u>Combination Products</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">A Licensed Product may be made, used, imported or sold in combination
      with or as part of Combination Products. Notwithstanding any other provision of this Agreement to the contrary, to calculate the value of Net Sales of Combination Products, the gross sales of such Combination Products will be multiplied by the
      fraction A/(A + B) where A is the fair market value of the Licensed Product when sold separately, and B is the fair market value of the Other Agent(s) when sold separately. Allowed deductions may then be subtracted from the proportion of gross sales
      attributable to the Licensed Product to compute Net Sales.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font: 10pt Times New Roman,Times,serif;">5.2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i><u>Royalty Stacking</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">On a Licensed Product-by-Licensed Product and country-by-country basis,
      in the event that Licensee is legally required to pay royalties to a third party for licenses to intellectual property rights entered into by Licensee to avoid infringement of such rights by the Exploitation of a Licensed Product in a country, then
      Licensee may deduct an amount equal to fifty percent (50%) of any such third party royalties from any royalty amounts due to Licensor under <u>Section 5.2.2</u> for Net Sales of such Licensed Product in such country, provided that notwithstanding
      anything set forth in this Agreement to the contrary, in no event shall the royalty payments under <u>Section 5.2.2</u> otherwise due to Licensor for such Licensed Product in such country be less than fifty percent (50%) of the percentage set forth
      in <u>Section 5.2.2</u> of <u>Exhibit A</u> (the <i>&#8220;<u>Royalty on Net Sales</u>&#8221;).</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Records and Reports</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.1.&#160;&#160;<i><u>Reports on Development Activities.</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee shall maintain materially complete, current and accurate records
      of material development and commercialization activities conducted by Licensee hereunder, and all data and other material information resulting from such activities. Such records shall fully reflect all material work done and results achieved in the
      performance of the development and commercialization activities in good scientific manner appropriate for regulatory and patent purposes. Licensee shall document all material studies and informal written study records according to Applicable Laws.
      Licensor shall have the right to review and copy such records maintained by Licensee at reasonable times and to obtain access to the originals to the extent reasonably necessary or useful for regulatory and patent purposes. Licensee shall provide
      Licensor with written reports detailing Licensee&#8217;s development and commercialization activities under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.2.&#160;&#160;<i><u>Regulatory Reports.</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee shall keep Licensor informed of regulatory developments relating
      to any Licensed Products in the Field in the Territory through semi-annual written updates, which updates shall be provided to Licensor and at least every six (6) months during the Term and upon Licensor&#8217;s reasonable request therefor. Licensee shall
      provide Licensor with copies of all regulatory materials generated in support of developing and/or commercializing Licensed Products in the Field in the Territory, and Licensee hereby grants to Licensor a right of reference (as such term is defined
      21 C.F.R. &#167; 314.3(b)) to all such regulatory materials and data for the purpose of developing and/or commercializing products, including Licensed Products, outside the Field, during the Term and thereafter.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 12 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.3.&#160;&#160;<u>Regulatory Responsibilities.</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Subject to the terms and conditions of this Agreement, Licensee shall be
      solely responsible for all regulatory matters for Licensed Products in the Field in the Territory, including preparing and filing any and all regulatory materials for each Licensed Product, at its sole expense.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.4.&#160;&#160;<u>Notification of Threatened Action.</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Each Party shall immediately notify the other Party of any information it
      receives regarding any threatened or pending action, inspection or communication by or from any third party, including without limitation a regulatory authority, which may materially affect the development, commercialization or regulatory status of a
      Licensed Product in the Field in the Territory. Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.5.&#160;&#160;<u>Remedial Actions.</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Each Party will notify the other Party immediately, and promptly confirm
      such notice in writing, if it obtains information indicating that any Licensed Product may be subject to any recall, corrective action or other regulatory action with respect to a Licensed Product taken by virtue of Applicable Laws (a <i>&#8220;<u>Remedial



          Action</u>&#8221;).</i> The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.6.&#160;&#160;<u>Pediatric Priority Review Vouchers.</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">If Licensee or an Affiliate of Licensee shall own or control a PRV that
      is granted based on approval of a Licensed Product, Licensee shall notify Licensor within thirty (30) days of the granting of such PRV, and within thirty (30) days of the sale of such PRV, Licensee shall pay Licensor the percentage set forth in <u>Section



        5.3.6</u> of <u>Exhibit A</u> of any proceeds received by Licensee or its Affiliate as consideration for such PRV.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.3.7.&#160;&#160;<i><u>Royalty Reports and Payments.</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1in; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Within thirty (30) days following the end of each calendar quarter,
      commencing with the calendar quarter in which the First Commercial Sale of any Licensed Product is made anywhere in the Territory, Licensee shall provide Licensor with a report containing the following information for the applicable calendar quarter,
      on a Licensed Product basis: (i) the amount of Net Sales in the Territory; (ii) an itemized calculation of Net Sales in the Territory showing deductions provided for in the definition of &#8220;Net Sales&#8221;; (iii) a calculation of the royalty payment due on
      such Net Sales; and (iv) the exchange rate for such country. Concurrent with the delivery of the applicable quarterly report, Licensee shall pay in U.S. dollars all amounts due to Licensor pursuant to this Agreement with respect to Net Sales by
      Licensee and its Affiliates and sublicensees for such calendar quarter. All payments due to Licensor hereunder shall be made in U.S. dollars by wire transfer of immediately available funds into an account designated by Licensor.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Audit and Inspection Rights</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee and its Affiliates and sublicensees will maintain complete and
      accurate records in sufficient detail to permit Licensor to confirm the accuracy of the calculation of payments under this Agreement, including royalty payments and the achievement of Milestones. Upon reasonable prior notice, such records shall be
      available during regular business hours (without undue disruption of Licensee&#8217;s business) for a period of four (4) years from the end of the calendar year to which they pertain for examination by an independent accountant selected by Licensor and
      reasonably acceptable to Licensee, for the sole purpose of verifying the accuracy of the reports and payments furnished by Licensee pursuant to this Agreement. Any such auditor shall not disclose Licensee&#8217;s Confidential Information, except to the
      extent such disclosure is necessary to verify the accuracy of the reports furnished by Licensee or the amount of payments due by Licensee to Licensor under this Agreement. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days
      from the accountant&#8217;s report, plus interest (as set forth above) from the original due date. Licensor shall bear the full cost of such audit unless such audit discloses an underpayment by Licensee of more than five percent (5%) of the amount due, in
      which case Licensee shall bear the full cost of such audit and shall promptly remit to Licensor the underpaid amounts.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 13 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.5. &#160; &#160;&#160;&#160;&#160;&#160; <i><u>Taxes</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Each Party shall be solely responsible for the payment of all taxes
      imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar
      obligations in respect of payments made by a Party to the other Party under this Agreement. To the extent either Party is required to deduct and withhold taxes on any payment to the other Party, such Party shall pay the amounts of such taxes to the
      proper governmental authority in a timely manner and promptly transmit to the other Party an official tax certificate or other evidence of such withholding sufficient to enable the other Party to claim such payment of taxes. Each Party shall provide
      the other Party with any tax forms that may be reasonably necessary in order for the other Party to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with
      reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing
      such withholding tax or value added tax.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.6.&#160;&#160;&#160; &#160; &#160;&#160; <i><u>Late Payment</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">If Licensor does not receive payment of any sum due to it on or before
      the due date, (each, a <i>&#8220;<u>Late Payment</u>&#8221;</i>)<i>, </i>Licensee shall pay to Licensor an amount equal to ten percent (10%) of such Late Payment (<i>&#8220;<u>Late Payment Penalty</u>&#8217;&#8217;</i>)<i>, </i>and such Late Payment shall not be considered
      paid in full until Licensor has received from Licensee both the full amount of such Late Payment and the Late Payment Penalty. Simple interest shall accrue on the sum due to Licensor, including the Late Payment Penalty, until the date of payment at
      the per annum rate of two percent (2%) over the then-current prime rate reported in <i>The Wall Street Journal</i> or the maximum rate allowable by Applicable Laws, whichever is lower.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 6</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Warranties</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.1&#160;&#160;&#160; &#160;&#160; &#160;&#160; <i><u>Representations, Warranties and Covenants of Licensor</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.1.1&#160;&#160; Licensor hereby represents and warrants to Licensee that, as of
      the Third Amendment Effective Date, it is the owner or licensee of the Licensed Patents and the Auxiliary Technology Patents, and it has the right, power and authority to grant the rights set forth in <u>Section 2.1</u> of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.1.2&#160;&#160;&#160; Licensor hereby represents and warrants to Licensee that, as of
      the Third Amendment Effective Date, the execution and performance of Licensor&#8217;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensor to any third
      party, including, without limitation, any Affiliate of Licensor.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 14 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.1.3 Licensor hereby represents and warrants to Licensee that neither
      Licensor nor any of its Affiliates is a party to any litigation, arbitration, mediation or other similar legal proceeding.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;">6<font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">.2&#160;&#160;&#160;&#160; &#160;&#160; &#160; <i><u>Representations, Warranties and Covenants of Licensee</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.2.1&#160;&#160; Licensee hereby represents and warrants to Licensor that, as of
      the Third Amendment Effective Date, the execution and performance of Licensee&#8217;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensee to any third
      party, including, without limitation, any Affiliate of Licensee.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.2.2&#160;&#160;&#160; Licensee hereby represents and warrants to Licensor that neither
      Licensee nor any of its Affiliates is a party to any litigation, arbitration, mediation or other similar legal proceeding.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.2.3&#160;&#160;&#160; Licensee hereby represents, warrants and covenants to Licensor
      that Licensed Products will be manufactured and sold in compliance with all Applicable Laws, including, without limitation, in accordance with all applicable rules and regulations of the FDA or other Regulatory Authority.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.3&#160;&#160;&#160; &#160; &#160;&#160;&#160; <i><u>Disclaimer</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Except as expressly provided in <u>Section 6.1</u>, nothing in this
      Agreement will be construed as:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.3.1&#160;&#160;&#160;&#160;&#160;a warranty or representation by Licensor as to the validity or
      scope of any of the Licensed Technology, Auxiliary Technologies or the Auxiliary Technology Patents;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.3.2&#160;&#160;&#160;&#160;&#160;a warranty or representation by Licensor that anything made,
      used, sold or otherwise disposed of under the licenses granted in this Agreement, or the practice of the Licensed Technology, Auxiliary Technologies or the Auxiliary Technology Patents, will or will not infringe patents of third parties; or</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.3.3&#160;&#160;&#160;&#160;&#160;an obligation of Licensor to bring or prosecute actions or
      suits against third parties for infringement of Licensed Patents or Auxiliary Technology Patents or misappropriation of Licensed Know-How.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.4&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <i><u>Express Disclaimer</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, LICENSOR IS PROVIDING THE
      LICENSED TECHNOLOGY, THE AUXILIARY TECHNOLOGIES, AND THE AUXILIARY TECHNOLOGY PATENTS &#8220;AS IS.&#8221; EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS, EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
      INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT AND ASSUMES ANY RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION OF
      PRODUCTS INCORPORATING OR MADE BY USE OF LICENSED PATENTS OR AUXILIARY TECHNOLOGY PATENTS UNDER THIS AGREEMENT, IN NO EVENT WILL EITHER PARTY, OR ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AFFILIATES OR AGENTS, BE LIABLE FOR ANY SPECIAL,
      INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES OF ANY KIND, WHETHER GROUNDED IN TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, CONTRACT OR OTHERWISE.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 15 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 7</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Term and Termination</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.1.&#160;&#160; &#160; &#160;&#160;&#160;&#160; <i><u>Term</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">The term of this Agreement will begin on the Third Amendment Effective
      Date and will not terminate unless terminated under the provisions of this <u>Section 7</u> (the &#8220;<i><u>Term</u>&#8221;).</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.&#160;&#160; &#160; &#160;&#160;&#160;&#160; <i><u>Termination by Licensor</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensor may, at its option, terminate this Agreement, upon written
      notice to Licensee of any of the following events or otherwise as provided in this Agreement:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to the provisions set forth in <u>Section 10</u>,
      any material breach of any of Licensee&#8217;s obligations under this Agreement, which Licensee fails to remedy within sixty (60) days after receipt of written notice by Licensor of such material breach and Licensor&#8217;s demand that it be cured;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to the provisions set forth in <u>Section 10,</u>
      the filing in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee or if
      Licensee is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof, or if Licensee will propose or be a party to any dissolution or
      liquidation, or if Licensee will make an assignment for the benefit of its creditors, or if at any time Licensee voluntarily enters into proceedings for winding up or dissolution of business; <i><u>provided, however</u>, </i>if Licensee provides
      for the cure of all of its defaults under this Agreement (if any) and provides adequate assurance of its future performance of its obligations to Licensor&#8217;s reasonable satisfaction, then Licensor shall not have the right to terminate this Agreement
      pursuant to this <u>Section 7.2.2</u>;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to the provisions set forth in <u>Section 4.3</u>,
      Licensee&#8217;s failure to timely achieve the Milestones;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to the provisions set forth in <u>Section 5</u>,
      Licensee&#8217;s failure to timely make any payment required to be made to Licensor as set forth in <u>Section 5</u> or <u>Exhibit A</u>, which Licensee fails to remedy within thirty (30) days after receipt of written notice by Licensor of such failure
      and Licensor&#8217;s demand that it be cured;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Licensee&#8217;s use, practice or Exploitation of the Licensed
      Technology. Auxiliary Technologies or the Auxiliary Technology Patents outside of the Field or for the development or Exploitation of products other than Licensed Products, which Licensee fails to remedy within thirty (30) days after receipt of
      written notice by Licensor and Licensor&#8217;s demand that it be cured;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any breach of Licensee&#8217;s obligations under <u>Section 7.5</u>
      or <u>Section 11.13,</u> which Licensee fails to remedy within thirty (30) days after receipt of written notice by Licensor and Licensor&#8217;s demand that it be cured; or</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font>&#160;&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 16 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Licensee&#8217;s failure to comply with the obligation to
      maintain in full force and effect the required insurance coverage in accordance with <u>Section 9.3, </u>which Licensee fails to remedy within thirty (30) days after receipt of written notice by Licensor of such material breach and Licensor&#8217;s
      demand that it be cured.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.2.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nothing in the foregoing subsections of this <u>Section
        7.2</u> shall prohibit Licensor from pursuing any other remedies at law which it may have in connection with Licensee&#8217;s uncured material breach. For the avoidance of doubt. Licensor&#8217;s right to terminate under <u>Section 7.2.3</u>, <u>7.2.4</u>, <u>7.2.5</u>,
      <u>7.2.6</u>, or <u>7.2.7</u> shall not be subject to the provisions set forth in <u>Section 10</u>, shall not expire, and any such termination shall take effect upon written notice to Licensee.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.3.&#160; &#160; &#160;&#160;&#160;&#160;&#160; <i><u>Partial Termination by Licensor</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">In the event the events or conditions set forth in <u>Section 7.2</u>
      pertain only to a particular Licensed Product, Licensor may elect to terminate this Agreement in-part with respect to that Licensed Product, and upon such termination in-part the Agreement will otherwise remain in effect.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.4.&#160;&#160;&#160; &#160; &#160;&#160; <i><u>Termination by Licensee</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee may, at its option, terminate this Agreement in its entirety,
      upon written notice to Licensor of any of the following events or otherwise as provided in this Agreement:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; at any time without cause, by giving at least one hundred
      and twenty (120) days prior written notice of such termination to Licensor; or</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to the provisions set forth in <u>Section 10</u>,
      upon any material breach of Licensor&#8217;s express representations, warranties or covenants set forth in <u>Section 6.1</u>, which Licensor fails to remedy within sixty (60) days after receipt of written notice by Licensee of such material breach and
      Licensee&#8217;s demand that it be cured.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nothing in the foregoing subsections of this <u>Section
        7.4</u> shall prohibit Licensee from pursuing any and all rights and remedies it may have under this Agreement or at law<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"></sup> or in equity.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 74pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.5.&#160;&#160;&#160;&#160; &#160;&#160;&#160; <i><u>Challenging Validity</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Except to the extent unenforceable under Applicable Law in the Territory,
      Licensor may terminate this Agreement by written notice to Licensee in the event of a breach of <u>Section 11.13</u> by Licensee, its Affiliates or sublicensees or in the event that Licensee or any of its Affiliates challenges, in any formal
      proceeding, the validity, patentability, enforceability, scope, construction or inventorship of any of the Licensed Patents or Auxiliary Technology Patents or assists any third party in any such challenge. If a sublicensee of Licensee brings any such
      challenge or assists a third party in bringing any such challenge (except as required under a court order or subpoena), then Licensor may send a written demand to Licensee to terminate such sublicense. If Licensee fails to so terminate such
      sublicense within thirty (30) days after Licensor&#8217;s demand, Licensor may terminate this Agreement. In the event Licensor is not able to terminate this Agreement pursuant to this <u>Section 7.5</u> under Applicable Law, then with respect to those
      countries in which this Agreement may not be terminated (i) Licensee shall pay the Royalty on Net Sales and Sublicense Fees to Licensor at the rate of twice (2X) the rate specified in <u>Section 5.2.2</u> and <u>Section 5.2.3</u>, as applicable, in
      respect of Net Sales of all Licensed Products sold and all Sublicense Fees earned or received by Licensee during the pendency of such action and, should the outcome of such action determine that any claim of a Licensor Patent challenged by Licensee
      (including its Affiliates) is both valid and infringed by a Licensed Product, Licensee shall pay the Royalty on Net Sales and Sublicense Fees to Licensor at the rate of three times (3X) the rate specified in <u>Section 5.2.2</u> and <u>Section
        5.2.3</u>, as applicable, in respect of all Licensed Products thereafter sold. Licensee shall reimburse Licensor for its legal costs and expenses incurred in defending any such challenge, regardless of the outcome.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 17 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Effects of Termination; Termination of License</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Upon a termination of this Agreement for any reason, Licensee&#8217;s rights to
      the Licensed Technology, Auxiliary Technologies, and the Auxiliary Technology Patents, inclusive of the Licensed Products, which have been granted hereunder and all use thereof will terminate, any and all rights in the Licensed Technology, Auxiliary
      Technologies, and the Auxiliary Technology Patents, inclusive of the Licensed Products, will revert back to Licensor and Licensee will cease using the Cell Lines, and will cease selling, offering for sale, importing, exporting, developing and
      commercializing all Licensed Products. Upon Licensor&#8217;s request, in the event of a termination of this Agreement in its entirety. Licensee will destroy or return the Cell Lines and all copies, except for the copies to be retained by Licensee&#8217;s legal
      counsel, of any media or materials which have been provided by Licensor to Licensee and are the property of Licensor, including but not limited to all data, documentation, notes, plans, drawings, copies, samples and computer code. Upon termination of
      this Agreement other than termination by Licensor in accordance with <u>Section 7.2,</u> Licensee, Licensee&#8217;s Affiliates and Licensee&#8217;s sublicensees may complete and sell any work-in-progress and inventory of Licensed Products that exist as of the
      effective date of termination provided that (i) Licensee pays Licensor the applicable royalty on such Net Sales in accordance with the terms and conditions of this Agreement, and (ii) Licensee, Licensee&#8217;s Affiliates and Licensee&#8217;s sublicensees shall
      complete and sell all work-in-progress and inventory of Licensed Products within six (6) months after the effective date of termination.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Effect on Sublicenses</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">In the event that this Agreement is terminated by Licensor in accordance
      with <u>Section 7.2</u>, and if Licensee requests that a given sublicense(s) survive such termination, any such surviving sublicense(s) shall be considered a direct license from Licensor to such surviving sublicensee; provided that such sublicensee
      agrees in writing that (i) Licensor is entitled to enforce all relevant provisions directly against such sublicensee, and (ii) Licensor shall not assume, and shall not be responsible to such sublicensee for. any representations, warranties or
      obligations of Licensee to such sublicensee, other than to permit such sublicensee to exercise any rights to the Licensed Technology, Auxiliary Technologies, and the Auxiliary Technology Patents sublicensed to such sublicensee by Licensee.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Right to Reference Regulatory Filings</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Upon termination of this Agreement pursuant to <u>Sections 7.2</u>, <u>7.3</u>
      or <u>7.4</u>, Licensee will permit Licensor and its Affiliates, licensors, licensees and sublicensees to reference Regulatory Approvals obtained from, and filings made by Licensee with Regulatory Authorities with respect to the Licensed Products in
      the Field at no cost to Licensor. In addition, at Licensor&#8217;s reasonable request, Licensee will allow Licensor to review at Licensee&#8217;s offices all records required by Regulatory Authorities to be maintained with respect to the development, sale,
      storage, handling, shipping and use of the Licensed Products in the Field, and all reimbursement approval files pertaining to the Licensed Products in the Field.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Accrued Obligations</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Expiration or termination of this Agreement will not release either Party
      from any obligation that matured prior to the effective date of such expiration or termination. Upon expiration or termination of this Agreement for any reason, any unpaid amounts payable to Licensor shall become immediately due, and payment thereof
      shall remain an ongoing obligation of Licensee until such amount is paid in full.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 18 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">7.10.&#160; &#160; &#160;&#160; <i><u>Survival</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Upon expiration or termination of this Agreement, <u>Sections 2.3</u>, <u>2.4</u>,
      <u>5.4</u>, <u>6.3</u>, <u>6.4</u>, <u>7.5-7.9</u>, <u>8.6</u>, and <u>9-11</u> will, with related definitions, survive and remain in full force and effect.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 8</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Protection of Intellectual Property Rights</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.1.&#160;&#160;&#160; &#160; &#160;&#160; <i><u>Patent Prosecution</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">During the Term, Licensor will be responsible for preparing, filing,
      prosecuting and maintaining all patent applications and patents included in the Licensed Patents and the Auxiliary Technology Patents in the Territory. For the sake of clarity, as used herein the term &#8220;prosecution&#8221; shall include interference,
      opposition, and derivation proceedings in connection with the Licensed Patents and the Auxiliary Technology Patents. Licensor shall select patent counsel to conduct such activities regarding the Licensed Patents and the Auxiliary Technology Patents.
      Licensor shall cause all patent applications and patents included in the Licensed Patents and the Auxiliary Technology Patents in the Territory to be diligently prosecuted, and in the event Licensor decides to irrevocably discontinue prosecution of
      any patent applications included in the Licensed Patents or the Auxiliary Technology Patents, or irrevocably allow any patents included in the Licensed Patents or the Auxiliary Technology Patents to lapse, Licensor shall provide Licensee notice
      therof in accordance with <u>Section 8.2</u>. All Patent Expenses will be borne by Licensee <i>pro rata, </i>whereby Licensee&#8217;s <i>pro rata</i> share of such Patent Expenses shall equal 1/n of such Patent Expenses, where &#8220;n&#8221; equals the total
      number of licenses of the Licensed Patents or Auxiliary Technology Patents at the time such Patent Expenses were incurred, as determined by Licensor in its sole discretion. Licensee has no obligation to pay any Patent Expenses that were incurred
      prior to the Effective Date.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.2.&#160;&#160;&#160;&#160;&#160; &#160;&#160; <i>Licensee&#8217;s Right to Take Over Prosecution or Pay Fees.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">In the event that Licensor decides to irrevocably discontinue prosecution
      of any patent applications included in the Licensed Patents or the Auxiliary Technology Patents without filing a continuing or divisional application, Licensor will notify Licensee thereof within such time as may be reasonably necessary for Licensee
      to continue such prosecution on Licensor&#8217;s behalf, and Licensee will have the right, but not the obligation, to so continue such prosecution at its own cost and expense. In the event that Licensor decides to allow any patents included in the Licensed
      Patents or the Auxiliary Technology Patents to lapse as a result of nonpayment of an annuity, maintenance fee, or equivalent, Licensor will notify Licensee thereof within such time as may be reasonably necessary for Licensee to make such payment on
      Licensor&#8217;s behalf, and Licensee will have the right, but not the obligation, to pay the annuity, maintenance fee, or equivalent at its own cost and expense.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.3.&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<i><u>Enforcement of Licensed Patents</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.3.1.&#160;&#160;&#160;&#160;&#160;&#160; <i><u>Notice</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">If either Party becomes aware of any infringement in the Field, anywhere
      in the Territory, of any issued patent within the Licensed Patents or the Auxiliary Technology Patents, such Party will notify the other Party in writing within thirty (30) days to that effect.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font>&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 19 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 39pt; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.3.2.&#160; &#160; &#160;&#160; <i><u>Infringement of Licensed Patents or
          Auxiliary Technology Patents by Third Parties.</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 39pt; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 112pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.3.2.1&#160;In the case of any infringement of any Licensed Patent or
      Auxiliary Technology Patent by any third party, Licensor will have the first right, but not the obligation, to cause such third party to cease infringement and to otherwise enforce such Licensed Patent or Auxiliary Technology Patent, or to defend the
      Licensed Patent or Auxiliary Technology Patent in any declaratory judgment action brought by third party(ies) which alleges the invalidity, unenforceability or non-infringement of the rights associated with the Licensed Patent or Auxiliary Technology
      Patent. All costs and expenses associated with defending the Licensed Patent or Auxiliary Technology Patent in any such declaratory judgment action will be borne by Licensor, <i><u>provided, however</u>,</i> that, in the event such declaratory
      judgment action resulted from or occurred during discussions (regarding any subject matter whatsoever) between the third party and Licensee, then all costs and expenses associated with defending the Licensed Patent or Auxiliary Technology Patent in
      the declaratory judgment action will be borne by Licensee. Licensee will cooperate and provide reasonable assistance in any action described in this <u>Section 8.3.2.1</u>. Except for providing such cooperation and reasonable assistance, Licensee
      will have no obligation regarding the legal actions described herein; <i><u>provided that</u></i> if required to enable Licensor to initiate or continue such action, Licensee will join such action at Licensor&#8217;s request and expense. Any recovery or
      compensation resulting from such proceeding will first be used to reimburse Licensee for any unreimbursed expenses incurred in connection with providing assistance or joining the proceeding at Licensor&#8217;s request, and the remainder, if any. will
      belong entirely to Licensor.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 112pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 112pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.3.2.2&#160;If Licensor does not. within a reasonable period after becoming
      aware of a third party infringement of the Licensed Patents or Auxiliary Technology Patents in the Field, but in any event no less than ninety (90) calendar days from the date of receipt of written notice from Licensee, (i) initiate legal proceedings
      against such threatened or actual infringement, or defend legal proceedings brought by a third party, as provided in <u>Section 8.3.2.1</u> above, or (ii) take other reasonable steps to cause such infringement to terminate (for example, by
      initiating licensing discussions), Licensee may deliver written notice to Licensor that it intends to take action to cause such infringement to terminate, and subject to Licensor&#8217;s prior written consent. Licensee may take such action as it deems
      reasonably necessary to enforce its rights in the Licensed Patents or Auxiliary Technology Patents in the Field, including, without limitation, to bring, at its own expense, an infringement action or file any other appropriate action or claim related
      to such infringement against any third party. Licensor will, at the reasonable request of Licensee, cooperate and provide reasonable assistance in any action taken by Licensee and described in this <u>Section 8.3.2.2</u> and, if required to enable
      Licensee to initiate or continue such action, will join such action at Licensee&#8217;s reasonable request, all at Licensee&#8217;s cost and expense. Any recovery or compensation resulting from such proceeding undertaken by Licensee will first be used to
      reimburse Licensor for any unreimbursed expenses in connection with providing assistance at or joining the proceeding at Licensee&#8217;s request, then to reimburse Licensee for any expenses, and thereafter to reimburse Licensor for any other unreimbursed
      expenses incurred in connection with the proceeding (including attorneys&#8217; fees, expert witness fees, court fees, and related charges), and the remainder, if any, will be shared equally by Licensor and Licensee.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 112pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Infringement of Third-Party Rights</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Each Party will promptly notify the other Party in writing of any notice
      or claim of any allegation of infringement or commencement against it of any suit or action for infringement of a third-party patent based upon or arising from actions taken under the licenses granted in this Agreement <i>(&#8216;&#8216;<u>Third-Party
          Infringement Claim</u>&#8221;).</i> If such Third-Party Infringement Claim is alleged or commenced against Licensee, Licensee will have the sole right to defend and settle such Third-Party Infringement Claim, and Licensee will not be obligated to enter
      into negotiations with such third party to obtain rights for either Licensee or Licensor under the third-party patent. If such Third-Party Infringement Claim is alleged or commenced against Licensor, Licensee will have the first right, but not the
      obligation, to defend and settle such Third-Party Infringement Claim, <i><u>provided, however</u>,</i> that Licensee will not be obligated to enter into negotiations with such third party to obtain rights for Licensor under the third-party patent.
      With respect to any such defense by Licensee of a Third-Party Infringement Claim alleged or commenced against Licensor, Licensee will not make any settlements of such Third-Party Infringement Claim that would materially adversely affect Licensor&#8217;s
      rights or interests in the Licensed Technology, Auxiliary Technologies or the Auxiliary Technology Patents without first obtaining Licensor&#8217;s prior written consent. If Licensee opts not to defend or settle such Third-Party Infringement Claim alleged
      or commenced against Licensor, Licensee will notify Licensor of such decision and, at Licensor&#8217;s expense, Licensor will have the right to undertake the defense or settlement of such Third-Party Infringement Claim.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 20 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 42pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Patent Marking</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee will mark Licensed Products sold or distributed by Licensee (and
      will require that Licensee&#8217;s Affiliates and sublicensees mark Licensed Products sold or distributed by Licensee&#8217;s sublicensees) in a given country in the Territory with a notice that will recite that such Licensed Products are made under one or more
      of the Licensed Patents or Auxiliary Technology Patents, in the manner and with such prominence as is legally required or, if there is no legal requirement, as is customary for such proprietary notices in such country.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Confidential Information</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Each Party shall maintain the Confidential Information of the other Party
      in strict confidence, and will not disclose, divulge or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement, or with the
      express written consent of the Party who provided such Confidential Information. Each Party will maintain the confidentiality of the other Party&#8217;s confidential information using methods and practices that are substantially similar to those that the
      receiving Party uses to maintain the confidentiality of its own confidential information, but in no event less than a reasonable degree of care. Except as may be authorized in advance in writing by the disclosing Party, the receiving Party&#8217; will only
      grant access to the Confidential Information to its employees and agents as necessary to carry out activities under this Agreement and such employees and agents will have entered into non-disclosure agreements consistent with the terms of this <u>Section



        8.6</u>. The obligations of confidentiality described above will not pertain to that part of any Confidential Information to the extent that it is supported by competent written proof that:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.1.&#160;&#160;&#160;&#160;&#160;such information was lawfully in the receiving Party&#8217;s
      possession or control prior to the time it received the information from the disclosing Party;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.2.&#160;&#160;&#160;&#160;&#160;such information was developed by the receiving Party
      independently of and without reference to the Confidential Information of the disclosing Party;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.3.&#160;&#160;&#160;&#160;&#160;such information was, at the time it was disclosed to or
      obtained by the receiving Party, or thereafter became, available to the public through no act or omission of the Party holding such information; or</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.4.&#160;&#160;&#160;&#160;&#160;such information was lawfully obtained by the receiving Party
      from a third party that has the right to disclose such information free of any obligations of confidentiality.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 21 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.5.&#160;&#160;&#160;&#160;&#160;In addition, a receiving Party may disclose such Confidential
      Information to the limited extent required to do so by Applicable Law or a proper legal, governmental or other competent authority, or by the rules of any securities exchange on which any security issued by either Party is traded, or included in any
      filing or action taken by the receiving Party to obtain or maintain government clearance or approval to market a subject Licensed Product. Except where impracticable, such required Party shall give the other Party reasonable advance notice of such
      disclosure requirement and shall afford the other Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, or, where it is impracticable to give an advance notice, such required Party shall give
      the other Party reasonable notice promptly after such required disclosure. In the event of any such required disclosure, the required Party shall disclose only that portion of the Confidential Information legally required to be disclosed.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.6.6&#160;&#160;&#160;&#160;&#160;&#160;In addition, either Party may disclose this Agreement and the
      terms hereof (including providing a copy hereof, redacted as appropriate) to any bona fide potential permitted sublicensee or successor to said Party&#8217;s interest under this Agreement, to a bona fide potential lender from which said Party is
      considering borrowing money, to a bona fide potential collaborator in connection with development or commercialization of Licensed Products, or to any bona fide financial investor from which said Party may take money; <i><u>provided, however</u>,</i>
      in any such case said Party shall first obtain a written obligation of confidentiality no less stringent than that imposed in this <u>Section 8.6</u> from the bona fide potential permitted sublicensee or successor, bona fide potential lender, bona
      fide potential collaborator or bona fide financial investor.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 78pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 43pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Use of Names</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 43pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Neither Party may identify the other Party in any promotional advertising
      or other promotional materials to be disseminated to the public or any portion thereof, or use the name of any staff member or employee of the other Party or any trademark, service mark, trade name, symbol or logo that is associated with the other
      Party, without the other Party&#8217;s prior written consent. Notwithstanding the foregoing, and for the avoidance of doubt, without the consent of the other Party either Party may comply with disclosure requirements of all Applicable Laws relating to its
      business, including, without limitation. United States and state securities laws. Each Party may include the other Party&#8217;s name, logo, and a brief description of such other Party on said Party&#8217;s website.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Press Releases</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">The Parties shall mutually agree upon the timing and content of any press
      releases or other public announcement relating to this Agreement and the transactions contemplated herein; provided, however, that subject to <u>Section 2.4.2</u>, the foregoing shall not apply to publication of scientific findings in the form of
      Licensed Products or in connection with the Exploitation of Licensed Products.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 9</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Indemnification; Insurance</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 43pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Indemnification by Licensee</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 43pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee will indemnify, defend and hold harmless Licensor, its
      Affiliates and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, heirs, and assigns (each a <i>&#8220;<u>Licensor Indemnitee</u>&#8221;), </i>against all third party suits, actions, claims,
      proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and attorneys&#8217; fees), including claims resulting from or connected to the death of or injury to any person or persons, or any damage to
      property, resulting from, arising out of, or otherwise attributable to Licensee&#8217;s or, as applicable Licensee&#8217;s Affiliate&#8217;s or sublicensee&#8217;s: (a) negligence or misconduct, (b) failure to comply with Applicable Laws or the terms of this Agreement,
      including any breach of Licensee&#8217;s express representations and warranties set forth in this Agreement, (c) Exploitation of Licensed Products or the exercise of the licenses granted under this Agreement, including the production, manufacture, sale,
      use, lease, consumption, administration, shipping, storage, transfer, advertisement, analysis, measurement, description, or characterization of the Licensed Technology, Auxiliary Technologies, Auxiliary Technology Patents, Improvements, Improvement
      Patents, Cell Lines or Licensed Products, or any activity arising from or in connection with any right or obligation of Licensee hereunder, except in each case to the extent resulting from, arising out of, or otherwise attributable to Licensor&#8217;s
      breach of any express representation, warranty or covenant set forth in <u>Section 6.1</u>. The Licensor will promptly give notice to Licensee of any suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses which might
      be covered by this <u>Section 9.1</u> and Licensee will have the right to defend the same, including selection of counsel and control of the proceedings; <u>provided that</u> Licensee will not, without the written consent of Licensor, settle or
      consent to the entry of any judgment with respect to any such third party claim (x) that does not release the Licensor Indemnitee(s) from all liability with respect to such third party claim or (y) which may materially adversely affect Licensor or
      the Licensor Indemnitee or under which Licensor or the Licensor Indemnitee would incur any obligation or liability, other than one as to which Licensee has an indemnity obligation hereunder. Licensor agrees to fully cooperate and aid such defense.
      Licensor at all times reserves the right to select and retain counsel of its own at its own expense to defend Licensor&#8217;s interests.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 44pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 22 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Indemnification by Licensor</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensor will indemnify, defend and hold harmless Licensee, its
      Affiliates and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, heirs, and assigns (each a <i>&#8216;&#8216;<u>Licensee Indemnitee</u>&#8221;), </i>against all third party suits, actions, claims,
      proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and attorneys&#8217; fees), including claims resulting from or connected to the death of or injury to any person or persons, or any damage to
      property, resulting from, arising out of, or otherwise attributable to Licensor&#8217;s breach of Licensor&#8217;s express representations and warranties set forth in <u>Section 6.1</u> of this Agreement, except to the extent resulting from, arising out of, or
      otherwise attributable to Licensee&#8217;s breach of any express representation, warranty or covenant set forth in <u>Section 6.2</u>. Licensee will promptly give notice to Licensor of any suits, actions, claims, proceedings, liabilities, demands,
      damages, losses, or expenses which might be covered by this <u>Section 9.2</u> and Licensor will have the right to defend the same, including selection of counsel and control of the proceedings; <u>provided that</u> Licensor will not, without the
      written consent of Licensee, settle or consent to the entry of any judgment with respect to any such third party claim (x) that does not release the Licensee Indemnitee(s) from all liability with respect to such third party claim or (y) which may
      materially adversely affect Licensee or the Licensee Indemnitee or under which Licensee or the Licensee Indemnitee would incur any obligation or liability, other than one as to which Licensor has an indemnity obligation hereunder. Licensee agrees to
      fully cooperate and aid such defense. Licensee at all times reserves the right to select and retain counsel of its own at its own expense to defend Licensee&#8217;s interests.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Insurance</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee shall maintain in full force and effect during the Term and for
      a period of three (3) years after expiration or termination of this Agreement, worker&#8217;s compensation, general liability and professional liability, clinical trial liability, and product liability insurance coverage, all in such amounts and with such
      scope of coverages as are reasonably sufficient to cover Licensee&#8217;s obligations under this Agreement (including Licensee&#8217;s indemnity obligations set forth in <u>Section 9.1</u>) and as are customary in the life sciences and pharmaceutical
      industries. Upon written request. Licensee shall provide evidence of such insurance to Licensor. Licensor shall be named as an additional insured with respect to such insurance policies, and Licensee shall ensure that Licensor will receive no less
      than fourteen (14) days&#8217; prior notice of any cancellation, non-renewal or material change in such insurance coverage.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 23 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 10&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Alternative Dispute Resolution</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.1.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Negotiation</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">In the event of any dispute or disagreement between the Parties as to the
      interpretation of any provision of this Agreement or any other related document (or the performance of any obligations hereunder or thereunder), the matter, upon written request of either Party, shall be referred to representatives of the Parties for
      decision, each Party being represented by an Executive Officer (the <i>&#8220;<u>Representatives</u>&#8221;).</i> The Representatives shall promptly meet in a good faith effort to resolve the dispute. If the Representatives do not mutually agree upon a decision
      within thirty (30) calendar days after reference of the matter to them, each of the Parties shall be free to exercise the remedies available to it under <u>Section 10.2</u>. Each Party may extend the period of time for negotiation among the
      Representatives for an additional period of fourteen (14) calendar days on one (1) occasion per dispute.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.2.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Submission to Arbitration</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">If the Parties are unable to resolve such dispute pursuant to <u>Section
        10.1</u>, the dispute shall be submitted to binding arbitration (without any recourse to the federal or state courts except to enforce any arbitral award or. within forty five (45) days of an Arbitrator&#8217;s rendering of a final decision, to appeal
      such final decision based solely on a claim that the Arbitrator engaged in gross misconduct or made a material error or miscalculation in his or her decision) in accordance with the rules of JAMS/End Dispute <i>(&#8220;<u>JAMS</u>&#8221;) </i>then in force
      (except as expressly modified below), and the arbitration hearings shall be held before a single arbitrator (&#8220;<i><u>Arbitrator</u>&#8221;)</i> in Boston, Massachusetts. The Parties agree to appoint an Arbitrator who is knowledgeable in the biotechnology
      and/or life sciences industries. If the Parties cannot agree upon an Arbitrator within ten (10) days after a demand for arbitration has been filed with the JAMS by either of them, either or both Parties may request the JAMS to name a panel of five
      (5) candidates to serve as Arbitrator. The Parties shall each, in successive rounds (with the Party demanding the arbitration having the first chance to strike a name), strike one name off this list until only one name remains, and such last- named
      person shall be the Arbitrator.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.3.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Conduct of Arbitration</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">The Arbitrator shall be required to (a) follow the substantive rules of
      Massachusetts State or Federal law, as applicable, (b) require all testimony to be transcribed, and (c) accompany his or her award with findings of fact and a statement of reasons for the decision. The Arbitrator shall have the authority to permit
      discovery for no more than thirty (30) days, to the extent deemed appropriate by the Arbitrator, upon reasonable request of a Party. The Arbitrator shall have no power or authority to (i) add to or detract from the written agreement of the Parties
      set forth herein, (ii) modify or disregard any provision of this Agreement or any of the other related documents, or (iii) address or resolve any issue not submitted by the Parties. The Arbitrator shall hold proceedings during a period of no longer
      than thirty (30) calendar days promptly following conclusion of discovery, and the Arbitrator shall render a final decision within thirty (30) days following conclusion of the hearings. The Arbitrator shall have the power to grant injunctive relief
      (without the necessity of a Party posting a bond) in the event a Party has violated the confidentiality provisions set forth in this Agreement, but shall have no power to award punitive and/or exemplary damages in the event of a breach. In the event
      of any conflict between the commercial arbitration rules then in effect and the provisions of this Agreement, the provisions of this Agreement shall prevail and be controlling.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 24 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.4.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Interim Relief</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Either Party may, without waiving any remedy under this Agreement, apply
      to the Arbitrator for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any
      injunctive or provisional relief necessary to protect the rights regarding the Intellectual Property of that Party pending the arbitration award. The Arbitrator shall have no authority to award punitive or any other type of damages not measured by a
      Party&#8217;s compensatory damages.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.5.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Cost of Arbitration</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Each Party shall share in the actual and direct costs of the engagement
      of the Arbitrator, but the prevailing Party in the arbitration shall be reimbursed by the non-prevailing Party for the prevailing Party&#8217;s fees and costs of arbitration (e.g., the costs, fees and expenses of outside experts and counsel retained by the
      prevailing Party). If one Party is not deemed by the Arbitrator to be the primary prevailing Party, then each Party will pay its own costs, fees and expenses (including attorneys&#8217; fees) and an equal share of the Arbitrator&#8217;s fees and any
      administrative fees of arbitration.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.6.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Excluded Claims</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Unless otherwise mutually agreed upon by the Parties in writing, any
      Excluded Claims shall be brought in the federal court for the District Court of Massachusetts, if federal jurisdiction is available, or, alternatively, in the state courts in Suffolk County, Massachusetts. Each of the Parties hereby submits to the
      exclusive jurisdiction of such courts for the purpose of any such litigation; <i><u>provided, however</u>,</i> that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in
      any other manner provided by law. Each Party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in
      any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation. As used in this <u>Section 10.6</u>. the term &#8220;<i><u>Excluded Claim</u>&#8221; </i>means a dispute,
      controversy or claim that concerns: (x) the scope, construction, validity or infringement of a patent, trademark or copyright: (y) any antitrust, antimonopoly or competition law or regulation, whether or not statutory&#8217;: or (z) the Licensee&#8217;s or, as
      applicable Licensee&#8217;s Affiliates or sublicensee(s), Exploitation of Licensed Products or use of the Licensed Technology. Auxiliary Technologies, or the Auxiliary Technology Patents outside of the Field.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.7.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Injunctive Relief; Specific Performance</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Notwithstanding anything to the contrary herein, nothing in this <u>Section



        10</u> shall preclude a Party from seeking injunctive relief or specific performance in a court of competent jurisdiction.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10.8.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Confidentiality</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Except to the extent necessary to confirm an award or as may be required
      by law, neither a Party nor an Arbitrator may disclose the existence, content, or results of the arbitration without the prior written consent of both Parties, except to its directors and officers. In no event shall arbitration be initiated after the
      date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable Massachusetts statute of limitations.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 41pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 25 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Section 11</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i><u>Miscellaneous</u></i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.1.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Compliance with Law</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">In connection with its Exploitation of Licensed Products, Licensee agrees
      to comply with all Applicable Laws. Without limiting the foregoing, by entering into this Agreement, the Parties specifically intend to comply with all Applicable Laws pertaining to Licensed Products, including (i) the federal anti-kickback statute
      (42 U.S.C. &#167;1320a-7b) and the related safe harbor regulations; and (ii) the Limitation on Certain Physician Referrals, also referred to as the <i>&#8220;Stark Law&#8217;&#8217;</i> (42 U.S.C. &#167;1395nn). Accordingly, no part of any consideration paid hereunder is a
      prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services; nor are the payments intended to induce illegal referrals of business.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.2.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Assignment</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">This Agreement will be binding upon and will inure to the benefit of each
      Party and each Party&#8217;s respective transferees, successors and assigns, pursuant to the provisions set forth below. Licensee may not transfer or assign this Agreement without the prior written consent of Licensor, except as provided in this <u>Section



        11.2</u>. In the event that a third party (the <i>&#8220;<u>Acquiring Party</u>&#8221;)</i> acquires all or substantially all of Licensee&#8217;s business, capital stock or assets, whether by sale, merger, change of control, operation of law or otherwise (an <i>&#8220;<u>Acquisition</u>&#8221;),</i>
      the rights granted to Licensee under this Agreement pertaining to any and all Licensed Products shall inure to the benefit of the Acquiring Party. For the avoidance of doubt, in the event of an Acquisition, the Acquiring Party will be responsible for
      all payments and other obligations set forth in this Agreement, including, but not limited to, all payments set forth herein, and any obligations that matured prior to the Acquisition date. Upon an Acquisition, any unpaid portion of any deferred
      payments payable to Licensor hereunder shall become immediately due, and payment thereof shall remain an ongoing obligation of the Acquiring Party until such amount is paid in full. Any attempted assignment in contravention of this <u>Section 11.2</u>
      will be null and void.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.3.&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Entire Agreement</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 39pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">This Agreement constitutes the entire agreement between the Parties
      hereto with respect to the subject matter thereof, amends and restates the Prior Agreement in its entirety, and supersedes all previous negotiations, commitments, and writings with respect to such subject matter. Without limiting the foregoing, any
      terms or provisions of the Prior Agreement not included in this Agreement are terminated as of the Third Amendment Effective Date. Notwithstanding the foregoing, and for the avoidance of doubt, any and all rights granted to Licensee under the
      Original Agreement, the First Amended and Restated Agreement, or the Prior Agreement, and not granted in this Agreement, are terminated as to Licensee and its sublicensees (if any), and shall revert back to Licensor as of the Third Amendment
      Effective Date, and Licensee hereby releases Licensor and Licensor&#8217;s other licensees from any and all claims with respect to such rights under the Original Agreement, the First Amended and Restated Agreement, or the Prior Agreement. Neither Party
      shall be obligated by any undertaking or representation regarding that subject matter other than those expressly stated herein or as may be subsequently agreed to by the Parties hereto in writing. In the event of any conflict or inconsistency between
      any provision of any Exhibit hereto and any provision of this Agreement, the provisions of this Agreement shall prevail.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 26 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font: 10pt Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.4.&#160; &#160; &#160;&#160;&#160; <i><u>Amendment</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">No amendment, modification or supplement of any provision of this
      Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.5.&#160;&#160;&#160; &#160; &#160; <i><u>Notices</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Any notice required to be given pursuant to the provisions of this
      Agreement will be in writing and will be deemed to have been given at the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by telecopier, facsimile or
      electronic transmission, including PDF (portable document format), delivery by a professional courier service or delivery by first class, certified or registered mail (postage prepaid) addressed to the Party for whom intended at the address below, or
      at such changed address as the Party will have specified by written notice in accordance with this <u>Section 11.5</u>; <i><u>provided, however</u>,</i> that any notice of change of address will be effective only upon actual receipt.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">If to Licensor:&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font: 10pt Times New Roman,Times,serif;">c/o Factor Bioscience Inc.&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Attn: Matt Angel, Ph.D., CEO&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1035 Cambridge Street, Suite 17B&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Cambridge, MA 02141</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font: 10pt Times New Roman,Times,serif;">matt.angel@factorbio.com</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">If to Licensee:&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font: 10pt Times New Roman,Times,serif;">c/o Novellus, Inc.&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Attn: Christopher Rohde, Ph.D., President&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1035 Cambridge Street, Suite 17B&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Cambridge, MA 02141&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">chris.rohde@novellustx.com</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 76pt; text-indent: 0in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.6. &#160; &#160;&#160;&#160;&#160; <i><u>Governing Law</u>.</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 38pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 76pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.6.1.&#160;&#160;&#160;&#160;The substantive law governing this Agreement (which shall be
      applied in the arbitration) shall be, with respect to disputes involving general contract or trade secret matters, the internal laws of the Commonwealth of Massachusetts, and with respect to matters involving patents, the United States Patent Act, as
      to copyright matters, the United States Copyright Act, and as to trademark matters, the United States Trademark Act, each as amended from time to time. Any award rendered by the Arbitrator shall be final, conclusive and binding upon the Parties to
      this Agreement, and judgment thereon may be entered and enforced in any state or federal court of competent jurisdiction.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 76pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 76pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11.6.2.&#160;&#160;&#160;&#160;If any provisions of this Agreement are or will come into
      conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the Parties or this Agreement, those provisions will be deemed automatically deleted, if such deletion is allowed by relevant law, and the
      remaining terms and conditions of this Agreement will remain in full force and effect. If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or inappropriate in effect, the Parties agree to substitute
      new terms as similar in effect to the present terms of this Agreement as may be allowed under Applicable Law.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 76pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 76pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 27 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 76pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 0.5in; background-color: transparent;">11.7. &#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>Descriptive Headings</u>.</i></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="background-color: white;">This Agreement has been prepared jointly by the Parties and shall not be
      strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. Licensee hereby acknowledges that Licensor
      owns and/or has in-licensed the Licensed Technology, Auxiliary Technologies, and the Auxiliary Technology Patents, and the use of the term &#8220;license&#8221; hereunder with reference to the rights granted to Licensee is understood by the Parties to mean
      either a direct license of Licensor&#8217;s ownership interest in the subject Licensed Technology, Auxiliary Technology, or Auxiliary Technology Patent or a sublicense of Licensor&#8217;s in-licensed interest in the subject Licensed Technology, Auxiliary
      Technology or Auxiliary Technology Patent, as applicable. The headings of each Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the
      particular Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense (and/or). The term &#8220;including&#8221; as used herein means including, without
      limiting the generality of any description preceding such term.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">11.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Independent Contractors</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="background-color: white;">Both Parties are independent contractors under this Agreement. Nothing
      contained in this Agreement will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one
      Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other
      Party in any respect whatsoever. Notwithstanding anything contained herein to the contrary, and for the avoidance of doubt, Licensor shall not be deemed an Affiliate of Licensee, and Licensee shall not be deemed an Affiliate of Licensor.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">11.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Severability</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="background-color: white;">The illegality or partial illegality of any provision of this Agreement will
      not affect the validity of the remainder of the Agreement, or any provision thereof, and the illegality or partial illegality of any provision of this Agreement will not affect the validity of the Agreement in any jurisdiction in which such
      determination of illegality or partial illegality has not been made, except in either case to the extent such illegality or partial illegality causes the Agreement to no longer contain all of the material provisions reasonably expected by the Parties
      to be contained therein. Moreover, in the event that a court of competent jurisdiction determines that any provision of this Agreement is illegal or partially illegal, then it is the intention of the Parties that such provision be modified to the
      minimum extent deemed necessary by such court to make such provision enforceable and to give effect to the original intention of the Parties.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;"><font style="font-style: normal;">11.10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Waiver of Compliance</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 37pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-indent: 0.5in; background-color: transparent; text-align: justify;"><font style="background-color: white;">The failure of either Party to comply with any obligation, covenant,
      agreement or condition under this Agreement may be waived by the Party entitled to the benefit thereof only by a written instrument signed by the Party on granting such waiver, but such waiver or failure to insist upon strict compliance with such
      obligation, covenant, agreement or condition will not operate as a waiver of, or estoppel with respect to. any subsequent or other failure. The failure of any Party to enforce at any time any of the provisions of this Agreement will in no way be
      construed to be a waiver of any such provision, nor in any way to affect the validity of the Agreement or any part thereof or the right of any Party thereafter to enforce each and every such provision. No waiver of any breach of such provisions will
      be held to be waiver of any other or </font>subsequent breach.</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 28 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">11.11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Counterparts</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">This Agreement may be executed by original or facsimile signature in any
      number of counterparts, each of which need not contain the signature of more than one Party but all such counterparts taken together will constitute one and the same agreement.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">11.12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Authority</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">The persons signing on behalf of Licensor and Licensee hereby warrant and
      represent that they have authority to execute this Agreement on behalf of the Party for whom they have signed.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal;">11.13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="font-family: Times New Roman,Times,serif; background-color: white;"><i><u>Non-Disparagement</u>.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-family: Times New Roman,Times,serif; background-color: white;">Licensee on behalf of itself, its
      Affiliates and sublicensees hereby covenants and agrees that it shall not make, write or publish any statement, assertion or claim that disclaims, disparages, denies, questions or otherwise challenges or casts doubt upon the validity, enforceability,
      scope, construction or inventorship of any patent Controlled by Licensor (including, but not limited to, any pending or issued claim(s) within the Licensed Patents or the Auxiliary Technology Patents). The provisions set forth in this </font><u>Section



      11.13</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">shall take effect on the Effective Date, shall not require any further consideration or performance of Licensor, shall remain in effect regardless of any
      event that may occur hereunder or otherwise, including any breach of this Agreement by either Party, shall survive the termination or expiration of this Agreement, and, upon the termination or expiration of this Agreement, shall, with related
      definitions, remain in full force and effect for five (5) years. If any part of this </font><u>Section 11.13</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">shall be deemed illegal or unenforceable by a court of
      competent jurisdiction, that part shall be deemed automatically deleted, such deletion being made as narrowly as possible (and, if possible, only in said jurisdiction) to maintain, as much as possible, the intent of this </font><u>Section 11.13,</u>
    <font style="font-family: Times New Roman,Times,serif; background-color: white;">and the remainder of this </font><u>Section 11.13</u> <font style="font-family: Times New Roman,Times,serif; background-color: white;">shall, with related definitions,
      remain in full force and effect.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal; background-color: white;">11.14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><i><u>Non-Solicitation</u>.</i></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">During the Term, neither Party shall, without the prior written consent of
      the other Party, directly or indirectly solicit for employment any employee of the other Party or any of its Affiliates or subsidiaries, or any person who has terminated his or her employment with the other Party or any of its Affiliates or
      subsidiaries within the previous twelve (12)-month period prior to any purported solicitation; <i><u>provided, however,</u></i> the foregoing will not prevent a Party from employing any such person who contacts such Party on his or her own
      initiative without any direct or indirect solicitation by or encouragement from the soliciting or hiring person. General advertising which is not directed at any specific employee of a Party will not be deemed solicitation, and hiring of employees of
      such Party which are solicited in this manner will not be a breach of this provision.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="font-style: normal; background-color: white;">11.15&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><i><u>Force Majeure</u>.</i></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">Neither Party hereto shall be liable for failures and delays in performance
      due to strikes, lockouts, fires, acts of God or the public enemy, riots, incendiaries, interference by civil or military authorities, acts of terrorism, endemic, pandemic, and the results related to such acts, compliance with the law s of various
      states/countries, or with the orders of any governmental authorities, delays in transit or delivery on the part of transportation companies, failures of communication facilities, or any failure of sources of material.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 29 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;"><font style="background-color: white;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 0.5in; background-color: transparent;">11.16 &#160;&#160;&#160;&#160;&#160;&#160;&#160;<i><u>No Preferential Treatment, Fraudulent Conveyance, Insolvency</u>.</i></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 0.5in; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">11.16.1&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">The Parties have not
      entered into this Agreement to provide any preferential treatment under section 547 of title 11 of the United States Code, as amended (the &#8220;Bankruptcy Code&#8221;) or any other applicable insolvency law.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">11.16.2&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">Neither the execution or
      delivery of this Agreement or the consummation of the transactions hereunder were entered into with the intent by the Parties to effectuate a transaction that may be avoided under section 548(a) of the Bankruptcy Code, the Uniform Fraudulent Transfer
      Act (the &#8220;UFTA&#8221;), or any other applicable insolvency law. The Parties received reasonably equivalent value in exchange for the obligations provided hereunder. The transactions contemplated hereunder are not subject to avoidance under section 548(a)
      of the Bankruptcy Code, the UFTA, or any applicable insolvency law.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">11.16.3&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">As of the Third Amendment
      Effective Date, Licensor does not intend to file for protection or seek relief under title 11 of the Bankruptcy Code or any similar federal or state law providing for the relief of debtors. The Licensor is not now insolvent (as such term is defined
      in the Bankruptcy Code or any other applicable law relating to insolvency).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">11.16.4&#160;<font style="font-family: Times New Roman,Times,serif; background-color: white;">Notwithstanding any other
      provision of this Agreement to the contrary, in the event that Licensor becomes a debtor under the Bankruptcy Code and rejects this Agreement pursuant to section 365 of the Bankruptcy Code (a &#8220;Bankruptcy Rejection&#8221;): (a) any and all of the licensee
      and sublicensee rights of Licensee arising under or otherwise set forth in this Agreement, shall be deemed fully retained by and vested in Licensee as protected intellectual property rights under section 365(n)(l)(B) of the Bankruptcy Code and
      further shall be deemed to exist immediately before the commencement of the bankruptcy case in which Licensor is the debtor; (b) Licensee shall have all of the rights afforded to non-debtor licensees and sublicensees under section 365(n) of the
      Bankruptcy Code and all other applicable laws; and (c) to the extent any rights of Licensee under this Agreement that arise after the termination or expiration of this Agreement are determined by a bankruptcy court to not be &#8220;intellectual property
      rights&#8221; for purposes of section 365(n), all of such rights shall remain vested in and fully retained by Licensee after any Bankruptcy Rejection as though this Agreement were terminated or expired. Licensee shall under no circumstances be required to
      terminate this Agreement after a Bankruptcy Rejection in order to enjoy or acquire any of its rights under this Agreement, but retains the right to do so in accordance herewith.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 73pt; background-color: transparent;">&#160;</p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;"><font style="background-color: white;"><i>Remainder of page intentionally left blank.</i></font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 30 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left; text-indent: 35pt; background-color: transparent;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left; text-indent: 35pt; background-color: transparent;"><font style="background-color: white;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Third Amended
      and Restated Exclusive License Agreement as of the Third Amendment Effective Date.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left; text-indent: 35pt; background-color: transparent;">&#160;</p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;"><font style="background-color: white;"><b>Factor Bioscience Limited</b></font></p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse;">

      <tr style="vertical-align: top;">
        <td style="text-align: left; font-size: 10pt; vertical-align: bottom;"><font style="font-family: Times New Roman,Times,serif; color: black;">By:</font></td>
        <td colspan="2" style="text-align: left; font-size: 10pt; border-bottom: 1pt solid Black;"><img src="img001_v1.jpg" alt="(GRAPHIC)"></td>
        <td style="text-align: left; font-size: 10pt;">&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="text-align: left; font-size: 10pt; width: 3%;">&#160;</td>
        <td style="text-align: left; font-size: 10pt; width: 8%;"><font style="font-family: Times New Roman,Times,serif; color: black;">Name:</font></td>
        <td style="text-align: left; font-size: 10pt; width: 39%;"><font style="font-family: Times New Roman,Times,serif; color: black;">Matt Angel</font></td>
        <td style="text-align: left; font-size: 10pt; width: 50%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="text-align: left; font-size: 10pt;">&#160;</td>
        <td style="text-align: left; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif; color: black;">Title:</font></td>
        <td style="text-align: left; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif; color: black;">President and Chief Executive Officer</font></td>
        <td style="text-align: left; font-size: 10pt;">&#160;</td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; background-color: transparent;"><font style="background-color: white;"><b>Novellus Therapeutics Limited</b></font></p>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse;">

      <tr style="vertical-align: top;">
        <td style="text-align: left; vertical-align: bottom;"><font style="font-family: Times New Roman,Times,serif;">By:</font></td>
        <td colspan="2" style="font-weight: bold; border-bottom: 1pt solid Black;"><img src="img002_v1.jpg" alt="(GRAPHIC)"></td>
        <td style="font-weight: bold;">&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="text-align: left; width: 3%;">&#160;</td>
        <td style="text-align: left; width: 8%;"><font style="font-family: Times New Roman,Times,serif;">Name:</font></td>
        <td style="text-align: left; width: 39%;"><font style="font-family: Times New Roman,Times,serif;">Christopher Rohde</font></td>
        <td style="text-align: left; width: 50%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="text-align: left;">&#160;</td>
        <td style="text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Title:</font></td>
        <td style="text-align: left;"><font style="font-family: Times New Roman,Times,serif;">President</font></td>
        <td style="text-align: left;">&#160;</td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">Factor Bioscience Limited. Novellus Therapeutics Limited</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; background-color: transparent;">&#160;</p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">- 31 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin: 0px; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Times New Roman,Times,serif;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><u>Exhibit A</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Financial Terms</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0in;"></td>
        <td style="width: 1in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Sec. 5.1</i></font></td>
        <td> <font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee shall pay to Licensor the Upfront Fee of $2,749,700, which Upfront Fee has been fully paid as of the Third Amendment Effective Date.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 71.3pt; text-align: justify; text-indent: -71.3pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0in;"></td>
        <td style="width: 1in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Sec. 5.2.1</i></font></td>
        <td> <font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">For each Licensed Product, each time a Milestone set forth below is achieved by Licensee (or an Affiliate of Licensee) (and such Milestone is not otherwise achieved
            through a sublicense as provided in <u>Section 2.2</u>), Licensee shall pay to Licensor the corresponding Milestone Payment set forth below:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 71pt; text-align: justify; text-indent: -71pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 70%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse; margin-left: 1.1in;">

      <tr style="vertical-align: bottom; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 50%; border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Milestone</b></font></td>
        <td style="width: 20%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center; vertical-align: top;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Milestone Payment</b></font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman,Times,serif;">
        <td colspan="2" style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b><i>Development Milestones</i></b></font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman,Times,serif;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">IND Filing with a
            Regulatory Authority</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center; vertical-align: top;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$2,000,000</font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman,Times,serif;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: justify;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">First









            Patient Enrolled in a Phase I Clinical Trial</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center; vertical-align: top;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$1,500,000</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman,Times,serif;">
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">First









            Patient Enrolled in a Phase IIb Clinical Trial or Phase III Clinical Trial</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$2,500,000</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman,Times,serif;">
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Application









            for Regulatory Approval filed with a Regulatory Authority</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$5,000,000</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman,Times,serif;">
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Regulatory









            Approval of Licensed Product by Regulatory Authority by FDA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$20,000,000</font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman,Times,serif;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Regulatory Approval of
            Licensed Product by EMA</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center; vertical-align: top;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$10,000,000</font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman,Times,serif;">
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Regulatory Approval of Licensed Product in Japan</font></td>
        <td style="border: 1pt solid Black; font: 10pt Times New Roman,Times,serif; padding-right: 5pt; padding-left: 5pt; text-align: center; vertical-align: top;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">$10,000,000</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 71pt; text-align: justify; text-indent: -71pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#160;</i></font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0in;"></td>
        <td style="width: 1in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Sec. 5.2.2</i></font></td>
        <td> <font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Commencing upon the First Commercial Sale of a Licensed Product by Licensee or, as applicable Licensee&#8217;s sublicensee(s), in any country in the Territory, on a calendar
            quarter basis, Licensee shall pay to Licensor a Royalty on Net Sales equal to five percent (5.0%) of Net Sales of such Licensed Product.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 71pt; text-align: justify; text-indent: -71pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0in;"></td>
        <td style="width: 1in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Sec. 5.2.3</i></font></td>
        <td> <font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee shall, within thirty (30) days of receipt of any Sublicense Fees, pay to Licensor twenty percent (20%) of said Sublicense Fees.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 71pt; text-align: justify; text-indent: -71pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0in;"></td>
        <td style="width: 1in;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Sec. 5.3.6</i></font></td>
        <td> <font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensee shall, within thirty (30) days of receipt of any proceeds from the sale of a PRV, pay to Licensor twenty percent (20%) of said proceeds.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 71pt; text-align: justify; text-indent: -71pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font: 10pt Times New Roman,Times,serif;"><u>Exhibit 1.5</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Auxiliary Technologies</i></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">

      <tr style="vertical-align: top; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 0px; font: 10pt Times New Roman,Times,serif;"></td>
        <td style="width: 0.25in; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1.</font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#8220;<u>mRNA Vectorization of Gene-Editing Proteins</u>&#8221;</i> means the methods and compositions disclosed in U.S. Patent
            10,662,410.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">

      <tr style="vertical-align: top; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 0px; font: 10pt Times New Roman,Times,serif;"></td>
        <td style="width: 0.25in; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2.</font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#8220;<u>Chromatin Context-Sensitive Gene-Editing Endonuclease</u>&#8221;</i> means the methods and compositions disclosed in U.S.
            Patent 9,447,395.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">

      <tr style="vertical-align: top; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 0px; font: 10pt Times New Roman,Times,serif;"></td>
        <td style="width: 0.25in; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">3.</font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#8220;<u>Combined mRNA Gene-Editing &amp; Cell Reprogramming</u>&#8221;</i> means the methods and compositions disclosed in U.S.
            Patent 10,472,611.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">

      <tr style="vertical-align: top; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 0px; font: 10pt Times New Roman,Times,serif;"></td>
        <td style="width: 0.25in; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">4.</font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#8220;<u>Gene Editing Checkpoint Molecule Genes for the Treatment of Cancer</u>&#8221;</i> means the methods and compositions
            disclosed in U.S. Patent 10,137,206.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">

      <tr style="vertical-align: top; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 0px; font: 10pt Times New Roman,Times,serif;"></td>
        <td style="width: 0.25in; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">5.</font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#8220;<u>ToRNAdo Nucleic-Acid Delivery System</u>&#8221;</i> means the methods and compositions disclosed in U.S. Patent
            10,501,404.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">

      <tr style="vertical-align: top; font: 10pt Times New Roman,Times,serif;">
        <td style="width: 0px; font: 10pt Times New Roman,Times,serif;"></td>
        <td style="width: 0.25in; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6.</font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>&#8220;<u>Insertion of Sequences into Safe-Harbor Loci</u>&#8221;</i> means the methods and compositions disclosed in U.S. Patent
            10,724,053.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b><u>Exhibit 1.6</u></b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Auxiliary Technology Patents</font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 166.1pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr>
        <td style="width: 11%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket



              Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="text-align: center; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; vertical-align: middle;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.&#160;</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
        </td>
        <td style="vertical-align: middle; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. Publication Date</b></font></td>
        <td style="text-align: center; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; vertical-align: middle;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.&#160;</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date&#160;</b></font></p>
        </td>
        <td style="vertical-align: middle; width: 13%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case Status/Description</b></font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001AU</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Australia</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2012347919</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2012347919</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-13-2013</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2012347919&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-18-2017&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001AUD1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Australia</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016277545</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016277545&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-28-2017&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001AUD3</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Australia</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019203662&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-24-2019&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019203662&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-14-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001AUD4</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Australia</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2020202780&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-27-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001BR</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Brazil</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11201401366</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">45 Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CA</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Canada</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2,858,148</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CN</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20128006822&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">3.0 Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">104080482</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">ZL201280068 223.0 Nov-25-2015</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CND1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20151085201&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9.3 Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">105316278</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Feb-10-2016</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">ZL201510852 019.3 May-29-2017</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CND2</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20151085368&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9.7 Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">105368854</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-02-2016</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">ZL201510853 689.7 Aug-13-2019</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CND3</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20151085369









            0.X Dec-05-2012</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">105420232</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-23-2016</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">ZL201510853









            690.x Apr-17-2020</font></td>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr>
        <td style="width: 11%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="text-align: center; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; vertical-align: middle;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.&#160;</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date&#160;</b></font></p>
        </td>
        <td style="vertical-align: middle; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. Publication Date</b></font></td>
        <td style="text-align: center; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; vertical-align: middle;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.&#160;</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date&#160;</b></font></p>
        </td>
        <td style="vertical-align: middle; width: 13%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case



              Status/Description</b></font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CND4</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-02-2020</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001EP</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Europe</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12813595.1</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2014</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-31-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001CH</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Switzerland</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12813595.1</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2014</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-31-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001DE</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Germany</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12813595.1</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2014</font></p>
        </td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">602012033063.5</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-31-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001FR</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">France</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12813595.1</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2014</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-31-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001GB</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Great Britain</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12813595.1</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2014</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-31-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">001IE</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Ireland</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12813595.1</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2014</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2788033</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-31-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001EPD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Europe</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">17170810.0</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-02-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">EP3260140</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-27-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001HK</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Hong Kong</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15103141.5</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1202443</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-02-2015</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1202443</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-23-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 7pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001HKD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Hong Kong</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16108558.9</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1220490A</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-05-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1220490</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Feb-23-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 7pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001HKD2</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Hong
            Kong</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16110473.7</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1222203A</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-23-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr>
        <td style="width: 11%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication No.</b></font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication Date</b></font></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b></font></p>
        </td>
        <td style="vertical-align: bottom; width: 13%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case



              Status/Description</b></font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001HKD4</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Hong Kong</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">18101023.9</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jan-23-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1241704A.</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-15-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001JP</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Japan</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2014-546024</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015-506673A</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-5-2015</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6073916</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jan-13-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001JPD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Japan</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016-213019&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-31-2016&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017-023156A</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Feb-2-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6294944</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Feb-23-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001KR</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Republic of Korea</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10-2014-7018569 Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20140109925 A</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-16-2014</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001MX</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mexico</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">MX/a/2014/00 6663 Dec-05-2012</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">P184014MX&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-17-2015&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">354995</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-27-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001MXD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mexico</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">MX/a/2018/00 3987
            Mar-28-2018</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001RU</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Russian Federation</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2014127505</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-05-2012</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">2014127505A</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-30-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2624139</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-30-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001RUD2</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Russian Federation</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018112719&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-10-2018&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001C7</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/402,175</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-02-2019</font></p>
        </td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019-0270968</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-05-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,472,611&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-12-2019&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001C8</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/567,059&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-11-2019&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019-0390174</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-26-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001C9</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/776,765&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jan-30-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,662,410</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-26-2020</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr>
        <td style="width: 11%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication No.</b></font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication Date</b></font></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b></font></p>
        </td>
        <td style="vertical-align: bottom; width: 13%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case



              Status/Description</b></font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001010</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/857,894&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-24-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001011</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/869,232</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-07-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001012</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/913,306</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-26-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-001013</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR TRANSFECTING CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/913,315</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-26-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005AU</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Australia</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2013337651&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-01-2013&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2013337651&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-28-2019&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005BR</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Brazil</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">11201500980&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">45 Nov-01-2013</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005BRD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Brazil</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12201902567 8-0 Dec-04-2019</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005BRD2</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Brazil</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12201902568 1-0.</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-04-2019&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005BRD3</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Brazil</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">12201902568 3-7 Dec-04-2019</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005CA</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Canada</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2,890,110&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-01-2013&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px 0pt 1.9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;<font style="font-size: 10pt;">&#160;</font></font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr>
        <td style="width: 11%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. Publication Date</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b></font></p>
        </td>
        <td style="vertical-align: bottom; width: 13%; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case



              Status/Description</b></font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005CN</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20138005662 0.0 Nov-01-2013</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">104769112</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-08-2015</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005EP</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Europe</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">13850281.0</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-01-2013&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2914728</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-9-2015</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005EPD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Europe</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">EP 20184168.1</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-06-2020</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005HK</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Hong Kong</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16102376.2</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-01-2013</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">1214304</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-22-2016</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005JP</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Japan</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015-540833</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-01-2013</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015-534817</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-07-2015</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">6510416</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-12-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005JPD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Japan</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018-073676&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-06-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018-115207</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-26-2018</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005KR</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Korea</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10-2015-7013918 Nov-01-2013</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20150080573</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-09-2015</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005KRD1</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Korea</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND
            PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10-2020-7015879 Jun-03-2020</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005MX</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mexico</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">MX/a/2015/00









            5346 Nov-01-2013</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;">
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">363017</font></p>
          <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mar-04-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-bottom: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">License Agreement,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: left;"><font style="font-family: Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin: 0pt 0px;"><font style="font-family: Times New Roman,Times,serif;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr style="text-align: center; vertical-align: middle;">
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. <br>
              Publication Date</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b></font></p>
        </td>
        <td style="vertical-align: bottom; width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case Status/Description</b></font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005MXD1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Mexico</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR EXPRESSING
            PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">MX/a/2019/00</font></p>
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2498<br>
              Mar-01-2009</font></p>
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005RU</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Russian Federation</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015120524 <br>
            Nov-01-2013</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015120524A <br>
            Dec-20-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2711249 <br>
            Jan-15-2020</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005RUD1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Russian Federation</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019143431</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-24-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">14/701,199</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-30-2015</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015-0267189 <br>
            Sep-24-2015</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,447,395 <br>
            Sep-20-2016</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">14/735,603 <br>
            Jun-10-2015</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2015-0275193 <br>
            Oct-01-2015</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,376,669 <br>
            Jun-28-2016</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C2</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/156,806 <br>
            May-17-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016-0251649 <br>
            Sep-01-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,464,285 <br>
            Oct-11-2016</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C3</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/156,829 <br>
            May-17-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016-0251639 <br>
            Sep-01-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,487,768 <br>
            Nov-08-2016</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C4</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/270,469</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-20-2016</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017-0015983 <br>
            Jan-19-2017</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,657,282 <br>
            May-23-2017</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C5</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/487,088</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-13-2017</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017-0218400







            <br>
            Aug-03-2017</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,758,797
            <br>
            Sep-12-2017</font></td>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"></p>
  <p style="font: 10pt/90% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font></p>
  <p style="font: 10pt/90% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"></p>
  <p style="font: 10pt/95% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited<br style="clear: both;">
    </font></p>
  <p style="font: 10pt/95% Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt/95% Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr style="text-align: center; vertical-align: middle;">
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: bottom; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/117% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt/117% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/117% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
          <p style="font: 10pt/117% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: bottom; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. <br>
              Publication Date</b></font></td>
        <td style="vertical-align: bottom; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b>&#160;</font></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b>&#160;</font></p>
        </td>
        <td style="vertical-align: bottom; width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case Status/Description</b></font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C6</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/670,639</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Aug-07-2017</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017-0362612 <br>
            Dec-21-2017</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,415,060 <br>
            Sep-17-2019</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C7</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/523,558</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-30-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019-0345519 <br>
            Nov-14-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C8</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/654,532</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-16-2019</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2020-0032295 <br>
            Jan-30-2020</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C9</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/654,536</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-16-2019</font></p>
        </td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2020-0032296 <br>
            Jan-30-2020</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,752,917</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Aug-25-2020</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C11</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/655,744&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-17-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2020-0032297 <br>
            Jan-30-2020</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,724,053 <br>
            Jul-28-2020</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C12</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/655,760</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-17-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2020-0040363 <br>
            Feb-06-2020</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-005C17</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR EXPRESSING PROTEINS IN CELLS</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/912,321</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-25-2020</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010AU</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Australia</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017312113 <br>
            Dec-03-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010CA</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Canada</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">3,033,788
            <br>
            Feb-12-2019</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"></p>
  <p style="font: 10pt/92% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font></p>
  <p style="font: 10pt/92% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellas Therapeutics Limited<br style="clear: both;">
    </font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr style="text-align: center; vertical-align: middle;">
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. <br>
              Publication Date</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/124% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font>&#160;</p>
          <p style="font: 10pt/124% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b></font></p>
          <p style="font: 10pt/124% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: bottom; width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case Status/Description</b></font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010CN</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">China</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20178005963</font></p>
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/125% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">27 Mar-27-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">109803977 <br>
            May-24-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010EP</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Europe</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">17842152.5 <br>
            Mar-11-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">3500585 <br>
            Jun-26-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010HK</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Hong Kong</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">62-19000231.6 <br>
            Dec-23-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010IN</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">India</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">20192700233 2 <br>
            Jan-24-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 14pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010IL</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Israel</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">264439 <br>
            Jan-23-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">264439D0 <br>
            Feb-28-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010JP</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Japan</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019-509510 <br>
            Feb-15-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010NZ</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">New Zealand</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">748925 <br>
            Dec-03-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010B</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS
            AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/881,721</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jan-26-2018</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018-0177893 <br>
            Jun-28-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,137,206 <br>
            Nov-27-2018</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-010C3</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/030,675
            <br>
            Jul-09-2018</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019-0000997







            <br>
            Jan-03-2019</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,369,233</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Aug-06-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
        </td>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"></p>
  <p style="font: 10pt/87% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font></p>
  <p style="font: 10pt/87% Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited<br style="clear: both;">
    </font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr style="text-align: center; vertical-align: middle;">
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. <br>
              Publication Date</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b></font>&#160;</p>
        </td>
        <td style="vertical-align: bottom; width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case Status/Description</b></font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012PR</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS AND
            USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">62/870,245</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-03-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012PR2</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS
            AND USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">62/880,435 <br>
            Jul-30-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012PR3</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS AND
            USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">63/023,654&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-12-2020</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS
            AND USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/920,556 <br>
            Jul-03-2020</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012PC</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS
            AND USES THEREOF</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PCT/US20/40 813 <br>
            Jul-03-2020</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS AND
            USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/526,621</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Aug-12-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,501,404 <br>
            Dec-10-2019</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012AC1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS
            AND USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/660,299</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-22-2019</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,556,855 <br>
            Feb-11-2020</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012AC2</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS AND
            USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/660,317</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-22-2019</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,611,722</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-07-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012AC3</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS AND
            USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/746,279</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jan-17-2020</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,752,576</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Aug-25-2020</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-012C4</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">CATIONIC LIPIDS AND USES THEREOF</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/930,901</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-16-2020&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"></p>
  <p style="font: 10pt/92% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">License Agreement,</font></p>
  <p style="font: 10pt/92% Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="text-align: center; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><u>Exhibit 1.19</u></font></p>
  <p style="text-align: left; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="text-align: center; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>Improvement Patents &#160;</i></font></p>
  <p style="text-align: center; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="text-align: center; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><i>[To be added during the Term] &#160;</i></font></p>
  <p style="text-align: left; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="text-align: left; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"> <font style="font: 10pt Times New Roman,Times,serif;">License Agreement,</font> <font style="font: 10pt Times New Roman,Times,serif;">&#160;</font></p>
  <p style="text-align: left; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Times New Roman,Times,serif;">Factor Bioscience Limited, Novellus Therapeutics Limited</font> <font style="font: 10pt Times New Roman,Times,serif;">&#160;</font></p>
  <div style="margin-bottom: 10pt; clear: both; margin-top: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><u>Exhibit 1.25</u></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Licensed Patents</font></p>
  <p style="font: italic 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman,Times,serif; border-collapse: collapse;">

      <tr style="text-align: center; vertical-align: middle;">
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Docket Number</b></font></td>
        <td style="width: 12%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Country</b></font></td>
        <td style="width: 22%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%; vertical-align: middle;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Title</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application No.</b></font></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Application Date</b></font></p>
          <p style="font: 10pt/122% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Publication



              No. <br>
              Publication Date</b></font></td>
        <td style="vertical-align: top; width: 14%; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration No.</b></font></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt/120% Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Registration Date</b>&#160;</font></p>
        </td>
        <td style="vertical-align: bottom; width: 12%; border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><b>Case Status/Description</b></font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR REPROGRAMMING CELLS TO A LESS DIFFERENTIATED STATE</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">13/465,490</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-07-2012&#160;</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2013-0029418 <br>
            Jan-31-2013</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">8,497,124 <br>
            Jul-30-2013</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C1</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PRODUCTS FOR
            TRANSFECTION AND REPROGRAMMING</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">13/931,251</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-28-2013</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2013-0344602 <br>
            Oct-15-2013</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,127,248 <br>
            Sep-08-2015</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C2</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS OF
            REPROGRAMMING CELLS TO A LESS DIFFERENTIATED STATE</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">14/810,123</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jul-27-2015</font>&#160;</p>
        </td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016-0010060 <br>
            Jan-14-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,399,761 <br>
            Jul-26-2016</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C3</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/178,190&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Jun-9-2016</font>&#160;</p>
        </td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2016-0281059 <br>
            Sep-29-2016</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,562,218 <br>
            Feb-07-2017</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C4</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/358,818</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Nov-22-2016</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017-0073644 <br>
            Mar-16-2017</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,695,401 <br>
            Jul-04-2017</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C5</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/605,513&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">May-25-2017</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2017-0267979 <br>
            Sep-21-2017</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,879,228 <br>
            Jan-30-2018</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C6</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/844,063&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Dec-15-2017</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
        </td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018-0105800 <br>
            Apr-19-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">9,969,983 <br>
            May-15-2018</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C7</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">15/947,741</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-06-2018</font></p>
        </td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018-0230438 <br>
            Aug-16-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,131,882 <br>
            Nov-20-2018</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C8</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%; vertical-align: top;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 8pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/037,597 <br>
            Jul-17-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2018-0327720 <br>
            Nov-15-2018</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,301,599 <br>
            May-28-2019</font></td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C9</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS
            FOR TRANSFECTION</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/374,482</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Apr-03-2019</font></p>
        </td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2019-0225944 <br>
            Jul-25-2019</font></td>
        <td style="border-top: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">10,443,045&#160;</font></p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Oct-15-2019</font></p>
        </td>
        <td style="border-top: 1pt solid Black; border-right: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">PATENTED</font></td>
      </tr>
      <tr style="text-align: center; vertical-align: middle;">
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">FAB-003C10</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">USA</font></td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">METHODS AND PRODUCTS FOR TRANSFECTION</font></td>
        <td style="vertical-align: bottom; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt;">
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">16/562,497</font>&#160;</p>
          <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Sep-06-2019</font></p>
        </td>
        <td style="vertical-align: top; border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">2020-0048616 <br>
            Feb-13-2020</font></td>
        <td style="border-top: 1pt solid Black; border-bottom: 1pt solid Black; border-left: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">N/A</font></td>
        <td style="border: 1pt solid Black; padding-right: 0.5pt; padding-left: 0.5pt; line-height: 122%;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Pending</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;">License Agreement,</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Factor Bioscience Limited, Novellus Therapeutics Limited</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;</font></p>
  <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>brhc10043851_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 31.1</div>
        <div style="text-align: center; font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</div>
        <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div>&#160;<br>
        </div>
        <div style="text-align: justify;">I, Matthew Angel, certify that:</div>
        <div>&#160;<br>
        </div>
        <div>1. I have reviewed this Quarterly Report on Form 10-Q of Eterna Therapeutics Inc.</div>
        <div>&#160;<br>
        </div>
        <div>2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
          misleading with respect to the period covered by this report.</div>
        <div>&#160;<br>
        </div>
        <div>3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
          for, the periods presented in this report.</div>
        <div>&#160;<br>
        </div>
        <div>4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
          defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
        <div>&#160;<br>
        </div>
        <div>(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
          subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
        <div>&#160;<br>
        </div>
        <div>(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
          the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
        <div>&#160;<br>
        </div>
        <div>(c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
          report based on such evaluation; and</div>
        <div>&#160;<br>
        </div>
        <div>(d) disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect,
          the registrant&#8217;s internal control over financial reporting.</div>
        <div>&#160;<br>
        </div>
        <div>5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors:</div>
        <div>&#160;<br>
        </div>
        <div>(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report
          financial information; and</div>
        <div>&#160;<br>
        </div>
        <div>(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls.</div>
        <div>&#160;<br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9a6a6477d6f544649ece7dfe5fe1bbb7">

            <tr>
              <td style="width: 49.98%; vertical-align: top;">
                <div>Date: November 14, 2022</div>
              </td>
              <td style="width: 50.02%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: justify;">/s/ Matthew Angel</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.98%; vertical-align: top;">&#160;</td>
              <td style="width: 50.02%; vertical-align: bottom;">
                <div style="text-align: justify;">Matthew Angel</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.98%; vertical-align: top;">&#160;</td>
              <td style="width: 50.02%; vertical-align: bottom;">
                <div style="text-align: justify;">Interim Chief Executive Officer and President</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.98%; vertical-align: top;">&#160;</td>
              <td style="width: 50.02%; vertical-align: bottom;">
                <div style="text-align: justify; font-style: italic;">(Principal Executive Officer)</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div>&#160;
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>brhc10043851_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 31.2</div>
        <div>&#160;<br>
        </div>
        <div style="text-align: center; font-weight: bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</div>
        <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div>&#160;<br>
        </div>
        <div style="text-align: justify;">I, Andrew Jackson, certify that:</div>
        <div>&#160;<br>
        </div>
        <div>1. I have reviewed this Quarterly Report on Form 10-Q of Eterna Therapeutics Inc.</div>
        <div>&#160;<br>
        </div>
        <div>2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
          misleading with respect to the period covered by this report.</div>
        <div>&#160;<br>
        </div>
        <div>3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
          for, the periods presented in this report.</div>
        <div>&#160;<br>
        </div>
        <div>4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
          defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
        <div>(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
          subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
        <div>&#160;<br>
        </div>
        <div>(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
          the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
        <div>&#160;<br>
        </div>
        <div>(c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
          report based on such evaluation; and</div>
        <div>&#160;<br>
        </div>
        <div>(d) disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect,
          the registrant&#8217;s internal control over financial reporting.</div>
        <div>&#160;<br>
        </div>
        <div>5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors:</div>
        <div>&#160;<br>
        </div>
        <div>(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report
          financial information; and</div>
        <div>&#160;<br>
        </div>
        <div>(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls.</div>
        <div>&#160;<br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf16cadb0686444e195a697786fa4c7bd">

            <tr>
              <td style="width: 49.98%; vertical-align: top;">
                <div>Date: November 14, 2022</div>
              </td>
              <td style="width: 50.02%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: justify;">/s/ Andrew Jackson</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.98%; vertical-align: top;">&#160;</td>
              <td style="width: 50.02%; vertical-align: bottom;">
                <div style="text-align: justify;">Andrew Jackson</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.98%; vertical-align: top;">&#160;</td>
              <td style="width: 50.02%; vertical-align: bottom;">
                <div style="text-align: justify;">Chief Financial Officer</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.98%; vertical-align: top;">&#160;</td>
              <td style="width: 50.02%; vertical-align: bottom;">
                <div style="text-align: justify; font-style: italic;">(Principal Financial Officer)</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div><br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>brhc10043851_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 32.1</div>
        <div> <br>
        </div>
        <div style="text-align: center; font-weight: bold;">CERTIFICATION PURSUANT TO 18 U.S.C. 1350,</div>
        <div style="text-align: center; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div> <br>
        </div>
        <div>In connection with the Quarterly Report on Form 10-Q of Eterna Therapeutics Inc. for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned
          certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:</div>
        <div> <br>
        </div>
        <div>1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
        <div> <br>
        </div>
        <div>2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Eterna Therapeutics Inc. for the period presented therein.</div>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb006177509cc41e9b52973c736e659a4">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>Date: November 14, 2022</div>
              </td>
              <td style="width: 50%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">/s/ Matthew Angel</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: justify;">Matthew Angel</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: justify;">Interim Chief Executive Officer and President</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: justify; font-style: italic;">(Principal Executive Officer)</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. &#167; 1350 and is not being filed as part of the Report or as a separate disclosure document.</div>
        <div> <br>
        </div>
        <div> <br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>brhc10043851_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 22.10.2.5096
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 32.2</div>
        <div> <br>
        </div>
        <div style="text-align: center; font-weight: bold;">CERTIFICATION PURSUANT TO 18 U.S.C. 1350,</div>
        <div style="text-align: center; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div> <br>
        </div>
        <div>In connection with the Quarterly Report on Form 10-Q of Eterna Therapeutics Inc. for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned
          certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:</div>
        <div> <br>
        </div>
        <div>1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
        <div> <br>
        </div>
        <div>2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Eterna Therapeutics Inc. for the period presented therein.</div>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" id="zd8e1e0bfce0e4e16a00f0ec6b4e84fc9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>Date: November 14, 2022</div>
              </td>
              <td style="width: 50%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: justify;">/s/ Andrew Jackson</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: justify;">Andrew Jackson</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: justify;">Chief Financial Officer</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: justify; font-style: italic;">(Principal Financial Officer)</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. &#167; 1350 and is not being filed as part of the Report or as a separate disclosure document.</div>
        <div style="text-align: justify;">
          <div><br>
          </div>
          <br>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><br>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>erna-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<xs:schema targetNamespace="http://eternatx.com/20220930" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:erna="http://eternatx.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://eternatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="CondensedConsolidatedStatementsOfOperationsParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS-->
        <link:definition>020100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity" id="CondensedConsolidatedStatementsOfStockholdersAndMembersEquity">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical" id="CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY-->
        <link:definition>030100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>060100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LiquidityAndCapitalResources" id="LiquidityAndCapitalResources">
        <link:definition>060200 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions" id="MergerDispositionAndAcquisitionTransactions">
        <link:definition>060300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/Leases" id="Leases">
        <link:definition>060500 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill" id="InprocessResearchDevelopmentAndGoodwill">
        <link:definition>060600 - Disclosure - IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CeoSeparationAgreement" id="CeoSeparationAgreement">
        <link:definition>060700 - Disclosure - CEO SEPARATION AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060800 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
        <link:definition>060900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>061100 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>061200 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/EarningsPerShare" id="EarningsPerShare">
        <link:definition>061300 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
        <link:definition>061400 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061500 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" id="DescriptionOfBusinessAndBasisOfPresentationPolicies">
        <!--Parent Role: DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION-->
        <link:definition>070100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
        <!--Parent Role: RECENT ACCOUNTING PRONOUNCEMENTS-->
        <link:definition>071400 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables" id="MergerDispositionAndAcquisitionTransactionsTables">
        <!--Parent Role: MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS-->
        <link:definition>080300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: FAIR VALUE OF FINANCIAL INSTRUMENTS-->
        <link:definition>080400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LeasesTables" id="LeasesTables">
        <!--Parent Role: LEASES-->
        <link:definition>080500 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER LIABILITIES-->
        <link:definition>080900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>081100 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
        <!--Parent Role: EARNINGS PER SHARE-->
        <link:definition>081300 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" id="DescriptionOfBusinessAndBasisOfPresentationDetails">
        <!--Parent Role: DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION-->
        <link:definition>090100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LiquidityAndCapitalResourcesDetails" id="LiquidityAndCapitalResourcesDetails">
        <!--Parent Role: LIQUIDITY AND CAPITAL RESOURCES-->
        <link:definition>090200 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails" id="MergerDispositionAndAcquisitionTransactionsMergerDetails">
        <!--Parent Role: MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS-->
        <link:definition>090300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <!--Parent Role: MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS-->
        <link:definition>090302 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails" id="MergerDispositionAndAcquisitionTransactionsDispositionDetails">
        <!--Parent Role: MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS-->
        <link:definition>090304 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Disposition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" id="MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
        <!--Parent Role: MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS-->
        <link:definition>090306 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" id="MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails">
        <!--Parent Role: MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS-->
        <link:definition>090308 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Investment in NoveCite (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" id="FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails">
        <!--Parent Role: FAIR VALUE OF FINANCIAL INSTRUMENTS-->
        <link:definition>090400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS, Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails" id="FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails">
        <!--Parent Role: FAIR VALUE OF FINANCIAL INSTRUMENTS-->
        <link:definition>090402 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS, Changes in Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LeasesOperatingLeaseDetails" id="LeasesOperatingLeaseDetails">
        <!--Parent Role: LEASES-->
        <link:definition>090500 - Disclosure - LEASES, Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails" id="LeasesNetOperatingLeaseExpensesDetails">
        <!--Parent Role: LEASES-->
        <link:definition>090502 - Disclosure - LEASES, Net Operating Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" id="LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails">
        <!--Parent Role: LEASES-->
        <link:definition>090504 - Disclosure - LEASES, Operating Lease Right-of-use Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <!--Parent Role: LEASES-->
        <link:definition>090506 - Disclosure - LEASES, Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2">
        <!--Parent Role: LEASES, Maturities of Operating Lease Liabilities (Details)-->
        <link:definition>090508 - Disclosure - LEASES, Maturities of Operating Lease Liabilities (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails" id="InprocessResearchDevelopmentAndGoodwillDetails">
        <!--Parent Role: IN-PROCESS RESEARCH & DEVELOPMENT AND GOODWILL-->
        <link:definition>090600 - Disclosure - IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CeoSeparationAgreementDetails" id="CeoSeparationAgreementDetails">
        <!--Parent Role: CEO SEPARATION AGREEMENT-->
        <link:definition>090700 - Disclosure - CEO SEPARATION AGREEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: RELATED PARTY TRANSACTIONS-->
        <link:definition>090800 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails" id="AccruedExpensesAndOtherLiabilitiesDetails">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER LIABILITIES-->
        <link:definition>090900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails" id="CommitmentsAndContingenciesLegalMattersDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES, Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails" id="CommitmentsAndContingenciesLicensingAgreementsDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>091002 - Disclosure - COMMITMENTS AND CONTINGENCIES, Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails" id="CommitmentsAndContingenciesRoyaltyAgreementsDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>091004 - Disclosure - COMMITMENTS AND CONTINGENCIES, Royalty Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091100 - Disclosure - STOCK-BASED COMPENSATION, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails" id="StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091102 - Disclosure - STOCK-BASED COMPENSATION, Weighted-Average Assumptions Used for Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails" id="StockbasedCompensationSummaryOfStockOptionsDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091104 - Disclosure - STOCK-BASED COMPENSATION, Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationRsusDetails" id="StockbasedCompensationRsusDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091106 - Disclosure - STOCK-BASED COMPENSATION, RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails" id="StockbasedCompensationNumberOfRsusVestedAndSettledDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091108 - Disclosure - STOCK-BASED COMPENSATION, Number of RSUs Vested and Settled (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails" id="StockbasedCompensationSummaryOfRsusDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091110 - Disclosure - STOCK-BASED COMPENSATION, Summary of RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails" id="StockbasedCompensationRestrictedStockDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091112 - Disclosure - STOCK-BASED COMPENSATION, Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" id="StockbasedCompensationStockbasedCompensationExpenseDetails">
        <!--Parent Role: STOCK-BASED COMPENSATION-->
        <link:definition>091114 - Disclosure - STOCK-BASED COMPENSATION, Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails" id="StockholdersEquityPrivatePlacementOfEquityDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>091200 - Disclosure - STOCKHOLDERS' EQUITY, Private Placement of Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/StockholdersEquityMergerDetails" id="StockholdersEquityMergerDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>091202 - Disclosure - STOCKHOLDERS' EQUITY, Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/EarningsPerShareDetails" id="EarningsPerShareDetails">
        <!--Parent Role: EARNINGS PER SHARE-->
        <link:definition>091300 - Disclosure - EARNINGS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eternatx.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: SUBSEQUENT EVENTS-->
        <link:definition>091500 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" id="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentsOfPaycheckProtectionProgramLoan" id="erna_PaymentsOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CashPaidDuringThePeriodForAbstract" id="erna_CashPaidDuringThePeriodForAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GainOnTerminationOfLease" id="erna_GainOnTerminationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LossOnNonControllingInvestment" id="erna_LossOnNonControllingInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="WarrantLiabilitiesExpense" id="erna_WarrantLiabilitiesExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInOperatingLeaseLiabilities" id="erna_IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GainLossOnDisposalOfFixedAssets" id="erna_GainLossOnDisposalOfFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="InitialMeasurementOfRightOfUseAssetsAndLiabilities" id="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromIssuanceOfCommonStockToLincolnPark" id="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" id="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ConversionOfWarrantLiabilityToEquity" id="erna_ConversionOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ResearchAndDevelopmentInProcessAssetAcquisition" id="erna_ResearchAndDevelopmentInProcessAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" id="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" id="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentsToAcquireProductiveAssetsNet" id="erna_PaymentsToAcquireProductiveAssetsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" id="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IssuanceOfCommonStockForSeriesAPreferredStockDividend" id="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IssuanceOfCommonStockForAssetAcquisition" id="erna_IssuanceOfCommonStockForAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="InitialMeasurementOfOperatingLeaseLiabilities" id="erna_InitialMeasurementOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="InitialMeasurementOfFinanceLeaseLiabilities" id="erna_InitialMeasurementOfFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LIQUIDITYANDCAPITALRESOURCESAbstract" id="erna_LIQUIDITYANDCAPITALRESOURCESAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAndCapitalResourcesTextBlock" id="erna_LiquidityAndCapitalResourcesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfBoardSeats" id="erna_NumberOfBoardSeats" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CitiusPharmaceuticalsIncMember" id="erna_CitiusPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NoveCiteINCMember" id="erna_NoveCiteINCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromSaleOfRights" id="erna_ProceedsFromSaleOfRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PercentageOfAdditionalRightsOffering" id="erna_PercentageOfAdditionalRightsOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NTNBuzztimeIncMember" id="erna_NTNBuzztimeIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" id="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="BeneficialHoldersContractualCommitmentsToInvest" id="erna_BeneficialHoldersContractualCommitmentsToInvest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PurchasePriceAllocationMember" id="erna_PurchasePriceAllocationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProFormaFairValueAdjustmentToAssetsMember" id="erna_ProFormaFairValueAdjustmentToAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LegalMattersAbstract" id="erna_LegalMattersAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LossContingencyNumberOfArbitrationPanel" id="erna_LossContingencyNumberOfArbitrationPanel" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LossContingencyDamagesSoughtExpectedEquityPercentage" id="erna_LossContingencyDamagesSoughtExpectedEquityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NovellusTherapeuticsLimitedMember" id="erna_NovellusTherapeuticsLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DheshGovenderMember" id="erna_DheshGovenderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LossContingencyDamagesSoughtExpectedSalary" id="erna_LossContingencyDamagesSoughtExpectedSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RoyaltyAgreementsAbstract" id="erna_RoyaltyAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" id="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" id="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InvestorRoyaltyAgreementMember" id="erna_InvestorRoyaltyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaboratorRoyaltyAgreementMember" id="erna_CollaboratorRoyaltyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfSharesConsideredAsFractionalInReverseStock" id="erna_NumberOfSharesConsideredAsFractionalInReverseStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReverseStockSplitAbstract" id="erna_ReverseStockSplitAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" id="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ReverseStockSplitPolicyTextBlock" id="erna_ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfAwardsVestedAndSettledAbstract" id="erna_NumberOfAwardsVestedAndSettledAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockWithheldToCoverTaxes" id="erna_CommonStockWithheldToCoverTaxes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="Two022PerformanceBasedRestrictedStockUnitsMember" id="erna_Two022PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPerformanceGoalsAreSubjectToAchieve" id="erna_NumberOfPerformanceGoalsAreSubjectToAchieve" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeMember" id="erna_EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChiefExecutiveOfficerAndPresidentMember" id="erna_ChiefExecutiveOfficerAndPresidentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" id="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NewFacilityLeaseAbstract" id="erna_NewFacilityLeaseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OverSubscriptionAmountReceived" id="erna_OverSubscriptionAmountReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CommonWarrantsMember" id="erna_CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreFundedWarrantsMember" id="erna_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DispositionAbstract" id="erna_DispositionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" id="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" id="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromDispositionAbstract" id="erna_ProceedsFromDispositionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" id="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" id="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NTNBusinessMember" id="erna_NTNBusinessMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LesseeOperatingAndFinanceLeasesTextBlock" id="erna_LesseeOperatingAndFinanceLeasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BaseRentPerSquareFoot" id="erna_BaseRentPerSquareFoot" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingLeaseArea" id="erna_OperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="UnamortizedLeaseholdImprovements" id="erna_UnamortizedLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="InitialMeasurementOfOperatingLeaseROUAssets" id="erna_InitialMeasurementOfOperatingLeaseROUAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PercentageBaseRentIncreaseOnEachAnniversary" id="erna_PercentageBaseRentIncreaseOnEachAnniversary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="LesseeCommitmentToPurchaseProperty" id="erna_LesseeCommitmentToPurchaseProperty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PerformanceBasedStockOptionGrantMember" id="erna_PerformanceBasedStockOptionGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TimeBasedStockOptionGrantMember" id="erna_TimeBasedStockOptionGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InterimChiefExecutiveOfficerMember" id="erna_InterimChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FacilitySubleaseAbstract" id="erna_FacilitySubleaseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExacisOptionAgreementAbstract" id="erna_ExacisOptionAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TermToPaySecurityDeposit" id="erna_TermToPaySecurityDeposit" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingLeasesMonthlyBaseRent" id="erna_OperatingLeasesMonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ERSquibbSonsLLCMember" id="erna_ERSquibbSonsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExacisBiotherapeuticsIncMember" id="erna_ExacisBiotherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OptionFee" id="erna_OptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" id="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" id="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MergerAbstract" id="erna_MergerAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightIssued" id="erna_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockIssuedDuringPeriodSharesAcquisitions1" id="erna_StockIssuedDuringPeriodSharesAcquisitions1" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrivatePlacementOfEquityAbstract" id="erna_PrivatePlacementOfEquityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ObligationToPayLiquidatedDamagesPercentage" id="erna_ObligationToPayLiquidatedDamagesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ConsecutiveCalendarDays" id="erna_ConsecutiveCalendarDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" id="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="TransactionFeesPayable" id="erna_TransactionFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ClassOfWarrantOrRightExercised" id="erna_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightsExercisableTerm" id="erna_ClassOfWarrantOrRightsExercisableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="VariableRateTransactionsPeriod" id="erna_VariableRateTransactionsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AggregateCalendarDays" id="erna_AggregateCalendarDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PIPEInvestorMember" id="erna_PIPEInvestorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WriteOffOfOperatingLeaseLiability" id="erna_WriteOffOfOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="OperatingLeaseAssestAbstract" id="erna_OperatingLeaseAssestAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrincipalPaymentsOnOperatingLeaseLiabilities" id="erna_PrincipalPaymentsOnOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="RemeasurementOfOperatingLeaseRightOfUseAsset" id="erna_RemeasurementOfOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="WriteOffOfOperatingLeaseRightOfUseAsset" id="erna_WriteOffOfOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" id="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" id="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" id="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" id="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LicensingAgreementsAbstract" id="erna_LicensingAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LossContingencyPercentageOfRoyaltyPayable" id="erna_LossContingencyPercentageOfRoyaltyPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MilestonePayments" id="erna_MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LossContingencyNonRefundableOptionFee" id="erna_LossContingencyNonRefundableOptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PercentageOfRevenue" id="erna_PercentageOfRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AmountRequireToPayInitialLicenseFees" id="erna_AmountRequireToPayInitialLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AmountObligatedToPayInYearTwo" id="erna_AmountObligatedToPayInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AdditionalFeesObligatedToPay" id="erna_AdditionalFeesObligatedToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AmountObligatedToPayInYearOne" id="erna_AmountObligatedToPayInYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NoveCiteMember" id="erna_NoveCiteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NovellusLtdAndFactorBioscienceMember" id="erna_NovellusLtdAndFactorBioscienceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InitialLicenseFees" id="erna_InitialLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="UniversityOfSouthFloridaMember" id="erna_UniversityOfSouthFloridaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" id="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AssetAcquisitionSharePrice" id="erna_AssetAcquisitionSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PercentageOfDiscountOnFairValueOfRestrictedShares" id="erna_PercentageOfDiscountOnFairValueOfRestrictedShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AssetAcquisitionRestrictedSharesSharePrice" id="erna_AssetAcquisitionRestrictedSharesSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AssetAcquisitionFairValueOfConsiderationPaid" id="erna_AssetAcquisitionFairValueOfConsiderationPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AcquisitionAgreementNonCompetitivePeriod" id="erna_AcquisitionAgreementNonCompetitivePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EscrowShares" id="erna_EscrowShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" id="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="EachLockUpAgreementExtendsTerm" id="erna_EachLockUpAgreementExtendsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfCommonStockSubjectToLockUpAgreement" id="erna_PercentageOfCommonStockSubjectToLockUpAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" id="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" id="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AssetAcquisitionUnrestrictedSharesSharePrice" id="erna_AssetAcquisitionUnrestrictedSharesSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockIssuedDuringPeriodRestrictedSharesAcquisitions" id="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NovellusIncMember" id="erna_NovellusIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LockUpPeriodForRestrictedShares" id="erna_LockUpPeriodForRestrictedShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedResearchAndDevelopmentExpenses" id="erna_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedGeneralAndAdministrativeExpenses" id="erna_AccruedGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="InsurancePolicyPremiums" id="erna_InsurancePolicyPremiums" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CurrentPortionOfLicenseFeeObligation" id="erna_CurrentPortionOfLicenseFeeObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LongTermPortionOfLicenseFeeObligation" id="erna_LongTermPortionOfLicenseFeeObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CommonStockToBeRetainedByNTNValueStockholders" id="erna_CommonStockToBeRetainedByNTNValueStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonStockToBeRetainedByNTNSharesStockholders" id="erna_CommonStockToBeRetainedByNTNSharesStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueStockPurchaseAgreement" id="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueInLieuOfDividends" id="erna_StockIssuedDuringPeriodValueInLieuOfDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesInLieuOfDividends" id="erna_StockIssuedDuringPeriodSharesInLieuOfDividends" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueAcquisitions2" id="erna_StockIssuedDuringPeriodValueAcquisitions2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesAcquisitions2" id="erna_StockIssuedDuringPeriodSharesAcquisitions2" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommonUnitsMember" id="erna_CommonUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesPrivateOffering" id="erna_StockIssuedDuringPeriodSharesPrivateOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValueAcquisitions1" id="erna_StockIssuedDuringPeriodValueAcquisitions1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValuePrivateOffering" id="erna_StockIssuedDuringPeriodValuePrivateOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MembershipEquityMember" id="erna_MembershipEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" id="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CEOSEPARATIONAGREEMENTAbstract" id="erna_CEOSEPARATIONAGREEMENTAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChiefExecutiveOfficerSeparationAgreementTextBlock" id="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SeparationAgreementAbstract" id="erna_SeparationAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" id="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PaymentToOfficerBaseSalary" id="erna_PaymentToOfficerBaseSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MilestoneOptionsMember" id="erna_MilestoneOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FactorBioscienceIncMember" id="erna_FactorBioscienceIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MonthlyMasterServicesAgreementFeesPayable" id="erna_MonthlyMasterServicesAgreementFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AgreedWaivePayment" id="erna_AgreedWaivePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NoticePeriodForSupersedingTerminationProvisions" id="erna_NoticePeriodForSupersedingTerminationProvisions" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RelatedPartyTransactionPeriodicFeesPaymentAmount" id="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MasterServiceAgreementInitialFeesPayable" id="erna_MasterServiceAgreementInitialFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ReimburseCostsIncurredOrPaid" id="erna_ReimburseCostsIncurredOrPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfMonthlyInstallmentsForFeesPayable" id="erna_NumberOfMonthlyInstallmentsForFeesPayable" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" id="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NoticePeriodForFirstTerminationOfContract" id="erna_NoticePeriodForFirstTerminationOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>erna-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesNetOperatingLeaseExpensesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="calculation: Assets to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="Cash" xlink:title="calculation: AssetsCurrent to Cash" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" xlink:title="OtherReceivablesNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="OtherReceivablesNetCurrent" xlink:title="calculation: AssetsCurrent to OtherReceivablesNetCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="EquityMethodInvestments" xlink:title="calculation: Assets to EquityMethodInvestments" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OtherLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to OtherLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to FinanceLeaseLiabilityCurrent" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to DerivativeLiabilitiesNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to FinanceLeaseLiabilityNoncurrent" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to PreferredStockDividendsAndOtherAdjustments" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="NoncashMergerRelatedCosts" xlink:title="calculation: OperatingExpenses to NoncashMergerRelatedCosts" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentInProcess" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="calculation: NonoperatingIncomeExpense to GainLossOnDispositionOfAssets1" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossOnNonControllingInvestment" xlink:label="LossOnNonControllingInvestment" xlink:title="LossOnNonControllingInvestment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="LossOnNonControllingInvestment" xlink:title="calculation: NonoperatingIncomeExpense to LossOnNonControllingInvestment" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WarrantLiabilitiesExpense" xlink:label="WarrantLiabilitiesExpense" xlink:title="WarrantLiabilitiesExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="WarrantLiabilitiesExpense" xlink:title="calculation: NonoperatingIncomeExpense to WarrantLiabilitiesExpense" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="NetIncomeLoss" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to NetIncomeLoss" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ResearchAndDevelopmentInProcessAssetAcquisition" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseImpairmentLoss" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NoncashMergerRelatedCosts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NoncashMergerRelatedCosts" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:label="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnForgivenessOfPaycheckProtectionProgramLoan" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainOnTerminationOfLease" xlink:label="GainOnTerminationOfLease" xlink:title="GainOnTerminationOfLease" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainOnTerminationOfLease" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainOnTerminationOfLease" order="17.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="ImpairmentOfOngoingProject" xlink:title="ImpairmentOfOngoingProject" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ImpairmentOfOngoingProject" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ImpairmentOfOngoingProject" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainLossOnDisposalOfFixedAssets" xlink:label="GainLossOnDisposalOfFixedAssets" xlink:title="GainLossOnDisposalOfFixedAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDisposalOfFixedAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDisposalOfFixedAssets" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets1" order="14.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossOnNonControllingInvestment" xlink:label="LossOnNonControllingInvestment" xlink:title="LossOnNonControllingInvestment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="LossOnNonControllingInvestment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to LossOnNonControllingInvestment" order="19.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WarrantLiabilitiesExpense" xlink:label="WarrantLiabilitiesExpense" xlink:title="WarrantLiabilitiesExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="WarrantLiabilitiesExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to WarrantLiabilitiesExpense" order="18.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherNoncurrentAssets" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="IncreaseDecreaseInOtherReceivables" xlink:title="IncreaseDecreaseInOtherReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherReceivables" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherReceivables" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOperatingLeaseLiabilities" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:label="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:title="ProceedsFromIssuanceOfCommonStockToLincolnPark" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStockToLincolnPark" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromOtherEquity" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromOtherEquity" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:label="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:title="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsOfPaycheckProtectionProgramLoan" xlink:label="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="PaymentsOfPaycheckProtectionProgramLoan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfPaycheckProtectionProgramLoan" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:label="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:title="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:label="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:title="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" order="7.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="ProceedsFromSalesOfAssetsInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSalesOfAssetsInvestingActivities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="ProceedsFromDivestitureOfBusinesses" xlink:title="ProceedsFromDivestitureOfBusinesses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromDivestitureOfBusinesses" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromDivestitureOfBusinesses" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireProductiveAssetsNet" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to PaymentsToAcquireProductiveAssets" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="CashAcquiredFromAcquisition" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to CashAcquiredFromAcquisition" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="VariableLeaseCost" xlink:title="calculation: LeaseCost to VariableLeaseCost" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="OperatingLeaseCost" xlink:title="calculation: LeaseCost to OperatingLeaseCost" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="SubleaseIncome" xlink:title="calculation: LeaseCost to SubleaseIncome" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiability" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiability" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentExpenses" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentExpenses" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedGeneralAndAdministrativeExpenses" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedGeneralAndAdministrativeExpenses" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InsurancePolicyPremiums" xlink:label="InsurancePolicyPremiums" xlink:title="InsurancePolicyPremiums" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilitiesCurrent" xlink:to="InsurancePolicyPremiums" xlink:title="calculation: OtherLiabilitiesCurrent to InsurancePolicyPremiums" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CurrentPortionOfLicenseFeeObligation" xlink:label="CurrentPortionOfLicenseFeeObligation" xlink:title="CurrentPortionOfLicenseFeeObligation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilitiesCurrent" xlink:to="CurrentPortionOfLicenseFeeObligation" xlink:title="calculation: OtherLiabilitiesCurrent to CurrentPortionOfLicenseFeeObligation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="OtherLiabilities" xlink:title="OtherLiabilities" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LongTermPortionOfLicenseFeeObligation" xlink:label="LongTermPortionOfLicenseFeeObligation" xlink:title="LongTermPortionOfLicenseFeeObligation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilities" xlink:to="LongTermPortionOfLicenseFeeObligation" xlink:title="calculation: OtherLiabilities to LongTermPortionOfLicenseFeeObligation" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="OtherSundryLiabilitiesNoncurrent" xlink:title="OtherSundryLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherLiabilities" xlink:to="OtherSundryLiabilitiesNoncurrent" xlink:title="calculation: OtherLiabilities to OtherSundryLiabilitiesNoncurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>erna-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://eternatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#EarningsPerShareDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockholdersEquityMergerDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockholdersEquityMergerDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockholdersEquityPrivatePlacementOfEquityDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationRestrictedStockDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationSummaryOfRsusDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationNumberOfRsusVestedAndSettledDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationRsusDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationRsusDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationSummaryOfStockOptionsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingenciesRoyaltyAgreementsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingenciesLicensingAgreementsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingenciesLegalMattersDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CeoSeparationAgreementDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CeoSeparationAgreementDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#InprocessResearchDevelopmentAndGoodwillDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesNetOperatingLeaseExpensesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsDispositionDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsMergerDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="erna-20220930.xsd#EarningsPerShareTables" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilitiesTables" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesTables" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesTables" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsTables" />
  <link:roleRef roleURI="http://eternatx.com/role/RecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="erna-20220930.xsd#RecentAccountingPronouncementsPolicies" />
  <link:roleRef roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" xlink:href="erna-20220930.xsd#DescriptionOfBusinessAndBasisOfPresentationPolicies" />
  <link:roleRef roleURI="http://eternatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="erna-20220930.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://eternatx.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="erna-20220930.xsd#RecentAccountingPronouncements" />
  <link:roleRef roleURI="http://eternatx.com/role/EarningsPerShare" xlink:type="simple" xlink:href="erna-20220930.xsd#EarningsPerShare" />
  <link:roleRef roleURI="http://eternatx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="erna-20220930.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilities" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilities" />
  <link:roleRef roleURI="http://eternatx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="erna-20220930.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://eternatx.com/role/CeoSeparationAgreement" xlink:type="simple" xlink:href="erna-20220930.xsd#CeoSeparationAgreement" />
  <link:roleRef roleURI="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill" xlink:type="simple" xlink:href="erna-20220930.xsd#InprocessResearchDevelopmentAndGoodwill" />
  <link:roleRef roleURI="http://eternatx.com/role/Leases" xlink:type="simple" xlink:href="erna-20220930.xsd#Leases" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactions" />
  <link:roleRef roleURI="http://eternatx.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="erna-20220930.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" xlink:href="erna-20220930.xsd#DescriptionOfBusinessAndBasisOfPresentation" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfStockholdersAndMembersEquity" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20220930.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="definition: StatementLineItems to AssetsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: StatementLineItems to LiabilitiesCurrentAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: StatementLineItems to DerivativeLiabilitiesNoncurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: StatementLineItems to OperatingLeaseLiabilityNoncurrent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="definition: StatementLineItems to FinanceLeaseLiabilityNoncurrent" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="definition: StatementLineItems to OtherLiabilitiesNoncurrent" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Liabilities" xlink:title="definition: StatementLineItems to Liabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityAbstract" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquity" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockValue" xlink:title="definition: StatementLineItems to PreferredStockValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockValue" xlink:title="definition: StatementLineItems to CommonStockValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdditionalPaidInCapital" xlink:title="definition: StatementLineItems to AdditionalPaidInCapital" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StatementLineItems to RetainedEarningsAccumulatedDeficit" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccountsPayableCurrent" xlink:title="definition: StatementLineItems to AccountsPayableCurrent" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: StatementLineItems to AccruedLiabilitiesCurrent" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: StatementLineItems to OperatingLeaseLiabilityCurrent" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="definition: StatementLineItems to FinanceLeaseLiabilityCurrent" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherLiabilitiesCurrent" xlink:title="definition: StatementLineItems to OtherLiabilitiesCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrent" xlink:title="definition: StatementLineItems to LiabilitiesCurrent" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrentAbstract" xlink:title="definition: StatementLineItems to AssetsCurrentAbstract" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Cash" xlink:title="definition: StatementLineItems to Cash" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" xlink:title="OtherReceivablesNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherReceivablesNetCurrent" xlink:title="definition: StatementLineItems to OtherReceivablesNetCurrent" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: StatementLineItems to PrepaidExpenseAndOtherAssetsCurrent" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrent" xlink:title="definition: StatementLineItems to AssetsCurrent" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: StatementLineItems to PropertyPlantAndEquipmentNet" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: StatementLineItems to OperatingLeaseRightOfUseAsset" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Goodwill" xlink:title="definition: StatementLineItems to Goodwill" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="definition: StatementLineItems to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityMethodInvestments" xlink:title="definition: StatementLineItems to EquityMethodInvestments" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: StatementLineItems to OtherAssetsNoncurrent" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Assets" xlink:title="definition: StatementLineItems to Assets" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="34.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to PreferredStockParOrStatedValuePerShare" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: StatementLineItems to PreferredStockSharesAuthorized" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="definition: StatementLineItems to PreferredStockSharesIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: StatementLineItems to PreferredStockSharesOutstanding" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockLiquidationPreferenceValue" xlink:title="definition: StatementLineItems to PreferredStockLiquidationPreferenceValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to CommonStockParOrStatedValuePerShare" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: StatementLineItems to CommonStockSharesAuthorized" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: StatementLineItems to CommonStockSharesIssued" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to CommonStockSharesOutstanding" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ReverseStockSplitAbstract" xlink:title="definition: StatementLineItems to ReverseStockSplitAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:label="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueAcquisitions1" xlink:label="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="StockIssuedDuringPeriodValueAcquisitions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountAcquisitions" xlink:label="PartnersCapitalAccountAcquisitions" xlink:title="PartnersCapitalAccountAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PartnersCapitalAccountAcquisitions" xlink:title="definition: StatementLineItems to PartnersCapitalAccountAcquisitions" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsAcquisitions" xlink:label="PartnersCapitalAccountUnitsAcquisitions" xlink:title="PartnersCapitalAccountUnitsAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PartnersCapitalAccountUnitsAcquisitions" xlink:title="definition: StatementLineItems to PartnersCapitalAccountUnitsAcquisitions" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValuePrivateOffering" xlink:label="StockIssuedDuringPeriodValuePrivateOffering" xlink:title="StockIssuedDuringPeriodValuePrivateOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValuePrivateOffering" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValuePrivateOffering" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesPrivateOffering" xlink:label="StockIssuedDuringPeriodSharesPrivateOffering" xlink:title="StockIssuedDuringPeriodSharesPrivateOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesPrivateOffering" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesPrivateOffering" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockToBeRetainedByNTNValueStockholders" xlink:label="CommonStockToBeRetainedByNTNValueStockholders" xlink:title="CommonStockToBeRetainedByNTNValueStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockToBeRetainedByNTNValueStockholders" xlink:title="definition: StatementLineItems to CommonStockToBeRetainedByNTNValueStockholders" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockToBeRetainedByNTNSharesStockholders" xlink:label="CommonStockToBeRetainedByNTNSharesStockholders" xlink:title="CommonStockToBeRetainedByNTNSharesStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockToBeRetainedByNTNSharesStockholders" xlink:title="definition: StatementLineItems to CommonStockToBeRetainedByNTNSharesStockholders" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockPurchaseAgreement" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockPurchaseAgreement" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueInLieuOfDividends" xlink:label="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="StockIssuedDuringPeriodValueInLieuOfDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInLieuOfDividends" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:label="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="StockIssuedDuringPeriodSharesInLieuOfDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInLieuOfDividends" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="StockIssuedDuringPeriodValueAcquisitions2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions2" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="StockIssuedDuringPeriodSharesAcquisitions2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions2" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:label="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:label="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="definition: StatementLineItems to SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:title="AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalStockSplit" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendsPreferredStockCash" xlink:title="definition: StatementLineItems to DividendsPreferredStockCash" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockDividendsShares" xlink:title="definition: StatementLineItems to PreferredStockDividendsShares" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="37.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MembershipEquityMember" xlink:label="MembershipEquityMember" xlink:title="MembershipEquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="MembershipEquityMember" xlink:title="definition: EquityComponentDomain to MembershipEquityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="definition: EquityComponentDomain to PreferredStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="definition: ClassOfStockDomain to CommonClassAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="definition: ClassOfStockDomain to CommonClassBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonUnitsMember" xlink:title="definition: ClassOfStockDomain to CommonUnitsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityNoteAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: StatementLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: StatementTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LiquidityAndCapitalResources" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/Leases" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CeoSeparationAgreement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/EarningsPerShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/RecentAccountingPronouncements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/RecentAccountingPronouncementsPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstrumentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/EarningsPerShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ReverseStockSplitAbstract" xlink:title="definition: BusinessAcquisitionLineItems to ReverseStockSplitAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: BusinessAcquisitionLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:label="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:title="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:title="definition: BusinessAcquisitionLineItems to CashPaidForFractionalSharesInConnectionWithReverseStockSplit" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfSharesConsideredAsFractionalInReverseStock" xlink:label="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:title="NumberOfSharesConsideredAsFractionalInReverseStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:title="definition: BusinessAcquisitionLineItems to NumberOfSharesConsideredAsFractionalInReverseStock" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: BusinessAcquisitionLineItems to CommonStockParOrStatedValuePerShare" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentOwnershipPercentage" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="NoveCiteINCMember" xlink:title="definition: EquityMethodInvesteeNameDomain to NoveCiteINCMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NewFacilityLeaseAbstract" xlink:label="NewFacilityLeaseAbstract" xlink:title="NewFacilityLeaseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NewFacilityLeaseAbstract" xlink:title="definition: SubsequentEventLineItems to NewFacilityLeaseAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="AreaOfRealEstateProperty" xlink:title="definition: SubsequentEventLineItems to AreaOfRealEstateProperty" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="LineOfCredit" xlink:title="LineOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LineOfCredit" xlink:title="definition: SubsequentEventLineItems to LineOfCredit" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RestrictedCash" xlink:title="definition: SubsequentEventLineItems to RestrictedCash" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="PledgingPurposeAxis" xlink:title="PledgingPurposeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="PledgingPurposeAxis" xlink:title="definition: SubsequentEventTable to PledgingPurposeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain" xlink:title="PledgingPurposeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PledgingPurposeAxis" xlink:to="PledgingPurposeDomain" xlink:title="definition: PledgingPurposeAxis to PledgingPurposeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain_2" xlink:title="PledgingPurposeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PledgingPurposeAxis" xlink:to="PledgingPurposeDomain_2" xlink:title="definition: PledgingPurposeAxis to PledgingPurposeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="LetterOfCreditMember" xlink:title="LetterOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PledgingPurposeDomain" xlink:to="LetterOfCreditMember" xlink:title="definition: PledgingPurposeDomain to LetterOfCreditMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionSharePrice" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: BusinessAcquisitionLineItems to CommonStockSharesOutstanding" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="Goodwill" xlink:title="definition: BusinessAcquisitionLineItems to Goodwill" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:label="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="definition: BusinessAcquisitionLineItems to ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BeneficialHoldersContractualCommitmentsToInvest" xlink:label="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="BeneficialHoldersContractualCommitmentsToInvest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="definition: BusinessAcquisitionLineItems to BeneficialHoldersContractualCommitmentsToInvest" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfAdditionalRightsOffering" xlink:label="PercentageOfAdditionalRightsOffering" xlink:title="PercentageOfAdditionalRightsOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfAdditionalRightsOffering" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfAdditionalRightsOffering" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromSaleOfRights" xlink:label="ProceedsFromSaleOfRights" xlink:title="ProceedsFromSaleOfRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ProceedsFromSaleOfRights" xlink:title="definition: BusinessAcquisitionLineItems to ProceedsFromSaleOfRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="Goodwill" xlink:title="definition: BusinessAcquisitionLineItems to Goodwill" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="NonrecurringAdjustmentAxis" xlink:title="NonrecurringAdjustmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="NonrecurringAdjustmentAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to NonrecurringAdjustmentAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain" xlink:title="NonrecurringAdjustmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonrecurringAdjustmentAxis" xlink:to="NonrecurringAdjustmentDomain" xlink:title="definition: NonrecurringAdjustmentAxis to NonrecurringAdjustmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain_2" xlink:title="NonrecurringAdjustmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonrecurringAdjustmentAxis" xlink:to="NonrecurringAdjustmentDomain_2" xlink:title="definition: NonrecurringAdjustmentAxis to NonrecurringAdjustmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProFormaFairValueAdjustmentToAssetsMember" xlink:label="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="ProFormaFairValueAdjustmentToAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonrecurringAdjustmentDomain" xlink:to="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="definition: NonrecurringAdjustmentDomain to ProFormaFairValueAdjustmentToAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PurchasePriceAllocationMember" xlink:label="PurchasePriceAllocationMember" xlink:title="PurchasePriceAllocationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonrecurringAdjustmentDomain" xlink:to="PurchasePriceAllocationMember" xlink:title="definition: NonrecurringAdjustmentDomain to PurchasePriceAllocationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DispositionAbstract" xlink:label="DispositionAbstract" xlink:title="DispositionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DispositionAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DispositionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromDispositionAbstract" xlink:label="ProceedsFromDispositionAbstract" xlink:title="ProceedsFromDispositionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ProceedsFromDispositionAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to ProceedsFromDispositionAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationTransactionCosts" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:label="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:label="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationLeaseLiability" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationGoodwill1" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationOtherAssets" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="25.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBusinessMember" xlink:label="NTNBusinessMember" xlink:title="NTNBusinessMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="NTNBusinessMember" xlink:title="definition: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to NTNBusinessMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentOwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodValueAcquisitions" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionSharePrice" xlink:label="AssetAcquisitionSharePrice" xlink:title="AssetAcquisitionSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionSharePrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodValueNewIssues" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EscrowShares" xlink:label="EscrowShares" xlink:title="EscrowShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EscrowShares" xlink:title="definition: BusinessAcquisitionLineItems to EscrowShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AcquisitionAgreementNonCompetitivePeriod" xlink:label="AcquisitionAgreementNonCompetitivePeriod" xlink:title="AcquisitionAgreementNonCompetitivePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AcquisitionAgreementNonCompetitivePeriod" xlink:title="definition: BusinessAcquisitionLineItems to AcquisitionAgreementNonCompetitivePeriod" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EachLockUpAgreementExtendsTerm" xlink:title="definition: BusinessAcquisitionLineItems to EachLockUpAgreementExtendsTerm" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfCommonStockSubjectToLockUpAgreement" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireProductiveAssetsNet" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodRestrictedSharesAcquisitions" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LockUpPeriodForRestrictedShares" xlink:label="LockUpPeriodForRestrictedShares" xlink:title="LockUpPeriodForRestrictedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="LockUpPeriodForRestrictedShares" xlink:title="definition: BusinessAcquisitionLineItems to LockUpPeriodForRestrictedShares" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionUnrestrictedSharesSharePrice" xlink:label="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="AssetAcquisitionUnrestrictedSharesSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionUnrestrictedSharesSharePrice" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:label="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="PercentageOfDiscountOnFairValueOfRestrictedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfDiscountOnFairValueOfRestrictedShares" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionRestrictedSharesSharePrice" xlink:label="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="AssetAcquisitionRestrictedSharesSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionRestrictedSharesSharePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireProductiveAssets" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="CashAcquiredFromAcquisition" xlink:title="definition: BusinessAcquisitionLineItems to CashAcquiredFromAcquisition" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionFairValueOfConsiderationPaid" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireInvestments" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireInvestments" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="definition: BusinessAcquisitionLineItems to ResearchAndDevelopmentInProcessAssetAcquisition" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="26.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="NoveCiteINCMember" xlink:title="definition: EquityMethodInvesteeNameDomain to NoveCiteINCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="AssetAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to AssetAcquisitionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain_2" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain_2" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: AssetAcquisitionDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusIncMember" xlink:label="NovellusIncMember" xlink:title="NovellusIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusIncMember" xlink:title="definition: AssetAcquisitionDomain to NovellusIncMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:title="definition: RelatedPartyDomain to ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="InvestmentsAbstract" xlink:title="definition: BusinessAcquisitionLineItems to InvestmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentOwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: BusinessAcquisitionLineItems to MinorityInterestOwnershipPercentageByParent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfBoardSeats" xlink:label="NumberOfBoardSeats" xlink:title="NumberOfBoardSeats" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfBoardSeats" xlink:title="definition: BusinessAcquisitionLineItems to NumberOfBoardSeats" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestments" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestments" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:title="EquityMethodInvestmentRealizedGainLossOnDisposal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentRealizedGainLossOnDisposal" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="NoveCiteINCMember" xlink:title="definition: EquityMethodInvesteeNameDomain to NoveCiteINCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to OwnershipAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CitiusPharmaceuticalsIncMember" xlink:label="CitiusPharmaceuticalsIncMember" xlink:title="CitiusPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="CitiusPharmaceuticalsIncMember" xlink:title="definition: OwnershipDomain to CitiusPharmaceuticalsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ClassOfWarrantOrRightExercised" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ClassOfWarrantOrRightExercised" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ProceedsFromIssuanceOfWarrants" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ClassOfWarrantOrRightOutstanding" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByLiabilityClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to DerivativeFinancialInstrumentsLiabilitiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="InvestmentTypeAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to InvestmentTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember_2" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember_2" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="PIPEInvestorMember" xlink:title="definition: InvestmentTypeCategorizationMember to PIPEInvestorMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OverSubscriptionAmountReceived" xlink:label="OverSubscriptionAmountReceived" xlink:title="OverSubscriptionAmountReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OverSubscriptionAmountReceived" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OverSubscriptionAmountReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to StockRepurchaseProgramAuthorizedAmount1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="LiabilitiesFairValueAdjustment" xlink:title="LiabilitiesFairValueAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueAdjustment" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueAdjustment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ProceedsFromWarrantExercises" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ProceedsFromWarrantExercises" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesOperatingLeaseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CeoSeparationAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SeparationAgreementAbstract" xlink:label="SeparationAgreementAbstract" xlink:title="SeparationAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="SeparationAgreementAbstract" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to SeparationAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="PaymentsForPostemploymentBenefits" xlink:title="PaymentsForPostemploymentBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="PaymentsForPostemploymentBenefits" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to PaymentsForPostemploymentBenefits" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentToOfficerBaseSalary" xlink:label="PaymentToOfficerBaseSalary" xlink:title="PaymentToOfficerBaseSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="PaymentToOfficerBaseSalary" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to PaymentToOfficerBaseSalary" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:label="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:title="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="SharePrice" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to SharePrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:title="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:title="definition: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable to TitleOfIndividualAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MilestoneOptionsMember" xlink:label="MilestoneOptionsMember" xlink:title="MilestoneOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="MilestoneOptionsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to MilestoneOptionsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AgreedWaivePayment" xlink:label="AgreedWaivePayment" xlink:title="AgreedWaivePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="AgreedWaivePayment" xlink:title="definition: RelatedPartyTransactionLineItems to AgreedWaivePayment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MasterServiceAgreementInitialFeesPayable" xlink:label="MasterServiceAgreementInitialFeesPayable" xlink:title="MasterServiceAgreementInitialFeesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="MasterServiceAgreementInitialFeesPayable" xlink:title="definition: RelatedPartyTransactionLineItems to MasterServiceAgreementInitialFeesPayable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfMonthlyInstallmentsForFeesPayable" xlink:label="NumberOfMonthlyInstallmentsForFeesPayable" xlink:title="NumberOfMonthlyInstallmentsForFeesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfMonthlyInstallmentsForFeesPayable" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfMonthlyInstallmentsForFeesPayable" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:label="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:title="RelatedPartyTransactionPeriodicFeesPaymentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionPeriodicFeesPaymentAmount" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MonthlyMasterServicesAgreementFeesPayable" xlink:label="MonthlyMasterServicesAgreementFeesPayable" xlink:title="MonthlyMasterServicesAgreementFeesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="MonthlyMasterServicesAgreementFeesPayable" xlink:title="definition: RelatedPartyTransactionLineItems to MonthlyMasterServicesAgreementFeesPayable" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:label="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:title="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:title="definition: RelatedPartyTransactionLineItems to DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoticePeriodForFirstTerminationOfContract" xlink:label="NoticePeriodForFirstTerminationOfContract" xlink:title="NoticePeriodForFirstTerminationOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NoticePeriodForFirstTerminationOfContract" xlink:title="definition: RelatedPartyTransactionLineItems to NoticePeriodForFirstTerminationOfContract" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoticePeriodForSupersedingTerminationProvisions" xlink:label="NoticePeriodForSupersedingTerminationProvisions" xlink:title="NoticePeriodForSupersedingTerminationProvisions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NoticePeriodForSupersedingTerminationProvisions" xlink:title="definition: RelatedPartyTransactionLineItems to NoticePeriodForSupersedingTerminationProvisions" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="definition: RelatedPartyTransactionLineItems to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReimburseCostsIncurredOrPaid" xlink:label="ReimburseCostsIncurredOrPaid" xlink:title="ReimburseCostsIncurredOrPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ReimburseCostsIncurredOrPaid" xlink:title="definition: RelatedPartyTransactionLineItems to ReimburseCostsIncurredOrPaid" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FactorBioscienceIncMember" xlink:label="FactorBioscienceIncMember" xlink:title="FactorBioscienceIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="FactorBioscienceIncMember" xlink:title="definition: RelatedPartyDomain to FactorBioscienceIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to SubsequentEventTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="AccruedLiabilitiesCurrentAbstract" xlink:title="definition: RestructuringCostAndReserveLineItems to AccruedLiabilitiesCurrentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="OtherLiabilitiesAbstract" xlink:title="OtherLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="OtherLiabilitiesAbstract" xlink:title="definition: RestructuringCostAndReserveLineItems to OtherLiabilitiesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CurrentPortionOfLicenseFeeObligation" xlink:label="CurrentPortionOfLicenseFeeObligation" xlink:title="CurrentPortionOfLicenseFeeObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="CurrentPortionOfLicenseFeeObligation" xlink:title="definition: RestructuringCostAndReserveLineItems to CurrentPortionOfLicenseFeeObligation" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InsurancePolicyPremiums" xlink:label="InsurancePolicyPremiums" xlink:title="InsurancePolicyPremiums" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="InsurancePolicyPremiums" xlink:title="definition: RestructuringCostAndReserveLineItems to InsurancePolicyPremiums" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="OtherLiabilitiesCurrent" xlink:title="definition: RestructuringCostAndReserveLineItems to OtherLiabilitiesCurrent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LongTermPortionOfLicenseFeeObligation" xlink:label="LongTermPortionOfLicenseFeeObligation" xlink:title="LongTermPortionOfLicenseFeeObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="LongTermPortionOfLicenseFeeObligation" xlink:title="definition: RestructuringCostAndReserveLineItems to LongTermPortionOfLicenseFeeObligation" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="OtherSundryLiabilitiesNoncurrent" xlink:title="OtherSundryLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="OtherSundryLiabilitiesNoncurrent" xlink:title="definition: RestructuringCostAndReserveLineItems to OtherSundryLiabilitiesNoncurrent" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="OtherLiabilities" xlink:title="OtherLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="OtherLiabilities" xlink:title="definition: RestructuringCostAndReserveLineItems to OtherLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="definition: RestructuringCostAndReserveLineItems to EmployeeRelatedLiabilitiesCurrent" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="AccruedResearchAndDevelopmentExpenses" xlink:title="definition: RestructuringCostAndReserveLineItems to AccruedResearchAndDevelopmentExpenses" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="AccruedGeneralAndAdministrativeExpenses" xlink:title="definition: RestructuringCostAndReserveLineItems to AccruedGeneralAndAdministrativeExpenses" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: RestructuringCostAndReserveLineItems to AccruedLiabilitiesCurrent" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="definition: RestructuringCostAndReserveLineItems to AccruedProfessionalFeesCurrent" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="definition: RestructuringCostAndReserveLineItems to ScheduleOfRestructuringAndRelatedCostsTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="definition: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain_2" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain_2" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="definition: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfRestructuringAndRelatedCostsTable to TitleOfIndividualAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LegalMattersAbstract" xlink:label="LegalMattersAbstract" xlink:title="LegalMattersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LegalMattersAbstract" xlink:title="definition: LossContingenciesLineItems to LegalMattersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyDamagesSoughtExpectedSalary" xlink:label="LossContingencyDamagesSoughtExpectedSalary" xlink:title="LossContingencyDamagesSoughtExpectedSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyDamagesSoughtExpectedSalary" xlink:title="definition: LossContingenciesLineItems to LossContingencyDamagesSoughtExpectedSalary" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:label="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="LossContingencyDamagesSoughtExpectedEquityPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="definition: LossContingenciesLineItems to LossContingencyDamagesSoughtExpectedEquityPercentage" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="LossContingencyDamagesSoughtValue" xlink:title="LossContingencyDamagesSoughtValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyDamagesSoughtValue" xlink:title="definition: LossContingenciesLineItems to LossContingencyDamagesSoughtValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyNumberOfArbitrationPanel" xlink:label="LossContingencyNumberOfArbitrationPanel" xlink:title="LossContingencyNumberOfArbitrationPanel" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyNumberOfArbitrationPanel" xlink:title="definition: LossContingenciesLineItems to LossContingencyNumberOfArbitrationPanel" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="LitigationSettlementAmountAwardedToOtherParty" xlink:title="LitigationSettlementAmountAwardedToOtherParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LitigationSettlementAmountAwardedToOtherParty" xlink:title="definition: LossContingenciesLineItems to LitigationSettlementAmountAwardedToOtherParty" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DheshGovenderMember" xlink:label="DheshGovenderMember" xlink:title="DheshGovenderMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="DheshGovenderMember" xlink:title="definition: RelatedPartyDomain to DheshGovenderMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LicensingAgreementsAbstract" xlink:label="LicensingAgreementsAbstract" xlink:title="LicensingAgreementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LicensingAgreementsAbstract" xlink:title="definition: LossContingenciesLineItems to LicensingAgreementsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyPercentageOfRoyaltyPayable" xlink:label="LossContingencyPercentageOfRoyaltyPayable" xlink:title="LossContingencyPercentageOfRoyaltyPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyPercentageOfRoyaltyPayable" xlink:title="definition: LossContingenciesLineItems to LossContingencyPercentageOfRoyaltyPayable" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyNonRefundableOptionFee" xlink:label="LossContingencyNonRefundableOptionFee" xlink:title="LossContingencyNonRefundableOptionFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyNonRefundableOptionFee" xlink:title="definition: LossContingenciesLineItems to LossContingencyNonRefundableOptionFee" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialLicenseFees" xlink:label="InitialLicenseFees" xlink:title="InitialLicenseFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="InitialLicenseFees" xlink:title="definition: LossContingenciesLineItems to InitialLicenseFees" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AdditionalFeesObligatedToPay" xlink:label="AdditionalFeesObligatedToPay" xlink:title="AdditionalFeesObligatedToPay" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AdditionalFeesObligatedToPay" xlink:title="definition: LossContingenciesLineItems to AdditionalFeesObligatedToPay" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountRequireToPayInitialLicenseFees" xlink:label="AmountRequireToPayInitialLicenseFees" xlink:title="AmountRequireToPayInitialLicenseFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AmountRequireToPayInitialLicenseFees" xlink:title="definition: LossContingenciesLineItems to AmountRequireToPayInitialLicenseFees" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountObligatedToPayInYearOne" xlink:label="AmountObligatedToPayInYearOne" xlink:title="AmountObligatedToPayInYearOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AmountObligatedToPayInYearOne" xlink:title="definition: LossContingenciesLineItems to AmountObligatedToPayInYearOne" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountObligatedToPayInYearTwo" xlink:label="AmountObligatedToPayInYearTwo" xlink:title="AmountObligatedToPayInYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AmountObligatedToPayInYearTwo" xlink:title="definition: LossContingenciesLineItems to AmountObligatedToPayInYearTwo" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="MilestonePayments" xlink:title="definition: LossContingenciesLineItems to MilestonePayments" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfRevenue" xlink:label="PercentageOfRevenue" xlink:title="PercentageOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfRevenue" xlink:title="definition: LossContingenciesLineItems to PercentageOfRevenue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="LegalEntityAxis" xlink:title="definition: LossContingenciesTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_UniversityOfSouthFloridaMember" xlink:label="UniversityOfSouthFloridaMember" xlink:title="UniversityOfSouthFloridaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="UniversityOfSouthFloridaMember" xlink:title="definition: EntityDomain to UniversityOfSouthFloridaMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusLtdAndFactorBioscienceMember" xlink:label="NovellusLtdAndFactorBioscienceMember" xlink:title="NovellusLtdAndFactorBioscienceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NovellusLtdAndFactorBioscienceMember" xlink:title="definition: RelatedPartyDomain to NovellusLtdAndFactorBioscienceMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteMember" xlink:label="NoveCiteMember" xlink:title="NoveCiteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NoveCiteMember" xlink:title="definition: RelatedPartyDomain to NoveCiteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="StatementScenarioAxis" xlink:title="definition: LossContingenciesTable to StatementScenarioAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RoyaltyAgreementsAbstract" xlink:label="RoyaltyAgreementsAbstract" xlink:title="RoyaltyAgreementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="RoyaltyAgreementsAbstract" xlink:title="definition: LossContingenciesLineItems to RoyaltyAgreementsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:label="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="definition: LossContingenciesLineItems to PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:label="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="definition: LossContingenciesLineItems to PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LossContingenciesTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InvestorRoyaltyAgreementMember" xlink:label="InvestorRoyaltyAgreementMember" xlink:title="InvestorRoyaltyAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="InvestorRoyaltyAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to InvestorRoyaltyAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CollaboratorRoyaltyAgreementMember" xlink:label="CollaboratorRoyaltyAgreementMember" xlink:title="CollaboratorRoyaltyAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaboratorRoyaltyAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaboratorRoyaltyAgreementMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ProceedsFromStockOptionsExercised" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TimeBasedStockOptionGrantMember" xlink:label="TimeBasedStockOptionGrantMember" xlink:title="TimeBasedStockOptionGrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="TimeBasedStockOptionGrantMember" xlink:title="definition: EmployeeStockOptionMember to TimeBasedStockOptionGrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PerformanceBasedStockOptionGrantMember" xlink:label="PerformanceBasedStockOptionGrantMember" xlink:title="PerformanceBasedStockOptionGrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="PerformanceBasedStockOptionGrantMember" xlink:title="definition: EmployeeStockOptionMember to PerformanceBasedStockOptionGrantMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain_2" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain_2" xlink:title="definition: VestingAxis to VestingDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="definition: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InterimChiefExecutiveOfficerMember" xlink:label="InterimChiefExecutiveOfficerMember" xlink:title="InterimChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InterimChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InterimChiefExecutiveOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationRsusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfAwardsVestedAndSettledAbstract" xlink:label="NumberOfAwardsVestedAndSettledAbstract" xlink:title="NumberOfAwardsVestedAndSettledAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfAwardsVestedAndSettledAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfAwardsVestedAndSettledAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockWithheldToCoverTaxes" xlink:label="CommonStockWithheldToCoverTaxes" xlink:title="CommonStockWithheldToCoverTaxes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockWithheldToCoverTaxes" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockWithheldToCoverTaxes" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:label="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:title="NumberOfPerformanceGoalsAreSubjectToAchieve" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfPerformanceGoalsAreSubjectToAchieve" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="PaymentsForPostemploymentBenefits" xlink:title="PaymentsForPostemploymentBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PaymentsForPostemploymentBenefits" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PaymentsForPostemploymentBenefits" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharePrice" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_Two022PerformanceBasedRestrictedStockUnitsMember" xlink:label="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:title="Two022PerformanceBasedRestrictedStockUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:title="definition: RestrictedStockUnitsRSUMember to Two022PerformanceBasedRestrictedStockUnitsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EmployeeMember" xlink:label="EmployeeMember" xlink:title="EmployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeeMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to EmployeeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChiefExecutiveOfficerAndPresidentMember" xlink:label="ChiefExecutiveOfficerAndPresidentMember" xlink:title="ChiefExecutiveOfficerAndPresidentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerAndPresidentMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerAndPresidentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:title="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PrivatePlacementOfEquityAbstract" xlink:label="PrivatePlacementOfEquityAbstract" xlink:title="PrivatePlacementOfEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="PrivatePlacementOfEquityAbstract" xlink:title="definition: SubsidiarySaleOfStockLineItems to PrivatePlacementOfEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="definition: SubsidiarySaleOfStockLineItems to StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="definition: SubsidiarySaleOfStockLineItems to StockRepurchaseProgramAuthorizedAmount1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_VariableRateTransactionsPeriod" xlink:label="VariableRateTransactionsPeriod" xlink:title="VariableRateTransactionsPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="VariableRateTransactionsPeriod" xlink:title="definition: SubsidiarySaleOfStockLineItems to VariableRateTransactionsPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightsExercisableTerm" xlink:label="ClassOfWarrantOrRightsExercisableTerm" xlink:title="ClassOfWarrantOrRightsExercisableTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightsExercisableTerm" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightsExercisableTerm" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: SubsidiarySaleOfStockLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: SubsidiarySaleOfStockLineItems to WarrantsAndRightsOutstandingTerm" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercised" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightExercised" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOfWarrants" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: SubsidiarySaleOfStockLineItems to ClassOfWarrantOrRightOutstanding" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="definition: SubsidiarySaleOfStockLineItems to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OverSubscriptionAmountReceived" xlink:label="OverSubscriptionAmountReceived" xlink:title="OverSubscriptionAmountReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="OverSubscriptionAmountReceived" xlink:title="definition: SubsidiarySaleOfStockLineItems to OverSubscriptionAmountReceived" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:label="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:title="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:title="definition: SubsidiarySaleOfStockLineItems to ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligationToPayLiquidatedDamagesPercentage" xlink:label="ObligationToPayLiquidatedDamagesPercentage" xlink:title="ObligationToPayLiquidatedDamagesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ObligationToPayLiquidatedDamagesPercentage" xlink:title="definition: SubsidiarySaleOfStockLineItems to ObligationToPayLiquidatedDamagesPercentage" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TransactionFeesPayable" xlink:label="TransactionFeesPayable" xlink:title="TransactionFeesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="TransactionFeesPayable" xlink:title="definition: SubsidiarySaleOfStockLineItems to TransactionFeesPayable" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ConsecutiveCalendarDays" xlink:label="ConsecutiveCalendarDays" xlink:title="ConsecutiveCalendarDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ConsecutiveCalendarDays" xlink:title="definition: SubsidiarySaleOfStockLineItems to ConsecutiveCalendarDays" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AggregateCalendarDays" xlink:label="AggregateCalendarDays" xlink:title="AggregateCalendarDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="AggregateCalendarDays" xlink:title="definition: SubsidiarySaleOfStockLineItems to AggregateCalendarDays" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="LossContingencyEstimateOfPossibleLoss" xlink:title="LossContingencyEstimateOfPossibleLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="LossContingencyEstimateOfPossibleLoss" xlink:title="definition: SubsidiarySaleOfStockLineItems to LossContingencyEstimateOfPossibleLoss" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="LossContingencyDamagesPaidValue" xlink:title="LossContingencyDamagesPaidValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="LossContingencyDamagesPaidValue" xlink:title="definition: SubsidiarySaleOfStockLineItems to LossContingencyDamagesPaidValue" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="definition: SubsidiarySaleOfStockLineItems to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="InvestmentTypeAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to InvestmentTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember_2" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember_2" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="PIPEInvestorMember" xlink:title="definition: InvestmentTypeCategorizationMember to PIPEInvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockholdersEquityMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MergerAbstract" xlink:label="MergerAbstract" xlink:title="MergerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="MergerAbstract" xlink:title="definition: ClassOfStockLineItems to MergerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SharesIssued" xlink:title="definition: ClassOfStockLineItems to SharesIssued" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfStockSharesConverted1" xlink:title="definition: ClassOfStockLineItems to ConversionOfStockSharesConverted1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightIssued" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesAcquisitions1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="definition: ClassOfStockDomain to CommonClassAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="definition: ClassOfStockDomain to CommonClassBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfStockByClassTable to BusinessAcquisitionAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to ClassOfWarrantOrRightAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://eternatx.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FacilitySubleaseAbstract" xlink:label="FacilitySubleaseAbstract" xlink:title="FacilitySubleaseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="FacilitySubleaseAbstract" xlink:title="definition: SubsequentEventLineItems to FacilitySubleaseAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ExacisOptionAgreementAbstract" xlink:label="ExacisOptionAgreementAbstract" xlink:title="ExacisOptionAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ExacisOptionAgreementAbstract" xlink:title="definition: SubsequentEventLineItems to ExacisOptionAgreementAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OptionFee" xlink:label="OptionFee" xlink:title="OptionFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="OptionFee" xlink:title="definition: SubsequentEventLineItems to OptionFee" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="AreaOfRealEstateProperty" xlink:title="definition: SubsequentEventLineItems to AreaOfRealEstateProperty" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: SubsequentEventLineItems to LesseeOperatingLeaseTermOfContract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="definition: SubsequentEventLineItems to LesseeOperatingLeaseRenewalTerm" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TermToPaySecurityDeposit" xlink:label="TermToPaySecurityDeposit" xlink:title="TermToPaySecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="TermToPaySecurityDeposit" xlink:title="definition: SubsequentEventLineItems to TermToPaySecurityDeposit" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="LineOfCredit" xlink:title="LineOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LineOfCredit" xlink:title="definition: SubsequentEventLineItems to LineOfCredit" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeasesMonthlyBaseRent" xlink:label="OperatingLeasesMonthlyBaseRent" xlink:title="OperatingLeasesMonthlyBaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="OperatingLeasesMonthlyBaseRent" xlink:title="definition: SubsequentEventLineItems to OperatingLeasesMonthlyBaseRent" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ERSquibbSonsLLCMember" xlink:label="ERSquibbSonsLLCMember" xlink:title="ERSquibbSonsLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ERSquibbSonsLLCMember" xlink:title="definition: RelatedPartyDomain to ERSquibbSonsLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ExacisBiotherapeuticsIncMember" xlink:label="ExacisBiotherapeuticsIncMember" xlink:title="ExacisBiotherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ExacisBiotherapeuticsIncMember" xlink:title="definition: RelatedPartyDomain to ExacisBiotherapeuticsIncMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="PledgingPurposeAxis" xlink:title="PledgingPurposeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="PledgingPurposeAxis" xlink:title="definition: SubsequentEventTable to PledgingPurposeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain" xlink:title="PledgingPurposeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PledgingPurposeAxis" xlink:to="PledgingPurposeDomain" xlink:title="definition: PledgingPurposeAxis to PledgingPurposeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain_2" xlink:title="PledgingPurposeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PledgingPurposeAxis" xlink:to="PledgingPurposeDomain_2" xlink:title="definition: PledgingPurposeAxis to PledgingPurposeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="LetterOfCreditMember" xlink:title="LetterOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PledgingPurposeDomain" xlink:to="LetterOfCreditMember" xlink:title="definition: PledgingPurposeDomain to LetterOfCreditMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>erna-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" id="us-gaap_AreaOfRealEstateProperty_lbl">Area of premises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xlink:title="label: AreaOfRealEstateProperty to us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl">Legal expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl1">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1">Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:title="AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl">Accrual for fractional shares to be paid in cash in connection with reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalStockSplit to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl1">Adjustments to Additional Paid in Capital, Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalStockSplit to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock-based compensation expense recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl2">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Total potential common shares excluded from computation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="AssetAcquisitionTableTextBlock" xlink:title="AssetAcquisitionTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionTableTextBlock_lbl">Fair Value of Asset Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:title="label: AssetAcquisitionTableTextBlock to us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionAxis_lbl">Asset Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:title="label: AssetAcquisitionAxis to us-gaap_AssetAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionDomain_lbl">Asset Acquisition [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xlink:title="label: AssetAcquisitionDomain to us-gaap_AssetAcquisitionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="AssetsAndLiabilitiesLesseeAbstract" xlink:title="AssetsAndLiabilitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:title="label: AssetsAndLiabilitiesLesseeAbstract to us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl">Carrying value of assets sold [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:title="label: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl">Accounts payable, accrued liabilities and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl">Prepaid expense and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAxis_lbl">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:title="label: BusinessAcquisitionAxis to us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionSharePrice_lbl">Closing price of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:title="label: BusinessAcquisitionSharePrice to us-gaap_BusinessAcquisitionSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionSharePrice_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionSharePrice_lbl1">Business Acquisition, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl1" xlink:title="label: BusinessAcquisitionSharePrice to us-gaap_BusinessAcquisitionSharePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAcquireeDomain_lbl">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:title="label: BusinessAcquisitionAcquireeDomain to us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationsAbstract_lbl">MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:title="label: BusinessCombinationsAbstract to us-gaap_BusinessCombinationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionLineItems_lbl">Business Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:title="label: BusinessAcquisitionLineItems to us-gaap_BusinessAcquisitionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl">Number of common stock issued in exchange of membership interests (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl">Percentage of outstanding common stock received by members and financial adviser</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:title="label: BusinessAcquisitionPercentageOfVotingInterestsAcquired to us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xlink:title="label: BusinessAcquisitionPercentageOfVotingInterestsAcquired to us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl">Total consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:title="label: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts to us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1">Purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xlink:title="label: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts to us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationDescriptionAbstract_lbl">Description of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xlink:title="label: BusinessCombinationDescriptionAbstract to us-gaap_BusinessCombinationDescriptionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationDescriptionAbstract_lbl1">Acquisitions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl1" xlink:title="label: BusinessCombinationDescriptionAbstract to us-gaap_BusinessCombinationDescriptionAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationDescriptionAbstract_lbl2" xml:lang="en-US" id="us-gaap_BusinessCombinationDescriptionAbstract_lbl2">Merger Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl2" xlink:title="label: BusinessCombinationDescriptionAbstract to us-gaap_BusinessCombinationDescriptionAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl">Net assets acquired, excluding goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl">Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Cash_lbl" xml:lang="en-US" id="us-gaap_Cash_lbl">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl" xlink:title="label: Cash to us-gaap_Cash_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Cash_lbl1" xml:lang="en-US" id="us-gaap_Cash_lbl1">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl1" xlink:title="label: Cash to us-gaap_Cash_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" id="us-gaap_CashAcquiredFromAcquisition_lbl">Cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:title="label: CashAcquiredFromAcquisition to us-gaap_CashAcquiredFromAcquisition_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAcquiredFromAcquisition_lbl1" xml:lang="en-US" id="us-gaap_CashAcquiredFromAcquisition_lbl1">Cash Acquired from Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl1" xlink:title="label: CashAcquiredFromAcquisition to us-gaap_CashAcquiredFromAcquisition_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Number of rights options converted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Warrants exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2">Warrants to be outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis_lbl">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl">Number of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Warrants exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain_lbl">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">COMMITMENTS AND CONTINGENCIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl1" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassCMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl">Common Class C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonClassCMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl1">Class C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl1" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassCMember_lbl2" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl2">Common Class C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl2" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl">Common Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonClassAMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl1">Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl1" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassAMember_lbl2" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl2">Common Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl2" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl">Common Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonClassBMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl1">Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl1" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassBMember_lbl2" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl2">Common Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl2" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.005 par value, 100,000 shares authorized at September 30, 2022 and December 31, 2021; 2,942 and 2,601 issued and outstanding at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Number of shares of common stock owned by Brooklyn stockholders immediately before the Merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesConverted1_lbl">Number of shares converted to common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:title="label: ConversionOfStockSharesConverted1 to us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesConverted1_lbl1">Conversion of Stock, Shares Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1" xlink:title="label: ConversionOfStockSharesConverted1 to us-gaap_ConversionOfStockSharesConverted1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockMember_lbl">Preferred Stock Converted into Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:title="label: ConvertiblePreferredStockMember to us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US" id="us-gaap_CustomerRelationshipsMember_lbl">Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:title="label: CustomerRelationshipsMember to us-gaap_CustomerRelationshipsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerRelationshipsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerRelationshipsMember_lbl1" xml:lang="en-US" id="us-gaap_CustomerRelationshipsMember_lbl1">Customer Relationships [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl1" xlink:title="label: CustomerRelationshipsMember to us-gaap_CustomerRelationshipsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:title="label: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DepositsAssetsNoncurrent_lbl">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:title="label: DepositsAssetsNoncurrent to us-gaap_DepositsAssetsNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US" id="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl">Warrant Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:title="label: DerivativeFinancialInstrumentsLiabilitiesMember to us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DerivativeLiabilitiesNoncurrent_lbl">Warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:title="label: DerivativeLiabilitiesNoncurrent to us-gaap_DerivativeLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">STOCK-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">STOCK-BASED COMPENSATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationGoodwill1 to us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationGoodwill1 to us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationIntangibleAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationIntangibleAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl">Prepaids and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationDeferredRevenue to us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment to us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment to us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents to us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents to us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities to us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl">Disposal Group Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:title="label: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl">Total loss on sale of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:title="label: DisposalGroupNotDiscontinuedOperationGainLossOnDisposal to us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl">Cash dividends to Series A preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPreferredStockCash_lbl1" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl1">Dividends, Preferred Stock, Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl1" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Anti-dilutive Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Net loss per common share - basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl1">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl">EARNINGS PER SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl1">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl1" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">EARNINGS PER SHARE [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeSeveranceMember_lbl">Employee Severance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xlink:title="label: EmployeeSeveranceMember to us-gaap_EmployeeSeveranceMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl">Ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1">Percentage of total outstanding equity interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:title="EquityMethodInvestmentRealizedGainLossOnDisposal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl">Losses on investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xlink:title="label: EquityMethodInvestmentRealizedGainLossOnDisposal to us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl">Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl1">Investment in non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl">Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByLiabilityClassAxis_lbl">Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:title="label: FairValueByLiabilityClassAxis to us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl">Liabilities Measured at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl">Fair value at March 9, 2022 (issuance date)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl1">Warrants fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl">Fair value, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1">Fair value, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl">Changes in Fair Value of Warrant Liabilities [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl">Finance lease liabilities, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:title="label: FinanceLeaseLiabilityNoncurrent to us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl">Principal payments on finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityCurrent_lbl">Finance lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:title="label: FinanceLeaseLiabilityCurrent to us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl">Loss on sale of NTN assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl1">Loss on sale of NTN assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl">Impairment of goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl">IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill_lbl" xml:lang="en-US" id="us-gaap_Goodwill_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="ImpairmentOfOngoingProject" xlink:title="ImpairmentOfOngoingProject" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfOngoingProject_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ImpairmentOfOngoingProject_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfOngoingProject_lbl">Non-cash impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfOngoingProject" xlink:to="us-gaap_ImpairmentOfOngoingProject_lbl" xlink:title="label: ImpairmentOfOngoingProject to us-gaap_ImpairmentOfOngoingProject_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfOngoingProject_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfOngoingProject_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfOngoingProject_lbl1">Impairment of in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfOngoingProject" xlink:to="us-gaap_ImpairmentOfOngoingProject_lbl1" xlink:title="label: ImpairmentOfOngoingProject to us-gaap_ImpairmentOfOngoingProject_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfOngoingProject_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfOngoingProject_lbl2" xml:lang="en-US" id="us-gaap_ImpairmentOfOngoingProject_lbl2">Impairment of Ongoing Project</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfOngoingProject" xlink:to="us-gaap_ImpairmentOfOngoingProject_lbl2" xlink:title="label: ImpairmentOfOngoingProject to us-gaap_ImpairmentOfOngoingProject_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl">Disposal Group Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl">Other non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:title="label: IncreaseDecreaseInOtherNoncurrentAssets to us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" xlink:title="label: IncreaseDecreaseInOtherNoncurrentAssets to us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="IncreaseDecreaseInOtherReceivables" xlink:title="IncreaseDecreaseInOtherReceivables" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherReceivables_lbl">Other receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:title="label: IncreaseDecreaseInOtherReceivables to us-gaap_IncreaseDecreaseInOtherReceivables_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherReceivables_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherReceivables_lbl1">Increase (Decrease) in Other Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl1" xlink:title="label: IncreaseDecreaseInOtherReceivables to us-gaap_IncreaseDecreaseInOtherReceivables_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl">In-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:title="label: IndefiniteLivedIntangibleAssetsExcludingGoodwill to us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" xml:lang="en-US" id="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" xlink:title="label: IndefiniteLivedIntangibleAssetsExcludingGoodwill to us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="us-gaap_InvestmentTypeCategorizationMember_lbl">Investments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:title="label: InvestmentTypeCategorizationMember to us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="us-gaap_InvestmentTypeAxis_lbl">Investment Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:title="label: InvestmentTypeAxis to us-gaap_InvestmentTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsAbstract_lbl">Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl" xlink:title="label: InvestmentsAbstract to us-gaap_InvestmentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl">Extension term of sublease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1">Extended lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl">Term of sublease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1">Lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Less: Imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Maturities of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl">Operating Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="LeaseCostAbstract" xlink:title="LeaseCostAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" id="us-gaap_LeaseCostAbstract_lbl">Net Operating Lease Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xlink:title="label: LeaseCostAbstract to us-gaap_LeaseCostAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LeaseCost_lbl" xml:lang="en-US" id="us-gaap_LeaseCost_lbl">Total lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:title="label: LeaseCost to us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCost_lbl1" xml:lang="en-US" id="us-gaap_LeaseCost_lbl1">Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCost" xlink:to="us-gaap_LeaseCost_lbl1" xlink:title="label: LeaseCost to us-gaap_LeaseCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LeaseCostTableTextBlock_lbl">Net Operating Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:title="label: LeaseCostTableTextBlock to us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesAbstract_lbl">LEASES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="LetterOfCreditMember" xlink:title="LetterOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US" id="us-gaap_LetterOfCreditMember_lbl">Letter of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" xlink:title="label: LetterOfCreditMember to us-gaap_LetterOfCreditMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="LiabilitiesFairValueAdjustment" xlink:title="LiabilitiesFairValueAdjustment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueAdjustment_lbl">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:title="label: LiabilitiesFairValueAdjustment to us-gaap_LiabilitiesFairValueAdjustment_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl">Liabilities, fair value disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl1">Liabilities, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl">Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:title="label: LiabilitiesFairValueDisclosureAbstract to us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl">Liabilities transferred upon sale [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:title="label: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="LineOfCredit" xlink:title="LineOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="us-gaap_LineOfCredit_lbl">Letter of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:title="label: LineOfCredit to us-gaap_LineOfCredit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="LitigationSettlementAmountAwardedToOtherParty" xlink:title="LitigationSettlementAmountAwardedToOtherParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US" id="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl">Litigation settlement, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:title="label: LitigationSettlementAmountAwardedToOtherParty to us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl1" xml:lang="en-US" id="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl1">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl1" xlink:title="label: LitigationSettlementAmountAwardedToOtherParty to us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="LossContingencyDamagesPaidValue" xlink:title="LossContingencyDamagesPaidValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US" id="us-gaap_LossContingencyDamagesPaidValue_lbl">Liquidated damages payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:title="label: LossContingencyDamagesPaidValue to us-gaap_LossContingencyDamagesPaidValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="LossContingencyDamagesSoughtValue" xlink:title="LossContingencyDamagesSoughtValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" id="us-gaap_LossContingencyDamagesSoughtValue_lbl">Loss contingency, damages sought, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:title="label: LossContingencyDamagesSoughtValue to us-gaap_LossContingencyDamagesSoughtValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesLineItems_lbl">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:title="label: LossContingenciesLineItems to us-gaap_LossContingenciesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesTable_lbl">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:title="label: LossContingenciesTable to us-gaap_LossContingenciesTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="LossContingencyEstimateOfPossibleLoss" xlink:title="LossContingencyEstimateOfPossibleLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xml:lang="en-US" id="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl">Estimated contingent loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xlink:title="label: LossContingencyEstimateOfPossibleLoss to us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:title="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl">MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:title="label: MergersAcquisitionsAndDispositionsDisclosuresTextBlock to us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl">Ownership percentage by Citius</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="NonrecurringAdjustmentAxis" xlink:title="NonrecurringAdjustmentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonrecurringAdjustmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonrecurringAdjustmentAxis_lbl" xml:lang="en-US" id="us-gaap_NonrecurringAdjustmentAxis_lbl">Nonrecurring Adjustment [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentAxis_lbl" xlink:title="label: NonrecurringAdjustmentAxis to us-gaap_NonrecurringAdjustmentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain" xlink:title="NonrecurringAdjustmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonrecurringAdjustmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonrecurringAdjustmentDomain_lbl" xml:lang="en-US" id="us-gaap_NonrecurringAdjustmentDomain_lbl">Nonrecurring Adjustment [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonrecurringAdjustmentDomain" xlink:to="us-gaap_NonrecurringAdjustmentDomain_lbl" xlink:title="label: NonrecurringAdjustmentDomain to us-gaap_NonrecurringAdjustmentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Cash flows used in investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl">RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:title="label: NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract to us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock to us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NoncashMergerRelatedCosts_lbl" xml:lang="en-US" id="us-gaap_NoncashMergerRelatedCosts_lbl">Transaction costs - shares to Financial Advisor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:title="label: NoncashMergerRelatedCosts to us-gaap_NoncashMergerRelatedCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NoncashMergerRelatedCosts_lbl1" xml:lang="en-US" id="us-gaap_NoncashMergerRelatedCosts_lbl1">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl1" xlink:title="label: NoncashMergerRelatedCosts to us-gaap_NoncashMergerRelatedCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashMergerRelatedCosts_lbl2" xml:lang="en-US" id="us-gaap_NoncashMergerRelatedCosts_lbl2">Noncash Merger Related Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl2" xlink:title="label: NoncashMergerRelatedCosts to us-gaap_NoncashMergerRelatedCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseImpairmentLoss_lbl">Impairment of right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:title="label: OperatingLeaseImpairmentLoss to us-gaap_OperatingLeaseImpairmentLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseImpairmentLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseImpairmentLoss_lbl1">Impairment of ROU assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl1" xlink:title="label: OperatingLeaseImpairmentLoss to us-gaap_OperatingLeaseImpairmentLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl">Operating lease liabilities, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1">Less non-current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl">Amortization of right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1">Amortization of operating lease ROU assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Operating lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl2">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="OperatingLeaseLiabilityAbstract" xlink:title="OperatingLeaseLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityAbstract_lbl">Operating Lease, Liability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:title="label: OperatingLeaseLiabilityAbstract to us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Maturities of Operating Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl">Total operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating lease liabilities, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl2">Operating lease liabilities, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl2" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Right-of-use assets - operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Operating lease ROU assets, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl2">Operating lease ROU assets, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseCost_lbl">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="OtherLiabilitiesTableTextBlock" xlink:title="OtherLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesTableTextBlock_lbl">Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xlink:title="label: OtherLiabilitiesTableTextBlock to us-gaap_OtherLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesTableTextBlock_lbl1">Other Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock_lbl1" xlink:title="label: OtherLiabilitiesTableTextBlock to us-gaap_OtherLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="OtherSundryLiabilitiesNoncurrent" xlink:title="OtherSundryLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:title="label: OtherSundryLiabilitiesNoncurrent to us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl1">Other Sundry Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl1" xlink:title="label: OtherSundryLiabilitiesNoncurrent to us-gaap_OtherSundryLiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" xlink:title="OtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherReceivablesNetCurrent_lbl">Other receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:title="label: OtherReceivablesNetCurrent to us-gaap_OtherReceivablesNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="OtherLiabilitiesAbstract" xlink:title="OtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesAbstract_lbl">Other Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesAbstract_lbl" xlink:title="label: OtherLiabilitiesAbstract to us-gaap_OtherLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpensesAbstract" xlink:label="OtherExpensesAbstract" xlink:title="OtherExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherExpensesAbstract_lbl">Other income (expense), net:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:title="label: OtherExpensesAbstract to us-gaap_OtherExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherExpensesAbstract_lbl1">Other Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl1" xlink:title="label: OtherExpensesAbstract to us-gaap_OtherExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl1">Total other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl2">Other Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl2" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="OtherLiabilities" xlink:title="OtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilities_lbl">Total other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:title="label: OtherLiabilities to us-gaap_OtherLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilities_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilities_lbl1">Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl1" xlink:title="label: OtherLiabilities to us-gaap_OtherLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl1">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other (expense) income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain" xlink:title="PledgingPurposeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PledgingPurposeDomain_lbl" xml:lang="en-US" id="us-gaap_PledgingPurposeDomain_lbl">Pledging Purpose [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PledgingPurposeDomain" xlink:to="us-gaap_PledgingPurposeDomain_lbl" xlink:title="label: PledgingPurposeDomain to us-gaap_PledgingPurposeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="PledgingPurposeAxis" xlink:title="PledgingPurposeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PledgingPurposeAxis_lbl" xml:lang="en-US" id="us-gaap_PledgingPurposeAxis_lbl">Pledging Purpose [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl" xlink:title="label: PledgingPurposeAxis to us-gaap_PledgingPurposeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsAcquisitions" xlink:label="PartnersCapitalAccountUnitsAcquisitions" xlink:title="PartnersCapitalAccountUnitsAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl">Issuance of common stock to Brooklyn members (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountUnitsAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" xlink:title="label: PartnersCapitalAccountUnitsAcquisitions to us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1">Partners' Capital Account, Units, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountUnitsAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" xlink:title="label: PartnersCapitalAccountUnitsAcquisitions to us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountAcquisitions" xlink:label="PartnersCapitalAccountAcquisitions" xlink:title="PartnersCapitalAccountAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PartnersCapitalAccountAcquisitions_lbl" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountAcquisitions_lbl">Issuance of common stock to Brooklyn members</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountAcquisitions_lbl" xlink:title="label: PartnersCapitalAccountAcquisitions to us-gaap_PartnersCapitalAccountAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PartnersCapitalAccountAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountAcquisitions_lbl1">Partners' Capital Account, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountAcquisitions_lbl1" xlink:title="label: PartnersCapitalAccountAcquisitions to us-gaap_PartnersCapitalAccountAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl">Payroll tax remitted on net share settlement of equity awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:title="label: PaymentsRelatedToTaxWithholdingForShareBasedCompensation to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" xlink:title="label: PaymentsRelatedToTaxWithholdingForShareBasedCompensation to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl">Dividends paid to Series A preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xlink:title="label: PaymentsOfDividendsPreferredStockAndPreferenceStock to us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" xlink:title="label: PaymentsOfDividendsPreferredStockAndPreferenceStock to us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="PaymentsForPostemploymentBenefits" xlink:title="PaymentsForPostemploymentBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForPostemploymentBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PaymentsForPostemploymentBenefits_lbl" xml:lang="en-US" id="us-gaap_PaymentsForPostemploymentBenefits_lbl">Lump sum cash severance paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForPostemploymentBenefits" xlink:to="us-gaap_PaymentsForPostemploymentBenefits_lbl" xlink:title="label: PaymentsForPostemploymentBenefits to us-gaap_PaymentsForPostemploymentBenefits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForPostemploymentBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsForPostemploymentBenefits_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForPostemploymentBenefits_lbl1">Severance benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForPostemploymentBenefits" xlink:to="us-gaap_PaymentsForPostemploymentBenefits_lbl1" xlink:title="label: PaymentsForPostemploymentBenefits to us-gaap_PaymentsForPostemploymentBenefits_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForPostemploymentBenefits_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForPostemploymentBenefits_lbl2" xml:lang="en-US" id="us-gaap_PaymentsForPostemploymentBenefits_lbl2">Payments for Postemployment Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForPostemploymentBenefits" xlink:to="us-gaap_PaymentsForPostemploymentBenefits_lbl2" xlink:title="label: PaymentsForPostemploymentBenefits to us-gaap_PaymentsForPostemploymentBenefits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireInvestments_lbl">Less amount of cash paid for NoveCite investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:title="label: PaymentsToAcquireInvestments to us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireInvestments_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireInvestments_lbl1">Payments to Acquire Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl1" xlink:title="label: PaymentsToAcquireInvestments to us-gaap_PaymentsToAcquireInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireProductiveAssets_lbl">Cash paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:title="label: PaymentsToAcquireProductiveAssets to us-gaap_PaymentsToAcquireProductiveAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreferenceValue_lbl">Preferred stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:title="label: PreferredStockLiquidationPreferenceValue to us-gaap_PreferredStockLiquidationPreferenceValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendsShares_lbl">Cash dividends to Series A preferred stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl" xlink:title="label: PreferredStockDividendsShares to us-gaap_PreferredStockDividendsShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl">Series A preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl1">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl1">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred stock, $0.005 par value, 1,000 shares authorized, 156 designated and outstanding of Series A convertible preferred stock at September 30, 2022 and December 31, 2021, $156 liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl">Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises_lbl">Exercise of pre-funded warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromWarrantExercises_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises_lbl1">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl1" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="ProceedsFromSalesOfAssetsInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl">Purchase of NTN, net of cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfAssetsInvestingActivities" xlink:to="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xlink:title="label: ProceedsFromSalesOfAssetsInvestingActivities to us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1">Proceeds from Sales of Assets, Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfAssetsInvestingActivities" xlink:to="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" xlink:title="label: ProceedsFromSalesOfAssetsInvestingActivities to us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl">Sale of rights, title and interest in and to the assets relating to the business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:title="label: ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets to us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" xlink:title="label: ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets to us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="ProceedsFromDivestitureOfBusinesses" xlink:title="ProceedsFromDivestitureOfBusinesses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl">Proceeds from the sale of NTN assets, net of cash disposed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:title="label: ProceedsFromDivestitureOfBusinesses to us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from issuance of common stock and warrants in connection with private offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromOtherEquity_lbl">Proceeds from sale of members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:title="label: ProceedsFromOtherEquity to us-gaap_ProceedsFromOtherEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromOtherEquity_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromOtherEquity_lbl1">Proceeds from Other Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl1" xlink:title="label: ProceedsFromOtherEquity to us-gaap_ProceedsFromOtherEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl">Aggregate exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl">Proceeds from the sales of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl">Related Party Transaction [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:title="label: RelatedPartyTransactionDueFromToRelatedPartyAbstract to us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentInProcess_lbl">In-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:title="label: ResearchAndDevelopmentInProcess to us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:title="label: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost to us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1">Research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost to us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl">RSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">RSU [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl2">Restricted Common Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl">Restricted Common Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedCash_lbl" xml:lang="en-US" id="us-gaap_RestrictedCash_lbl">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:title="label: RestrictedCash to us-gaap_RestrictedCash_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="us-gaap_RestructuringCostAndReserveLineItems_lbl">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:title="label: RestructuringCostAndReserveLineItems to us-gaap_RestructuringCostAndReserveLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="us-gaap_RestructuringCostAndReserveAxis_lbl">Restructuring Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:title="label: RestructuringCostAndReserveAxis to us-gaap_RestructuringCostAndReserveAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" id="us-gaap_SubleaseIncome_lbl">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubleaseIncome_lbl1" xml:lang="en-US" id="us-gaap_SubleaseIncome_lbl1">Sublease Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl1" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl">Warrant expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl">Number of accelerated vesting stock option (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl">Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl">Incremental fair value of stock options recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl">Options exercisable period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl">Tangible and Intangible Assets Acquired and Liabilities Assumed, Based on Estimated Fair Values</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:title="label: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock to us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Weighted-Average Assumptions Used for Stock Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl">Changes in Warrant Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:title="label: ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock to us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Computation of Diluted Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTable to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:title="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:title="label: ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable to us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:title="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl">Disposition Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:title="label: ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock to us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:title="label: ScheduleOfRestructuringAndRelatedCostsTable to us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl1">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Restricted stock units vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl">Vesting on one-year Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:title="label: ShareBasedCompensationAwardTrancheOneMember to us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" xlink:title="label: ShareBasedCompensationAwardTrancheOneMember to us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Number of stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:title="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl">Stock-Based Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:title="label: ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract to us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl1" xlink:title="label: ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract to us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Stock price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharePrice_lbl1" xml:lang="en-US" id="us-gaap_SharePrice_lbl1">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl1" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl2" xml:lang="en-US" id="us-gaap_SharePrice_lbl2">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl2" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Share-Based Compensation Abstract [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">RSUs Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1">Number of RSUs granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl">Number of RSUs cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Unvested restricted common stock forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Number of stock units awards outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Unvested restricted stock outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">RSUs vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Weightage-Average Assumptions Used for Stock Options Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl">Stock options exercised, intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Weighted average volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Weighted average risk-free rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Number of stock option awards outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Stock option outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="us-gaap_SharesIssued_lbl">Number of shares issued in merger agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssued_lbl1" xml:lang="en-US" id="us-gaap_SharesIssued_lbl1">Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl">Gross proceeds received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:title="label: StockRepurchaseProgramAuthorizedAmount1 to us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1">Aggregate gross purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" xlink:title="label: StockRepurchaseProgramAuthorizedAmount1 to us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="us-gaap_StockIssued1_lbl">Issuance of common stock for business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssued1_lbl1" xml:lang="en-US" id="us-gaap_StockIssued1_lbl1">Stock Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl1" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl">Private placement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:title="label: StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased to us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl">Issuance of common stock from vested restricted stock units (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1">Restricted stock replaced during the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl">Issuance of common stock to Financial Advisor upon consummation of merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1">Acquisition of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl">Lock-up agreements shares received in acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1">Number of common stock issued as compensation for services (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl">Common stock issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Fair value of shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Issuance of common stock from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl">Issuance of common stock to Financial Advisor upon consummation of merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1">Acquisition agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Issuance of common stock from the exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Stock option exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl">Issuance of common stock from vested restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:title="label: StockIssuedDuringPeriodValueRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl">Stock conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1">Stock conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl">STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl1">Stockholders' Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl1" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">SUBSEQUENT EVENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockLineItems_lbl">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:title="label: SubsidiarySaleOfStockLineItems to us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:title="label: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeNamesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TradeNamesMember_lbl" xml:lang="en-US" id="us-gaap_TradeNamesMember_lbl">Trade Names [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xlink:title="label: TradeNamesMember to us-gaap_TradeNamesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="us-gaap_TypeOfRestructuringDomain_lbl">Type of Restructuring [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xlink:title="label: TypeOfRestructuringDomain to us-gaap_TypeOfRestructuringDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="us-gaap_VestingAxis_lbl">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:title="label: VestingAxis to us-gaap_VestingAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="us-gaap_VestingDomain_lbl">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xlink:title="label: VestingDomain to us-gaap_VestingDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" id="us-gaap_VariableLeaseCost_lbl">Variable lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:title="label: VariableLeaseCost to us-gaap_VariableLeaseCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl">Warrants outstanding weighted average contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="srt_ChiefExecutiveOfficerMember_lbl">Dr. Federoff's [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:title="label: ChiefExecutiveOfficerMember to srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ChiefExecutiveOfficerMember_lbl1" xml:lang="en-US" id="srt_ChiefExecutiveOfficerMember_lbl1">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl1" xlink:title="label: ChiefExecutiveOfficerMember to srt_ChiefExecutiveOfficerMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" id="srt_EquityMethodInvesteeNameDomain_lbl">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xlink:title="label: EquityMethodInvesteeNameDomain to srt_EquityMethodInvesteeNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain_lbl" xml:lang="en-US" id="srt_OwnershipDomain_lbl">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xlink:title="label: OwnershipDomain to srt_OwnershipDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis_lbl" xml:lang="en-US" id="srt_OwnershipAxis_lbl">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:title="label: OwnershipAxis to srt_OwnershipAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeAxis_lbl1" xml:lang="en-US" id="srt_RangeAxis_lbl1">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl1" xlink:title="label: RangeAxis to srt_RangeAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember_lbl" xml:lang="en-US" id="srt_ScenarioForecastMember_lbl">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain_lbl">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" id="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis_lbl" xml:lang="en-US" id="srt_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="srt_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" id="dei_DocumentQuarterlyReport_lbl">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="dei_LegalEntityAxis_lbl">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:title="label: LegalEntityAxis to dei_LegalEntityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:label xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityDomain_lbl" xml:lang="en-US" id="dei_EntityDomain_lbl">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:title="label: EntityDomain to dei_EntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="EntityInformationFormerLegalOrRegisteredName" xlink:title="EntityInformationFormerLegalOrRegisteredName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US" id="dei_EntityInformationFormerLegalOrRegisteredName_lbl">Entity Information, Former Legal or Registered Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:title="label: EntityInformationFormerLegalOrRegisteredName to dei_EntityInformationFormerLegalOrRegisteredName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl">Value of stock issued without any restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:to="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions to erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1">Stock Issued During Period, Unrestricted Shares, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:to="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions to erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2">Unrestricted shares, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:to="erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions to erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl">Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:to="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesAcquisitions to erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1">Stock Issued During Period, Unrestricted Shares, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:to="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesAcquisitions to erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2">Unrestricted shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:to="erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesAcquisitions to erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" xml:lang="en-US" id="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl">The percentage of shares of common stock subject to the lock-up agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:to="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" xlink:title="label: PercentageOfCommonStockSubjectToLockUpAgreement to erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" xml:lang="en-US" id="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1">Percentage of Common Stock Subject to Lock-up Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:to="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" xlink:title="label: PercentageOfCommonStockSubjectToLockUpAgreement to erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" xml:lang="en-US" id="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2">Percentage of common stock subject to the lock-up agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:to="erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" xlink:title="label: PercentageOfCommonStockSubjectToLockUpAgreement to erna_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:label xlink:type="resource" xlink:label="erna_EachLockUpAgreementExtendsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_EachLockUpAgreementExtendsTerm_lbl" xml:lang="en-US" id="erna_EachLockUpAgreementExtendsTerm_lbl">The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EachLockUpAgreementExtendsTerm" xlink:to="erna_EachLockUpAgreementExtendsTerm_lbl" xlink:title="label: EachLockUpAgreementExtendsTerm to erna_EachLockUpAgreementExtendsTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_EachLockUpAgreementExtendsTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_EachLockUpAgreementExtendsTerm_lbl1" xml:lang="en-US" id="erna_EachLockUpAgreementExtendsTerm_lbl1">Each Lock-up Agreement Extends Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EachLockUpAgreementExtendsTerm" xlink:to="erna_EachLockUpAgreementExtendsTerm_lbl1" xlink:title="label: EachLockUpAgreementExtendsTerm to erna_EachLockUpAgreementExtendsTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_EachLockUpAgreementExtendsTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_EachLockUpAgreementExtendsTerm_lbl2" xml:lang="en-US" id="erna_EachLockUpAgreementExtendsTerm_lbl2">Each lock-up agreement extend term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EachLockUpAgreementExtendsTerm" xlink:to="erna_EachLockUpAgreementExtendsTerm_lbl2" xlink:title="label: EachLockUpAgreementExtendsTerm to erna_EachLockUpAgreementExtendsTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl">Value of stock issued with restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:to="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesValueAcquisitions to erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1">Stock Issued During Period, Restricted Shares, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:to="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesValueAcquisitions to erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2">Restricted shares, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:to="erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesValueAcquisitions to erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EscrowShares" xlink:label="EscrowShares" xlink:title="EscrowShares" />
    <link:label xlink:type="resource" xlink:label="erna_EscrowShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_EscrowShares_lbl" xml:lang="en-US" id="erna_EscrowShares_lbl">Number of shares have been placed in escrow shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowShares" xlink:to="erna_EscrowShares_lbl" xlink:title="label: EscrowShares to erna_EscrowShares_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_EscrowShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_EscrowShares_lbl1" xml:lang="en-US" id="erna_EscrowShares_lbl1">Escrow Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowShares" xlink:to="erna_EscrowShares_lbl1" xlink:title="label: EscrowShares to erna_EscrowShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_EscrowShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_EscrowShares_lbl2" xml:lang="en-US" id="erna_EscrowShares_lbl2">Escrow shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowShares" xlink:to="erna_EscrowShares_lbl2" xlink:title="label: EscrowShares to erna_EscrowShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AcquisitionAgreementNonCompetitivePeriod" xlink:label="AcquisitionAgreementNonCompetitivePeriod" xlink:title="AcquisitionAgreementNonCompetitivePeriod" />
    <link:label xlink:type="resource" xlink:label="erna_AcquisitionAgreementNonCompetitivePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AcquisitionAgreementNonCompetitivePeriod_lbl" xml:lang="en-US" id="erna_AcquisitionAgreementNonCompetitivePeriod_lbl">The Acquisition Agreement contains non-competition and non-solicitation provisions pursuant to which the Seller has agreed not to engage in certain competitive activities for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionAgreementNonCompetitivePeriod" xlink:to="erna_AcquisitionAgreementNonCompetitivePeriod_lbl" xlink:title="label: AcquisitionAgreementNonCompetitivePeriod to erna_AcquisitionAgreementNonCompetitivePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AcquisitionAgreementNonCompetitivePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AcquisitionAgreementNonCompetitivePeriod_lbl1" xml:lang="en-US" id="erna_AcquisitionAgreementNonCompetitivePeriod_lbl1">Acquisition Agreement, Non Competitive Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionAgreementNonCompetitivePeriod" xlink:to="erna_AcquisitionAgreementNonCompetitivePeriod_lbl1" xlink:title="label: AcquisitionAgreementNonCompetitivePeriod to erna_AcquisitionAgreementNonCompetitivePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AcquisitionAgreementNonCompetitivePeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AcquisitionAgreementNonCompetitivePeriod_lbl2" xml:lang="en-US" id="erna_AcquisitionAgreementNonCompetitivePeriod_lbl2">Non-compete period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionAgreementNonCompetitivePeriod" xlink:to="erna_AcquisitionAgreementNonCompetitivePeriod_lbl2" xlink:title="label: AcquisitionAgreementNonCompetitivePeriod to erna_AcquisitionAgreementNonCompetitivePeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl" xml:lang="en-US" id="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl">Amount of fair value of consideration paid in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl" xlink:title="label: AssetAcquisitionFairValueOfConsiderationPaid to erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" xml:lang="en-US" id="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl1">Asset Acquisition, Fair Value of Consideration Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" xlink:title="label: AssetAcquisitionFairValueOfConsiderationPaid to erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" xml:lang="en-US" id="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl2">Total fair value of consideration paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" xlink:title="label: AssetAcquisitionFairValueOfConsiderationPaid to erna_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionRestrictedSharesSharePrice" xlink:label="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="AssetAcquisitionRestrictedSharesSharePrice" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl" xml:lang="en-US" id="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl">Price of a single share of a number of saleable stocks paid or offered with restrictions to be paid in asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionRestrictedSharesSharePrice" xlink:to="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl" xlink:title="label: AssetAcquisitionRestrictedSharesSharePrice to erna_AssetAcquisitionRestrictedSharesSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl1" xml:lang="en-US" id="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl1">Asset Acquisition, Restricted Shares, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionRestrictedSharesSharePrice" xlink:to="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl1" xlink:title="label: AssetAcquisitionRestrictedSharesSharePrice to erna_AssetAcquisitionRestrictedSharesSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl2" xml:lang="en-US" id="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl2">Restricted shares, fair value per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionRestrictedSharesSharePrice" xlink:to="erna_AssetAcquisitionRestrictedSharesSharePrice_lbl2" xlink:title="label: AssetAcquisitionRestrictedSharesSharePrice to erna_AssetAcquisitionRestrictedSharesSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:label="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="PercentageOfDiscountOnFairValueOfRestrictedShares" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" xml:lang="en-US" id="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl">Percentage of discount on restricted shares, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:to="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" xlink:title="label: PercentageOfDiscountOnFairValueOfRestrictedShares to erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" xml:lang="en-US" id="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1">Percentage of Discount on Fair Value of Restricted Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:to="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" xlink:title="label: PercentageOfDiscountOnFairValueOfRestrictedShares to erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" xml:lang="en-US" id="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2">Percentage of discount on fair value restricted shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:to="erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" xlink:title="label: PercentageOfDiscountOnFairValueOfRestrictedShares to erna_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionSharePrice" xlink:label="AssetAcquisitionSharePrice" xlink:title="AssetAcquisitionSharePrice" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AssetAcquisitionSharePrice_lbl" xml:lang="en-US" id="erna_AssetAcquisitionSharePrice_lbl">Price of a single share of a number of saleable stocks paid or offered to be paid in asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionSharePrice" xlink:to="erna_AssetAcquisitionSharePrice_lbl" xlink:title="label: AssetAcquisitionSharePrice to erna_AssetAcquisitionSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AssetAcquisitionSharePrice_lbl1" xml:lang="en-US" id="erna_AssetAcquisitionSharePrice_lbl1">Asset Acquisition, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionSharePrice" xlink:to="erna_AssetAcquisitionSharePrice_lbl1" xlink:title="label: AssetAcquisitionSharePrice to erna_AssetAcquisitionSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AssetAcquisitionSharePrice_lbl2" xml:lang="en-US" id="erna_AssetAcquisitionSharePrice_lbl2">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionSharePrice" xlink:to="erna_AssetAcquisitionSharePrice_lbl2" xlink:title="label: AssetAcquisitionSharePrice to erna_AssetAcquisitionSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" />
    <link:label xlink:type="resource" xlink:label="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl" xml:lang="en-US" id="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl">Person with designation of chair of the board of directors, former chief executive officer and president.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:to="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl" xlink:title="label: ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember to erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl1" xml:lang="en-US" id="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl1">Chair of the Board of Directors, Former Chief Executive Officer and President [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:to="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl1" xlink:title="label: ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember to erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl2" xml:lang="en-US" id="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl2">Chair of the Board of Directors, Former Chief Executive Officer and President [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:to="erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl2" xlink:title="label: ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember to erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_UniversityOfSouthFloridaMember" xlink:label="UniversityOfSouthFloridaMember" xlink:title="UniversityOfSouthFloridaMember" />
    <link:label xlink:type="resource" xlink:label="erna_UniversityOfSouthFloridaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_UniversityOfSouthFloridaMember_lbl" xml:lang="en-US" id="erna_UniversityOfSouthFloridaMember_lbl">Legal entity involved in litigation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UniversityOfSouthFloridaMember" xlink:to="erna_UniversityOfSouthFloridaMember_lbl" xlink:title="label: UniversityOfSouthFloridaMember to erna_UniversityOfSouthFloridaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_UniversityOfSouthFloridaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_UniversityOfSouthFloridaMember_lbl1" xml:lang="en-US" id="erna_UniversityOfSouthFloridaMember_lbl1">University of South Florida [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UniversityOfSouthFloridaMember" xlink:to="erna_UniversityOfSouthFloridaMember_lbl1" xlink:title="label: UniversityOfSouthFloridaMember to erna_UniversityOfSouthFloridaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_UniversityOfSouthFloridaMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_UniversityOfSouthFloridaMember_lbl2" xml:lang="en-US" id="erna_UniversityOfSouthFloridaMember_lbl2">University of South Florida [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UniversityOfSouthFloridaMember" xlink:to="erna_UniversityOfSouthFloridaMember_lbl2" xlink:title="label: UniversityOfSouthFloridaMember to erna_UniversityOfSouthFloridaMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialLicenseFees" xlink:label="InitialLicenseFees" xlink:title="InitialLicenseFees" />
    <link:label xlink:type="resource" xlink:label="erna_InitialLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InitialLicenseFees_lbl" xml:lang="en-US" id="erna_InitialLicenseFees_lbl">Initial license fees required to pay including non-refundable fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialLicenseFees" xlink:to="erna_InitialLicenseFees_lbl" xlink:title="label: InitialLicenseFees to erna_InitialLicenseFees_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InitialLicenseFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InitialLicenseFees_lbl1" xml:lang="en-US" id="erna_InitialLicenseFees_lbl1">Initial License Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialLicenseFees" xlink:to="erna_InitialLicenseFees_lbl1" xlink:title="label: InitialLicenseFees to erna_InitialLicenseFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InitialLicenseFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InitialLicenseFees_lbl2" xml:lang="en-US" id="erna_InitialLicenseFees_lbl2">Initial license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialLicenseFees" xlink:to="erna_InitialLicenseFees_lbl2" xlink:title="label: InitialLicenseFees to erna_InitialLicenseFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusLtdAndFactorBioscienceMember" xlink:label="NovellusLtdAndFactorBioscienceMember" xlink:title="NovellusLtdAndFactorBioscienceMember" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusLtdAndFactorBioscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NovellusLtdAndFactorBioscienceMember_lbl" xml:lang="en-US" id="erna_NovellusLtdAndFactorBioscienceMember_lbl">The name of companies involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusLtdAndFactorBioscienceMember" xlink:to="erna_NovellusLtdAndFactorBioscienceMember_lbl" xlink:title="label: NovellusLtdAndFactorBioscienceMember to erna_NovellusLtdAndFactorBioscienceMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusLtdAndFactorBioscienceMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NovellusLtdAndFactorBioscienceMember_lbl1" xml:lang="en-US" id="erna_NovellusLtdAndFactorBioscienceMember_lbl1">Novellus Ltd. and Factor Bioscience [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusLtdAndFactorBioscienceMember" xlink:to="erna_NovellusLtdAndFactorBioscienceMember_lbl1" xlink:title="label: NovellusLtdAndFactorBioscienceMember to erna_NovellusLtdAndFactorBioscienceMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusLtdAndFactorBioscienceMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NovellusLtdAndFactorBioscienceMember_lbl2" xml:lang="en-US" id="erna_NovellusLtdAndFactorBioscienceMember_lbl2">Licensors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusLtdAndFactorBioscienceMember" xlink:to="erna_NovellusLtdAndFactorBioscienceMember_lbl2" xlink:title="label: NovellusLtdAndFactorBioscienceMember to erna_NovellusLtdAndFactorBioscienceMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteMember" xlink:label="NoveCiteMember" xlink:title="NoveCiteMember" />
    <link:label xlink:type="resource" xlink:label="erna_NoveCiteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NoveCiteMember_lbl" xml:lang="en-US" id="erna_NoveCiteMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteMember" xlink:to="erna_NoveCiteMember_lbl" xlink:title="label: NoveCiteMember to erna_NoveCiteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NoveCiteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NoveCiteMember_lbl1" xml:lang="en-US" id="erna_NoveCiteMember_lbl1">NoveCite [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteMember" xlink:to="erna_NoveCiteMember_lbl1" xlink:title="label: NoveCiteMember to erna_NoveCiteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NoveCiteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NoveCiteMember_lbl2" xml:lang="en-US" id="erna_NoveCiteMember_lbl2">NoveCite [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteMember" xlink:to="erna_NoveCiteMember_lbl2" xlink:title="label: NoveCiteMember to erna_NoveCiteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountObligatedToPayInYearOne" xlink:label="AmountObligatedToPayInYearOne" xlink:title="AmountObligatedToPayInYearOne" />
    <link:label xlink:type="resource" xlink:label="erna_AmountObligatedToPayInYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AmountObligatedToPayInYearOne_lbl" xml:lang="en-US" id="erna_AmountObligatedToPayInYearOne_lbl">The entity is obligated to pay additional fees to the Licensors in first year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearOne" xlink:to="erna_AmountObligatedToPayInYearOne_lbl" xlink:title="label: AmountObligatedToPayInYearOne to erna_AmountObligatedToPayInYearOne_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AmountObligatedToPayInYearOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AmountObligatedToPayInYearOne_lbl1" xml:lang="en-US" id="erna_AmountObligatedToPayInYearOne_lbl1">Amount Obligated to Pay in Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearOne" xlink:to="erna_AmountObligatedToPayInYearOne_lbl1" xlink:title="label: AmountObligatedToPayInYearOne to erna_AmountObligatedToPayInYearOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AmountObligatedToPayInYearOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AmountObligatedToPayInYearOne_lbl2" xml:lang="en-US" id="erna_AmountObligatedToPayInYearOne_lbl2">Additional fees obligated to pay in 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearOne" xlink:to="erna_AmountObligatedToPayInYearOne_lbl2" xlink:title="label: AmountObligatedToPayInYearOne to erna_AmountObligatedToPayInYearOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AdditionalFeesObligatedToPay" xlink:label="AdditionalFeesObligatedToPay" xlink:title="AdditionalFeesObligatedToPay" />
    <link:label xlink:type="resource" xlink:label="erna_AdditionalFeesObligatedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AdditionalFeesObligatedToPay_lbl" xml:lang="en-US" id="erna_AdditionalFeesObligatedToPay_lbl">The entity is obligated to pay additional fees to Licensors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFeesObligatedToPay" xlink:to="erna_AdditionalFeesObligatedToPay_lbl" xlink:title="label: AdditionalFeesObligatedToPay to erna_AdditionalFeesObligatedToPay_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AdditionalFeesObligatedToPay_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AdditionalFeesObligatedToPay_lbl1" xml:lang="en-US" id="erna_AdditionalFeesObligatedToPay_lbl1">Additional Fees Obligated to Pay</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFeesObligatedToPay" xlink:to="erna_AdditionalFeesObligatedToPay_lbl1" xlink:title="label: AdditionalFeesObligatedToPay to erna_AdditionalFeesObligatedToPay_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AdditionalFeesObligatedToPay_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AdditionalFeesObligatedToPay_lbl2" xml:lang="en-US" id="erna_AdditionalFeesObligatedToPay_lbl2">Amount require to pay of initial license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFeesObligatedToPay" xlink:to="erna_AdditionalFeesObligatedToPay_lbl2" xlink:title="label: AdditionalFeesObligatedToPay to erna_AdditionalFeesObligatedToPay_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountObligatedToPayInYearTwo" xlink:label="AmountObligatedToPayInYearTwo" xlink:title="AmountObligatedToPayInYearTwo" />
    <link:label xlink:type="resource" xlink:label="erna_AmountObligatedToPayInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AmountObligatedToPayInYearTwo_lbl" xml:lang="en-US" id="erna_AmountObligatedToPayInYearTwo_lbl">The entity is obligated to pay additional fees to the Licensors in second year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearTwo" xlink:to="erna_AmountObligatedToPayInYearTwo_lbl" xlink:title="label: AmountObligatedToPayInYearTwo to erna_AmountObligatedToPayInYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AmountObligatedToPayInYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AmountObligatedToPayInYearTwo_lbl1" xml:lang="en-US" id="erna_AmountObligatedToPayInYearTwo_lbl1">Amount Obligated to Pay in Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearTwo" xlink:to="erna_AmountObligatedToPayInYearTwo_lbl1" xlink:title="label: AmountObligatedToPayInYearTwo to erna_AmountObligatedToPayInYearTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AmountObligatedToPayInYearTwo_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AmountObligatedToPayInYearTwo_lbl2" xml:lang="en-US" id="erna_AmountObligatedToPayInYearTwo_lbl2">Additional fees obligated to pay in 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearTwo" xlink:to="erna_AmountObligatedToPayInYearTwo_lbl2" xlink:title="label: AmountObligatedToPayInYearTwo to erna_AmountObligatedToPayInYearTwo_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountRequireToPayInitialLicenseFees" xlink:label="AmountRequireToPayInitialLicenseFees" xlink:title="AmountRequireToPayInitialLicenseFees" />
    <link:label xlink:type="resource" xlink:label="erna_AmountRequireToPayInitialLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AmountRequireToPayInitialLicenseFees_lbl" xml:lang="en-US" id="erna_AmountRequireToPayInitialLicenseFees_lbl">Amount require to pay out of the total initial license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountRequireToPayInitialLicenseFees" xlink:to="erna_AmountRequireToPayInitialLicenseFees_lbl" xlink:title="label: AmountRequireToPayInitialLicenseFees to erna_AmountRequireToPayInitialLicenseFees_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AmountRequireToPayInitialLicenseFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AmountRequireToPayInitialLicenseFees_lbl1" xml:lang="en-US" id="erna_AmountRequireToPayInitialLicenseFees_lbl1">Amount Require to Pay Initial License Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountRequireToPayInitialLicenseFees" xlink:to="erna_AmountRequireToPayInitialLicenseFees_lbl1" xlink:title="label: AmountRequireToPayInitialLicenseFees to erna_AmountRequireToPayInitialLicenseFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AmountRequireToPayInitialLicenseFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AmountRequireToPayInitialLicenseFees_lbl2" xml:lang="en-US" id="erna_AmountRequireToPayInitialLicenseFees_lbl2">Amount obligated to pay in license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountRequireToPayInitialLicenseFees" xlink:to="erna_AmountRequireToPayInitialLicenseFees_lbl2" xlink:title="label: AmountRequireToPayInitialLicenseFees to erna_AmountRequireToPayInitialLicenseFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfRevenue" xlink:label="PercentageOfRevenue" xlink:title="PercentageOfRevenue" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageOfRevenue_lbl" xml:lang="en-US" id="erna_PercentageOfRevenue_lbl">Percentage of revenue from receives any revenue involving the original cell line included in the licensed technology, then Novellus, Ltd shall remit to NoveCite.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRevenue" xlink:to="erna_PercentageOfRevenue_lbl" xlink:title="label: PercentageOfRevenue to erna_PercentageOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageOfRevenue_lbl1" xml:lang="en-US" id="erna_PercentageOfRevenue_lbl1">Percentage of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRevenue" xlink:to="erna_PercentageOfRevenue_lbl1" xlink:title="label: PercentageOfRevenue to erna_PercentageOfRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageOfRevenue_lbl2" xml:lang="en-US" id="erna_PercentageOfRevenue_lbl2">Percentage of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRevenue" xlink:to="erna_PercentageOfRevenue_lbl2" xlink:title="label: PercentageOfRevenue to erna_PercentageOfRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyNonRefundableOptionFee" xlink:label="LossContingencyNonRefundableOptionFee" xlink:title="LossContingencyNonRefundableOptionFee" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyNonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LossContingencyNonRefundableOptionFee_lbl" xml:lang="en-US" id="erna_LossContingencyNonRefundableOptionFee_lbl">The amount of Non-refundable option fee in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNonRefundableOptionFee" xlink:to="erna_LossContingencyNonRefundableOptionFee_lbl" xlink:title="label: LossContingencyNonRefundableOptionFee to erna_LossContingencyNonRefundableOptionFee_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyNonRefundableOptionFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LossContingencyNonRefundableOptionFee_lbl1" xml:lang="en-US" id="erna_LossContingencyNonRefundableOptionFee_lbl1">Loss Contingency, Non-refundable Option Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNonRefundableOptionFee" xlink:to="erna_LossContingencyNonRefundableOptionFee_lbl1" xlink:title="label: LossContingencyNonRefundableOptionFee to erna_LossContingencyNonRefundableOptionFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyNonRefundableOptionFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LossContingencyNonRefundableOptionFee_lbl2" xml:lang="en-US" id="erna_LossContingencyNonRefundableOptionFee_lbl2">Non-refundable option fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNonRefundableOptionFee" xlink:to="erna_LossContingencyNonRefundableOptionFee_lbl2" xlink:title="label: LossContingencyNonRefundableOptionFee to erna_LossContingencyNonRefundableOptionFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:label xlink:type="resource" xlink:label="erna_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_MilestonePayments_lbl" xml:lang="en-US" id="erna_MilestonePayments_lbl">The amount of milestones upfront payment on licenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="erna_MilestonePayments_lbl" xlink:title="label: MilestonePayments to erna_MilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_MilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_MilestonePayments_lbl1" xml:lang="en-US" id="erna_MilestonePayments_lbl1">Milestone Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="erna_MilestonePayments_lbl1" xlink:title="label: MilestonePayments to erna_MilestonePayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_MilestonePayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_MilestonePayments_lbl2" xml:lang="en-US" id="erna_MilestonePayments_lbl2">Milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="erna_MilestonePayments_lbl2" xlink:title="label: MilestonePayments to erna_MilestonePayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyPercentageOfRoyaltyPayable" xlink:label="LossContingencyPercentageOfRoyaltyPayable" xlink:title="LossContingencyPercentageOfRoyaltyPayable" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyPercentageOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LossContingencyPercentageOfRoyaltyPayable_lbl" xml:lang="en-US" id="erna_LossContingencyPercentageOfRoyaltyPayable_lbl">Percentage of royalty payable from one party to another in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPercentageOfRoyaltyPayable" xlink:to="erna_LossContingencyPercentageOfRoyaltyPayable_lbl" xlink:title="label: LossContingencyPercentageOfRoyaltyPayable to erna_LossContingencyPercentageOfRoyaltyPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyPercentageOfRoyaltyPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LossContingencyPercentageOfRoyaltyPayable_lbl1" xml:lang="en-US" id="erna_LossContingencyPercentageOfRoyaltyPayable_lbl1">Loss contingency, Percentage of Royalty Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPercentageOfRoyaltyPayable" xlink:to="erna_LossContingencyPercentageOfRoyaltyPayable_lbl1" xlink:title="label: LossContingencyPercentageOfRoyaltyPayable to erna_LossContingencyPercentageOfRoyaltyPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyPercentageOfRoyaltyPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LossContingencyPercentageOfRoyaltyPayable_lbl2" xml:lang="en-US" id="erna_LossContingencyPercentageOfRoyaltyPayable_lbl2">Percentage of royalty payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPercentageOfRoyaltyPayable" xlink:to="erna_LossContingencyPercentageOfRoyaltyPayable_lbl2" xlink:title="label: LossContingencyPercentageOfRoyaltyPayable to erna_LossContingencyPercentageOfRoyaltyPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LicensingAgreementsAbstract" xlink:label="LicensingAgreementsAbstract" xlink:title="LicensingAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_LicensingAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LicensingAgreementsAbstract_lbl1" xml:lang="en-US" id="erna_LicensingAgreementsAbstract_lbl1">Licensing Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAgreementsAbstract" xlink:to="erna_LicensingAgreementsAbstract_lbl1" xlink:title="label: LicensingAgreementsAbstract to erna_LicensingAgreementsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LicensingAgreementsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LicensingAgreementsAbstract_lbl2" xml:lang="en-US" id="erna_LicensingAgreementsAbstract_lbl2">Licensing Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAgreementsAbstract" xlink:to="erna_LicensingAgreementsAbstract_lbl2" xlink:title="label: LicensingAgreementsAbstract to erna_LicensingAgreementsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:label="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:title="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl" xml:lang="en-US" id="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl">Tabular disclosure of the number RSUs vested and settled.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:to="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl" xlink:title="label: ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock to erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl1" xml:lang="en-US" id="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl1">Schedule of Restricted Stock Units Vested and Settled [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:to="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl1" xlink:title="label: ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock to erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl2" xml:lang="en-US" id="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl2">RSUs Vested and Settled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:to="erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl2" xlink:title="label: ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock to erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:label="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:title="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl" xml:lang="en-US" id="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl">Tabular disclosure for stock option granted during the year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:to="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl" xlink:title="label: ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock to erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl1" xml:lang="en-US" id="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl1">Share-Based Payment Arrangement, Option, Grants in Period [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:to="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl1" xlink:title="label: ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock to erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl2" xml:lang="en-US" id="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl2">Stock Option Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:to="erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl2" xlink:title="label: ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock to erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:label="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:title="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl" xml:lang="en-US" id="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl">Tabular disclosure of the equity options or other equity instruments granted during the year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:to="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl" xlink:title="label: ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock to erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl1" xml:lang="en-US" id="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl1">Share-Based Payment Arrangement, Restricted Stock Unit, Grant in Period [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:to="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl1" xlink:title="label: ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock to erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl2" xml:lang="en-US" id="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl2">RSU Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:to="erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl2" xlink:title="label: ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock to erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:title="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl">Tabular disclosure for lessee's operating lease right-of-use assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock to erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1">Operating Lease Right-of-use Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:title="label: OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock to erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" xml:lang="en-US" id="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2">Operating Lease Right-of-use Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" xlink:title="label: OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock to erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WriteOffOfOperatingLeaseRightOfUseAsset" xlink:label="WriteOffOfOperatingLeaseRightOfUseAsset" xlink:title="WriteOffOfOperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl">Write-off of operating lease right-of-use asset due to lease termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfOperatingLeaseRightOfUseAsset" xlink:to="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl" xlink:title="label: WriteOffOfOperatingLeaseRightOfUseAsset to erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl1">Write-off of Operating Lease Right-of-use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfOperatingLeaseRightOfUseAsset" xlink:to="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: WriteOffOfOperatingLeaseRightOfUseAsset to erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl2" xml:lang="en-US" id="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl2">Write off of ROU asset due to lease termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfOperatingLeaseRightOfUseAsset" xlink:to="erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl2" xlink:title="label: WriteOffOfOperatingLeaseRightOfUseAsset to erna_WriteOffOfOperatingLeaseRightOfUseAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:label="RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:title="RemeasurementOfOperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl">Amount of remeasurement of operating lease right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:to="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl" xlink:title="label: RemeasurementOfOperatingLeaseRightOfUseAsset to erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl1">Remeasurement of Operating Lease Right-of-use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:to="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: RemeasurementOfOperatingLeaseRightOfUseAsset to erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl2" xml:lang="en-US" id="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl2">Remeasurement of ROU asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:to="erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl2" xlink:title="label: RemeasurementOfOperatingLeaseRightOfUseAsset to erna_RemeasurementOfOperatingLeaseRightOfUseAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:label="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:title="PrincipalPaymentsOnOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl">Principal payments on operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:to="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" xlink:title="label: PrincipalPaymentsOnOperatingLeaseLiabilities to erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1">Principal payments on operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:to="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" xlink:title="label: PrincipalPaymentsOnOperatingLeaseLiabilities to erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl2" xml:lang="en-US" id="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl2">Principal payments on operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:to="erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl2" xlink:title="label: PrincipalPaymentsOnOperatingLeaseLiabilities to erna_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeaseAssestAbstract" xlink:label="OperatingLeaseAssestAbstract" xlink:title="OperatingLeaseAssestAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseAssestAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_OperatingLeaseAssestAbstract_lbl1" xml:lang="en-US" id="erna_OperatingLeaseAssestAbstract_lbl1">Operating Lease, Asset [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseAssestAbstract" xlink:to="erna_OperatingLeaseAssestAbstract_lbl1" xlink:title="label: OperatingLeaseAssestAbstract to erna_OperatingLeaseAssestAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WriteOffOfOperatingLeaseLiability" xlink:label="WriteOffOfOperatingLeaseLiability" xlink:title="WriteOffOfOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="erna_WriteOffOfOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_WriteOffOfOperatingLeaseLiability_lbl" xml:lang="en-US" id="erna_WriteOffOfOperatingLeaseLiability_lbl">Write-off of operating lease liability due to lease termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfOperatingLeaseLiability" xlink:to="erna_WriteOffOfOperatingLeaseLiability_lbl" xlink:title="label: WriteOffOfOperatingLeaseLiability to erna_WriteOffOfOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_WriteOffOfOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_WriteOffOfOperatingLeaseLiability_lbl1" xml:lang="en-US" id="erna_WriteOffOfOperatingLeaseLiability_lbl1">Write- off of Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfOperatingLeaseLiability" xlink:to="erna_WriteOffOfOperatingLeaseLiability_lbl1" xlink:title="label: WriteOffOfOperatingLeaseLiability to erna_WriteOffOfOperatingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_WriteOffOfOperatingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_WriteOffOfOperatingLeaseLiability_lbl2" xml:lang="en-US" id="erna_WriteOffOfOperatingLeaseLiability_lbl2">Write off of operating lease liability due to lease termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfOperatingLeaseLiability" xlink:to="erna_WriteOffOfOperatingLeaseLiability_lbl2" xlink:title="label: WriteOffOfOperatingLeaseLiability to erna_WriteOffOfOperatingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:label xlink:type="resource" xlink:label="erna_PIPEInvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PIPEInvestorMember_lbl" xml:lang="en-US" id="erna_PIPEInvestorMember_lbl">A private investment in public equity, often called a PIPE deal, involves the selling of publicly traded common shares or some form of preferred stock or convertible security to private investors. It is an allocation of shares in a public company not through a public offering in a stock exchange. PIPE deals are part of the primary market. In the U.S., a PIPE offering may be registered with the Securities and Exchange Commission on a registration statement or may be completed as an unregistered private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PIPEInvestorMember" xlink:to="erna_PIPEInvestorMember_lbl" xlink:title="label: PIPEInvestorMember to erna_PIPEInvestorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PIPEInvestorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PIPEInvestorMember_lbl1" xml:lang="en-US" id="erna_PIPEInvestorMember_lbl1">PIPE Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PIPEInvestorMember" xlink:to="erna_PIPEInvestorMember_lbl1" xlink:title="label: PIPEInvestorMember to erna_PIPEInvestorMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PIPEInvestorMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PIPEInvestorMember_lbl2" xml:lang="en-US" id="erna_PIPEInvestorMember_lbl2">PIPE Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PIPEInvestorMember" xlink:to="erna_PIPEInvestorMember_lbl2" xlink:title="label: PIPEInvestorMember to erna_PIPEInvestorMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AggregateCalendarDays" xlink:label="AggregateCalendarDays" xlink:title="AggregateCalendarDays" />
    <link:label xlink:type="resource" xlink:label="erna_AggregateCalendarDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AggregateCalendarDays_lbl" xml:lang="en-US" id="erna_AggregateCalendarDays_lbl">In the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered in specified aggregate calendar days (which need not be consecutive calendar days) during any 12-month period for resale in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateCalendarDays" xlink:to="erna_AggregateCalendarDays_lbl" xlink:title="label: AggregateCalendarDays to erna_AggregateCalendarDays_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AggregateCalendarDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AggregateCalendarDays_lbl1" xml:lang="en-US" id="erna_AggregateCalendarDays_lbl1">Aggregate Calendar Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateCalendarDays" xlink:to="erna_AggregateCalendarDays_lbl1" xlink:title="label: AggregateCalendarDays to erna_AggregateCalendarDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AggregateCalendarDays_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AggregateCalendarDays_lbl2" xml:lang="en-US" id="erna_AggregateCalendarDays_lbl2">Aggregate calendar days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateCalendarDays" xlink:to="erna_AggregateCalendarDays_lbl2" xlink:title="label: AggregateCalendarDays to erna_AggregateCalendarDays_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_VariableRateTransactionsPeriod" xlink:label="VariableRateTransactionsPeriod" xlink:title="VariableRateTransactionsPeriod" />
    <link:label xlink:type="resource" xlink:label="erna_VariableRateTransactionsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_VariableRateTransactionsPeriod_lbl" xml:lang="en-US" id="erna_VariableRateTransactionsPeriod_lbl">Pursuant to the Purchase Agreement, the Company is prohibited from issuing equity in variable rate transactions for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateTransactionsPeriod" xlink:to="erna_VariableRateTransactionsPeriod_lbl" xlink:title="label: VariableRateTransactionsPeriod to erna_VariableRateTransactionsPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_VariableRateTransactionsPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_VariableRateTransactionsPeriod_lbl1" xml:lang="en-US" id="erna_VariableRateTransactionsPeriod_lbl1">Variable Rate Transactions Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateTransactionsPeriod" xlink:to="erna_VariableRateTransactionsPeriod_lbl1" xlink:title="label: VariableRateTransactionsPeriod to erna_VariableRateTransactionsPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_VariableRateTransactionsPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_VariableRateTransactionsPeriod_lbl2" xml:lang="en-US" id="erna_VariableRateTransactionsPeriod_lbl2">Variable rate transaction period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateTransactionsPeriod" xlink:to="erna_VariableRateTransactionsPeriod_lbl2" xlink:title="label: VariableRateTransactionsPeriod to erna_VariableRateTransactionsPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightsExercisableTerm" xlink:label="ClassOfWarrantOrRightsExercisableTerm" xlink:title="ClassOfWarrantOrRightsExercisableTerm" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightsExercisableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ClassOfWarrantOrRightsExercisableTerm_lbl" xml:lang="en-US" id="erna_ClassOfWarrantOrRightsExercisableTerm_lbl">Warrants or rights exercisable term, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightsExercisableTerm" xlink:to="erna_ClassOfWarrantOrRightsExercisableTerm_lbl" xlink:title="label: ClassOfWarrantOrRightsExercisableTerm to erna_ClassOfWarrantOrRightsExercisableTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightsExercisableTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ClassOfWarrantOrRightsExercisableTerm_lbl1" xml:lang="en-US" id="erna_ClassOfWarrantOrRightsExercisableTerm_lbl1">Class of Warrant or Rights Exercisable Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightsExercisableTerm" xlink:to="erna_ClassOfWarrantOrRightsExercisableTerm_lbl1" xlink:title="label: ClassOfWarrantOrRightsExercisableTerm to erna_ClassOfWarrantOrRightsExercisableTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightsExercisableTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ClassOfWarrantOrRightsExercisableTerm_lbl2" xml:lang="en-US" id="erna_ClassOfWarrantOrRightsExercisableTerm_lbl2">Warrant exercisable term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightsExercisableTerm" xlink:to="erna_ClassOfWarrantOrRightsExercisableTerm_lbl2" xlink:title="label: ClassOfWarrantOrRightsExercisableTerm to erna_ClassOfWarrantOrRightsExercisableTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" id="erna_ClassOfWarrantOrRightExercised_lbl">Number of warrants or rights exercised during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercised" xlink:to="erna_ClassOfWarrantOrRightExercised_lbl" xlink:title="label: ClassOfWarrantOrRightExercised to erna_ClassOfWarrantOrRightExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ClassOfWarrantOrRightExercised_lbl1" xml:lang="en-US" id="erna_ClassOfWarrantOrRightExercised_lbl1">Class of Warrant or Right Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercised" xlink:to="erna_ClassOfWarrantOrRightExercised_lbl1" xlink:title="label: ClassOfWarrantOrRightExercised to erna_ClassOfWarrantOrRightExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_ClassOfWarrantOrRightExercised_lbl2" xml:lang="en-US" id="erna_ClassOfWarrantOrRightExercised_lbl2">Warrants exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercised" xlink:to="erna_ClassOfWarrantOrRightExercised_lbl2" xlink:title="label: ClassOfWarrantOrRightExercised to erna_ClassOfWarrantOrRightExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" xml:lang="en-US" id="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl">Percentage of securities that would be issuable upon the exercise of warrants or rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:to="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights to erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" xml:lang="en-US" id="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1">Class of Warrant or Right Percent of Securities that Would be Issuable Upon Exercise of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:to="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights to erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" xml:lang="en-US" id="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2">Percentage of warrants exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:to="erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" xlink:title="label: ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights to erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TransactionFeesPayable" xlink:label="TransactionFeesPayable" xlink:title="TransactionFeesPayable" />
    <link:label xlink:type="resource" xlink:label="erna_TransactionFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_TransactionFeesPayable_lbl" xml:lang="en-US" id="erna_TransactionFeesPayable_lbl">Fees incurred related to PIPE transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionFeesPayable" xlink:to="erna_TransactionFeesPayable_lbl" xlink:title="label: TransactionFeesPayable to erna_TransactionFeesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_TransactionFeesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_TransactionFeesPayable_lbl1" xml:lang="en-US" id="erna_TransactionFeesPayable_lbl1">Transaction Fees Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionFeesPayable" xlink:to="erna_TransactionFeesPayable_lbl1" xlink:title="label: TransactionFeesPayable to erna_TransactionFeesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_TransactionFeesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_TransactionFeesPayable_lbl2" xml:lang="en-US" id="erna_TransactionFeesPayable_lbl2">Transaction fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionFeesPayable" xlink:to="erna_TransactionFeesPayable_lbl2" xlink:title="label: TransactionFeesPayable to erna_TransactionFeesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:label="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:title="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" />
    <link:label xlink:type="resource" xlink:label="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl" xml:lang="en-US" id="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl">Pursuant to the registration rights agreement, obligation to pay the PIPE Investor liquidated damages equal to the Subscription Amount per month.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:to="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl" xlink:title="label: ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth to erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl1" xml:lang="en-US" id="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl1">Obligation to Pay Liquidated Damages Percentage on Subscription Amount per Month</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:to="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl1" xlink:title="label: ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth to erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl2" xml:lang="en-US" id="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl2">Obligation to pay liquidated damages per month</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:to="erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl2" xlink:title="label: ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth to erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ConsecutiveCalendarDays" xlink:label="ConsecutiveCalendarDays" xlink:title="ConsecutiveCalendarDays" />
    <link:label xlink:type="resource" xlink:label="erna_ConsecutiveCalendarDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ConsecutiveCalendarDays_lbl" xml:lang="en-US" id="erna_ConsecutiveCalendarDays_lbl">In the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered in specified consecutive calendar days for resale, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsecutiveCalendarDays" xlink:to="erna_ConsecutiveCalendarDays_lbl" xlink:title="label: ConsecutiveCalendarDays to erna_ConsecutiveCalendarDays_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ConsecutiveCalendarDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ConsecutiveCalendarDays_lbl1" xml:lang="en-US" id="erna_ConsecutiveCalendarDays_lbl1">Consecutive Calendar Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsecutiveCalendarDays" xlink:to="erna_ConsecutiveCalendarDays_lbl1" xlink:title="label: ConsecutiveCalendarDays to erna_ConsecutiveCalendarDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ConsecutiveCalendarDays_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ConsecutiveCalendarDays_lbl2" xml:lang="en-US" id="erna_ConsecutiveCalendarDays_lbl2">Consecutive calendar days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsecutiveCalendarDays" xlink:to="erna_ConsecutiveCalendarDays_lbl2" xlink:title="label: ConsecutiveCalendarDays to erna_ConsecutiveCalendarDays_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligationToPayLiquidatedDamagesPercentage" xlink:label="ObligationToPayLiquidatedDamagesPercentage" xlink:title="ObligationToPayLiquidatedDamagesPercentage" />
    <link:label xlink:type="resource" xlink:label="erna_ObligationToPayLiquidatedDamagesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ObligationToPayLiquidatedDamagesPercentage_lbl" xml:lang="en-US" id="erna_ObligationToPayLiquidatedDamagesPercentage_lbl">Pursuant to the registration rights agreement, obligation to pay the PIPE Investor liquidated damages percentage of aggregate payment on Subscription Amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToPayLiquidatedDamagesPercentage" xlink:to="erna_ObligationToPayLiquidatedDamagesPercentage_lbl" xlink:title="label: ObligationToPayLiquidatedDamagesPercentage to erna_ObligationToPayLiquidatedDamagesPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ObligationToPayLiquidatedDamagesPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ObligationToPayLiquidatedDamagesPercentage_lbl1" xml:lang="en-US" id="erna_ObligationToPayLiquidatedDamagesPercentage_lbl1">Obligation to Pay Liquidated Damages Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToPayLiquidatedDamagesPercentage" xlink:to="erna_ObligationToPayLiquidatedDamagesPercentage_lbl1" xlink:title="label: ObligationToPayLiquidatedDamagesPercentage to erna_ObligationToPayLiquidatedDamagesPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ObligationToPayLiquidatedDamagesPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ObligationToPayLiquidatedDamagesPercentage_lbl2" xml:lang="en-US" id="erna_ObligationToPayLiquidatedDamagesPercentage_lbl2">Obligated to pay liquidated damages percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligationToPayLiquidatedDamagesPercentage" xlink:to="erna_ObligationToPayLiquidatedDamagesPercentage_lbl2" xlink:title="label: ObligationToPayLiquidatedDamagesPercentage to erna_ObligationToPayLiquidatedDamagesPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PrivatePlacementOfEquityAbstract" xlink:label="PrivatePlacementOfEquityAbstract" xlink:title="PrivatePlacementOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_PrivatePlacementOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PrivatePlacementOfEquityAbstract_lbl1" xml:lang="en-US" id="erna_PrivatePlacementOfEquityAbstract_lbl1">Private Placement of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="erna_PrivatePlacementOfEquityAbstract_lbl1" xlink:title="label: PrivatePlacementOfEquityAbstract to erna_PrivatePlacementOfEquityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PrivatePlacementOfEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PrivatePlacementOfEquityAbstract_lbl2" xml:lang="en-US" id="erna_PrivatePlacementOfEquityAbstract_lbl2">Private Placement of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="erna_PrivatePlacementOfEquityAbstract_lbl2" xlink:title="label: PrivatePlacementOfEquityAbstract to erna_PrivatePlacementOfEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl">Number of shares of stock issued during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl1">Stock Issued During Period, Shares, Acquisitions1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl2">Stock issued, shares, acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl3">Issuance of common stock for business combination (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to erna_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" id="erna_ClassOfWarrantOrRightIssued_lbl">Number of shares issued into which the class of warrant or right may be converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="erna_ClassOfWarrantOrRightIssued_lbl" xlink:title="label: ClassOfWarrantOrRightIssued to erna_ClassOfWarrantOrRightIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ClassOfWarrantOrRightIssued_lbl1" xml:lang="en-US" id="erna_ClassOfWarrantOrRightIssued_lbl1">Class of Warrant or Right, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="erna_ClassOfWarrantOrRightIssued_lbl1" xlink:title="label: ClassOfWarrantOrRightIssued to erna_ClassOfWarrantOrRightIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ClassOfWarrantOrRightIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ClassOfWarrantOrRightIssued_lbl2" xml:lang="en-US" id="erna_ClassOfWarrantOrRightIssued_lbl2">Number of rights options issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="erna_ClassOfWarrantOrRightIssued_lbl2" xlink:title="label: ClassOfWarrantOrRightIssued to erna_ClassOfWarrantOrRightIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MergerAbstract" xlink:label="MergerAbstract" xlink:title="MergerAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_MergerAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_MergerAbstract_lbl1" xml:lang="en-US" id="erna_MergerAbstract_lbl1">Merger [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAbstract" xlink:to="erna_MergerAbstract_lbl1" xlink:title="label: MergerAbstract to erna_MergerAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:label="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:title="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" xml:lang="en-US" id="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" xlink:title="label: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" xml:lang="en-US" id="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1">Lessee Operating Lease Weighted Average Remaining Lease Term And Discount Rate Abstract [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" xlink:title="label: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" xml:lang="en-US" id="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2">Weighted Average Remaining Lease Term and Discount Rate [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" xlink:title="label: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US" id="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl">Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following latest fiscal year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour to erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" xml:lang="en-US" id="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1">Lessee, Operating Lease, Liability, Payments Due after Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour to erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl2" xml:lang="en-US" id="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl2">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl2" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour to erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OptionFee" xlink:label="OptionFee" xlink:title="OptionFee" />
    <link:label xlink:type="resource" xlink:label="erna_OptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_OptionFee_lbl" xml:lang="en-US" id="erna_OptionFee_lbl">The amount of option fee in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionFee" xlink:to="erna_OptionFee_lbl" xlink:title="label: OptionFee to erna_OptionFee_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_OptionFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_OptionFee_lbl1" xml:lang="en-US" id="erna_OptionFee_lbl1">Option Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionFee" xlink:to="erna_OptionFee_lbl1" xlink:title="label: OptionFee to erna_OptionFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_OptionFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_OptionFee_lbl2" xml:lang="en-US" id="erna_OptionFee_lbl2">Option fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionFee" xlink:to="erna_OptionFee_lbl2" xlink:title="label: OptionFee to erna_OptionFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ExacisBiotherapeuticsIncMember" xlink:label="ExacisBiotherapeuticsIncMember" xlink:title="ExacisBiotherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="erna_ExacisBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ExacisBiotherapeuticsIncMember_lbl" xml:lang="en-US" id="erna_ExacisBiotherapeuticsIncMember_lbl">A Delaware corporation the company entered into Option Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExacisBiotherapeuticsIncMember" xlink:to="erna_ExacisBiotherapeuticsIncMember_lbl" xlink:title="label: ExacisBiotherapeuticsIncMember to erna_ExacisBiotherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ExacisBiotherapeuticsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ExacisBiotherapeuticsIncMember_lbl1" xml:lang="en-US" id="erna_ExacisBiotherapeuticsIncMember_lbl1">Exacis Biotherapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExacisBiotherapeuticsIncMember" xlink:to="erna_ExacisBiotherapeuticsIncMember_lbl1" xlink:title="label: ExacisBiotherapeuticsIncMember to erna_ExacisBiotherapeuticsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ExacisBiotherapeuticsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ExacisBiotherapeuticsIncMember_lbl2" xml:lang="en-US" id="erna_ExacisBiotherapeuticsIncMember_lbl2">Exacis Biotherapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExacisBiotherapeuticsIncMember" xlink:to="erna_ExacisBiotherapeuticsIncMember_lbl2" xlink:title="label: ExacisBiotherapeuticsIncMember to erna_ExacisBiotherapeuticsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ERSquibbSonsLLCMember" xlink:label="ERSquibbSonsLLCMember" xlink:title="ERSquibbSonsLLCMember" />
    <link:label xlink:type="resource" xlink:label="erna_ERSquibbSonsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ERSquibbSonsLLCMember_lbl" xml:lang="en-US" id="erna_ERSquibbSonsLLCMember_lbl">A Delaware limited liability company ("Sublessor"), for office, laboratory and research and development space (the "Premises").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ERSquibbSonsLLCMember" xlink:to="erna_ERSquibbSonsLLCMember_lbl" xlink:title="label: ERSquibbSonsLLCMember to erna_ERSquibbSonsLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ERSquibbSonsLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ERSquibbSonsLLCMember_lbl1" xml:lang="en-US" id="erna_ERSquibbSonsLLCMember_lbl1">E.R. Squibb &amp; Sons, L.L.C. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ERSquibbSonsLLCMember" xlink:to="erna_ERSquibbSonsLLCMember_lbl1" xlink:title="label: ERSquibbSonsLLCMember to erna_ERSquibbSonsLLCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ERSquibbSonsLLCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ERSquibbSonsLLCMember_lbl2" xml:lang="en-US" id="erna_ERSquibbSonsLLCMember_lbl2">E.R. Squibb &amp; Sons, L.L.C. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ERSquibbSonsLLCMember" xlink:to="erna_ERSquibbSonsLLCMember_lbl2" xlink:title="label: ERSquibbSonsLLCMember to erna_ERSquibbSonsLLCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeasesMonthlyBaseRent" xlink:label="OperatingLeasesMonthlyBaseRent" xlink:title="OperatingLeasesMonthlyBaseRent" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeasesMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_OperatingLeasesMonthlyBaseRent_lbl" xml:lang="en-US" id="erna_OperatingLeasesMonthlyBaseRent_lbl">The amount of rental expense payable per month for operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesMonthlyBaseRent" xlink:to="erna_OperatingLeasesMonthlyBaseRent_lbl" xlink:title="label: OperatingLeasesMonthlyBaseRent to erna_OperatingLeasesMonthlyBaseRent_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeasesMonthlyBaseRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_OperatingLeasesMonthlyBaseRent_lbl1" xml:lang="en-US" id="erna_OperatingLeasesMonthlyBaseRent_lbl1">Operating Leases, Monthly Base Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesMonthlyBaseRent" xlink:to="erna_OperatingLeasesMonthlyBaseRent_lbl1" xlink:title="label: OperatingLeasesMonthlyBaseRent to erna_OperatingLeasesMonthlyBaseRent_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeasesMonthlyBaseRent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_OperatingLeasesMonthlyBaseRent_lbl2" xml:lang="en-US" id="erna_OperatingLeasesMonthlyBaseRent_lbl2">Monthly base rent payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesMonthlyBaseRent" xlink:to="erna_OperatingLeasesMonthlyBaseRent_lbl2" xlink:title="label: OperatingLeasesMonthlyBaseRent to erna_OperatingLeasesMonthlyBaseRent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TermToPaySecurityDeposit" xlink:label="TermToPaySecurityDeposit" xlink:title="TermToPaySecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="erna_TermToPaySecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_TermToPaySecurityDeposit_lbl" xml:lang="en-US" id="erna_TermToPaySecurityDeposit_lbl">The term to pay, sub lessor a security deposit primary landlord's consent to the Sublease in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermToPaySecurityDeposit" xlink:to="erna_TermToPaySecurityDeposit_lbl" xlink:title="label: TermToPaySecurityDeposit to erna_TermToPaySecurityDeposit_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_TermToPaySecurityDeposit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_TermToPaySecurityDeposit_lbl1" xml:lang="en-US" id="erna_TermToPaySecurityDeposit_lbl1">Term to Pay Security Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermToPaySecurityDeposit" xlink:to="erna_TermToPaySecurityDeposit_lbl1" xlink:title="label: TermToPaySecurityDeposit to erna_TermToPaySecurityDeposit_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_TermToPaySecurityDeposit_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_TermToPaySecurityDeposit_lbl2" xml:lang="en-US" id="erna_TermToPaySecurityDeposit_lbl2">Term to pay security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermToPaySecurityDeposit" xlink:to="erna_TermToPaySecurityDeposit_lbl2" xlink:title="label: TermToPaySecurityDeposit to erna_TermToPaySecurityDeposit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ExacisOptionAgreementAbstract" xlink:label="ExacisOptionAgreementAbstract" xlink:title="ExacisOptionAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_ExacisOptionAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ExacisOptionAgreementAbstract_lbl1" xml:lang="en-US" id="erna_ExacisOptionAgreementAbstract_lbl1">Exacis Option Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExacisOptionAgreementAbstract" xlink:to="erna_ExacisOptionAgreementAbstract_lbl1" xlink:title="label: ExacisOptionAgreementAbstract to erna_ExacisOptionAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ExacisOptionAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ExacisOptionAgreementAbstract_lbl2" xml:lang="en-US" id="erna_ExacisOptionAgreementAbstract_lbl2">Exacis Option Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExacisOptionAgreementAbstract" xlink:to="erna_ExacisOptionAgreementAbstract_lbl2" xlink:title="label: ExacisOptionAgreementAbstract to erna_ExacisOptionAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FacilitySubleaseAbstract" xlink:label="FacilitySubleaseAbstract" xlink:title="FacilitySubleaseAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_FacilitySubleaseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_FacilitySubleaseAbstract_lbl1" xml:lang="en-US" id="erna_FacilitySubleaseAbstract_lbl1">Facility Sublease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FacilitySubleaseAbstract" xlink:to="erna_FacilitySubleaseAbstract_lbl1" xlink:title="label: FacilitySubleaseAbstract to erna_FacilitySubleaseAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_FacilitySubleaseAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_FacilitySubleaseAbstract_lbl2" xml:lang="en-US" id="erna_FacilitySubleaseAbstract_lbl2">Facility Sublease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FacilitySubleaseAbstract" xlink:to="erna_FacilitySubleaseAbstract_lbl2" xlink:title="label: FacilitySubleaseAbstract to erna_FacilitySubleaseAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InterimChiefExecutiveOfficerMember" xlink:label="InterimChiefExecutiveOfficerMember" xlink:title="InterimChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="erna_InterimChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InterimChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="erna_InterimChiefExecutiveOfficerMember_lbl">Person with designation of interim chief executive officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterimChiefExecutiveOfficerMember" xlink:to="erna_InterimChiefExecutiveOfficerMember_lbl" xlink:title="label: InterimChiefExecutiveOfficerMember to erna_InterimChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InterimChiefExecutiveOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InterimChiefExecutiveOfficerMember_lbl1" xml:lang="en-US" id="erna_InterimChiefExecutiveOfficerMember_lbl1">Interim Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterimChiefExecutiveOfficerMember" xlink:to="erna_InterimChiefExecutiveOfficerMember_lbl1" xlink:title="label: InterimChiefExecutiveOfficerMember to erna_InterimChiefExecutiveOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InterimChiefExecutiveOfficerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InterimChiefExecutiveOfficerMember_lbl2" xml:lang="en-US" id="erna_InterimChiefExecutiveOfficerMember_lbl2">Dr. Matthew Angel [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterimChiefExecutiveOfficerMember" xlink:to="erna_InterimChiefExecutiveOfficerMember_lbl2" xlink:title="label: InterimChiefExecutiveOfficerMember to erna_InterimChiefExecutiveOfficerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl">The number of extended post-termination exercise period under the share-based compensation arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod to erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl1" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl1">Share-based Compensation Arrangement By Share-based Payment Award, Extended Post-Termination, Exercise Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod to erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl2" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl2">Exercise period of extended post-termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod to erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl">The number of monthly installments for vesting of remaining shares in share-based compensation arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares to erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1">Share-based Compensation Arrangement by Share-based Payment, Number of Monthly Installments for Vesting of Remaining Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares to erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2">Number of monthly installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares to erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TimeBasedStockOptionGrantMember" xlink:label="TimeBasedStockOptionGrantMember" xlink:title="TimeBasedStockOptionGrantMember" />
    <link:label xlink:type="resource" xlink:label="erna_TimeBasedStockOptionGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_TimeBasedStockOptionGrantMember_lbl" xml:lang="en-US" id="erna_TimeBasedStockOptionGrantMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on time basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TimeBasedStockOptionGrantMember" xlink:to="erna_TimeBasedStockOptionGrantMember_lbl" xlink:title="label: TimeBasedStockOptionGrantMember to erna_TimeBasedStockOptionGrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_TimeBasedStockOptionGrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_TimeBasedStockOptionGrantMember_lbl1" xml:lang="en-US" id="erna_TimeBasedStockOptionGrantMember_lbl1">Time-Based Stock Option Grant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TimeBasedStockOptionGrantMember" xlink:to="erna_TimeBasedStockOptionGrantMember_lbl1" xlink:title="label: TimeBasedStockOptionGrantMember to erna_TimeBasedStockOptionGrantMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_TimeBasedStockOptionGrantMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_TimeBasedStockOptionGrantMember_lbl2" xml:lang="en-US" id="erna_TimeBasedStockOptionGrantMember_lbl2">Time-Based Grant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TimeBasedStockOptionGrantMember" xlink:to="erna_TimeBasedStockOptionGrantMember_lbl2" xlink:title="label: TimeBasedStockOptionGrantMember to erna_TimeBasedStockOptionGrantMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PerformanceBasedStockOptionGrantMember" xlink:label="PerformanceBasedStockOptionGrantMember" xlink:title="PerformanceBasedStockOptionGrantMember" />
    <link:label xlink:type="resource" xlink:label="erna_PerformanceBasedStockOptionGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PerformanceBasedStockOptionGrantMember_lbl" xml:lang="en-US" id="erna_PerformanceBasedStockOptionGrantMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceBasedStockOptionGrantMember" xlink:to="erna_PerformanceBasedStockOptionGrantMember_lbl" xlink:title="label: PerformanceBasedStockOptionGrantMember to erna_PerformanceBasedStockOptionGrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PerformanceBasedStockOptionGrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PerformanceBasedStockOptionGrantMember_lbl1" xml:lang="en-US" id="erna_PerformanceBasedStockOptionGrantMember_lbl1">Performance-Based Stock Option Grant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceBasedStockOptionGrantMember" xlink:to="erna_PerformanceBasedStockOptionGrantMember_lbl1" xlink:title="label: PerformanceBasedStockOptionGrantMember to erna_PerformanceBasedStockOptionGrantMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PerformanceBasedStockOptionGrantMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PerformanceBasedStockOptionGrantMember_lbl2" xml:lang="en-US" id="erna_PerformanceBasedStockOptionGrantMember_lbl2">Milestone Grant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceBasedStockOptionGrantMember" xlink:to="erna_PerformanceBasedStockOptionGrantMember_lbl2" xlink:title="label: PerformanceBasedStockOptionGrantMember to erna_PerformanceBasedStockOptionGrantMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeCommitmentToPurchaseProperty" xlink:label="LesseeCommitmentToPurchaseProperty" xlink:title="LesseeCommitmentToPurchaseProperty" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeCommitmentToPurchaseProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LesseeCommitmentToPurchaseProperty_lbl" xml:lang="en-US" id="erna_LesseeCommitmentToPurchaseProperty_lbl">The amount of property for which lessee committed to purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeCommitmentToPurchaseProperty" xlink:to="erna_LesseeCommitmentToPurchaseProperty_lbl" xlink:title="label: LesseeCommitmentToPurchaseProperty to erna_LesseeCommitmentToPurchaseProperty_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeCommitmentToPurchaseProperty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LesseeCommitmentToPurchaseProperty_lbl1" xml:lang="en-US" id="erna_LesseeCommitmentToPurchaseProperty_lbl1">Lessee, Commitment to Purchase Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeCommitmentToPurchaseProperty" xlink:to="erna_LesseeCommitmentToPurchaseProperty_lbl1" xlink:title="label: LesseeCommitmentToPurchaseProperty to erna_LesseeCommitmentToPurchaseProperty_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeCommitmentToPurchaseProperty_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LesseeCommitmentToPurchaseProperty_lbl2" xml:lang="en-US" id="erna_LesseeCommitmentToPurchaseProperty_lbl2">Commitment to purchase equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeCommitmentToPurchaseProperty" xlink:to="erna_LesseeCommitmentToPurchaseProperty_lbl2" xlink:title="label: LesseeCommitmentToPurchaseProperty to erna_LesseeCommitmentToPurchaseProperty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageBaseRentIncreaseOnEachAnniversary" xlink:label="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="PercentageBaseRentIncreaseOnEachAnniversary" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl" xml:lang="en-US" id="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl">The percentage of base rent increase on each anniversary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageBaseRentIncreaseOnEachAnniversary" xlink:to="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl" xlink:title="label: PercentageBaseRentIncreaseOnEachAnniversary to erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" xml:lang="en-US" id="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl1">Percentage, Base Rent Increase on each Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageBaseRentIncreaseOnEachAnniversary" xlink:to="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" xlink:title="label: PercentageBaseRentIncreaseOnEachAnniversary to erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" xml:lang="en-US" id="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl2">Percentage of increase in base rent on each year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageBaseRentIncreaseOnEachAnniversary" xlink:to="erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" xlink:title="label: PercentageBaseRentIncreaseOnEachAnniversary to erna_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseROUAssets" xlink:label="InitialMeasurementOfOperatingLeaseROUAssets" xlink:title="InitialMeasurementOfOperatingLeaseROUAssets" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl" xml:lang="en-US" id="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl">The fair value of initial measurement of operating lease ROU assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseROUAssets" xlink:to="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl" xlink:title="label: InitialMeasurementOfOperatingLeaseROUAssets to erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl1" xml:lang="en-US" id="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl1">Initial Measurement of Operating Lease ROU Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseROUAssets" xlink:to="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl1" xlink:title="label: InitialMeasurementOfOperatingLeaseROUAssets to erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl2" xml:lang="en-US" id="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl2">Initial measurement of operating lease ROU assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseROUAssets" xlink:to="erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl2" xlink:title="label: InitialMeasurementOfOperatingLeaseROUAssets to erna_InitialMeasurementOfOperatingLeaseROUAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_UnamortizedLeaseholdImprovements" xlink:label="UnamortizedLeaseholdImprovements" xlink:title="UnamortizedLeaseholdImprovements" />
    <link:label xlink:type="resource" xlink:label="erna_UnamortizedLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_UnamortizedLeaseholdImprovements_lbl" xml:lang="en-US" id="erna_UnamortizedLeaseholdImprovements_lbl">The amount of unamortized leasehold improvements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedLeaseholdImprovements" xlink:to="erna_UnamortizedLeaseholdImprovements_lbl" xlink:title="label: UnamortizedLeaseholdImprovements to erna_UnamortizedLeaseholdImprovements_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_UnamortizedLeaseholdImprovements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_UnamortizedLeaseholdImprovements_lbl1" xml:lang="en-US" id="erna_UnamortizedLeaseholdImprovements_lbl1">Unamortized Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedLeaseholdImprovements" xlink:to="erna_UnamortizedLeaseholdImprovements_lbl1" xlink:title="label: UnamortizedLeaseholdImprovements to erna_UnamortizedLeaseholdImprovements_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_UnamortizedLeaseholdImprovements_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_UnamortizedLeaseholdImprovements_lbl2" xml:lang="en-US" id="erna_UnamortizedLeaseholdImprovements_lbl2">Unamortized leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedLeaseholdImprovements" xlink:to="erna_UnamortizedLeaseholdImprovements_lbl2" xlink:title="label: UnamortizedLeaseholdImprovements to erna_UnamortizedLeaseholdImprovements_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeaseArea" xlink:label="OperatingLeaseArea" xlink:title="OperatingLeaseArea" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_OperatingLeaseArea_lbl" xml:lang="en-US" id="erna_OperatingLeaseArea_lbl">Area of leased property under operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseArea" xlink:to="erna_OperatingLeaseArea_lbl" xlink:title="label: OperatingLeaseArea to erna_OperatingLeaseArea_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseArea_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_OperatingLeaseArea_lbl1" xml:lang="en-US" id="erna_OperatingLeaseArea_lbl1">Operating Lease Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseArea" xlink:to="erna_OperatingLeaseArea_lbl1" xlink:title="label: OperatingLeaseArea to erna_OperatingLeaseArea_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_OperatingLeaseArea_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_OperatingLeaseArea_lbl2" xml:lang="en-US" id="erna_OperatingLeaseArea_lbl2">Operating lease area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseArea" xlink:to="erna_OperatingLeaseArea_lbl2" xlink:title="label: OperatingLeaseArea to erna_OperatingLeaseArea_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BaseRentPerSquareFoot" xlink:label="BaseRentPerSquareFoot" xlink:title="BaseRentPerSquareFoot" />
    <link:label xlink:type="resource" xlink:label="erna_BaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_BaseRentPerSquareFoot_lbl" xml:lang="en-US" id="erna_BaseRentPerSquareFoot_lbl">Amount of base rent expense per square foot for leased asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRentPerSquareFoot" xlink:to="erna_BaseRentPerSquareFoot_lbl" xlink:title="label: BaseRentPerSquareFoot to erna_BaseRentPerSquareFoot_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_BaseRentPerSquareFoot_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_BaseRentPerSquareFoot_lbl1" xml:lang="en-US" id="erna_BaseRentPerSquareFoot_lbl1">Base Rent per Square Foot</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRentPerSquareFoot" xlink:to="erna_BaseRentPerSquareFoot_lbl1" xlink:title="label: BaseRentPerSquareFoot to erna_BaseRentPerSquareFoot_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_BaseRentPerSquareFoot_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_BaseRentPerSquareFoot_lbl2" xml:lang="en-US" id="erna_BaseRentPerSquareFoot_lbl2">Base rent (per square foot)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRentPerSquareFoot" xlink:to="erna_BaseRentPerSquareFoot_lbl2" xlink:title="label: BaseRentPerSquareFoot to erna_BaseRentPerSquareFoot_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="LesseeOperatingAndFinanceLeasesTextBlock" xlink:title="LesseeOperatingAndFinanceLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xml:lang="en-US" id="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl">The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of lessee's finance and operating lease and maturity analysis of finance and operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:title="label: LesseeOperatingAndFinanceLeasesTextBlock to erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl1" xml:lang="en-US" id="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl1">Lessee Operating and Finance Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl1" xlink:title="label: LesseeOperatingAndFinanceLeasesTextBlock to erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl2" xml:lang="en-US" id="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl2">LEASES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl2" xlink:title="label: LesseeOperatingAndFinanceLeasesTextBlock to erna_LesseeOperatingAndFinanceLeasesTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl">Aggregate proceeds received from assume advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Assume Advance/Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2">Assume advance/loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBusinessMember" xlink:label="NTNBusinessMember" xlink:title="NTNBusinessMember" />
    <link:label xlink:type="resource" xlink:label="erna_NTNBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NTNBusinessMember_lbl" xml:lang="en-US" id="erna_NTNBusinessMember_lbl">Name of the disposal group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBusinessMember" xlink:to="erna_NTNBusinessMember_lbl" xlink:title="label: NTNBusinessMember to erna_NTNBusinessMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NTNBusinessMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NTNBusinessMember_lbl1" xml:lang="en-US" id="erna_NTNBusinessMember_lbl1">NTN Business [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBusinessMember" xlink:to="erna_NTNBusinessMember_lbl1" xlink:title="label: NTNBusinessMember to erna_NTNBusinessMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NTNBusinessMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NTNBusinessMember_lbl2" xml:lang="en-US" id="erna_NTNBusinessMember_lbl2">NTN Business [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBusinessMember" xlink:to="erna_NTNBusinessMember_lbl2" xlink:title="label: NTNBusinessMember to erna_NTNBusinessMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl">Amount classified as software development cost attributable to disposal group held for sale or disposed of.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts to erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1">Disposal Group, Including Discontinued Operation, Software development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts to erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2">Software development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts to erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl">Aggregate proceeds received from interest on advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Interest on Advance/Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2">Interest on advance/loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:label="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl">Amount classified as Lease liability attributable to disposal group held for sale or disposed of.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationLeaseLiability to erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1">Disposal Group, Including Discontinued Operation, Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationLeaseLiability to erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationLeaseLiability to erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl">Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromCash to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromCash to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromCash to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl">Aggregate proceeds received from escrow deposits in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Escrow</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2">Escrow</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow to erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromDispositionAbstract" xlink:label="ProceedsFromDispositionAbstract" xlink:title="ProceedsFromDispositionAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromDispositionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ProceedsFromDispositionAbstract_lbl1" xml:lang="en-US" id="erna_ProceedsFromDispositionAbstract_lbl1">Proceeds from Disposition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDispositionAbstract" xlink:to="erna_ProceedsFromDispositionAbstract_lbl1" xlink:title="label: ProceedsFromDispositionAbstract to erna_ProceedsFromDispositionAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromDispositionAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ProceedsFromDispositionAbstract_lbl2" xml:lang="en-US" id="erna_ProceedsFromDispositionAbstract_lbl2">Proceeds from sale [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDispositionAbstract" xlink:to="erna_ProceedsFromDispositionAbstract_lbl2" xlink:title="label: ProceedsFromDispositionAbstract to erna_ProceedsFromDispositionAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl">Amount of costs of the business disposal including legal, accounting, and other costs incurred to consummate the business disposition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationTransactionCosts to erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationTransactionCosts to erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationTransactionCosts to erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:label="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl">Amount classified as Obligations under finance leases attributable to disposal group held for sale or disposed of.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases to erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1">Disposal Group, Including Discontinued Operation, Obligations under finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases to erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" xml:lang="en-US" id="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2">Obligations under finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:to="erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases to erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DispositionAbstract" xlink:label="DispositionAbstract" xlink:title="DispositionAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_DispositionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DispositionAbstract_lbl1" xml:lang="en-US" id="erna_DispositionAbstract_lbl1">Disposition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DispositionAbstract" xlink:to="erna_DispositionAbstract_lbl1" xlink:title="label: DispositionAbstract to erna_DispositionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="erna_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PreFundedWarrantsMember_lbl" xml:lang="en-US" id="erna_PreFundedWarrantsMember_lbl">A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="erna_PreFundedWarrantsMember_lbl" xlink:title="label: PreFundedWarrantsMember to erna_PreFundedWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PreFundedWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PreFundedWarrantsMember_lbl1" xml:lang="en-US" id="erna_PreFundedWarrantsMember_lbl1">Pre-funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="erna_PreFundedWarrantsMember_lbl1" xlink:title="label: PreFundedWarrantsMember to erna_PreFundedWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PreFundedWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PreFundedWarrantsMember_lbl2" xml:lang="en-US" id="erna_PreFundedWarrantsMember_lbl2">Pre-funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="erna_PreFundedWarrantsMember_lbl2" xlink:title="label: PreFundedWarrantsMember to erna_PreFundedWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="erna_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CommonWarrantsMember_lbl" xml:lang="en-US" id="erna_CommonWarrantsMember_lbl">A common warrant represents the right to purchase a company's stock at a specific price and at a specific date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonWarrantsMember" xlink:to="erna_CommonWarrantsMember_lbl" xlink:title="label: CommonWarrantsMember to erna_CommonWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CommonWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CommonWarrantsMember_lbl1" xml:lang="en-US" id="erna_CommonWarrantsMember_lbl1">Common Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonWarrantsMember" xlink:to="erna_CommonWarrantsMember_lbl1" xlink:title="label: CommonWarrantsMember to erna_CommonWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CommonWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_CommonWarrantsMember_lbl2" xml:lang="en-US" id="erna_CommonWarrantsMember_lbl2">Common Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonWarrantsMember" xlink:to="erna_CommonWarrantsMember_lbl2" xlink:title="label: CommonWarrantsMember to erna_CommonWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OverSubscriptionAmountReceived" xlink:label="OverSubscriptionAmountReceived" xlink:title="OverSubscriptionAmountReceived" />
    <link:label xlink:type="resource" xlink:label="erna_OverSubscriptionAmountReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_OverSubscriptionAmountReceived_lbl" xml:lang="en-US" id="erna_OverSubscriptionAmountReceived_lbl">Over-subscription amount received in PIPE (Private Investment in Public Equity) transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverSubscriptionAmountReceived" xlink:to="erna_OverSubscriptionAmountReceived_lbl" xlink:title="label: OverSubscriptionAmountReceived to erna_OverSubscriptionAmountReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_OverSubscriptionAmountReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_OverSubscriptionAmountReceived_lbl1" xml:lang="en-US" id="erna_OverSubscriptionAmountReceived_lbl1">Over-Subscription Amount Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverSubscriptionAmountReceived" xlink:to="erna_OverSubscriptionAmountReceived_lbl1" xlink:title="label: OverSubscriptionAmountReceived to erna_OverSubscriptionAmountReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_OverSubscriptionAmountReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_OverSubscriptionAmountReceived_lbl2" xml:lang="en-US" id="erna_OverSubscriptionAmountReceived_lbl2">Over-subscription amount received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverSubscriptionAmountReceived" xlink:to="erna_OverSubscriptionAmountReceived_lbl2" xlink:title="label: OverSubscriptionAmountReceived to erna_OverSubscriptionAmountReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NewFacilityLeaseAbstract" xlink:label="NewFacilityLeaseAbstract" xlink:title="NewFacilityLeaseAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_NewFacilityLeaseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NewFacilityLeaseAbstract_lbl1" xml:lang="en-US" id="erna_NewFacilityLeaseAbstract_lbl1">New Facility Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewFacilityLeaseAbstract" xlink:to="erna_NewFacilityLeaseAbstract_lbl1" xlink:title="label: NewFacilityLeaseAbstract to erna_NewFacilityLeaseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:label="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" xml:lang="en-US" id="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1">Detailed information about Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" xlink:title="label: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" xml:lang="en-US" id="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2">Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" xlink:title="label: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChiefExecutiveOfficerAndPresidentMember" xlink:label="ChiefExecutiveOfficerAndPresidentMember" xlink:title="ChiefExecutiveOfficerAndPresidentMember" />
    <link:label xlink:type="resource" xlink:label="erna_ChiefExecutiveOfficerAndPresidentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ChiefExecutiveOfficerAndPresidentMember_lbl" xml:lang="en-US" id="erna_ChiefExecutiveOfficerAndPresidentMember_lbl">Person with designation of chief executive officer and president.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerAndPresidentMember" xlink:to="erna_ChiefExecutiveOfficerAndPresidentMember_lbl" xlink:title="label: ChiefExecutiveOfficerAndPresidentMember to erna_ChiefExecutiveOfficerAndPresidentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ChiefExecutiveOfficerAndPresidentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ChiefExecutiveOfficerAndPresidentMember_lbl1" xml:lang="en-US" id="erna_ChiefExecutiveOfficerAndPresidentMember_lbl1">Chief Executive Officer and President [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerAndPresidentMember" xlink:to="erna_ChiefExecutiveOfficerAndPresidentMember_lbl1" xlink:title="label: ChiefExecutiveOfficerAndPresidentMember to erna_ChiefExecutiveOfficerAndPresidentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ChiefExecutiveOfficerAndPresidentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ChiefExecutiveOfficerAndPresidentMember_lbl2" xml:lang="en-US" id="erna_ChiefExecutiveOfficerAndPresidentMember_lbl2">Dr. Federoff [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerAndPresidentMember" xlink:to="erna_ChiefExecutiveOfficerAndPresidentMember_lbl2" xlink:title="label: ChiefExecutiveOfficerAndPresidentMember to erna_ChiefExecutiveOfficerAndPresidentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EmployeeMember" xlink:label="EmployeeMember" xlink:title="EmployeeMember" />
    <link:label xlink:type="resource" xlink:label="erna_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_EmployeeMember_lbl" xml:lang="en-US" id="erna_EmployeeMember_lbl">One of the employee of the entity, appointed to the position.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeMember" xlink:to="erna_EmployeeMember_lbl" xlink:title="label: EmployeeMember to erna_EmployeeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_EmployeeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_EmployeeMember_lbl1" xml:lang="en-US" id="erna_EmployeeMember_lbl1">Employee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeMember" xlink:to="erna_EmployeeMember_lbl1" xlink:title="label: EmployeeMember to erna_EmployeeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_EmployeeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_EmployeeMember_lbl2" xml:lang="en-US" id="erna_EmployeeMember_lbl2">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeMember" xlink:to="erna_EmployeeMember_lbl2" xlink:title="label: EmployeeMember to erna_EmployeeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl">Represents the number of performance goals not achieved under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved to erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl1" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Performance Goal not Achieved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved to erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl2" xml:lang="en-US" id="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl2">Number of performance goals not achieved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:to="erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved to erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:label="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:title="NumberOfPerformanceGoalsAreSubjectToAchieve" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl" xml:lang="en-US" id="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl">The number of performance goals are subject to achieve under 2022 performance based restricted stock units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:to="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl" xlink:title="label: NumberOfPerformanceGoalsAreSubjectToAchieve to erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl1" xml:lang="en-US" id="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl1">Number of Performance Goals are Subject to Achieve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:to="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl1" xlink:title="label: NumberOfPerformanceGoalsAreSubjectToAchieve to erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl2" xml:lang="en-US" id="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl2">Number of performance goals are subject to achieve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:to="erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl2" xlink:title="label: NumberOfPerformanceGoalsAreSubjectToAchieve to erna_NumberOfPerformanceGoalsAreSubjectToAchieve_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_Two022PerformanceBasedRestrictedStockUnitsMember" xlink:label="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:title="Two022PerformanceBasedRestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US" id="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl">The name of awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:to="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:title="label: Two022PerformanceBasedRestrictedStockUnitsMember to erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl1" xml:lang="en-US" id="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl1">2022 Performance-Based Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:to="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl1" xlink:title="label: Two022PerformanceBasedRestrictedStockUnitsMember to erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl2" xml:lang="en-US" id="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl2">2022 PSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:to="erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl2" xlink:title="label: Two022PerformanceBasedRestrictedStockUnitsMember to erna_Two022PerformanceBasedRestrictedStockUnitsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockWithheldToCoverTaxes" xlink:label="CommonStockWithheldToCoverTaxes" xlink:title="CommonStockWithheldToCoverTaxes" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockWithheldToCoverTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CommonStockWithheldToCoverTaxes_lbl" xml:lang="en-US" id="erna_CommonStockWithheldToCoverTaxes_lbl">The number of shares of common stock withheld to cover the withholding taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWithheldToCoverTaxes" xlink:to="erna_CommonStockWithheldToCoverTaxes_lbl" xlink:title="label: CommonStockWithheldToCoverTaxes to erna_CommonStockWithheldToCoverTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockWithheldToCoverTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CommonStockWithheldToCoverTaxes_lbl1" xml:lang="en-US" id="erna_CommonStockWithheldToCoverTaxes_lbl1">Common Stock Withheld to Cover Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWithheldToCoverTaxes" xlink:to="erna_CommonStockWithheldToCoverTaxes_lbl1" xlink:title="label: CommonStockWithheldToCoverTaxes to erna_CommonStockWithheldToCoverTaxes_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockWithheldToCoverTaxes_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_CommonStockWithheldToCoverTaxes_lbl2" xml:lang="en-US" id="erna_CommonStockWithheldToCoverTaxes_lbl2">Common stock withheld to cover taxes (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWithheldToCoverTaxes" xlink:to="erna_CommonStockWithheldToCoverTaxes_lbl2" xlink:title="label: CommonStockWithheldToCoverTaxes to erna_CommonStockWithheldToCoverTaxes_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfAwardsVestedAndSettledAbstract" xlink:label="NumberOfAwardsVestedAndSettledAbstract" xlink:title="NumberOfAwardsVestedAndSettledAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfAwardsVestedAndSettledAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NumberOfAwardsVestedAndSettledAbstract_lbl1" xml:lang="en-US" id="erna_NumberOfAwardsVestedAndSettledAbstract_lbl1">Number of Awards Vested and Settled [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAwardsVestedAndSettledAbstract" xlink:to="erna_NumberOfAwardsVestedAndSettledAbstract_lbl1" xlink:title="label: NumberOfAwardsVestedAndSettledAbstract to erna_NumberOfAwardsVestedAndSettledAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfAwardsVestedAndSettledAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NumberOfAwardsVestedAndSettledAbstract_lbl2" xml:lang="en-US" id="erna_NumberOfAwardsVestedAndSettledAbstract_lbl2">Number of RSUs Vested and Settled [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAwardsVestedAndSettledAbstract" xlink:to="erna_NumberOfAwardsVestedAndSettledAbstract_lbl2" xlink:title="label: NumberOfAwardsVestedAndSettledAbstract to erna_NumberOfAwardsVestedAndSettledAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitPolicyTextBlock" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:title="ReverseStockSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="erna_ReverseStockSplitPolicyTextBlock_lbl">Disclosure of accounting policy for the reverse stock split during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitPolicyTextBlock" xlink:to="erna_ReverseStockSplitPolicyTextBlock_lbl" xlink:title="label: ReverseStockSplitPolicyTextBlock to erna_ReverseStockSplitPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ReverseStockSplitPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ReverseStockSplitPolicyTextBlock_lbl1" xml:lang="en-US" id="erna_ReverseStockSplitPolicyTextBlock_lbl1">Reverse Stock Split [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitPolicyTextBlock" xlink:to="erna_ReverseStockSplitPolicyTextBlock_lbl1" xlink:title="label: ReverseStockSplitPolicyTextBlock to erna_ReverseStockSplitPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ReverseStockSplitPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ReverseStockSplitPolicyTextBlock_lbl2" xml:lang="en-US" id="erna_ReverseStockSplitPolicyTextBlock_lbl2">Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitPolicyTextBlock" xlink:to="erna_ReverseStockSplitPolicyTextBlock_lbl2" xlink:title="label: ReverseStockSplitPolicyTextBlock to erna_ReverseStockSplitPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:label="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:title="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl" xml:lang="en-US" id="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl">Amount of cash outflow for fractional shares in connection with reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:to="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl" xlink:title="label: CashPaidForFractionalSharesInConnectionWithReverseStockSplit to erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl1" xml:lang="en-US" id="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl1">Cash Paid for Fractional Shares in Connection with Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:to="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl1" xlink:title="label: CashPaidForFractionalSharesInConnectionWithReverseStockSplit to erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl2" xml:lang="en-US" id="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl2">Amount paid for fractional share in connection with reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:to="erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl2" xlink:title="label: CashPaidForFractionalSharesInConnectionWithReverseStockSplit to erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_ReverseStockSplitAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ReverseStockSplitAbstract_lbl1" xml:lang="en-US" id="erna_ReverseStockSplitAbstract_lbl1">Reverse Stock-Split [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitAbstract" xlink:to="erna_ReverseStockSplitAbstract_lbl1" xlink:title="label: ReverseStockSplitAbstract to erna_ReverseStockSplitAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ReverseStockSplitAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_ReverseStockSplitAbstract_lbl2" xml:lang="en-US" id="erna_ReverseStockSplitAbstract_lbl2">Reverse Stock-Split [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitAbstract" xlink:to="erna_ReverseStockSplitAbstract_lbl2" xlink:title="label: ReverseStockSplitAbstract to erna_ReverseStockSplitAbstract_lbl2" />
    <link:label xlink:type="resource" xlink:label="erna_ReverseStockSplitAbstract_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ReverseStockSplitAbstract_lbl3" xml:lang="en-US" id="erna_ReverseStockSplitAbstract_lbl3">Reverse Stock-Split [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitAbstract" xlink:to="erna_ReverseStockSplitAbstract_lbl3" xlink:title="label: ReverseStockSplitAbstract to erna_ReverseStockSplitAbstract_lbl3" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfSharesConsideredAsFractionalInReverseStock" xlink:label="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:title="NumberOfSharesConsideredAsFractionalInReverseStock" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl" xml:lang="en-US" id="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl">Number of shares considered as fractional in reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:to="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl" xlink:title="label: NumberOfSharesConsideredAsFractionalInReverseStock to erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl1" xml:lang="en-US" id="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl1">Number of Shares Considered as Fractional in Reverse Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:to="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl1" xlink:title="label: NumberOfSharesConsideredAsFractionalInReverseStock to erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl2" xml:lang="en-US" id="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl2">Number of fractional shares considered in reverse stock split (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:to="erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl2" xlink:title="label: NumberOfSharesConsideredAsFractionalInReverseStock to erna_NumberOfSharesConsideredAsFractionalInReverseStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CollaboratorRoyaltyAgreementMember" xlink:label="CollaboratorRoyaltyAgreementMember" xlink:title="CollaboratorRoyaltyAgreementMember" />
    <link:label xlink:type="resource" xlink:label="erna_CollaboratorRoyaltyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CollaboratorRoyaltyAgreementMember_lbl" xml:lang="en-US" id="erna_CollaboratorRoyaltyAgreementMember_lbl">Collaborative royalty arrangement in licensing deal with the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaboratorRoyaltyAgreementMember" xlink:to="erna_CollaboratorRoyaltyAgreementMember_lbl" xlink:title="label: CollaboratorRoyaltyAgreementMember to erna_CollaboratorRoyaltyAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CollaboratorRoyaltyAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CollaboratorRoyaltyAgreementMember_lbl1" xml:lang="en-US" id="erna_CollaboratorRoyaltyAgreementMember_lbl1">Collaborator Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaboratorRoyaltyAgreementMember" xlink:to="erna_CollaboratorRoyaltyAgreementMember_lbl1" xlink:title="label: CollaboratorRoyaltyAgreementMember to erna_CollaboratorRoyaltyAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CollaboratorRoyaltyAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_CollaboratorRoyaltyAgreementMember_lbl2" xml:lang="en-US" id="erna_CollaboratorRoyaltyAgreementMember_lbl2">Collaborator Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaboratorRoyaltyAgreementMember" xlink:to="erna_CollaboratorRoyaltyAgreementMember_lbl2" xlink:title="label: CollaboratorRoyaltyAgreementMember to erna_CollaboratorRoyaltyAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InvestorRoyaltyAgreementMember" xlink:label="InvestorRoyaltyAgreementMember" xlink:title="InvestorRoyaltyAgreementMember" />
    <link:label xlink:type="resource" xlink:label="erna_InvestorRoyaltyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InvestorRoyaltyAgreementMember_lbl" xml:lang="en-US" id="erna_InvestorRoyaltyAgreementMember_lbl">Arrangement other than collaborative applicable to investor royalty.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorRoyaltyAgreementMember" xlink:to="erna_InvestorRoyaltyAgreementMember_lbl" xlink:title="label: InvestorRoyaltyAgreementMember to erna_InvestorRoyaltyAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InvestorRoyaltyAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InvestorRoyaltyAgreementMember_lbl1" xml:lang="en-US" id="erna_InvestorRoyaltyAgreementMember_lbl1">Investor Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorRoyaltyAgreementMember" xlink:to="erna_InvestorRoyaltyAgreementMember_lbl1" xlink:title="label: InvestorRoyaltyAgreementMember to erna_InvestorRoyaltyAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InvestorRoyaltyAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InvestorRoyaltyAgreementMember_lbl2" xml:lang="en-US" id="erna_InvestorRoyaltyAgreementMember_lbl2">Investor Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorRoyaltyAgreementMember" xlink:to="erna_InvestorRoyaltyAgreementMember_lbl2" xlink:title="label: InvestorRoyaltyAgreementMember to erna_InvestorRoyaltyAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:label="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" xml:lang="en-US" id="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl">Percentage of royalty receive equal to revenues generated from disposition of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:to="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" xlink:title="label: PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness to erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" xml:lang="en-US" id="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1">Percentage of Royalty Receive Equal to Revenues from Sale of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:to="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" xlink:title="label: PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness to erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" xml:lang="en-US" id="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2">Percentage of royalty receive equal to revenues from sale of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:to="erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" xlink:title="label: PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness to erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:label="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" xml:lang="en-US" id="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl">Percentage of additional royalty payable on gross sales by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:to="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" xlink:title="label: PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales to erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" xml:lang="en-US" id="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1">Percentage of Payment Of Additional Royalty On Gross Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:to="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" xlink:title="label: PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales to erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" xml:lang="en-US" id="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2">Percentage of payment of additional royalty on gross sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:to="erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" xlink:title="label: PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales to erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RoyaltyAgreementsAbstract" xlink:label="RoyaltyAgreementsAbstract" xlink:title="RoyaltyAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_RoyaltyAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_RoyaltyAgreementsAbstract_lbl1" xml:lang="en-US" id="erna_RoyaltyAgreementsAbstract_lbl1">Royalty Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyAgreementsAbstract" xlink:to="erna_RoyaltyAgreementsAbstract_lbl1" xlink:title="label: RoyaltyAgreementsAbstract to erna_RoyaltyAgreementsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_RoyaltyAgreementsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_RoyaltyAgreementsAbstract_lbl2" xml:lang="en-US" id="erna_RoyaltyAgreementsAbstract_lbl2">Royalty Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyAgreementsAbstract" xlink:to="erna_RoyaltyAgreementsAbstract_lbl2" xlink:title="label: RoyaltyAgreementsAbstract to erna_RoyaltyAgreementsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyDamagesSoughtExpectedSalary" xlink:label="LossContingencyDamagesSoughtExpectedSalary" xlink:title="LossContingencyDamagesSoughtExpectedSalary" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyDamagesSoughtExpectedSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LossContingencyDamagesSoughtExpectedSalary_lbl" xml:lang="en-US" id="erna_LossContingencyDamagesSoughtExpectedSalary_lbl">The monetary amount of salary promised to the plaintiff seeks in the legal matter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedSalary" xlink:to="erna_LossContingencyDamagesSoughtExpectedSalary_lbl" xlink:title="label: LossContingencyDamagesSoughtExpectedSalary to erna_LossContingencyDamagesSoughtExpectedSalary_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyDamagesSoughtExpectedSalary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LossContingencyDamagesSoughtExpectedSalary_lbl1" xml:lang="en-US" id="erna_LossContingencyDamagesSoughtExpectedSalary_lbl1">Loss Contingency, Damages Sought, Expected Salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedSalary" xlink:to="erna_LossContingencyDamagesSoughtExpectedSalary_lbl1" xlink:title="label: LossContingencyDamagesSoughtExpectedSalary to erna_LossContingencyDamagesSoughtExpectedSalary_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyDamagesSoughtExpectedSalary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LossContingencyDamagesSoughtExpectedSalary_lbl2" xml:lang="en-US" id="erna_LossContingencyDamagesSoughtExpectedSalary_lbl2">Defendants salary promised against plaintiff</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedSalary" xlink:to="erna_LossContingencyDamagesSoughtExpectedSalary_lbl2" xlink:title="label: LossContingencyDamagesSoughtExpectedSalary to erna_LossContingencyDamagesSoughtExpectedSalary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DheshGovenderMember" xlink:label="DheshGovenderMember" xlink:title="DheshGovenderMember" />
    <link:label xlink:type="resource" xlink:label="erna_DheshGovenderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DheshGovenderMember_lbl" xml:lang="en-US" id="erna_DheshGovenderMember_lbl">Dhesh Govender, a former short-term consultant of the entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DheshGovenderMember" xlink:to="erna_DheshGovenderMember_lbl" xlink:title="label: DheshGovenderMember to erna_DheshGovenderMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DheshGovenderMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DheshGovenderMember_lbl1" xml:lang="en-US" id="erna_DheshGovenderMember_lbl1">Dhesh Govender [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DheshGovenderMember" xlink:to="erna_DheshGovenderMember_lbl1" xlink:title="label: DheshGovenderMember to erna_DheshGovenderMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DheshGovenderMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DheshGovenderMember_lbl2" xml:lang="en-US" id="erna_DheshGovenderMember_lbl2">Govender [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DheshGovenderMember" xlink:to="erna_DheshGovenderMember_lbl2" xlink:title="label: DheshGovenderMember to erna_DheshGovenderMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusTherapeuticsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NovellusTherapeuticsLimitedMember_lbl" xml:lang="en-US" id="erna_NovellusTherapeuticsLimitedMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusTherapeuticsLimitedMember" xlink:to="erna_NovellusTherapeuticsLimitedMember_lbl" xlink:title="label: NovellusTherapeuticsLimitedMember to erna_NovellusTherapeuticsLimitedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusTherapeuticsLimitedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NovellusTherapeuticsLimitedMember_lbl1" xml:lang="en-US" id="erna_NovellusTherapeuticsLimitedMember_lbl1">Novellus Therapeutics Limited [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusTherapeuticsLimitedMember" xlink:to="erna_NovellusTherapeuticsLimitedMember_lbl1" xlink:title="label: NovellusTherapeuticsLimitedMember to erna_NovellusTherapeuticsLimitedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusTherapeuticsLimitedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NovellusTherapeuticsLimitedMember_lbl2" xml:lang="en-US" id="erna_NovellusTherapeuticsLimitedMember_lbl2">Novellus, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusTherapeuticsLimitedMember" xlink:to="erna_NovellusTherapeuticsLimitedMember_lbl2" xlink:title="label: NovellusTherapeuticsLimitedMember to erna_NovellusTherapeuticsLimitedMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:label="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="LossContingencyDamagesSoughtExpectedEquityPercentage" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" xml:lang="en-US" id="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl">The percentage of equity promised to the plaintiff seeks in the legal matter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:to="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" xlink:title="label: LossContingencyDamagesSoughtExpectedEquityPercentage to erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" xml:lang="en-US" id="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1">Loss Contingency, Damages Sought, Expected Equity Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:to="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" xlink:title="label: LossContingencyDamagesSoughtExpectedEquityPercentage to erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" xml:lang="en-US" id="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2">Percentage of equity promised against plaintiff</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:to="erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" xlink:title="label: LossContingencyDamagesSoughtExpectedEquityPercentage to erna_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyNumberOfArbitrationPanel" xlink:label="LossContingencyNumberOfArbitrationPanel" xlink:title="LossContingencyNumberOfArbitrationPanel" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyNumberOfArbitrationPanel_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LossContingencyNumberOfArbitrationPanel_lbl" xml:lang="en-US" id="erna_LossContingencyNumberOfArbitrationPanel_lbl">Represents the number member in arbitration panel pertaining to a loss contingency during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfArbitrationPanel" xlink:to="erna_LossContingencyNumberOfArbitrationPanel_lbl" xlink:title="label: LossContingencyNumberOfArbitrationPanel to erna_LossContingencyNumberOfArbitrationPanel_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyNumberOfArbitrationPanel_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LossContingencyNumberOfArbitrationPanel_lbl1" xml:lang="en-US" id="erna_LossContingencyNumberOfArbitrationPanel_lbl1">Loss Contingency, Number of Arbitration Panel Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfArbitrationPanel" xlink:to="erna_LossContingencyNumberOfArbitrationPanel_lbl1" xlink:title="label: LossContingencyNumberOfArbitrationPanel to erna_LossContingencyNumberOfArbitrationPanel_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LossContingencyNumberOfArbitrationPanel_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LossContingencyNumberOfArbitrationPanel_lbl2" xml:lang="en-US" id="erna_LossContingencyNumberOfArbitrationPanel_lbl2">Number of member arbitration panel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfArbitrationPanel" xlink:to="erna_LossContingencyNumberOfArbitrationPanel_lbl2" xlink:title="label: LossContingencyNumberOfArbitrationPanel to erna_LossContingencyNumberOfArbitrationPanel_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LegalMattersAbstract" xlink:label="LegalMattersAbstract" xlink:title="LegalMattersAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_LegalMattersAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LegalMattersAbstract_lbl1" xml:lang="en-US" id="erna_LegalMattersAbstract_lbl1">Legal Matters [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalMattersAbstract" xlink:to="erna_LegalMattersAbstract_lbl1" xlink:title="label: LegalMattersAbstract to erna_LegalMattersAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LegalMattersAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LegalMattersAbstract_lbl2" xml:lang="en-US" id="erna_LegalMattersAbstract_lbl2">Legal Matters [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalMattersAbstract" xlink:to="erna_LegalMattersAbstract_lbl2" xlink:title="label: LegalMattersAbstract to erna_LegalMattersAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProFormaFairValueAdjustmentToAssetsMember" xlink:label="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="ProFormaFairValueAdjustmentToAssetsMember" />
    <link:label xlink:type="resource" xlink:label="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl" xml:lang="en-US" id="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl">Fair value adjustment to acquisition-date assets reported in proforma information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaFairValueAdjustmentToAssetsMember" xlink:to="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl" xlink:title="label: ProFormaFairValueAdjustmentToAssetsMember to erna_ProFormaFairValueAdjustmentToAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl1" xml:lang="en-US" id="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl1">Pro Forma Fair Value Adjustment to Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaFairValueAdjustmentToAssetsMember" xlink:to="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl1" xlink:title="label: ProFormaFairValueAdjustmentToAssetsMember to erna_ProFormaFairValueAdjustmentToAssetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl2" xml:lang="en-US" id="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl2">Fair Value Adjustment to Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaFairValueAdjustmentToAssetsMember" xlink:to="erna_ProFormaFairValueAdjustmentToAssetsMember_lbl2" xlink:title="label: ProFormaFairValueAdjustmentToAssetsMember to erna_ProFormaFairValueAdjustmentToAssetsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PurchasePriceAllocationMember" xlink:label="PurchasePriceAllocationMember" xlink:title="PurchasePriceAllocationMember" />
    <link:label xlink:type="resource" xlink:label="erna_PurchasePriceAllocationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PurchasePriceAllocationMember_lbl" xml:lang="en-US" id="erna_PurchasePriceAllocationMember_lbl">Purchase price allocation of acquisition-date assets and liability assumed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchasePriceAllocationMember" xlink:to="erna_PurchasePriceAllocationMember_lbl" xlink:title="label: PurchasePriceAllocationMember to erna_PurchasePriceAllocationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PurchasePriceAllocationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PurchasePriceAllocationMember_lbl1" xml:lang="en-US" id="erna_PurchasePriceAllocationMember_lbl1">Purchase Price Allocation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchasePriceAllocationMember" xlink:to="erna_PurchasePriceAllocationMember_lbl1" xlink:title="label: PurchasePriceAllocationMember to erna_PurchasePriceAllocationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" xml:lang="en-US" id="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl">The amount of software development costs recognized as of the acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:to="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts to erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" xml:lang="en-US" id="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Software Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:to="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts to erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" xml:lang="en-US" id="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2">Software development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:to="erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts to erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BeneficialHoldersContractualCommitmentsToInvest" xlink:label="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="BeneficialHoldersContractualCommitmentsToInvest" />
    <link:label xlink:type="resource" xlink:label="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl" xml:lang="en-US" id="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl">Amount of contractual commitment made by beneficial holders to invest in the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialHoldersContractualCommitmentsToInvest" xlink:to="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl" xlink:title="label: BeneficialHoldersContractualCommitmentsToInvest to erna_BeneficialHoldersContractualCommitmentsToInvest_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl1" xml:lang="en-US" id="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl1">Beneficial Holders Contractual Commitments To Invest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialHoldersContractualCommitmentsToInvest" xlink:to="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl1" xlink:title="label: BeneficialHoldersContractualCommitmentsToInvest to erna_BeneficialHoldersContractualCommitmentsToInvest_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl2" xml:lang="en-US" id="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl2">Beneficial holders contractual commitments to invest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialHoldersContractualCommitmentsToInvest" xlink:to="erna_BeneficialHoldersContractualCommitmentsToInvest_lbl2" xlink:title="label: BeneficialHoldersContractualCommitmentsToInvest to erna_BeneficialHoldersContractualCommitmentsToInvest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:label="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" />
    <link:label xlink:type="resource" xlink:label="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" xml:lang="en-US" id="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl">Amount of cash and cash equivalents obligated to maintain under merger agreement on balance sheet at the effective time of the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:to="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" xlink:title="label: ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement to erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" xml:lang="en-US" id="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1">Obligated to Maintain Cash and Cash Equivalents Under Merger Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:to="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" xlink:title="label: ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement to erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" xml:lang="en-US" id="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2">Cash and cash equivalents obligated to have under merger agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:to="erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" xlink:title="label: ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement to erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:label xlink:type="resource" xlink:label="erna_NTNBuzztimeIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NTNBuzztimeIncMember_lbl" xml:lang="en-US" id="erna_NTNBuzztimeIncMember_lbl">Name of acquiree entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBuzztimeIncMember" xlink:to="erna_NTNBuzztimeIncMember_lbl" xlink:title="label: NTNBuzztimeIncMember to erna_NTNBuzztimeIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NTNBuzztimeIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NTNBuzztimeIncMember_lbl1" xml:lang="en-US" id="erna_NTNBuzztimeIncMember_lbl1">NTN Buzztime, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBuzztimeIncMember" xlink:to="erna_NTNBuzztimeIncMember_lbl1" xlink:title="label: NTNBuzztimeIncMember to erna_NTNBuzztimeIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NTNBuzztimeIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NTNBuzztimeIncMember_lbl2" xml:lang="en-US" id="erna_NTNBuzztimeIncMember_lbl2">NTN Buzztime, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBuzztimeIncMember" xlink:to="erna_NTNBuzztimeIncMember_lbl2" xlink:title="label: NTNBuzztimeIncMember to erna_NTNBuzztimeIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfAdditionalRightsOffering" xlink:label="PercentageOfAdditionalRightsOffering" xlink:title="PercentageOfAdditionalRightsOffering" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfAdditionalRightsOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PercentageOfAdditionalRightsOffering_lbl" xml:lang="en-US" id="erna_PercentageOfAdditionalRightsOffering_lbl">Percentage of additional right offering made by the entity for unit holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalRightsOffering" xlink:to="erna_PercentageOfAdditionalRightsOffering_lbl" xlink:title="label: PercentageOfAdditionalRightsOffering to erna_PercentageOfAdditionalRightsOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfAdditionalRightsOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PercentageOfAdditionalRightsOffering_lbl1" xml:lang="en-US" id="erna_PercentageOfAdditionalRightsOffering_lbl1">Percentage of Additional Rights Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalRightsOffering" xlink:to="erna_PercentageOfAdditionalRightsOffering_lbl1" xlink:title="label: PercentageOfAdditionalRightsOffering to erna_PercentageOfAdditionalRightsOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PercentageOfAdditionalRightsOffering_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PercentageOfAdditionalRightsOffering_lbl2" xml:lang="en-US" id="erna_PercentageOfAdditionalRightsOffering_lbl2">Percentage of additional rights offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalRightsOffering" xlink:to="erna_PercentageOfAdditionalRightsOffering_lbl2" xlink:title="label: PercentageOfAdditionalRightsOffering to erna_PercentageOfAdditionalRightsOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromSaleOfRights" xlink:label="ProceedsFromSaleOfRights" xlink:title="ProceedsFromSaleOfRights" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromSaleOfRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ProceedsFromSaleOfRights_lbl" xml:lang="en-US" id="erna_ProceedsFromSaleOfRights_lbl">The cash inflow from the sale of rights during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfRights" xlink:to="erna_ProceedsFromSaleOfRights_lbl" xlink:title="label: ProceedsFromSaleOfRights to erna_ProceedsFromSaleOfRights_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromSaleOfRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ProceedsFromSaleOfRights_lbl1" xml:lang="en-US" id="erna_ProceedsFromSaleOfRights_lbl1">Proceeds From Sale Of Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfRights" xlink:to="erna_ProceedsFromSaleOfRights_lbl1" xlink:title="label: ProceedsFromSaleOfRights to erna_ProceedsFromSaleOfRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromSaleOfRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ProceedsFromSaleOfRights_lbl2" xml:lang="en-US" id="erna_ProceedsFromSaleOfRights_lbl2">Proceeds from right offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfRights" xlink:to="erna_ProceedsFromSaleOfRights_lbl2" xlink:title="label: ProceedsFromSaleOfRights to erna_ProceedsFromSaleOfRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:label xlink:type="resource" xlink:label="erna_NoveCiteINCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NoveCiteINCMember_lbl" xml:lang="en-US" id="erna_NoveCiteINCMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteINCMember" xlink:to="erna_NoveCiteINCMember_lbl" xlink:title="label: NoveCiteINCMember to erna_NoveCiteINCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NoveCiteINCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NoveCiteINCMember_lbl1" xml:lang="en-US" id="erna_NoveCiteINCMember_lbl1">NoveCite, INC. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteINCMember" xlink:to="erna_NoveCiteINCMember_lbl1" xlink:title="label: NoveCiteINCMember to erna_NoveCiteINCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NoveCiteINCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NoveCiteINCMember_lbl2" xml:lang="en-US" id="erna_NoveCiteINCMember_lbl2">NoveCite, INC. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteINCMember" xlink:to="erna_NoveCiteINCMember_lbl2" xlink:title="label: NoveCiteINCMember to erna_NoveCiteINCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CitiusPharmaceuticalsIncMember" xlink:label="CitiusPharmaceuticalsIncMember" xlink:title="CitiusPharmaceuticalsIncMember" />
    <link:label xlink:type="resource" xlink:label="erna_CitiusPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CitiusPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="erna_CitiusPharmaceuticalsIncMember_lbl">Represents Citius Pharmaceuticals, Inc. Ownership interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CitiusPharmaceuticalsIncMember" xlink:to="erna_CitiusPharmaceuticalsIncMember_lbl" xlink:title="label: CitiusPharmaceuticalsIncMember to erna_CitiusPharmaceuticalsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CitiusPharmaceuticalsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CitiusPharmaceuticalsIncMember_lbl1" xml:lang="en-US" id="erna_CitiusPharmaceuticalsIncMember_lbl1">Citius Pharmaceuticals, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CitiusPharmaceuticalsIncMember" xlink:to="erna_CitiusPharmaceuticalsIncMember_lbl1" xlink:title="label: CitiusPharmaceuticalsIncMember to erna_CitiusPharmaceuticalsIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfBoardSeats" xlink:label="NumberOfBoardSeats" xlink:title="NumberOfBoardSeats" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfBoardSeats_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NumberOfBoardSeats_lbl" xml:lang="en-US" id="erna_NumberOfBoardSeats_lbl">Number of members of the company's management holds board seats on board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardSeats" xlink:to="erna_NumberOfBoardSeats_lbl" xlink:title="label: NumberOfBoardSeats to erna_NumberOfBoardSeats_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfBoardSeats_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NumberOfBoardSeats_lbl1" xml:lang="en-US" id="erna_NumberOfBoardSeats_lbl1">Number of Board Seats</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardSeats" xlink:to="erna_NumberOfBoardSeats_lbl1" xlink:title="label: NumberOfBoardSeats to erna_NumberOfBoardSeats_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfBoardSeats_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NumberOfBoardSeats_lbl2" xml:lang="en-US" id="erna_NumberOfBoardSeats_lbl2">Number of board seats</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardSeats" xlink:to="erna_NumberOfBoardSeats_lbl2" xlink:title="label: NumberOfBoardSeats to erna_NumberOfBoardSeats_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LiquidityAndCapitalResourcesTextBlock_lbl" xml:lang="en-US" id="erna_LiquidityAndCapitalResourcesTextBlock_lbl">The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="erna_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to erna_LiquidityAndCapitalResourcesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LiquidityAndCapitalResourcesTextBlock_lbl1" xml:lang="en-US" id="erna_LiquidityAndCapitalResourcesTextBlock_lbl1">Liquidity And Capital Resources [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="erna_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to erna_LiquidityAndCapitalResourcesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LiquidityAndCapitalResourcesTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LiquidityAndCapitalResourcesTextBlock_lbl2" xml:lang="en-US" id="erna_LiquidityAndCapitalResourcesTextBlock_lbl2">LIQUIDITY AND CAPITAL RESOURCES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="erna_LiquidityAndCapitalResourcesTextBlock_lbl2" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to erna_LiquidityAndCapitalResourcesTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:label="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:title="LIQUIDITYANDCAPITALRESOURCESAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_LIQUIDITYANDCAPITALRESOURCESAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LIQUIDITYANDCAPITALRESOURCESAbstract_lbl1" xml:lang="en-US" id="erna_LIQUIDITYANDCAPITALRESOURCESAbstract_lbl1">LIQUIDITY AND CAPITAL RESOURCES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:to="erna_LIQUIDITYANDCAPITALRESOURCESAbstract_lbl1" xlink:title="label: LIQUIDITYANDCAPITALRESOURCESAbstract to erna_LIQUIDITYANDCAPITALRESOURCESAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfFinanceLeaseLiabilities" xlink:label="InitialMeasurementOfFinanceLeaseLiabilities" xlink:title="InitialMeasurementOfFinanceLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl" xml:lang="en-US" id="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl">The fair value of initial measurement of finance lease liabilities in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfFinanceLeaseLiabilities" xlink:to="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl" xlink:title="label: InitialMeasurementOfFinanceLeaseLiabilities to erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl1" xml:lang="en-US" id="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl1">Initial Measurement of Finance Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfFinanceLeaseLiabilities" xlink:to="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl1" xlink:title="label: InitialMeasurementOfFinanceLeaseLiabilities to erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl2" xml:lang="en-US" id="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl2">Initial measurement of finance lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfFinanceLeaseLiabilities" xlink:to="erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl2" xlink:title="label: InitialMeasurementOfFinanceLeaseLiabilities to erna_InitialMeasurementOfFinanceLeaseLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseLiabilities" xlink:label="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="InitialMeasurementOfOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl">The fair value of initial measurement of operating lease liabilities in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseLiabilities" xlink:to="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl" xlink:title="label: InitialMeasurementOfOperatingLeaseLiabilities to erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl1">Initial Measurement of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseLiabilities" xlink:to="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" xlink:title="label: InitialMeasurementOfOperatingLeaseLiabilities to erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" xml:lang="en-US" id="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl2">Initial measurement of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseLiabilities" xlink:to="erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" xlink:title="label: InitialMeasurementOfOperatingLeaseLiabilities to erna_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockForAssetAcquisition" xlink:label="IssuanceOfCommonStockForAssetAcquisition" xlink:title="IssuanceOfCommonStockForAssetAcquisition" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockForAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_IssuanceOfCommonStockForAssetAcquisition_lbl" xml:lang="en-US" id="erna_IssuanceOfCommonStockForAssetAcquisition_lbl">The issuance of common stock for asset acquisition in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForAssetAcquisition" xlink:to="erna_IssuanceOfCommonStockForAssetAcquisition_lbl" xlink:title="label: IssuanceOfCommonStockForAssetAcquisition to erna_IssuanceOfCommonStockForAssetAcquisition_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockForAssetAcquisition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_IssuanceOfCommonStockForAssetAcquisition_lbl1" xml:lang="en-US" id="erna_IssuanceOfCommonStockForAssetAcquisition_lbl1">Issuance of Common Stock for Asset Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForAssetAcquisition" xlink:to="erna_IssuanceOfCommonStockForAssetAcquisition_lbl1" xlink:title="label: IssuanceOfCommonStockForAssetAcquisition to erna_IssuanceOfCommonStockForAssetAcquisition_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockForAssetAcquisition_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_IssuanceOfCommonStockForAssetAcquisition_lbl2" xml:lang="en-US" id="erna_IssuanceOfCommonStockForAssetAcquisition_lbl2">Issuance of common Stock for Novellus acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForAssetAcquisition" xlink:to="erna_IssuanceOfCommonStockForAssetAcquisition_lbl2" xlink:title="label: IssuanceOfCommonStockForAssetAcquisition to erna_IssuanceOfCommonStockForAssetAcquisition_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:label="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:title="IssuanceOfCommonStockForSeriesAPreferredStockDividend" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" xml:lang="en-US" id="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl">The fair value of issuance of common stock for Series A preferred stock dividend in non-cash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:to="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" xlink:title="label: IssuanceOfCommonStockForSeriesAPreferredStockDividend to erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" xml:lang="en-US" id="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1">Issuance of Common Stock for Series A Preferred Stock Dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:to="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" xlink:title="label: IssuanceOfCommonStockForSeriesAPreferredStockDividend to erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" xml:lang="en-US" id="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2">Issuance of common stock for Series A preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:to="erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" xlink:title="label: IssuanceOfCommonStockForSeriesAPreferredStockDividend to erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:label="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:title="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl" xml:lang="en-US" id="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl">Amount of cash outflow for accrual of fractional shares to be paid in connection with reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:to="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl" xlink:title="label: AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit to erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl1" xml:lang="en-US" id="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl1">Accrual for Fractional Shares to be Paid in Connection with Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:to="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl1" xlink:title="label: AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit to erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl2" xml:lang="en-US" id="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl2">Accrual for fractional shares to be paid in connection with reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:to="erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl2" xlink:title="label: AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit to erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsToAcquireProductiveAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PaymentsToAcquireProductiveAssetsNet_lbl" xml:lang="en-US" id="erna_PaymentsToAcquireProductiveAssetsNet_lbl">The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="erna_PaymentsToAcquireProductiveAssetsNet_lbl" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to erna_PaymentsToAcquireProductiveAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsToAcquireProductiveAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PaymentsToAcquireProductiveAssetsNet_lbl1" xml:lang="en-US" id="erna_PaymentsToAcquireProductiveAssetsNet_lbl1">Cash paid, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="erna_PaymentsToAcquireProductiveAssetsNet_lbl1" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to erna_PaymentsToAcquireProductiveAssetsNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsToAcquireProductiveAssetsNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PaymentsToAcquireProductiveAssetsNet_lbl2" xml:lang="en-US" id="erna_PaymentsToAcquireProductiveAssetsNet_lbl2">Cash paid, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="erna_PaymentsToAcquireProductiveAssetsNet_lbl2" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to erna_PaymentsToAcquireProductiveAssetsNet_lbl2" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsToAcquireProductiveAssetsNet_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_PaymentsToAcquireProductiveAssetsNet_lbl3" xml:lang="en-US" id="erna_PaymentsToAcquireProductiveAssetsNet_lbl3">Purchase of Novellus, net of common stock issue and cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="erna_PaymentsToAcquireProductiveAssetsNet_lbl3" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to erna_PaymentsToAcquireProductiveAssetsNet_lbl3" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:label="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:title="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl" xml:lang="en-US" id="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl">Amount of cash flows from issuance of common stock from exercise of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:to="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl" xlink:title="label: IssuanceOfCommonStockFromExerciseOfPreFundedWarrants to erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl1" xml:lang="en-US" id="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl1">Issuance of Common Stock from Exercise of Pre-funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:to="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl1" xlink:title="label: IssuanceOfCommonStockFromExerciseOfPreFundedWarrants to erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl2" xml:lang="en-US" id="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl2">Issuance of common stock from exercise of pre-funded warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:to="erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl2" xlink:title="label: IssuanceOfCommonStockFromExerciseOfPreFundedWarrants to erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:label="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" />
    <link:label xlink:type="resource" xlink:label="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US" id="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl">Amount of gain (loss) on forgiveness of PPP loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:title="label: GainLossOnForgivenessOfPaycheckProtectionProgramLoan to erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" xml:lang="en-US" id="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1">Gain (Loss) on Forgiveness of Paycheck Protection Program Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" xlink:title="label: GainLossOnForgivenessOfPaycheckProtectionProgramLoan to erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" xml:lang="en-US" id="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2">Gain on forgiveness of PPP loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" xlink:title="label: GainLossOnForgivenessOfPaycheckProtectionProgramLoan to erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:label xlink:type="resource" xlink:label="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" xml:lang="en-US" id="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl">The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" xml:lang="en-US" id="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1">Research and Development in Process, Asset Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" xml:lang="en-US" id="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" />
    <link:label xlink:type="resource" xlink:label="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" xml:lang="en-US" id="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3">In-process R&amp;D acquired in Novellus asset acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to erna_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ConversionOfWarrantLiabilityToEquity" xlink:label="ConversionOfWarrantLiabilityToEquity" xlink:title="ConversionOfWarrantLiabilityToEquity" />
    <link:label xlink:type="resource" xlink:label="erna_ConversionOfWarrantLiabilityToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ConversionOfWarrantLiabilityToEquity_lbl" xml:lang="en-US" id="erna_ConversionOfWarrantLiabilityToEquity_lbl">The conversion of warrant liability to equity in non-cash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfWarrantLiabilityToEquity" xlink:to="erna_ConversionOfWarrantLiabilityToEquity_lbl" xlink:title="label: ConversionOfWarrantLiabilityToEquity to erna_ConversionOfWarrantLiabilityToEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ConversionOfWarrantLiabilityToEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ConversionOfWarrantLiabilityToEquity_lbl1" xml:lang="en-US" id="erna_ConversionOfWarrantLiabilityToEquity_lbl1">Conversion of Warrant Liability to Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfWarrantLiabilityToEquity" xlink:to="erna_ConversionOfWarrantLiabilityToEquity_lbl1" xlink:title="label: ConversionOfWarrantLiabilityToEquity to erna_ConversionOfWarrantLiabilityToEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ConversionOfWarrantLiabilityToEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ConversionOfWarrantLiabilityToEquity_lbl2" xml:lang="en-US" id="erna_ConversionOfWarrantLiabilityToEquity_lbl2">Conversion of warrant liability to equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfWarrantLiabilityToEquity" xlink:to="erna_ConversionOfWarrantLiabilityToEquity_lbl2" xlink:title="label: ConversionOfWarrantLiabilityToEquity to erna_ConversionOfWarrantLiabilityToEquity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:label="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:title="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" />
    <link:label xlink:type="resource" xlink:label="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl" xml:lang="en-US" id="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl">The cash inflow from the fees incurred in connection with the common stock issued to Lincoln Park to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:to="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl" xlink:title="label: FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark to erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl1" xml:lang="en-US" id="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl1">Fees Incurred in Connection With the Common Stock Issued to Lincoln Park</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:to="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl1" xlink:title="label: FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark to erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl2" xml:lang="en-US" id="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl2">Fees incurred in connection with the common stock issued to Lincoln Park</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:to="erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl2" xlink:title="label: FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark to erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:label="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:title="ProceedsFromIssuanceOfCommonStockToLincolnPark" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl" xml:lang="en-US" id="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl">The cash inflow from the proceeds from issuance of common stock to Lincoln Park to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:to="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStockToLincolnPark to erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl1" xml:lang="en-US" id="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl1">Proceeds From Issuance of Common Stock to Lincoln Park</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:to="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStockToLincolnPark to erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl2" xml:lang="en-US" id="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl2">Proceeds from issuance of common stock to Lincoln Park</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:to="erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStockToLincolnPark to erna_ProceedsFromIssuanceOfCommonStockToLincolnPark_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:label="InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:title="InitialMeasurementOfRightOfUseAssetsAndLiabilities" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US" id="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl">The fair value of Initial measurement of ROU assets and liabilities in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:to="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl" xlink:title="label: InitialMeasurementOfRightOfUseAssetsAndLiabilities to erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl1" xml:lang="en-US" id="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl1">Initial Measurement of Right-of-Use Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:to="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl1" xlink:title="label: InitialMeasurementOfRightOfUseAssetsAndLiabilities to erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl2" xml:lang="en-US" id="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl2">Initial measurement of ROU assets, net of tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:to="erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl2" xlink:title="label: InitialMeasurementOfRightOfUseAssetsAndLiabilities to erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainLossOnDisposalOfFixedAssets" xlink:label="GainLossOnDisposalOfFixedAssets" xlink:title="GainLossOnDisposalOfFixedAssets" />
    <link:label xlink:type="resource" xlink:label="erna_GainLossOnDisposalOfFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_GainLossOnDisposalOfFixedAssets_lbl" xml:lang="en-US" id="erna_GainLossOnDisposalOfFixedAssets_lbl">Amount of gain (loss) on sale or disposal of fixed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDisposalOfFixedAssets" xlink:to="erna_GainLossOnDisposalOfFixedAssets_lbl" xlink:title="label: GainLossOnDisposalOfFixedAssets to erna_GainLossOnDisposalOfFixedAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_GainLossOnDisposalOfFixedAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_GainLossOnDisposalOfFixedAssets_lbl1" xml:lang="en-US" id="erna_GainLossOnDisposalOfFixedAssets_lbl1">Gain (Loss) on Disposal of Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDisposalOfFixedAssets" xlink:to="erna_GainLossOnDisposalOfFixedAssets_lbl1" xlink:title="label: GainLossOnDisposalOfFixedAssets to erna_GainLossOnDisposalOfFixedAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_GainLossOnDisposalOfFixedAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_GainLossOnDisposalOfFixedAssets_lbl2" xml:lang="en-US" id="erna_GainLossOnDisposalOfFixedAssets_lbl2">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDisposalOfFixedAssets" xlink:to="erna_GainLossOnDisposalOfFixedAssets_lbl2" xlink:title="label: GainLossOnDisposalOfFixedAssets to erna_GainLossOnDisposalOfFixedAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl">The increase (decrease) during the reporting period in the operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiabilities to erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiabilities to erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" xml:lang="en-US" id="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiabilities to erna_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WarrantLiabilitiesExpense" xlink:label="WarrantLiabilitiesExpense" xlink:title="WarrantLiabilitiesExpense" />
    <link:label xlink:type="resource" xlink:label="erna_WarrantLiabilitiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_WarrantLiabilitiesExpense_lbl" xml:lang="en-US" id="erna_WarrantLiabilitiesExpense_lbl">Amount of expenses related to warrant liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesExpense" xlink:to="erna_WarrantLiabilitiesExpense_lbl" xlink:title="label: WarrantLiabilitiesExpense to erna_WarrantLiabilitiesExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_WarrantLiabilitiesExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_WarrantLiabilitiesExpense_lbl1" xml:lang="en-US" id="erna_WarrantLiabilitiesExpense_lbl1">Warrant Liabilities Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesExpense" xlink:to="erna_WarrantLiabilitiesExpense_lbl1" xlink:title="label: WarrantLiabilitiesExpense to erna_WarrantLiabilitiesExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_WarrantLiabilitiesExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_WarrantLiabilitiesExpense_lbl2" xml:lang="en-US" id="erna_WarrantLiabilitiesExpense_lbl2">Gain on lease warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesExpense" xlink:to="erna_WarrantLiabilitiesExpense_lbl2" xlink:title="label: WarrantLiabilitiesExpense to erna_WarrantLiabilitiesExpense_lbl2" />
    <link:label xlink:type="resource" xlink:label="erna_WarrantLiabilitiesExpense_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_WarrantLiabilitiesExpense_lbl3" xml:lang="en-US" id="erna_WarrantLiabilitiesExpense_lbl3">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesExpense" xlink:to="erna_WarrantLiabilitiesExpense_lbl3" xlink:title="label: WarrantLiabilitiesExpense to erna_WarrantLiabilitiesExpense_lbl3" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossOnNonControllingInvestment" xlink:label="LossOnNonControllingInvestment" xlink:title="LossOnNonControllingInvestment" />
    <link:label xlink:type="resource" xlink:label="erna_LossOnNonControllingInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LossOnNonControllingInvestment_lbl" xml:lang="en-US" id="erna_LossOnNonControllingInvestment_lbl">Amount of loss on non-controlling investment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossOnNonControllingInvestment" xlink:to="erna_LossOnNonControllingInvestment_lbl" xlink:title="label: LossOnNonControllingInvestment to erna_LossOnNonControllingInvestment_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LossOnNonControllingInvestment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LossOnNonControllingInvestment_lbl1" xml:lang="en-US" id="erna_LossOnNonControllingInvestment_lbl1">Loss on Non-controlling Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossOnNonControllingInvestment" xlink:to="erna_LossOnNonControllingInvestment_lbl1" xlink:title="label: LossOnNonControllingInvestment to erna_LossOnNonControllingInvestment_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LossOnNonControllingInvestment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LossOnNonControllingInvestment_lbl2" xml:lang="en-US" id="erna_LossOnNonControllingInvestment_lbl2">Loss on non-controlling investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossOnNonControllingInvestment" xlink:to="erna_LossOnNonControllingInvestment_lbl2" xlink:title="label: LossOnNonControllingInvestment to erna_LossOnNonControllingInvestment_lbl2" />
    <link:label xlink:type="resource" xlink:label="erna_LossOnNonControllingInvestment_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_LossOnNonControllingInvestment_lbl3" xml:lang="en-US" id="erna_LossOnNonControllingInvestment_lbl3">Loss on non-controlling investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossOnNonControllingInvestment" xlink:to="erna_LossOnNonControllingInvestment_lbl3" xlink:title="label: LossOnNonControllingInvestment to erna_LossOnNonControllingInvestment_lbl3" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainOnTerminationOfLease" xlink:label="GainOnTerminationOfLease" xlink:title="GainOnTerminationOfLease" />
    <link:label xlink:type="resource" xlink:label="erna_GainOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_GainOnTerminationOfLease_lbl" xml:lang="en-US" id="erna_GainOnTerminationOfLease_lbl">Amount of gain on termination of lease before expiration of lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainOnTerminationOfLease" xlink:to="erna_GainOnTerminationOfLease_lbl" xlink:title="label: GainOnTerminationOfLease to erna_GainOnTerminationOfLease_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_GainOnTerminationOfLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_GainOnTerminationOfLease_lbl1" xml:lang="en-US" id="erna_GainOnTerminationOfLease_lbl1">Gain on Termination of Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainOnTerminationOfLease" xlink:to="erna_GainOnTerminationOfLease_lbl1" xlink:title="label: GainOnTerminationOfLease to erna_GainOnTerminationOfLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_GainOnTerminationOfLease_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_GainOnTerminationOfLease_lbl2" xml:lang="en-US" id="erna_GainOnTerminationOfLease_lbl2">Gain on lease termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainOnTerminationOfLease" xlink:to="erna_GainOnTerminationOfLease_lbl2" xlink:title="label: GainOnTerminationOfLease to erna_GainOnTerminationOfLease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CashPaidDuringThePeriodForAbstract" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:title="CashPaidDuringThePeriodForAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_CashPaidDuringThePeriodForAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CashPaidDuringThePeriodForAbstract_lbl1" xml:lang="en-US" id="erna_CashPaidDuringThePeriodForAbstract_lbl1">Cash Paid During the Period for [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="erna_CashPaidDuringThePeriodForAbstract_lbl1" xlink:title="label: CashPaidDuringThePeriodForAbstract to erna_CashPaidDuringThePeriodForAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CashPaidDuringThePeriodForAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_CashPaidDuringThePeriodForAbstract_lbl2" xml:lang="en-US" id="erna_CashPaidDuringThePeriodForAbstract_lbl2">Cash paid during the period for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="erna_CashPaidDuringThePeriodForAbstract_lbl2" xlink:title="label: CashPaidDuringThePeriodForAbstract to erna_CashPaidDuringThePeriodForAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsOfPaycheckProtectionProgramLoan" xlink:label="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="PaymentsOfPaycheckProtectionProgramLoan" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US" id="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl">The amount of cash outflow for payment of paycheck protection program loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfPaycheckProtectionProgramLoan" xlink:to="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl" xlink:title="label: PaymentsOfPaycheckProtectionProgramLoan to erna_PaymentsOfPaycheckProtectionProgramLoan_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl1" xml:lang="en-US" id="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl1">Payments of Paycheck Protection Program Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfPaycheckProtectionProgramLoan" xlink:to="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl1" xlink:title="label: PaymentsOfPaycheckProtectionProgramLoan to erna_PaymentsOfPaycheckProtectionProgramLoan_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl2" xml:lang="en-US" id="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl2">Repayment of NTN's PPP loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfPaycheckProtectionProgramLoan" xlink:to="erna_PaymentsOfPaycheckProtectionProgramLoan_lbl2" xlink:title="label: PaymentsOfPaycheckProtectionProgramLoan to erna_PaymentsOfPaycheckProtectionProgramLoan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:label="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:title="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" />
    <link:label xlink:type="resource" xlink:label="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" xml:lang="en-US" id="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl">The fair value of preferred stock issued in a reverse merger transaction in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:to="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger to erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" xml:lang="en-US" id="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1">Noncash or Part Noncash Acquisition, Preferred Shares Issued in Connection with Reverse Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:to="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" xlink:title="label: NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger to erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" xml:lang="en-US" id="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2">Series A preferred stock retained in business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:to="erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" xlink:title="label: NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger to erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionUnrestrictedSharesSharePrice" xlink:label="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="AssetAcquisitionUnrestrictedSharesSharePrice" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" xml:lang="en-US" id="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl">Price of a single share of a number of saleable stocks paid or offered without any restrictions to be paid in asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:to="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" xlink:title="label: AssetAcquisitionUnrestrictedSharesSharePrice to erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" xml:lang="en-US" id="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1">Asset Acquisition, Unrestricted Shares, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:to="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" xlink:title="label: AssetAcquisitionUnrestrictedSharesSharePrice to erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" xml:lang="en-US" id="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2">Unrestricted shares, fair value per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:to="erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" xlink:title="label: AssetAcquisitionUnrestrictedSharesSharePrice to erna_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl">Number of shares of stock issued with restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:to="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesAcquisitions to erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1">Stock Issued During Period, Restricted Shares, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:to="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesAcquisitions to erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2">Restricted shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:to="erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesAcquisitions to erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusIncMember" xlink:label="NovellusIncMember" xlink:title="NovellusIncMember" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NovellusIncMember_lbl" xml:lang="en-US" id="erna_NovellusIncMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusIncMember" xlink:to="erna_NovellusIncMember_lbl" xlink:title="label: NovellusIncMember to erna_NovellusIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NovellusIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NovellusIncMember_lbl1" xml:lang="en-US" id="erna_NovellusIncMember_lbl1">Novellus, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusIncMember" xlink:to="erna_NovellusIncMember_lbl1" xlink:title="label: NovellusIncMember to erna_NovellusIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LockUpPeriodForRestrictedShares" xlink:label="LockUpPeriodForRestrictedShares" xlink:title="LockUpPeriodForRestrictedShares" />
    <link:label xlink:type="resource" xlink:label="erna_LockUpPeriodForRestrictedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LockUpPeriodForRestrictedShares_lbl" xml:lang="en-US" id="erna_LockUpPeriodForRestrictedShares_lbl">The period in which shares are locked-up, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpPeriodForRestrictedShares" xlink:to="erna_LockUpPeriodForRestrictedShares_lbl" xlink:title="label: LockUpPeriodForRestrictedShares to erna_LockUpPeriodForRestrictedShares_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LockUpPeriodForRestrictedShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LockUpPeriodForRestrictedShares_lbl1" xml:lang="en-US" id="erna_LockUpPeriodForRestrictedShares_lbl1">Lock-up Period for Restricted Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpPeriodForRestrictedShares" xlink:to="erna_LockUpPeriodForRestrictedShares_lbl1" xlink:title="label: LockUpPeriodForRestrictedShares to erna_LockUpPeriodForRestrictedShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_LockUpPeriodForRestrictedShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_LockUpPeriodForRestrictedShares_lbl2" xml:lang="en-US" id="erna_LockUpPeriodForRestrictedShares_lbl2">Lock-up period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpPeriodForRestrictedShares" xlink:to="erna_LockUpPeriodForRestrictedShares_lbl2" xlink:title="label: LockUpPeriodForRestrictedShares to erna_LockUpPeriodForRestrictedShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:label xlink:type="resource" xlink:label="erna_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="erna_AccruedResearchAndDevelopmentExpenses_lbl">Amount of accrued research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpenses" xlink:to="erna_AccruedResearchAndDevelopmentExpenses_lbl" xlink:title="label: AccruedResearchAndDevelopmentExpenses to erna_AccruedResearchAndDevelopmentExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AccruedResearchAndDevelopmentExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AccruedResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US" id="erna_AccruedResearchAndDevelopmentExpenses_lbl1">Accrued Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpenses" xlink:to="erna_AccruedResearchAndDevelopmentExpenses_lbl1" xlink:title="label: AccruedResearchAndDevelopmentExpenses to erna_AccruedResearchAndDevelopmentExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AccruedResearchAndDevelopmentExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AccruedResearchAndDevelopmentExpenses_lbl2" xml:lang="en-US" id="erna_AccruedResearchAndDevelopmentExpenses_lbl2">Accrued research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpenses" xlink:to="erna_AccruedResearchAndDevelopmentExpenses_lbl2" xlink:title="label: AccruedResearchAndDevelopmentExpenses to erna_AccruedResearchAndDevelopmentExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:label xlink:type="resource" xlink:label="erna_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AccruedGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="erna_AccruedGeneralAndAdministrativeExpenses_lbl">Amount of accrued general and administrative expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedGeneralAndAdministrativeExpenses" xlink:to="erna_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:title="label: AccruedGeneralAndAdministrativeExpenses to erna_AccruedGeneralAndAdministrativeExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AccruedGeneralAndAdministrativeExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AccruedGeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US" id="erna_AccruedGeneralAndAdministrativeExpenses_lbl1">Accrued General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedGeneralAndAdministrativeExpenses" xlink:to="erna_AccruedGeneralAndAdministrativeExpenses_lbl1" xlink:title="label: AccruedGeneralAndAdministrativeExpenses to erna_AccruedGeneralAndAdministrativeExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AccruedGeneralAndAdministrativeExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AccruedGeneralAndAdministrativeExpenses_lbl2" xml:lang="en-US" id="erna_AccruedGeneralAndAdministrativeExpenses_lbl2">Accrued general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedGeneralAndAdministrativeExpenses" xlink:to="erna_AccruedGeneralAndAdministrativeExpenses_lbl2" xlink:title="label: AccruedGeneralAndAdministrativeExpenses to erna_AccruedGeneralAndAdministrativeExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InsurancePolicyPremiums" xlink:label="InsurancePolicyPremiums" xlink:title="InsurancePolicyPremiums" />
    <link:label xlink:type="resource" xlink:label="erna_InsurancePolicyPremiums_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_InsurancePolicyPremiums_lbl" xml:lang="en-US" id="erna_InsurancePolicyPremiums_lbl">Amount of liability for insurance policy premiums.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsurancePolicyPremiums" xlink:to="erna_InsurancePolicyPremiums_lbl" xlink:title="label: InsurancePolicyPremiums to erna_InsurancePolicyPremiums_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_InsurancePolicyPremiums_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_InsurancePolicyPremiums_lbl1" xml:lang="en-US" id="erna_InsurancePolicyPremiums_lbl1">Insurance Policy Premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsurancePolicyPremiums" xlink:to="erna_InsurancePolicyPremiums_lbl1" xlink:title="label: InsurancePolicyPremiums to erna_InsurancePolicyPremiums_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_InsurancePolicyPremiums_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_InsurancePolicyPremiums_lbl2" xml:lang="en-US" id="erna_InsurancePolicyPremiums_lbl2">Insurance policy premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsurancePolicyPremiums" xlink:to="erna_InsurancePolicyPremiums_lbl2" xlink:title="label: InsurancePolicyPremiums to erna_InsurancePolicyPremiums_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CurrentPortionOfLicenseFeeObligation" xlink:label="CurrentPortionOfLicenseFeeObligation" xlink:title="CurrentPortionOfLicenseFeeObligation" />
    <link:label xlink:type="resource" xlink:label="erna_CurrentPortionOfLicenseFeeObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CurrentPortionOfLicenseFeeObligation_lbl" xml:lang="en-US" id="erna_CurrentPortionOfLicenseFeeObligation_lbl">Current portion of License Fee Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentPortionOfLicenseFeeObligation" xlink:to="erna_CurrentPortionOfLicenseFeeObligation_lbl" xlink:title="label: CurrentPortionOfLicenseFeeObligation to erna_CurrentPortionOfLicenseFeeObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CurrentPortionOfLicenseFeeObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CurrentPortionOfLicenseFeeObligation_lbl1" xml:lang="en-US" id="erna_CurrentPortionOfLicenseFeeObligation_lbl1">Current portion of License Fee Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentPortionOfLicenseFeeObligation" xlink:to="erna_CurrentPortionOfLicenseFeeObligation_lbl1" xlink:title="label: CurrentPortionOfLicenseFeeObligation to erna_CurrentPortionOfLicenseFeeObligation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LongTermPortionOfLicenseFeeObligation" xlink:label="LongTermPortionOfLicenseFeeObligation" xlink:title="LongTermPortionOfLicenseFeeObligation" />
    <link:label xlink:type="resource" xlink:label="erna_LongTermPortionOfLicenseFeeObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_LongTermPortionOfLicenseFeeObligation_lbl" xml:lang="en-US" id="erna_LongTermPortionOfLicenseFeeObligation_lbl">Long-term portion of License Fee Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPortionOfLicenseFeeObligation" xlink:to="erna_LongTermPortionOfLicenseFeeObligation_lbl" xlink:title="label: LongTermPortionOfLicenseFeeObligation to erna_LongTermPortionOfLicenseFeeObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_LongTermPortionOfLicenseFeeObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_LongTermPortionOfLicenseFeeObligation_lbl1" xml:lang="en-US" id="erna_LongTermPortionOfLicenseFeeObligation_lbl1">Long-term portion of License Fee Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPortionOfLicenseFeeObligation" xlink:to="erna_LongTermPortionOfLicenseFeeObligation_lbl1" xlink:title="label: LongTermPortionOfLicenseFeeObligation to erna_LongTermPortionOfLicenseFeeObligation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockToBeRetainedByNTNValueStockholders" xlink:label="CommonStockToBeRetainedByNTNValueStockholders" xlink:title="CommonStockToBeRetainedByNTNValueStockholders" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl" xml:lang="en-US" id="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl">Value of common stock to be retained by NTN stockholders during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockToBeRetainedByNTNValueStockholders" xlink:to="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl" xlink:title="label: CommonStockToBeRetainedByNTNValueStockholders to erna_CommonStockToBeRetainedByNTNValueStockholders_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl1" xml:lang="en-US" id="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl1">Common Stock to be Retained by NTN, Value, Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockToBeRetainedByNTNValueStockholders" xlink:to="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl1" xlink:title="label: CommonStockToBeRetainedByNTNValueStockholders to erna_CommonStockToBeRetainedByNTNValueStockholders_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl2" xml:lang="en-US" id="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl2">Common stock to be retained by NTN stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockToBeRetainedByNTNValueStockholders" xlink:to="erna_CommonStockToBeRetainedByNTNValueStockholders_lbl2" xlink:title="label: CommonStockToBeRetainedByNTNValueStockholders to erna_CommonStockToBeRetainedByNTNValueStockholders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockToBeRetainedByNTNSharesStockholders" xlink:label="CommonStockToBeRetainedByNTNSharesStockholders" xlink:title="CommonStockToBeRetainedByNTNSharesStockholders" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl" xml:lang="en-US" id="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl">Number of shares of common stock to be retained by NTN stockholders during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockToBeRetainedByNTNSharesStockholders" xlink:to="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl" xlink:title="label: CommonStockToBeRetainedByNTNSharesStockholders to erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl1" xml:lang="en-US" id="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl1">Common Stock to be Retained by NTN, Shares, Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockToBeRetainedByNTNSharesStockholders" xlink:to="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl1" xlink:title="label: CommonStockToBeRetainedByNTNSharesStockholders to erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl2" xml:lang="en-US" id="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl2">Common stock to be retained by NTN stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockToBeRetainedByNTNSharesStockholders" xlink:to="erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl2" xlink:title="label: CommonStockToBeRetainedByNTNSharesStockholders to erna_CommonStockToBeRetainedByNTNSharesStockholders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl">Equity impact of the value of stock that has been issued in a stock purchase agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1">Stock Issued During Period, Value, Stock Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to erna_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl">Number of shares that have been issued in a stock purchase agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1">Stock Issued During Period, Shares, Stock Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueInLieuOfDividends" xlink:label="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="StockIssuedDuringPeriodValueInLieuOfDividends" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl">Value of stock issued during the period in Lieu of Dividends to be paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:to="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" xlink:title="label: StockIssuedDuringPeriodValueInLieuOfDividends to erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1">Stock Issued During Period, Value, in Lieu of Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:to="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInLieuOfDividends to erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:to="erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInLieuOfDividends to erna_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:label="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="StockIssuedDuringPeriodSharesInLieuOfDividends" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl">Number of shares issued during the period in lieu of dividends to be paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:to="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInLieuOfDividends to erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1">Stock Issued During Period, Shares, in Lieu of Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:to="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInLieuOfDividends to erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:to="erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInLieuOfDividends to erna_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl">Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:to="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants to erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1">Stock Issued During Period Value Exercise of Pre-funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:to="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants to erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl2">Issuance of common stock from exercise of pre-funded warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:to="erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl2" xlink:title="label: StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants to erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl">Total number of shares issued during the period, including exercise of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants to erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1">Stock Issued During Period Shares Exercise of Pre-funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants to erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl2">Issuance of common stock from exercise of pre-funded warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants to erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="StockIssuedDuringPeriodValueAcquisitions2" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl">Value of stock issued pursuant to acquisitions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions2" xlink:to="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions2 to erna_StockIssuedDuringPeriodValueAcquisitions2_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl1">Stock Issued During Period, Value, Acquisitions2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions2" xlink:to="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions2 to erna_StockIssuedDuringPeriodValueAcquisitions2_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl2">Issuance of common stock in connection with the acquisition of Novellus, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions2" xlink:to="erna_StockIssuedDuringPeriodValueAcquisitions2_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions2 to erna_StockIssuedDuringPeriodValueAcquisitions2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="StockIssuedDuringPeriodSharesAcquisitions2" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl">Number of shares of stock issued during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions2 to erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl1">Stock Issued During Period, Shares, Acquisitions2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions2 to erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl2">Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions2 to erna_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:label xlink:type="resource" xlink:label="erna_CommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_CommonUnitsMember_lbl" xml:lang="en-US" id="erna_CommonUnitsMember_lbl">Classification of common stock that has different rights than provided to common units, representing ownership interest in a corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="erna_CommonUnitsMember_lbl" xlink:title="label: CommonUnitsMember to erna_CommonUnitsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_CommonUnitsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CommonUnitsMember_lbl1" xml:lang="en-US" id="erna_CommonUnitsMember_lbl1">Common Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="erna_CommonUnitsMember_lbl1" xlink:title="label: CommonUnitsMember to erna_CommonUnitsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_CommonUnitsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="erna_CommonUnitsMember_lbl2" xml:lang="en-US" id="erna_CommonUnitsMember_lbl2">Common [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="erna_CommonUnitsMember_lbl2" xlink:title="label: CommonUnitsMember to erna_CommonUnitsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesPrivateOffering" xlink:label="StockIssuedDuringPeriodSharesPrivateOffering" xlink:title="StockIssuedDuringPeriodSharesPrivateOffering" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl">Number of shares that have been issued in private offering during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivateOffering" xlink:to="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl" xlink:title="label: StockIssuedDuringPeriodSharesPrivateOffering to erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl1">Stock Issued During Period, Shares, Private Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivateOffering" xlink:to="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesPrivateOffering to erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl2">Issuance of common stock in connection with private offering (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivateOffering" xlink:to="erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesPrivateOffering to erna_StockIssuedDuringPeriodSharesPrivateOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" />
    <link:label xlink:type="resource" xlink:label="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" xml:lang="en-US" id="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl">Amount of decrease (increase) in additional paid in capital (APIC) for the increase in redemption of temporary equity as the result of a triggering event associated with the temporary equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:to="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity to erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" xml:lang="en-US" id="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1">Adjustments to Additional Paid in Capital, Elimination Historical Member Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:to="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity to erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" xml:lang="en-US" id="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2">Elimination of Brooklyn's historical members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:to="erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity to erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueAcquisitions1" xlink:label="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="StockIssuedDuringPeriodValueAcquisitions1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl">Value of stock issued pursuant to acquisitions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions1 to erna_StockIssuedDuringPeriodValueAcquisitions1_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl1">Stock Issued During Period, Value, Acquisitions1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions1 to erna_StockIssuedDuringPeriodValueAcquisitions1_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl2">Issuance of common stock for business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions1" xlink:to="erna_StockIssuedDuringPeriodValueAcquisitions1_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions1 to erna_StockIssuedDuringPeriodValueAcquisitions1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:label="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl">Value of stock related to Forfeiture of unvested restricted stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:to="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" xlink:title="label: StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock to erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1">Stock Issued During Period, Value, Forfeiture of Unvested Restricted Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:to="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" xlink:title="label: StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock to erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2">Forfeiture of unvested restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:to="erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" xlink:title="label: StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock to erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValuePrivateOffering" xlink:label="StockIssuedDuringPeriodValuePrivateOffering" xlink:title="StockIssuedDuringPeriodValuePrivateOffering" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl">Equity impact of the value of stock that has been issued in private offering during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValuePrivateOffering" xlink:to="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl" xlink:title="label: StockIssuedDuringPeriodValuePrivateOffering to erna_StockIssuedDuringPeriodValuePrivateOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl1">Stock Issued During Period, Value, Private Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValuePrivateOffering" xlink:to="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl1" xlink:title="label: StockIssuedDuringPeriodValuePrivateOffering to erna_StockIssuedDuringPeriodValuePrivateOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl2">Issuance of common stock in connection with private offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValuePrivateOffering" xlink:to="erna_StockIssuedDuringPeriodValuePrivateOffering_lbl2" xlink:title="label: StockIssuedDuringPeriodValuePrivateOffering to erna_StockIssuedDuringPeriodValuePrivateOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl">Equity impact of the value of new stock issued of preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders to erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1">Stock Issued During Period, Value, New Issues of Preferred Stock, Retained by Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders to erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2">Series A preferred stock retained in business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders to erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MembershipEquityMember" xlink:label="MembershipEquityMember" xlink:title="MembershipEquityMember" />
    <link:label xlink:type="resource" xlink:label="erna_MembershipEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_MembershipEquityMember_lbl" xml:lang="en-US" id="erna_MembershipEquityMember_lbl">Equity membership interest in entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembershipEquityMember" xlink:to="erna_MembershipEquityMember_lbl" xlink:title="label: MembershipEquityMember to erna_MembershipEquityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_MembershipEquityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_MembershipEquityMember_lbl1" xml:lang="en-US" id="erna_MembershipEquityMember_lbl1">Membership Equity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembershipEquityMember" xlink:to="erna_MembershipEquityMember_lbl1" xlink:title="label: MembershipEquityMember to erna_MembershipEquityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_MembershipEquityMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_MembershipEquityMember_lbl2" xml:lang="en-US" id="erna_MembershipEquityMember_lbl2">Membership Equity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembershipEquityMember" xlink:to="erna_MembershipEquityMember_lbl2" xlink:title="label: MembershipEquityMember to erna_MembershipEquityMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:label="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl">Value of stock issued pursuant to rights offering membership units during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:to="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" xlink:title="label: StockIssuedDuringPeriodValueRightsOfferingMembershipUnits to erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1">Stock Issued During Period, Value, Rights Offering Membership Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:to="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" xlink:title="label: StockIssuedDuringPeriodValueRightsOfferingMembershipUnits to erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2">Brooklyn rights offerings membership units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:to="erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" xlink:title="label: StockIssuedDuringPeriodValueRightsOfferingMembershipUnits to erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:label="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" />
    <link:label xlink:type="resource" xlink:label="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" xml:lang="en-US" id="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl">Number of shares Forfeiture of unvested restricted stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:to="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" xlink:title="label: SharesIssuedSharesForfeitureOfUnvestedRestrictedStock to erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" xml:lang="en-US" id="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1">Shares Issued, Shares, Forfeiture of unvested restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:to="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" xlink:title="label: SharesIssuedSharesForfeitureOfUnvestedRestrictedStock to erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" xml:lang="en-US" id="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2">Forfeiture of unvested restricted stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:to="erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" xlink:title="label: SharesIssuedSharesForfeitureOfUnvestedRestrictedStock to erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl">Equity impact of the shares of new stock issued of preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders to erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1">Stock Issued During Period, Shares, New Issues of Preferred Stock, Retained by Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders to erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xml:lang="en-US" id="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2">Series A preferred stock retained in business combination (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders to erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CEOSEPARATIONAGREEMENTAbstract" xlink:label="CEOSEPARATIONAGREEMENTAbstract" xlink:title="CEOSEPARATIONAGREEMENTAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_CEOSEPARATIONAGREEMENTAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_CEOSEPARATIONAGREEMENTAbstract_lbl1" xml:lang="en-US" id="erna_CEOSEPARATIONAGREEMENTAbstract_lbl1">CEO SEPARATION AGREEMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CEOSEPARATIONAGREEMENTAbstract" xlink:to="erna_CEOSEPARATIONAGREEMENTAbstract_lbl1" xlink:title="label: CEOSEPARATIONAGREEMENTAbstract to erna_CEOSEPARATIONAGREEMENTAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:label="ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:title="ChiefExecutiveOfficerSeparationAgreementTextBlock" />
    <link:label xlink:type="resource" xlink:label="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl" xml:lang="en-US" id="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl">The entire disclosure pertaining to chief executive officer separation agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:to="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl" xlink:title="label: ChiefExecutiveOfficerSeparationAgreementTextBlock to erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl1" xml:lang="en-US" id="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl1">Chief Executive Officer Separation Agreement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:to="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl1" xlink:title="label: ChiefExecutiveOfficerSeparationAgreementTextBlock to erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl2" xml:lang="en-US" id="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl2">CEO SEPARATION AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:to="erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl2" xlink:title="label: ChiefExecutiveOfficerSeparationAgreementTextBlock to erna_ChiefExecutiveOfficerSeparationAgreementTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SeparationAgreementAbstract" xlink:label="SeparationAgreementAbstract" xlink:title="SeparationAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="erna_SeparationAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_SeparationAgreementAbstract_lbl1" xml:lang="en-US" id="erna_SeparationAgreementAbstract_lbl1">Separation Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeparationAgreementAbstract" xlink:to="erna_SeparationAgreementAbstract_lbl1" xlink:title="label: SeparationAgreementAbstract to erna_SeparationAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_SeparationAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_SeparationAgreementAbstract_lbl2" xml:lang="en-US" id="erna_SeparationAgreementAbstract_lbl2">Separation Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeparationAgreementAbstract" xlink:to="erna_SeparationAgreementAbstract_lbl2" xlink:title="label: SeparationAgreementAbstract to erna_SeparationAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:label="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:title="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" />
    <link:label xlink:type="resource" xlink:label="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl" xml:lang="en-US" id="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl">Amount of severance benefit, would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:to="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl" xlink:title="label: SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits to erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl1" xml:lang="en-US" id="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl1">Severance Benefit Receivable Based on Performance Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:to="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl1" xlink:title="label: SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits to erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl2" xml:lang="en-US" id="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl2">Severance benefit receivable based on performance restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:to="erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl2" xlink:title="label: SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits to erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentToOfficerBaseSalary" xlink:label="PaymentToOfficerBaseSalary" xlink:title="PaymentToOfficerBaseSalary" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentToOfficerBaseSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_PaymentToOfficerBaseSalary_lbl" xml:lang="en-US" id="erna_PaymentToOfficerBaseSalary_lbl">Amount of cash outflows for payment of annual base salary for a period of twelve months after the expiration of the applicable revocation period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentToOfficerBaseSalary" xlink:to="erna_PaymentToOfficerBaseSalary_lbl" xlink:title="label: PaymentToOfficerBaseSalary to erna_PaymentToOfficerBaseSalary_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentToOfficerBaseSalary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_PaymentToOfficerBaseSalary_lbl1" xml:lang="en-US" id="erna_PaymentToOfficerBaseSalary_lbl1">Payment to Officer Base Salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentToOfficerBaseSalary" xlink:to="erna_PaymentToOfficerBaseSalary_lbl1" xlink:title="label: PaymentToOfficerBaseSalary to erna_PaymentToOfficerBaseSalary_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_PaymentToOfficerBaseSalary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_PaymentToOfficerBaseSalary_lbl2" xml:lang="en-US" id="erna_PaymentToOfficerBaseSalary_lbl2">Payment of annual base salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentToOfficerBaseSalary" xlink:to="erna_PaymentToOfficerBaseSalary_lbl2" xlink:title="label: PaymentToOfficerBaseSalary to erna_PaymentToOfficerBaseSalary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MilestoneOptionsMember" xlink:label="MilestoneOptionsMember" xlink:title="MilestoneOptionsMember" />
    <link:label xlink:type="resource" xlink:label="erna_MilestoneOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_MilestoneOptionsMember_lbl" xml:lang="en-US" id="erna_MilestoneOptionsMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions based on milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestoneOptionsMember" xlink:to="erna_MilestoneOptionsMember_lbl" xlink:title="label: MilestoneOptionsMember to erna_MilestoneOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_MilestoneOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_MilestoneOptionsMember_lbl1" xml:lang="en-US" id="erna_MilestoneOptionsMember_lbl1">Milestone Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestoneOptionsMember" xlink:to="erna_MilestoneOptionsMember_lbl1" xlink:title="label: MilestoneOptionsMember to erna_MilestoneOptionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_MilestoneOptionsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_MilestoneOptionsMember_lbl2" xml:lang="en-US" id="erna_MilestoneOptionsMember_lbl2">Milestone Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestoneOptionsMember" xlink:to="erna_MilestoneOptionsMember_lbl2" xlink:title="label: MilestoneOptionsMember to erna_MilestoneOptionsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FactorBioscienceIncMember" xlink:label="FactorBioscienceIncMember" xlink:title="FactorBioscienceIncMember" />
    <link:label xlink:type="resource" xlink:label="erna_FactorBioscienceIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_FactorBioscienceIncMember_lbl" xml:lang="en-US" id="erna_FactorBioscienceIncMember_lbl">A corporation the company entered into agreement to provide the Company with MRNA cell engineering research support services, including access to certain facilities, equipment, materials and training, and the Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FactorBioscienceIncMember" xlink:to="erna_FactorBioscienceIncMember_lbl" xlink:title="label: FactorBioscienceIncMember to erna_FactorBioscienceIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_FactorBioscienceIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_FactorBioscienceIncMember_lbl1" xml:lang="en-US" id="erna_FactorBioscienceIncMember_lbl1">Factor Bioscience Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FactorBioscienceIncMember" xlink:to="erna_FactorBioscienceIncMember_lbl1" xlink:title="label: FactorBioscienceIncMember to erna_FactorBioscienceIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_FactorBioscienceIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_FactorBioscienceIncMember_lbl2" xml:lang="en-US" id="erna_FactorBioscienceIncMember_lbl2">Factor Bioscience Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FactorBioscienceIncMember" xlink:to="erna_FactorBioscienceIncMember_lbl2" xlink:title="label: FactorBioscienceIncMember to erna_FactorBioscienceIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MonthlyMasterServicesAgreementFeesPayable" xlink:label="MonthlyMasterServicesAgreementFeesPayable" xlink:title="MonthlyMasterServicesAgreementFeesPayable" />
    <link:label xlink:type="resource" xlink:label="erna_MonthlyMasterServicesAgreementFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_MonthlyMasterServicesAgreementFeesPayable_lbl" xml:lang="en-US" id="erna_MonthlyMasterServicesAgreementFeesPayable_lbl">The monthly master service agreement ("MSA") fees payable to related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MonthlyMasterServicesAgreementFeesPayable" xlink:to="erna_MonthlyMasterServicesAgreementFeesPayable_lbl" xlink:title="label: MonthlyMasterServicesAgreementFeesPayable to erna_MonthlyMasterServicesAgreementFeesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_MonthlyMasterServicesAgreementFeesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_MonthlyMasterServicesAgreementFeesPayable_lbl1" xml:lang="en-US" id="erna_MonthlyMasterServicesAgreementFeesPayable_lbl1">Monthly Master Services Agreement Fees Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MonthlyMasterServicesAgreementFeesPayable" xlink:to="erna_MonthlyMasterServicesAgreementFeesPayable_lbl1" xlink:title="label: MonthlyMasterServicesAgreementFeesPayable to erna_MonthlyMasterServicesAgreementFeesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_MonthlyMasterServicesAgreementFeesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_MonthlyMasterServicesAgreementFeesPayable_lbl2" xml:lang="en-US" id="erna_MonthlyMasterServicesAgreementFeesPayable_lbl2">Monthly master services agreement fees payable initial 12-month</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MonthlyMasterServicesAgreementFeesPayable" xlink:to="erna_MonthlyMasterServicesAgreementFeesPayable_lbl2" xlink:title="label: MonthlyMasterServicesAgreementFeesPayable to erna_MonthlyMasterServicesAgreementFeesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AgreedWaivePayment" xlink:label="AgreedWaivePayment" xlink:title="AgreedWaivePayment" />
    <link:label xlink:type="resource" xlink:label="erna_AgreedWaivePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_AgreedWaivePayment_lbl" xml:lang="en-US" id="erna_AgreedWaivePayment_lbl">The amount agreed to waive payment as per waiver agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreedWaivePayment" xlink:to="erna_AgreedWaivePayment_lbl" xlink:title="label: AgreedWaivePayment to erna_AgreedWaivePayment_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_AgreedWaivePayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_AgreedWaivePayment_lbl1" xml:lang="en-US" id="erna_AgreedWaivePayment_lbl1">Agreed Waive Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreedWaivePayment" xlink:to="erna_AgreedWaivePayment_lbl1" xlink:title="label: AgreedWaivePayment to erna_AgreedWaivePayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_AgreedWaivePayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_AgreedWaivePayment_lbl2" xml:lang="en-US" id="erna_AgreedWaivePayment_lbl2">Agreed waive payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreedWaivePayment" xlink:to="erna_AgreedWaivePayment_lbl2" xlink:title="label: AgreedWaivePayment to erna_AgreedWaivePayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoticePeriodForSupersedingTerminationProvisions" xlink:label="NoticePeriodForSupersedingTerminationProvisions" xlink:title="NoticePeriodForSupersedingTerminationProvisions" />
    <link:label xlink:type="resource" xlink:label="erna_NoticePeriodForSupersedingTerminationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NoticePeriodForSupersedingTerminationProvisions_lbl" xml:lang="en-US" id="erna_NoticePeriodForSupersedingTerminationProvisions_lbl">The Master Services Agreement (or "MSA") contains customary confidentiality provisions and representations and warranties of the parties, and the Master Services Agreement (or "MSA") may be terminated by ether party prior notice, subject to any superseding termination provisions contained in a particular work order, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodForSupersedingTerminationProvisions" xlink:to="erna_NoticePeriodForSupersedingTerminationProvisions_lbl" xlink:title="label: NoticePeriodForSupersedingTerminationProvisions to erna_NoticePeriodForSupersedingTerminationProvisions_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NoticePeriodForSupersedingTerminationProvisions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NoticePeriodForSupersedingTerminationProvisions_lbl1" xml:lang="en-US" id="erna_NoticePeriodForSupersedingTerminationProvisions_lbl1">Notice Period for Superseding Termination Provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodForSupersedingTerminationProvisions" xlink:to="erna_NoticePeriodForSupersedingTerminationProvisions_lbl1" xlink:title="label: NoticePeriodForSupersedingTerminationProvisions to erna_NoticePeriodForSupersedingTerminationProvisions_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NoticePeriodForSupersedingTerminationProvisions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NoticePeriodForSupersedingTerminationProvisions_lbl2" xml:lang="en-US" id="erna_NoticePeriodForSupersedingTerminationProvisions_lbl2">Notice period for superseding termination provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodForSupersedingTerminationProvisions" xlink:to="erna_NoticePeriodForSupersedingTerminationProvisions_lbl2" xlink:title="label: NoticePeriodForSupersedingTerminationProvisions to erna_NoticePeriodForSupersedingTerminationProvisions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:label="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:title="RelatedPartyTransactionPeriodicFeesPaymentAmount" />
    <link:label xlink:type="resource" xlink:label="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl" xml:lang="en-US" id="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl">The amount of required periodic fees payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:to="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl" xlink:title="label: RelatedPartyTransactionPeriodicFeesPaymentAmount to erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl1" xml:lang="en-US" id="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl1">Related Party Transaction, Periodic Fees Payment, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:to="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl1" xlink:title="label: RelatedPartyTransactionPeriodicFeesPaymentAmount to erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl2" xml:lang="en-US" id="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl2">Monthly installment fees amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:to="erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl2" xlink:title="label: RelatedPartyTransactionPeriodicFeesPaymentAmount to erna_RelatedPartyTransactionPeriodicFeesPaymentAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MasterServiceAgreementInitialFeesPayable" xlink:label="MasterServiceAgreementInitialFeesPayable" xlink:title="MasterServiceAgreementInitialFeesPayable" />
    <link:label xlink:type="resource" xlink:label="erna_MasterServiceAgreementInitialFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_MasterServiceAgreementInitialFeesPayable_lbl" xml:lang="en-US" id="erna_MasterServiceAgreementInitialFeesPayable_lbl">The amount agreed to pay an initial fee under Master Services Agreement (or "MSA").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MasterServiceAgreementInitialFeesPayable" xlink:to="erna_MasterServiceAgreementInitialFeesPayable_lbl" xlink:title="label: MasterServiceAgreementInitialFeesPayable to erna_MasterServiceAgreementInitialFeesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_MasterServiceAgreementInitialFeesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_MasterServiceAgreementInitialFeesPayable_lbl1" xml:lang="en-US" id="erna_MasterServiceAgreementInitialFeesPayable_lbl1">Master Service Agreement, Initial Fees Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MasterServiceAgreementInitialFeesPayable" xlink:to="erna_MasterServiceAgreementInitialFeesPayable_lbl1" xlink:title="label: MasterServiceAgreementInitialFeesPayable to erna_MasterServiceAgreementInitialFeesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_MasterServiceAgreementInitialFeesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_MasterServiceAgreementInitialFeesPayable_lbl2" xml:lang="en-US" id="erna_MasterServiceAgreementInitialFeesPayable_lbl2">Master services agreement, initial fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MasterServiceAgreementInitialFeesPayable" xlink:to="erna_MasterServiceAgreementInitialFeesPayable_lbl2" xlink:title="label: MasterServiceAgreementInitialFeesPayable to erna_MasterServiceAgreementInitialFeesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReimburseCostsIncurredOrPaid" xlink:label="ReimburseCostsIncurredOrPaid" xlink:title="ReimburseCostsIncurredOrPaid" />
    <link:label xlink:type="resource" xlink:label="erna_ReimburseCostsIncurredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_ReimburseCostsIncurredOrPaid_lbl" xml:lang="en-US" id="erna_ReimburseCostsIncurredOrPaid_lbl">The amount reimburse for costs already incurred or paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimburseCostsIncurredOrPaid" xlink:to="erna_ReimburseCostsIncurredOrPaid_lbl" xlink:title="label: ReimburseCostsIncurredOrPaid to erna_ReimburseCostsIncurredOrPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_ReimburseCostsIncurredOrPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_ReimburseCostsIncurredOrPaid_lbl1" xml:lang="en-US" id="erna_ReimburseCostsIncurredOrPaid_lbl1">Reimburse Costs Incurred or Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimburseCostsIncurredOrPaid" xlink:to="erna_ReimburseCostsIncurredOrPaid_lbl1" xlink:title="label: ReimburseCostsIncurredOrPaid to erna_ReimburseCostsIncurredOrPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_ReimburseCostsIncurredOrPaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_ReimburseCostsIncurredOrPaid_lbl2" xml:lang="en-US" id="erna_ReimburseCostsIncurredOrPaid_lbl2">Reimburse costs incurred or paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimburseCostsIncurredOrPaid" xlink:to="erna_ReimburseCostsIncurredOrPaid_lbl2" xlink:title="label: ReimburseCostsIncurredOrPaid to erna_ReimburseCostsIncurredOrPaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfMonthlyInstallmentsForFeesPayable" xlink:label="NumberOfMonthlyInstallmentsForFeesPayable" xlink:title="NumberOfMonthlyInstallmentsForFeesPayable" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl" xml:lang="en-US" id="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl">The number of equal monthly installments for initial fees payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMonthlyInstallmentsForFeesPayable" xlink:to="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl" xlink:title="label: NumberOfMonthlyInstallmentsForFeesPayable to erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl1" xml:lang="en-US" id="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl1">Number of Monthly Installments for Fees Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMonthlyInstallmentsForFeesPayable" xlink:to="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl1" xlink:title="label: NumberOfMonthlyInstallmentsForFeesPayable to erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl2" xml:lang="en-US" id="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl2">Number of monthly installments for fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMonthlyInstallmentsForFeesPayable" xlink:to="erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl2" xlink:title="label: NumberOfMonthlyInstallmentsForFeesPayable to erna_NumberOfMonthlyInstallmentsForFeesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:label="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:title="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" />
    <link:label xlink:type="resource" xlink:label="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl" xml:lang="en-US" id="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl">Amount of deposit paid which will be applied to the last month of the first work order.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:to="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl" xlink:title="label: DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder to erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl1" xml:lang="en-US" id="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl1">Deposit Paid to be Applied to Last Month of First Work Order</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:to="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl1" xlink:title="label: DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder to erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl2" xml:lang="en-US" id="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl2">Deposit paid to be applied to last month of first work order</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:to="erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl2" xlink:title="label: DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder to erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder_lbl2" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoticePeriodForFirstTerminationOfContract" xlink:label="NoticePeriodForFirstTerminationOfContract" xlink:title="NoticePeriodForFirstTerminationOfContract" />
    <link:label xlink:type="resource" xlink:label="erna_NoticePeriodForFirstTerminationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="erna_NoticePeriodForFirstTerminationOfContract_lbl" xml:lang="en-US" id="erna_NoticePeriodForFirstTerminationOfContract_lbl">The Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with prior notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodForFirstTerminationOfContract" xlink:to="erna_NoticePeriodForFirstTerminationOfContract_lbl" xlink:title="label: NoticePeriodForFirstTerminationOfContract to erna_NoticePeriodForFirstTerminationOfContract_lbl" />
    <link:label xlink:type="resource" xlink:label="erna_NoticePeriodForFirstTerminationOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="erna_NoticePeriodForFirstTerminationOfContract_lbl1" xml:lang="en-US" id="erna_NoticePeriodForFirstTerminationOfContract_lbl1">Notice Period for First Termination of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodForFirstTerminationOfContract" xlink:to="erna_NoticePeriodForFirstTerminationOfContract_lbl1" xlink:title="label: NoticePeriodForFirstTerminationOfContract to erna_NoticePeriodForFirstTerminationOfContract_lbl1" />
    <link:label xlink:type="resource" xlink:label="erna_NoticePeriodForFirstTerminationOfContract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="erna_NoticePeriodForFirstTerminationOfContract_lbl2" xml:lang="en-US" id="erna_NoticePeriodForFirstTerminationOfContract_lbl2">Notice period for first termination of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoticePeriodForFirstTerminationOfContract" xlink:to="erna_NoticePeriodForFirstTerminationOfContract_lbl2" xlink:title="label: NoticePeriodForFirstTerminationOfContract to erna_NoticePeriodForFirstTerminationOfContract_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>erna-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://eternatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#EarningsPerShareDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockholdersEquityMergerDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockholdersEquityMergerDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockholdersEquityPrivatePlacementOfEquityDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationRestrictedStockDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationSummaryOfRsusDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationNumberOfRsusVestedAndSettledDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationRsusDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationRsusDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationSummaryOfStockOptionsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingenciesRoyaltyAgreementsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingenciesLicensingAgreementsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingenciesLegalMattersDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/CeoSeparationAgreementDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#CeoSeparationAgreementDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#InprocessResearchDevelopmentAndGoodwillDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesNetOperatingLeaseExpensesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsDispositionDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsMergerDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" xlink:href="erna-20220930.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" />
  <link:roleRef roleURI="http://eternatx.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="erna-20220930.xsd#EarningsPerShareTables" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilitiesTables" />
  <link:roleRef roleURI="http://eternatx.com/role/LeasesTables" xlink:type="simple" xlink:href="erna-20220930.xsd#LeasesTables" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactionsTables" />
  <link:roleRef roleURI="http://eternatx.com/role/RecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="erna-20220930.xsd#RecentAccountingPronouncementsPolicies" />
  <link:roleRef roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" xlink:href="erna-20220930.xsd#DescriptionOfBusinessAndBasisOfPresentationPolicies" />
  <link:roleRef roleURI="http://eternatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="erna-20220930.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://eternatx.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="erna-20220930.xsd#RecentAccountingPronouncements" />
  <link:roleRef roleURI="http://eternatx.com/role/EarningsPerShare" xlink:type="simple" xlink:href="erna-20220930.xsd#EarningsPerShare" />
  <link:roleRef roleURI="http://eternatx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="erna-20220930.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://eternatx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="erna-20220930.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://eternatx.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="erna-20220930.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://eternatx.com/role/AccruedExpensesAndOtherLiabilities" xlink:type="simple" xlink:href="erna-20220930.xsd#AccruedExpensesAndOtherLiabilities" />
  <link:roleRef roleURI="http://eternatx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="erna-20220930.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://eternatx.com/role/CeoSeparationAgreement" xlink:type="simple" xlink:href="erna-20220930.xsd#CeoSeparationAgreement" />
  <link:roleRef roleURI="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill" xlink:type="simple" xlink:href="erna-20220930.xsd#InprocessResearchDevelopmentAndGoodwill" />
  <link:roleRef roleURI="http://eternatx.com/role/Leases" xlink:type="simple" xlink:href="erna-20220930.xsd#Leases" />
  <link:roleRef roleURI="http://eternatx.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="erna-20220930.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions" xlink:type="simple" xlink:href="erna-20220930.xsd#MergerDispositionAndAcquisitionTransactions" />
  <link:roleRef roleURI="http://eternatx.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="erna-20220930.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" xlink:href="erna-20220930.xsd#DescriptionOfBusinessAndBasisOfPresentation" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfStockholdersAndMembersEquity" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://eternatx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="erna-20220930.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20220930.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="EntityInformationFormerLegalOrRegisteredName" xlink:title="EntityInformationFormerLegalOrRegisteredName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInformationFormerLegalOrRegisteredName" xlink:title="presentation: CoverAbstract to EntityInformationFormerLegalOrRegisteredName" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Cash" xlink:title="presentation: AssetsCurrentAbstract to Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" xlink:title="OtherReceivablesNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherReceivablesNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsCurrentAbstract to PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsCurrentAbstract to OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsCurrentAbstract to Goodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="presentation: AssetsCurrentAbstract to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="EquityMethodInvestments" xlink:title="presentation: AssetsCurrentAbstract to EquityMethodInvestments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherAssetsNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Assets" xlink:title="presentation: AssetsCurrentAbstract to Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="presentation: StatementLineItems to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DerivativeLiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to FinanceLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: StatementTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockLiquidationPreferenceValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockLiquidationPreferenceValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="NoncashMergerRelatedCosts" xlink:title="presentation: OperatingExpensesAbstract to NoncashMergerRelatedCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpensesAbstract" xlink:label="OtherExpensesAbstract" xlink:title="OtherExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: OtherExpensesAbstract to GainLossOnDispositionOfAssets1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WarrantLiabilitiesExpense" xlink:label="WarrantLiabilitiesExpense" xlink:title="WarrantLiabilitiesExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="WarrantLiabilitiesExpense" xlink:title="presentation: OtherExpensesAbstract to WarrantLiabilitiesExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossOnNonControllingInvestment" xlink:label="LossOnNonControllingInvestment" xlink:title="LossOnNonControllingInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="LossOnNonControllingInvestment" xlink:title="presentation: OtherExpensesAbstract to LossOnNonControllingInvestment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: OtherExpensesAbstract to OtherNonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: OtherExpensesAbstract to NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OtherExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="presentation: IncomeStatementAbstract to PreferredStockDividendsAndOtherAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: StatementTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: ReverseStockSplitAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ReverseStockSplitAbstract" xlink:title="presentation: StatementLineItems to ReverseStockSplitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MembershipEquityMember" xlink:label="MembershipEquityMember" xlink:title="MembershipEquityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="MembershipEquityMember" xlink:title="presentation: StatementEquityComponentsAxis to MembershipEquityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="PreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="presentation: ClassOfStockDomain to CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="presentation: ClassOfStockDomain to CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonUnitsMember" xlink:title="presentation: ClassOfStockDomain to CommonUnitsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:label="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueAcquisitions1" xlink:label="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="StockIssuedDuringPeriodValueAcquisitions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAcquisitions1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountAcquisitions" xlink:label="PartnersCapitalAccountAcquisitions" xlink:title="PartnersCapitalAccountAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="PartnersCapitalAccountAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to PartnersCapitalAccountAcquisitions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsAcquisitions" xlink:label="PartnersCapitalAccountUnitsAcquisitions" xlink:title="PartnersCapitalAccountUnitsAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="PartnersCapitalAccountUnitsAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to PartnersCapitalAccountUnitsAcquisitions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAcquisitions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValuePrivateOffering" xlink:label="StockIssuedDuringPeriodValuePrivateOffering" xlink:title="StockIssuedDuringPeriodValuePrivateOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValuePrivateOffering" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValuePrivateOffering" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesPrivateOffering" xlink:label="StockIssuedDuringPeriodSharesPrivateOffering" xlink:title="StockIssuedDuringPeriodSharesPrivateOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesPrivateOffering" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesPrivateOffering" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockToBeRetainedByNTNValueStockholders" xlink:label="CommonStockToBeRetainedByNTNValueStockholders" xlink:title="CommonStockToBeRetainedByNTNValueStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockToBeRetainedByNTNValueStockholders" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockToBeRetainedByNTNValueStockholders" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockToBeRetainedByNTNSharesStockholders" xlink:label="CommonStockToBeRetainedByNTNSharesStockholders" xlink:title="CommonStockToBeRetainedByNTNSharesStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockToBeRetainedByNTNSharesStockholders" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockToBeRetainedByNTNSharesStockholders" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockPurchaseAgreement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockPurchaseAgreement" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueInLieuOfDividends" xlink:label="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="StockIssuedDuringPeriodValueInLieuOfDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInLieuOfDividends" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:label="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="StockIssuedDuringPeriodSharesInLieuOfDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInLieuOfDividends" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="StockIssuedDuringPeriodValueAcquisitions2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions2" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="StockIssuedDuringPeriodSharesAcquisitions2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAcquisitions2" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:label="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:label="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" order="25.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:title="AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalStockSplit" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DividendsPreferredStockCash" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DividendsPreferredStockCash" order="32.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="PreferredStockDividendsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to PreferredStockDividendsShares" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: StatementTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="StockholdersEquityNoteAbstract" xlink:title="presentation: StatementLineItems to StockholdersEquityNoteAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseImpairmentLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="ImpairmentOfOngoingProject" xlink:title="ImpairmentOfOngoingProject" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfOngoingProject" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ImpairmentOfOngoingProject" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ResearchAndDevelopmentInProcessAssetAcquisition" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NoncashMergerRelatedCosts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NoncashMergerRelatedCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets1" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainLossOnDisposalOfFixedAssets" xlink:label="GainLossOnDisposalOfFixedAssets" xlink:title="GainLossOnDisposalOfFixedAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDisposalOfFixedAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDisposalOfFixedAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:label="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnForgivenessOfPaycheckProtectionProgramLoan" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_GainOnTerminationOfLease" xlink:label="GainOnTerminationOfLease" xlink:title="GainOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnTerminationOfLease" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainOnTerminationOfLease" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WarrantLiabilitiesExpense" xlink:label="WarrantLiabilitiesExpense" xlink:title="WarrantLiabilitiesExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="WarrantLiabilitiesExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to WarrantLiabilitiesExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossOnNonControllingInvestment" xlink:label="LossOnNonControllingInvestment" xlink:title="LossOnNonControllingInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossOnNonControllingInvestment" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to LossOnNonControllingInvestment" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="IncreaseDecreaseInOtherReceivables" xlink:title="IncreaseDecreaseInOtherReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherReceivables" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherNoncurrentAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherNoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOperatingLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireProductiveAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="ProceedsFromSalesOfAssetsInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSalesOfAssetsInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="ProceedsFromDivestitureOfBusinesses" xlink:title="ProceedsFromDivestitureOfBusinesses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromDivestitureOfBusinesses" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromDivestitureOfBusinesses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:label="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:title="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to IssuanceOfCommonStockFromExerciseOfPreFundedWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:label="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:title="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:label="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:title="ProceedsFromIssuanceOfCommonStockToLincolnPark" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockToLincolnPark" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStockToLincolnPark" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:label="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:title="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromOtherEquity" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromOtherEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsOfPaycheckProtectionProgramLoan" xlink:label="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="PaymentsOfPaycheckProtectionProgramLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfPaycheckProtectionProgramLoan" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CashPaidDuringThePeriodForAbstract" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:title="CashPaidDuringThePeriodForAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: CashPaidDuringThePeriodForAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="IncomeTaxesPaidNet" xlink:title="presentation: CashPaidDuringThePeriodForAbstract to IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="CashPaidDuringThePeriodForAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to CashPaidDuringThePeriodForAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ConversionOfWarrantLiabilityToEquity" xlink:label="ConversionOfWarrantLiabilityToEquity" xlink:title="ConversionOfWarrantLiabilityToEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfWarrantLiabilityToEquity" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to ConversionOfWarrantLiabilityToEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:label="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:title="IssuanceOfCommonStockForSeriesAPreferredStockDividend" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to IssuanceOfCommonStockForSeriesAPreferredStockDividend" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockIssued1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to StockIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_IssuanceOfCommonStockForAssetAcquisition" xlink:label="IssuanceOfCommonStockForAssetAcquisition" xlink:title="IssuanceOfCommonStockForAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfCommonStockForAssetAcquisition" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to IssuanceOfCommonStockForAssetAcquisition" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:label="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:title="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:label="InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:title="InitialMeasurementOfRightOfUseAssetsAndLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InitialMeasurementOfRightOfUseAssetsAndLiabilities" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InitialMeasurementOfRightOfUseAssetsAndLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseLiabilities" xlink:label="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="InitialMeasurementOfOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InitialMeasurementOfOperatingLeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfFinanceLeaseLiabilities" xlink:label="InitialMeasurementOfFinanceLeaseLiabilities" xlink:title="InitialMeasurementOfFinanceLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InitialMeasurementOfFinanceLeaseLiabilities" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InitialMeasurementOfFinanceLeaseLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LiquidityAndCapitalResources">
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:label="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:title="LIQUIDITYANDCAPITALRESOURCESAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:to="LiquidityAndCapitalResourcesTextBlock" xlink:title="presentation: LIQUIDITYANDCAPITALRESOURCESAbstract to LiquidityAndCapitalResourcesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:title="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="LesseeOperatingAndFinanceLeasesTextBlock" xlink:title="LesseeOperatingAndFinanceLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingAndFinanceLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingAndFinanceLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CeoSeparationAgreement">
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CEOSEPARATIONAGREEMENTAbstract" xlink:label="CEOSEPARATIONAGREEMENTAbstract" xlink:title="CEOSEPARATIONAGREEMENTAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:label="ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:title="ChiefExecutiveOfficerSeparationAgreementTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CEOSEPARATIONAGREEMENTAbstract" xlink:to="ChiefExecutiveOfficerSeparationAgreementTextBlock" xlink:title="presentation: CEOSEPARATIONAGREEMENTAbstract to ChiefExecutiveOfficerSeparationAgreementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/EarningsPerShare">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/RecentAccountingPronouncements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:title="presentation: NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract to NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitPolicyTextBlock" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:title="ReverseStockSplitPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ReverseStockSplitPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ReverseStockSplitPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="PriorPeriodReclassificationAdjustmentDescription" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to PriorPeriodReclassificationAdjustmentDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/RecentAccountingPronouncementsPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:title="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="AssetAcquisitionTableTextBlock" xlink:title="AssetAcquisitionTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="AssetAcquisitionTableTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to AssetAcquisitionTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCostTableTextBlock" xlink:title="presentation: LeasesAbstract to LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:title="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: LeasesAbstract to OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="OtherLiabilitiesTableTextBlock" xlink:title="OtherLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="OtherLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to OtherLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:label="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:title="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:label="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:title="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:label="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:title="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/EarningsPerShareTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="NoveCiteINCMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to NoveCiteINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: BusinessCombinationDescriptionAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: ReverseStockSplitAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:label="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:title="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="CashPaidForFractionalSharesInConnectionWithReverseStockSplit" xlink:title="presentation: ReverseStockSplitAbstract to CashPaidForFractionalSharesInConnectionWithReverseStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfSharesConsideredAsFractionalInReverseStock" xlink:label="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:title="NumberOfSharesConsideredAsFractionalInReverseStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="NumberOfSharesConsideredAsFractionalInReverseStock" xlink:title="presentation: ReverseStockSplitAbstract to NumberOfSharesConsideredAsFractionalInReverseStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ReverseStockSplitAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to ReverseStockSplitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:label="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:title="LIQUIDITYANDCAPITALRESOURCESAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:label="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="Cash" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:to="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="presentation: LIQUIDITYANDCAPITALRESOURCESAbstract to DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="PledgingPurposeAxis" xlink:title="PledgingPurposeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain" xlink:title="PledgingPurposeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="LetterOfCreditMember" xlink:title="LetterOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PledgingPurposeDomain" xlink:to="LetterOfCreditMember" xlink:title="presentation: PledgingPurposeDomain to LetterOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PledgingPurposeAxis" xlink:to="PledgingPurposeDomain" xlink:title="presentation: PledgingPurposeAxis to PledgingPurposeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="PledgingPurposeAxis" xlink:title="presentation: SubsequentEventTable to PledgingPurposeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NewFacilityLeaseAbstract" xlink:label="NewFacilityLeaseAbstract" xlink:title="NewFacilityLeaseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewFacilityLeaseAbstract" xlink:to="AreaOfRealEstateProperty" xlink:title="presentation: NewFacilityLeaseAbstract to AreaOfRealEstateProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="LineOfCredit" xlink:title="LineOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewFacilityLeaseAbstract" xlink:to="LineOfCredit" xlink:title="presentation: NewFacilityLeaseAbstract to LineOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="RestrictedCash" xlink:title="RestrictedCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewFacilityLeaseAbstract" xlink:to="RestrictedCash" xlink:title="presentation: NewFacilityLeaseAbstract to RestrictedCash" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NewFacilityLeaseAbstract" xlink:title="presentation: SubsequentEventLineItems to NewFacilityLeaseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LIQUIDITYANDCAPITALRESOURCESAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: LIQUIDITYANDCAPITALRESOURCESAbstract to SubsequentEventTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionSharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: BusinessCombinationDescriptionAbstract to CommonStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="Goodwill" xlink:title="presentation: BusinessCombinationDescriptionAbstract to Goodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="NonrecurringAdjustmentAxis" xlink:title="NonrecurringAdjustmentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain" xlink:title="NonrecurringAdjustmentDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProFormaFairValueAdjustmentToAssetsMember" xlink:label="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="ProFormaFairValueAdjustmentToAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonrecurringAdjustmentDomain" xlink:to="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="presentation: NonrecurringAdjustmentDomain to ProFormaFairValueAdjustmentToAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PurchasePriceAllocationMember" xlink:label="PurchasePriceAllocationMember" xlink:title="PurchasePriceAllocationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonrecurringAdjustmentDomain" xlink:to="PurchasePriceAllocationMember" xlink:title="presentation: NonrecurringAdjustmentDomain to PurchasePriceAllocationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonrecurringAdjustmentAxis" xlink:to="NonrecurringAdjustmentDomain" xlink:title="presentation: NonrecurringAdjustmentAxis to NonrecurringAdjustmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="NonrecurringAdjustmentAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to NonrecurringAdjustmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="Goodwill" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to Goodwill" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:label="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="presentation: BusinessAcquisitionLineItems to ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BeneficialHoldersContractualCommitmentsToInvest" xlink:label="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="BeneficialHoldersContractualCommitmentsToInvest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="presentation: BusinessAcquisitionLineItems to BeneficialHoldersContractualCommitmentsToInvest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfAdditionalRightsOffering" xlink:label="PercentageOfAdditionalRightsOffering" xlink:title="PercentageOfAdditionalRightsOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfAdditionalRightsOffering" xlink:title="presentation: BusinessAcquisitionLineItems to PercentageOfAdditionalRightsOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromSaleOfRights" xlink:label="ProceedsFromSaleOfRights" xlink:title="ProceedsFromSaleOfRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ProceedsFromSaleOfRights" xlink:title="presentation: BusinessAcquisitionLineItems to ProceedsFromSaleOfRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBusinessMember" xlink:label="NTNBusinessMember" xlink:title="NTNBusinessMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="NTNBusinessMember" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to NTNBusinessMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DispositionAbstract" xlink:label="DispositionAbstract" xlink:title="DispositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="presentation: DispositionAbstract to ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ProceedsFromDispositionAbstract" xlink:label="ProceedsFromDispositionAbstract" xlink:title="ProceedsFromDispositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="ProceedsFromDispositionAbstract" xlink:title="presentation: DispositionAbstract to ProceedsFromDispositionAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationGoodwill1" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationOtherAssets" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="presentation: DispositionAbstract to AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:label="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:label="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="presentation: DispositionAbstract to LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="presentation: DispositionAbstract to DisposalGroupIncludingDiscontinuedOperationTransactionCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="presentation: DispositionAbstract to DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DispositionAbstract" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DispositionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="presentation: BusinessCombinationsAbstract to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="NoveCiteINCMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to NoveCiteINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: AssetAcquisitionDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusIncMember" xlink:label="NovellusIncMember" xlink:title="NovellusIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusIncMember" xlink:title="presentation: AssetAcquisitionDomain to NovellusIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="presentation: AssetAcquisitionAxis to AssetAcquisitionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="AssetAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" xlink:title="presentation: RelatedPartyDomain to ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesAcquisitions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodValueAcquisitions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionSharePrice" xlink:label="AssetAcquisitionSharePrice" xlink:title="AssetAcquisitionSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionSharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EscrowShares" xlink:label="EscrowShares" xlink:title="EscrowShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EscrowShares" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EscrowShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AcquisitionAgreementNonCompetitivePeriod" xlink:label="AcquisitionAgreementNonCompetitivePeriod" xlink:title="AcquisitionAgreementNonCompetitivePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AcquisitionAgreementNonCompetitivePeriod" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AcquisitionAgreementNonCompetitivePeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EachLockUpAgreementExtendsTerm" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EachLockUpAgreementExtendsTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PercentageOfCommonStockSubjectToLockUpAgreement" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireProductiveAssetsNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodRestrictedSharesAcquisitions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LockUpPeriodForRestrictedShares" xlink:label="LockUpPeriodForRestrictedShares" xlink:title="LockUpPeriodForRestrictedShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="LockUpPeriodForRestrictedShares" xlink:title="presentation: BusinessCombinationDescriptionAbstract to LockUpPeriodForRestrictedShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionUnrestrictedSharesSharePrice" xlink:label="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="AssetAcquisitionUnrestrictedSharesSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionUnrestrictedSharesSharePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:label="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="PercentageOfDiscountOnFairValueOfRestrictedShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PercentageOfDiscountOnFairValueOfRestrictedShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionRestrictedSharesSharePrice" xlink:label="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="AssetAcquisitionRestrictedSharesSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionRestrictedSharesSharePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireProductiveAssets" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="presentation: BusinessCombinationDescriptionAbstract to CashAcquiredFromAcquisition" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionFairValueOfConsiderationPaid" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireInvestments" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireInvestments" order="22.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="presentation: BusinessCombinationDescriptionAbstract to ResearchAndDevelopmentInProcessAssetAcquisition" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="NoveCiteINCMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to NoveCiteINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CitiusPharmaceuticalsIncMember" xlink:label="CitiusPharmaceuticalsIncMember" xlink:title="CitiusPharmaceuticalsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="CitiusPharmaceuticalsIncMember" xlink:title="presentation: OwnershipDomain to CitiusPharmaceuticalsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: InvestmentsAbstract to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: InvestmentsAbstract to MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfBoardSeats" xlink:label="NumberOfBoardSeats" xlink:title="NumberOfBoardSeats" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="NumberOfBoardSeats" xlink:title="presentation: InvestmentsAbstract to NumberOfBoardSeats" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="EquityMethodInvestments" xlink:title="presentation: InvestmentsAbstract to EquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:title="EquityMethodInvestmentRealizedGainLossOnDisposal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:title="presentation: InvestmentsAbstract to EquityMethodInvestmentRealizedGainLossOnDisposal" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="InvestmentsAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to InvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to DerivativeFinancialInstrumentsLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="presentation: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByLiabilityClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeCategorizationMember" xlink:to="PIPEInvestorMember" xlink:title="presentation: InvestmentTypeCategorizationMember to PIPEInvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="presentation: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="InvestmentTypeAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to InvestmentTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ClassOfWarrantOrRightExercised" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to ClassOfWarrantOrRightExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to ClassOfWarrantOrRightOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to LiabilitiesFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OverSubscriptionAmountReceived" xlink:label="OverSubscriptionAmountReceived" xlink:title="OverSubscriptionAmountReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="OverSubscriptionAmountReceived" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to OverSubscriptionAmountReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to StockRepurchaseProgramAuthorizedAmount1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="LiabilitiesFairValueAdjustment" xlink:title="LiabilitiesFairValueAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="LiabilitiesFairValueAdjustment" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to LiabilitiesFairValueAdjustment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to ProceedsFromWarrantExercises" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesOperatingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeaseArea" xlink:label="OperatingLeaseArea" xlink:title="OperatingLeaseArea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseArea" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseArea" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_BaseRentPerSquareFoot" xlink:label="BaseRentPerSquareFoot" xlink:title="BaseRentPerSquareFoot" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="BaseRentPerSquareFoot" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to BaseRentPerSquareFoot" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageBaseRentIncreaseOnEachAnniversary" xlink:label="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="PercentageBaseRentIncreaseOnEachAnniversary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to PercentageBaseRentIncreaseOnEachAnniversary" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseRenewalTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseROUAssets" xlink:label="InitialMeasurementOfOperatingLeaseROUAssets" xlink:title="InitialMeasurementOfOperatingLeaseROUAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="InitialMeasurementOfOperatingLeaseROUAssets" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to InitialMeasurementOfOperatingLeaseROUAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseLiabilities" xlink:label="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="InitialMeasurementOfOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to InitialMeasurementOfOperatingLeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseImpairmentLoss" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeCommitmentToPurchaseProperty" xlink:label="LesseeCommitmentToPurchaseProperty" xlink:title="LesseeCommitmentToPurchaseProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeCommitmentToPurchaseProperty" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeCommitmentToPurchaseProperty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_UnamortizedLeaseholdImprovements" xlink:label="UnamortizedLeaseholdImprovements" xlink:title="UnamortizedLeaseholdImprovements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="UnamortizedLeaseholdImprovements" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to UnamortizedLeaseholdImprovements" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="DepositsAssetsNoncurrent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to DepositsAssetsNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="LeaseCostAbstract" xlink:title="LeaseCostAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LeaseCostAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="SubleaseIncome" xlink:title="presentation: LeaseCostAbstract to SubleaseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="VariableLeaseCost" xlink:title="presentation: LeaseCostAbstract to VariableLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="LeaseCost" xlink:title="presentation: LeaseCostAbstract to LeaseCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCostAbstract" xlink:title="presentation: LeasesAbstract to LeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="AssetsAndLiabilitiesLesseeAbstract" xlink:title="AssetsAndLiabilitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeaseAssestAbstract" xlink:label="OperatingLeaseAssestAbstract" xlink:title="OperatingLeaseAssestAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseROUAssets" xlink:label="InitialMeasurementOfOperatingLeaseROUAssets" xlink:title="InitialMeasurementOfOperatingLeaseROUAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="InitialMeasurementOfOperatingLeaseROUAssets" xlink:title="presentation: OperatingLeaseAssestAbstract to InitialMeasurementOfOperatingLeaseROUAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseImpairmentLoss" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:label="RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:title="RemeasurementOfOperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="RemeasurementOfOperatingLeaseRightOfUseAsset" xlink:title="presentation: OperatingLeaseAssestAbstract to RemeasurementOfOperatingLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WriteOffOfOperatingLeaseRightOfUseAsset" xlink:label="WriteOffOfOperatingLeaseRightOfUseAsset" xlink:title="WriteOffOfOperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="WriteOffOfOperatingLeaseRightOfUseAsset" xlink:title="presentation: OperatingLeaseAssestAbstract to WriteOffOfOperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset_2" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseRightOfUseAsset_2" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAndLiabilitiesLesseeAbstract" xlink:to="OperatingLeaseAssestAbstract" xlink:title="presentation: AssetsAndLiabilitiesLesseeAbstract to OperatingLeaseAssestAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="OperatingLeaseLiabilityAbstract" xlink:title="OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialMeasurementOfOperatingLeaseLiabilities" xlink:label="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="InitialMeasurementOfOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="presentation: OperatingLeaseLiabilityAbstract to InitialMeasurementOfOperatingLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:label="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:title="PrincipalPaymentsOnOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:title="presentation: OperatingLeaseLiabilityAbstract to PrincipalPaymentsOnOperatingLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_WriteOffOfOperatingLeaseLiability" xlink:label="WriteOffOfOperatingLeaseLiability" xlink:title="WriteOffOfOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="WriteOffOfOperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilityAbstract to WriteOffOfOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability_2" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiability_2" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAndLiabilitiesLesseeAbstract" xlink:to="OperatingLeaseLiabilityAbstract" xlink:title="presentation: AssetsAndLiabilitiesLesseeAbstract to OperatingLeaseLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="AssetsAndLiabilitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to AssetsAndLiabilitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:label="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:title="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="presentation: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to Goodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="ImpairmentOfOngoingProject" xlink:title="ImpairmentOfOngoingProject" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ImpairmentOfOngoingProject" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ImpairmentOfOngoingProject" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="SharePrice" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="GoodwillImpairmentLoss" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to GoodwillImpairmentLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CeoSeparationAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CEOSEPARATIONAGREEMENTAbstract" xlink:label="CEOSEPARATIONAGREEMENTAbstract" xlink:title="CEOSEPARATIONAGREEMENTAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:title="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable to TitleOfIndividualAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MilestoneOptionsMember" xlink:label="MilestoneOptionsMember" xlink:title="MilestoneOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="MilestoneOptionsMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to MilestoneOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:title="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SeparationAgreementAbstract" xlink:label="SeparationAgreementAbstract" xlink:title="SeparationAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="PaymentsForPostemploymentBenefits" xlink:title="PaymentsForPostemploymentBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeparationAgreementAbstract" xlink:to="PaymentsForPostemploymentBenefits" xlink:title="presentation: SeparationAgreementAbstract to PaymentsForPostemploymentBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PaymentToOfficerBaseSalary" xlink:label="PaymentToOfficerBaseSalary" xlink:title="PaymentToOfficerBaseSalary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeparationAgreementAbstract" xlink:to="PaymentToOfficerBaseSalary" xlink:title="presentation: SeparationAgreementAbstract to PaymentToOfficerBaseSalary" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeparationAgreementAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: SeparationAgreementAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeparationAgreementAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: SeparationAgreementAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:label="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:title="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeparationAgreementAbstract" xlink:to="SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" xlink:title="presentation: SeparationAgreementAbstract to SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SeparationAgreementAbstract" xlink:to="SharePrice" xlink:title="presentation: SeparationAgreementAbstract to SharePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="SeparationAgreementAbstract" xlink:title="presentation: DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems to SeparationAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:title="presentation: ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable to DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CEOSEPARATIONAGREEMENTAbstract" xlink:to="ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:title="presentation: CEOSEPARATIONAGREEMENTAbstract to ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FactorBioscienceIncMember" xlink:label="FactorBioscienceIncMember" xlink:title="FactorBioscienceIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="FactorBioscienceIncMember" xlink:title="presentation: RelatedPartyDomain to FactorBioscienceIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AgreedWaivePayment" xlink:label="AgreedWaivePayment" xlink:title="AgreedWaivePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="AgreedWaivePayment" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to AgreedWaivePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MasterServiceAgreementInitialFeesPayable" xlink:label="MasterServiceAgreementInitialFeesPayable" xlink:title="MasterServiceAgreementInitialFeesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="MasterServiceAgreementInitialFeesPayable" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to MasterServiceAgreementInitialFeesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfMonthlyInstallmentsForFeesPayable" xlink:label="NumberOfMonthlyInstallmentsForFeesPayable" xlink:title="NumberOfMonthlyInstallmentsForFeesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="NumberOfMonthlyInstallmentsForFeesPayable" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to NumberOfMonthlyInstallmentsForFeesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:label="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:title="RelatedPartyTransactionPeriodicFeesPaymentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="RelatedPartyTransactionPeriodicFeesPaymentAmount" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to RelatedPartyTransactionPeriodicFeesPaymentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MonthlyMasterServicesAgreementFeesPayable" xlink:label="MonthlyMasterServicesAgreementFeesPayable" xlink:title="MonthlyMasterServicesAgreementFeesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="MonthlyMasterServicesAgreementFeesPayable" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to MonthlyMasterServicesAgreementFeesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:label="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:title="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoticePeriodForFirstTerminationOfContract" xlink:label="NoticePeriodForFirstTerminationOfContract" xlink:title="NoticePeriodForFirstTerminationOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="NoticePeriodForFirstTerminationOfContract" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to NoticePeriodForFirstTerminationOfContract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoticePeriodForSupersedingTerminationProvisions" xlink:label="NoticePeriodForSupersedingTerminationProvisions" xlink:title="NoticePeriodForSupersedingTerminationProvisions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="NoticePeriodForSupersedingTerminationProvisions" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to NoticePeriodForSupersedingTerminationProvisions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ReimburseCostsIncurredOrPaid" xlink:label="ReimburseCostsIncurredOrPaid" xlink:title="ReimburseCostsIncurredOrPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="ReimburseCostsIncurredOrPaid" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to ReimburseCostsIncurredOrPaid" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="presentation: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="presentation: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentExpenses" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedResearchAndDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedGeneralAndAdministrativeExpenses" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedGeneralAndAdministrativeExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedProfessionalFeesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="AccruedLiabilitiesCurrentAbstract" xlink:title="presentation: RestructuringCostAndReserveLineItems to AccruedLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="OtherLiabilitiesAbstract" xlink:title="OtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CurrentPortionOfLicenseFeeObligation" xlink:label="CurrentPortionOfLicenseFeeObligation" xlink:title="CurrentPortionOfLicenseFeeObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesAbstract" xlink:to="CurrentPortionOfLicenseFeeObligation" xlink:title="presentation: OtherLiabilitiesAbstract to CurrentPortionOfLicenseFeeObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InsurancePolicyPremiums" xlink:label="InsurancePolicyPremiums" xlink:title="InsurancePolicyPremiums" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesAbstract" xlink:to="InsurancePolicyPremiums" xlink:title="presentation: OtherLiabilitiesAbstract to InsurancePolicyPremiums" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: OtherLiabilitiesAbstract to OtherLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LongTermPortionOfLicenseFeeObligation" xlink:label="LongTermPortionOfLicenseFeeObligation" xlink:title="LongTermPortionOfLicenseFeeObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesAbstract" xlink:to="LongTermPortionOfLicenseFeeObligation" xlink:title="presentation: OtherLiabilitiesAbstract to LongTermPortionOfLicenseFeeObligation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="OtherSundryLiabilitiesNoncurrent" xlink:title="OtherSundryLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesAbstract" xlink:to="OtherSundryLiabilitiesNoncurrent" xlink:title="presentation: OtherLiabilitiesAbstract to OtherSundryLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="OtherLiabilities" xlink:title="OtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesAbstract" xlink:to="OtherLiabilities" xlink:title="presentation: OtherLiabilitiesAbstract to OtherLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="OtherLiabilitiesAbstract" xlink:title="presentation: RestructuringCostAndReserveLineItems to OtherLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveLineItems" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfRestructuringAndRelatedCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_DheshGovenderMember" xlink:label="DheshGovenderMember" xlink:title="DheshGovenderMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="DheshGovenderMember" xlink:title="presentation: RelatedPartyDomain to DheshGovenderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LegalMattersAbstract" xlink:label="LegalMattersAbstract" xlink:title="LegalMattersAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyDamagesSoughtExpectedSalary" xlink:label="LossContingencyDamagesSoughtExpectedSalary" xlink:title="LossContingencyDamagesSoughtExpectedSalary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyDamagesSoughtExpectedSalary" xlink:title="presentation: LegalMattersAbstract to LossContingencyDamagesSoughtExpectedSalary" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:label="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="LossContingencyDamagesSoughtExpectedEquityPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="presentation: LegalMattersAbstract to LossContingencyDamagesSoughtExpectedEquityPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="LossContingencyDamagesSoughtValue" xlink:title="LossContingencyDamagesSoughtValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyDamagesSoughtValue" xlink:title="presentation: LegalMattersAbstract to LossContingencyDamagesSoughtValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyNumberOfArbitrationPanel" xlink:label="LossContingencyNumberOfArbitrationPanel" xlink:title="LossContingencyNumberOfArbitrationPanel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyNumberOfArbitrationPanel" xlink:title="presentation: LegalMattersAbstract to LossContingencyNumberOfArbitrationPanel" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="LitigationSettlementAmountAwardedToOtherParty" xlink:title="LitigationSettlementAmountAwardedToOtherParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LitigationSettlementAmountAwardedToOtherParty" xlink:title="presentation: LegalMattersAbstract to LitigationSettlementAmountAwardedToOtherParty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="LegalMattersAbstract" xlink:title="presentation: LossContingenciesLineItems to LegalMattersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_UniversityOfSouthFloridaMember" xlink:label="UniversityOfSouthFloridaMember" xlink:title="UniversityOfSouthFloridaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="UniversityOfSouthFloridaMember" xlink:title="presentation: EntityDomain to UniversityOfSouthFloridaMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LegalEntityAxis" xlink:title="presentation: LossContingenciesTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NovellusLtdAndFactorBioscienceMember" xlink:label="NovellusLtdAndFactorBioscienceMember" xlink:title="NovellusLtdAndFactorBioscienceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NovellusLtdAndFactorBioscienceMember" xlink:title="presentation: RelatedPartyDomain to NovellusLtdAndFactorBioscienceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NoveCiteMember" xlink:label="NoveCiteMember" xlink:title="NoveCiteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NoveCiteMember" xlink:title="presentation: RelatedPartyDomain to NoveCiteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: LossContingenciesTable to StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LicensingAgreementsAbstract" xlink:label="LicensingAgreementsAbstract" xlink:title="LicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyPercentageOfRoyaltyPayable" xlink:label="LossContingencyPercentageOfRoyaltyPayable" xlink:title="LossContingencyPercentageOfRoyaltyPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="LossContingencyPercentageOfRoyaltyPayable" xlink:title="presentation: LicensingAgreementsAbstract to LossContingencyPercentageOfRoyaltyPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_LossContingencyNonRefundableOptionFee" xlink:label="LossContingencyNonRefundableOptionFee" xlink:title="LossContingencyNonRefundableOptionFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="LossContingencyNonRefundableOptionFee" xlink:title="presentation: LicensingAgreementsAbstract to LossContingencyNonRefundableOptionFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InitialLicenseFees" xlink:label="InitialLicenseFees" xlink:title="InitialLicenseFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="InitialLicenseFees" xlink:title="presentation: LicensingAgreementsAbstract to InitialLicenseFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AdditionalFeesObligatedToPay" xlink:label="AdditionalFeesObligatedToPay" xlink:title="AdditionalFeesObligatedToPay" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AdditionalFeesObligatedToPay" xlink:title="presentation: LicensingAgreementsAbstract to AdditionalFeesObligatedToPay" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountRequireToPayInitialLicenseFees" xlink:label="AmountRequireToPayInitialLicenseFees" xlink:title="AmountRequireToPayInitialLicenseFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AmountRequireToPayInitialLicenseFees" xlink:title="presentation: LicensingAgreementsAbstract to AmountRequireToPayInitialLicenseFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountObligatedToPayInYearOne" xlink:label="AmountObligatedToPayInYearOne" xlink:title="AmountObligatedToPayInYearOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AmountObligatedToPayInYearOne" xlink:title="presentation: LicensingAgreementsAbstract to AmountObligatedToPayInYearOne" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AmountObligatedToPayInYearTwo" xlink:label="AmountObligatedToPayInYearTwo" xlink:title="AmountObligatedToPayInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AmountObligatedToPayInYearTwo" xlink:title="presentation: LicensingAgreementsAbstract to AmountObligatedToPayInYearTwo" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="MilestonePayments" xlink:title="presentation: LicensingAgreementsAbstract to MilestonePayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfRevenue" xlink:label="PercentageOfRevenue" xlink:title="PercentageOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="PercentageOfRevenue" xlink:title="presentation: LicensingAgreementsAbstract to PercentageOfRevenue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="LicensingAgreementsAbstract" xlink:title="presentation: LossContingenciesLineItems to LicensingAgreementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InvestorRoyaltyAgreementMember" xlink:label="InvestorRoyaltyAgreementMember" xlink:title="InvestorRoyaltyAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="InvestorRoyaltyAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to InvestorRoyaltyAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CollaboratorRoyaltyAgreementMember" xlink:label="CollaboratorRoyaltyAgreementMember" xlink:title="CollaboratorRoyaltyAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaboratorRoyaltyAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaboratorRoyaltyAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LossContingenciesTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_RoyaltyAgreementsAbstract" xlink:label="RoyaltyAgreementsAbstract" xlink:title="RoyaltyAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:label="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementsAbstract" xlink:to="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="presentation: RoyaltyAgreementsAbstract to PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:label="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementsAbstract" xlink:to="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="presentation: RoyaltyAgreementsAbstract to PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="RoyaltyAgreementsAbstract" xlink:title="presentation: LossContingenciesLineItems to RoyaltyAgreementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TimeBasedStockOptionGrantMember" xlink:label="TimeBasedStockOptionGrantMember" xlink:title="TimeBasedStockOptionGrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="TimeBasedStockOptionGrantMember" xlink:title="presentation: EmployeeStockOptionMember to TimeBasedStockOptionGrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PerformanceBasedStockOptionGrantMember" xlink:label="PerformanceBasedStockOptionGrantMember" xlink:title="PerformanceBasedStockOptionGrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="PerformanceBasedStockOptionGrantMember" xlink:title="presentation: EmployeeStockOptionMember to PerformanceBasedStockOptionGrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="presentation: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="presentation: VestingAxis to VestingDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_InterimChiefExecutiveOfficerMember" xlink:label="InterimChiefExecutiveOfficerMember" xlink:title="InterimChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InterimChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InterimChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to AllocatedShareBasedCompensationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ProceedsFromStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationRsusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfAwardsVestedAndSettledAbstract" xlink:label="NumberOfAwardsVestedAndSettledAbstract" xlink:title="NumberOfAwardsVestedAndSettledAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfAwardsVestedAndSettledAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: NumberOfAwardsVestedAndSettledAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonStockWithheldToCoverTaxes" xlink:label="CommonStockWithheldToCoverTaxes" xlink:title="CommonStockWithheldToCoverTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfAwardsVestedAndSettledAbstract" xlink:to="CommonStockWithheldToCoverTaxes" xlink:title="presentation: NumberOfAwardsVestedAndSettledAbstract to CommonStockWithheldToCoverTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfAwardsVestedAndSettledAbstract" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:title="presentation: NumberOfAwardsVestedAndSettledAbstract to StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfAwardsVestedAndSettledAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfAwardsVestedAndSettledAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_Two022PerformanceBasedRestrictedStockUnitsMember" xlink:label="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:title="Two022PerformanceBasedRestrictedStockUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="Two022PerformanceBasedRestrictedStockUnitsMember" xlink:title="presentation: RestrictedStockUnitsRSUMember to Two022PerformanceBasedRestrictedStockUnitsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_EmployeeMember" xlink:label="EmployeeMember" xlink:title="EmployeeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeeMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to EmployeeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ChiefExecutiveOfficerAndPresidentMember" xlink:label="ChiefExecutiveOfficerAndPresidentMember" xlink:title="ChiefExecutiveOfficerAndPresidentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerAndPresidentMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerAndPresidentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:label="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:title="NumberOfPerformanceGoalsAreSubjectToAchieve" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="NumberOfPerformanceGoalsAreSubjectToAchieve" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to NumberOfPerformanceGoalsAreSubjectToAchieve" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="PaymentsForPostemploymentBenefits" xlink:title="PaymentsForPostemploymentBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="PaymentsForPostemploymentBenefits" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to PaymentsForPostemploymentBenefits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to AllocatedShareBasedCompensationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:title="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeCategorizationMember" xlink:to="PIPEInvestorMember" xlink:title="presentation: InvestmentTypeCategorizationMember to PIPEInvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="presentation: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="InvestmentTypeAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to InvestmentTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PrivatePlacementOfEquityAbstract" xlink:label="PrivatePlacementOfEquityAbstract" xlink:title="PrivatePlacementOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="presentation: PrivatePlacementOfEquityAbstract to StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="presentation: PrivatePlacementOfEquityAbstract to StockRepurchaseProgramAuthorizedAmount1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_VariableRateTransactionsPeriod" xlink:label="VariableRateTransactionsPeriod" xlink:title="VariableRateTransactionsPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="VariableRateTransactionsPeriod" xlink:title="presentation: PrivatePlacementOfEquityAbstract to VariableRateTransactionsPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightsExercisableTerm" xlink:label="ClassOfWarrantOrRightsExercisableTerm" xlink:title="ClassOfWarrantOrRightsExercisableTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightsExercisableTerm" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightsExercisableTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: PrivatePlacementOfEquityAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: PrivatePlacementOfEquityAbstract to WarrantsAndRightsOutstandingTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightExercised" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ProceedsFromIssuanceOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="presentation: PrivatePlacementOfEquityAbstract to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OverSubscriptionAmountReceived" xlink:label="OverSubscriptionAmountReceived" xlink:title="OverSubscriptionAmountReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="OverSubscriptionAmountReceived" xlink:title="presentation: PrivatePlacementOfEquityAbstract to OverSubscriptionAmountReceived" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:label="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:title="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ObligationToPayLiquidatedDamagesPercentage" xlink:label="ObligationToPayLiquidatedDamagesPercentage" xlink:title="ObligationToPayLiquidatedDamagesPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ObligationToPayLiquidatedDamagesPercentage" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ObligationToPayLiquidatedDamagesPercentage" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TransactionFeesPayable" xlink:label="TransactionFeesPayable" xlink:title="TransactionFeesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="TransactionFeesPayable" xlink:title="presentation: PrivatePlacementOfEquityAbstract to TransactionFeesPayable" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ConsecutiveCalendarDays" xlink:label="ConsecutiveCalendarDays" xlink:title="ConsecutiveCalendarDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ConsecutiveCalendarDays" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ConsecutiveCalendarDays" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_AggregateCalendarDays" xlink:label="AggregateCalendarDays" xlink:title="AggregateCalendarDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="AggregateCalendarDays" xlink:title="presentation: PrivatePlacementOfEquityAbstract to AggregateCalendarDays" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="LossContingencyEstimateOfPossibleLoss" xlink:title="LossContingencyEstimateOfPossibleLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="LossContingencyEstimateOfPossibleLoss" xlink:title="presentation: PrivatePlacementOfEquityAbstract to LossContingencyEstimateOfPossibleLoss" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="LossContingencyDamagesPaidValue" xlink:title="LossContingencyDamagesPaidValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="LossContingencyDamagesPaidValue" xlink:title="presentation: PrivatePlacementOfEquityAbstract to LossContingencyDamagesPaidValue" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="PrivatePlacementOfEquityAbstract" xlink:title="presentation: SubsidiarySaleOfStockLineItems to PrivatePlacementOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockLineItems" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="presentation: StockholdersEquityNoteAbstract to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/StockholdersEquityMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="presentation: ClassOfStockDomain to CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="presentation: ClassOfStockDomain to CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfStockByClassTable to BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_MergerAbstract" xlink:label="MergerAbstract" xlink:title="MergerAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="SharesIssued" xlink:title="presentation: MergerAbstract to SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="ConversionOfStockSharesConverted1" xlink:title="presentation: MergerAbstract to ConversionOfStockSharesConverted1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="ClassOfWarrantOrRightIssued" xlink:title="presentation: MergerAbstract to ClassOfWarrantOrRightIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: MergerAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="presentation: MergerAbstract to StockIssuedDuringPeriodSharesAcquisitions1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="MergerAbstract" xlink:title="presentation: ClassOfStockLineItems to MergerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to ClassOfWarrantOrRightAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ERSquibbSonsLLCMember" xlink:label="ERSquibbSonsLLCMember" xlink:title="ERSquibbSonsLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ERSquibbSonsLLCMember" xlink:title="presentation: RelatedPartyDomain to ERSquibbSonsLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ExacisBiotherapeuticsIncMember" xlink:label="ExacisBiotherapeuticsIncMember" xlink:title="ExacisBiotherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ExacisBiotherapeuticsIncMember" xlink:title="presentation: RelatedPartyDomain to ExacisBiotherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="PledgingPurposeAxis" xlink:title="PledgingPurposeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="PledgingPurposeDomain" xlink:title="PledgingPurposeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="LetterOfCreditMember" xlink:title="LetterOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PledgingPurposeDomain" xlink:to="LetterOfCreditMember" xlink:title="presentation: PledgingPurposeDomain to LetterOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PledgingPurposeAxis" xlink:to="PledgingPurposeDomain" xlink:title="presentation: PledgingPurposeAxis to PledgingPurposeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="PledgingPurposeAxis" xlink:title="presentation: SubsequentEventTable to PledgingPurposeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_FacilitySubleaseAbstract" xlink:label="FacilitySubleaseAbstract" xlink:title="FacilitySubleaseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FacilitySubleaseAbstract" xlink:to="AreaOfRealEstateProperty" xlink:title="presentation: FacilitySubleaseAbstract to AreaOfRealEstateProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FacilitySubleaseAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: FacilitySubleaseAbstract to LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FacilitySubleaseAbstract" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="presentation: FacilitySubleaseAbstract to LesseeOperatingLeaseRenewalTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_TermToPaySecurityDeposit" xlink:label="TermToPaySecurityDeposit" xlink:title="TermToPaySecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FacilitySubleaseAbstract" xlink:to="TermToPaySecurityDeposit" xlink:title="presentation: FacilitySubleaseAbstract to TermToPaySecurityDeposit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="LineOfCredit" xlink:title="LineOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FacilitySubleaseAbstract" xlink:to="LineOfCredit" xlink:title="presentation: FacilitySubleaseAbstract to LineOfCredit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OperatingLeasesMonthlyBaseRent" xlink:label="OperatingLeasesMonthlyBaseRent" xlink:title="OperatingLeasesMonthlyBaseRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FacilitySubleaseAbstract" xlink:to="OperatingLeasesMonthlyBaseRent" xlink:title="presentation: FacilitySubleaseAbstract to OperatingLeasesMonthlyBaseRent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="FacilitySubleaseAbstract" xlink:title="presentation: SubsequentEventLineItems to FacilitySubleaseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_ExacisOptionAgreementAbstract" xlink:label="ExacisOptionAgreementAbstract" xlink:title="ExacisOptionAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="erna-20220930.xsd#erna_OptionFee" xlink:label="OptionFee" xlink:title="OptionFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExacisOptionAgreementAbstract" xlink:to="OptionFee" xlink:title="presentation: ExacisOptionAgreementAbstract to OptionFee" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ExacisOptionAgreementAbstract" xlink:title="presentation: SubsequentEventLineItems to ExacisOptionAgreementAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !4 'X# 2(  A$! Q$!_\0
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M  TFE94B&HS(78X 9D4*/Q-+^T=975[\+;W[*LCQP3Q3W*QC+&%6^8CZ<'Z
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M=L]&TUIFM+4,L9F8,YRQ8Y( [D]JS_"VC72W<NM:X5?5;A<*@^[;I_<7^O\
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img001_v1.jpg
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 40&3 P$1  (1 0,1 ?_$ 'H  0 " P$! 0
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MMBVLS]?>IRZC?0,\RQJ;."_RP[M\V&1O].>(G'QQDXR [M=T0=] 0$! 0$!
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M(T%I].Z-"Y/==MM?;CWU&0,F9M9VV9,.'22+MQ'V./@YK4'T)K6M:&M :T>
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M=X?)YOPY06E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0!GVH" @(" @("#S)'')&Z.1@?&X8<QP!!'O!08\F']#?E[/ ?+^G[D'
MM 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 'M^] 0$! 0$! 0$! 0$! 0$! 0$! 0
2$! 0$! 0$! 0$! 0$! 0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img002_v1.jpg
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 6@%- P$1  (1 0,1 ?_$ 'X  0 #  ,! 0
M       $!08! @,'" $!                     !   00! @,%!00'!@<
M     0 " P0%$08A,1)!46$B$W&!0A0'D3)2%<%B<H(C0S6AL>$S4V.R<X,D
M1!8W$0$                     _]H # ,!  (1 Q$ /P#]4@ #@-$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0?.OJ]G=Q;=DVYF\4^:2E!D&QY>C%RFK2-(=J.]IXA!
M]"@FBGACGA>)(I6A\;V\0YKAJ"/:$'= 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$!!3[HP1S-*M7#FM,%RK9)<-=60S-?(W]Y@+4$#
M8,SH<;9P,SM;.!L/IG_D'26J?9Z#VM]H*#3H" @(" @(" @(" @(" @(" @(
M" @("#(_4S=-_:N$IY^(C\MIY"L,X.D.=\C._P!"1S>XL?*Q^NO(=R#6M<US
M0YI#FN&K7#B"#VA!R@(" @(" @(" @(" @(" @Q^6C9A=_XK+L\E7/QOQ&0_
M#\Q&TV*4A]S)HO$N:@V" @(" @(" @(" @(" @(" @(" @(" @K-SX"GN';N
M2P=T U<E6EK2:C702-+0X>+3Q'B@S?T:R=NWL&A3R#B<IA2_$Y /UZ_5HO,&
MKM2>+FL#M=>U!MT! 0$! 0$! 0$! 0$! 0$%-O#;[,_MR[C->BQ(SKI3\C%9
MB/7!*/V)6M*#UVQF!F,#3R!C,,DT8]:!WWHY6\)&.\6N!""T0$! 0$! 0$!
M0$! 00LGF\+BH73Y2_6H0M&KI;4T<+0#PU+GEH00J^]=I6G]%7+U++O]F5D@
MY:\V$A!-JYO$6R15NPS$'0]#VNT/N*":@(" @(" @PN%D.'^J.;Q);T5<]7B
MR]31IT,\;17LCJY:Z1L=IXH-T@H=S[UP>VY:,.1,SILBY[:L5>"2P\B(!SW%
ML37$-:"-24$_"Y_#9NF+F*MQW*^I:7Q.!T<.;7#L([B@GH" @(" @(" @("
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MO /Y.?4<[62(Z\W0O=]A\$$?:T\>X]\YC<4;2ZABV?D^-F(\KY&N+K3F?LO
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9(" @(" @(" @(" @(" @(" @(" @("#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732759584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eterna Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10355 Science Center Drive, Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Brooklyn ImmunoTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.005 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,942,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732859888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 13,254<span></span>
</td>
<td class="nump">$ 16,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">15,852<span></span>
</td>
<td class="nump">18,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">2,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in non-controlling interest</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,926<span></span>
</td>
<td class="nump">31,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,230<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">3,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,690<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,113<span></span>
</td>
<td class="nump">6,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.005 par value, 100,000 shares authorized at September 30, 2022 and December 31, 2021; 2,942 and 2,601 issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">169,596<span></span>
</td>
<td class="nump">166,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(160,799)<span></span>
</td>
<td class="num">(140,701)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">8,813<span></span>
</td>
<td class="nump">25,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">20,926<span></span>
</td>
<td class="nump">31,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.005 par value, 1,000 shares authorized, 156 designated and outstanding of Series A convertible preferred stock at September 30, 2022 and December 31, 2021, $156 liquidation preference</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734978912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference | $</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734635376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 4,963<span></span>
</td>
<td class="nump">$ 1,491<span></span>
</td>
<td class="nump">$ 8,430<span></span>
</td>
<td class="nump">$ 8,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,538<span></span>
</td>
<td class="nump">5,990<span></span>
</td>
<td class="nump">80,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,341<span></span>
</td>
<td class="nump">4,247<span></span>
</td>
<td class="nump">14,060<span></span>
</td>
<td class="nump">10,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,765<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,304<span></span>
</td>
<td class="nump">86,276<span></span>
</td>
<td class="nump">28,480<span></span>
</td>
<td class="nump">105,210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,304)<span></span>
</td>
<td class="num">(86,276)<span></span>
</td>
<td class="num">(28,480)<span></span>
</td>
<td class="num">(105,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of NTN assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_WarrantLiabilitiesExpense', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossOnNonControllingInvestment', window );">Loss on non-controlling investment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(932)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">8,395<span></span>
</td>
<td class="num">(9,383)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(7,311)<span></span>
</td>
<td class="num">(85,986)<span></span>
</td>
<td class="num">(20,085)<span></span>
</td>
<td class="num">(114,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,316)<span></span>
</td>
<td class="num">(85,986)<span></span>
</td>
<td class="num">(20,090)<span></span>
</td>
<td class="num">(114,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Series A preferred stock dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (7,316)<span></span>
</td>
<td class="num">$ (85,986)<span></span>
</td>
<td class="num">$ (20,098)<span></span>
</td>
<td class="num">$ (114,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (34.03)<span></span>
</td>
<td class="num">$ (7.04)<span></span>
</td>
<td class="num">$ (56.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (34.03)<span></span>
</td>
<td class="num">$ (7.04)<span></span>
</td>
<td class="num">$ (56.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossOnNonControllingInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss on non-controlling investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossOnNonControllingInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_WarrantLiabilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_WarrantLiabilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732764064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)<br></strong></div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Sep. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ReverseStockSplitAbstract', window );"><strong>Reverse Stock-Split [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ReverseStockSplitAbstract', window );"><strong>Reverse Stock-Split [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ReverseStockSplitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ReverseStockSplitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752727473072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Class A [Member]</div>
</th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Class B [Member]</div>
</th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Class C [Member]</div>
</th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Common [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 23,202<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (18,141)<span></span>
</td>
<td class="nump">$ 7,659<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits', window );">Brooklyn rights offerings membership units</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity', window );">Elimination of Brooklyn's historical members' equity</a></td>
<td class="num">(33,702)<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueAcquisitions1', window );">Issuance of common stock for business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesAcquisitions1', window );">Issuance of common stock for business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders', window );">Series A preferred stock retained in business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders', window );">Series A preferred stock retained in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountAcquisitions', window );">Issuance of common stock to Brooklyn members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsAcquisitions', window );">Issuance of common stock to Brooklyn members (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Financial Advisor upon consummation of merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,765<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Financial Advisor upon consummation of merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueStockPurchaseAgreement', window );">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">52,025<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement', window );">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueInLieuOfDividends', window );">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesInLieuOfDividends', window );">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueAcquisitions2', window );">Issuance of common stock in connection with the acquisition of Novellus, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesAcquisitions2', window );">Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(114,593)<span></span>
</td>
<td class="num">(114,593)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">164,258<span></span>
</td>
<td class="num">(132,742)<span></span>
</td>
<td class="nump">31,530<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">100,347<span></span>
</td>
<td class="num">(46,756)<span></span>
</td>
<td class="nump">53,603<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CommonStockToBeRetainedByNTNValueStockholders', window );">Common stock to be retained by NTN stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CommonStockToBeRetainedByNTNSharesStockholders', window );">Common stock to be retained by NTN stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueStockPurchaseAgreement', window );">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement', window );">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueInLieuOfDividends', window );">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesInLieuOfDividends', window );">Issuance of common stock in lieu of cash dividend to Series A preferred stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueAcquisitions2', window );">Issuance of common stock in connection with the acquisition of Novellus, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesAcquisitions2', window );">Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(85,986)<span></span>
</td>
<td class="num">(85,986)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">164,258<span></span>
</td>
<td class="num">(132,742)<span></span>
</td>
<td class="nump">31,530<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">166,190<span></span>
</td>
<td class="num">(140,701)<span></span>
</td>
<td class="nump">25,503<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValuePrivateOffering', window );">Issuance of common stock in connection with private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesPrivateOffering', window );">Issuance of common stock in connection with private offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock from vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock from vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants', window );">Issuance of common stock from exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants', window );">Issuance of common stock from exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Cash dividends to Series A preferred stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Cash dividends to Series A preferred stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,090)<span></span>
</td>
<td class="num">(20,090)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">169,596<span></span>
</td>
<td class="num">(160,799)<span></span>
</td>
<td class="nump">8,813<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">168,246<span></span>
</td>
<td class="num">(153,483)<span></span>
</td>
<td class="nump">14,778<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock from vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock from vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants', window );">Issuance of common stock from exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants', window );">Issuance of common stock from exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,316)<span></span>
</td>
<td class="num">(7,316)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 169,596<span></span>
</td>
<td class="num">$ (160,799)<span></span>
</td>
<td class="nump">$ 8,813<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in redemption of temporary equity as the result of a triggering event associated with the temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CommonStockToBeRetainedByNTNSharesStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock to be retained by NTN stockholders during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CommonStockToBeRetainedByNTNSharesStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CommonStockToBeRetainedByNTNValueStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock to be retained by NTN stockholders during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CommonStockToBeRetainedByNTNValueStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares Forfeiture of unvested restricted stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesAcquisitions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesAcquisitions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesInLieuOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period in lieu of dividends to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesInLieuOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the shares of new stock issued of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesPrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been issued in private offering during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesPrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been issued in a stock purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueAcquisitions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueAcquisitions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Forfeiture of unvested restricted stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueInLieuOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period in Lieu of Dividends to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueInLieuOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValuePrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been issued in private offering during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValuePrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to rights offering membership units during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodValueStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been issued in a stock purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodValueStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the different classes of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the number of units for each class of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=66023778&amp;loc=d3e9334-128500<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=66023778&amp;loc=d3e9337-128500<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=66023778&amp;loc=d3e9298-128500<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 05<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=66006417&amp;loc=d3e8580-128490<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732339840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (Parenthetical)<br></strong></div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Sep. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732603552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,090)<span></span>
</td>
<td class="num">$ (114,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of right-of-use asset</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfOngoingProject', window );">Impairment of in-process research and development</a></td>
<td class="nump">5,990<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ResearchAndDevelopmentInProcessAssetAcquisition', window );">In-process R&amp;D acquired in Novellus asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Transaction costs - shares to Financial Advisor</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of NTN assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_GainLossOnDisposalOfFixedAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan', window );">Gain on forgiveness of PPP loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_GainOnTerminationOfLease', window );">Gain on lease termination</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_WarrantLiabilitiesExpense', window );">Gain on lease warrant liabilities</a></td>
<td class="num">(10,493)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossOnNonControllingInvestment', window );">Loss on non-controlling investment</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivable</a></td>
<td class="num">(237)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(575)<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">4,043<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,541)<span></span>
</td>
<td class="num">(16,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PaymentsToAcquireProductiveAssetsNet', window );">Purchase of Novellus, net of common stock issue and cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sales of fixed assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfAssetsInvestingActivities', window );">Purchase of NTN, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the sale of NTN assets, net of cash disposed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(22,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants in connection with private offering</a></td>
<td class="nump">11,993<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants', window );">Issuance of common stock from exercise of pre-funded warrants</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payroll tax remitted on net share settlement of equity awards</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Dividends paid to Series A preferred stockholders</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ProceedsFromIssuanceOfCommonStockToLincolnPark', window );">Proceeds from issuance of common stock to Lincoln Park</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark', window );">Fees incurred in connection with the common stock issued to Lincoln Park</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from sale of members' equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PaymentsOfPaycheckProtectionProgramLoan', window );">Repayment of NTN's PPP loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,986<span></span>
</td>
<td class="nump">62,004<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(3,731)<span></span>
</td>
<td class="nump">22,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,985<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">13,254<span></span>
</td>
<td class="nump">24,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CashPaidDuringThePeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ConversionOfWarrantLiabilityToEquity', window );">Conversion of warrant liability to equity</a></td>
<td class="nump">867<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend', window );">Issuance of common stock for Series A preferred stock dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_IssuanceOfCommonStockForAssetAcquisition', window );">Issuance of common Stock for Novellus acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger', window );">Series A preferred stock retained in business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities', window );">Initial measurement of ROU assets, net of tenant improvement allowance</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfOperatingLeaseLiabilities', window );">Initial measurement of operating lease liabilities</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfFinanceLeaseLiabilities', window );">Initial measurement of finance lease liabilities</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CashPaidDuringThePeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CashPaidDuringThePeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ConversionOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The conversion of warrant liability to equity in non-cash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ConversionOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the fees incurred in connection with the common stock issued to Lincoln Park to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_GainLossOnDisposalOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_GainLossOnDisposalOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on forgiveness of PPP loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_GainOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_GainOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of finance lease liabilities in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of operating lease liabilities in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of Initial measurement of ROU assets and liabilities in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_IssuanceOfCommonStockForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The issuance of common stock for asset acquisition in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_IssuanceOfCommonStockForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of issuance of common stock for Series A preferred stock dividend in non-cash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash flows from issuance of common stock from exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossOnNonControllingInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss on non-controlling investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossOnNonControllingInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of preferred stock issued in a reverse merger transaction in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PaymentsOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for payment of paycheck protection program loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PaymentsOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PaymentsToAcquireProductiveAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PaymentsToAcquireProductiveAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ProceedsFromIssuanceOfCommonStockToLincolnPark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the proceeds from issuance of common stock to Lincoln Park to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ProceedsFromIssuanceOfCommonStockToLincolnPark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ResearchAndDevelopmentInProcessAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ResearchAndDevelopmentInProcessAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_WarrantLiabilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_WarrantLiabilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfOngoingProject">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfOngoingProject</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752739487920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
         </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1)</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></div>
              </td>

  </tr>


</table>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Description of Business</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On October 11, 2022, Eterna Therapeutics Inc., a Delaware corporation, (&#8220;Eterna&#8221; or the &#8220;Company&#8221;), filed with the Secretary of State of the State of Delaware a Certificate of A<span style="font-size: 10pt;">mendment to its Restated Certificate of Incorporation, as amended (the &#8220;Charter&#8221;), to change its name from Brooklyn ImmunoTherapeutics, Inc. to Eterna Therapeutics Inc., which became effective on October 17, 2022
                  (the &#8220;Name Change&#8221;). The Name Change did not require approval of the Company&#8217;s stockholders and did not affect the rights of the Company&#8217;s security holders. </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In connection with the Name Change, the trading symbol of the Company&#8217;s common stock, par value
                $0.005 per share (&#8220;common stock&#8221;), on The Nasdaq Global Market changed from &#8220;BTX&#8221; to &#8220;ERNA.&#8221;</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Eterna, together with its subsidiaries including Brooklyn ImmunoTherapeutics LLC (<span style="font-size: 10pt;">&#8220;Brooklyn LLC&#8221;), Novellus,
                Inc. (&#8220;Novellus&#8221;) and Novellus Therapeutics Limited (&#8220;Novellus Ltd.&#8221;), is a biopharmaceutical company using its mRNA technology platform, including mRNA-based cell reprogramming and gene editing technologies, to create next generation mRNA,
                gene editing and cell therapies, including iPSC therapies for multiple therapeutic indications. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company also plans to develop and advance a pipeline of therapeutic products both internally and through strategic partnerships. </span>As used herein, the
                &#8220;Company&#8221; refers collectively to Eterna and its subsidiaries.</span></div>

<div><br/></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2020, Eterna (then known as &#8220;NTN Buzztime, Inc.&#8221;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of Eterna
              (the &#8220;Merger Sub&#8221;), entered into an agreement and plan of merger and reorganization (the &#8220;Merger Agreement&#8221;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned
              subsidiary of Eterna and as the surviving company of the merger (the &#8220;Merger&#8221;). The Merger closed on March 25, 2021. In connection with the Merger, the Company changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.,&#8221;
              <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and, as described above, the Company has since changed
                its name to Eterna Therapeutics Inc. </span>The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Eterna sold its rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN
              Buzztime, Inc.&#8221; (the &#8220;Disposition&#8221;) prior to the Merger to eGames.com Holdings LLC (&#8220;eGames.com&#8221;) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Eterna and eGames.com (the &#8220;Asset
              Purchase Agreement&#8221;). </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">On July 16, 2021, Eterna and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an
          agreement and plan of acquisition (the &#8220;Novellus Acquisition Agreement&#8221;) with (a) Novellus LLC, (b) Novellus (the sole equity holder of Novellus Ltd. and, prior to the closing under the Novellus Acquisition Agreement, a subsidiary of Novellus
          LLC), and (c) a seller representative (the &#8220;Novellus Acquisition&#8221;), pursuant to which Eterna acquired Novellus and its subsidiary, Novellus Ltd. As part of the Novellus Acquisition, Eterna also acquired 25.0% of the total outstanding equity interests of NoveCite, Inc. (&#8220;NoveCite&#8221;), a corporation focused on developing an allogeneic mesenchymal stem cell product for patients
          with acute respiratory distress syndrome, including from COVID-19. </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Basis of Presentation</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The


          accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial statements and with the instructions to
          Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited financial statements include all the
          normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented.<br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">These































          condensed consolidated financial statements should be read together with the audited consolidated financial statements and notes thereto contained in Eterna&#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2021 filed with the
          Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 30, 2022 (the &#8220;10-K/A&#8221;). The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements contained in the 10-K/A but does
          not include all of the information and footnotes required by GAAP for complete financial statements. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be anticipated
          for the entire year ending December 31, 2022, or any other period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman'; font-style: italic;">Reverse Stock Split</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">A<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">s approved by the Company&#8217;s stockholders at the Company&#8217;s Annual Meeting of Stockholders held
              on September 21, 2022, the Company effected a reverse stock split of its common stock at a ratio of <span style="-sec-ix-hidden:Fact_b943329114c841ec8b57e15e6be15da4">1-for-20</span>, as determined by the
              Company&#8217;s Board of Directors within the parameters approved by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split&#8221;).&#160; The Reverse Stock Split became effective under Delaware law at 11:59 p.m. Eastern time on October 16, 2022.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common stock were automatically
            combined and reclassified into one issued and outstanding share of common stock. The Reverse Stock Split did not affect any stockholder&#8217;s ownership percentage of the common stock, alter the par value of the common stock or modify any voting
            rights or other terms of the common stock. The number of authorized shares of common stock under the Charter remains unchanged. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares to
            which a stockholder would otherwise be entitled, the Company paid an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the then fair value of a share as determined in good
            faith by the Board. The Company paid an aggregate of $719 for a total of 175 fractional shares.<br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">All share and per share data in this Quarterly Report on Form 10-Q have been adjusted for all periods presented to reflect the Reverse
            Stock Split.</div>

<div><br/>
        </div>

<div>
         <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-style: italic;">Reclassifications</span><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain reclassifications have been made
          to Eterna&#8217;s prior years&#8217; financial statements to conform to the current year presentation. These reclassifications had no effect on Eterna&#8217;s previously reported results of operations or accumulated deficit.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752738042992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND CAPITAL RESOURCES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LIQUIDITYANDCAPITALRESOURCESAbstract', window );"><strong>LIQUIDITY AND CAPITAL RESOURCES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LiquidityAndCapitalResourcesTextBlock', window );">LIQUIDITY AND CAPITAL RESOURCES</a></td>
<td class="text">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2)</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">LIQUIDITY AND CAPITAL RESOURCES</div>
              </td>

  </tr>


</table>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting clinical trials and providing general and
              administrative support for operations. As of September 30, 2022, the Company had a cash balance of approximately $13.3 million and
              an accumulated deficit of approximately $160.8 million. For the three and nine months ended September 30, 2022, the Company
              incurred a net loss of $7.3 million and $20.1 million, respectively, and for the nine months ended September 30, 2022, the Company used cash in operating activities of $15.5 million.</span><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160; <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">October 18, 2022, the Company
                entered into a facility sublease agreement (the &#8220;Sublease&#8221;) for approximately 45,500 square feet of office and laboratory space
                in Somerville, Massachusetts.&#160; Pursuant to the Sublease, the Company delivered to the sublessor a security deposit in the form of a letter of credit in the amount of $4.1 million, which will be reduced on an incremental basis throughout the term of the lease.&#160; The letter of credit was issued by the Company&#8217;s commercial bank, which
                required that the Company cash collateralize the letter of credit by depositing $4.1 million in a restricted cash account with
                such bank.&#160; The amount of required restricted cash collateral will decline in parallel with the reduction in the amount of the letter of credit over the term of the sublease.&#160; The Company&#8217;s deposit of this restricted cash reduced the amount
                of working capital the Company has to fund its operations. See Note 15,&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Subsequent

                Events,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#160;for more information on the
                Subleas</span>e.</div>

<div><span style="font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;"> </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
             <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In connection with preparing the accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022, the Company&#8217;s management concluded that there is substantial doubt regarding
              the Company&#8217;s ability to continue as a going concern because it does not expect to have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these financial statements.
              The Company will need to raise additional capital, which could be through the remaining availability under an equity line purchase agreement with Lincoln Park Capital Fund, LLC (the &#8220;Second Purchase Agreement&#8221;) (to the extent the Company is
              permitted to use such agreement) (see Note 12), public or private equity offerings, debt financings, corporate collaborations or other means. The Company may also seek governmental grants to support its clinical trials and preclinical trials.
              The Company currently has no arrangements for such capital and no assurances can be given that it will be able to raise such capital when needed, on acceptable terms, or at all. </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The
              accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may
              result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LIQUIDITYANDCAPITALRESOURCESAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LIQUIDITYANDCAPITALRESOURCESAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752825094960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</a></td>
<td class="text">
<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3)</div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</div>
                  </td>

  </tr>


</table>
          </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 27pt; margin-left: 9pt; font-variant: normal; text-transform: none;">Merger</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On August 12, 2020, Eterna, Brooklyn LLC and the Merger Sub
          entered into the Merger Agreement, and the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes. Brooklyn LLC, as the accounting
          acquirer, recorded the assets acquired and liabilities assumed of Eterna in the Merger at their fair values as of the acquisition date.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Brooklyn LLC was determined to be the accounting acquirer
          based upon the terms of the Merger and other factors including that (i) Brooklyn LLC members, received common stock in the Merger that represented 96.35%
          of Eterna&#8217;s outstanding common stock on a fully diluted basis, (ii) all of the directors of Eterna immediately after the Merger were designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC&#8217;s
          management became the management of Eterna immediately after the Merger.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">At the closing of the Merger, all the outstanding membership
          interests of Brooklyn LLC converted into the right to receive an aggregate of approximately 1,999,000 shares of common stock, of which
          53,000 shares were issued as compensation to Brooklyn LLC&#8217;s financial advisor for its services to Brooklyn LLC in connection with the
          Merger.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The purchase price of $8.2 million, which represents the consideration transferred in the Merger to stockholders of Eterna immediately before the Merger, was calculated
          based on the closing price of $108 per share for approximately 76,000 shares common stock that those stockholders owned on March 25, 2021 immediately prior to the Merger because that represented a more reliable measure of the fair value of
          consideration transferred in the Merger.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Under the acquisition method of accounting, the total
          purchase price has been allocated to the acquired tangible and intangible assets and assumed liabilities of Eterna based on their estimated fair values as of March 25, 2021, the Merger closing date. Because the consideration paid by Brooklyn LLC
          in the Merger is more than the estimated fair values of Eterna&#8217;s net assets deemed to be acquired, goodwill is equal to the difference of approximately $8.6
          million, which has been calculated using the fair values of the net assets of Eterna as of March 25, 2021.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The allocation of the purchase price to the tangible and
          intangible assets acquired and liabilities deemed to be assumed from Eterna, based on their estimated fair values as of March 25, 2021, is as follows (in thousands):</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Historical</div>
                <div style="text-align: center; font-weight: bold;"> Balance</div>
                <div style="text-align: center; font-weight: bold;"> Sheet of</div>
                <div style="text-align: center; font-weight: bold;"> Eterna at</div>
                <div style="text-align: center; font-weight: bold;"> March 25, 2021</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Fair Value</div>
                <div style="text-align: center; font-weight: bold;">Adjustment </div>
                <div style="text-align: center; font-weight: bold;">to</div>
                <div style="text-align: center; font-weight: bold;"> Eterna</div>
                <div style="text-align: center; font-weight: bold;">Pre-Merger</div>
                <div style="text-align: center; font-weight: bold;"> Assets</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;" valign="bottom">
                <div><span style="font-weight: bold;">Purchase </span></div>
                <div><span style="font-weight: bold;">Price</span></div>
                <div><span style="font-weight: bold;"> Allocation</span></div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>148</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>148</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Accounts receivable</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>103</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>103</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Prepaid expense and other current assets</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>329</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>329</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Property and equipment, net</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>1,015</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>1,015</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Software development costs</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,296</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>(368</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>928</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Customers</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>548</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>548</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Trade name</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>299</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>299</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Accounts payable, accrued liabilities and other current liabilities</div>
                </div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(3,781</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(3,781</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Net assets acquired, excluding goodwill</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>(890</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>479</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>(411</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Total consideration</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>8,178</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Net assets acquired, excluding goodwill</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(411</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Goodwill</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>8,589</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Brooklyn LLC was obligated under the Merger Agreement to have
          $10.0 million in cash and cash equivalents on its balance sheet at the effective time of the Merger. To ensure Brooklyn LLC had the
          required funds, certain beneficial holders of Brooklyn LLC&#8217;s Class A membership interests entered into contractual commitments to invest $10.0
          million into Brooklyn LLC immediately prior to the closing of the Merger. During March 2021, Eterna offered its Class A unit holders an additional 5%
          rights offering for an additional $0.5 million to be raised by a rights offering. Eterna received funds from the rights offering
          between February 17, 2021 and April 5, 2021.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-indent: 36pt;">Disposition</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 26, 2021, Eterna sold its rights, title and interest
          in and to the assets relating to the business it operated (under the name NTN Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2.0 million and assumption of specified liabilities relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the
          Disposition are as follows (in thousands):</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Proceeds from sale:</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">Cash</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">132</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Escrow</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>50</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Assume advance/loans</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,700</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Interest on advance/loans</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>68</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Carrying value of assets sold:</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(14</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Accounts receivable</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(75</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Prepaids and other current assets</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(124</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Property and equipment, net</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(1,014</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Software development costs</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(927</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Customers</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(548</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Trade name</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(299</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Goodwill</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(8,589</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Other assets</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(103</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Liabilities transferred upon sale:</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Accounts payable and accrued expenses</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>113</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Obligations under finance leases</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>17</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Lease liability</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>26</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Deferred revenue</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>55</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Other current liabilities</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>149</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Transaction costs</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(265</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Total loss on sale of assets</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">(9,648</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">)</div>
              </td>

  </tr>


</table>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 36pt; font-variant: normal; text-transform: none;">Acquisition</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On July 16, 2021, Eterna and Brooklyn Acquisition Sub, Inc.
          entered into the Novellus Acquisition Agreement. The Novellus Acquisition closed contemporaneously with the execution and delivery of the Novellus Acquisition Agreement. At the closing:</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: left;"><span style="font-family: 'Times New Roman';">&#9679;</span></div>
                </td>

    <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: justify;">Eterna acquired all of the outstanding equity interests of Novellus as the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, following which, Novellus, as the surviving
                    corporation, became Eterna&#8217;s wholly owned subsidiary and Novellus Ltd. became Eterna&#8217;s indirectly owned subsidiary; and</div>
                </td>

  </tr>


</table>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: left;"><span style="font-family: 'Times New Roman';">&#9679;</span></div>
                </td>

    <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: justify;">Eterna acquired 25.0% of the total outstanding equity interests of NoveCite.</div>
                </td>

  </tr>


</table>

<div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As consideration for the Novellus Acquisition, Eterna paid $22.9 million in cash and delivered approximately 351,000
          shares of common stock, which under the terms of the Novellus Acquisition Agreement, were valued at a total of $102.0 million based on
          an agreed upon price of $290.5060 per share. At the date of issuance, the fair value of the shares was approximately $58.7 million.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Novellus Acquisition Agreement contained customary
          representations, warranties and certain indemnification provisions. Approximately 37,000 of the shares issued as consideration were
          placed in escrow to secure indemnification obligations to Eterna under the Novellus Acquisition Agreement, and all such shares were released to the sellers in July 2022. The Novellus Acquisition Agreement also contains certain non-competition and
          non-solicitation provisions pursuant to which Novellus LLC agreed not to engage in certain competitive activities for a period of five years
          following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus prior to the Novellus Acquisition continued their employment, or were otherwise engaged by Eterna, immediately following the
          Novellus Acquisition.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with the Novellus Acquisition, the co-founders
          of Novellus entered into lock-up agreements with respect to approximately 169,000 of the shares of common stock received in the
          Novellus Acquisition, and Eterna&#8217;s Chairman of the Board and its former Chief Executive Officer and President entered into identical lock-up agreements with respect to their current holdings of Eterna stock. Each lock-up agreement extends for a
          period of three years, provided that up to 75% of the shares of common stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on the Nasdaq exceeds specified
          thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period. </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal;">The


          Company expects the Novellus Acquisition will advance its evolution into a platform company with a pipeline of next generation mRNA cellular and gene editing programs. In addition, the acquisition of Novellus Ltd. builds on the License Agreement
          (as defined in Note 10). As a result of the Novellus Acquisition, in accordance with the terms of the Novellus-Factor License Agreement, the rights and obligations of Novellus Ltd. thereunder pertaining to any and all licensed products have
          inured to Eterna. The License Agreement with Factor Bioscience Limited (&#8220;Factor Limited&#8221;) under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene editing and cell therapy products,
          remained unchanged after the completion of the Novellus Acquisition.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Although Eterna acquired all of the outstanding equity
          interests of Novellus, the Company accounted for the Novellus Acquisition as an asset acquisition (as the assets acquired did not constitute a business as defined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805,&#160;<span style="font-style: italic;">Business Combinations</span>),&#160;and was measured by the amount of cash paid and by the fair value of the shares of common stock issued. As a result, substantially all of the value acquired was attributed to in-process research and
          development (IPR&amp;D), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities, as discussed further below.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Eterna paid $22.9 million in cash, net of cash acquired, as part of the consideration for the Novellus Acquisition, of which $1.0 million was paid in cash for the investment in NoveCite. Eterna also issued approximately 351,000
          shares of the Company&#8217;s common stock, of which approximately 182,000 shares are unrestricted and 169,000 shares are subject to the three-year
          lockup. The unrestricted shares were valued at $201 per share, which was the closing price of Eterna&#8217;s common stock on July 16, 2021.
          The fair value of the restricted shares was discounted by approximately 35% to $130.60 per restricted share, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">The resulting fair value of the asset acquired is as follows
          (in thousands):</span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Fair Value of</div>
                <div style="text-align: center; font-weight: bold;">Consideration</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Cash paid</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>22,882</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Cash acquired</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(28</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Unrestricted shares</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>36,628</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">Restricted shares</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>22,056</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Total fair value of consideration paid</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>81,538</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">Less amount of cash paid for NoveCite investment</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(1,000</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Fair value of IPR&amp;D acquired</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>80,538</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">IPR&amp;D that is acquired through an asset purchase that has
          no alternative future uses and no separate economic values from its original intended purpose is expensed in the period the cost is incurred. Accordingly, the Company expensed the fair value of the IPR&amp;D during the third quarter of 2021 in
          the amount of $80.5 million.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Investment in NoveCite</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal;">As
          a result of the Novellus Acquisition,&#160; Eterna acquired and currently owns 25% of NoveCite and Citius Pharmaceuticals, Inc. (&#8220;Citius&#8221;)
          owns the remaining 75%. A member of the Company&#8217;s management is entitled to hold one of three board seats on NoveCite&#8217;s board of directors. Citius&#8217; s officers and directors hold the other two board seats. The Company is accounting for its interest in NoveCite
          under ASC Topic 323, <span style="font-style: italic;">Investments &#8211; Equity<span style="font-style: italic;"> Meth</span>od and Joint&#160;Ventures</span>.&#160;The investment was recorded at cost, which was $1.0 million&#160;and is adjusted for the Company&#8217;s share of&#160;NoveCite&#8217;s earnings or losses, which are reflected in the accompanying condensed consolidated statement of operations.
          The investment may also reflect an equity loss in the event that circumstances indicate an other-than-temporary impairment. For the three and nine months ended September 30, 2022, the Company recorded approximately $21,000 and $0.9 million, respectively,
          in losses from its investment in NoveCite, and of the $0.9 million loss for the nine months ended September 30, 2022, $0.5 million related to NoveCite&#8217;s year ended December 31, 2021. The Company does not guarantee obligations of NoveCite nor is it otherwise committed
          to providing further financial support for NoveCite. Therefore, the Company will record losses only up to its investment carrying amount.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733628160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold;">4)<br/>
              </td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">FAIR VALUE OF FINANCIAL INSTRUMENTS</div>
              </td>

  </tr>


</table>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Fair


















          value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest
          priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</div>

<div>&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>
                <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';">&#9679;</span></span></div>
                      </td>

    <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Level
                          1 Inputs &#8211; Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</div>
                      </td>

  </tr>


</table>
              </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>
                <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';">&#9679;</span></span></div>
                      </td>

    <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Level
                          2 Inputs &#8211; Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in
                          active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities,
                          prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</div>
                      </td>

  </tr>


</table>
              </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>
                <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';">&#9679;</span></span></div>
                      </td>

    <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Level
                          3 Inputs &#8211; Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.</div>
                      </td>

  </tr>


</table>
              </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
        <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">T<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">here were no liabilities measured at fair value as of Decem</span>ber 31, 2021.
                The following tables summarize the liabilities that are measured at fair value as of September 30, 2022 (in thousands)</span>:</div>

<div> <br/>
          </div>

<div>
            <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of September 30,
                      2022</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 1</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 2</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 3</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Liabilities:</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Warrant liabilities - Common Warrants</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
          </div>

<div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">  <br/></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">On
          March 9, 2022, the Company issued pre-funded warrants exercisable for approximately 68,000 shares of common stock (the &#8220;Pre-Funded
          Warrants&#8221;) and warrants exercisable for approximately 343,000 shares of common stock (the &#8220;Common Warrants&#8221;) to the PIPE Investor in
          connection with the PIPE Transaction (as each such term is defined in Note 12). On July 12, 2022, the PIPE Investor exercised its 68,000
          Pre-Funded Warrants at an exercise price of $0.10 per share for an aggregate exercise price of approximately $7,000 in cash. The Company issued 68,000
          shares of common stock to the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds. Following the exercise, no Pre-Funded
          Warrants remained outstanding. See Note 12 for more information related to the PIPE Transaction.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC
              815-40,&#160;Derivatives and Hedging, Contracts in Entity&#8217;s Own Equity&#160;(&#8220;ASC 815-40&#8221;), as these warrants provide for a cashless settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40.&#160; These warrant
              liabilities were measured at fair value at inception and are then subsequently measured on a recurring basis, with changes in fair value presented within the Company&#8217;s statements of operations.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common
              Warrants, which is considered a Level 3 fair value measurement.&#160; Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the Company&#8217;s control.&#160; A significant change in
              one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company&#8217;s warrant liabilities, which could also result in material non-cash gains or losses being reported in the
              Company&#8217;s consolidated statement of operations.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The estimated fair value of the Pre-Funded Warrants was deemed a Level 2 measurement as all significant inputs to the valuation model used to estimate the fair value of the Pre-Funded Warrants were directly
                  observable from the Company&#8217;s publicly-traded common stock. Upon exercise of the Pre-Funded Warrants on July 12, 2022, the Company reclassified the fair value of the Pre-Funded Warrants<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> to equity</span> as of such date.</span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $12.6 million in the aggregate, which was $0.6 million more
            than the $12.0 million proceeds received in the PIPE Transaction.&#160; The excess $0.6 million represents an inducement to the purchaser to enter into the PIPE Transaction and was recorded in warrant liabilities expense in the accompanying consolidated
            statement of operations.&#160; Given the Company&#8217;s capital requirements and market conditions, the Company consummated this financing on market terms available at the time of the transaction. </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
        </div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company remeasured the fair value of the Common Warrants as of September 30, 2022. The following table presents the changes in the warrant
            liabilities from the issuance date (in thousands): </div>

<div>&#160;</div>

<div>
            <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pre-Funded <span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrants</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> (Level 2)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> Common Warrants</span></div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>(Level 3)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>Total Warrant</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Liabilities</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at January 1, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at March 9, 2022 (issuance date)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,646</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9,943</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12,589</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(1,779</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(9,310</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(11,089</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Exercise of pre-funded warrants</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(867</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(867</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at September 30, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
            </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733664736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LesseeOperatingAndFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">LEASES</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <span style="font-style: italic; font-weight: bold;">Operating Leases</span><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company has operating leases for office and laboratory space in the borough of Manhattan in New York, New York and in Cambridge, Massachusetts, which expire in 2026 and 2028, respectively. On March 31, 2022, the
            Company entered into a facility lease in San Diego, California (the &#8220;San Diego Lease&#8221;) with Torrey Pines Science Center Limited Partnership for approximately 5,200 square feet of laboratory and office space. The term of the San Diego Lease is 62 months and
            the lease commencement date was April 19, 2022. The San Diego Lease will expire in June 2027. See Note 15 for information regarding an additional lease the Company entered into in October 2022.</span> </div>

<div>&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Base rent for the San Diego Lease is $6.35
          per square foot in the first year of the San Diego Lease, with a rent abatement for the second and third full months of the first year. The base rent will increase by approximately 3% on each anniversary of the lease commencement date. The Company is also required to pay its share of operating expenses and property taxes. The San Diego Lease provides for a one-time
          option to extend the lease term for an additional five years at the then fair rental value. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recorded a $1.7 million right-of-use (&#8220;ROU&#8221;) asset and $1.7 million lease liabilities
            for the San Diego Lease.</span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span></span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the second quarter of 2022, the Company decided to
            consolidate its research and development efforts in Cambridge, Massachusetts, and the Company intends to sublease the San Diego laboratory and office space.&#160; As a result, the Company recognized an impairment charge of approximately $0.8 million on the San Diego Lease ROU asset </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">during the nine months ended September 30, 2022, which is recorded in general and administrative expense on the condensed
            consolidated statements of operations. There was no impairment charge recognized for the three months ended September 30, 2022.&#160;</span></div>

<div><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On March 5, 2022, the Company entered into an Agreement to Assign Space Lease with Regen Lab USA LLC (&#8220;Regen&#8221;) pursuant to which the Company
          agreed to assign its Brooklyn, New York lease (the &#8220;Brooklyn Lease&#8221;) to Regen. The effective date of the assignment was contingent upon, among other things, a consent from BioBat, Inc. (the &#8220;Landlord&#8221;). Additionally, Regen agreed to purchase
          certain equipment from the Company for $50,000, partly reimburse the Company $50,000 toward certain existing unamortized leasehold improvements, and to reimburse the Company for the existing security deposit the Company had under the Brooklyn Lease of approximately
          $63,000.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">O<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">n March 25, 2022, the Company entered into an Assignment and Assumption of Lease Agreement (the &#8220;Assignment Agreement&#8221;) with Regen,
                which included the Landlord&#8217;s consent to the assignment. The effective date of the assignment was March 28, 2022.&#160; Under the Assignment Agreement, Regen (i) accepted the assignment of the Brooklyn Lease; (ii) assumed all of the obligations,
                liabilities, covenants and conditions of the Company&#8217;s as tenant under the Brooklyn Lease; (iii) assumed and agreed to perform and observe all of the obligations, terms, requirements, covenants and conditions to be performed or observed by
                the Company under the Brooklyn Lease; and (iv) made all of the representations and warranties under the Brooklyn Lease with the same force and effect as if Regen had executed the Brooklyn Lease originally as the tenant.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">N<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">otwithstanding Regen&#8217;s assumption of the Brooklyn Lease, the Company remains liable and responsible for the due keeping, and full
                performance and observance, of all the provisions of the Brooklyn Lease applicable to the tenant thereunder.&#160;&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As a result of the Assignment Agreement, the Company wrote off the remaining ROU asset balance and the corresponding lease liability</span>.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company accounts for leases under ASC 842,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: normal;">&#160;Leases</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. Operating leases are included in
          &#8220;Right-of use assets - operating leases&#8221; within the Company&#8217;s balance sheets and represent the Company&#8217;s right to use an underlying asset for the lease term. The Company&#8217;s related obligation to make lease payments are included in &#8220;Operating lease
          liabilities, non-current&#8221; and &#8220;Operating lease liabilities, current&#8221; within the Company&#8217;s balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Because the
          rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense for lease
          payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet and are recognized as lease expense on a straight-line basis over the lease term.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as
        payments for insurance, tax payments and other miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are
        expensed when the obligation for those payments is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the net operating lease expenses were as follows (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Three months ended September 30,</span><br/>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
              </div>
            </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021</span> <br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">143</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">187</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Sublease income</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(21</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(21</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Variable lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">60</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">6</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">182</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">172</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Nine months ended September 30,</span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">2022</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021<br/>
                </span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating lease expense</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">476</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">501</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Sublease income</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">(63</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">(62</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Variable lease expense</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">113</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">16</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total lease expense</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">526</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">455</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The tables below show the beginning
          balances of the operating ROU assets and lease liabilities as of January 1, 2022 and the ending balances as of September, 2022, including the changes during the period (in thousands).</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
          </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ROU Assets</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease ROU assets at
                January 1, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,567</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Initial measurement of operating lease ROU assets</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,706</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Amortization of operating lease
                ROU assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(267</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Impairment of ROU assets</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(772</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Remeasurement of ROU asset<br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Write off of ROU asset due to lease termination</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(1,372</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease ROU assets at
                September 30, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,912</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-indent: 0px; text-transform: none;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Liabilities</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease liabilities at
                January 1, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,723</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Initial measurement of operating lease liabilities</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,706</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Principal payments on operating
                lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(223</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Write off of operating lease liability due to lease termination</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(1,453</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease liabilities at
                September 30, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,752</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less non-current portion</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,317</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Current portion at September 30,
                2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">436</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">As of September 30, 2022, the Company&#8217;s operating leases had a weighted-average
        remaining life of 4.9 years with a weighted-average discount rate of 8.97%.&#160; <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; font-variant: normal;">The maturities of the operating lease liabilities are as follows (in thousands):</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2022</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">166</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2023</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">673</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2024</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">688</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2025</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">703</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2026</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">708</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Thereafter</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">470</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Total payments</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <br/>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,408</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Less imputed interest</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(656</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Total operating lease liabilities</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,752</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LesseeOperatingAndFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of lessee's finance and operating lease and maturity analysis of finance and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LesseeOperatingAndFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752737977008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6)<br/>
              </td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL<br/>
                </div>
              </td>

  </tr>


</table>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In 2018, the Company acquired IRX Therapeutics (&#8220;IRX&#8221;), which was accounted for as a business combination. The Company recorded IPR&amp;D in the
          amount of $6.0 million, which represented the fair value assigned to technologies that were acquired in connection with the IRX
          acquisition and which have not reached technological feasibility and have no alternative future use. IPR&amp;D assets acquired in a business combination are considered to be indefinite lived until the completion or abandonment of the associated
          research and development projects. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;D assets, these assets are then deemed
          definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;D assets,
          calculated as the excess of carrying value of the IPR&amp;D assets over fair value.</div>

<div><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company also recorded goodwill in the amount of $2.0
          million related to the IRX acquisition. Goodwill and indefinite-lived IPR&amp;D assets are not amortized but are tested for impairment annually, or more frequently if the Company becomes aware of any events occurring or changes in circumstances
          that indicate that the fair value of the entity is less than its carrying values.</div>

<div><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In June 2022, the Company received results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III or IVA squamous cell carcinoma of the oral
            cavity. The IRX-2 multi-cytokine biologic immunotherapy represents substantially all the fair value assigned to the technologies of IRX that the Company acquired. Despite outcomes that favored IRX-2 in certain predefined subgroups, the INSPIRE
            trial did not meet the primary endpoint of Event-Free Survival (at two years of follow up). Significant additional clinical development work would be required to advance IRX-2 in the form of additional Phase 2 and 3 studies to further evaluate
            the treatment effect of IRX-2 in patient subgroups and in combination with checkpoint inhibitor therapies. The INSPIRE trial was the only Company-sponsored study of IRX-2. IRX-2 has been studied externally in other clinical settings outside of
            head and neck cancer in the form of investigator sponsored trials, which have either ended or are not currently active. Based on the totality of available information, the Company currently does not have plans to further develop the IRX-2
            product candidate. As such, the Company determined that the carrying value of the IPR&amp;D asset was impaired and recognized a non-cash impairment charge of approximately $6.0 million on the condensed consolidated statement of operations during the second quarter of 2022, which reduced the value of the asset to zero.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As of September 30, 2022, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair value of
          the entity is less than its carrying value of goodwill. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the
          decline in the Company&#8217;s stock price from $10.40 per share as of June 30, 2022 to $4.94 per share as of September 30, 2022, the Company determined that there were indications of impairment. Accordingly, the Company proceeded to the first step in the
          quantitative assessment of impairment and determined that the fair value of the reporting unit exceeded the carrying amount of goodwill, and therefore, the goodwill was not impaired as of September 30, 2022. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733629392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CEO SEPARATION AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CEOSEPARATIONAGREEMENTAbstract', window );"><strong>CEO SEPARATION AGREEMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ChiefExecutiveOfficerSeparationAgreementTextBlock', window );">CEO SEPARATION AGREEMENT</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                  <div style="font-weight: bold;">7)</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="font-weight: bold;">CEO SEPARATION AGREEMENT</div>
                </td>

  </tr>


</table>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">On May 24, 2022, Dr. Howard J. Federoff resigned as the Company&#8217;s Chief Executive
        Officer and President effective May 26, 2022. In connection with Dr. Federoff&#8217;s resignation, the Company entered into a&#160;<span style="color: rgb(0, 0, 0);">Separation Agreement and General Release with Dr. Federoff (the &#8220;Separation Agreement&#8221;),
          pursuant to which Dr. Federoff resigned from his positions as Chief Executive Officer and as an officer, director and employee of the Company and all subsidiaries. Dr. Federoff&#8217;s resignation from the Board was not due to any disagreement with the
          Company on any matter relating to the Company&#8217;s operations, policies or practices. In consideration for Dr. Federoff&#8217;s execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Dr. Federoff will
          receive following benefits under the Separation Agreement:</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $0.2 million, representing Dr. Federoff&#8217;s
                target bonus for 2022;</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">payment of Dr. Federoff&#8217;s annual base salary for a period of twelve months after the expiration of the applicable revocation period (the &#8220;Separation Period&#8221;), for a total gross amount equal to $0.5 million;</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">payment of Dr. Federoff&#8217;s premiums for continued health benefits provided under COBRA for the Separation Period;</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">full acceleration of the vesting of all outstanding options (with the exception of the Milestone Grant (as defined below) options) that would have vested during the Separation Period, and such options,
                together with outstanding options that vested prior to the separation date, representing collectively approximately 76,000
                shares of common stock, may be exercised for a period of thirty-six months after the separation date (see Note 11 for
                modification accounting impact);</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><span style="color: rgb(0, 0, 0); font-size: 10pt;">acceleration and vesting of 25/36</span><span style="font-size: 10pt;"><sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><span style="color: rgb(0, 0, 0);">&#160;of the Milestone Grant options, representing collectively approximately 21,000 shares of
                    common stock, may be exercised for a period of thirty-six months after the separation date (see Note 11 for modification
                    accounting impact); and</span></span></div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;">


  <tr>

    <td style="width: 18pt; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#9679;</span></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $0.1 million, representing the value Dr.
                Federoff would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period, assuming the performance metrics were waived and
                assuming a per share value of $16.20.</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Separation Agreement also includes certain other customary representations,
        warranties and covenants of Dr. Federoff, and provides for reimbursement of certain expenses incurred by Dr Federoff. The Separation Agreement supersedes all other agreements or arrangements between Dr. Federoff and the Company regarding the
        subject matter of the agreement, including those with respect to severance payments and benefits.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CEOSEPARATIONAGREEMENTAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CEOSEPARATIONAGREEMENTAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ChiefExecutiveOfficerSeparationAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to chief executive officer separation agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ChiefExecutiveOfficerSeparationAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752738011168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<div>
      <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-weight: bold;">RELATED PARTY TRANSACTIONS</span></div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On September 9, 2022, the Company entered into
        a Master Services Agreement (the &#8220;MSA&#8221;) with Factor Bioscience Inc. (&#8220;Factor&#8221;), pursuan</span>t to which Factor has agreed to provide services to the Company as agreed between the Company and Factor and as set forth in one or more work orders under
      the MSA, including the first work order included in the MSA. Under the first work order, Factor has agreed to provide the Company with mRNA cell engineering research support services, including access to certain facilities, equipment, materials and
      training, and the Company has agreed to pay Factor an initial fee of $5.0 million, payable in twelve equal monthly installments of approximately $0.4 million.
      Following the initial 12-month period, the Company has agreed to pay Factor a monthly fee of $0.4 million until such time as the first work
      order under the MSA is terminated. The Company paid a deposit of $0.4 million, which will be applied to the last month of the first work
      order.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The
      Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with 120
      days&#8217; prior notice. Factor may terminate such work order only on and after the fourth anniversary of the date of the MSA, su<span style="font-family: 'Times New Roman';">bject to providing the Company with 120 days&#8217; prior notice. The MSA contains customary confidentiality provisions and representations and warranties of the parties, and the MSA may be terminated by ether party
        upon 30 days&#8217; prior notice, subject to any superseding termination provisions contained in a particular work order.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">In connection with entering into the MSA, on September
          9, 2022, Factor&#8217;s subsidiary, Factor Limited, entered into a waiver agreement (the &#8220;Waiver Agreement&#8221;) with Brooklyn LLC, pursuant to which Factor Limited agreed to waive payment of $3.5 million otherwise payable to it (the &#8220;License Fee Obligation&#8221;) in October 2022 by Brooklyn LLC under a license agreement by and among Factor Limited, Novellus Ltd., and
          Brooklyn LLC.&#160; See Note 10, </span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">License Agreements</span><span style="font-size: 10pt; font-family: 'Times New Roman';">, for more information on this
          agreement. </span><span style="font-family: 'Times New Roman';">Under the terms of the Waiver Agreement, the License Fee Obligation is waived conditionally on the Company paying Factor Inc. amounts due under the MSA.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman';"> </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As a
        result of entering into the Waiver Agreement and the MSA on September 9, 2022, the Company recognized $3.5 million in research and
        development expense, as the license does not have an alternative future use, and a corresponding liability.<br/>
      </div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On
        September 1, 2022, Novellus and Eterna entered into a Second Amendment to the Limited Waiver and Assignment Agreement (the &#8220;Waiver and Assignment Agreement&#8221;) with Drs. Matthew Angel and Christopher Rohde (the &#8220;Founders&#8221;) whereby the Company has
        agreed to be responsible for all future, reasonable and substantiated legal fees, costs, settlements and judgments incurred by the Founders, the Company or Novellus for certain claims and actions and any pending or future litigation brought against
        the Founders, Novellus and/or the Company by or on behalf of the Westman and Sowydra legal matters described in Note 10 (the &#8220;Covered Claims&#8221;). The Founders will continue to be solely responsible for any payments made to satisfy a judgement or
        settlement of any pending or future wage act claims. Under the Waiver and Assignment Agreement, the Founders agreed that they are not entitled to, and waived any right to, indemnification or advancement of past, present or future legal fees, costs,
        judgments, settlement or other liabilities they may have been entitled to receive from the Company or Novellus in respect of the Covered Claims. The Company and the Founders will share in any recoveries up to the point at which the parties have
        been fully compensated for legal fees, costs and expenses incurred, with the Company retaining any excess recoveries. The Company has the sole authority to direct and control the prosecution, defense and settlement of the Covered Claims.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On Sept<span style="font-size: 10pt;">ember
              6, 2022, the </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company entered into an
              assignment and assumption of contracts agreement (the &#8220;Assignment and Assumption Agreement&#8221;) with Factor, pursuant to which the Company assumed certain contracts with third parties that Factor had previously entered into in anticipation of
              entering into a sublease for premises in Somerville, Massachusetts.&#160; In October 2022, the Company entered into a sublease for the premises (see Note 15).&#160; Under the Assignment and Assumption Agreement, the Company agreed to reimburse Factor
              for costs already incurred or paid by it under the assumed contracts in the amount of approximately $0.1 million, and the Company
              assumed the future obligations under these contracts, which relate to the design and build-out of the subleased space.</span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The
            MSA, any work orders under the MSA, the Waiver Agreement, the Waiver and Assignment Agreement, and the Assignment and Assumption Agreement have been deemed related party transactions, as the Company&#8217;s Interim Chief Executive Officer, Dr.
            Matthew Angel, is also the Chairman and Chief Executive Officer of Factor and the Director of Factor Limited.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733683136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                  <div style="text-align: left;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9)</span>
                  </div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold;">ACCRUED EXPENSES AND OTHER LIABILITIES</div>
                </td>

  </tr>


</table>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following (in thousands):</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold; text-align: center; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>September 30,</div>
                <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</span></div>
              </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">December 31,<br/>
                <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</span></td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued compensation </div>
              </td>

    <td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,701</div>
              </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">656</div>
              </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued research and development expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">373</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">222</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued general and administrative expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,156</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">371</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total accrued expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3,230</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,249</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other liabilities consisted of the following (in thousands):</div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">September 30,</div>
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2021<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Current portion of License Fee Obligation<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,750</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Insurance policy premiums</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">898</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">247</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Total other current liabilities<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">2,648</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">247</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">Long term portion of License Fee Obligation<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,642</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">48</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">48</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total other liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,690</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">48</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><br/>
          </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued compensation at September 30,
                2022 includes approximately $1.0 million of severance, of which, approximately $0.3 million relates to severance for Dr. Federoff pursuant to the Separation Agreement discussed above.</span> </span>Accrued general and administration expenses at
            September 30, 2022 includes $0.6 million for legal-related matters.</span><br/>
        </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733560736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">10)<br/>
              </span> </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">COMMITMENTS AND CONTINGENCIES</div>
            </td>

  </tr>


</table>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">Legal Matters<br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated
          with such actions are expensed as incurred. In addition, the Company assesses the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
          reasonably estimated.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); text-indent: 36pt;"><span style="text-decoration: underline;"><span style="font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dhesh Govender v. Brooklyn
              Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)</span></span></div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">On
            or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn LLC and certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh
            Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges that Brooklyn LLC and certain of its officers and directors (&#8220;defendants&#8221;) engaged in unlawful and discriminatory
            conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire
            him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell
            reprogramming technology to Brooklyn LLC, he was promised a $0.5 million salary and 7% of the equity of Brooklyn LLC. Based on these and other allegations, plaintiff seeks damages of not less than $10 million<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">. By Order dated November 10,&#160;2021, the Court granted defendants&#8217; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn
              LLC.&#160; Govender thereafter filed his Statement of Claim (the &#8220;Demand&#8221;) with the American Arbitration Association (&#8220;AAA&#8221;), Case No. 01-21-0017-9417, on December 15,&#160;2021 against the same defendants, and served it on defendants&#8217; counsel on
              February 3,&#160;2022. In his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender 7% of the equity of Brooklyn LLC and to employ Govender at a $0.5 million annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against Brooklyn LLC and Cherington based on the breach of these same promises and a
              claim for quantum meruit against the Brooklyn LLC. In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded $100 million and is seeking damages in an amount to be determined at the hearing. Defendants filed an answering statement to the Demand on February 28,&#160;2022 and the
              parties have selected a three</span><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-member arbitration panel. The date on which arbitration is
                scheduled to begin has not yet been set. Defendants intend to vigorously defend themselv</span>es against these claims.</span> At this stage in the litigation, the Company is not able to predict the probability of a favorable or unfavorable
            outcome. </div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: 36pt;"><span style="text-decoration: underline;">Emerald Private Equity Fund, LLC Matter</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                        </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#8220;Emerald&#8221;), a stockholder of Eterna, made a demand pursuant to 8
                          Del. C. 220 to inspect certain books and records of Eterna. The stated purpose of the demand was to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock
                          certificates, including investigating whether: (i) Eterna&#8217;s stock certificates were issued in accordance with the Merger Agreement; (ii)&#160;certain restrictions on the sale of Eterna common stock following the Merger were proper and
                          applied without favor; (iii) anyone received priority in post-Merger issuances of Eterna&#8217;s stock certificates that allowed them to benefit from an increase in the trading price of Eterna&#8217;s common stock; and (iv) it<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> should pursue remedial
                            measures and/or report alleged misconduct to the SEC. Eterna responded to the demand letter and produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement
                            entered into among the parties, including certain additional stockholders who subsequently joined as parties to such agreement. In October 2021, Emerald requested that Eterna produce additional information related to the
                            authority, purpose and justification for the restriction imposed on the sale of Eterna common stock following the Merger and the timing of share delivery to Eterna stockholders, following which request Eterna agreed to produce
                            certain additional information and emails relating to these topics.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On March 30,&#160;2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and former directors of the
                              Company, and the Company&#8217;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims for breach
                              of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty. Emerald&#8217;s counsel expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor on
                              behalf of individual stockholders whom counsel represents in addition to Emerald (collectively, the &#8220;Emerald Plaintiffs&#8221;); and the Company engaged in such discussions in lieu of incurring the legal costs anticipated in respect
                              of litigating </span>the Emerald Plaintiffs&#8217; claims, all of which the Company disputes.&#160; Following such discussions, with no admission of wrongdoing, the Company and the Emerald Plaintiffs entered into a confidential
                            settlement agreement, pursuant to which the Company paid $1.2 million in full settlement of all of the Emerald
                            Plaintiffs&#8217; purported claims, including a release by the Emerald Plaintiffs in favor of the Company in respect of any and all such claims<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">. </span><br/>
                            </span></div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="text-decoration: underline;">John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949
                              (Middlesex County (Massachusetts) Superior Court)</span></div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County
                              (Massachusetts) Superior Court against Novellus, Inc. and the company&#8217;s founders and former executives, Dr. Christopher Rohde and Dr. Matthew Angel (collectively, &#8220;Defendants&#8221;). The case includes allegations that Novellus,
                              Inc. violated the Massachusetts Wage Act. Eterna acquired Novellus, Inc. on July 16,&#160;2021. Mr. Westman&#8217;s claims relate to alleged conduct that took place before Eterna acquired Novellus, Inc. Defense and liability in
                              association with any Wage Act claims have been assumed by Dr. Rohde and Dr. Angel. On December 24,&#160;2021, Westman dismissed the case without prejudice so the parties could mediate the matter. The parties&#8217; February 2022
                              mediation was unsuccessful and the dispute is currently pending in arbitration.</span></div>

<div><span style="font-style: italic;"><br/>
                            </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;">Novellus, Inc</span><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">. <span style="font-style: normal;">v. Sowyrda et al</span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;">., C.A. No.
                                  2184CV02436-BLS2</span></span></div>

<div><span style="font-style: normal;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; background-color: rgb(255, 255, 255);"><br/>
                            </div>

<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);">On October 25, 2021 Novellus, Inc. filed a complaint in the Superior Court of Massachusetts,
                              Suffolk County, against former Novellus, Inc. employees Paul Sowyrda and John Westman and certain other former investors in Novellus LLC (Novellus, Inc.&#8217;s former parent company prior to the Company&#8217;s acquisition of Novellus,
                              Inc.), alleging breach of fiduciary duty, breach of contract and civil conspiracy. Eterna acquired Novellus, Inc. on July 16, 2021. On May 27, 2022 Novellus, Inc. amended the complaint to withdraw all claims against all
                              defendants except Paul Sowyrda and John Westman. On July 1, 2022, Westman filed a motion to compel arbitration or in the alternative, to stay the litigation pending the disposition of certain litigation in the Court of
                              Chancery for the State of Delaware filed by Mr. Sowyrda against Novellus LLC, Dr. Christopher Rohde, Dr. Matthew Angel, Leonard Mazur and Factor Bioscience, Inc. captioned&#160;<span style="font-style: italic;">Zelickson et al., v.
                                Angel et al.,</span>&#160;C.A. 2021-1014-JRS and by Westman against Novellus LLC captioned&#160;<span style="font-style: italic;">Westman v. Novellus LLC</span>, C.A. No. 2021-0882-NAC (the &#8220;Delaware Actions&#8221;). On July 1, 2022,
                              Sowyrda answered the complaint and asserted counterclaims against Novellus, Inc, and third-party defendants Dr. Matthew Angel and Dr. Christopher Rohde alleging violations of the Massachusetts Wage Act, Massachusetts Minimum
                              Fair Wage Law, the Fair Labor Standards Act, breach of contract, unjust enrichment and quantum meruit. Sowyrda also joined in Westman&#8217;s motion to stay the case pending the Delaware Actions. Novellus, Inc.&#8217;s claims and Mr.
                              Sowyrda&#8217;s counterclaims relate to alleged conduct that took place before Eterna acquired Novellus, Inc. Defense and liability in association with any Wage Act claims have been assumed by Dr. Rohde and Dr. Angel. The Company
                              filed its opposition to Sowyrda and Westman&#8217;s motions on August 19, 2022.&#160; On September 9, 2022, Westman and Sowyrda filed replies in support of their motions and requested to be heard.&#160; The hearing is scheduled for November
                              16, 2022.</div>

<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);"> <br/>
                            </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Under applicable Delaware law and Novellus Inc.&#8217;s organizational documents, the Company may be required to advance or reimburse certain legal
                                expenses incurred by former officers and directors of Novellus, Inc. in connection with the foregoing Westman and Sowyrda matters. However, a future advance or reimbursement is not currently probable nor can it be reasonably
                                estimated.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">Licensing Agreements</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">USF</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Brooklyn LLC has license agreements with University of
                South Florida Research Association, Inc. (&#8220;USF&#8221;), granting Brooklyn LLC the right to sell, market, and distribute IRX-2, subject to a 7%
                royalty payable to USF based on a percentage of gross product sales. Under the license agreement with USF, Brooklyn LLC is obligated to repay patent prosecution expenses incurred by USF. To date, Brooklyn LLC has not recorded any product
                sales, or obligations related to USF patent prosecution expenses. The license agreement terminates upon the expiration of the IRX-2 patents.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">Novellus Ltd. and Factor Limited</span> <br/>
              </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"> <br/>
              </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">In December 2020, Brooklyn LLC entered into option agreements (the
                  &#8220;Option Agreements&#8221;) with Novellus Ltd. and Factor Limited (together, the &#8220;Licensors&#8221;) to obtain the right to exclusively license the Licensors&#8217; intellectual property and mRNA cell reprogramming and gene editing technology for use in the
                  development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia (the &#8220;Licensed Technology&#8221;). The option was exercisable
                  before February 28, 2021 (or April 30, 2021 if the Merger had not closed by that date) and required Brooklyn LLC to pay a non-refundable option fee of $0.5 million and then an initial license fee of $4.0 million <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(including
                    the non-refundable fee of $0.5 million) in order to exercise the option.</span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"> <br/>
                </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"> In April 2021, Brooklyn LLC and the Licensors amended the Option Agreements to extend the exercise period to May 21, 2021 and to require Brooklyn LLC to pay a total $1.0 million of the $4.0 million
                  initial license fees to the Licensors by April 15, 2021.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                  </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In
                    April 2021, Brooklyn LLC and the Licensors entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) pursuant to which Brooklyn LLC acquired an exclusive worldwide license to the Licensed Technology <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for use in the development of certain mRNA,
                      gene-editing, and cellular therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia. </span>Under the terms of the License Agreement, Brooklyn
                    LLC is obligated to pay the Licensors a total of $4.0 million in connection with the execution of the License Agreement, all
                    of which was paid as of June 2021.</span></div>

<div><span style="font-size: 10pt;"><br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As a result of the Novellus Acquisition, in accordance with the terms of the Novellus-Factor License Agreement, the rights and obligations of Novellus Ltd. thereunder pertaining to any and all licensed
                      products have inured to Eterna<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The agreement with Factor Limited under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain
                        next-generation mRNA gene editing and cell therapy products, remained unchanged after the completion of the Novellus Acquisition. Accordingly, under the License Agreement,</span> Brooklyn LLC remained obligated to pay to Factor
                      Limited a fee</span> of $3.5 million in October 2022, which would have been in addition to a fee of $2.5 million paid to Factor Limited in October 2021. <span style="letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In connection with the Company entering into the MSA (see Note 8), Factor Limited
                      entered into the Waiver Agreement with Brooklyn LLC, pursuant to which Factor Limited waived payment of the $3.5 million
                      otherwise payable to it in October 2022 by Brooklyn LLC</span>.</span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><br/>
                </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Brooklyn LLC is also
                    required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of
                    these milestones, Brooklyn LLC will be obligated to pay, in the case of development and regulatory milestones, milestone payments to the Licensors in specified amounts and, in the case of commercialization milestones, specified
                    royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely achieve certain delineated milestones, the Licensors will have the right to terminate Brooklyn
                    LLC&#8217;s rights under provisions of the License Agreement relating to those milestones.</span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">Novellus Ltd. also has a license agreement with Factor Limited, which was entered into in February 2015, amended in June
                    2018 and March 2020, and then amended and restated in November 2020 (the &#8220;Novellus-Factor License Agreement&#8221;).&#160; The Novellus-Factor License Agreement grants to Novellus Ltd. an exclusive license to use certain technology owned by Factor
                    Limited for the development of mesenchymal stem cell-based cellular therapies for treating diseases and conditions in humans and animals&#160; (the &#8220;Novellus-Factor Licensed Technology&#8221;). Under the License Agreement, Novellus Ltd. in turn
                    granted a sublicense to Brooklyn LLC to use the Novellus-Factor Licensed Technology to develop up to four mesenchymal stem cell-based therapy products for use in the treatment of cancer in humans.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">Under the Novellus-Factor License Agreement, Novellus Ltd. is required to use commercially reasonably efforts to achieve
                    certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. The Novellus-Factor License Agreement states that upon its achievement of these milestones,
                    Novellus Ltd. will be obligated to make milestone payments of up to $51.0 million in aggregate to Factor Limited as well as
                    specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus Ltd. fails to timely achieve certain delineated milestones under the Novellus-Factor License Agreement,
                    Factor Limited could seek to terminate the license granted thereunder. The Novellus-Factor License Agreement provides that in the event of termination of the Novellus-Factor License Agreement, if Novellus Ltd. requests that its
                    sublicense to Brooklyn LLC under the License Agreement survive such termination, such sublicense shall be considered a direct license from Factor Limited to Brooklyn LLC, provided that Brooklyn LLC agrees in writing that (i) Factor
                    Limited is entitled to enforce all relevant provisions directly against Brooklyn LLC, and (ii) Factor Limited shall not assume, and shall not be responsible to Brooklyn LLC for, any representations, warranties or obligations of Novellus
                    Ltd. to Brooklyn LLC, other than to permit Brooklyn LLC to exercise any rights to the technology sublicensed by Novellus Ltd. to Brooklyn LLC.&#160; Factor Limited also agreed under the License Agreement that upon the termination of the
                    Novellus-Factor License Agreement for any reason other than Brooklyn LLC&#8217;s breach of the License Agreement, the rights and licenses granted to Brooklyn LLC by Novellus Ltd. under the License Agreement shall survive such termination of
                    the Novellus-Factor License Agreement, and Factor Limited grants to Brooklyn LLC such rights and licenses on the same terms and conditions as granted by Novellus Ltd. to Brooklyn LLC under the License Agreement.. Following the
                    expiration of one of the delineated milestone deadlines in the Novellus-Factor License Agreement without Novellus Ltd.&#8217;s achievement of the required regulatory filing on November 1, 2022, Novellus Ltd., Brooklyn LLC and Factor began
                    discussions regarding an amendment to the terms of the License Agreement and the Novellus-Factor License Agreement in order for Brooklyn LLC, among other things, to directly license the Novellus-Factor Licensed Technology from Factor
                    and consolidate and amend the milestone, payment and other terms with respect thereto accordingly. There can be no assurance that such an amendment will be made on the forgoing terms, if at all.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;">&#160;</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">NoveCite</span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><span style="text-decoration: underline;"> <br/>
                          </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;"> </span>In October 2020, Novellus Ltd. (as
                          sublicensor) and NoveCite (as sublicensee) entered into an exclusive license agreement (the &#8220;Sublicense&#8221;) to license novel cellular therapy for acute respiratory distress syndrome, which NoveCite is licensing from Factor Limited.
                          Under the sublicense agreement, NoveCite is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified
                          commercialization milestones. In general, upon its achievement of these milestones, NoveCite will be obligated, in the case of development and regulatory milestones, to make milestone payments to the Novellus Ltd. in specified
                          amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers.</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"><span style="text-decoration: underline;"><br/>
                          </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">Under the terms of the Sublicense, in the event
                          that Novellus Ltd. receives any revenue involving the original cell line included in the licensed technology, then Novellus Ltd. shall remit to NoveCite 50% of such revenue.<span style="text-decoration: underline;"><br/>
                          </span></div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">Royalty Agreements</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">Collaborator Royalty Agreement</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Effective June 22, 2018, IRX terminated its Research,
        Development and Option Facilitation Agreement and its Options Agreement (the &#8220;RDO and Options Agreements&#8221;) with a collaborative partner (the &#8220;Collaborator&#8221;), pursuant to a termination agreement (the &#8220;Termination Agreement&#8221;). <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Termination Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. </span>In connection
        with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and Brooklyn LLC has no obligation to refund any payments received from the Collaborator. As consideration for
        entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of revenues from the sale of IRX-2, for the
        period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2 or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"> <span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Royalty Agreement with certain former IRX Therapeutics Investors</span></span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#8220;IRX Investor Royalty Agreement<span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#8221;</span>)
            with certain investors who participated in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. Pursuant to the IRX Investor Royalty Agreement,
            when Brooklyn LLC becomes obligated to pay royalties to USF under the agreement described above under &#8220;Licensing Agreements-USF,&#8221; it will pay an additional royalty of 1% of gross sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement.
            Brooklyn LLC has not recognized any revenues to date, and no royalties are due pursuant to any of the above-mentioned royalty agreements.</span> </div>

<div><span style="text-decoration: underline;"> <br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="text-decoration: underline;">Investor Royalty Agreement</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; text-indent: 36pt;">On
          March 22, 2021, Brooklyn LLC restated its royalty agreement with certain beneficial holders of Brooklyn ImmunoTherapeutics Investors GP LLC and Brooklyn ImmunoTherapeutics Investors LP, whereby such beneficial holders will continue to receive, on
          an annual basis, royalties in an aggregate amount equal to 4% of the net revenues of IRX-2, a cytokine-based therapy being developed
          by Brooklyn LLC to treat patients with cancer.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733596688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">11)<br/>
              </span> </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal; font-variant: normal; text-transform: none;">STOCK-BASED COMPENSATION</div>
              </div>
            </td>

  </tr>


</table>
    </div>

<div><span style="font-family: 'Times New Roman';">&#160; <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
     <br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Stock Options</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the Company
        granted the following stock options (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">&#160;</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">&#160;</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock options granted</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">188</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">12</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">287</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">180</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The following weighted-average assumptions were used for stock options granted during the three and nine months ended
        September 30, 2022 and 2021:</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">Three months ended September 30,</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average risk-free rate</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">2.64%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0.97%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average volatility</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">89.80%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">143.29%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expected term</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.73 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.08 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span> </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Nine months ended September 30,</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average risk-free rate</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">2.54%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">1.06%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average volatility</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">91.20%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">134.88%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expected term</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.30 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.08 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">  </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the three and nine months ended September 30, 2022, options to purchase approximately 124,000 shares of common stock were granted to Dr. Matthew Angel, the Company&#8217;s Interim Chief Executive Officer. Dr. Angel&#8217;s stock options vest at rate of 1/24 on the grant
        date with the remaining options to vest in 46 substantially equal monthly installments thereafter. For the nine months ended September
        30, 2022,</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> stock options to
        purchase </span>approximately 21,000 shares of common stock were granted to Dr. Howard J. Federoff, who served as the Company&#8217;s Chief
      Executive Officer and President until May 26, 2022 (the &#8220;March 2022 Stock Option Grant&#8221;). The March 2022 Stock Option Grant vests in 36
      substantially equal monthly installments from the grant date and had an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the nine months ended September 30, 2021</span>, options to purchase approximately 161,000 shares of common stock were granted to Dr. Federoff upon his appointment as Chief Executive Officer and President in April 2021. Approximately 131,000 stock options were under a time-based grant (the &#8220;Time-Based Grant&#8221;) and approximately 30,000 stock options were under a performance-based grant (the &#8220;Milestone Grant&#8221;). The Time-Based Grant vests over four years, with 25% vesting on the one-year anniversary of the grant date and
      the remaining options vesting in 36 substantially equal monthly installments thereafter. The Milestone Grant vests upon the first
      concurrence by the U.S. Food and Drug Administration that a proposed investigation may proceed following review of a Company filed investigational new drug application in connection with that the License Agreement. Both the Time-Based Grant and the
      Milestone Grant had an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">Vesting of all stock options grants is subject to continuous service with the Company
      through such vesting dates.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">As discussed above, pursuant to the Separation Agreement with Dr. Federoff, the Company&#160;<span style="color: rgb(0, 0, 0);">accelerated the vesting of approximately 7,000 stock options under the March 2022 Stock Option Grant and
        approximately 33,000 stock options under the Time-Based Grant. The Company also waived the performance condition under the Milestone
        Grant and accelerated the vesting of approximately 21,000 stock options under the Milestone Grant. Lastly, the Company extended the
        post-termination exercise period from 90 days to 36 months immediately following the Separation Date for all options that were vested after such accelerations.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-size: 10pt;">The above modifications to Dr. Federoff&#8217;s stock options grants resulted in modification accounting under ASC 718,&#160;</span><span style="font-style: italic; color: rgb(0, 0, 0); font-size: 10pt;">Compensation &#8211; Stock Compensation.&#160;</span><span style="color: rgb(0, 0, 0); font-size: 10pt;">As a result, the Company immediately recognized approximately $0.1 million for the incremental fair value of stock options that were vested prior to the modification by calculating the difference&#160;</span><span style="font-size: 10pt;">between the fair
        value of the modified award and the fair value of the original award immediately before it was modified. For stock options that were not vested prior to the modification but then vested as a result of the acceleration, the Company reversed any
        stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized approximately $0.1
        million of stock compensation expense in full since there was no future service period required to be provided.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2021, there were 65 options exercised for total cash proceeds of $10,202.
      The options exercised had a total intrinsic value of $57,212. There were no options exercised during the three and nine months ended September 30, 2022.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">As of September 30, 2022, there were approximately 362,000 stock options outstanding.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Restricted Stock Units</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the Company granted
      the following restricted stock units (&#8220;RSUs&#8221;) (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">RSUs Granted</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">6</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">55</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">11</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The Company recognizes the fair value of RSUs granted as expense on
      a straight-line basis over the requisite service period. For performance based RSUs, the Company begins recognizing the expense once the achievement of the related performance goal is determined to be probable.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Outstanding RSUs are settled in an equal number of shares of common
      stock on the vesting date of the award. An RSU award is settled only to the extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal
      number of shares of common stock without any offsetting payment by the recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">In lieu of paying cash to satisfy withholding taxes due upon the
      settlement of vested RSUs, at the Company&#8217;s discretion, an employee may elect to have shares of common stock withheld that would otherwise be issued at settlement, the value of which is equal to the amount of withholding taxes payable. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the number of RSUs that vested and were settled during the three and nine months ended
        September 30, 2022, as well as the number of shares of common stock withheld to cover the withholding taxes and the net shares issued upon settlement (in thousands):</span></span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Three months ended</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Nine months ended</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">RSUs vested</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Common stock withheld to cover
              taxes</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(1</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Common stock issued</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The 55,000 RSUs granted during the nine months ended September 30, 2022 are performance-based RSUs (the &#8220;2022 PSUs&#8221;), of which approximately 21,000 were awarded to Dr. Federoff. The 2022 PSUs are subject to the achievement of four
      performance goals, which are weighted equally. Once a performance goal is achieved, the tranche of shares allocated to that performance goal will be earned and will begin to vest over a three-year annual basis beginning on the date the performance goal was achieved. If a performance goal is not achieved, the tranche of shares allocated to that performance goal will be
      unearned and forfeited. As of September 30, 2022, two of the performance goals were not achieved by the due date, and as a result,
      approximately 28,000 2022 PSUs were cancelled and any previously recognized stock compensation expense was reversed.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Pursuant to Dr. Federoff&#8217;s Separation Agreement, Dr. Federoff&#8217;s 21,000 2022 PSUs were canceled in full (a portion of which included the PSUs allocated to the performance goal that was not achieved timely), and&#160;<span style="color: rgb(0, 0, 0);">a lump sum cash severance benefit in the amount of $0.1 million was paid to Dr. Federoff, which represents
        the value Dr. Federoff would have received if he were entitled to receive a settlement of a pro rata portion of his 2022 PSUs through the expiration of the Separation Period, assuming the performance metrics were waived and assuming a per share
        value of $16.20. Any stock compensation expense previously recognized on Dr. Federoff&#8217;s 2022 PSUs was reversed and approximately $0.1 million was recognized as compensation expense.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">As of September 30, 2022, there were approximately 15,000 RSUs outstanding.<br/>
      <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Restricted Stock</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">Pursuant to the Merger, Brooklyn LLC&#8217;s approximately 3,000 outstanding restricted common units were exchanged for approximately 32,000 shares of Eterna&#8217;s restricted common stock. There were no changes to any conditions and requirements of the restricted common stock. The shares vested quarterly beginning on March 31, 2021 and were to continue
      through December 31, 2022, contingent on continued service. Due to the modification of the restricted common units, the fair value of the restricted common stock immediately after the Merger was compared to the fair value of the restricted common
      units immediately prior to the Merger, and the change in fair value of $0.3 million was recognized in the statement of operations during
      the nine months ended September 30, 2021. The Company recognizes the fair value of restricted common stock as an expense on a straight-line basis over the requisite service period.&#160; During the nine months ended September 30, 2022, approximately 4,000 shares of unvested restricted common stock were forfeited due to the holders of such shares no longer providing services to the Company.&#160; As of
      September 30, 2022, there were no shares of unvested restricted stock outstanding.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Stock-Based Compensation Expense</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt; margin-right: 0.5pt;">For the three and nine months ended September 30, 2022 and 2021,
      the Company recognized stock-based compensation expense as follows, which includes the expense related to Dr. Federoff&#8217;s modified awards discussed above (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">Research and development</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">183</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">448</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,075</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,018</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">General and administrative</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">293</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,281</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,463</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">2,284</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">Total</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">476</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,729</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">2,538</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">3,302</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733708224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify;">12)</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">STOCKHOLDERS&#8217; EQUITY<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
              </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"><span style="font-weight: normal;"> <br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Private Placement of
            Equity</div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On March 6, 2022, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;PIPE Investor&#8221;)
                providing for the private placement (the &#8220;PIPE Transaction&#8221;) to the PIPE Investor of approximately 343,000 units (collectively,
                the &#8220;Units&#8221;), each Unit consisting of (i) one share of the Company&#8217;s common stock (or, in lieu thereof, one Pre-Funded Warrant
                to purchase one share of common stock) and (ii) one warrant (the &#8220;Common Warrants&#8221;) to purchase one share of common stock, for an aggregate gross purchase price of approximately $12.0 million (the &#8220;Subscription Amount&#8221;). The PIPE Transaction closed on March 9, 2022. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Pursuant to the Purchase Agreement, the Company is prohibited from issuing equity in variable
                  rate transactions for a period of one-year following consummation of the PIPE Transaction, including issuing equity under the
                  Second Purchase Agreement.</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each Pre-Funded Warrant had an exercise price of $0.10 per share of common stock, was immediately exercisable, could be
              exercised at any time, had no expiration date and was subject to customary adjustments. The Pre-Funded Warrants could not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof. Upon the closing of the PIPE Transaction, the Company issued 275,000 shares of common stock and issued Pre-Funded Warrants representing approximately 68,000 shares of common stock. On July 12, 2022, the PIPE Investor exercised its&#160;68,000
              Pre-Funded Warrants at an exercise price of $0.10 per share<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">for an aggregate exercise price of $6,786, in cash. The Company issued 68,000 shares of common stock to
                  the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds. Subsequent to the exercise, no Pre-Funded Warrants
                  remained outstanding.</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span>
              <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Each Common Warrant has an exercise price of $38.20 per share, becomes exercisable six months following the closing of the PIPE Transaction, expires <span style="-sec-ix-hidden:Fact_5b09bcc1ce7d4736a68839d07677b3d8">five-and-one-half </span> years from the date of issuance and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, subject to increase to 9.99% at the option of the holder.</div>

<div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As of September 30, 2022, the Company had 343,000
              Common Warrants outstanding with a weighted average exercise price of $38.20 per share and a weighted average contractual life of 4.95 years.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">The





























































            Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a cashless settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These
            warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the statement of operations. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Upon exercise of the Common Warrants and Pre-Funded Warrants, the fair value on the exercise date is reclassified from warrant
              liabilities to equity</span>.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $12.6 million in the aggregate, which was $0.6 million more
              than the Subscription Amount. The excess $0.6 million represents an inducement to the PIPE Investor to enter into the PIPE
              Transaction and was recorded in warrant liabilities expense in the accompanying consolidated statement of operations. Given the Company&#8217;s capital requirements and market conditions, the Company consummated this financing on market terms
              available at the time of the transaction.</div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; margin-right: 2pt;">The Company incurred fees of approximately $1.0 million through September 30, 2022 related to the PIPE Transaction, which were allocated to the fair value of the Common Warrants and the Pre-Funded Warrants and recorded in other expense, net on the
              accompanying condensed consolidated statement of operations.</div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the PIPE Transaction, the Company and the PIPE Investor also entered into a registration rights agreement, dated March 6,
              2022, pursuant to which the Company agreed to prepare and file a registration statement with the SEC no later than 15 days following the filing date of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021
              Annual Report&#8221;) to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants. The Company agreed to use its best efforts to
              have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed the 2021 Annual Report on April 15, 2022
              and the registration statement on April 29, 2022. The resale registration statement became effective on May 11, 2022.</div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the registration rights agreement, the Company is obligated to pay the PIPE Investor liquidated damages equal to 2% of the Subscription Amount per month, with a maximum aggregate payment of 12% of the Subscription Amount, in the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered for resale
              thereunder for more than 10 consecutive calendar days or more than an aggregate of <span style="-sec-ix-hidden:Fact_35a0d29cf6104e00b3095ed13c7f4044">fifteen</span> calendar days (which need not be consecutive calendar days) during any 12-month period.</div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On May 24, 2022, the Company provided the PIPE Investor with notice that it was not able to resell the securities registered for resale under
              the registration agreement because the Company had not timely filed its Quarterly Report on Form 10-Q (the &#8220;Q1 2022 10-Q&#8221;) with the SEC, and that the PIPE Investor could not use the registration statement to resell the related securities
              until the Company filed the Q1 2022 10-Q.&#160; Because the PIPE Investor was unable to use the registration statement for at least 10
              consecutive calendar days, the Company accrued $0.2 million during the first quarter of 2022 for the contingent loss the Company
              incurred as liquidated damages as a result of the late Q1 2022 10Q filing, which is recorded in other expense, net for the nine months ended September 30, 2022 in the accompanying condensed consolidated statements of operations.&#160; The Company
              paid such $0.2 million liquidated damages payment in June 2022.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> On June 30, 2022, the Company filed its Q1 2022 10-Q along with the 10-K/A, and on July 1, 2022, the Company provided its notice to the PIPE
              Investor that it may resume use of the resale registration statement.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify; text-indent: 36pt;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify; text-indent: 36pt;"><span style="font-weight: normal;"> <span style="font-style: italic;">Merger</span></span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; text-indent: 0px; text-transform: none; background-color: rgb(255, 255, 255);"><span style="font-weight: normal;"> <br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">Under the terms of the Merger
              Agreement </span></span>(see Note 3)<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">, on March 25, 2021, Eterna issued shares of common stock to the equity holders of Brooklyn LLC. The 87,000
              Class A units of Brooklyn LLC were converted into </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> 1,114,000 shares of common stock; the 15,000,000 Class B units were converted into </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> 126,000
              shares of common stock; the 10,000,000 Class C units were converted into </span></span>approximately 84,000<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> shares of common stock; </span></span>approximately 630,000<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> shares of common units were
              converted into </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> 31,000 shares of common stock, and 10,500,000 rights options were converted into </span></span>approximately 591,000<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> shares of common stock. <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">Eterna</span></span> also
              issued </span></span>approximately<span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;"> 53,000 shares of common stock to its financial advisor pursuant to the Merger Agreement</span></span>.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733602496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS PER SHARE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">
<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify;">13)</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">EARNINGS PER SHARE</span> </div>
                  </td>

  </tr>


</table>
          </div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period
          including the weighted average effect of the Pre-Funded Warrants the Company issued in connection with the PIPE Transaction, the exercise of which requires little or no consideration for the delivery of shares of common stock. The Company
          determined that the exercise of the Pre-Funded Warrants requires nominal consideration for the delivery of shares of common stock, and as such, has considered the 68,000 shares underlying the Pre-Funded Warrants to be outstanding effective on March 9, 2022 for the purposes of calculating basic EPS. Diluted net loss per share is calculated by
          dividing net loss by the weighted-average number of common shares outstanding (including the weighted average effect of the Pre-Funded Warrants) plus dilutive securities. Stock options, RSUs, warrants and other convertible securities are
          considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. Diluted net loss per share is the same as basic net loss per share in periods where the
          effect of potentially dilutive shares of common stock are antidilutive. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table presents the amount of stock options, RSUs, warrants and convertible preferred stock that were excluded from the computation of diluted net loss per
          common share for the three and nine months ended September 30, 2022 and 2021, as their effect was anti-dilutive:</span></div>

<div><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Three and Nine months ended September 30,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; text-align: center;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Stock options</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">362</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">180</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">RSUs</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">15</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">11</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Warrants</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">343</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Preferred stock converted into common stock</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Total potential common shares excluded from computation</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">722</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">193</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752737977008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">14)<br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">RECENT ACCOUNTING PRONOUNCEMENTS</div>
          </td>

  </tr>


</table>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span>
     </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> September 2022, the Financial Accounting Standard Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2022-04,&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Liabilities&#8212;Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier
        Finance Program Obligations&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(&#8220;ASU












        2022-04&#8221;). ASU 2022-04 requires a buyer that uses supplier finance programs to make annual disclosures about the program&#8217;s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and
        associated roll-forward information. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is
        effective for fiscal years beginning after December 15, 2023. The Company does not expect a material impact on its financial statements as a result of adopting this amendment.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In June 2022, the FASB issued ASU No. 2022-03,&#160;Fair Value Measurement (Topic 820): Fair Value Measurement
        of Equity Securities&#160;Subject to Contractual Sale Restrictions&#160;(&#8220;ASU 2022-03&#8221;). The FASB issued ASU 2022-03 to (1) clarify the&#160;guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual
        restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity related securities subject to contractual sale restrictions that are measured at
        fair value in accordance with Topic 820. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair
        value. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years with early adoption permitted. The Company is evaluating when to adopt the amendments in ASU 2022-02. The Company
        does not expect a material impact as a result of adopting this amendment.</span>  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733602496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">15)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">SUBSEQUENT EVENTS</div>
              </td>

  </tr>


</table>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Facility Sublease</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On October 18, 2022, the Company entered into the Sublease with E.R. Squibb &amp; Sons, L.L.C., a Delaware
            limited liability company and subsidiary of Bristol-Myers Squibb Company (&#8220;Sublessor&#8221;), for office, laboratory and research and development space (the &#8220;Premises&#8221;). The Premises consists of approximately 45,500 square feet on the ninth floor of the building currently under construction located at 250 Water Street, Somerville, Massachusetts 02141.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal; text-indent: 36pt;">The Sublease rent commences on the date that is the earlier of (i) the date that the Company commences
            business operations from the Premises and (ii) the date that is the one-year anniversary of the later to occur of (A) October 18, 2022 and (B) the date that Sublessor obtains the primary landlord&#8217;s consent for the Sublease (such applicable
            date, the &#8220;Rent Commencement Date&#8221;). The Sublease has a term of 10 years from the Rent Commencement Date (the &#8220;Term&#8221;), subject to a
            five-year extension in accordance with the terms of the Sublease.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; text-indent: 36pt;">Pursuant to the Sublease, within <span style="-sec-ix-hidden:Fact_8744bc3fa0f34851947cbc5afae0d9dc">two</span> business days following receipt of the primary landlord&#8217;s consent to the Sublease, the Company will pay Sublessor a security deposit in the form of a letter of credit
            in the amount of approximately $4.1 million. Provided there are no events of default by the Company under the Sublease, the letter of
            credit will be reduced on an incremental basis throughout the Term. Pursuant to the Sublease, the Company has agreed to pay base rent of approximately $0.5
            million per month during the first year of the Term, increasing on an incremental basis each subsequent year of the Term, as well as traditional lease expenses including, certain taxes, operating expenses and utilities.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: italic; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; text-indent: 36pt;">Exacis Option Agreement (Related Party Transaction)</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal; text-indent: 36pt;">On October 8, 2022, the Company entered into an option agreement (the &#8220;Option Agreement&#8221;) with Exacis
            Biotherapeutics, Inc., a Delaware corporation (&#8220;Exacis&#8221;), pursuant to which Exacis granted the Company the option to negotiate and enter into an exclusive worldwide license to certain of the technology licensed by Exacis for the treatment of
            cancer in humans (the &#8220;Option&#8221;). The Option Agreement provides that the Company will pay Exacis a fee of $0.3 million for the Option,
            which would be creditable against the fees or purchase price payable under any such license if entered into by the Company in accordance with Option Agreement. The Option Agreement provides for certain payments upon the execution of a
            definitive license agreement, which would become payable only upon execution, and in accordance with the terms, of the applicable license agreement, if any.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; text-indent: 36pt;">The Option Agreement has been deemed a related party transaction, as one of the Company&#8217;s Board members, Dr. Gregory
            Fiore, is the Chief Executive Officer of Exacis.<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> Additionally, the Company&#8217;s Interim Chief Executive Office, Dr. Matthew Angel, is </span><span style="font-size: 10pt; font-family: 'Times New Roman';">Chairman of Exacis&#8217; scientific advisory board. Dr. Angel is also the Chairman and Chief Executive Officer of Factor, which is </span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the majority shareholder</span> of Exacis.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; text-indent: 36pt;"> <br/>
          </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732762544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Basis of Presentation</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The


          accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial statements and with the instructions to
          Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited financial statements include all the
          normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented.<br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">These































          condensed consolidated financial statements should be read together with the audited consolidated financial statements and notes thereto contained in Eterna&#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2021 filed with the
          Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 30, 2022 (the &#8220;10-K/A&#8221;). The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements contained in the 10-K/A but does
          not include all of the information and footnotes required by GAAP for complete financial statements. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be anticipated
          for the entire year ending December 31, 2022, or any other period.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman'; font-style: italic;">Reverse Stock Split</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">A<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">s approved by the Company&#8217;s stockholders at the Company&#8217;s Annual Meeting of Stockholders held
              on September 21, 2022, the Company effected a reverse stock split of its common stock at a ratio of <span style="-sec-ix-hidden:Fact_b943329114c841ec8b57e15e6be15da4">1-for-20</span>, as determined by the
              Company&#8217;s Board of Directors within the parameters approved by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split&#8221;).&#160; The Reverse Stock Split became effective under Delaware law at 11:59 p.m. Eastern time on October 16, 2022.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common stock were automatically
            combined and reclassified into one issued and outstanding share of common stock. The Reverse Stock Split did not affect any stockholder&#8217;s ownership percentage of the common stock, alter the par value of the common stock or modify any voting
            rights or other terms of the common stock. The number of authorized shares of common stock under the Charter remains unchanged. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares to
            which a stockholder would otherwise be entitled, the Company paid an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the then fair value of a share as determined in good
            faith by the Board. The Company paid an aggregate of $719 for a total of 175 fractional shares.<br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';">All share and per share data in this Quarterly Report on Form 10-Q have been adjusted for all periods presented to reflect the Reverse
            Stock Split.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">
<div>
         <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-style: italic;">Reclassifications</span><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain reclassifications have been made
          to Eterna&#8217;s prior years&#8217; financial statements to conform to the current year presentation. These reclassifications had no effect on Eterna&#8217;s previously reported results of operations or accumulated deficit.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the reverse stock split during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733549872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> September 2022, the Financial Accounting Standard Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2022-04,&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Liabilities&#8212;Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier
        Finance Program Obligations&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(&#8220;ASU












        2022-04&#8221;). ASU 2022-04 requires a buyer that uses supplier finance programs to make annual disclosures about the program&#8217;s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and
        associated roll-forward information. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is
        effective for fiscal years beginning after December 15, 2023. The Company does not expect a material impact on its financial statements as a result of adopting this amendment.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In June 2022, the FASB issued ASU No. 2022-03,&#160;Fair Value Measurement (Topic 820): Fair Value Measurement
        of Equity Securities&#160;Subject to Contractual Sale Restrictions&#160;(&#8220;ASU 2022-03&#8221;). The FASB issued ASU 2022-03 to (1) clarify the&#160;guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual
        restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity related securities subject to contractual sale restrictions that are measured at
        fair value in accordance with Topic 820. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair
        value. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years with early adoption permitted. The Company is evaluating when to adopt the amendments in ASU 2022-02. The Company
        does not expect a material impact as a result of adopting this amendment.</span>  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752731221856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Tangible and Intangible Assets Acquired and Liabilities Assumed, Based on Estimated Fair Values</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The allocation of the purchase price to the tangible and
          intangible assets acquired and liabilities deemed to be assumed from Eterna, based on their estimated fair values as of March 25, 2021, is as follows (in thousands):</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Historical</div>
                <div style="text-align: center; font-weight: bold;"> Balance</div>
                <div style="text-align: center; font-weight: bold;"> Sheet of</div>
                <div style="text-align: center; font-weight: bold;"> Eterna at</div>
                <div style="text-align: center; font-weight: bold;"> March 25, 2021</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Fair Value</div>
                <div style="text-align: center; font-weight: bold;">Adjustment </div>
                <div style="text-align: center; font-weight: bold;">to</div>
                <div style="text-align: center; font-weight: bold;"> Eterna</div>
                <div style="text-align: center; font-weight: bold;">Pre-Merger</div>
                <div style="text-align: center; font-weight: bold;"> Assets</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;" valign="bottom">
                <div><span style="font-weight: bold;">Purchase </span></div>
                <div><span style="font-weight: bold;">Price</span></div>
                <div><span style="font-weight: bold;"> Allocation</span></div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>148</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>148</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Accounts receivable</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>103</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>103</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Prepaid expense and other current assets</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>329</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>329</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Property and equipment, net</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>1,015</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>1,015</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Software development costs</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,296</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>(368</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>928</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Customers</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>548</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>548</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Trade name</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>299</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>299</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Accounts payable, accrued liabilities and other current liabilities</div>
                </div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(3,781</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>-</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(3,781</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Net assets acquired, excluding goodwill</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>(890</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>479</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>(411</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; text-indent: -9pt; margin-left: 9pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Total consideration</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>8,178</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Net assets acquired, excluding goodwill</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(411</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">Goodwill</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>8,589</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposition Details</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 26, 2021, Eterna sold its rights, title and interest
          in and to the assets relating to the business it operated (under the name NTN Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2.0 million and assumption of specified liabilities relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the
          Disposition are as follows (in thousands):</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Proceeds from sale:</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">Cash</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">132</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Escrow</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>50</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Assume advance/loans</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,700</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Interest on advance/loans</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>68</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Carrying value of assets sold:</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Cash and cash equivalents</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(14</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Accounts receivable</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(75</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Prepaids and other current assets</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(124</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Property and equipment, net</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(1,014</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Software development costs</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(927</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Customers</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(548</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Trade name</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(299</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Goodwill</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(8,589</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Other assets</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>(103</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Liabilities transferred upon sale:</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Accounts payable and accrued expenses</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>113</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Obligations under finance leases</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>17</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Lease liability</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>26</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-align: left;">Deferred revenue</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>55</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Other current liabilities</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>149</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Transaction costs</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(265</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div style="text-align: left; font-weight: bold;">Total loss on sale of assets</div>
              </td>

    <td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-weight: bold;">(9,648</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="font-weight: bold;">)</div>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Fair Value of Asset Acquired</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">The resulting fair value of the asset acquired is as follows
          (in thousands):</span>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Fair Value of</div>
                <div style="text-align: center; font-weight: bold;">Consideration</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Cash paid</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>22,882</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div style="text-align: left;">Cash acquired</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>(28</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Unrestricted shares</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>36,628</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">Restricted shares</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>22,056</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Total fair value of consideration paid</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>81,538</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left;">Less amount of cash paid for NoveCite investment</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(1,000</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left;">Fair value of IPR&amp;D acquired</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>80,538</div>
              </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752826362624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Liabilities Measured at Fair Value</a></td>
<td class="text">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
        <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">T<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">here were no liabilities measured at fair value as of Decem</span>ber 31, 2021.
                The following tables summarize the liabilities that are measured at fair value as of September 30, 2022 (in thousands)</span>:</div>

<div> <br/>
          </div>

<div>
            <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of September 30,
                      2022</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 1</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 2</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Level 3</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Liabilities:</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Warrant liabilities - Common Warrants</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
          </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Changes in Warrant Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company remeasured the fair value of the Common Warrants as of September 30, 2022. The following table presents the changes in the warrant
            liabilities from the issuance date (in thousands): </div>

<div>&#160;</div>

<div>
            <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pre-Funded <span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrants</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> (Level 2)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> Common Warrants</span></div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>(Level 3)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>Total Warrant</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Liabilities</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at January 1, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at March 9, 2022 (issuance date)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,646</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9,943</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12,589</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(1,779</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(9,310</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(11,089</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Exercise of pre-funded warrants</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(867</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(867</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value at September 30, 2022</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">633</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
            </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752737944624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Net Operating Lease Expense</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the net operating lease expenses were as follows (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Three months ended September 30,</span><br/>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
              </div>
            </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021</span> <br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">143</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">187</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Sublease income</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(21</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(21</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Variable lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">60</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">6</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">182</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">172</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Nine months ended September 30,</span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">2022</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021<br/>
                </span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating lease expense</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">476</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">501</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Sublease income</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">(63</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">(62</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Variable lease expense</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">113</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">16</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total lease expense</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">526</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">455</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock', window );">Operating Lease Right-of-use Assets and Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The tables below show the beginning
          balances of the operating ROU assets and lease liabilities as of January 1, 2022 and the ending balances as of September, 2022, including the changes during the period (in thousands).</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
          </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ROU Assets</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease ROU assets at
                January 1, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,567</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Initial measurement of operating lease ROU assets</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,706</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Amortization of operating lease
                ROU assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(267</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Impairment of ROU assets</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(772</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Remeasurement of ROU asset<br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Write off of ROU asset due to lease termination</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(1,372</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease ROU assets at
                September 30, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,912</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-indent: 0px; text-transform: none;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Liabilities</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease liabilities at
                January 1, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,723</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Initial measurement of operating lease liabilities</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,706</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Principal payments on operating
                lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(223</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Write off of operating lease liability due to lease termination</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(1,453</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Operating lease liabilities at
                September 30, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,752</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less non-current portion</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,317</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Current portion at September 30,
                2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">436</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; font-variant: normal;">The maturities of the operating lease liabilities are as follows (in thousands):</span>
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2022</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">166</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2023</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">673</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2024</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">688</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2025</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">703</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="text-indent: 0pt;">2026</span><br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">708</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Thereafter</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">470</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Total payments</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <br/>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,408</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Less imputed interest</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(656</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Total operating lease liabilities</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,752</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating lease right-of-use assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752826361248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following (in thousands):</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold; text-align: center; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>September 30,</div>
                <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</span></div>
              </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">December 31,<br/>
                <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</span></td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued compensation </div>
              </td>

    <td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,701</div>
              </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">656</div>
              </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued research and development expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">373</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">222</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued general and administrative expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,156</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">371</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total accrued expenses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3,230</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,249</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other Liabilities</a></td>
<td class="text">
<div><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other liabilities consisted of the following (in thousands):</div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">September 30,</div>
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2021<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Current portion of License Fee Obligation<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,750</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Insurance policy premiums</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">898</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">247</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">Total other current liabilities<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">2,648</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">247</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">Long term portion of License Fee Obligation<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,642</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">48</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">48</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total other liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,690</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">48</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732998816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock', window );">Stock Option Granted</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the Company
        granted the following stock options (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">&#160;</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">&#160;</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock options granted</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">188</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">12</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">287</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">180</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used for Stock Options Granted</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;">The following weighted-average assumptions were used for stock options granted during the three and nine months ended
        September 30, 2022 and 2021:</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">Three months ended September 30,</td>

    <td colspan="1" rowspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average risk-free rate</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">2.64%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0.97%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average volatility</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">89.80%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">143.29%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expected term</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.73 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.08 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span> </div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Nine months ended September 30,</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2021</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average risk-free rate</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">2.54%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">1.06%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted average volatility</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">91.20%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">134.88%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;">0%</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expected term</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.30 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.08 years</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock', window );">RSU Granted</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">During the three and nine months ended September 30, 2022 and 2021, the Company granted
      the following restricted stock units (&#8220;RSUs&#8221;) (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">RSUs Granted</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">6</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">55</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">11</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock', window );">RSUs Vested and Settled</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the number of RSUs that vested and were settled during the three and nine months ended
        September 30, 2022, as well as the number of shares of common stock withheld to cover the withholding taxes and the net shares issued upon settlement (in thousands):</span></span>
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Three months ended</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Nine months ended</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
          </td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2022</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">RSUs vested</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><br/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Common stock withheld to cover
              taxes</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);"/>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(1</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">)</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Common stock issued</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2</div>
          </td>

    <td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt; margin-right: 0.5pt;">For the three and nine months ended September 30, 2022 and 2021,
      the Company recognized stock-based compensation expense as follows, which includes the expense related to Dr. Federoff&#8217;s modified awards discussed above (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine months ended September 30,</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
            </div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">Research and development</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">183</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">448</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,075</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,018</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">General and administrative</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">293</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,281</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,463</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">2,284</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">Total</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">476</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">1,729</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">2,538</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="color: rgb(0, 0, 0);">3,302</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number RSUs vested and settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752733572896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS PER SHARE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss per Common Share</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table presents the amount of stock options, RSUs, warrants and convertible preferred stock that were excluded from the computation of diluted net loss per
          common share for the three and nine months ended September 30, 2022 and 2021, as their effect was anti-dilutive:</span>
<div><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Three and Nine months ended September 30,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; text-align: center;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Stock options</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">362</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">180</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">RSUs</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">15</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">11</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Warrants</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">343</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Preferred stock converted into common stock</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">2</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">Total potential common shares excluded from computation</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">722</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;">193</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732890448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 21, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 17, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jul. 16, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ReverseStockSplitAbstract', window );"><strong>Reverse Stock-Split [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit', window );">Amount paid for fractional share in connection with reverse stock split | $</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NumberOfSharesConsideredAsFractionalInReverseStock', window );">Number of fractional shares considered in reverse stock split (in shares) | shares</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember', window );">NoveCite, INC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of total outstanding equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fractional shares in connection with reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NumberOfSharesConsideredAsFractionalInReverseStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares considered as fractional in reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NumberOfSharesConsideredAsFractionalInReverseStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ReverseStockSplitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ReverseStockSplitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732789760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND CAPITAL RESOURCES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 18, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 13,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(160,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (140,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,316)<span></span>
</td>
<td class="num">$ (85,986)<span></span>
</td>
<td class="num">(20,090)<span></span>
</td>
<td class="num">$ (114,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,541)<span></span>
</td>
<td class="num">$ (16,656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NewFacilityLeaseAbstract', window );"><strong>New Facility Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of premises | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NewFacilityLeaseAbstract', window );"><strong>New Facility Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NewFacilityLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NewFacilityLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752731260336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Merger (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Merger Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares of common stock owned by Brooklyn stockholders immediately before the Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,942,000<span></span>
</td>
<td class="nump">2,601,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Merger Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of outstanding common stock received by members and financial adviser</a></td>
<td class="nump">96.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common stock issued in exchange of membership interests (in shares)</a></td>
<td class="nump">1,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued as compensation for services (in shares)</a></td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Purchase price</a></td>
<td class="nump">$ 8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Closing price of common stock (in dollars per share)</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares of common stock owned by Brooklyn stockholders immediately before the Merger (in shares)</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734369152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement', window );">Cash and cash equivalents obligated to have under merger agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_BeneficialHoldersContractualCommitmentsToInvest', window );">Beneficial holders contractual commitments to invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfAdditionalRightsOffering', window );">Percentage of additional rights offering</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ProceedsFromSaleOfRights', window );">Proceeds from right offering</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Fair Value Adjustment to Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Fair Value Adjustment to Assets [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Fair Value Adjustment to Assets [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Purchase Price Allocation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Purchase Price Allocation [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Purchase Price Allocation [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_BeneficialHoldersContractualCommitmentsToInvest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual commitment made by beneficial holders to invest in the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_BeneficialHoldersContractualCommitmentsToInvest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of software development costs recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents obligated to maintain under merger agreement on balance sheet at the effective time of the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageOfAdditionalRightsOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional right offering made by the entity for unit holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageOfAdditionalRightsOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ProceedsFromSaleOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of rights during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ProceedsFromSaleOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=erna_NTNBuzztimeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=erna_ProFormaFairValueAdjustmentToAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=erna_ProFormaFairValueAdjustmentToAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=erna_PurchasePriceAllocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=erna_PurchasePriceAllocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732209440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Disposition (Details) - NTN Business [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DispositionAbstract', window );"><strong>Disposition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Sale of rights, title and interest in and to the assets relating to the business</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ProceedsFromDispositionAbstract', window );"><strong>Proceeds from sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash', window );">Cash</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow', window );">Escrow</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans', window );">Assume advance/loans</a></td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans', window );">Interest on advance/loans</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Carrying value of assets sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="num">(1,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="num">(927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="num">(8,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities transferred upon sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases', window );">Obligations under finance leases</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability', window );">Lease liability</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Total loss on sale of assets</a></td>
<td class="num">(9,648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=erna_NTNBusinessMember', window );">Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Carrying value of assets sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(548)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=erna_NTNBusinessMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Carrying value of assets sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">$ (299)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as Lease liability attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as Obligations under finance leases attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received from assume advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received from escrow deposits in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received from interest on advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as software development cost attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of the business disposal including legal, accounting, and other costs incurred to consummate the business disposition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DispositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DispositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ProceedsFromDispositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ProceedsFromDispositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=erna_NTNBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=erna_NTNBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734743568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,765,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PaymentsToAcquireProductiveAssetsNet', window );">Cash paid, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,854,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ResearchAndDevelopmentInProcessAssetAcquisition', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80,538,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=erna_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition of common stock (in shares)</a></td>
<td class="nump">351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition agreement</a></td>
<td class="nump">$ 102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AssetAcquisitionSharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 290.506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of shares issued</a></td>
<td class="nump">$ 58,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_EscrowShares', window );">Escrow shares (in shares)</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AcquisitionAgreementNonCompetitivePeriod', window );">Non-compete period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PaymentsToAcquireProductiveAssetsNet', window );">Cash paid, net</a></td>
<td class="nump">$ 22,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions', window );">Unrestricted shares, issued (in shares)</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions', window );">Restricted shares, issued (in shares)</a></td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LockUpPeriodForRestrictedShares', window );">Lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AssetAcquisitionUnrestrictedSharesSharePrice', window );">Unrestricted shares, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfDiscountOnFairValueOfRestrictedShares', window );">Percentage of discount on fair value restricted shares</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AssetAcquisitionRestrictedSharesSharePrice', window );">Restricted shares, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 130.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid</a></td>
<td class="nump">$ 22,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions', window );">Unrestricted shares, value</a></td>
<td class="nump">36,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions', window );">Restricted shares, value</a></td>
<td class="nump">22,056,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AssetAcquisitionFairValueOfConsiderationPaid', window );">Total fair value of consideration paid</a></td>
<td class="nump">81,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Less amount of cash paid for NoveCite investment</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ResearchAndDevelopmentInProcessAssetAcquisition', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="nump">$ 80.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=erna_NovellusIncMember', window );">Novellus, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_EachLockUpAgreementExtendsTerm', window );">Each lock-up agreement extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=erna_NovellusIncMember', window );">Novellus, Inc. [Member] | Chair of the Board of Directors, Former Chief Executive Officer and President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Lock-up agreements shares received in acquisition (in shares)</a></td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=erna_NovellusIncMember', window );">Novellus, Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfCommonStockSubjectToLockUpAgreement', window );">Percentage of common stock subject to the lock-up agreement</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember', window );">NoveCite, INC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of total outstanding equity interests</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AcquisitionAgreementNonCompetitivePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Acquisition Agreement contains non-competition and non-solicitation provisions pursuant to which the Seller has agreed not to engage in certain competitive activities for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AcquisitionAgreementNonCompetitivePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AssetAcquisitionFairValueOfConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of consideration paid in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AssetAcquisitionFairValueOfConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AssetAcquisitionRestrictedSharesSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered with restrictions to be paid in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AssetAcquisitionRestrictedSharesSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AssetAcquisitionUnrestrictedSharesSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered without any restrictions to be paid in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AssetAcquisitionUnrestrictedSharesSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_EachLockUpAgreementExtendsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_EachLockUpAgreementExtendsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_EscrowShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares have been placed in escrow shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_EscrowShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LockUpPeriodForRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period in which shares are locked-up, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LockUpPeriodForRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PaymentsToAcquireProductiveAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PaymentsToAcquireProductiveAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageOfCommonStockSubjectToLockUpAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares of common stock subject to the lock-up agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageOfCommonStockSubjectToLockUpAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageOfDiscountOnFairValueOfRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount on restricted shares, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageOfDiscountOnFairValueOfRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ResearchAndDevelopmentInProcessAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ResearchAndDevelopmentInProcessAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued with restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued with restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued without any restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=erna_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=erna_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=erna_NovellusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=erna_NovellusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732142720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Investment in NoveCite (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>USD ($) </div>
<div>BoardMember</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember', window );">NoveCite, INC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NumberOfBoardSeats', window );">Number of board seats | BoardMember</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Losses on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember', window );">NoveCite, INC. [Member] | Citius Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by Citius</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NumberOfBoardSeats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of members of the company's management holds board seats on board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NumberOfBoardSeats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=erna_NoveCiteINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=erna_CitiusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=erna_CitiusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752729092640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS, Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Mar. 06, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember', window );">PIPE Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member] | PIPE Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate exercise price</a></td>
<td class="nump">$ 6,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember', window );">Common Warrants [Member] | PIPE Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Common Warrants [Member] | Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Common Warrants [Member] | Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Common Warrants [Member] | Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732214336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS, Changes in Warrant Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in Fair Value of Warrant Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OverSubscriptionAmountReceived', window );">Over-subscription amount received</a></td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Gross proceeds received</a></td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at March 9, 2022 (issuance date)</a></td>
<td class="nump">12,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(11,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="num">(867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in Fair Value of Warrant Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at March 9, 2022 (issuance date)</a></td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(1,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="num">(867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in Fair Value of Warrant Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in Fair Value of Warrant Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at March 9, 2022 (issuance date)</a></td>
<td class="nump">9,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(9,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OverSubscriptionAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Over-subscription amount received in PIPE (Private Investment in Public Equity) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OverSubscriptionAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752725142848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES, Operating Lease (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">62 months<span></span>
</td>
<td class="text">62 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_BaseRentPerSquareFoot', window );">Base rent (per square foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageBaseRentIncreaseOnEachAnniversary', window );">Percentage of increase in base rent on each year</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extended lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfOperatingLeaseROUAssets', window );">Initial measurement of operating lease ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfOperatingLeaseLiabilities', window );">Initial measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706,000<span></span>
</td>
<td class="nump">$ 866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of ROU assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (772,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LesseeCommitmentToPurchaseProperty', window );">Commitment to purchase equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_UnamortizedLeaseholdImprovements', window );">Unamortized leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_BaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent expense per square foot for leased asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_BaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of operating lease liabilities in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfOperatingLeaseROUAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of operating lease ROU assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfOperatingLeaseROUAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LesseeCommitmentToPurchaseProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property for which lessee committed to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LesseeCommitmentToPurchaseProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased property under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageBaseRentIncreaseOnEachAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of base rent increase on each anniversary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageBaseRentIncreaseOnEachAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_UnamortizedLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unamortized leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_UnamortizedLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752738426128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES, Net Operating Lease Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Net Operating Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732794960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES, Operating Lease Right-of-use Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OperatingLeaseAssestAbstract', window );"><strong>Operating Lease, Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfOperatingLeaseROUAssets', window );">Initial measurement of operating lease ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="num">$ (243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of ROU assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(772)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_RemeasurementOfOperatingLeaseRightOfUseAsset', window );">Remeasurement of ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_WriteOffOfOperatingLeaseRightOfUseAsset', window );">Write off of ROU asset due to lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets, Ending</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialMeasurementOfOperatingLeaseLiabilities', window );">Initial measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrincipalPaymentsOnOperatingLeaseLiabilities', window );">Principal payments on operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_WriteOffOfOperatingLeaseLiability', window );">Write off of operating lease liability due to lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities, Ending</a></td>
<td class="nump">2,752<span></span>
</td>
<td class="nump">2,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less non-current portion</a></td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of operating lease liabilities in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialMeasurementOfOperatingLeaseROUAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of operating lease ROU assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialMeasurementOfOperatingLeaseROUAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OperatingLeaseAssestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OperatingLeaseAssestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PrincipalPaymentsOnOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal payments on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PrincipalPaymentsOnOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_RemeasurementOfOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of remeasurement of operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_RemeasurementOfOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_WriteOffOfOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of operating lease liability due to lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_WriteOffOfOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_WriteOffOfOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of operating lease right-of-use asset due to lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_WriteOffOfOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734355488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES, Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract', window );"><strong>Weighted Average Remaining Lease Term and Discount Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="nump">3,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,752<span></span>
</td>
<td class="nump">$ 2,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752731216512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,990<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfOngoingProject', window );">Non-cash impairment charges</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 5,990<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfOngoingProject">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfOngoingProject</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752826373296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CEO SEPARATION AGREEMENT (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SeparationAgreementAbstract', window );"><strong>Separation Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Dr. Federoff's [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SeparationAgreementAbstract', window );"><strong>Separation Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPostemploymentBenefits', window );">Severance benefit</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PaymentToOfficerBaseSalary', window );">Payment of annual base salary</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding (in shares)</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits', window );">Severance benefit receivable based on performance restricted stock</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Dr. Federoff's [Member] | Milestone Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_SeparationAgreementAbstract', window );"><strong>Separation Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding (in shares)</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PaymentToOfficerBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflows for payment of annual base salary for a period of twelve months after the expiration of the applicable revocation period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PaymentToOfficerBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_SeparationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_SeparationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of severance benefit, would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflows for payments of postemployment benefits (such as severance pay and health insurance benefits) recognized during the period. Postemployment benefits are benefits paid to employees after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=erna_MilestoneOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=erna_MilestoneOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732174352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 09, 2022 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,963<span></span>
</td>
<td class="nump">$ 1,491<span></span>
</td>
<td class="nump">$ 8,430<span></span>
</td>
<td class="nump">$ 8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_FactorBioscienceIncMember', window );">Factor Bioscience Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AgreedWaivePayment', window );">Agreed waive payment</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MasterServiceAgreementInitialFeesPayable', window );">Master services agreement, initial fees payable</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NumberOfMonthlyInstallmentsForFeesPayable', window );">Number of monthly installments for fees payable | Installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_RelatedPartyTransactionPeriodicFeesPaymentAmount', window );">Monthly installment fees amount</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MonthlyMasterServicesAgreementFeesPayable', window );">Monthly master services agreement fees payable initial 12-month</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder', window );">Deposit paid to be applied to last month of first work order</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NoticePeriodForFirstTerminationOfContract', window );">Notice period for first termination of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NoticePeriodForSupersedingTerminationProvisions', window );">Notice period for superseding termination provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_FactorBioscienceIncMember', window );">Factor Bioscience Inc. [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ReimburseCostsIncurredOrPaid', window );">Reimburse costs incurred or paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AgreedWaivePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount agreed to waive payment as per waiver agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AgreedWaivePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deposit paid which will be applied to the last month of the first work order.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_MasterServiceAgreementInitialFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount agreed to pay an initial fee under Master Services Agreement (or "MSA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_MasterServiceAgreementInitialFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_MonthlyMasterServicesAgreementFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The monthly master service agreement ("MSA") fees payable to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_MonthlyMasterServicesAgreementFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NoticePeriodForFirstTerminationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with prior notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NoticePeriodForFirstTerminationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NoticePeriodForSupersedingTerminationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Master Services Agreement (or "MSA") contains customary confidentiality provisions and representations and warranties of the parties, and the Master Services Agreement (or "MSA") may be terminated by ether party prior notice, subject to any superseding termination provisions contained in a particular work order, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NoticePeriodForSupersedingTerminationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NumberOfMonthlyInstallmentsForFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equal monthly installments for initial fees payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NumberOfMonthlyInstallmentsForFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ReimburseCostsIncurredOrPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reimburse for costs already incurred or paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ReimburseCostsIncurredOrPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_RelatedPartyTransactionPeriodicFeesPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of required periodic fees payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_RelatedPartyTransactionPeriodicFeesPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_FactorBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_FactorBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732901904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,701<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">3,230<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal expenses</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CurrentPortionOfLicenseFeeObligation', window );">Current portion of License Fee Obligation</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InsurancePolicyPremiums', window );">Insurance policy premiums</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LongTermPortionOfLicenseFeeObligation', window );">Long-term portion of License Fee Obligation</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total other liabilities</a></td>
<td class="nump">1,690<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Dr. Federoff's [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CurrentPortionOfLicenseFeeObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of License Fee Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CurrentPortionOfLicenseFeeObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InsurancePolicyPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for insurance policy premiums.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InsurancePolicyPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LongTermPortionOfLicenseFeeObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of License Fee Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LongTermPortionOfLicenseFeeObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732310448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES, Legal Matters (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>USD ($) </div>
<div>BoardMember</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyDamagesSoughtExpectedSalary', window );">Defendants salary promised against plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyDamagesSoughtExpectedEquityPercentage', window );">Percentage of equity promised against plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_DheshGovenderMember', window );">Govender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyDamagesSoughtExpectedSalary', window );">Defendants salary promised against plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyDamagesSoughtExpectedEquityPercentage', window );">Percentage of equity promised against plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyNumberOfArbitrationPanel', window );">Number of member arbitration panel | BoardMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_DheshGovenderMember', window );">Govender [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LegalMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LegalMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossContingencyDamagesSoughtExpectedEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of equity promised to the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossContingencyDamagesSoughtExpectedEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossContingencyDamagesSoughtExpectedSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The monetary amount of salary promised to the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossContingencyDamagesSoughtExpectedSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossContingencyNumberOfArbitrationPanel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number member in arbitration panel pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossContingencyNumberOfArbitrationPanel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_DheshGovenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_DheshGovenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734720080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES, Licensing Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Apr. 13, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusLtdAndFactorBioscienceMember', window );">Licensors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyNonRefundableOptionFee', window );">Non-refundable option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_InitialLicenseFees', window );">Initial license fees</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AdditionalFeesObligatedToPay', window );">Amount require to pay of initial license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AmountRequireToPayInitialLicenseFees', window );">Amount obligated to pay in license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AmountObligatedToPayInYearOne', window );">Additional fees obligated to pay in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusLtdAndFactorBioscienceMember', window );">Licensors [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AmountObligatedToPayInYearTwo', window );">Additional fees obligated to pay in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NoveCiteMember', window );">NoveCite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfRevenue', window );">Percentage of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=erna_UniversityOfSouthFloridaMember', window );">University of South Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_LossContingencyPercentageOfRoyaltyPayable', window );">Percentage of royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AdditionalFeesObligatedToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity is obligated to pay additional fees to Licensors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AdditionalFeesObligatedToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AmountObligatedToPayInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity is obligated to pay additional fees to the Licensors in first year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AmountObligatedToPayInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AmountObligatedToPayInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity is obligated to pay additional fees to the Licensors in second year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AmountObligatedToPayInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AmountRequireToPayInitialLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount require to pay out of the total initial license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AmountRequireToPayInitialLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_InitialLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial license fees required to pay including non-refundable fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_InitialLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossContingencyNonRefundableOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Non-refundable option fee in licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossContingencyNonRefundableOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_LossContingencyPercentageOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable from one party to another in licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_LossContingencyPercentageOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestones upfront payment on licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue from receives any revenue involving the original cell line included in the licensed technology, then Novellus, Ltd shall remit to NoveCite.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusLtdAndFactorBioscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NovellusLtdAndFactorBioscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NoveCiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_NoveCiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=erna_UniversityOfSouthFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=erna_UniversityOfSouthFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752728337648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES, Royalty Agreements (Details)<br></strong></div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Jun. 22, 2018</div></th>
<th class="th"><div>May 01, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=erna_InvestorRoyaltyAgreementMember', window );">Investor Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_RoyaltyAgreementsAbstract', window );"><strong>Royalty Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness', window );">Percentage of royalty receive equal to revenues from sale of business</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales', window );">Percentage of payment of additional royalty on gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=erna_CollaboratorRoyaltyAgreementMember', window );">Collaborator Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_RoyaltyAgreementsAbstract', window );"><strong>Royalty Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness', window );">Percentage of royalty receive equal to revenues from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional royalty payable on gross sales by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty receive equal to revenues generated from disposition of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_RoyaltyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_RoyaltyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=erna_InvestorRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=erna_InvestorRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=erna_CollaboratorRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=erna_CollaboratorRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752737272944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Stock Option Activity (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734883424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Weighted-Average Assumptions Used for Stock Options Granted (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weightage-Average Assumptions Used for Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free rate</a></td>
<td class="nump">2.64%<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Weighted average volatility</a></td>
<td class="nump">89.80%<span></span>
</td>
<td class="nump">143.29%<span></span>
</td>
<td class="nump">91.20%<span></span>
</td>
<td class="nump">134.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734035424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Summary of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 476,000<span></span>
</td>
<td class="nump">$ 1,729,000<span></span>
</td>
<td class="nump">$ 2,538,000<span></span>
</td>
<td class="nump">$ 3,302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Dr. Federoff's [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock option awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares)</a></td>
<td class="nump">188,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Incremental fair value of stock options recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options exercised, intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock option awards outstanding (in shares)</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod', window );">Exercise period of extended post-termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod', window );">Exercise period of extended post-termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Dr. Matthew Angel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares)</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares', window );">Number of monthly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Dr. Federoff's [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares', window );">Number of monthly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of accelerated vesting stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=erna_TimeBasedStockOptionGrantMember', window );">Time-Based Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares', window );">Number of monthly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of accelerated vesting stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=erna_TimeBasedStockOptionGrantMember', window );">Time-Based Grant [Member] | Vesting on one-year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=erna_PerformanceBasedStockOptionGrantMember', window );">Milestone Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of accelerated vesting stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of extended post-termination exercise period under the share-based compensation arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of monthly installments for vesting of remaining shares in share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=erna_InterimChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=erna_InterimChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=erna_TimeBasedStockOptionGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=erna_TimeBasedStockOptionGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=erna_PerformanceBasedStockOptionGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=erna_PerformanceBasedStockOptionGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752729080816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, RSUs (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Abstract [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732230128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Number of RSUs Vested and Settled (Details) - RSUs [Member] - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NumberOfAwardsVestedAndSettledAbstract', window );"><strong>Number of RSUs Vested and Settled [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_CommonStockWithheldToCoverTaxes', window );">Common stock withheld to cover taxes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_CommonStockWithheldToCoverTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock withheld to cover the withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_CommonStockWithheldToCoverTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NumberOfAwardsVestedAndSettledAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NumberOfAwardsVestedAndSettledAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734655312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Summary of RSUs (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>Goals </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized | $</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="nump">$ 3,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of stock units awards outstanding (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=erna_Two022PerformanceBasedRestrictedStockUnitsMember', window );">2022 PSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_NumberOfPerformanceGoalsAreSubjectToAchieve', window );">Number of performance goals are subject to achieve | Goals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved', window );">Number of performance goals not achieved | Goals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=erna_Two022PerformanceBasedRestrictedStockUnitsMember', window );">2022 PSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=erna_Two022PerformanceBasedRestrictedStockUnitsMember', window );">2022 PSUs [Member] | Dr. Federoff [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPostemploymentBenefits', window );">Lump sum cash severance paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_NumberOfPerformanceGoalsAreSubjectToAchieve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of performance goals are subject to achieve under 2022 performance based restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_NumberOfPerformanceGoalsAreSubjectToAchieve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of performance goals not achieved under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflows for payments of postemployment benefits (such as severance pay and health insurance benefits) recognized during the period. Postemployment benefits are benefits paid to employees after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=erna_Two022PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=erna_Two022PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=erna_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=erna_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=erna_ChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=erna_ChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752731245904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Restricted Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="nump">$ 3,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Common Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock replaced during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock outstanding (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock replaced during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Unvested restricted common stock forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752734900272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION, Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="nump">$ 3,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 1,281<span></span>
</td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 2,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752728522160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Private Placement of Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Mar. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Aggregate gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OverSubscriptionAmountReceived', window );">Over-subscription amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights', window );">Percentage of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ClassOfWarrantOrRightsExercisableTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights', window );">Percentage of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember', window );">PIPE Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Aggregate gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_VariableRateTransactionsPeriod', window );">Variable rate transaction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OverSubscriptionAmountReceived', window );">Over-subscription amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth', window );">Obligation to pay liquidated damages per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_TransactionFeesPayable', window );">Transaction fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ConsecutiveCalendarDays', window );">Consecutive calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_AggregateCalendarDays', window );">Aggregate calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimated contingent loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Liquidated damages payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember', window );">PIPE Investor [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ObligationToPayLiquidatedDamagesPercentage', window );">Obligated to pay liquidated damages percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember', window );">PIPE Investor [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Warrant expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember', window );">PIPE Investor [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate exercise price</a></td>
<td class="nump">$ 6,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_AggregateCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered in specified aggregate calendar days (which need not be consecutive calendar days) during any 12-month period for resale in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_AggregateCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of securities that would be issuable upon the exercise of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ClassOfWarrantOrRightsExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants or rights exercisable term, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ClassOfWarrantOrRightsExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ConsecutiveCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered in specified consecutive calendar days for resale, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ConsecutiveCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ObligationToPayLiquidatedDamagesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pursuant to the registration rights agreement, obligation to pay the PIPE Investor liquidated damages percentage of aggregate payment on Subscription Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ObligationToPayLiquidatedDamagesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pursuant to the registration rights agreement, obligation to pay the PIPE Investor liquidated damages equal to the Subscription Amount per month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OverSubscriptionAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Over-subscription amount received in PIPE (Private Investment in Public Equity) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OverSubscriptionAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_PrivatePlacementOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_PrivatePlacementOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_TransactionFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees incurred related to PIPE transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_TransactionFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_VariableRateTransactionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pursuant to the Purchase Agreement, the Company is prohibited from issuing equity in variable rate transactions for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_VariableRateTransactionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=erna_PIPEInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752732812976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Merger (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesAcquisitions1', window );">Stock issued, shares, acquisition (in shares)</a></td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">1,114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ClassOfWarrantOrRightIssued', window );">Number of rights options issued (in shares)</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of rights options converted (in shares)</a></td>
<td class="nump">591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_StockIssuedDuringPeriodSharesAcquisitions1', window );">Stock issued, shares, acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_MergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_MergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_StockIssuedDuringPeriodSharesAcquisitions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_StockIssuedDuringPeriodSharesAcquisitions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752728825904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">722,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">343,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Preferred Stock Converted into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to be outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=erna_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139752728810096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 18, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_FacilitySubleaseAbstract', window );"><strong>Facility Sublease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">62 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term of sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_FacilitySubleaseAbstract', window );"><strong>Facility Sublease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of premises | ft&#178;</a></td>
<td class="nump">45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_FacilitySubleaseAbstract', window );"><strong>Facility Sublease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Letter of credit</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E.R. Squibb &amp; Sons, L.L.C. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_FacilitySubleaseAbstract', window );"><strong>Facility Sublease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of premises | ft&#178;</a></td>
<td class="nump">45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of sublease</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term of sublease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_TermToPaySecurityDeposit', window );">Term to pay security deposit</a></td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OperatingLeasesMonthlyBaseRent', window );">Monthly base rent payable</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | E.R. Squibb &amp; Sons, L.L.C. [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_FacilitySubleaseAbstract', window );"><strong>Facility Sublease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Letter of credit</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Exacis Biotherapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_ExacisOptionAgreementAbstract', window );"><strong>Exacis Option Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_erna_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_ExacisOptionAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_ExacisOptionAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_FacilitySubleaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_FacilitySubleaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OperatingLeasesMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rental expense payable per month for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OperatingLeasesMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of option fee in licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_erna_TermToPaySecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term to pay, sub lessor a security deposit primary landlord's consent to the Sublease in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">erna_TermToPaySecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>erna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_ERSquibbSonsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_ERSquibbSonsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_ExacisBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=erna_ExacisBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>brhc10043851_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:erna="http://eternatx.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="erna-20220930.xsd" xlink:type="simple"/>
    <context id="c20220101to20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20221111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="c20220701to20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210630_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">erna:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">erna:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20221017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20220921to20220921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-09-21</startDate>
            <endDate>2022-09-21</endDate>
        </period>
    </context>
    <context id="c20221018_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-18</instant>
        </period>
    </context>
    <context id="c20221018_PledgingPurposeAxis_LetterOfCreditMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-18</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:PurchasePriceAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:PurchasePriceAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:PurchasePriceAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">erna:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">erna:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">erna:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20220101to20220930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AssetAcquisitionAxis_NovellusIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210716_OwnershipAxis_CitiusPharmaceuticalsIncMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">erna:CitiusPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20210716to20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">erna:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220309_ClassOfWarrantOrRightAxis_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="c20220309_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="c20220714_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="c20211231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2022-03-05</instant>
        </period>
    </context>
    <context id="c20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:MilestoneOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="c20220524to20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:MilestoneOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-09</instant>
        </period>
    </context>
    <context id="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20221001to20221031_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:FactorBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c20220930_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:DheshGovenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:DheshGovenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="c20220805to20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-08-05</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_LegalEntityAxis_UniversityOfSouthFloridaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">erna:UniversityOfSouthFloridaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-15</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c20220101to20220930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220930_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:NoveCiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">erna:InvestorRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">erna:CollaboratorRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-22</startDate>
            <endDate>2018-06-22</endDate>
        </period>
    </context>
    <context id="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">erna:InvestorRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-01</startDate>
            <endDate>2012-05-01</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AwardTypeAxis_TimeBasedStockOptionGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:TimeBasedStockOptionGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:PerformanceBasedStockOptionGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:TimeBasedStockOptionGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:TimeBasedStockOptionGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:PerformanceBasedStockOptionGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20210701to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_EmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">erna:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">erna:Two022PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220101to20220930_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220930_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20210701to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220306_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">erna:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220712_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="c20220930_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220930_InvestmentTypeAxis_PIPEInvestorMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20220331_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220601to20220630_InvestmentTypeAxis_PIPEInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">erna:PIPEInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20210325_StatementClassOfStockAxis_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_StatementClassOfStockAxis_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_StatementClassOfStockAxis_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ERSquibbSonsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-18</instant>
        </period>
    </context>
    <context id="c20221018to20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ERSquibbSonsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-18</startDate>
            <endDate>2022-10-18</endDate>
        </period>
    </context>
    <context id="c20221018_PledgingPurposeAxis_LetterOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ERSquibbSonsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-18</instant>
        </period>
    </context>
    <context id="c20221008to20221008_RelatedPartyTransactionsByRelatedPartyAxis_ExacisBiotherapeuticsIncMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">erna:ExacisBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-08</startDate>
            <endDate>2022-10-08</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>pure</measure>
    </unit>
    <unit id="U005">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U006">
        <measure>erna:BoardMember</measure>
    </unit>
    <unit id="U007">
        <measure>erna:Installment</measure>
    </unit>
    <unit id="U008">
        <measure>erna:Goals</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20220101to20220930"
      id="Fact_c22ccf8961c24411a4dc3128a2a7bde8">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20220101to20220930"
      id="Fact_a942b6f54f4e4ec5859321d3fdad4855">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20220101to20220930"
      id="Fact_abb101a7ebd449109dd1e62fdde53300">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20220101to20220930"
      id="Fact_39b484f2dcd947b2bb3afcb659813a82">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20220101to20220930"
      id="Fact_4a6e57997870416c838e962abca99627">0000748592</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_a01fe878e0064f3999e272199bd42d2c"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_7ee35f032c0c4b188f3eb65a7a37136f"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_c63bc29191b04902b61f2975f98f0e21"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20221017to20221017_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_f5174a00983f4b74a313cc26b70a9518"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20220921to20220921"
      decimals="2"
      id="Fact_b943329114c841ec8b57e15e6be15da4"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      id="Fact_5b09bcc1ce7d4736a68839d07677b3d8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <erna:AggregateCalendarDays
      contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember"
      id="Fact_35a0d29cf6104e00b3095ed13c7f4044">P15D</erna:AggregateCalendarDays>
    <erna:TermToPaySecurityDeposit
      contextRef="c20221018to20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_8744bc3fa0f34851947cbc5afae0d9dc">P2D</erna:TermToPaySecurityDeposit>
    <dei:DocumentType
      contextRef="c20220101to20220930"
      id="Fact_65a5bd1dc56e4e9fa76fe4c159364cb1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20220101to20220930"
      id="Fact_f5695269fd9849b1ad3e287311e756db">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20220101to20220930"
      id="Fact_1a5e02a723a44803911ce76215333228">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20220101to20220930"
      id="Fact_8f0bb10d72d14a57a69b5a993fd689db">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20220101to20220930"
      id="Fact_90945eedff1d43ccb6b9f2cf10eb4255">001-11460</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20220101to20220930"
      id="Fact_667a4cb77c0e4f97a5f98867d5da68f7">Eterna Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220101to20220930"
      id="Fact_365d4ddc9f38423e9711b8d4963edc92">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220101to20220930"
      id="Fact_97b5b2e4b47d404f9034ad5fbfd3ff25">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220101to20220930"
      id="Fact_24198666a6e1424db0ed06e7967ad2a3">10355 Science Center Drive, Suite 150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20220101to20220930"
      id="Fact_7ddd7994e15149029c9b495d3f55e217">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220101to20220930"
      id="Fact_d6a7dfe18d2540d191c1187b4d1f1189">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220101to20220930"
      id="Fact_0e555dd5288741d7b9cd4cb57dbe1c83">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220101to20220930"
      id="Fact_aec6d7905fe745589eba585f16b05baa">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220101to20220930"
      id="Fact_3140b70708c34c3b9a68858bc300e443">582-1199</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="c20220101to20220930"
      id="Fact_6074edd9bee54855854a1942219ed966">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:Security12bTitle
      contextRef="c20220101to20220930"
      id="Fact_784fd6f68af849e29a263038edce410e">Common stock, $0.005 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220101to20220930"
      id="Fact_e013b520c9f44ff789c9f63b9dd0b8af">ERNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20220101to20220930"
      id="Fact_62cb464167ec4dbf90e91b7d4085fc8e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20220101to20220930"
      id="Fact_76afc7460ee64ea68778bff5cb3053c1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20220101to20220930"
      id="Fact_bd444aff6e7b4585aa924e220d53ef0e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20220101to20220930"
      id="Fact_6ad38af2f2c743f7a2915bc8443fc032">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20220101to20220930"
      id="Fact_ccf1d8e8266345448d6fdca3a5cd7b08">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220101to20220930"
      id="Fact_b9f91141568345a09bf6e35e6d05b327">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20220101to20220930"
      id="Fact_95af04fbd2c948c29a2cb7458163301a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20221111"
      decimals="INF"
      id="Fact_bc957f6268e2465a826577b07f033e50"
      unitRef="U001">2942120</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="c20220930"
      decimals="-3"
      id="Fact_95dda23c92d847678e06bd2488a77e2c"
      unitRef="U002">13254000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="c20211231"
      decimals="-3"
      id="Fact_00fbac43fe3841daa4f9f17da38d8a8c"
      unitRef="U002">16985000</us-gaap:Cash>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_eb3475879c984b229da0795b69991627"
      unitRef="U002">926000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ee182beb80e7427a8e44921a96eb5c21"
      unitRef="U002">684000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_924d072972a64dd2b93231a29a239d7a"
      unitRef="U002">1672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_633ad162eaa44dc4a84145c32d193f57"
      unitRef="U002">1097000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_b1a7b6ef9531485da0a1aaaacd639959"
      unitRef="U002">15852000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_5ad64840ea984061bb9d10cc8681d789"
      unitRef="U002">18766000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20220930"
      decimals="-3"
      id="Fact_95132a85f15144539816df2bb02a1d59"
      unitRef="U002">231000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20211231"
      decimals="-3"
      id="Fact_616e4d8489d14af6aed2f9d5c53fce4f"
      unitRef="U002">670000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20220930"
      decimals="-3"
      id="Fact_2d6c8bfbafe64faeb5325d376d987e88"
      unitRef="U002">1912000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d3cbf3d126324979a3925bafe52a7e54"
      unitRef="U002">2567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="c20220930"
      decimals="-3"
      id="Fact_8c5567a64f284563936e2406a212f5be"
      unitRef="U002">2044000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a91021e738a643ea81d1a3e80a79f3b8"
      unitRef="U002">2044000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20220930"
      decimals="-3"
      id="Fact_2563293303b0443184d81479b5fd26fe"
      unitRef="U002">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20211231"
      decimals="-3"
      id="Fact_305c31e3e34e447498e6f4e82b5a4c36"
      unitRef="U002">5990000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="c20220930"
      decimals="-3"
      id="Fact_f765a194746c48209deb2d7ac37174bf"
      unitRef="U002">68000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="c20211231"
      decimals="-3"
      id="Fact_e1f3e4ff044e4d9596113337af2cbe4a"
      unitRef="U002">1000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_61ebf41ddf65449da4bbbaf14da5eec2"
      unitRef="U002">819000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_c031daa388624efd81b9d901e8502cfd"
      unitRef="U002">488000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20220930"
      decimals="-3"
      id="Fact_c7903c4571694ce9b1482fe730890507"
      unitRef="U002">20926000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ee512d5e84194a08af027857dfe049d1"
      unitRef="U002">31525000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_ddf230f2796345b395bd34589bc38b79"
      unitRef="U002">1150000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_33a32138c0854027ad3522b61cc19cfa"
      unitRef="U002">1755000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_b61db524492d4b58bfb731f1120e6aff"
      unitRef="U002">3230000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d831c2cccf664f6d8fc457e89d5ba8c0"
      unitRef="U002">1249000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_b94f6793cab6457eb78f7e1832ba896a"
      unitRef="U002">436000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ef94ba6be7944a3c824a289d1e306ede"
      unitRef="U002">426000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_4ab857f59f684ab7b4112fcaaba43176"
      unitRef="U002">3000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ffa5412b98704597b7f7a281764b4787"
      unitRef="U002">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_8dd64977a66549d6920b51ec5a568387"
      unitRef="U002">2648000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f9fd8dad044942f499343933f2acd4fb"
      unitRef="U002">247000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_6be829a26ca64ba286ba625da0ea7b54"
      unitRef="U002">7467000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_9b27efcee29f42e691e5c5ab0193ece9"
      unitRef="U002">3677000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_81c39921f8f1494584e9b0e0df2f3e0d"
      unitRef="U002">633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_3d35589e2cd049a4b429279cfc9bb764"
      unitRef="U002">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_abf2a7f4593748bdb9998514f383eb09"
      unitRef="U002">2317000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_b71b9a9e7c01476da652aa1645264aa9"
      unitRef="U002">2297000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_7d1d456de236466c812db0aeddf79a74"
      unitRef="U002">6000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_51cf461ba5c24747bc7e12d6b0ba9df1"
      unitRef="U002">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_993b24efd49d450d9d4bd629f60f4d81"
      unitRef="U002">1690000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_12693b77fb904038aee287c909bdd16b"
      unitRef="U002">48000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20220930"
      decimals="-3"
      id="Fact_47d0c88d67d143fd882dbfd3c41ba003"
      unitRef="U002">12113000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20211231"
      decimals="-3"
      id="Fact_c4685ad725a0456896a4daaea179f7cc"
      unitRef="U002">6022000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20220930"
      decimals="3"
      id="Fact_c0ea5613ea6d40f0b9dffe14abd1edc5"
      unitRef="U003">0.005</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20211231"
      decimals="3"
      id="Fact_bcd8709d033f428e8173ed7775036d5c"
      unitRef="U003">0.005</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20220930"
      decimals="-3"
      id="Fact_4ac7253f1c734f6ea97099ac1ba020da"
      unitRef="U001">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4a03470ef4d44c388f86bc6c1a210cb6"
      unitRef="U001">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20220930"
      decimals="-3"
      id="Fact_f02586de8d224caaadf31d214af57aa9"
      unitRef="U001">156000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20211231"
      decimals="-3"
      id="Fact_cf2c9722e4d248b3800a3c6265700290"
      unitRef="U001">156000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20220930"
      decimals="-3"
      id="Fact_9249699cab6b4d61b305f727f21d5fb3"
      unitRef="U001">156000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20211231"
      decimals="-3"
      id="Fact_62790db89ed1415c8007a230ba3678a0"
      unitRef="U001">156000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ebb9e8aebf25456688cf39b98102f735"
      unitRef="U002">156000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c20220930"
      decimals="-3"
      id="Fact_6d87828446cb4966bfa8abfdc0b31371"
      unitRef="U002">156000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_bf15d0c11c1f4cf69948bff8bdbae6bb"
      unitRef="U002">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_45395650bc8540d6bb8258ab24654d4f"
      unitRef="U002">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20220930"
      decimals="3"
      id="Fact_bff4899c7a4c455b8db15fdbcecbf908"
      unitRef="U003">0.005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20211231"
      decimals="3"
      id="Fact_257c1ec62cdd4252b18550449dd232ac"
      unitRef="U003">0.005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20211231"
      decimals="-3"
      id="Fact_7119e67f1a7d414fbf6f3bffc85e9a59"
      unitRef="U001">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20220930"
      decimals="-3"
      id="Fact_3e6a98d480254a9d85432242ebb4f684"
      unitRef="U001">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20220930"
      decimals="-3"
      id="Fact_f601d269d9c04248b625a64786b12601"
      unitRef="U001">2942000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20220930"
      decimals="-3"
      id="Fact_2e2aaa0c1032417d9bb0449e4aa7a77f"
      unitRef="U001">2942000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20211231"
      decimals="-3"
      id="Fact_7915b2a904804cc7a5afe329e97d0616"
      unitRef="U001">2601000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20211231"
      decimals="-3"
      id="Fact_697836017c014cf592042b99e699dc22"
      unitRef="U001">2601000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="c20220930"
      decimals="-3"
      id="Fact_2b231a38168d4d269f9df29f7d542e8a"
      unitRef="U002">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ca85d9de920342b1b645849103698793"
      unitRef="U002">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20220930"
      decimals="-3"
      id="Fact_67dbf3fddadd48278c72fff99da58c09"
      unitRef="U002">169596000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0f4c94f4fa8e4d368768b6209f607800"
      unitRef="U002">166190000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20220930"
      decimals="-3"
      id="Fact_1e9c34acc7db4ab88c524eb84650e8ca"
      unitRef="U002">-160799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20211231"
      decimals="-3"
      id="Fact_05e0332d63fc428795de517bc62f82c3"
      unitRef="U002">-140701000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20220930"
      decimals="-3"
      id="Fact_25a6999c8d124f7399563b7bb55bef01"
      unitRef="U002">8813000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_7598124631174cfd8973ed650ad791d0"
      unitRef="U002">25503000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20220930"
      decimals="-3"
      id="Fact_cf6023ac81b54e04b6ab6b340a1e0533"
      unitRef="U002">20926000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_9ffeeb1208514f12a9d7a2f5890fbd93"
      unitRef="U002">31525000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_fcb8f0cde1114c07b550fe04507d8d18"
      unitRef="U002">4963000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_4baba3fedfaa46a5b44db1c0124b5198"
      unitRef="U002">1491000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_840636f9220643929a58cb20b249e345"
      unitRef="U002">8430000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_efa411487c7443d29e55f55e87d5d015"
      unitRef="U002">8456000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_382a802f7726496388367cc0debdf509"
      unitRef="U002">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_9b0a112c6c794a4e93e1d33ce49087b0"
      unitRef="U002">80538000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_9ad72ade040a4b049b70fbb4d86b37e5"
      unitRef="U002">5990000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_71bc332108c244b9b954c382194c95fd"
      unitRef="U002">80538000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_a52d436b986e479da3662e6dc4297aa6"
      unitRef="U002">3341000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_f8204a263ca04f61a729589f0d936e76"
      unitRef="U002">4247000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_fd15a7fd2684495fb7d50e75cdb9117d"
      unitRef="U002">14060000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_7645bfe81afb45acad87078dec96eafc"
      unitRef="U002">10451000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_14386ef69dd1497dbb51a88bb6d0c53d"
      unitRef="U002">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_f8a575a4b02e43fdbd4ba3d9b3546157"
      unitRef="U002">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_d881b244f47947a8b160e83a1efa1174"
      unitRef="U002">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_5f4f246c7004423686bd87e095dbd87c"
      unitRef="U002">5765000</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:OperatingExpenses
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_48719b92a24c4ac5b2752149e44e1201"
      unitRef="U002">8304000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_4a0f638652f34b16ba1639fb8bbc6055"
      unitRef="U002">86276000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_39c253dbb5124f45971363183669fe36"
      unitRef="U002">28480000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_24377a5b3c9b43b1848b682ef0a833b2"
      unitRef="U002">105210000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_2d897a233ebb4ad0be4ade512ee55fa6"
      unitRef="U002">-8304000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_f179c2fd71e547b0aa066aa61e5535d0"
      unitRef="U002">-86276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_1418c70c8e0f435f865efb9432688699"
      unitRef="U002">-28480000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_6efb307c97c54042bf83014798879f7d"
      unitRef="U002">-105210000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_30173ad10791464cb91b3418ca4a142f"
      unitRef="U002">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_6a74ee0f9a064b45b437a3a4273a4417"
      unitRef="U002">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_6855e694e42144c7b1e331b1e40854b9"
      unitRef="U002">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_3ce596e5f1b14ed8bb5ffe5706ac2a4c"
      unitRef="U002">-9648000</us-gaap:GainLossOnDispositionOfAssets1>
    <erna:WarrantLiabilitiesExpense
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_09993d5225204b7caa6ca7d4f40c6c92"
      unitRef="U002">-1024000</erna:WarrantLiabilitiesExpense>
    <erna:WarrantLiabilitiesExpense
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_e7b4de36b2c3466b8050a0a431426175"
      unitRef="U002">0</erna:WarrantLiabilitiesExpense>
    <erna:WarrantLiabilitiesExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_950d79fa9d0449eea6c47ce7e73aa85e"
      unitRef="U002">-10493000</erna:WarrantLiabilitiesExpense>
    <erna:WarrantLiabilitiesExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_457867c777044514a66cfe9c09fc092e"
      unitRef="U002">0</erna:WarrantLiabilitiesExpense>
    <erna:LossOnNonControllingInvestment
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_3f038166563149a4b083bd752f644e9c"
      unitRef="U002">21000</erna:LossOnNonControllingInvestment>
    <erna:LossOnNonControllingInvestment
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_ff416c1f37d94c02887a46fab3796636"
      unitRef="U002">0</erna:LossOnNonControllingInvestment>
    <erna:LossOnNonControllingInvestment
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_1e724508381b4cb58c9bf82a1a02ef1d"
      unitRef="U002">932000</erna:LossOnNonControllingInvestment>
    <erna:LossOnNonControllingInvestment
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_f739b0840a1947a89a84d0ff18a851e8"
      unitRef="U002">0</erna:LossOnNonControllingInvestment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_ee661a9bed9d491b9df675ac429fb866"
      unitRef="U002">-10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_199635d1118e4377867adddf06737e38"
      unitRef="U002">290000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_ac6ed153c95941a09af234023c7d9448"
      unitRef="U002">-1166000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_dbe81c3a14c2421aabf1a11d26ed5c98"
      unitRef="U002">265000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_a59c4e37d799493a8bb5aedd6001fd20"
      unitRef="U002">993000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_7c0d2eab914c4a1487c58810e0911177"
      unitRef="U002">290000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_8823257c2d30437c9572d21385e75ab6"
      unitRef="U002">8395000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_cf4114f4f3c84db8bb9c94125102779c"
      unitRef="U002">-9383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_f47bf0eadbfa4111a27aa9d511c15bc5"
      unitRef="U002">-7311000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_fdcecb32554d4bc4b992eaf96dcee39b"
      unitRef="U002">-85986000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_3e4f3e101c7141cf82f2b57b70fd0a2e"
      unitRef="U002">-20085000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_3b5cc27450944f468a1f738d5f3f8590"
      unitRef="U002">-114593000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_fc6f21bd0e78406b811157f565b27b8a"
      unitRef="U002">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_02deff61da1a4f9c884053ac6c784e0f"
      unitRef="U002">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_e88ac563e8de48ce962a6e8c736d439a"
      unitRef="U002">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_e99828cc53da4df892f67bb5c75db10e"
      unitRef="U002">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_68213818e5ac47a097dfde7f03c1e393"
      unitRef="U002">-7316000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_438c5c00826b4c08836c403e9cade373"
      unitRef="U002">-85986000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_cd0915f19365455195d370c781cc246b"
      unitRef="U002">-20090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_a97d3e8b54b34845b74ae6c11feb13f2"
      unitRef="U002">-114593000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_05c6e75ae7bb463ba96c2871b7032d49"
      unitRef="U002">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_0305675da2e5442589390b4539a1aafb"
      unitRef="U002">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_bd5dc0b6c5b54b8caa9510ca37735228"
      unitRef="U002">8000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_9a99306c5734409895f7d86828cfb424"
      unitRef="U002">8000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_4e1e088824dd44ad923a8e25ceb358b6"
      unitRef="U002">-7316000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_f2597401e7e44824a30433ffe906adfe"
      unitRef="U002">-85986000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_4b0ff00d58bd4918b7bb38e7b1fb271e"
      unitRef="U002">-20098000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_22922fe6a31b430cbd66cbf73ae129dc"
      unitRef="U002">-114601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220701to20220930"
      decimals="2"
      id="Fact_433df7f7277f4b94946da8bad192474e"
      unitRef="U003">-2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220701to20220930"
      decimals="2"
      id="Fact_34e303eedf6d4022a679cd466dff4c2d"
      unitRef="U003">-2.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20210701to20210930"
      decimals="2"
      id="Fact_1c308bf4448f4774b40f898bb89aae72"
      unitRef="U003">-34.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20210701to20210930"
      decimals="2"
      id="Fact_0cef766e9b09437393e9a0d493fc9b6c"
      unitRef="U003">-34.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220101to20220930"
      decimals="2"
      id="Fact_e9f58143840a447f9b4067028d43e66e"
      unitRef="U003">-7.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220101to20220930"
      decimals="2"
      id="Fact_cc5a8df7b9b1487a9cfd802b3997d0c2"
      unitRef="U003">-7.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20210101to20210930"
      decimals="2"
      id="Fact_7d74759038d44725b24221fed9ba6b8f"
      unitRef="U003">-56.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20210101to20210930"
      decimals="2"
      id="Fact_18faedef211946f2b18e747aeb2aa275"
      unitRef="U003">-56.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_81ee7bb08d264453a916fcb311c108d6"
      unitRef="U001">2941000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_4f9541bb27cc4aa086bff8336f667a4d"
      unitRef="U001">2941000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_dbe8c3fc5a704a71977e6e252771729f"
      unitRef="U001">2527000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_453bc034a8e241cca5854de8eef0bfe3"
      unitRef="U001">2527000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_9c2e2607e7e3449bb03e99107b4c46e2"
      unitRef="U001">2855000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_0ee05e117a8e4df5a41747e7d6f2d59e"
      unitRef="U001">2855000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c77751be56f0491fb9fe96fca6793fe4"
      unitRef="U001">2018000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_b198cc0dac9646a59e6c1831bdc2c158"
      unitRef="U001">2018000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e2b1e5f6e3d2472fbbd4cda74b830d74"
      unitRef="U001">2873000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fc9acbe443a1488780602ce81f7349ca"
      unitRef="U002">14000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20220630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_1abe70d599eb44ad9cfdf0acf3574c2c"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_09d5ea9090d7494c87c3f4fecb574035"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bc34b4dc0d464b8c920054614e603e7b"
      unitRef="U002">168246000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_df9f4f5a8fa741a1b0762e5ebf23f58a"
      unitRef="U002">-153483000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220630"
      decimals="-3"
      id="Fact_279677985b3547f185016ec45a37feaa"
      unitRef="U002">14778000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_bfe7ab6d1e244dababe0f4d5714061ab"
      unitRef="U001">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_cb90bc8369544e52896037b629152fd6"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_802db65fb4724881885a6daa89cb236c"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_b9d3a5a4b7a74715bff705c786e0d180"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3ce7f26849c3495fb70bae6f0e283562"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_829ec489744944e4bae388cd62901837"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_7ad4943a698d4e4a9aded186114bfa5a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_71a5d6ae75e840fe80eae9a376637987"
      unitRef="U001">68000</erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_00ba747d7bdb40318b5d188fcd41098c"
      unitRef="U002">1000</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_8527890a79b94939b2722840ae1e876d"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_e4eda11271d7443a99a8c71897768c6a"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0797c6283a124f8699f97e0fd7a9459b"
      unitRef="U002">874000</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_57843c145ebe43ecb9a95d2b3d090b37"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_99866d58b49049a492d4c2f018a02ba3"
      unitRef="U002">875000</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d41fb057fef04a6cb11a505c379c395f"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_f63c26ff66794367bd399cb3cb2af238"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_09f61981b16842c98bab19bf84baf6a0"
      unitRef="U002">476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_228dadd8388e4ad3a37bb31a83d06af1"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_34705c2d36f7498aaa185c95b67dd7b2"
      unitRef="U002">476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f8ab1ff8b1ad49e4a79b311ca2b91210"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_e92d5f1679d1432eae5422942281791e"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ffad54830ae94350bc63edb60d383888"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_759776caf8294e9e957be32e5dab1d73"
      unitRef="U002">-7316000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_3a37c7633df043bbb0924a16f5b9d1ca"
      unitRef="U002">-7316000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_957b736207134eb284af677a59e42abd"
      unitRef="U001">2942000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8a23c7aacc6949d2bfb703c4e5621e7a"
      unitRef="U002">15000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_0f7b80578ed9492887835f7c332c4d0f"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_6790578beb244af4a57129bb124da7fe"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e96858a7c6614da6b8c9513a4b75428e"
      unitRef="U002">169596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ed7fae5e76004e9bba2d9f8c0550ce26"
      unitRef="U002">-160799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220930"
      decimals="-3"
      id="Fact_368df00270254ce79f07eea8e0a1f3ee"
      unitRef="U002">8813000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f5f9105b14224cbb99dc01361ad5a86f"
      unitRef="U001">2601000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f3020c1167794977a8ec9aab3cad9453"
      unitRef="U002">13000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_06640b73e15143adb300a75a082567bc"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_032f7ac9b6a14b3cb09b5396c4978ca4"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b468a57b7cd940469e928beb550b4056"
      unitRef="U002">166190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_496eb1d627c4412aa0d7feab8a913352"
      unitRef="U002">-140701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_e94ead561ba6471e9c4486a14e484324"
      unitRef="U002">25503000</us-gaap:StockholdersEquity>
    <erna:StockIssuedDuringPeriodSharesPrivateOffering
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_775b46324ef146c3aab941aa9d6d56df"
      unitRef="U001">275000</erna:StockIssuedDuringPeriodSharesPrivateOffering>
    <erna:StockIssuedDuringPeriodValuePrivateOffering
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_16ae3ef190da4e819e2bddb844e3d817"
      unitRef="U002">1000</erna:StockIssuedDuringPeriodValuePrivateOffering>
    <erna:StockIssuedDuringPeriodSharesPrivateOffering
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_cf7a97b07ff74c58a2838ebe60865789"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesPrivateOffering>
    <erna:StockIssuedDuringPeriodValuePrivateOffering
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_e00e81f6ad414ac1b6e217dc3ea88293"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValuePrivateOffering>
    <erna:StockIssuedDuringPeriodValuePrivateOffering
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3a5ba8366af64d7497386891f28bb51b"
      unitRef="U002">-1000</erna:StockIssuedDuringPeriodValuePrivateOffering>
    <erna:StockIssuedDuringPeriodValuePrivateOffering
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_84f81fee9a19453782f26a048608e324"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValuePrivateOffering>
    <erna:StockIssuedDuringPeriodValuePrivateOffering
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_1d03d2d3cba84b6e8005167621e2c573"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValuePrivateOffering>
    <erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_1487d7b9183541209d2f916beea0a2f8"
      unitRef="U001">4000</erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_caef22008f2c471593e80d953e32ccd3"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_6c74f3e541cf4d95adf6c0b5409e6621"
      unitRef="U001">0</erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_50b6ff46684b4b8b8ba61b759fba71a3"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_52a75ef092af4e688d32ef5430b8f2af"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_51976fa252a44bf2878bbf9ad1cfc4dc"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_873f314b9d304f4aba6355eb40a0c975"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d07f5d53000047e4b11c6e0b31f354cb"
      unitRef="U001">2000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_791faa4608d84a088d844f0f7171cddf"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_4a7eb9c1e4254b4cbba19779aa2be98e"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_391f9f83e3df40bebeffd7b357cbc9be"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ad9ca0ea85b541db982ca5e50f17adac"
      unitRef="U002">-5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_97f1714710c740ddb6f2066d2c658f6c"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_a1c70049b98f4f48b4b7c0688a50cdb3"
      unitRef="U002">-5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_3a402bc4253f46d68b589579d2f6e235"
      unitRef="U001">68000</erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_cbb21e7c482040f29e36923147ada4b0"
      unitRef="U002">1000</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_7d11371e8ed14f72b1c36727888d7102"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_6a534cd711514dfb9454f891ec12e121"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_48de3c17782146bd816307e154c031ae"
      unitRef="U002">874000</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_38ca44441274479bb4e1621a698f2a53"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_a340242b6d894ff08fef03c92bd8a4a1"
      unitRef="U002">875000</erna:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a963576d4ce740baa26783d9ab445984"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_626394d824f84dea9510baee7404b687"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4f0e3056aeac490d8cf70d7565285aa3"
      unitRef="U002">2538000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_cae83c2d87ec4698a7035001fcbcd9ed"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_46f74bceffa14fd9b97e86861356b187"
      unitRef="U002">2538000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PreferredStockDividendsShares
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_905c69bc4c3c4e54b1f115b4d1fbcaeb"
      unitRef="U001">0</us-gaap:PreferredStockDividendsShares>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8377295197264ef189ce743c6c5bb9e9"
      unitRef="U002">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:PreferredStockDividendsShares
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_7e1c251c311d4114b6a4688ca6b9b679"
      unitRef="U001">0</us-gaap:PreferredStockDividendsShares>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_25aeb79e75104ec78d154dc690d79351"
      unitRef="U002">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b413b18e5d7743c580bc683ccc946add"
      unitRef="U002">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f627b0f7e6d54e02a38259107078849b"
      unitRef="U002">8000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_f0555db154844705b48a8207be11cf86"
      unitRef="U002">8000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_366507d07cf7426abc034636c79165a8"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_efcc057d623b436192469649086280b2"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_96e843585cc84eafb70d419ff2342f4b"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5b7fdb30633f44429260ef83f4db1fa3"
      unitRef="U002">-20090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_69886567761b46b9b1d7e7b5af856d84"
      unitRef="U002">-20090000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_5fc49a4b09414c61821d57b4ea751d81"
      unitRef="U001">2942000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_21fcd949d4df4da68eff31520a21e341"
      unitRef="U002">15000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_ceb5f0f23cf34f79ab9dde7aa308309f"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_c220cb2d33f54dfea8198f98dfb79d11"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_852f53d65f2244b582031afd4b0e757b"
      unitRef="U002">169596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2d8179ab377e477c89a43a2c99338b6e"
      unitRef="U002">-160799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220930"
      decimals="-3"
      id="Fact_efd9853d4a5144589d996fd23eccdf95"
      unitRef="U002">8813000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_8dc8b77171a6454785f233ab0e7f8d0f"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_607f5a87563149f790a67b6335829741"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e609f0a5c1aa44e09ea3282b523badef"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_be492d80f1124adabf3acb5f99097df1"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_dc7efe1fdbaa45e594572509cd350051"
      unitRef="U001">2235000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0203a8a94a1c4bfd9dad82ccf5cb107f"
      unitRef="U002">11000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20210630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_4a36cbe94d624fcdb6217aeda3121a50"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_1222a65f3f2d451391a4ec014ac856e4"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3c612c01955647409c2228395767a45a"
      unitRef="U002">100347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c6cbd6b8233c4f82988d1b97edca8196"
      unitRef="U002">-46756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630"
      decimals="-3"
      id="Fact_e2c5be7c330e4edca887070804a21b26"
      unitRef="U002">53603000</us-gaap:StockholdersEquity>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_375154bfc6ef4649bb5fb096072b1c67"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_fb53af3aac2e4dc0a2b478667fbd9571"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9f35c422191144aab59292a8780d5f14"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_78b5984c950d4ba8a4d2ca601f4c1af4"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNSharesStockholders
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a38f7d6977424c88893830475ac89e81"
      unitRef="U001">0</erna:CommonStockToBeRetainedByNTNSharesStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_be7e05cd0c984404b805073729237cc0"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNSharesStockholders
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_65a31d5504e0479c8ecc8e97ca5b3291"
      unitRef="U001">0</erna:CommonStockToBeRetainedByNTNSharesStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_843456884f7347c183222e85ef32fa57"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_33732403247349289dbf6cedd8882ca7"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_610ea90e95a8474dbe8868cb5cd757bc"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <erna:CommonStockToBeRetainedByNTNValueStockholders
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_62482dc873ae4cab81009cd948762113"
      unitRef="U002">0</erna:CommonStockToBeRetainedByNTNValueStockholders>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c28cb013ea594a06ad2b45193bd73e2a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f4bd79d7bc4e43f6b0271f5744e2e5f2"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6b283c6708d7428fa06a50afade59dd8"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_99cbd41249ab4f079fdce50159d2f8c0"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_48d3d6c06c064a97bceb14835e47003c"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_21a91f6767674dc585a800cf5f09ffd4"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_f9008bc51afa421d80aee222797a748f"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_2425cf5b97b64db893dd701bd31d094b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6d998797b62644a2a28bff8e493df581"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3a8bbea7a80e423683e84f0170224763"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_74c61979281a4ed988c2bc4144d4bcf0"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_2e47249a26a64aa0b237abe0b1d266cd"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_48b7de992f8c4dfaba9fc6424e38bd5b"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_965cb5109f914feab893b8f980adaa8b"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_4bf13b38407c45d8af2cfe29bb93e30b"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_16c3616510964ba0abd4dc80588ee189"
      unitRef="U001">17000</erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4417b6ff483a4c118dc6adffe67492cf"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_0011b94e259c4444b6e5946a7ca111ba"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_fa57761f05194bf3a11f9f5468806c54"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fed103d5a04844c1a8b38fded50c294a"
      unitRef="U002">3500000</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_4735ab0b7f224e40a93d01dc891d0d86"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_fe69fc5a9b514b1bac7b6978b22ffb52"
      unitRef="U002">3500000</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ef8126235c27495887e5eb2ec98d4fb4"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5a21d0dda16342e99a79e002875b9686"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_7efc3b96ca1b4aa285d0099961f5cec0"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_0e6562d8f995421a8427ae38a79fac94"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodSharesInLieuOfDividends
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2a7dc7b8dcfa41829d003bc0d7c1117d"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_91c15ad33e3b40028f9aee66660f8188"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodSharesInLieuOfDividends
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_01fe53ca68c64c32935acd3af1f16476"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_e502964f919d46218101d2d16063214e"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_1dda143f396f46c2b639aa19a8341657"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c09a8a1e4a66493093695e9655e5138e"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_50552a220de74c6b85007eacba9aca87"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5cbd78cedf0d4fda87bb27c60e36dbbd"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f445cb83af9f45e9bba160f8db7c7339"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_18f201d1c86f4ae482cfcc04eea90d1c"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_8133a4fd21724debbf20ac629c2d6816"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6b8368626bb64cf180ca18cc9802289a"
      unitRef="U001">351000</erna:StockIssuedDuringPeriodSharesAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_61a3ce401a514183bc6916be0d2775dd"
      unitRef="U002">2000</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_bde068c40eff426eb047f803490dc880"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_c5dd7297fdc84b018f2f725e502d6b08"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3cf4957e271a48caba825755af905628"
      unitRef="U002">58682000</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5f9f6310772f48339141b432fcaddc75"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_bc52b5f836fb4c11ab6a4add19dd503c"
      unitRef="U002">58684000</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_7003da87a2854562abb7d2507c391660"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b14d203bb3784570b3107668505baede"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f8a21cbe86174bdab533e2a04320688e"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_2bfa95f4adde4b789aff180ff0c6646d"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_aac17aa84ea84dc8b4536f6167a06a8b"
      unitRef="U001">1000</erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ede89710c5764f6db4716f4c64aac095"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_e98e4050540a4a4b8013afe555171cc6"
      unitRef="U001">0</erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_d6c4eaf5140848a7a11a468ee2f4e8a6"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a23e99bc098b49c7afd26ce7235e922c"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6a62243a58d546c3a2b96128e782fefe"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_0944ccf925e34afea9abc72d3e78c758"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c85123e981a14564aa6c86a27e01c328"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9ba66b814bdd426d8a4431767a3043a5"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6a91b006071f4059a14007f96f454f3c"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_53349258865f434da80086721b87e3c8"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4133be16eb334af1b4f2ff743182ce2b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_1a49017f3c2b4a58803af514d1a347c2"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5f781b2528e54840972a3b3ef5a994df"
      unitRef="U002">1729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_26dbe3b8dda343e69701c0ee177de157"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_258c6fc46b9f4fa38044ce636130dab1"
      unitRef="U002">1729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ff08e05589c74fa2b3a6142cd1db3d49"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_737241e6f5114e47bc6ac33daf97443a"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_a38c547565c5444da50de466e3fee353"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_27283385bf774b1a9e6a44d932d0ad32"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f236890827574369a0652b620655102b"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_f7019eab4baa45b7bd2d7fa0d69ad646"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e2741ac8ed25466e984aebe7342c1d07"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7c73e49331c3416a96e758999388d3d9"
      unitRef="U002">-85986000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_956d610af0bd4d609273758545bf0474"
      unitRef="U002">-85986000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d0462b8409bf4577824d03a131b363e7"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6b2e214910f449aa82f94dfff471fb85"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_8c13d5e36a0346e7830da2bbe1c0961f"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ff97f46517f14b7b8962850a2fb1f863"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c2632998ae6542c1b2362fe99d4da764"
      unitRef="U001">2602000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c01bce97e06c4ae8b15a404e4e738cc9"
      unitRef="U002">13000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_366177fc8d1b4f968f0694c9accee215"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_f4230244ce12426598ab5efcc51bb669"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_1f2f2602f23346fca2471ac20e20711d"
      unitRef="U002">164258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1f9a41097aaa4052884282f0fbc8a4fb"
      unitRef="U002">-132742000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930"
      decimals="-3"
      id="Fact_bbcaef06119d454baf65288b9cac08f8"
      unitRef="U002">31530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_7da0d186c5b0472a83f65197d0bb64ee"
      unitRef="U002">23202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e0f4c036eac24489bdcdaa9679ec0475"
      unitRef="U002">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9cdfe422f20342f3a6ab35ace6d0c1f2"
      unitRef="U002">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_a9e32a76c88e4b93a5a6a01a3740c2eb"
      unitRef="U002">198000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_bf582aaf1e264eee9f73d0d8ebb2a0e4"
      unitRef="U001">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4c06c522d2f4469a80ebe91cb9f117cd"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_b230468e82d34c28891689e2818ce30d"
      unitRef="U001">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_d0b3e41a40994d3d86273b1f8e2e68b8"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2a245f649d924d6986e4bbd572d537a0"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_abbd77055e1948dcb248b249ea42beaa"
      unitRef="U002">-18141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="-3"
      id="Fact_67698045274d47f88c4787bdfac95c8b"
      unitRef="U002">7659000</us-gaap:StockholdersEquity>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_3107b14302ab450eac40f7609252e35e"
      unitRef="U002">10500000</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_862f06c051d2414c96c86c4760b6fe6e"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_733a6dbef1b04db0b7ccf6aaef376bb6"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c40157a3b3c74cbcac9cc70784ebce02"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_bb4352eadec94980ae6d20ad255466c7"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_3822dc971c9847c481f5ea4e091d36d6"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0faeaaacc9d54b11bb4c7ea63722d7ad"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_225a021ae6d84b94baad9c112e025c4c"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_1e6722efa71944dfad64b2b36089df53"
      unitRef="U002">10500000</erna:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ad50f56a73fb431c9194ca80e290bec1"
      unitRef="U002">-33702000</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_dc51bef44d264b8d884790aee02f247b"
      unitRef="U002">-1400000</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_37be016efb8849b68723f2b94018e3b8"
      unitRef="U002">-1000000</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_df5cfdb565e04a2dad9d196262e4988e"
      unitRef="U002">-198000</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4e4d3db0bbdc4531ad246fe3574ea226"
      unitRef="U002">0</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_bda69ac828c546c89aaee9d890c0a2ca"
      unitRef="U002">0</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_134a9b20677347cabaeee9ab98807ec7"
      unitRef="U002">36300000</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d874a173d2904611b0bdb087eb70942c"
      unitRef="U002">0</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_54dfcb4a01864c08b018e23a84f88eb9"
      unitRef="U002">0</erna:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_92abea589ccc4a41a8ff26ea5950fca8"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d201d1dc92ef47448deadeac4c0260bd"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d2306f252978493483a094e729590a27"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_0d492f42e45a470aa56e5104f75f4fc6"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodSharesAcquisitions1
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_edd7a01607a6471f970d0c083731aa1f"
      unitRef="U001">76000</erna:StockIssuedDuringPeriodSharesAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ef1ac71eb6fb4c1698fedad4a8322f11"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodSharesAcquisitions1
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_7b4ba3556dd3480abb56eae1fb9c0e94"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_244c272909724fb49c2c9e8c923dc295"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ff8198c2ee864c9bb0e99dc20da44303"
      unitRef="U002">8177000</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_fec5f54e7bcb4c15ab0ed8d14cbf8177"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c0f021f7bb804d89b662051edd5192f5"
      unitRef="U002">8177000</erna:StockIssuedDuringPeriodValueAcquisitions1>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c970cfd84f594dbcbde8b46567bdf623"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5e1ab0702abe4fc0a1356d85c6f65883"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_cde930ac85064e7ab9c5d7891906ea26"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f999413487a8462ea4f964452710ef43"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e27dbdcd693d47fab1e11b9560e8d1c5"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_dce05b9ec97b41ceaf0f11e7851e87e8"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_fde11040ebaf4892bdd226c40b0738be"
      unitRef="U001">156000</erna:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_0759c7688558414faaf737e2bb98cb4d"
      unitRef="U002">1000</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_baa990ff1bb74a698984147f8eaea42b"
      unitRef="U002">-1000</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9f99788d588f4285808041c30196dbf2"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_34ac98851f68434b8477b32a45797746"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_cee00a579cf74aaf8da4b9fe94d94cc2"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_02178268805c4ec2ace149d10675b108"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_17271e6748e94bd1a48b79d0c29d21cd"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_bfc4fd8edea4486d843ab5d89d0b9d58"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountUnitsAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6d1a41081c5d4fceb02e39e137edd3f9"
      unitRef="U001">1946000</us-gaap:PartnersCapitalAccountUnitsAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_9714bf5b370646b88c58d47b72c83878"
      unitRef="U002">10000</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountUnitsAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_8c6bd22c340c47fab7aa97aa6c4e6be1"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountUnitsAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_0cce2bdda7e34101a36d655cef64ee60"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a502fffd17654797b7be258427333ed0"
      unitRef="U002">-10000</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9f29619645974b9fb1a0e18a74734557"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_d0cb7163e49d47238bf81118b960823b"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_026b204959dc43868348dac36a6137ec"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_4810f269dfd64c848c3f6b38a06800d7"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_95eea29db69a465da50e462e7a26b726"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_fda10bf67c504db3a3ce2a751002dfb7"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_684cb5ceb7e14dc6a0a14086e1e40e02"
      unitRef="U001">53000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_77c0c8e49f2d4ccf96f3f7d5aeaeef9f"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_020c172cd88d4093b0e2176b4876e8f2"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_ac39652da55f4c0682e6d31039803efd"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_237cb32e8c204018b56a0ad2f4c9ec1f"
      unitRef="U002">5765000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_23276eb99c674a9280fd3321b19387e5"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_ae8666b7ba8e41fab9ec3b68ea1c386a"
      unitRef="U002">5765000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c8f12874af2f4a80b0d75362704f35c1"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_506aff40cc2b40d0bfbab6cc43186a87"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_a53656f0853f45b18ce0989a8b4e1915"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_da87c9b89bba430bbaa74a3d2e6d4477"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_96f9f855eb114568b747b782e3403fdc"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_88d7a6f047264c88ac1b241faac61c00"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_897ff3ae1e254aa4b80769e641bb2e93"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_034eead3cc5a4b4c961fde8026c52e0e"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9757270358504de9b5aff351bf1b9715"
      unitRef="U002">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f0acd60cc06844f2ada854ed1d04b285"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_f96ee1ba8e4a400294dafe79b3be1142"
      unitRef="U002">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d4525aaf3c724341aa52d7ac6d8ff6f5"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c8248465f48c47d3ba81c2f1544137d0"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_04677b95a8c946c28a39c0ddb4e78f67"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5dcc093e28ee4a3085ef252781a7d090"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f765ae98485347299a1c5bbcdb5745b0"
      unitRef="U001">178000</erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_cd48f6f836e84141a55daef3d6a353a8"
      unitRef="U002">1000</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_d6980199fe5c44f9a395bb52e60ab20b"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_8854add4f3d44983be921dcfb51fb803"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bd52645c914e4a1e9ce35eae7120becb"
      unitRef="U002">52025000</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8527242625d94b1da428f856483f7464"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_951f81bd8ab94986a56a80cb0052867e"
      unitRef="U002">52026000</erna:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ca152f8d69f64b758706e85998a6c184"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_bd0c7de8b56a41eb9d6c3b4f3cb2a631"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9763421680284f7ebbae19772cec78e5"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_fd03420a8d8d4696a6e0817142a658be"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodSharesInLieuOfDividends
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8426e0b6404046f9bce96f990c1e2770"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f7c05b611b654edca5fb87af78b7ee39"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodSharesInLieuOfDividends
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_8d2f7134a0bd49d88bd908362bc0cd52"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_84b3cbe0f1de49bea0901dc64e5ea808"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_910d6a7376944c39bf1add620547f5ec"
      unitRef="U002">8000</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9b0c973e6bbf4e9fa0904892663ef8fb"
      unitRef="U002">-8000</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_7d60e7c383c74d6a842122f179ae42c9"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueInLieuOfDividends>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_659350083287482094e00fbc06ac5cf9"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_4b20042ef7ff40ec83915a41ce2f020e"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d0989d33b8644f8da2d3f4af3fa4a1e3"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_09e4c432746842089c25ebb48ef8b10a"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_1d0c305e9640427ba2f6f21f2736f792"
      unitRef="U001">351000</erna:StockIssuedDuringPeriodSharesAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c16e4008740b4bda845e5064b553bf98"
      unitRef="U002">2000</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_3b53e669fffa4be780ef649312102764"
      unitRef="U001">0</erna:StockIssuedDuringPeriodSharesAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_eabce3f267514a6289e7219bddf825ad"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_dae15234adaf4c5184a285823e18e7f6"
      unitRef="U002">58682000</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5399dbe4779946688b905a026782d75c"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_d03f8e2399bb465a86839290c42a183f"
      unitRef="U002">58684000</erna:StockIssuedDuringPeriodValueAcquisitions2>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_7bf2271ea9e74b52a19027e559d0b77b"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_132b6f124c834c5a90f15997d695f841"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_7d09a546d4d54a2286a11557c5669c1b"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_422df02bd91d4e8187a0a6d913a869eb"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2b42d848d1164d98a247dcd45ea6580b"
      unitRef="U001">2000</erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_be506cce459b4185b975e825b27fc11d"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_34ba18af2b9e42e98de1bfa9c3adbb47"
      unitRef="U001">0</erna:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_46102578d35648419ec11cba927f88c9"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5ad35b1ecb54460aa04809ef9ebdb829"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_14e648ce25ef4efaa3b36a4ffb6063e3"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_f0f07fc67ae34b9dae4fa47cd973b903"
      unitRef="U002">0</erna:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b3bc100c53804e1d8c4ebb6026553067"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_7d761ba3de0f4e9f8ae9c48956735534"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_db85315df79947bd858898cad4f13e75"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ace5de06d1f442f8827900c406902b7d"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2b57f37fe7824d15b360573b2847acb2"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_8af3bb858be04955bc4c28ba38fc9175"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_918e7ef1dde048d88cd2b1c1ae31356a"
      unitRef="U002">3302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_bc11676f28bb4dc0896218919723c7a9"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_7574f55f79454c949bb738995a4cf329"
      unitRef="U002">3302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_74ae1d95dbef49238652c544469cdaf0"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_cf1faabe035b4045b8282f107e3ff3ae"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_38ffae36546043e28d65b7eca4edbe55"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d48fc3916b084665aee183c5e197829f"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4dc6d64f0c1e48ec8a89b9c2b4c0ab5f"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_49b9d28bd40247b4a62b27cebeebb208"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cb5c3f9cb6094a6bbbb2b8abeb112b92"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3bd5d6e96c9c407d80656287617d9363"
      unitRef="U002">-114593000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_44effd0fb76044d2a093a7715c7cbc6b"
      unitRef="U002">-114593000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e6587047fc8d492ba668c185a2bbea93"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_1af030f8dac64b2481bc55c0663a50d2"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f6961af204ad4aa9b9a60bbba3221087"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c5b813d3cbb244fda7cd077d6b6b7d37"
      unitRef="U002">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b258b2f713fd4ee0aeed2e4334d6c9e1"
      unitRef="U001">2602000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_089f18010f0941aab348d2afd2cae608"
      unitRef="U002">13000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_70ac653f536b4ea8a97d3fdbd7379f76"
      unitRef="U001">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_d06447d404ab4c30b6725129651ff064"
      unitRef="U002">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7a9d8d8616e34b2c9372467199c63817"
      unitRef="U002">164258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b2d24eb83b9d4d429a14aac023dc63a9"
      unitRef="U002">-132742000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210930"
      decimals="-3"
      id="Fact_2b5685515f4348c9a725ce75ead2e0db"
      unitRef="U002">31530000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_6f4f0938e705409e94ac1b73bb1e3782"
      unitRef="U002">-20090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_6f3b8843d08e4ee9a23065b21d921a11"
      unitRef="U002">-114593000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_52c3a375a4bc4ef3a35ebac43a7a055b"
      unitRef="U002">144000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_46233d7668a1445c909bce61aa877bfe"
      unitRef="U002">93000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_6fb1e37bcaff4d3ea366570481288ecb"
      unitRef="U002">2538000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_e9daee9d9c134e3ba876a7acdd3e7f0d"
      unitRef="U002">3302000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_e8a57958dfa64ad9af1fda481bbc817a"
      unitRef="U002">267000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_846320f5f364420baaedabc15565c637"
      unitRef="U002">243000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_7d6e1951ffab441fa30136c75211d561"
      unitRef="U002">772000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c3f5998dca1f4449a63a37f0b621834e"
      unitRef="U002">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfOngoingProject
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_a9cbbd3606314678adf463b4ed119cbd"
      unitRef="U002">5990000</us-gaap:ImpairmentOfOngoingProject>
    <us-gaap:ImpairmentOfOngoingProject
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_4d4895a83d2a484bb975e46c5a9d5516"
      unitRef="U002">0</us-gaap:ImpairmentOfOngoingProject>
    <erna:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_8949226e2e194f478d957e45a54eacb4"
      unitRef="U002">0</erna:ResearchAndDevelopmentInProcessAssetAcquisition>
    <erna:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_1e47f412a1a64fdfa2a55ab511512bbe"
      unitRef="U002">80538000</erna:ResearchAndDevelopmentInProcessAssetAcquisition>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_845d862a50614f16816355c3df31707e"
      unitRef="U002">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_ea2dfa78201241efa117efa36c4e983e"
      unitRef="U002">5765000</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_fd03224a48344f47b38694ef12fd9665"
      unitRef="U002">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c92af19678294878b3796383c06fbc0d"
      unitRef="U002">-9648000</us-gaap:GainLossOnDispositionOfAssets1>
    <erna:GainLossOnDisposalOfFixedAssets
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_66db2d7e57854ec887f6e58344ea87ec"
      unitRef="U002">431000</erna:GainLossOnDisposalOfFixedAssets>
    <erna:GainLossOnDisposalOfFixedAssets
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_457e8979737d4828a06529ce29be430c"
      unitRef="U002">13000</erna:GainLossOnDisposalOfFixedAssets>
    <erna:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_cb1a3def19df4df8949ba142f62c4521"
      unitRef="U002">0</erna:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <erna:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_be6bb975355049c692cd068da360fa9c"
      unitRef="U002">310000</erna:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <erna:GainOnTerminationOfLease
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_d5112a306f0e42298775a537de0108f0"
      unitRef="U002">85000</erna:GainOnTerminationOfLease>
    <erna:GainOnTerminationOfLease
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_2aa8db5a59a44247bb110873cb5dfef2"
      unitRef="U002">0</erna:GainOnTerminationOfLease>
    <erna:WarrantLiabilitiesExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_3b7eea33734148619b2f90453f98759e"
      unitRef="U002">-10493000</erna:WarrantLiabilitiesExpense>
    <erna:WarrantLiabilitiesExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c0a2ab30569d4c15b138ec2457bdbe58"
      unitRef="U002">0</erna:WarrantLiabilitiesExpense>
    <erna:LossOnNonControllingInvestment
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_4b1f3da2cc1944009396c13fa39c4ba3"
      unitRef="U002">932000</erna:LossOnNonControllingInvestment>
    <erna:LossOnNonControllingInvestment
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_68a861101a8c4077a800bd61258f50fa"
      unitRef="U002">0</erna:LossOnNonControllingInvestment>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_321c1973cc5047a891af6441bdf24fb0"
      unitRef="U002">237000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c6ef839db990450f8b728fa2ddfbf06e"
      unitRef="U002">-5000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_520f5afb31b34c90ae1ef28e60bb64af"
      unitRef="U002">575000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_e64fdf9e0a804db3a0b4c84741503972"
      unitRef="U002">1109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_bf8dd294cc0b412bb83aa8debd6020d3"
      unitRef="U002">331000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_cf7683086b6848e5a5e5b5a2bf36f095"
      unitRef="U002">31000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_3d86258584294221bc4a8f1779bf05d1"
      unitRef="U002">1376000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_1017090743054a8b989bdcf7f1f92067"
      unitRef="U002">-196000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <erna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_ab893a212ace4afd9248c9af7adde3b7"
      unitRef="U002">-223000</erna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <erna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_ec6073fc08e24ab08f7ec95a1eaa1167"
      unitRef="U002">-226000</erna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_6388b59ba02b4c47b13572a9b8368eec"
      unitRef="U002">4043000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_6464b7360e484717bcde3755511ad950"
      unitRef="U002">202000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_6afe89da9d5e4371852a35cd6bcf978a"
      unitRef="U002">-15541000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_0d27849903f54936966c012f234980eb"
      unitRef="U002">-16656000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_907da751a9484053bd82995235768cfe"
      unitRef="U002">276000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_345be2badee34621acc0609312969b97"
      unitRef="U002">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <erna:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_c5bd8b3aa4154f859d554c4b6420f111"
      unitRef="U002">0</erna:PaymentsToAcquireProductiveAssetsNet>
    <erna:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_69f206947ce54d29b733c50460c1dd1f"
      unitRef="U002">22854000</erna:PaymentsToAcquireProductiveAssetsNet>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_4e447ab2f13b4cb1b5a9e8876cd4c63c"
      unitRef="U002">100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_80ce915fc2a0443bb431089b2edcb2e2"
      unitRef="U002">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_8738013835e34e668a0b8d2e26358450"
      unitRef="U002">0</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_5c08b6ebac864f6aa134d216b4f43f95"
      unitRef="U002">147000</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_8481d30f6c17452cbc0f049374130a54"
      unitRef="U002">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_4d634b1023414ddbb6c7b5e13d186617"
      unitRef="U002">119000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_86c765326cbf4488a9d5ef8f728cac04"
      unitRef="U002">-176000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_dd20e0dd75b346f6a76968736b843588"
      unitRef="U002">-22595000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_8f7ade7b2c2d4d62b6a51617dbace42f"
      unitRef="U002">11993000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_f2fe506cce404ab4bf920a520b6a4b28"
      unitRef="U002">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <erna:IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_5859c33254b2495bb38b0f83230d15a1"
      unitRef="U002">-7000</erna:IssuanceOfCommonStockFromExerciseOfPreFundedWarrants>
    <erna:IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_b055e8d842754478b839a675fdf6f1cb"
      unitRef="U002">0</erna:IssuanceOfCommonStockFromExerciseOfPreFundedWarrants>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_f1e98fc89dd24b2092775070c109ff70"
      unitRef="U002">5000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_8d18602ab28a439582665c4340208d05"
      unitRef="U002">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_2c5e2f636e9f480580f5a893f53b46ed"
      unitRef="U002">8000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_d4181d37f2dd40838e89408f34444526"
      unitRef="U002">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_64a0d4d8fdae42c599c8f93babc5abbc"
      unitRef="U002">1000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_734d170b64164bdd9743dcd2765beb9e"
      unitRef="U002">0</us-gaap:FinanceLeasePrincipalPayments>
    <erna:ProceedsFromIssuanceOfCommonStockToLincolnPark
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_6ce04020486c479b8ad2e96bd5a000f3"
      unitRef="U002">0</erna:ProceedsFromIssuanceOfCommonStockToLincolnPark>
    <erna:ProceedsFromIssuanceOfCommonStockToLincolnPark
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_f73da412b2e04317aa4d6e064ebd4e72"
      unitRef="U002">54106000</erna:ProceedsFromIssuanceOfCommonStockToLincolnPark>
    <erna:FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_8e4cc7acdd7e4685808343e0ec186918"
      unitRef="U002">0</erna:FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark>
    <erna:FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_effb9da0837d42a3a1898e6569447588"
      unitRef="U002">2080000</erna:FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_81e0f700f7b24b9da524e4208f788c87"
      unitRef="U002">0</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_9ab7998575c94e0091fea177541ae6c4"
      unitRef="U002">10500000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_2b77964f2c20484facd57a4d73fa6684"
      unitRef="U002">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_5ad45aa45f484cadbf65e6ec4aed9d88"
      unitRef="U002">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <erna:PaymentsOfPaycheckProtectionProgramLoan
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_bb728a9e854a4dfc85c9053211f0c4fe"
      unitRef="U002">0</erna:PaymentsOfPaycheckProtectionProgramLoan>
    <erna:PaymentsOfPaycheckProtectionProgramLoan
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_58b3dad94bc641a8b91d06894aa1f4bb"
      unitRef="U002">532000</erna:PaymentsOfPaycheckProtectionProgramLoan>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_7ee8c29eaf5d4137bd1dade481e9fe87"
      unitRef="U002">11986000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_a3c0168a36be4dc9b4e6aedd42e190c2"
      unitRef="U002">62004000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_a7ca9048f87f4fd2a35d9628a1157dbf"
      unitRef="U002">-3731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_d342d4143f6d43069d907c90637f390c"
      unitRef="U002">22753000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="-3"
      id="Fact_68ddc76da6d24c3ca6d775ad07700aa7"
      unitRef="U002">16985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20201231"
      decimals="-3"
      id="Fact_21e1369ba44b4e44af787746f2cb5a06"
      unitRef="U002">1630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20220930"
      decimals="-3"
      id="Fact_4e6af96bfd13497f9ce3100a1be4038f"
      unitRef="U002">13254000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20210930"
      decimals="-3"
      id="Fact_f3250412451646d5979ec858937827e3"
      unitRef="U002">24383000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_bc7be38cf8dc49669a94ff5a0b1da0a8"
      unitRef="U002">25000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_ab19eca704eb470ca2f10673d71b420b"
      unitRef="U002">13000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_011a88eee4e94cf1b2cd0165df3665a9"
      unitRef="U002">8000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_ed12edf98566485f87fecac4405cebab"
      unitRef="U002">0</us-gaap:IncomeTaxesPaidNet>
    <erna:ConversionOfWarrantLiabilityToEquity
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_c335264b146041fe8398812c77409dfb"
      unitRef="U002">867000</erna:ConversionOfWarrantLiabilityToEquity>
    <erna:ConversionOfWarrantLiabilityToEquity
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_ebcc6d18d2174f038cce4934d591455f"
      unitRef="U002">0</erna:ConversionOfWarrantLiabilityToEquity>
    <erna:IssuanceOfCommonStockForSeriesAPreferredStockDividend
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_838b2f6ec0db4d1e904cf78de38c237c"
      unitRef="U002">0</erna:IssuanceOfCommonStockForSeriesAPreferredStockDividend>
    <erna:IssuanceOfCommonStockForSeriesAPreferredStockDividend
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_26c392a725a0446299eda2ef70db1e49"
      unitRef="U002">8000</erna:IssuanceOfCommonStockForSeriesAPreferredStockDividend>
    <us-gaap:StockIssued1
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_b605189355444d24a4142fd3e8fad3c5"
      unitRef="U002">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_eefa35ba47fd41208551e33ee8ef2db6"
      unitRef="U002">8177000</us-gaap:StockIssued1>
    <erna:IssuanceOfCommonStockForAssetAcquisition
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_ade9a6799da04dcab1bee5f43e524958"
      unitRef="U002">0</erna:IssuanceOfCommonStockForAssetAcquisition>
    <erna:IssuanceOfCommonStockForAssetAcquisition
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_1ba3d69336304305a959dd13132b605d"
      unitRef="U002">58684000</erna:IssuanceOfCommonStockForAssetAcquisition>
    <erna:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_f4c255ac08514813bafeb28c359e9af5"
      unitRef="U002">0</erna:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger>
    <erna:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_6125f9343898419088c1928f1d5288aa"
      unitRef="U002">1000</erna:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger>
    <erna:InitialMeasurementOfRightOfUseAssetsAndLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_7d564310af0e485d8b60800f6518fbd1"
      unitRef="U002">1706000</erna:InitialMeasurementOfRightOfUseAssetsAndLiabilities>
    <erna:InitialMeasurementOfRightOfUseAssetsAndLiabilities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_5add340712bc4e5bbaf034afc3e70e55"
      unitRef="U002">816000</erna:InitialMeasurementOfRightOfUseAssetsAndLiabilities>
    <erna:InitialMeasurementOfOperatingLeaseLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_0d903887b38b48d8881b6cf15b8d5f36"
      unitRef="U002">1706000</erna:InitialMeasurementOfOperatingLeaseLiabilities>
    <erna:InitialMeasurementOfOperatingLeaseLiabilities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_a698a74a669a4b5bbc36d5446dfecf7b"
      unitRef="U002">866000</erna:InitialMeasurementOfOperatingLeaseLiabilities>
    <erna:InitialMeasurementOfFinanceLeaseLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_2e0cb3aa3c8e4789b4e8f0c5e3ab2a8b"
      unitRef="U002">10000</erna:InitialMeasurementOfFinanceLeaseLiabilities>
    <erna:InitialMeasurementOfFinanceLeaseLiabilities
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_db97c02767c8401ea8674c834a94ae83"
      unitRef="U002">0</erna:InitialMeasurementOfFinanceLeaseLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20220101to20220930"
      id="Text_c159c89179e84bc69ae87d8760bbfc7e">
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
         &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;"&gt;Description of Business&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;On October 11, 2022, Eterna Therapeutics Inc., a Delaware corporation, (&#x201c;Eterna&#x201d; or the &#x201c;Company&#x201d;), filed with the Secretary of State of the State of Delaware a Certificate of A&lt;span style="font-size: 10pt;"&gt;mendment to its Restated Certificate of Incorporation, as amended (the &#x201c;Charter&#x201d;), to change its name from Brooklyn ImmunoTherapeutics, Inc. to Eterna Therapeutics Inc., which became effective on October 17, 2022
                  (the &#x201c;Name Change&#x201d;). The Name Change did not require approval of the Company&#x2019;s stockholders and did not affect the rights of the Company&#x2019;s security holders. &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In connection with the Name Change, the trading symbol of the Company&#x2019;s common stock, par value
                $0.005 per share (&#x201c;common stock&#x201d;), on The Nasdaq Global Market changed from &#x201c;BTX&#x201d; to &#x201c;ERNA.&#x201d;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Eterna, together with its subsidiaries including Brooklyn ImmunoTherapeutics LLC (&lt;span style="font-size: 10pt;"&gt;&#x201c;Brooklyn LLC&#x201d;), Novellus,
                Inc. (&#x201c;Novellus&#x201d;) and Novellus Therapeutics Limited (&#x201c;Novellus Ltd.&#x201d;), is a biopharmaceutical company using its mRNA technology platform, including mRNA-based cell reprogramming and gene editing technologies, to create next generation mRNA,
                gene editing and cell therapies, including iPSC therapies for multiple therapeutic indications. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company also plans to develop and advance a pipeline of therapeutic products both internally and through strategic partnerships. &lt;/span&gt;As used herein, the
                &#x201c;Company&#x201d; refers collectively to Eterna and its subsidiaries.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On August 12, 2020, Eterna (then known as &#x201c;NTN Buzztime, Inc.&#x201d;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of Eterna
              (the &#x201c;Merger Sub&#x201d;), entered into an agreement and plan of merger and reorganization (the &#x201c;Merger Agreement&#x201d;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned
              subsidiary of Eterna and as the surviving company of the merger (the &#x201c;Merger&#x201d;). The Merger closed on March 25, 2021. In connection with the Merger, the Company changed its name from &#x201c;NTN Buzztime, Inc.&#x201d; to &#x201c;Brooklyn ImmunoTherapeutics, Inc.,&#x201d;
              &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and, as described above, the Company has since changed
                its name to Eterna Therapeutics Inc. &lt;/span&gt;The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 26, 2021, Eterna sold its rights, title and interest in and to the assets relating to the business operated under the name &#x201c;NTN
              Buzztime, Inc.&#x201d; (the &#x201c;Disposition&#x201d;) prior to the Merger to eGames.com Holdings LLC (&#x201c;eGames.com&#x201d;) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Eterna and eGames.com (the &#x201c;Asset
              Purchase Agreement&#x201d;). &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;On July 16, 2021, Eterna and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an
          agreement and plan of acquisition (the &#x201c;Novellus Acquisition Agreement&#x201d;) with (a) Novellus LLC, (b) Novellus (the sole equity holder of Novellus Ltd. and, prior to the closing under the Novellus Acquisition Agreement, a subsidiary of Novellus
          LLC), and (c) a seller representative (the &#x201c;Novellus Acquisition&#x201d;), pursuant to which Eterna acquired Novellus and its subsidiary, Novellus Ltd. As part of the Novellus Acquisition, Eterna also acquired 25.0% of the total outstanding equity interests of NoveCite, Inc. (&#x201c;NoveCite&#x201d;), a corporation focused on developing an allogeneic mesenchymal stem cell product for patients
          with acute respiratory distress syndrome, including from COVID-19. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The


          accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial statements and with the instructions to
          Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited financial statements include all the
          normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;These































          condensed consolidated financial statements should be read together with the audited consolidated financial statements and notes thereto contained in Eterna&#x2019;s Annual Report on Form 10-K/A for the year ended December 31, 2021 filed with the
          Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on June 30, 2022 (the &#x201c;10-K/A&#x201d;). The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements contained in the 10-K/A but does
          not include all of the information and footnotes required by GAAP for complete financial statements. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be anticipated
          for the entire year ending December 31, 2022, or any other period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Reverse Stock Split&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;A&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;s approved by the Company&#x2019;s stockholders at the Company&#x2019;s Annual Meeting of Stockholders held
              on September 21, 2022, the Company effected a reverse stock split of its common stock at a ratio of &lt;span style="-sec-ix-hidden:Fact_b943329114c841ec8b57e15e6be15da4"&gt;1-for-20&lt;/span&gt;, as determined by the
              Company&#x2019;s Board of Directors within the parameters approved by the Company&#x2019;s stockholders (the &#x201c;Reverse Stock Split&#x201d;).&#160; The Reverse Stock Split became effective under Delaware law at 11:59 p.m. Eastern time on October 16, 2022.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common stock were automatically
            combined and reclassified into one issued and outstanding share of common stock. The Reverse Stock Split did not affect any stockholder&#x2019;s ownership percentage of the common stock, alter the par value of the common stock or modify any voting
            rights or other terms of the common stock. The number of authorized shares of common stock under the Charter remains unchanged. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares to
            which a stockholder would otherwise be entitled, the Company paid an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the then fair value of a share as determined in good
            faith by the Board. The Company paid an aggregate of $719 for a total of 175 fractional shares.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;All share and per share data in this Quarterly Report on Form 10-Q have been adjusted for all periods presented to reflect the Reverse
            Stock Split.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;
         &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: italic;"&gt;Reclassifications&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Certain reclassifications have been made
          to Eterna&#x2019;s prior years&#x2019; financial statements to conform to the current year presentation. These reclassifications had no effect on Eterna&#x2019;s previously reported results of operations or accumulated deficit.&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20221017"
      decimals="3"
      id="Fact_c165c822cd464e0597d4a447d664ec59"
      unitRef="U003">0.005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="3"
      id="Fact_105ff8ca8ce2424a9d1f42d62c416bfc"
      unitRef="U004">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20220101to20220930"
      id="Text_981de089ea644818a2ff1997672bf5df">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The


          accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial statements and with the instructions to
          Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited financial statements include all the
          normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;These































          condensed consolidated financial statements should be read together with the audited consolidated financial statements and notes thereto contained in Eterna&#x2019;s Annual Report on Form 10-K/A for the year ended December 31, 2021 filed with the
          Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on June 30, 2022 (the &#x201c;10-K/A&#x201d;). The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements contained in the 10-K/A but does
          not include all of the information and footnotes required by GAAP for complete financial statements. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be anticipated
          for the entire year ending December 31, 2022, or any other period.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <erna:ReverseStockSplitPolicyTextBlock
      contextRef="c20220101to20220930"
      id="Text_d304fcff0eb94408ae8685ebfad5aa93">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Reverse Stock Split&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;A&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;s approved by the Company&#x2019;s stockholders at the Company&#x2019;s Annual Meeting of Stockholders held
              on September 21, 2022, the Company effected a reverse stock split of its common stock at a ratio of &lt;span style="-sec-ix-hidden:Fact_b943329114c841ec8b57e15e6be15da4"&gt;1-for-20&lt;/span&gt;, as determined by the
              Company&#x2019;s Board of Directors within the parameters approved by the Company&#x2019;s stockholders (the &#x201c;Reverse Stock Split&#x201d;).&#160; The Reverse Stock Split became effective under Delaware law at 11:59 p.m. Eastern time on October 16, 2022.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common stock were automatically
            combined and reclassified into one issued and outstanding share of common stock. The Reverse Stock Split did not affect any stockholder&#x2019;s ownership percentage of the common stock, alter the par value of the common stock or modify any voting
            rights or other terms of the common stock. The number of authorized shares of common stock under the Charter remains unchanged. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares to
            which a stockholder would otherwise be entitled, the Company paid an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the then fair value of a share as determined in good
            faith by the Board. The Company paid an aggregate of $719 for a total of 175 fractional shares.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;All share and per share data in this Quarterly Report on Form 10-Q have been adjusted for all periods presented to reflect the Reverse
            Stock Split.&lt;/div&gt;
</erna:ReverseStockSplitPolicyTextBlock>
    <erna:CashPaidForFractionalSharesInConnectionWithReverseStockSplit
      contextRef="c20220921to20220921"
      decimals="0"
      id="Fact_ae62bc3edff1451f8ad788641e3f8f77"
      unitRef="U002">719</erna:CashPaidForFractionalSharesInConnectionWithReverseStockSplit>
    <erna:NumberOfSharesConsideredAsFractionalInReverseStock
      contextRef="c20220921to20220921"
      decimals="0"
      id="Fact_5ebcf3ac588a4f1d958025c0a02e426a"
      unitRef="U001">175</erna:NumberOfSharesConsideredAsFractionalInReverseStock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="c20220101to20220930"
      id="Text_71c8f622b17c4c8e9d9a5535cd70cf24">
&lt;div&gt;
         &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: italic;"&gt;Reclassifications&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Certain reclassifications have been made
          to Eterna&#x2019;s prior years&#x2019; financial statements to conform to the current year presentation. These reclassifications had no effect on Eterna&#x2019;s previously reported results of operations or accumulated deficit.&lt;/div&gt;
</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <erna:LiquidityAndCapitalResourcesTextBlock
      contextRef="c20220101to20220930"
      id="Text_b6fb6892a9904282bc9f5185ebebb1c1">
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;LIQUIDITY AND CAPITAL RESOURCES&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting clinical trials and providing general and
              administrative support for operations. As of September 30, 2022, the Company had a cash balance of approximately $13.3 million and
              an accumulated deficit of approximately $160.8 million. For the three and nine months ended September 30, 2022, the Company
              incurred a net loss of $7.3 million and $20.1 million, respectively, and for the nine months ended September 30, 2022, the Company used cash in operating activities of $15.5 million.&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;October 18, 2022, the Company
                entered into a facility sublease agreement (the &#x201c;Sublease&#x201d;) for approximately 45,500 square feet of office and laboratory space
                in Somerville, Massachusetts.&#160; Pursuant to the Sublease, the Company delivered to the sublessor a security deposit in the form of a letter of credit in the amount of $4.1 million, which will be reduced on an incremental basis throughout the term of the lease.&#160; The letter of credit was issued by the Company&#x2019;s commercial bank, which
                required that the Company cash collateralize the letter of credit by depositing $4.1 million in a restricted cash account with
                such bank.&#160; The amount of required restricted cash collateral will decline in parallel with the reduction in the amount of the letter of credit over the term of the sublease.&#160; The Company&#x2019;s deposit of this restricted cash reduced the amount
                of working capital the Company has to fund its operations. See Note 15,&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;Subsequent

                Events,&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#160;for more information on the
                Subleas&lt;/span&gt;e.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with preparing the accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022, the Company&#x2019;s management concluded that there is substantial doubt regarding
              the Company&#x2019;s ability to continue as a going concern because it does not expect to have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these financial statements.
              The Company will need to raise additional capital, which could be through the remaining availability under an equity line purchase agreement with Lincoln Park Capital Fund, LLC (the &#x201c;Second Purchase Agreement&#x201d;) (to the extent the Company is
              permitted to use such agreement) (see Note 12), public or private equity offerings, debt financings, corporate collaborations or other means. The Company may also seek governmental grants to support its clinical trials and preclinical trials.
              The Company currently has no arrangements for such capital and no assurances can be given that it will be able to raise such capital when needed, on acceptable terms, or at all. &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The
              accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may
              result from uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/div&gt;
</erna:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:Cash
      contextRef="c20220930"
      decimals="-5"
      id="Fact_5b136a25e40941f49b4c632f2ebe786d"
      unitRef="U002">13300000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20220930"
      decimals="-5"
      id="Fact_a67afac2714f4d20b28c20a8bb37b38f"
      unitRef="U002">-160800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="c20220701to20220930"
      decimals="-5"
      id="Fact_c76543e934a44306b2678fc79346c5bd"
      unitRef="U002">-7300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220930"
      decimals="-5"
      id="Fact_0d724342b94c4d91932231988e54d487"
      unitRef="U002">-20100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20220930"
      decimals="-5"
      id="Fact_e6e8d4c3ae5444eba361b6922c288705"
      unitRef="U002">-15500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="c20221018_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_ce3defc24d654b8291da69da441d1c4f"
      unitRef="U005">45500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LineOfCredit
      contextRef="c20221018_PledgingPurposeAxis_LetterOfCreditMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_0ebf21638c7047ffa94928b9284a313b"
      unitRef="U002">4100000</us-gaap:LineOfCredit>
    <us-gaap:RestrictedCash
      contextRef="c20221018_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_0336b907ce804b83861b66334d4bdc15"
      unitRef="U002">4100000</us-gaap:RestrictedCash>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="c20220101to20220930"
      id="Text_fbcb17304ce04aa5b619ffb95c920909">
&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                    &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                    &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 27pt; margin-left: 9pt; font-variant: normal; text-transform: none;"&gt;Merger&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On August 12, 2020, Eterna, Brooklyn LLC and the Merger Sub
          entered into the Merger Agreement, and the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes. Brooklyn LLC, as the accounting
          acquirer, recorded the assets acquired and liabilities assumed of Eterna in the Merger at their fair values as of the acquisition date.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Brooklyn LLC was determined to be the accounting acquirer
          based upon the terms of the Merger and other factors including that (i) Brooklyn LLC members, received common stock in the Merger that represented 96.35%
          of Eterna&#x2019;s outstanding common stock on a fully diluted basis, (ii) all of the directors of Eterna immediately after the Merger were designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC&#x2019;s
          management became the management of Eterna immediately after the Merger.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;At the closing of the Merger, all the outstanding membership
          interests of Brooklyn LLC converted into the right to receive an aggregate of approximately 1,999,000 shares of common stock, of which
          53,000 shares were issued as compensation to Brooklyn LLC&#x2019;s financial advisor for its services to Brooklyn LLC in connection with the
          Merger.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The purchase price of $8.2 million, which represents the consideration transferred in the Merger to stockholders of Eterna immediately before the Merger, was calculated
          based on the closing price of $108 per share for approximately 76,000 shares common stock that those stockholders owned on March 25, 2021 immediately prior to the Merger because that represented a more reliable measure of the fair value of
          consideration transferred in the Merger.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Under the acquisition method of accounting, the total
          purchase price has been allocated to the acquired tangible and intangible assets and assumed liabilities of Eterna based on their estimated fair values as of March 25, 2021, the Merger closing date. Because the consideration paid by Brooklyn LLC
          in the Merger is more than the estimated fair values of Eterna&#x2019;s net assets deemed to be acquired, goodwill is equal to the difference of approximately $8.6
          million, which has been calculated using the fair values of the net assets of Eterna as of March 25, 2021.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The allocation of the purchase price to the tangible and
          intangible assets acquired and liabilities deemed to be assumed from Eterna, based on their estimated fair values as of March 25, 2021, is as follows (in thousands):&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Historical&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Balance&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Sheet of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Eterna at&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; March 25, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Fair Value&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Adjustment &lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;to&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Eterna&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Pre-Merger&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt;Purchase &lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt; Allocation&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Accounts receivable&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;103&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;103&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Prepaid expense and other current assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;329&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;329&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Property and equipment, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;1,015&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;1,015&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Software development costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,296&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(368&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;928&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Customers&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;548&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;548&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Trade name&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;299&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;299&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Accounts payable, accrued liabilities and other current liabilities&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(3,781&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(3,781&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(890&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;479&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(411&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Total consideration&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;8,178&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(411&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;8,589&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Brooklyn LLC was obligated under the Merger Agreement to have
          $10.0 million in cash and cash equivalents on its balance sheet at the effective time of the Merger. To ensure Brooklyn LLC had the
          required funds, certain beneficial holders of Brooklyn LLC&#x2019;s Class A membership interests entered into contractual commitments to invest $10.0
          million into Brooklyn LLC immediately prior to the closing of the Merger. During March 2021, Eterna offered its Class A unit holders an additional 5%
          rights offering for an additional $0.5 million to be raised by a rights offering. Eterna received funds from the rights offering
          between February 17, 2021 and April 5, 2021.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Disposition&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On March 26, 2021, Eterna sold its rights, title and interest
          in and to the assets relating to the business it operated (under the name NTN Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2.0 million and assumption of specified liabilities relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the
          Disposition are as follows (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Proceeds from sale:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;Cash&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;132&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Escrow&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;50&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Assume advance/loans&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,700&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Interest on advance/loans&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;68&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Carrying value of assets sold:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(14&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Accounts receivable&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(75&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Prepaids and other current assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(124&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Property and equipment, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(1,014&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Software development costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(927&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Customers&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(548&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Trade name&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(299&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(8,589&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Other assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(103&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Liabilities transferred upon sale:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Accounts payable and accrued expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;113&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Obligations under finance leases&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;17&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;26&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Deferred revenue&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;55&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Other current liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;149&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Transaction costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(265&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Total loss on sale of assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;(9,648&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 36pt; font-variant: normal; text-transform: none;"&gt;Acquisition&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On July 16, 2021, Eterna and Brooklyn Acquisition Sub, Inc.
          entered into the Novellus Acquisition Agreement. The Novellus Acquisition closed contemporaneously with the execution and delivery of the Novellus Acquisition Agreement. At the closing:&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                  &lt;div style="text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                  &lt;div style="text-align: justify;"&gt;Eterna acquired all of the outstanding equity interests of Novellus as the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, following which, Novellus, as the surviving
                    corporation, became Eterna&#x2019;s wholly owned subsidiary and Novellus Ltd. became Eterna&#x2019;s indirectly owned subsidiary; and&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                  &lt;div style="text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                  &lt;div style="text-align: justify;"&gt;Eterna acquired 25.0% of the total outstanding equity interests of NoveCite.&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As consideration for the Novellus Acquisition, Eterna paid $22.9 million in cash and delivered approximately 351,000
          shares of common stock, which under the terms of the Novellus Acquisition Agreement, were valued at a total of $102.0 million based on
          an agreed upon price of $290.5060 per share. At the date of issuance, the fair value of the shares was approximately $58.7 million.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Novellus Acquisition Agreement contained customary
          representations, warranties and certain indemnification provisions. Approximately 37,000 of the shares issued as consideration were
          placed in escrow to secure indemnification obligations to Eterna under the Novellus Acquisition Agreement, and all such shares were released to the sellers in July 2022. The Novellus Acquisition Agreement also contains certain non-competition and
          non-solicitation provisions pursuant to which Novellus LLC agreed not to engage in certain competitive activities for a period of five years
          following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus prior to the Novellus Acquisition continued their employment, or were otherwise engaged by Eterna, immediately following the
          Novellus Acquisition.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with the Novellus Acquisition, the co-founders
          of Novellus entered into lock-up agreements with respect to approximately 169,000 of the shares of common stock received in the
          Novellus Acquisition, and Eterna&#x2019;s Chairman of the Board and its former Chief Executive Officer and President entered into identical lock-up agreements with respect to their current holdings of Eterna stock. Each lock-up agreement extends for a
          period of three years, provided that up to 75% of the shares of common stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on the Nasdaq exceeds specified
          thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period. &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal;"&gt;The


          Company expects the Novellus Acquisition will advance its evolution into a platform company with a pipeline of next generation mRNA cellular and gene editing programs. In addition, the acquisition of Novellus Ltd. builds on the License Agreement
          (as defined in Note 10). As a result of the Novellus Acquisition, in accordance with the terms of the Novellus-Factor License Agreement, the rights and obligations of Novellus Ltd. thereunder pertaining to any and all licensed products have
          inured to Eterna. The License Agreement with Factor Bioscience Limited (&#x201c;Factor Limited&#x201d;) under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene editing and cell therapy products,
          remained unchanged after the completion of the Novellus Acquisition.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Although Eterna acquired all of the outstanding equity
          interests of Novellus, the Company accounted for the Novellus Acquisition as an asset acquisition (as the assets acquired did not constitute a business as defined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805,&#160;&lt;span style="font-style: italic;"&gt;Business Combinations&lt;/span&gt;),&#160;and was measured by the amount of cash paid and by the fair value of the shares of common stock issued. As a result, substantially all of the value acquired was attributed to in-process research and
          development (IPR&amp;amp;D), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities, as discussed further below.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Eterna paid $22.9 million in cash, net of cash acquired, as part of the consideration for the Novellus Acquisition, of which $1.0 million was paid in cash for the investment in NoveCite. Eterna also issued approximately 351,000
          shares of the Company&#x2019;s common stock, of which approximately 182,000 shares are unrestricted and 169,000 shares are subject to the three-year
          lockup. The unrestricted shares were valued at $201 per share, which was the closing price of Eterna&#x2019;s common stock on July 16, 2021.
          The fair value of the restricted shares was discounted by approximately 35% to $130.60 per restricted share, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;"&gt;The resulting fair value of the asset acquired is as follows
          (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Fair Value of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Consideration&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Cash paid&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;22,882&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Cash acquired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(28&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Unrestricted shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;36,628&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Restricted shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;22,056&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Total fair value of consideration paid&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;81,538&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Less amount of cash paid for NoveCite investment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(1,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Fair value of IPR&amp;amp;D acquired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;80,538&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;IPR&amp;amp;D that is acquired through an asset purchase that has
          no alternative future uses and no separate economic values from its original intended purpose is expensed in the period the cost is incurred. Accordingly, the Company expensed the fair value of the IPR&amp;amp;D during the third quarter of 2021 in
          the amount of $80.5 million.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Investment in NoveCite&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal;"&gt;As
          a result of the Novellus Acquisition,&#160; Eterna acquired and currently owns 25% of NoveCite and Citius Pharmaceuticals, Inc. (&#x201c;Citius&#x201d;)
          owns the remaining 75%. A member of the Company&#x2019;s management is entitled to hold one of three board seats on NoveCite&#x2019;s board of directors. Citius&#x2019; s officers and directors hold the other two board seats. The Company is accounting for its interest in NoveCite
          under ASC Topic 323, &lt;span style="font-style: italic;"&gt;Investments &#x2013; Equity&lt;span style="font-style: italic;"&gt; Meth&lt;/span&gt;od and Joint&#160;Ventures&lt;/span&gt;.&#160;The investment was recorded at cost, which was $1.0 million&#160;and is adjusted for the Company&#x2019;s share of&#160;NoveCite&#x2019;s earnings or losses, which are reflected in the accompanying condensed consolidated statement of operations.
          The investment may also reflect an equity loss in the event that circumstances indicate an other-than-temporary impairment. For the three and nine months ended September 30, 2022, the Company recorded approximately $21,000 and $0.9 million, respectively,
          in losses from its investment in NoveCite, and of the $0.9 million loss for the nine months ended September 30, 2022, $0.5 million related to NoveCite&#x2019;s year ended December 31, 2021. The Company does not guarantee obligations of NoveCite nor is it otherwise committed
          to providing further financial support for NoveCite. Therefore, the Company will record losses only up to its investment carrying amount.&lt;/div&gt;
</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="4"
      id="Fact_6345027e2351441ca473a39a9651c08d"
      unitRef="U004">0.9635</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_2789e6cb7042465a9dae17674df934ad"
      unitRef="U001">1999000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_3c34298cadee403e99c5230aa796c98e"
      unitRef="U001">53000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-5"
      id="Fact_227decf93219417199a7605f42a9d98c"
      unitRef="U002">8200000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_fb3b8ad711e04e6a8bf2b6c2b2fb567a"
      unitRef="U003">108</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_6ee5e4d5ec294648b86e84a862707a97"
      unitRef="U001">76000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Goodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-5"
      id="Fact_472f7ddf38ab474d8e5329a8f559e9e2"
      unitRef="U002">8600000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_c4998b5fcb854dbda6d5d8398d1e26e9">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The allocation of the purchase price to the tangible and
          intangible assets acquired and liabilities deemed to be assumed from Eterna, based on their estimated fair values as of March 25, 2021, is as follows (in thousands):&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Historical&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Balance&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Sheet of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Eterna at&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; March 25, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Fair Value&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Adjustment &lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;to&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Eterna&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Pre-Merger&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; Assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt;Purchase &lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&lt;span style="font-weight: bold;"&gt; Allocation&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Accounts receivable&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;103&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;103&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Prepaid expense and other current assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;329&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;329&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Property and equipment, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;1,015&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;1,015&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Software development costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,296&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(368&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;928&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Customers&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;548&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;548&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Trade name&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;299&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;299&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Accounts payable, accrued liabilities and other current liabilities&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(3,781&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(3,781&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(890&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;479&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(411&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; text-indent: -9pt; margin-left: 9pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Total consideration&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;8,178&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(411&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"&gt;Goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;8,589&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_2725424f41d8481391d5d9b74743798c"
      unitRef="U002">148000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_7d87050ae9ec4f008c9c341fa74d0ff9"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_d8ace7599d8747adb96381429da64b93"
      unitRef="U002">148000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_cb87f6125c9941798faca3b91b0fc241"
      unitRef="U002">103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_6150027b5c354d98927eaacab5da5e26"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_f156f9133848407b9a71d0ce72a589a6"
      unitRef="U002">103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_a2366e9700d343e0a60acbffb1de278e"
      unitRef="U002">329000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_ed3daa1edecb49d0aac9d037e3372471"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_fc45bfd49d5e4f2ab447d164788dd284"
      unitRef="U002">329000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_de133348dc744b73943b32d78de0ba45"
      unitRef="U002">1015000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_68e80322ecf64c28accbe07905b466c9"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_61e8e74da9d24dc3873dd9b556f4e377"
      unitRef="U002">1015000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_be407ced63244e4f9eec7e6feea2e91e"
      unitRef="U002">1296000</erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts>
    <erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_e7c09bf992d04167997ac7570b800df2"
      unitRef="U002">-368000</erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts>
    <erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_c2b4633c0f4b49baa15fd1028e20578d"
      unitRef="U002">928000</erna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact_4997f04d55164c74b3a474032d24a260"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_d791bf9a81764ef382af7ac319a41fdd"
      unitRef="U002">548000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_d5bc4102ca1c4c9c867ea007d3bea130"
      unitRef="U002">548000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember"
      decimals="-3"
      id="Fact_e2be2ae057604e9fadda2f32cc4e0d62"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_1a52d912e8cc4886aa3f303fd7f9205e"
      unitRef="U002">299000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_b6fbd1b00a084964be550dfe7081dafc"
      unitRef="U002">299000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_718b1a37aeb24eb6b75c9c6f255edfad"
      unitRef="U002">3781000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_43fa4f28ccda4ac4a7bf9580517ed159"
      unitRef="U002">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_c3c635779da24d1f96c46f9f49fc3eeb"
      unitRef="U002">3781000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_5561988841f0434e91fa9cd6ea091477"
      unitRef="U002">-890000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="-3"
      id="Fact_e2e9aeb6a23b4862b5d360b16f12cffb"
      unitRef="U002">479000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_1ef02e1de8154d69b9c4cf16a893a519"
      unitRef="U002">-411000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_83d8cd6575d64b17bc310467ccdd17ff"
      unitRef="U002">8178000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationMember"
      decimals="-3"
      id="Fact_dbeb92621a8e4652bbb1dd829640641f"
      unitRef="U002">-411000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-3"
      id="Fact_5765c3c9d34d498db67fb96ed0b497e3"
      unitRef="U002">8589000</us-gaap:Goodwill>
    <erna:ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-5"
      id="Fact_079ee68d81994e8c8e4ff9536be82f4a"
      unitRef="U002">10000000</erna:ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement>
    <erna:BeneficialHoldersContractualCommitmentsToInvest
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-5"
      id="Fact_50ca5d73004241d4ad356fb1b98dc32d"
      unitRef="U002">10000000</erna:BeneficialHoldersContractualCommitmentsToInvest>
    <erna:PercentageOfAdditionalRightsOffering
      contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="2"
      id="Fact_84250eda626c4b77909aabf344a072a5"
      unitRef="U004">0.05</erna:PercentageOfAdditionalRightsOffering>
    <erna:ProceedsFromSaleOfRights
      contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="-5"
      id="Fact_7e2bb9bbdaba40fc8633535d11d2d4d1"
      unitRef="U002">500000</erna:ProceedsFromSaleOfRights>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="c20220101to20220930"
      id="Text_a08043633ac149379ad703bbb3529414">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On March 26, 2021, Eterna sold its rights, title and interest
          in and to the assets relating to the business it operated (under the name NTN Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2.0 million and assumption of specified liabilities relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the
          Disposition are as follows (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Proceeds from sale:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;Cash&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;132&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Escrow&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;50&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Assume advance/loans&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,700&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Interest on advance/loans&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;68&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Carrying value of assets sold:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Cash and cash equivalents&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(14&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Accounts receivable&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(75&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Prepaids and other current assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(124&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Property and equipment, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(1,014&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Software development costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(927&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Customers&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(548&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Trade name&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(299&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(8,589&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Other assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;(103&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Liabilities transferred upon sale:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Accounts payable and accrued expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;113&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Obligations under finance leases&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;17&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Lease liability&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;26&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Deferred revenue&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;55&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Other current liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;149&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Transaction costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(265&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-weight: bold;"&gt;Total loss on sale of assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;(9,648&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-5"
      id="Fact_47491901f1a9498ba4d04cf776788f7c"
      unitRef="U002">2000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromCash
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_88a767ade9e645dc83886066da5f0482"
      unitRef="U002">132000</erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromCash>
    <erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_34581ffa0b6e455db516d2995b411d8d"
      unitRef="U002">50000</erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow>
    <erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_e71c580f0205445cbb1f08715ca869a4"
      unitRef="U002">1700000</erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans>
    <erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_3381c21b5e27475784ce770dd86d2d94"
      unitRef="U002">68000</erna:DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_277461b5b71e49b597d4bcdd00717feb"
      unitRef="U002">14000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_b0585c4c9fe4403bad8be1df2492ac88"
      unitRef="U002">75000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_01983c2f9ca34e15ac9a456d0cae9626"
      unitRef="U002">124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_4980ab42739144b0ba3c3f1b645a3eda"
      unitRef="U002">1014000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <erna:DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_005630643b6249838ae2371476146b35"
      unitRef="U002">927000</erna:DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_6559ccae4cb54d7997cc7388bbf83b06"
      unitRef="U002">548000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_7d71ce070dd5465397fc0ead5b2b99a7"
      unitRef="U002">299000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_350a220a8bb642adbec96a132ea49a90"
      unitRef="U002">8589000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_8c77542dadd448819c547cbb6bbd7f0d"
      unitRef="U002">103000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_9ea3916e259340e7b08b17cb2c926493"
      unitRef="U002">113000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities>
    <erna:DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_bb4bfb60be4547d4a711c58a3db1356b"
      unitRef="U002">17000</erna:DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases>
    <erna:DisposalGroupIncludingDiscontinuedOperationLeaseLiability
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_8375b3b4fa174987a6f2576877447acc"
      unitRef="U002">26000</erna:DisposalGroupIncludingDiscontinuedOperationLeaseLiability>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_3ff7f60b33764ef9812e88a611c48cea"
      unitRef="U002">55000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_387823009c274495afc867a527cf1353"
      unitRef="U002">149000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <erna:DisposalGroupIncludingDiscontinuedOperationTransactionCosts
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_55727fceace444cb84fec2fb6a354748"
      unitRef="U002">265000</erna:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="-3"
      id="Fact_5463a573ebb34ea4b9c50321772b8189"
      unitRef="U002">-9648000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="3"
      id="Fact_892449318ec8491c962c8b233e7c96cd"
      unitRef="U004">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_26070e6aebdf42f2bf71a638922e9461"
      unitRef="U002">22900000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_3a4cf21299214a1ebe070f6a006e26b8"
      unitRef="U001">351000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_c22eeb85867440d6acb5db7260e5f064"
      unitRef="U002">102000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <erna:AssetAcquisitionSharePrice
      contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="4"
      id="Fact_ef938c72808843b79e912311d6d3228f"
      unitRef="U003">290.506</erna:AssetAcquisitionSharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_43ba5e42f91647aca67d9faf1eca5a0f"
      unitRef="U002">58700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <erna:EscrowShares
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_1b708c91213540b49d0fce2431ab4382"
      unitRef="U001">37000</erna:EscrowShares>
    <erna:AcquisitionAgreementNonCompetitivePeriod
      contextRef="c20220101to20220930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      id="Fact_856c31a82a424c75b8ff755e89079e0d">P5Y</erna:AcquisitionAgreementNonCompetitivePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember"
      decimals="0"
      id="Fact_ac69959d13704697a9f8023d9b488a0b"
      unitRef="U001">169000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <erna:EachLockUpAgreementExtendsTerm
      contextRef="c20220101to20220930_AssetAcquisitionAxis_NovellusIncMember"
      id="Fact_11c9737e255a45cb8aaf7cbfbdb5e373">P3Y</erna:EachLockUpAgreementExtendsTerm>
    <erna:PercentageOfCommonStockSubjectToLockUpAgreement
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusIncMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_120ef8a092474508bdbe9d2be124c02d"
      unitRef="U004">0.75</erna:PercentageOfCommonStockSubjectToLockUpAgreement>
    <erna:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_5a9188ce4591487dadbe10257a893eed"
      unitRef="U002">22900000</erna:PaymentsToAcquireProductiveAssetsNet>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_0ca4da8c64e543339a2f15785854dd48"
      unitRef="U002">1000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_03b74eba589c4e048b544874baca8be5"
      unitRef="U001">351000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <erna:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_52178f86039e4c23a86344d6f2039da8"
      unitRef="U001">182000</erna:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions>
    <erna:StockIssuedDuringPeriodRestrictedSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_6ed03e4e86754f72abce63a4d4b2cedd"
      unitRef="U001">169000</erna:StockIssuedDuringPeriodRestrictedSharesAcquisitions>
    <erna:LockUpPeriodForRestrictedShares
      contextRef="c20220101to20220930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      id="Fact_d161f43c1fdd40ddaab5fe2c7385cec3">P3Y</erna:LockUpPeriodForRestrictedShares>
    <erna:AssetAcquisitionUnrestrictedSharesSharePrice
      contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_c13cc18bd21c4a1c881cbe9b27a09baa"
      unitRef="U003">201</erna:AssetAcquisitionUnrestrictedSharesSharePrice>
    <erna:PercentageOfDiscountOnFairValueOfRestrictedShares
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_eafb3ed229e246b189d184a53cdee839"
      unitRef="U004">0.35</erna:PercentageOfDiscountOnFairValueOfRestrictedShares>
    <erna:AssetAcquisitionRestrictedSharesSharePrice
      contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_855122ce93544dd79afc6107b219be54"
      unitRef="U003">130.6</erna:AssetAcquisitionRestrictedSharesSharePrice>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_3ac8744c64734e319bb6f2f33b766498">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;"&gt;The resulting fair value of the asset acquired is as follows
          (in thousands):&lt;/span&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Fair Value of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Consideration&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Cash paid&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;22,882&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Cash acquired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;(28&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Unrestricted shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;36,628&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Restricted shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;22,056&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Total fair value of consideration paid&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;81,538&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Less amount of cash paid for NoveCite investment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(1,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left;"&gt;Fair value of IPR&amp;amp;D acquired&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;80,538&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_39d4421ba124482f93efb8141e0cd044"
      unitRef="U002">22882000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_1deb707b9c76427c914e5172d23a51f7"
      unitRef="U002">28000</us-gaap:CashAcquiredFromAcquisition>
    <erna:StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_b7e5bb60c51547b2afb424ae5fdaba62"
      unitRef="U002">36628000</erna:StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions>
    <erna:StockIssuedDuringPeriodRestrictedSharesValueAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_7f9eb42232a84fb08c455d4684062dd7"
      unitRef="U002">22056000</erna:StockIssuedDuringPeriodRestrictedSharesValueAcquisitions>
    <erna:AssetAcquisitionFairValueOfConsiderationPaid
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_8e9c44cef3514ff1b96e7d73aae78726"
      unitRef="U002">81538000</erna:AssetAcquisitionFairValueOfConsiderationPaid>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_4ed1ea680cb4479e8214e6ec50da0d35"
      unitRef="U002">1000000</us-gaap:PaymentsToAcquireInvestments>
    <erna:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="-3"
      id="Fact_23117f13e1fe4d1a96e201957179c496"
      unitRef="U002">80538000</erna:ResearchAndDevelopmentInProcessAssetAcquisition>
    <erna:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="1"
      id="Fact_cac07234c12240be99feec51269f3e5d"
      unitRef="U002">80.5</erna:ResearchAndDevelopmentInProcessAssetAcquisition>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="2"
      id="Fact_d42ea9b878dc4aac9d4ef08746cd8aef"
      unitRef="U004">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20210716_OwnershipAxis_CitiusPharmaceuticalsIncMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="2"
      id="Fact_f559aec610414c84bd46a92ee1b45b3e"
      unitRef="U004">0.75</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <erna:NumberOfBoardSeats
      contextRef="c20210716to20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="INF"
      id="Fact_1137f9de8edf4ecd8923f916a9335174"
      unitRef="U006">3</erna:NumberOfBoardSeats>
    <us-gaap:EquityMethodInvestments
      contextRef="c20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="-5"
      id="Fact_9c811628c39e4b80bbfe51bb9eabbb0b"
      unitRef="U002">1000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c20220701to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="0"
      id="Fact_2d83d625ad174229a87f583420cd2ce3"
      unitRef="U002">21000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c20220101to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="-5"
      id="Fact_2e86197a27514fd8ace4e4fe2779776d"
      unitRef="U002">900000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c20220101to20220930_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="-5"
      id="Fact_57406785178349fb9526f30d188ea46c"
      unitRef="U002">900000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c20210101to20211231_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember"
      decimals="-5"
      id="Fact_ad83c074931e47cb927ef69380d01fc1"
      unitRef="U002">500000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20220101to20220930"
      id="Text_e7c69bb7250f40eca795c907e47ea32c">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold;"&gt;4)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Fair


















          value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest
          priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 18pt;"&gt;
                        &lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                        &lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Level
                          1 Inputs &#x2013; Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/div&gt;
                      &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 18pt;"&gt;
                        &lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                        &lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Level
                          2 Inputs &#x2013; Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in
                          active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities,
                          prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/div&gt;
                      &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 18pt;"&gt;
                        &lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                        &lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Level
                          3 Inputs &#x2013; Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.&lt;/div&gt;
                      &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
        &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;T&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;here were no liabilities measured at fair value as of Decem&lt;/span&gt;ber 31, 2021.
                The following tables summarize the liabilities that are measured at fair value as of September 30, 2022 (in thousands)&lt;/span&gt;:&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of September 30,
                      2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Description&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Liabilities:&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrant liabilities - Common Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;  &lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;On
          March 9, 2022, the Company issued pre-funded warrants exercisable for approximately 68,000 shares of common stock (the &#x201c;Pre-Funded
          Warrants&#x201d;) and warrants exercisable for approximately 343,000 shares of common stock (the &#x201c;Common Warrants&#x201d;) to the PIPE Investor in
          connection with the PIPE Transaction (as each such term is defined in Note 12). On July 12, 2022, the PIPE Investor exercised its 68,000
          Pre-Funded Warrants at an exercise price of $0.10 per share for an aggregate exercise price of approximately $7,000 in cash. The Company issued 68,000
          shares of common stock to the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds. Following the exercise, no Pre-Funded
          Warrants remained outstanding. See Note 12 for more information related to the PIPE Transaction.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC
              815-40,&#160;Derivatives and Hedging, Contracts in Entity&#x2019;s Own Equity&#160;(&#x201c;ASC 815-40&#x201d;), as these warrants provide for a cashless settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40.&#160; These warrant
              liabilities were measured at fair value at inception and are then subsequently measured on a recurring basis, with changes in fair value presented within the Company&#x2019;s statements of operations.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common
              Warrants, which is considered a Level 3 fair value measurement.&#160; Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the Company&#x2019;s control.&#160; A significant change in
              one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company&#x2019;s warrant liabilities, which could also result in material non-cash gains or losses being reported in the
              Company&#x2019;s consolidated statement of operations.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The estimated fair value of the Pre-Funded Warrants was deemed a Level 2 measurement as all significant inputs to the valuation model used to estimate the fair value of the Pre-Funded Warrants were directly
                  observable from the Company&#x2019;s publicly-traded common stock. Upon exercise of the Pre-Funded Warrants on July 12, 2022, the Company reclassified the fair value of the Pre-Funded Warrants&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; to equity&lt;/span&gt; as of such date.&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $12.6 million in the aggregate, which was $0.6 million more
            than the $12.0 million proceeds received in the PIPE Transaction.&#160; The excess $0.6 million represents an inducement to the purchaser to enter into the PIPE Transaction and was recorded in warrant liabilities expense in the accompanying consolidated
            statement of operations.&#160; Given the Company&#x2019;s capital requirements and market conditions, the Company consummated this financing on market terms available at the time of the transaction. &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company remeasured the fair value of the Common Warrants as of September 30, 2022. The following table presents the changes in the warrant
            liabilities from the issuance date (in thousands): &lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Pre-Funded &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Warrants&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; (Level 2)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; Common Warrants&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;(Level 3)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;Total Warrant&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value at January 1, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value at March 9, 2022 (issuance date)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,646&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,943&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;12,589&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in fair value of warrant liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(1,779&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(9,310&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(11,089&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;Exercise of pre-funded warrants&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(867&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(867&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value at September 30, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_4d476c48d31d495f848d9bf273e04d58">
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
        &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;T&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;here were no liabilities measured at fair value as of Decem&lt;/span&gt;ber 31, 2021.
                The following tables summarize the liabilities that are measured at fair value as of September 30, 2022 (in thousands)&lt;/span&gt;:&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of September 30,
                      2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Description&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Liabilities:&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrant liabilities - Common Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231"
      decimals="0"
      id="Fact_be73ba9fe1ef4009b8922f2e798b4c8a"
      unitRef="U002">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember"
      decimals="-3"
      id="Fact_d1a523ec4a4e482ba0195400255fd3b9"
      unitRef="U002">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember"
      decimals="-3"
      id="Fact_8dc070b8189c44e790209fe7de6f8987"
      unitRef="U002">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember"
      decimals="-3"
      id="Fact_6465159755f94fbbb2f941689a53515b"
      unitRef="U002">633000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact_7b60d649e06143abbb254b9a56b428d7"
      unitRef="U002">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact_9c2dff582b314261a508b2761ef72bb1"
      unitRef="U002">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20220930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_04bd0d10e6fb485ea572fbc9394ed578"
      unitRef="U002">633000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220309_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="0"
      id="Fact_7febd74da57d41e88e430b64cee83bb1"
      unitRef="U001">68000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220309_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      decimals="0"
      id="Fact_14c68fcd29a4420ebc7c89a5c2459458"
      unitRef="U001">343000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <erna:ClassOfWarrantOrRightExercised
      contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_bc5d557a32e2411092e001a56283a7ad"
      unitRef="U001">68000</erna:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="2"
      id="Fact_9b5b993e313e430da3692628ef65bf43"
      unitRef="U003">0.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-3"
      id="Fact_2a72c58017d54564a8e2df846aa8f6f9"
      unitRef="U002">7000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220714_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_e169b551d58d48d1953972ef4aacf72e"
      unitRef="U001">68000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="INF"
      id="Fact_9ecaf7255e1e48c49281bfb2117198de"
      unitRef="U001">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="c20220101to20220930"
      decimals="-5"
      id="Fact_d22c0402d7b745a4a8919b05cf5ee11a"
      unitRef="U002">12600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <erna:OverSubscriptionAmountReceived
      contextRef="c20220930"
      decimals="-5"
      id="Fact_8fb0ab5891924572a86da5b8218008fd"
      unitRef="U002">600000</erna:OverSubscriptionAmountReceived>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="c20220930"
      decimals="-5"
      id="Fact_79c91c8bd9b844a0be69a016a037fd21"
      unitRef="U002">12000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <erna:OverSubscriptionAmountReceived
      contextRef="c20220930"
      decimals="-5"
      id="Fact_c7da8a8adf694f20a2c8008740fd3f97"
      unitRef="U002">600000</erna:OverSubscriptionAmountReceived>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_55fe4c73466947d584f99fad7ef80692">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company remeasured the fair value of the Common Warrants as of September 30, 2022. The following table presents the changes in the warrant
            liabilities from the issuance date (in thousands): &lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Pre-Funded &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Warrants&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; (Level 2)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; Common Warrants&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;(Level 3)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;Total Warrant&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value at January 1, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value at March 9, 2022 (issuance date)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,646&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,943&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;12,589&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in fair value of warrant liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(1,779&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(9,310&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(11,089&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;Exercise of pre-funded warrants&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(867&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(867&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value at September 30, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;633&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;
</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20211231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact_30b638baa60d43d79b2af54cce00f786"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20211231_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_f418af7b0e2b4fc9973f4e0f6b4a4c68"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_404d563b3b2a4c1da82a610120608e6f"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact_ec2633eb628f4633b8cc9f6a5b1dac73"
      unitRef="U002">2646000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_94561e180bf04fd1939eb47c70e2dc11"
      unitRef="U002">9943000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_53040150b278457fb7bf494e3680fa29"
      unitRef="U002">12589000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact_abe8c62a25734b91a388d8fbaa2f247f"
      unitRef="U002">-1779000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_7d17e02c193e435d9c18950f155c6110"
      unitRef="U002">-9310000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_78e212dc44e14c6ca0f49ac85beb8a6e"
      unitRef="U002">-11089000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact_de5e5a43efcb42d4b67c57998b562d5a"
      unitRef="U002">867000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_7e4afd05ae75432693a06064548a421f"
      unitRef="U002">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_447738d40cb64d72a27a7cee33ce652b"
      unitRef="U002">867000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20220930_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact_5e58f01f1ac4426c865aae1afbddfa13"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact_6662b61d084f464ab24fc829e86c5dcf"
      unitRef="U002">633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20220930"
      decimals="-3"
      id="Fact_de0dfd48bff2411abb177b215eaa2ca5"
      unitRef="U002">633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <erna:LesseeOperatingAndFinanceLeasesTextBlock
      contextRef="c20220101to20220930"
      id="Text_841b46bb9bed4714a4243e1b8297e997">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;5)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;LEASES&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt; &lt;span style="font-style: italic; font-weight: bold;"&gt;Operating Leases&lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company has operating leases for office and laboratory space in the borough of Manhattan in New York, New York and in Cambridge, Massachusetts, which expire in 2026 and 2028, respectively. On March 31, 2022, the
            Company entered into a facility lease in San Diego, California (the &#x201c;San Diego Lease&#x201d;) with Torrey Pines Science Center Limited Partnership for approximately 5,200 square feet of laboratory and office space. The term of the San Diego Lease is 62 months and
            the lease commencement date was April 19, 2022. The San Diego Lease will expire in June 2027. See Note 15 for information regarding an additional lease the Company entered into in October 2022.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Base rent for the San Diego Lease is $6.35
          per square foot in the first year of the San Diego Lease, with a rent abatement for the second and third full months of the first year. The base rent will increase by approximately 3% on each anniversary of the lease commencement date. The Company is also required to pay its share of operating expenses and property taxes. The San Diego Lease provides for a one-time
          option to extend the lease term for an additional five years at the then fair rental value. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company recorded a $1.7 million right-of-use (&#x201c;ROU&#x201d;) asset and $1.7 million lease liabilities
            for the San Diego Lease.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the second quarter of 2022, the Company decided to
            consolidate its research and development efforts in Cambridge, Massachusetts, and the Company intends to sublease the San Diego laboratory and office space.&#160; As a result, the Company recognized an impairment charge of approximately $0.8 million on the San Diego Lease ROU asset &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;during the nine months ended September 30, 2022, which is recorded in general and administrative expense on the condensed
            consolidated statements of operations. There was no impairment charge recognized for the three months ended September 30, 2022.&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;On March 5, 2022, the Company entered into an Agreement to Assign Space Lease with Regen Lab USA LLC (&#x201c;Regen&#x201d;) pursuant to which the Company
          agreed to assign its Brooklyn, New York lease (the &#x201c;Brooklyn Lease&#x201d;) to Regen. The effective date of the assignment was contingent upon, among other things, a consent from BioBat, Inc. (the &#x201c;Landlord&#x201d;). Additionally, Regen agreed to purchase
          certain equipment from the Company for $50,000, partly reimburse the Company $50,000 toward certain existing unamortized leasehold improvements, and to reimburse the Company for the existing security deposit the Company had under the Brooklyn Lease of approximately
          $63,000.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;O&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;n March 25, 2022, the Company entered into an Assignment and Assumption of Lease Agreement (the &#x201c;Assignment Agreement&#x201d;) with Regen,
                which included the Landlord&#x2019;s consent to the assignment. The effective date of the assignment was March 28, 2022.&#160; Under the Assignment Agreement, Regen (i) accepted the assignment of the Brooklyn Lease; (ii) assumed all of the obligations,
                liabilities, covenants and conditions of the Company&#x2019;s as tenant under the Brooklyn Lease; (iii) assumed and agreed to perform and observe all of the obligations, terms, requirements, covenants and conditions to be performed or observed by
                the Company under the Brooklyn Lease; and (iv) made all of the representations and warranties under the Brooklyn Lease with the same force and effect as if Regen had executed the Brooklyn Lease originally as the tenant.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;N&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;otwithstanding Regen&#x2019;s assumption of the Brooklyn Lease, the Company remains liable and responsible for the due keeping, and full
                performance and observance, of all the provisions of the Brooklyn Lease applicable to the tenant thereunder.&#160;&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As a result of the Assignment Agreement, the Company wrote off the remaining ROU asset balance and the corresponding lease liability&lt;/span&gt;.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company accounts for leases under ASC 842,&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: normal;"&gt;&#160;Leases&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;. Operating leases are included in
          &#x201c;Right-of use assets - operating leases&#x201d; within the Company&#x2019;s balance sheets and represent the Company&#x2019;s right to use an underlying asset for the lease term. The Company&#x2019;s related obligation to make lease payments are included in &#x201c;Operating lease
          liabilities, non-current&#x201d; and &#x201c;Operating lease liabilities, current&#x201d; within the Company&#x2019;s balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Because the
          rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. Lease expense for lease
          payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet and are recognized as lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as
        payments for insurance, tax payments and other miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are
        expensed when the obligation for those payments is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2022 and 2021, the net operating lease expenses were as follows (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Three months ended September 30,&lt;/span&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;/span&gt; &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Operating lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;143&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;187&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Sublease income&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(21&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(21&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Variable lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;60&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;6&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Total lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;182&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;172&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Operating lease expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;476&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;501&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Sublease income&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;(63&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;(62&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Variable lease expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;113&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;16&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Total lease expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;526&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;455&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The tables below show the beginning
          balances of the operating ROU assets and lease liabilities as of January 1, 2022 and the ending balances as of September, 2022, including the changes during the period (in thousands).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt; &lt;/span&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating Lease&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ROU Assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease ROU assets at
                January 1, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,567&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Initial measurement of operating lease ROU assets&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,706&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Amortization of operating lease
                ROU assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(267&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Impairment of ROU assets&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(772&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Remeasurement of ROU asset&lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Write off of ROU asset due to lease termination&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(1,372&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease ROU assets at
                September 30, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,912&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-indent: 0px; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt; &lt;span style="font-weight: bold;"&gt; &lt;/span&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating Lease&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease liabilities at
                January 1, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,723&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Initial measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,706&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Principal payments on operating
                lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(223&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Write off of operating lease liability due to lease termination&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(1,453&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease liabilities at
                September 30, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,752&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Less non-current portion&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,317&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Current portion at September 30,
                2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;436&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;As of September 30, 2022, the Company&#x2019;s operating leases had a weighted-average
        remaining life of 4.9 years with a weighted-average discount rate of 8.97%.&#160; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; font-variant: normal;"&gt;The maturities of the operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of &lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;September 30,&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;166&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;673&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;688&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;703&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;708&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Thereafter&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;470&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Total payments&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,408&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;Less imputed interest&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(656&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Total operating lease liabilities&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,752&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</erna:LesseeOperatingAndFinanceLeasesTextBlock>
    <erna:OperatingLeaseArea
      contextRef="c20220930"
      decimals="0"
      id="Fact_cc221559d9394aee8dc245cbcc43e53c"
      unitRef="U005">5200</erna:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20220930"
      id="Fact_1c504f90a1ca4d46b648063076c9f9a1">P62M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <erna:BaseRentPerSquareFoot
      contextRef="c20220101to20220930"
      decimals="2"
      id="Fact_2383c150bf3e4a74b3075e653085441d"
      unitRef="U005">6.35</erna:BaseRentPerSquareFoot>
    <erna:PercentageBaseRentIncreaseOnEachAnniversary
      contextRef="c20220930"
      decimals="2"
      id="Fact_f0d8f2a36a8546c2a81042c0ec6b7615"
      unitRef="U004">0.03</erna:PercentageBaseRentIncreaseOnEachAnniversary>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20220930"
      id="Fact_6adf8f8a631f400d97ff793609aa0a5b">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <erna:InitialMeasurementOfOperatingLeaseROUAssets
      contextRef="c20220101to20220930"
      decimals="-5"
      id="Fact_45a6e57c4e64417abce233ad33368250"
      unitRef="U002">1700000</erna:InitialMeasurementOfOperatingLeaseROUAssets>
    <erna:InitialMeasurementOfOperatingLeaseLiabilities
      contextRef="c20220101to20220930"
      decimals="-5"
      id="Fact_d486aeff4a4e4740a68cefaf1d64cddd"
      unitRef="U002">1700000</erna:InitialMeasurementOfOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20220101to20220930"
      decimals="-5"
      id="Fact_12b268002bcc457cbe993ceb8d82dfcd"
      unitRef="U002">800000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20220701to20220930"
      decimals="-6"
      id="Fact_387bdeb3c4564fd58a8e657cc515ce28"
      unitRef="U002">-0</us-gaap:OperatingLeaseImpairmentLoss>
    <erna:LesseeCommitmentToPurchaseProperty
      contextRef="c20220305"
      decimals="0"
      id="Fact_ae3fce1988b6424f8c997a6220ce8ab8"
      unitRef="U002">50000</erna:LesseeCommitmentToPurchaseProperty>
    <erna:UnamortizedLeaseholdImprovements
      contextRef="c20220305"
      decimals="0"
      id="Fact_ada214d8ff1a48718efa2b514b5fcad7"
      unitRef="U002">50000</erna:UnamortizedLeaseholdImprovements>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="c20220305"
      decimals="0"
      id="Fact_71f7ff82f6d84c718d162cc3a6abd2dd"
      unitRef="U002">63000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_61c9f6b734834163875eb001b9438a4f">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2022 and 2021, the net operating lease expenses were as follows (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Three months ended September 30,&lt;/span&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;/span&gt; &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Operating lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;143&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;187&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Sublease income&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(21&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(21&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Variable lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;60&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;6&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Total lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;182&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;172&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Operating lease expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;476&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;501&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Sublease income&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;(63&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;(62&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Variable lease expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;113&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;16&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Total lease expense&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;526&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;455&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_f714280b44904704b7f470fdfb458aca"
      unitRef="U002">143000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_59ab5ebce2b44c799ad40e2efa2286c2"
      unitRef="U002">187000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_71fb24faa1a44db28d702768bff804e9"
      unitRef="U002">21000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_476656a0b6014c77b747b5dc8c54cd28"
      unitRef="U002">21000</us-gaap:SubleaseIncome>
    <us-gaap:VariableLeaseCost
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_8220a5079b844a8790df2dd75f4c7ea0"
      unitRef="U002">60000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_c7e6c3e8ea52415f866656fab0d54275"
      unitRef="U002">6000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_2186821e7d1f4a86b91ab9aec9b77b14"
      unitRef="U002">182000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_94ae51b470784d49b340c8f287fbf35b"
      unitRef="U002">172000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_1675da0fd8534879b85cbaa44393175d"
      unitRef="U002">476000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_e8744662352648bda34f17cb13832299"
      unitRef="U002">501000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_3230628a26cc4601bac365b26e5f782c"
      unitRef="U002">63000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_4281c7ad20cf47cdae4155eedab0e216"
      unitRef="U002">62000</us-gaap:SubleaseIncome>
    <us-gaap:VariableLeaseCost
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_0d0bf91fc5ba456d96f26eb4c39cc647"
      unitRef="U002">113000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_30953eecbb0342868deca75ee3950b2b"
      unitRef="U002">16000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_240181d4d9ad443d87844394cc362625"
      unitRef="U002">526000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_b98ef3b955034ecea3679b13afa71434"
      unitRef="U002">455000</us-gaap:LeaseCost>
    <erna:OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_0117423f6c5d4e8889085a4954592f89">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The tables below show the beginning
          balances of the operating ROU assets and lease liabilities as of January 1, 2022 and the ending balances as of September, 2022, including the changes during the period (in thousands).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt; &lt;/span&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating Lease&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ROU Assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease ROU assets at
                January 1, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,567&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Initial measurement of operating lease ROU assets&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,706&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Amortization of operating lease
                ROU assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(267&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Impairment of ROU assets&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(772&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Remeasurement of ROU asset&lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Write off of ROU asset due to lease termination&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(1,372&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease ROU assets at
                September 30, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,912&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-indent: 0px; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt; &lt;span style="font-weight: bold;"&gt; &lt;/span&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating Lease&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease liabilities at
                January 1, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,723&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Initial measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,706&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Principal payments on operating
                lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(223&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: -9.6px; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Write off of operating lease liability due to lease termination&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(1,453&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Operating lease liabilities at
                September 30, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,752&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Less non-current portion&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,317&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Current portion at September 30,
                2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;436&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</erna:OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20211231"
      decimals="-3"
      id="Fact_6f5b31eacfde450ba3ad63a35c3c9b67"
      unitRef="U002">2567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <erna:InitialMeasurementOfOperatingLeaseROUAssets
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_9c6d01a41f914d1884150a31e619a3a8"
      unitRef="U002">1706000</erna:InitialMeasurementOfOperatingLeaseROUAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_c92d138208584f03b3c3efa9bda66763"
      unitRef="U002">267000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_7e62267a9ba7400ba8fcf37f0bfed752"
      unitRef="U002">772000</us-gaap:OperatingLeaseImpairmentLoss>
    <erna:RemeasurementOfOperatingLeaseRightOfUseAsset
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_f552f885b9fd45b49bce7b44e59549f1"
      unitRef="U002">50000</erna:RemeasurementOfOperatingLeaseRightOfUseAsset>
    <erna:WriteOffOfOperatingLeaseRightOfUseAsset
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_bf8cc10dfbcc4c8398f529c5a6d83329"
      unitRef="U002">1372000</erna:WriteOffOfOperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20220930"
      decimals="-3"
      id="Fact_fe2834e7ffe54a0dbf8e59e90e4cb210"
      unitRef="U002">1912000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d2531558136b45ff9934795c981343ae"
      unitRef="U002">2723000</us-gaap:OperatingLeaseLiability>
    <erna:InitialMeasurementOfOperatingLeaseLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_5365a408e9d34f07925f723025617296"
      unitRef="U002">1706000</erna:InitialMeasurementOfOperatingLeaseLiabilities>
    <erna:PrincipalPaymentsOnOperatingLeaseLiabilities
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_f51173cd0c0344f2b641d134eefa50cf"
      unitRef="U002">223000</erna:PrincipalPaymentsOnOperatingLeaseLiabilities>
    <erna:WriteOffOfOperatingLeaseLiability
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_50939fb666e546af8c308f21fd03d55f"
      unitRef="U002">1453000</erna:WriteOffOfOperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20220930"
      decimals="-3"
      id="Fact_36bbdf685c2b46c29db293eab4e6e9e0"
      unitRef="U002">2752000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_f6cd93ed80b24f31b20d838b3269814c"
      unitRef="U002">2317000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_377d0ad909d54d5390510c06beefc8d0"
      unitRef="U002">436000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20220930"
      id="Fact_53f1f92662cb4919a08b7a6db4c8de53">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20220930"
      decimals="4"
      id="Fact_c1b072234c6c42c9bef4ea6992fb4321"
      unitRef="U004">0.0897</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_e2b159b4095a42d88f56aa812e76c0ed">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; font-variant: normal;"&gt;The maturities of the operating lease liabilities are as follows (in thousands):&lt;/span&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of &lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;September 30,&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;166&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;673&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;688&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;703&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;708&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Thereafter&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;470&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Total payments&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,408&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;Less imputed interest&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(656&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Total operating lease liabilities&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,752&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20220930"
      decimals="-3"
      id="Fact_4f649176fde24c4191ea8d77cf4603f0"
      unitRef="U002">166000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20220930"
      decimals="-3"
      id="Fact_c230693a7dec454e87cd3c8816446b8f"
      unitRef="U002">673000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20220930"
      decimals="-3"
      id="Fact_3e0000f665374646a40ad4a119f3e568"
      unitRef="U002">688000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20220930"
      decimals="-3"
      id="Fact_27d67a99fccd4b9eb0af560af710101b"
      unitRef="U002">703000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20220930"
      decimals="-3"
      id="Fact_6b9ec79b6ad34c079beb422dff1ef3b1"
      unitRef="U002">708000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <erna:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="c20220930"
      decimals="-3"
      id="Fact_2bcfceb944ae4fd691a94b23ad03427c"
      unitRef="U002">470000</erna:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20220930"
      decimals="-3"
      id="Fact_915ec453bc30406aba50958ea851af6b"
      unitRef="U002">3408000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20220930"
      decimals="-3"
      id="Fact_8e9b0d0a8797415c8ad5fc16174b45a1"
      unitRef="U002">656000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20220930"
      decimals="-3"
      id="Fact_72f45571f3204930a9680f7f13856fec"
      unitRef="U002">2752000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="c20220101to20220930"
      id="Text_5afc5ac629e546bdb31169d1b63098b8">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;IN-PROCESS RESEARCH &amp;amp; DEVELOPMENT AND GOODWILL&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In 2018, the Company acquired IRX Therapeutics (&#x201c;IRX&#x201d;), which was accounted for as a business combination. The Company recorded IPR&amp;amp;D in the
          amount of $6.0 million, which represented the fair value assigned to technologies that were acquired in connection with the IRX
          acquisition and which have not reached technological feasibility and have no alternative future use. IPR&amp;amp;D assets acquired in a business combination are considered to be indefinite lived until the completion or abandonment of the associated
          research and development projects. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;amp;D assets, these assets are then deemed
          definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;amp;D assets,
          calculated as the excess of carrying value of the IPR&amp;amp;D assets over fair value.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company also recorded goodwill in the amount of $2.0
          million related to the IRX acquisition. Goodwill and indefinite-lived IPR&amp;amp;D assets are not amortized but are tested for impairment annually, or more frequently if the Company becomes aware of any events occurring or changes in circumstances
          that indicate that the fair value of the entity is less than its carrying values.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In June 2022, the Company received results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III or IVA squamous cell carcinoma of the oral
            cavity. The IRX-2 multi-cytokine biologic immunotherapy represents substantially all the fair value assigned to the technologies of IRX that the Company acquired. Despite outcomes that favored IRX-2 in certain predefined subgroups, the INSPIRE
            trial did not meet the primary endpoint of Event-Free Survival (at two years of follow up). Significant additional clinical development work would be required to advance IRX-2 in the form of additional Phase 2 and 3 studies to further evaluate
            the treatment effect of IRX-2 in patient subgroups and in combination with checkpoint inhibitor therapies. The INSPIRE trial was the only Company-sponsored study of IRX-2. IRX-2 has been studied externally in other clinical settings outside of
            head and neck cancer in the form of investigator sponsored trials, which have either ended or are not currently active. Based on the totality of available information, the Company currently does not have plans to further develop the IRX-2
            product candidate. As such, the Company determined that the carrying value of the IPR&amp;amp;D asset was impaired and recognized a non-cash impairment charge of approximately $6.0 million on the condensed consolidated statement of operations during the second quarter of 2022, which reduced the value of the asset to zero.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of September 30, 2022, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair value of
          the entity is less than its carrying value of goodwill. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events. As a result of the
          decline in the Company&#x2019;s stock price from $10.40 per share as of June 30, 2022 to $4.94 per share as of September 30, 2022, the Company determined that there were indications of impairment. Accordingly, the Company proceeded to the first step in the
          quantitative assessment of impairment and determined that the fair value of the reporting unit exceeded the carrying amount of goodwill, and therefore, the goodwill was not impaired as of September 30, 2022. &lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20181231"
      decimals="-5"
      id="Fact_75e4b0fbb28e4c5cad098fd10b88c43d"
      unitRef="U002">6000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="c20220930"
      decimals="-5"
      id="Fact_1f05ffc379ed4ab4ae7bd984e3b41434"
      unitRef="U002">2000000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfOngoingProject
      contextRef="c20220401to20220630"
      decimals="-5"
      id="Fact_7f19dda955bd4e8981dd158780bfa56b"
      unitRef="U002">6000000</us-gaap:ImpairmentOfOngoingProject>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20220630"
      decimals="-3"
      id="Fact_7c4c9dac745d44c7a2e8ffb2e6141058"
      unitRef="U002">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:SharePrice
      contextRef="c20220630"
      decimals="2"
      id="Fact_e92534bee4f0498485817d6ece09b9a4"
      unitRef="U003">10.4</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20220930"
      decimals="2"
      id="Fact_2672ebdc756e448bbba54843db8f0278"
      unitRef="U003">4.94</us-gaap:SharePrice>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_e0e40dceb9d6474dbe028c8d3891b9f3"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <erna:ChiefExecutiveOfficerSeparationAgreementTextBlock
      contextRef="c20220101to20220930"
      id="Text_6ceabdf972514268a0aae5473fc3ec3b">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                  &lt;div style="font-weight: bold;"&gt;7)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;div style="font-weight: bold;"&gt;CEO SEPARATION AGREEMENT&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;On May 24, 2022, Dr. Howard J. Federoff resigned as the Company&#x2019;s Chief Executive
        Officer and President effective May 26, 2022. In connection with Dr. Federoff&#x2019;s resignation, the Company entered into a&#160;&lt;span style="color: rgb(0, 0, 0);"&gt;Separation Agreement and General Release with Dr. Federoff (the &#x201c;Separation Agreement&#x201d;),
          pursuant to which Dr. Federoff resigned from his positions as Chief Executive Officer and as an officer, director and employee of the Company and all subsidiaries. Dr. Federoff&#x2019;s resignation from the Board was not due to any disagreement with the
          Company on any matter relating to the Company&#x2019;s operations, policies or practices. In consideration for Dr. Federoff&#x2019;s execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Dr. Federoff will
          receive following benefits under the Separation Agreement:&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;a lump sum cash severance benefit in the amount of $0.2 million, representing Dr. Federoff&#x2019;s
                target bonus for 2022;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;payment of Dr. Federoff&#x2019;s annual base salary for a period of twelve months after the expiration of the applicable revocation period (the &#x201c;Separation Period&#x201d;), for a total gross amount equal to $0.5 million;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;payment of Dr. Federoff&#x2019;s premiums for continued health benefits provided under COBRA for the Separation Period;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;full acceleration of the vesting of all outstanding options (with the exception of the Milestone Grant (as defined below) options) that would have vested during the Separation Period, and such options,
                together with outstanding options that vested prior to the separation date, representing collectively approximately 76,000
                shares of common stock, may be exercised for a period of thirty-six months after the separation date (see Note 11 for
                modification accounting impact);&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;acceleration and vesting of 25/36&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;th&lt;/sup&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#160;of the Milestone Grant options, representing collectively approximately 21,000 shares of
                    common stock, may be exercised for a period of thirty-six months after the separation date (see Note 11 for modification
                    accounting impact); and&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="DSPFListTable" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;a lump sum cash severance benefit in the amount of $0.1 million, representing the value Dr.
                Federoff would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period, assuming the performance metrics were waived and
                assuming a per share value of $16.20.&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The Separation Agreement also includes certain other customary representations,
        warranties and covenants of Dr. Federoff, and provides for reimbursement of certain expenses incurred by Dr Federoff. The Separation Agreement supersedes all other agreements or arrangements between Dr. Federoff and the Company regarding the
        subject matter of the agreement, including those with respect to severance payments and benefits.&lt;/div&gt;
</erna:ChiefExecutiveOfficerSeparationAgreementTextBlock>
    <us-gaap:PaymentsForPostemploymentBenefits
      contextRef="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact_5780bd48292d4ec98ecf15649e2160de"
      unitRef="U002">200000</us-gaap:PaymentsForPostemploymentBenefits>
    <erna:PaymentToOfficerBaseSalary
      contextRef="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact_3cc98728802448f1ac4f1d69c57baa3e"
      unitRef="U002">500000</erna:PaymentToOfficerBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_b1d534549dad4a8cae8d6bdc40180383"
      unitRef="U001">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      id="Fact_5e928d07e4ee449d95a4c5ac3948ed01">P36M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_9d63c2593c694653b99329dbbc954272"
      unitRef="U001">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20220524to20220524_AwardTypeAxis_MilestoneOptionsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      id="Fact_7a3b7e327ffc49b7832de9bf64040bf8">P36M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <erna:SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits
      contextRef="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact_98debbbbdec4438689b462743d9060e5"
      unitRef="U002">100000</erna:SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits>
    <us-gaap:SharePrice
      contextRef="c20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="2"
      id="Fact_2be37a5534644febb55222d8ee1be18c"
      unitRef="U003">16.2</us-gaap:SharePrice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20220101to20220930"
      id="Text_126d9fc4c1f1413b8e9ade1b48543c02">
&lt;div&gt;
      &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-weight: bold;"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;div&gt; &lt;br/&gt;
      &lt;/div&gt;

    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On September 9, 2022, the Company entered into
        a Master Services Agreement (the &#x201c;MSA&#x201d;) with Factor Bioscience Inc. (&#x201c;Factor&#x201d;), pursuan&lt;/span&gt;t to which Factor has agreed to provide services to the Company as agreed between the Company and Factor and as set forth in one or more work orders under
      the MSA, including the first work order included in the MSA. Under the first work order, Factor has agreed to provide the Company with mRNA cell engineering research support services, including access to certain facilities, equipment, materials and
      training, and the Company has agreed to pay Factor an initial fee of $5.0 million, payable in twelve equal monthly installments of approximately $0.4 million.
      Following the initial 12-month period, the Company has agreed to pay Factor a monthly fee of $0.4 million until such time as the first work
      order under the MSA is terminated. The Company paid a deposit of $0.4 million, which will be applied to the last month of the first work
      order.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The
      Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with 120
      days&#x2019; prior notice. Factor may terminate such work order only on and after the fourth anniversary of the date of the MSA, su&lt;span style="font-family: 'Times New Roman';"&gt;bject to providing the Company with 120 days&#x2019; prior notice. The MSA contains customary confidentiality provisions and representations and warranties of the parties, and the MSA may be terminated by ether party
        upon 30 days&#x2019; prior notice, subject to any superseding termination provisions contained in a particular work order.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;In connection with entering into the MSA, on September
          9, 2022, Factor&#x2019;s subsidiary, Factor Limited, entered into a waiver agreement (the &#x201c;Waiver Agreement&#x201d;) with Brooklyn LLC, pursuant to which Factor Limited agreed to waive payment of $3.5 million otherwise payable to it (the &#x201c;License Fee Obligation&#x201d;) in October 2022 by Brooklyn LLC under a license agreement by and among Factor Limited, Novellus Ltd., and
          Brooklyn LLC.&#160; See Note 10, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;License Agreements&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;, for more information on this
          agreement. &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Under the terms of the Waiver Agreement, the License Fee Obligation is waived conditionally on the Company paying Factor Inc. amounts due under the MSA.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As a
        result of entering into the Waiver Agreement and the MSA on September 9, 2022, the Company recognized $3.5 million in research and
        development expense, as the license does not have an alternative future use, and a corresponding liability.&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On
        September 1, 2022, Novellus and Eterna entered into a Second Amendment to the Limited Waiver and Assignment Agreement (the &#x201c;Waiver and Assignment Agreement&#x201d;) with Drs. Matthew Angel and Christopher Rohde (the &#x201c;Founders&#x201d;) whereby the Company has
        agreed to be responsible for all future, reasonable and substantiated legal fees, costs, settlements and judgments incurred by the Founders, the Company or Novellus for certain claims and actions and any pending or future litigation brought against
        the Founders, Novellus and/or the Company by or on behalf of the Westman and Sowydra legal matters described in Note 10 (the &#x201c;Covered Claims&#x201d;). The Founders will continue to be solely responsible for any payments made to satisfy a judgement or
        settlement of any pending or future wage act claims. Under the Waiver and Assignment Agreement, the Founders agreed that they are not entitled to, and waived any right to, indemnification or advancement of past, present or future legal fees, costs,
        judgments, settlement or other liabilities they may have been entitled to receive from the Company or Novellus in respect of the Covered Claims. The Company and the Founders will share in any recoveries up to the point at which the parties have
        been fully compensated for legal fees, costs and expenses incurred, with the Company retaining any excess recoveries. The Company has the sole authority to direct and control the prosecution, defense and settlement of the Covered Claims.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On Sept&lt;span style="font-size: 10pt;"&gt;ember
              6, 2022, the &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Company entered into an
              assignment and assumption of contracts agreement (the &#x201c;Assignment and Assumption Agreement&#x201d;) with Factor, pursuant to which the Company assumed certain contracts with third parties that Factor had previously entered into in anticipation of
              entering into a sublease for premises in Somerville, Massachusetts.&#160; In October 2022, the Company entered into a sublease for the premises (see Note 15).&#160; Under the Assignment and Assumption Agreement, the Company agreed to reimburse Factor
              for costs already incurred or paid by it under the assumed contracts in the amount of approximately $0.1 million, and the Company
              assumed the future obligations under these contracts, which relate to the design and build-out of the subleased space.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The
            MSA, any work orders under the MSA, the Waiver Agreement, the Waiver and Assignment Agreement, and the Assignment and Assumption Agreement have been deemed related party transactions, as the Company&#x2019;s Interim Chief Executive Officer, Dr.
            Matthew Angel, is also the Chairman and Chief Executive Officer of Factor and the Director of Factor Limited.&lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <erna:MasterServiceAgreementInitialFeesPayable
      contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="-5"
      id="Fact_6aa5d70eadda40eca74ba44c34eaa9e5"
      unitRef="U002">5000000</erna:MasterServiceAgreementInitialFeesPayable>
    <erna:NumberOfMonthlyInstallmentsForFeesPayable
      contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="INF"
      id="Fact_bb5cebeae4564b3ba4d998927aa212f9"
      unitRef="U007">12</erna:NumberOfMonthlyInstallmentsForFeesPayable>
    <erna:RelatedPartyTransactionPeriodicFeesPaymentAmount
      contextRef="c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="-5"
      id="Fact_856e99631b5b426aab5e698cea63598f"
      unitRef="U002">400000</erna:RelatedPartyTransactionPeriodicFeesPaymentAmount>
    <erna:MonthlyMasterServicesAgreementFeesPayable
      contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="-5"
      id="Fact_045710f0cba54dcf86d345dc8e96da35"
      unitRef="U002">400000</erna:MonthlyMasterServicesAgreementFeesPayable>
    <erna:DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder
      contextRef="c20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="-5"
      id="Fact_59cdd6b5c3674b14b4a8b4838a47e2e5"
      unitRef="U002">400000</erna:DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder>
    <erna:NoticePeriodForFirstTerminationOfContract
      contextRef="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      id="Fact_18e02f788240462ca19c51eded213b52">P120D</erna:NoticePeriodForFirstTerminationOfContract>
    <erna:NoticePeriodForFirstTerminationOfContract
      contextRef="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      id="Fact_20242649880d4586b48d2964110340f9">P120D</erna:NoticePeriodForFirstTerminationOfContract>
    <erna:NoticePeriodForSupersedingTerminationProvisions
      contextRef="c20220101to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      id="Fact_4ae61c4572b341828f8f0bcce26f5666">P30D</erna:NoticePeriodForSupersedingTerminationProvisions>
    <erna:AgreedWaivePayment
      contextRef="c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="-5"
      id="Fact_0e4081618fdc4266a0cf9c63f774074e"
      unitRef="U002">3500000</erna:AgreedWaivePayment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20220701to20220930_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember"
      decimals="-5"
      id="Fact_c14eb8eff7594d629fa09fce4722a351"
      unitRef="U002">3500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <erna:ReimburseCostsIncurredOrPaid
      contextRef="c20221001to20221031_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_42deb91aba4445b8a4b9c6bd11af6700"
      unitRef="U002">100000</erna:ReimburseCostsIncurredOrPaid>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20220101to20220930"
      id="Text_11b1ef32b2cd47caa90778a9d86a8757">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                  &lt;div style="text-align: left;"&gt;&lt;span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9)&lt;/span&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold;"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;September 30,&lt;/div&gt;
                &lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;December 31,&lt;br/&gt;
                &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2021&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued compensation &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,701&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;656&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued research and development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;373&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;222&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued general and administrative expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,156&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;371&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total accrued expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3,230&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,249&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other liabilities consisted of the following (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;
                  &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2021&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Current portion of License Fee Obligation&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,750&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Insurance policy premiums&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;898&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;247&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Total other current liabilities&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;2,648&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;247&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Long term portion of License Fee Obligation&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,642&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;48&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;48&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total other liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,690&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;48&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued compensation at September 30,
                2022 includes approximately $1.0 million of severance, of which, approximately $0.3 million relates to severance for Dr. Federoff pursuant to the Separation Agreement discussed above.&lt;/span&gt; &lt;/span&gt;Accrued general and administration expenses at
            September 30, 2022 includes $0.6 million for legal-related matters.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_be17dfdfa79a4b779d61a265c3966534">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-weight: bold; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;September 30,&lt;/div&gt;
                &lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2022&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;December 31,&lt;br/&gt;
                &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2021&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued compensation &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,701&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;656&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued research and development expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;373&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;222&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Accrued general and administrative expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,156&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;371&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total accrued expenses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3,230&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,249&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_8600be0b34324917b8291cab948fe82b"
      unitRef="U002">1701000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d52f04c30f5046118bee60c3fdec7bcf"
      unitRef="U002">656000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <erna:AccruedResearchAndDevelopmentExpenses
      contextRef="c20220930"
      decimals="-3"
      id="Fact_d63d0d3959774aa8b8e2496dd81676f2"
      unitRef="U002">373000</erna:AccruedResearchAndDevelopmentExpenses>
    <erna:AccruedResearchAndDevelopmentExpenses
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ac782b051bba45f1ab2385e0580919b7"
      unitRef="U002">222000</erna:AccruedResearchAndDevelopmentExpenses>
    <erna:AccruedGeneralAndAdministrativeExpenses
      contextRef="c20220930"
      decimals="-3"
      id="Fact_d51d691816c84167aae9b5de677f3d94"
      unitRef="U002">1156000</erna:AccruedGeneralAndAdministrativeExpenses>
    <erna:AccruedGeneralAndAdministrativeExpenses
      contextRef="c20211231"
      decimals="-3"
      id="Fact_851bed016c0a4fc7a88e95d567863357"
      unitRef="U002">371000</erna:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_0b4c6b0c0d2a4519beb8a038cc1b039f"
      unitRef="U002">3230000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_1c55af4a38a44652b7aeb6c87bac4965"
      unitRef="U002">1249000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_30b8ae52d9f0481d8d28fd2e9a1e050f">
&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other liabilities consisted of the following (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;
                  &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2021&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Current portion of License Fee Obligation&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,750&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Insurance policy premiums&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;898&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;247&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;Total other current liabilities&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;2,648&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;247&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Long term portion of License Fee Obligation&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,642&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;48&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;48&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total other liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,690&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;48&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:OtherLiabilitiesTableTextBlock>
    <erna:CurrentPortionOfLicenseFeeObligation
      contextRef="c20220930"
      decimals="-3"
      id="Fact_4fb7d48e140249f2b86f1a05cee7777e"
      unitRef="U002">1750000</erna:CurrentPortionOfLicenseFeeObligation>
    <erna:CurrentPortionOfLicenseFeeObligation
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ccb12af633074fa0b20fbd79584c8efb"
      unitRef="U002">0</erna:CurrentPortionOfLicenseFeeObligation>
    <erna:InsurancePolicyPremiums
      contextRef="c20220930"
      decimals="-3"
      id="Fact_1e77684dc27842b89c1638bb12a489c4"
      unitRef="U002">898000</erna:InsurancePolicyPremiums>
    <erna:InsurancePolicyPremiums
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0d1efd98f995482e84e4f76327a88381"
      unitRef="U002">247000</erna:InsurancePolicyPremiums>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_cba88dfea7ea402b82f20dc479313c81"
      unitRef="U002">2648000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_2405aff9adff498ba4c19ea652862b74"
      unitRef="U002">247000</us-gaap:OtherLiabilitiesCurrent>
    <erna:LongTermPortionOfLicenseFeeObligation
      contextRef="c20220930"
      decimals="-3"
      id="Fact_3f458e152a594affa7286afdffd1bfe2"
      unitRef="U002">1642000</erna:LongTermPortionOfLicenseFeeObligation>
    <erna:LongTermPortionOfLicenseFeeObligation
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f724f89a1c7f44ae99f5d2b6eadb6ce4"
      unitRef="U002">0</erna:LongTermPortionOfLicenseFeeObligation>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="c20220930"
      decimals="-3"
      id="Fact_b90f90e12386498a9773106cb4ead436"
      unitRef="U002">48000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_295d76a02a8e46cfbc8648ece8c9b434"
      unitRef="U002">48000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="c20220930"
      decimals="-3"
      id="Fact_ab026b9a99c24a4e820d9211c3f093d6"
      unitRef="U002">1690000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="c20211231"
      decimals="-3"
      id="Fact_9af810c7949c48a09b5ff66ca343d640"
      unitRef="U002">48000</us-gaap:OtherLiabilities>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20220930_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-5"
      id="Fact_d1957ab0e61e4eb6827cbcb9357198a8"
      unitRef="U002">1000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20220930_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact_d81f07e7ca80455ea1261c948a051898"
      unitRef="U002">300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20220930"
      decimals="-5"
      id="Fact_cf7d3c8f390e440989e6280c729ceca4"
      unitRef="U002">600000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20220101to20220930"
      id="Text_4cf1c0a45d11426480401321d6af121c">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;10)&lt;br/&gt;
              &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Legal Matters&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated
          with such actions are expensed as incurred. In addition, the Company assesses the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
          reasonably estimated.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dhesh Govender v. Brooklyn
              Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;On
            or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn LLC and certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh
            Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges that Brooklyn LLC and certain of its officers and directors (&#x201c;defendants&#x201d;) engaged in unlawful and discriminatory
            conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire
            him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell
            reprogramming technology to Brooklyn LLC, he was promised a $0.5 million salary and 7% of the equity of Brooklyn LLC. Based on these and other allegations, plaintiff seeks damages of not less than $10 million&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;. By Order dated November 10,&#160;2021, the Court granted defendants&#x2019; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn
              LLC.&#160; Govender thereafter filed his Statement of Claim (the &#x201c;Demand&#x201d;) with the American Arbitration Association (&#x201c;AAA&#x201d;), Case No. 01-21-0017-9417, on December 15,&#160;2021 against the same defendants, and served it on defendants&#x2019; counsel on
              February 3,&#160;2022. In his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender 7% of the equity of Brooklyn LLC and to employ Govender at a $0.5 million annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against Brooklyn LLC and Cherington based on the breach of these same promises and a
              claim for quantum meruit against the Brooklyn LLC. In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded $100 million and is seeking damages in an amount to be determined at the hearing. Defendants filed an answering statement to the Demand on February 28,&#160;2022 and the
              parties have selected a three&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-member arbitration panel. The date on which arbitration is
                scheduled to begin has not yet been set. Defendants intend to vigorously defend themselv&lt;/span&gt;es against these claims.&lt;/span&gt; At this stage in the litigation, the Company is not able to predict the probability of a favorable or unfavorable
            outcome. &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Emerald Private Equity Fund, LLC Matter&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#x201c;Emerald&#x201d;), a stockholder of Eterna, made a demand pursuant to 8
                          Del. C. 220 to inspect certain books and records of Eterna. The stated purpose of the demand was to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock
                          certificates, including investigating whether: (i) Eterna&#x2019;s stock certificates were issued in accordance with the Merger Agreement; (ii)&#160;certain restrictions on the sale of Eterna common stock following the Merger were proper and
                          applied without favor; (iii) anyone received priority in post-Merger issuances of Eterna&#x2019;s stock certificates that allowed them to benefit from an increase in the trading price of Eterna&#x2019;s common stock; and (iv) it&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; should pursue remedial
                            measures and/or report alleged misconduct to the SEC. Eterna responded to the demand letter and produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement
                            entered into among the parties, including certain additional stockholders who subsequently joined as parties to such agreement. In October 2021, Emerald requested that Eterna produce additional information related to the
                            authority, purpose and justification for the restriction imposed on the sale of Eterna common stock following the Merger and the timing of share delivery to Eterna stockholders, following which request Eterna agreed to produce
                            certain additional information and emails relating to these topics.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On March 30,&#160;2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and former directors of the
                              Company, and the Company&#x2019;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims for breach
                              of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty. Emerald&#x2019;s counsel expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor on
                              behalf of individual stockholders whom counsel represents in addition to Emerald (collectively, the &#x201c;Emerald Plaintiffs&#x201d;); and the Company engaged in such discussions in lieu of incurring the legal costs anticipated in respect
                              of litigating &lt;/span&gt;the Emerald Plaintiffs&#x2019; claims, all of which the Company disputes.&#160; Following such discussions, with no admission of wrongdoing, the Company and the Emerald Plaintiffs entered into a confidential
                            settlement agreement, pursuant to which the Company paid $1.2 million in full settlement of all of the Emerald
                            Plaintiffs&#x2019; purported claims, including a release by the Emerald Plaintiffs in favor of the Company in respect of any and all such claims&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;. &lt;/span&gt;&lt;br/&gt;
                            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949
                              (Middlesex County (Massachusetts) Superior Court)&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;On&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County
                              (Massachusetts) Superior Court against Novellus, Inc. and the company&#x2019;s founders and former executives, Dr. Christopher Rohde and Dr. Matthew Angel (collectively, &#x201c;Defendants&#x201d;). The case includes allegations that Novellus,
                              Inc. violated the Massachusetts Wage Act. Eterna acquired Novellus, Inc. on July 16,&#160;2021. Mr. Westman&#x2019;s claims relate to alleged conduct that took place before Eterna acquired Novellus, Inc. Defense and liability in
                              association with any Wage Act claims have been assumed by Dr. Rohde and Dr. Angel. On December 24,&#160;2021, Westman dismissed the case without prejudice so the parties could mediate the matter. The parties&#x2019; February 2022
                              mediation was unsuccessful and the dispute is currently pending in arbitration.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: italic;"&gt;&lt;br/&gt;
                            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-left: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;"&gt;Novellus, Inc&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;. &lt;span style="font-style: normal;"&gt;v. Sowyrda et al&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;"&gt;., C.A. No.
                                  2184CV02436-BLS2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: normal;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; background-color: rgb(255, 255, 255);"&gt;&lt;br/&gt;
                            &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);"&gt;On October 25, 2021 Novellus, Inc. filed a complaint in the Superior Court of Massachusetts,
                              Suffolk County, against former Novellus, Inc. employees Paul Sowyrda and John Westman and certain other former investors in Novellus LLC (Novellus, Inc.&#x2019;s former parent company prior to the Company&#x2019;s acquisition of Novellus,
                              Inc.), alleging breach of fiduciary duty, breach of contract and civil conspiracy. Eterna acquired Novellus, Inc. on July 16, 2021. On May 27, 2022 Novellus, Inc. amended the complaint to withdraw all claims against all
                              defendants except Paul Sowyrda and John Westman. On July 1, 2022, Westman filed a motion to compel arbitration or in the alternative, to stay the litigation pending the disposition of certain litigation in the Court of
                              Chancery for the State of Delaware filed by Mr. Sowyrda against Novellus LLC, Dr. Christopher Rohde, Dr. Matthew Angel, Leonard Mazur and Factor Bioscience, Inc. captioned&#160;&lt;span style="font-style: italic;"&gt;Zelickson et al., v.
                                Angel et al.,&lt;/span&gt;&#160;C.A. 2021-1014-JRS and by Westman against Novellus LLC captioned&#160;&lt;span style="font-style: italic;"&gt;Westman v. Novellus LLC&lt;/span&gt;, C.A. No. 2021-0882-NAC (the &#x201c;Delaware Actions&#x201d;). On July 1, 2022,
                              Sowyrda answered the complaint and asserted counterclaims against Novellus, Inc, and third-party defendants Dr. Matthew Angel and Dr. Christopher Rohde alleging violations of the Massachusetts Wage Act, Massachusetts Minimum
                              Fair Wage Law, the Fair Labor Standards Act, breach of contract, unjust enrichment and quantum meruit. Sowyrda also joined in Westman&#x2019;s motion to stay the case pending the Delaware Actions. Novellus, Inc.&#x2019;s claims and Mr.
                              Sowyrda&#x2019;s counterclaims relate to alleged conduct that took place before Eterna acquired Novellus, Inc. Defense and liability in association with any Wage Act claims have been assumed by Dr. Rohde and Dr. Angel. The Company
                              filed its opposition to Sowyrda and Westman&#x2019;s motions on August 19, 2022.&#160; On September 9, 2022, Westman and Sowyrda filed replies in support of their motions and requested to be heard.&#160; The hearing is scheduled for November
                              16, 2022.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255);"&gt; &lt;br/&gt;
                            &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under applicable Delaware law and Novellus Inc.&#x2019;s organizational documents, the Company may be required to advance or reimburse certain legal
                                expenses incurred by former officers and directors of Novellus, Inc. in connection with the foregoing Westman and Sowyrda matters. However, a future advance or reimbursement is not currently probable nor can it be reasonably
                                estimated.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Licensing Agreements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;USF&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Brooklyn LLC has license agreements with University of
                South Florida Research Association, Inc. (&#x201c;USF&#x201d;), granting Brooklyn LLC the right to sell, market, and distribute IRX-2, subject to a 7%
                royalty payable to USF based on a percentage of gross product sales. Under the license agreement with USF, Brooklyn LLC is obligated to repay patent prosecution expenses incurred by USF. To date, Brooklyn LLC has not recorded any product
                sales, or obligations related to USF patent prosecution expenses. The license agreement terminates upon the expiration of the IRX-2 patents.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Novellus Ltd. and Factor Limited&lt;/span&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;In December 2020, Brooklyn LLC entered into option agreements (the
                  &#x201c;Option Agreements&#x201d;) with Novellus Ltd. and Factor Limited (together, the &#x201c;Licensors&#x201d;) to obtain the right to exclusively license the Licensors&#x2019; intellectual property and mRNA cell reprogramming and gene editing technology for use in the
                  development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia (the &#x201c;Licensed Technology&#x201d;). The option was exercisable
                  before February 28, 2021 (or April 30, 2021 if the Merger had not closed by that date) and required Brooklyn LLC to pay a non-refundable option fee of $0.5 million and then an initial license fee of $4.0 million &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(including
                    the non-refundable fee of $0.5 million) in order to exercise the option.&lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;br/&gt;
                &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt; In April 2021, Brooklyn LLC and the Licensors amended the Option Agreements to extend the exercise period to May 21, 2021 and to require Brooklyn LLC to pay a total $1.0 million of the $4.0 million
                  initial license fees to the Licensors by April 15, 2021.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In
                    April 2021, Brooklyn LLC and the Licensors entered into an exclusive license agreement (the &#x201c;License Agreement&#x201d;) pursuant to which Brooklyn LLC acquired an exclusive worldwide license to the Licensed Technology &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for use in the development of certain mRNA,
                      gene-editing, and cellular therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia. &lt;/span&gt;Under the terms of the License Agreement, Brooklyn
                    LLC is obligated to pay the Licensors a total of $4.0 million in connection with the execution of the License Agreement, all
                    of which was paid as of June 2021.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As a result of the Novellus Acquisition, in accordance with the terms of the Novellus-Factor License Agreement, the rights and obligations of Novellus Ltd. thereunder pertaining to any and all licensed
                      products have inured to Eterna&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. The agreement with Factor Limited under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain
                        next-generation mRNA gene editing and cell therapy products, remained unchanged after the completion of the Novellus Acquisition. Accordingly, under the License Agreement,&lt;/span&gt; Brooklyn LLC remained obligated to pay to Factor
                      Limited a fee&lt;/span&gt; of $3.5 million in October 2022, which would have been in addition to a fee of $2.5 million paid to Factor Limited in October 2021. &lt;span style="letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In connection with the Company entering into the MSA (see Note 8), Factor Limited
                      entered into the Waiver Agreement with Brooklyn LLC, pursuant to which Factor Limited waived payment of the $3.5 million
                      otherwise payable to it in October 2022 by Brooklyn LLC&lt;/span&gt;.&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Brooklyn LLC is also
                    required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of
                    these milestones, Brooklyn LLC will be obligated to pay, in the case of development and regulatory milestones, milestone payments to the Licensors in specified amounts and, in the case of commercialization milestones, specified
                    royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely achieve certain delineated milestones, the Licensors will have the right to terminate Brooklyn
                    LLC&#x2019;s rights under provisions of the License Agreement relating to those milestones.&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;Novellus Ltd. also has a license agreement with Factor Limited, which was entered into in February 2015, amended in June
                    2018 and March 2020, and then amended and restated in November 2020 (the &#x201c;Novellus-Factor License Agreement&#x201d;).&#160; The Novellus-Factor License Agreement grants to Novellus Ltd. an exclusive license to use certain technology owned by Factor
                    Limited for the development of mesenchymal stem cell-based cellular therapies for treating diseases and conditions in humans and animals&#160; (the &#x201c;Novellus-Factor Licensed Technology&#x201d;). Under the License Agreement, Novellus Ltd. in turn
                    granted a sublicense to Brooklyn LLC to use the Novellus-Factor Licensed Technology to develop up to four mesenchymal stem cell-based therapy products for use in the treatment of cancer in humans.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;Under the Novellus-Factor License Agreement, Novellus Ltd. is required to use commercially reasonably efforts to achieve
                    certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. The Novellus-Factor License Agreement states that upon its achievement of these milestones,
                    Novellus Ltd. will be obligated to make milestone payments of up to $51.0 million in aggregate to Factor Limited as well as
                    specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus Ltd. fails to timely achieve certain delineated milestones under the Novellus-Factor License Agreement,
                    Factor Limited could seek to terminate the license granted thereunder. The Novellus-Factor License Agreement provides that in the event of termination of the Novellus-Factor License Agreement, if Novellus Ltd. requests that its
                    sublicense to Brooklyn LLC under the License Agreement survive such termination, such sublicense shall be considered a direct license from Factor Limited to Brooklyn LLC, provided that Brooklyn LLC agrees in writing that (i) Factor
                    Limited is entitled to enforce all relevant provisions directly against Brooklyn LLC, and (ii) Factor Limited shall not assume, and shall not be responsible to Brooklyn LLC for, any representations, warranties or obligations of Novellus
                    Ltd. to Brooklyn LLC, other than to permit Brooklyn LLC to exercise any rights to the technology sublicensed by Novellus Ltd. to Brooklyn LLC.&#160; Factor Limited also agreed under the License Agreement that upon the termination of the
                    Novellus-Factor License Agreement for any reason other than Brooklyn LLC&#x2019;s breach of the License Agreement, the rights and licenses granted to Brooklyn LLC by Novellus Ltd. under the License Agreement shall survive such termination of
                    the Novellus-Factor License Agreement, and Factor Limited grants to Brooklyn LLC such rights and licenses on the same terms and conditions as granted by Novellus Ltd. to Brooklyn LLC under the License Agreement.. Following the
                    expiration of one of the delineated milestone deadlines in the Novellus-Factor License Agreement without Novellus Ltd.&#x2019;s achievement of the required regulatory filing on November 1, 2022, Novellus Ltd., Brooklyn LLC and Factor began
                    discussions regarding an amendment to the terms of the License Agreement and the Novellus-Factor License Agreement in order for Brooklyn LLC, among other things, to directly license the Novellus-Factor Licensed Technology from Factor
                    and consolidate and amend the milestone, payment and other terms with respect thereto accordingly. There can be no assurance that such an amendment will be made on the forgoing terms, if at all.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;NoveCite&lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;In October 2020, Novellus Ltd. (as
                          sublicensor) and NoveCite (as sublicensee) entered into an exclusive license agreement (the &#x201c;Sublicense&#x201d;) to license novel cellular therapy for acute respiratory distress syndrome, which NoveCite is licensing from Factor Limited.
                          Under the sublicense agreement, NoveCite is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified
                          commercialization milestones. In general, upon its achievement of these milestones, NoveCite will be obligated, in the case of development and regulatory milestones, to make milestone payments to the Novellus Ltd. in specified
                          amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;Under the terms of the Sublicense, in the event
                          that Novellus Ltd. receives any revenue involving the original cell line included in the licensed technology, then Novellus Ltd. shall remit to NoveCite 50% of such revenue.&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Royalty Agreements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Collaborator Royalty Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Effective June 22, 2018, IRX terminated its Research,
        Development and Option Facilitation Agreement and its Options Agreement (the &#x201c;RDO and Options Agreements&#x201d;) with a collaborative partner (the &#x201c;Collaborator&#x201d;), pursuant to a termination agreement (the &#x201c;Termination Agreement&#x201d;). &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Termination Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. &lt;/span&gt;In connection
        with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and Brooklyn LLC has no obligation to refund any payments received from the Collaborator. As consideration for
        entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of revenues from the sale of IRX-2, for the
        period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2 or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Royalty Agreement with certain former IRX Therapeutics Investors&lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#x201c;IRX Investor Royalty Agreement&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201d;&lt;/span&gt;)
            with certain investors who participated in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. Pursuant to the IRX Investor Royalty Agreement,
            when Brooklyn LLC becomes obligated to pay royalties to USF under the agreement described above under &#x201c;Licensing Agreements-USF,&#x201d; it will pay an additional royalty of 1% of gross sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement.
            Brooklyn LLC has not recognized any revenues to date, and no royalties are due pursuant to any of the above-mentioned royalty agreements.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Investor Royalty Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; text-indent: 36pt;"&gt;On
          March 22, 2021, Brooklyn LLC restated its royalty agreement with certain beneficial holders of Brooklyn ImmunoTherapeutics Investors GP LLC and Brooklyn ImmunoTherapeutics Investors LP, whereby such beneficial holders will continue to receive, on
          an annual basis, royalties in an aggregate amount equal to 4% of the net revenues of IRX-2, a cytokine-based therapy being developed
          by Brooklyn LLC to treat patients with cancer.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <erna:LossContingencyDamagesSoughtExpectedSalary
      contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_58298f1de2174aadb40d035bfc5d0752"
      unitRef="U002">500000</erna:LossContingencyDamagesSoughtExpectedSalary>
    <erna:LossContingencyDamagesSoughtExpectedEquityPercentage
      contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_e6dbb22f5e284e7089a3e9efd5340fbf"
      unitRef="U004">0.07</erna:LossContingencyDamagesSoughtExpectedEquityPercentage>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="-6"
      id="Fact_ca3bdd3d9be145a6afa3d341ea9d4a3c"
      unitRef="U002">10000000</us-gaap:LossContingencyDamagesSoughtValue>
    <erna:LossContingencyDamagesSoughtExpectedEquityPercentage
      contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="2"
      id="Fact_d139082c72e446d58a6e9d5f7547a94b"
      unitRef="U004">0.07</erna:LossContingencyDamagesSoughtExpectedEquityPercentage>
    <erna:LossContingencyDamagesSoughtExpectedSalary
      contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="-5"
      id="Fact_159f31ab295142a1bbf479891465d28c"
      unitRef="U002">500000</erna:LossContingencyDamagesSoughtExpectedSalary>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="-6"
      id="Fact_4885b66ea7f340dea5bb2236bcb11e18"
      unitRef="U002">100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <erna:LossContingencyNumberOfArbitrationPanel
      contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="INF"
      id="Fact_db4620d03bad48f5b9928e22d089c5ab"
      unitRef="U006">3</erna:LossContingencyNumberOfArbitrationPanel>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="c20220805to20220805"
      decimals="-5"
      id="Fact_6ae75c5847d844c886f9d1cb29e2b7f4"
      unitRef="U002">1200000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <erna:LossContingencyPercentageOfRoyaltyPayable
      contextRef="c20220101to20220930_LegalEntityAxis_UniversityOfSouthFloridaMember"
      decimals="2"
      id="Fact_8ba6369ce1894a938b0e56cf736e306c"
      unitRef="U004">0.07</erna:LossContingencyPercentageOfRoyaltyPayable>
    <erna:LossContingencyNonRefundableOptionFee
      contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_758444352bf447668f3a45799d09a299"
      unitRef="U002">500000</erna:LossContingencyNonRefundableOptionFee>
    <erna:InitialLicenseFees
      contextRef="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_c07af1f7628249b89d6e43ab11ab4bf6"
      unitRef="U002">4000000</erna:InitialLicenseFees>
    <erna:LossContingencyNonRefundableOptionFee
      contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_a26b483077444e52b502d441089069ec"
      unitRef="U002">500000</erna:LossContingencyNonRefundableOptionFee>
    <erna:AdditionalFeesObligatedToPay
      contextRef="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_73ecc6e76d104d3baa995965247d5bfc"
      unitRef="U002">1000000</erna:AdditionalFeesObligatedToPay>
    <erna:InitialLicenseFees
      contextRef="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_82f85b7906d24235854a00cdecf418f6"
      unitRef="U002">4000000</erna:InitialLicenseFees>
    <erna:AmountRequireToPayInitialLicenseFees
      contextRef="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_86729254208342a3bdb207d4e169eee0"
      unitRef="U002">4000000</erna:AmountRequireToPayInitialLicenseFees>
    <erna:AmountObligatedToPayInYearTwo
      contextRef="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="-5"
      id="Fact_5efb266fc3434c0ea8afca2b191c2d9e"
      unitRef="U002">3500000</erna:AmountObligatedToPayInYearTwo>
    <erna:AmountObligatedToPayInYearOne
      contextRef="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="-5"
      id="Fact_f3929e51def348e6a0a34430e5b147d9"
      unitRef="U002">2500000</erna:AmountObligatedToPayInYearOne>
    <erna:AmountObligatedToPayInYearTwo
      contextRef="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="-5"
      id="Fact_af1cb3eab82d4fa7ac29f5e806dade4b"
      unitRef="U002">3500000</erna:AmountObligatedToPayInYearTwo>
    <erna:MilestonePayments
      contextRef="c20220101to20220930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="-5"
      id="Fact_9b45c1703837495f91b61de71698475e"
      unitRef="U002">51000000</erna:MilestonePayments>
    <erna:PercentageOfRevenue
      contextRef="c20220930_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember"
      decimals="2"
      id="Fact_9f3f2d598a1c42d6880fe638c03c7629"
      unitRef="U004">0.50</erna:PercentageOfRevenue>
    <erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness
      contextRef="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember"
      decimals="2"
      id="Fact_d90f37171e90443789a8853a44211323"
      unitRef="U004">0.06</erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness>
    <erna:PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales
      contextRef="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"
      decimals="2"
      id="Fact_c1789a9d9592455cad7c444a83394701"
      unitRef="U004">0.01</erna:PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales>
    <erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness
      contextRef="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"
      decimals="2"
      id="Fact_d9e55ff9304c42a0b33210bba28c0a44"
      unitRef="U004">0.04</erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20220101to20220930"
      id="Text_70a2bde5640b4c6fbfb4f07f8c2ae6f1">
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;
      &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;11)&lt;br/&gt;
              &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                &lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal; font-variant: normal; text-transform: none;"&gt;STOCK-BASED COMPENSATION&lt;/div&gt;
              &lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
    &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
     &lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2022 and 2021, the Company
        granted the following stock options (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Three months ended September 30,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Nine months ended September 30,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2022&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Stock options granted&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;188&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;12&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;287&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;180&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;The following weighted-average assumptions were used for stock options granted during the three and nine months ended
        September 30, 2022 and 2021:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;Three months ended September 30,&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2021&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;2.64%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0.97%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;89.80%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;143.29%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.73 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.08 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Nine months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2021&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;2.54%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;1.06%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;91.20%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;134.88%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.30 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.08 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the three and nine months ended September 30, 2022, options to purchase approximately 124,000 shares of common stock were granted to Dr. Matthew Angel, the Company&#x2019;s Interim Chief Executive Officer. Dr. Angel&#x2019;s stock options vest at rate of 1/24 on the grant
        date with the remaining options to vest in 46 substantially equal monthly installments thereafter. For the nine months ended September
        30, 2022,&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; stock options to
        purchase &lt;/span&gt;approximately 21,000 shares of common stock were granted to Dr. Howard J. Federoff, who served as the Company&#x2019;s Chief
      Executive Officer and President until May 26, 2022 (the &#x201c;March 2022 Stock Option Grant&#x201d;). The March 2022 Stock Option Grant vests in 36
      substantially equal monthly installments from the grant date and had an exercise price equal to the closing price of the Company&#x2019;s common stock on the grant date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the nine months ended September 30, 2021&lt;/span&gt;, options to purchase approximately 161,000 shares of common stock were granted to Dr. Federoff upon his appointment as Chief Executive Officer and President in April 2021. Approximately 131,000 stock options were under a time-based grant (the &#x201c;Time-Based Grant&#x201d;) and approximately 30,000 stock options were under a performance-based grant (the &#x201c;Milestone Grant&#x201d;). The Time-Based Grant vests over four years, with 25% vesting on the one-year anniversary of the grant date and
      the remaining options vesting in 36 substantially equal monthly installments thereafter. The Milestone Grant vests upon the first
      concurrence by the U.S. Food and Drug Administration that a proposed investigation may proceed following review of a Company filed investigational new drug application in connection with that the License Agreement. Both the Time-Based Grant and the
      Milestone Grant had an exercise price equal to the closing price of the Company&#x2019;s common stock on the grant date.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;Vesting of all stock options grants is subject to continuous service with the Company
      through such vesting dates.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;As discussed above, pursuant to the Separation Agreement with Dr. Federoff, the Company&#160;&lt;span style="color: rgb(0, 0, 0);"&gt;accelerated the vesting of approximately 7,000 stock options under the March 2022 Stock Option Grant and
        approximately 33,000 stock options under the Time-Based Grant. The Company also waived the performance condition under the Milestone
        Grant and accelerated the vesting of approximately 21,000 stock options under the Milestone Grant. Lastly, the Company extended the
        post-termination exercise period from 90 days to 36 months immediately following the Separation Date for all options that were vested after such accelerations.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;The above modifications to Dr. Federoff&#x2019;s stock options grants resulted in modification accounting under ASC 718,&#160;&lt;/span&gt;&lt;span style="font-style: italic; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Compensation &#x2013; Stock Compensation.&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;As a result, the Company immediately recognized approximately $0.1 million for the incremental fair value of stock options that were vested prior to the modification by calculating the difference&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;between the fair
        value of the modified award and the fair value of the original award immediately before it was modified. For stock options that were not vested prior to the modification but then vested as a result of the acceleration, the Company reversed any
        stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized approximately $0.1
        million of stock compensation expense in full since there was no future service period required to be provided.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2021, there were 65 options exercised for total cash proceeds of $10,202.
      The options exercised had a total intrinsic value of $57,212. There were no options exercised during the three and nine months ended September 30, 2022.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;As of September 30, 2022, there were approximately 362,000 stock options outstanding.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2022 and 2021, the Company granted
      the following restricted stock units (&#x201c;RSUs&#x201d;) (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Three months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Nine months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;RSUs Granted&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;6&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;55&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;11&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;The Company recognizes the fair value of RSUs granted as expense on
      a straight-line basis over the requisite service period. For performance based RSUs, the Company begins recognizing the expense once the achievement of the related performance goal is determined to be probable.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;Outstanding RSUs are settled in an equal number of shares of common
      stock on the vesting date of the award. An RSU award is settled only to the extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal
      number of shares of common stock without any offsetting payment by the recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;In lieu of paying cash to satisfy withholding taxes due upon the
      settlement of vested RSUs, at the Company&#x2019;s discretion, an employee may elect to have shares of common stock withheld that would otherwise be issued at settlement, the value of which is equal to the amount of withholding taxes payable. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The following table shows the number of RSUs that vested and were settled during the three and nine months ended
        September 30, 2022, as well as the number of shares of common stock withheld to cover the withholding taxes and the net shares issued upon settlement (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Three months ended&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Nine months ended&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;RSUs vested&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Common stock withheld to cover
              taxes&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Common stock issued&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;The 55,000 RSUs granted during the nine months ended September 30, 2022 are performance-based RSUs (the &#x201c;2022 PSUs&#x201d;), of which approximately 21,000 were awarded to Dr. Federoff. The 2022 PSUs are subject to the achievement of four
      performance goals, which are weighted equally. Once a performance goal is achieved, the tranche of shares allocated to that performance goal will be earned and will begin to vest over a three-year annual basis beginning on the date the performance goal was achieved. If a performance goal is not achieved, the tranche of shares allocated to that performance goal will be
      unearned and forfeited. As of September 30, 2022, two of the performance goals were not achieved by the due date, and as a result,
      approximately 28,000 2022 PSUs were cancelled and any previously recognized stock compensation expense was reversed.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;Pursuant to Dr. Federoff&#x2019;s Separation Agreement, Dr. Federoff&#x2019;s 21,000 2022 PSUs were canceled in full (a portion of which included the PSUs allocated to the performance goal that was not achieved timely), and&#160;&lt;span style="color: rgb(0, 0, 0);"&gt;a lump sum cash severance benefit in the amount of $0.1 million was paid to Dr. Federoff, which represents
        the value Dr. Federoff would have received if he were entitled to receive a settlement of a pro rata portion of his 2022 PSUs through the expiration of the Separation Period, assuming the performance metrics were waived and assuming a per share
        value of $16.20. Any stock compensation expense previously recognized on Dr. Federoff&#x2019;s 2022 PSUs was reversed and approximately $0.1 million was recognized as compensation expense.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;As of September 30, 2022, there were approximately 15,000 RSUs outstanding.&lt;br/&gt;
      &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;Pursuant to the Merger, Brooklyn LLC&#x2019;s approximately 3,000 outstanding restricted common units were exchanged for approximately 32,000 shares of Eterna&#x2019;s restricted common stock. There were no changes to any conditions and requirements of the restricted common stock. The shares vested quarterly beginning on March 31, 2021 and were to continue
      through December 31, 2022, contingent on continued service. Due to the modification of the restricted common units, the fair value of the restricted common stock immediately after the Merger was compared to the fair value of the restricted common
      units immediately prior to the Merger, and the change in fair value of $0.3 million was recognized in the statement of operations during
      the nine months ended September 30, 2021. The Company recognizes the fair value of restricted common stock as an expense on a straight-line basis over the requisite service period.&#160; During the nine months ended September 30, 2022, approximately 4,000 shares of unvested restricted common stock were forfeited due to the holders of such shares no longer providing services to the Company.&#160; As of
      September 30, 2022, there were no shares of unvested restricted stock outstanding.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;"&gt;Stock-Based Compensation Expense&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt; margin-right: 0.5pt;"&gt;For the three and nine months ended September 30, 2022 and 2021,
      the Company recognized stock-based compensation expense as follows, which includes the expense related to Dr. Federoff&#x2019;s modified awards discussed above (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Three months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Nine months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;Research and development&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;183&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;448&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,075&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,018&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;General and administrative&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;293&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,281&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,463&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;2,284&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;Total&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;476&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,729&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;2,538&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;3,302&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <erna:ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_a42af0f817d24c2ebcb0d6af991c7f03">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2022 and 2021, the Company
        granted the following stock options (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Three months ended September 30,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Nine months ended September 30,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2022&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;Stock options granted&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;188&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;12&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;287&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;180&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</erna:ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_2faa9d20d3b240cb8eef651f788d93b9"
      unitRef="U001">188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_41f54f55f77a4644a6404863740ca254"
      unitRef="U001">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_0939cda5a6ea4849bfe37cf51034ac9f"
      unitRef="U001">287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_da081a8a08b44025bfdee2ae9529ced2"
      unitRef="U001">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_5cceeba9c96e484bac4dec338d0cbe9f">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;The following weighted-average assumptions were used for stock options granted during the three and nine months ended
        September 30, 2022 and 2021:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;Three months ended September 30,&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2021&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;2.64%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0.97%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;89.80%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;143.29%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.73 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.08 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Nine months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2021&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average risk-free rate&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;2.54%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;1.06%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted average volatility&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;91.20%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;134.88%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: center; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: center;"&gt;0%&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.30 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.08 years&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_5976be41533b45e0b8a785027c669fa1"
      unitRef="U004">0.0264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_1dc20fc7f86c440783584acbefc37d1e"
      unitRef="U004">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_0608028ed20146c98fd90188e301487a"
      unitRef="U004">0.898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_3a09567b3b604a1786c13909dfb9acdf"
      unitRef="U004">1.4329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_bd778c51ee8d4b6fad1685cb264f5d14"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_c25598ded7f04fb5bb27dbf832774826"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_b7a907c88d1b4d09b17794399918e0fb">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_2392378adfec43b493a5d4d507ea2dd4">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_ee09fc8516b341fc9d7b0ba637560a46"
      unitRef="U004">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_fd2d84ad9dbf433984f2d8fb8e65414c"
      unitRef="U004">0.0106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_f2b7174f083548978784fd40a6e9a334"
      unitRef="U004">0.912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_4b46408ed58e464d8c63d3681527e543"
      unitRef="U004">1.3488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_8450d75f9c1f42dabd9276f584686ec0"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_120d3aacb79f46fca7fea75ff5e79425"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_0e3c3126fd2b4bde94fadd4e8c75c4e0">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_60423c9e5abc427d927d2178c0aa07b3">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_e1ab66c85b9449f2b9784cb51a5de845"
      unitRef="U001">124000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_751a332ddb3e4068aad6295a9ecccd17"
      unitRef="U001">124000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_InterimChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact_844fe16f46424abeb43ba4c1df32f207"
      unitRef="U007">46</erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_6a62edfe53884f6ba370f09f01f815fd"
      unitRef="U001">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_44b665ef1db84db188b32f678d778a04"
      unitRef="U007">36</erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_9a9b140d72864ecd931ccd106a26af16"
      unitRef="U001">161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20210930_AwardTypeAxis_TimeBasedStockOptionGrantMember"
      decimals="0"
      id="Fact_c83705df58e4473a80a12a86bcf2a97b"
      unitRef="U001">131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20210930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember"
      decimals="0"
      id="Fact_82974d9ec2bf470bbcf948647a487caa"
      unitRef="U001">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember"
      id="Fact_ab40459d5bf743848c18a34120470150">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fact_558d1d3cf9c74090b7c2360a3d34cda9"
      unitRef="U004">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares
      contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember"
      decimals="0"
      id="Fact_12d57ec4feb44c86ac1e2a487706cf56"
      unitRef="U007">36</erna:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_8e8a8821e8134af48380122373341df7"
      unitRef="U001">7000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="c20220101to20220930_AwardTypeAxis_TimeBasedStockOptionGrantMember"
      decimals="0"
      id="Fact_9b633bc64c124c74aa029c1dc4a586f6"
      unitRef="U001">33000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="c20220101to20220930_AwardTypeAxis_PerformanceBasedStockOptionGrantMember"
      decimals="0"
      id="Fact_4e75b15fc4894eeeb8f5d8101527c7f7"
      unitRef="U001">21000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_c3603e31add344b8b02f5f086fe45931">P90D</erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod>
    <erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_fa4fbc744c5146eea172730e96a1e86a">P36M</erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact_77591ae9b93f420489cb91f40615ad6f"
      unitRef="U002">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact_ab38cf7dd1e34e24b2e3471a6624e6c7"
      unitRef="U002">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ddbc9972cbb843b79ad5e06226115479"
      unitRef="U001">65</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_0b854c1403434c3197344cad5830c0c4"
      unitRef="U001">65</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_822a7ce34d6f479da235e93ef9ca8246"
      unitRef="U002">10202</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_766d30aa1f604960968c6350f7d8a576"
      unitRef="U002">10202</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20210701to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_669206ca98d74caa91d9ac56a00f31af"
      unitRef="U002">57212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20210101to20210930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_12779a74bea441a38741a8ee045e682b"
      unitRef="U002">57212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_57de99d3e4064a55a22fb96eef0c8f89"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_29db51465b6a4e849f54ee557c86eef6"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20220930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ac7ba2c1f4b84da09969c1534bbb57e3"
      unitRef="U001">362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <erna:ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_82480ccdbaf14aaa93f1747e868977fa">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;During the three and nine months ended September 30, 2022 and 2021, the Company granted
      the following restricted stock units (&#x201c;RSUs&#x201d;) (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Three months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Nine months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;RSUs Granted&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;6&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;55&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;11&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</erna:ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_e13b0aff84f54f538571af27630ec445"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20210701to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_141ff9eda0044601a6bc89d9ff383510"
      unitRef="U001">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_6d03b86aacf543c4bfd6b676c6205a1b"
      unitRef="U001">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20210101to20210930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_1ee1f8fbaaff4384923706bc51416b36"
      unitRef="U001">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <erna:ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock
      contextRef="c20220101to20220930"
      id="Text_c47d53b3e1244a578725da6cdb8320a8">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The following table shows the number of RSUs that vested and were settled during the three and nine months ended
        September 30, 2022, as well as the number of shares of common stock withheld to cover the withholding taxes and the net shares issued upon settlement (in thousands):&lt;/span&gt;&lt;/span&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; margin-right: 0.5pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Three months ended&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Nine months ended&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;RSUs vested&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Common stock withheld to cover
              taxes&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Common stock issued&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</erna:ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_8fd8754640044a2abfbb584510499958"
      unitRef="U001">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_e3fa79163e4d45fa80f9251d5e505e1f"
      unitRef="U001">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <erna:CommonStockWithheldToCoverTaxes
      contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_2d0965c899eb4a77b236dc1a591fa9bf"
      unitRef="U001">0</erna:CommonStockWithheldToCoverTaxes>
    <erna:CommonStockWithheldToCoverTaxes
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_e78e32e4f9e049f7816f3edb7e3d00a6"
      unitRef="U001">1000</erna:CommonStockWithheldToCoverTaxes>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_009c607122434a5ebc6ae01b0e8c81cb"
      unitRef="U001">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_688f7e6b02eb47428a1a1cdccfc66354"
      unitRef="U001">2000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_EmployeeMember"
      decimals="0"
      id="Fact_fa5f82b38b6d43e2a889c499aa10a022"
      unitRef="U001">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember"
      decimals="0"
      id="Fact_c11de3071a964f718300ed9c868ec368"
      unitRef="U001">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <erna:NumberOfPerformanceGoalsAreSubjectToAchieve
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember"
      decimals="INF"
      id="Fact_691678523f4c45a18c779ad711a4c805"
      unitRef="U008">4</erna:NumberOfPerformanceGoalsAreSubjectToAchieve>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember"
      id="Fact_bc47722f805c42afa1c8294b7a1a98c4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember"
      decimals="INF"
      id="Fact_a514fe6c452b4a2892ae773fd2bc84b2"
      unitRef="U008">2</erna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember"
      decimals="0"
      id="Fact_f3b902a3ee8043508d84000fbab6978b"
      unitRef="U001">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember"
      decimals="0"
      id="Fact_495836093eb5433aa3997ee8b9092673"
      unitRef="U001">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:PaymentsForPostemploymentBenefits
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember"
      decimals="-5"
      id="Fact_46d73c3e6d5449edbc93532022ae4607"
      unitRef="U002">100000</us-gaap:PaymentsForPostemploymentBenefits>
    <us-gaap:SharePrice
      contextRef="c20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerAndPresidentMember"
      decimals="2"
      id="Fact_1c3c20eb104846f29a907b1eae4079ac"
      unitRef="U003">16.2</us-gaap:SharePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember"
      decimals="-5"
      id="Fact_6b5aaea1d9a54e639bfd3143505f6ed3"
      unitRef="U002">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_0a0d283f00d944b89bb93a395a4a7adc"
      unitRef="U001">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_e201db6ae964420aba4649d8f482680f"
      unitRef="U001">3000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_61e1b338927f4966b47b6c1925b6ca3e"
      unitRef="U001">32000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20210930_AwardTypeAxis_RestrictedStockMember"
      decimals="-5"
      id="Fact_1716d1d34eee47c2b646e90540642e5d"
      unitRef="U002">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20220101to20220930_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_8396aa2d88d94d9b89a9ed05f99c3e4f"
      unitRef="U001">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20220930_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_992bfb660892480f9b0a492a2b9d45c1"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20220101to20220930"
      id="Text_2a62e4701a9043609da3bdda0440e3d0">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt; margin-right: 0.5pt;"&gt;For the three and nine months ended September 30, 2022 and 2021,
      the Company recognized stock-based compensation expense as follows, which includes the expense related to Dr. Federoff&#x2019;s modified awards discussed above (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Three months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Nine months ended September 30,&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
            &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;Research and development&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;183&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;448&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,075&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,018&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;General and administrative&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;293&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,281&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,463&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;2,284&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;Total&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;476&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;1,729&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;2,538&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="color: rgb(0, 0, 0);"&gt;3,302&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220701to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_c8dc470446da4d44b10a08aee8522226"
      unitRef="U002">183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210701to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_0622702a8abf482fa375506f5cfb19ba"
      unitRef="U002">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_b9da6e98aab84db7bb448168b426dc91"
      unitRef="U002">1075000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20210930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_26650292092347f2a43b7c4c967f2b25"
      unitRef="U002">1018000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220701to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_d15928e35c44426f906575d77c7fa594"
      unitRef="U002">293000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210701to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_68a8f9b7c9d14fcf9232931f36efb808"
      unitRef="U002">1281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_20cdb1a942994265975a14143761efae"
      unitRef="U002">1463000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20210930_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_d020b2312d5f49fb841bf0ae4063c21a"
      unitRef="U002">2284000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_f7d1f0019a36420aba658900d71ee22e"
      unitRef="U002">476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_d1843381b88448609b7e17600b735120"
      unitRef="U002">1729000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_cc36e43ce78e4bebabd42218d2879056"
      unitRef="U002">2538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_c8dc6aff77aa4d6698970759e3aa0508"
      unitRef="U002">3302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20220101to20220930"
      id="Text_b2be21af16d24bb093b1de68f296d004">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify;"&gt;12)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-weight: normal;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Private Placement of
            Equity&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 6, 2022, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with an investor (the &#x201c;PIPE Investor&#x201d;)
                providing for the private placement (the &#x201c;PIPE Transaction&#x201d;) to the PIPE Investor of approximately 343,000 units (collectively,
                the &#x201c;Units&#x201d;), each Unit consisting of (i) one share of the Company&#x2019;s common stock (or, in lieu thereof, one Pre-Funded Warrant
                to purchase one share of common stock) and (ii) one warrant (the &#x201c;Common Warrants&#x201d;) to purchase one share of common stock, for an aggregate gross purchase price of approximately $12.0 million (the &#x201c;Subscription Amount&#x201d;). The PIPE Transaction closed on March 9, 2022. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Pursuant to the Purchase Agreement, the Company is prohibited from issuing equity in variable
                  rate transactions for a period of one-year following consummation of the PIPE Transaction, including issuing equity under the
                  Second Purchase Agreement.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Each Pre-Funded Warrant had an exercise price of $0.10 per share of common stock, was immediately exercisable, could be
              exercised at any time, had no expiration date and was subject to customary adjustments. The Pre-Funded Warrants could not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof. Upon the closing of the PIPE Transaction, the Company issued 275,000 shares of common stock and issued Pre-Funded Warrants representing approximately 68,000 shares of common stock. On July 12, 2022, the PIPE Investor exercised its&#160;68,000
              Pre-Funded Warrants at an exercise price of $0.10 per share&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;for an aggregate exercise price of $6,786, in cash. The Company issued 68,000 shares of common stock to
                  the PIPE Investor on July 14, 2022 upon receipt of the cash proceeds. Subsequent to the exercise, no Pre-Funded Warrants
                  remained outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
              &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Each Common Warrant has an exercise price of $38.20 per share, becomes exercisable six months following the closing of the PIPE Transaction, expires &lt;span style="-sec-ix-hidden:Fact_5b09bcc1ce7d4736a68839d07677b3d8"&gt;five-and-one-half &lt;/span&gt; years from the date of issuance and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, subject to increase to 9.99% at the option of the holder.&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of September 30, 2022, the Company had 343,000
              Common Warrants outstanding with a weighted average exercise price of $38.20 per share and a weighted average contractual life of 4.95 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;The





























































            Common Warrants and Pre-Funded Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a cashless settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These
            warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the statement of operations. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Upon exercise of the Common Warrants and Pre-Funded Warrants, the fair value on the exercise date is reclassified from warrant
              liabilities to equity&lt;/span&gt;.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair values of the Common Warrants and the Pre-Funded Warrants at the issuance date totaled $12.6 million in the aggregate, which was $0.6 million more
              than the Subscription Amount. The excess $0.6 million represents an inducement to the PIPE Investor to enter into the PIPE
              Transaction and was recorded in warrant liabilities expense in the accompanying consolidated statement of operations. Given the Company&#x2019;s capital requirements and market conditions, the Company consummated this financing on market terms
              available at the time of the transaction.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; margin-right: 2pt;"&gt;The Company incurred fees of approximately $1.0 million through September 30, 2022 related to the PIPE Transaction, which were allocated to the fair value of the Common Warrants and the Pre-Funded Warrants and recorded in other expense, net on the
              accompanying condensed consolidated statement of operations.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In connection with the PIPE Transaction, the Company and the PIPE Investor also entered into a registration rights agreement, dated March 6,
              2022, pursuant to which the Company agreed to prepare and file a registration statement with the SEC no later than 15 days following the filing date of the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 (the &#x201c;2021
              Annual Report&#x201d;) to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants. The Company agreed to use its best efforts to
              have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed the 2021 Annual Report on April 15, 2022
              and the registration statement on April 29, 2022. The resale registration statement became effective on May 11, 2022.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pursuant to the registration rights agreement, the Company is obligated to pay the PIPE Investor liquidated damages equal to 2% of the Subscription Amount per month, with a maximum aggregate payment of 12% of the Subscription Amount, in the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered for resale
              thereunder for more than 10 consecutive calendar days or more than an aggregate of &lt;span style="-sec-ix-hidden:Fact_35a0d29cf6104e00b3095ed13c7f4044"&gt;fifteen&lt;/span&gt; calendar days (which need not be consecutive calendar days) during any 12-month period.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 24, 2022, the Company provided the PIPE Investor with notice that it was not able to resell the securities registered for resale under
              the registration agreement because the Company had not timely filed its Quarterly Report on Form 10-Q (the &#x201c;Q1 2022 10-Q&#x201d;) with the SEC, and that the PIPE Investor could not use the registration statement to resell the related securities
              until the Company filed the Q1 2022 10-Q.&#160; Because the PIPE Investor was unable to use the registration statement for at least 10
              consecutive calendar days, the Company accrued $0.2 million during the first quarter of 2022 for the contingent loss the Company
              incurred as liquidated damages as a result of the late Q1 2022 10Q filing, which is recorded in other expense, net for the nine months ended September 30, 2022 in the accompanying condensed consolidated statements of operations.&#160; The Company
              paid such $0.2 million liquidated damages payment in June 2022.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; On June 30, 2022, the Company filed its Q1 2022 10-Q along with the 10-K/A, and on July 1, 2022, the Company provided its notice to the PIPE
              Investor that it may resume use of the resale registration statement.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-weight: normal;"&gt; &lt;span style="font-style: italic;"&gt;Merger&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: bold; text-indent: 0px; text-transform: none; background-color: rgb(255, 255, 255);"&gt;&lt;span style="font-weight: normal;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;Under the terms of the Merger
              Agreement &lt;/span&gt;&lt;/span&gt;(see Note 3)&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;, on March 25, 2021, Eterna issued shares of common stock to the equity holders of Brooklyn LLC. The 87,000
              Class A units of Brooklyn LLC were converted into &lt;/span&gt;&lt;/span&gt;approximately&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; 1,114,000 shares of common stock; the 15,000,000 Class B units were converted into &lt;/span&gt;&lt;/span&gt;approximately&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; 126,000
              shares of common stock; the 10,000,000 Class C units were converted into &lt;/span&gt;&lt;/span&gt;approximately 84,000&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; shares of common stock; &lt;/span&gt;&lt;/span&gt;approximately 630,000&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; shares of common units were
              converted into &lt;/span&gt;&lt;/span&gt;approximately&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; 31,000 shares of common stock, and 10,500,000 rights options were converted into &lt;/span&gt;&lt;/span&gt;approximately 591,000&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; shares of common stock. &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;Eterna&lt;/span&gt;&lt;/span&gt; also
              issued &lt;/span&gt;&lt;/span&gt;approximately&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt; 53,000 shares of common stock to its financial advisor pursuant to the Merger Agreement&lt;/span&gt;&lt;/span&gt;.&lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_5e4c53d37caa4a4aa66a76d4e7094cbd"
      unitRef="U001">343000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="INF"
      id="Fact_10e7581f6c6c4062b2c40b5b84d0437e"
      unitRef="U001">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="INF"
      id="Fact_933d21ee14154b9db6063bc73f5b47c9"
      unitRef="U001">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="INF"
      id="Fact_e7420cde835b45f4a526541b70f0aa21"
      unitRef="U001">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_9513ecad95154dfab151abfbeaf38ab6"
      unitRef="U002">12000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <erna:VariableRateTransactionsPeriod
      contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember"
      id="Fact_cedf2de1f35845f08f54f12af414cb45">P1Y</erna:VariableRateTransactionsPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="2"
      id="Fact_57a4de5823584082904ae05cb2b5219e"
      unitRef="U003">0.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_0b7361ebd7fb4053b337ce71488fdaae"
      unitRef="U004">0.0999</erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_b2df6e5f8ecf42c2bf4deae12863cd00"
      unitRef="U001">275000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_cb59e80d80764b67b09c1809e70fe3a5"
      unitRef="U001">68000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <erna:ClassOfWarrantOrRightExercised
      contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_b011b29945d14c63a1680bafed9b2b9f"
      unitRef="U001">68000</erna:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="2"
      id="Fact_73f551d8b3784387b38e263de40d61cb"
      unitRef="U003">0.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20220712to20220712_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_6d6981101e1246c8a73e99f72fa96651"
      unitRef="U002">6786</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220714_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="0"
      id="Fact_61c50c0140a440e1938d8a11d081eb5a"
      unitRef="U001">68000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20220712_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="INF"
      id="Fact_06a92160e6a8419bbe9338a74ee70b93"
      unitRef="U001">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      decimals="2"
      id="Fact_dd3b7ee8cbd74916bcb02824e850d864"
      unitRef="U003">38.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <erna:ClassOfWarrantOrRightsExercisableTerm
      contextRef="c20220101to20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      id="Fact_01af5c0a6f044620ab8e37c4e781677f">P6M</erna:ClassOfWarrantOrRightsExercisableTerm>
    <erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      decimals="4"
      id="Fact_b9d005106b5449668fc8becbe108d2e2"
      unitRef="U004">0.0499</erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights>
    <erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_04cf1dfcbbee4574887e87561eb101de"
      unitRef="U004">0.0999</erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      decimals="0"
      id="Fact_d8e24589dff5407c9b747866caf33c38"
      unitRef="U001">343000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      decimals="2"
      id="Fact_fae5492c2680461f9e3629e3c0f2a2fc"
      unitRef="U003">38.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20220930_ClassOfWarrantOrRightAxis_CommonWarrantsMember"
      id="Fact_ca8c2dc4094c4749b8861c52af4ec429">P4Y11M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_818ba13c72ad40cd92ff0c04a05589bf"
      unitRef="U002">12600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <erna:OverSubscriptionAmountReceived
      contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_c887bc9fd7b14f6980af9118235a87bd"
      unitRef="U002">600000</erna:OverSubscriptionAmountReceived>
    <erna:OverSubscriptionAmountReceived
      contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_478bc158fb6e4b6daf583f6b566399cc"
      unitRef="U002">600000</erna:OverSubscriptionAmountReceived>
    <erna:TransactionFeesPayable
      contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_c73826c98f9b423985ebec97be571366"
      unitRef="U002">1000000</erna:TransactionFeesPayable>
    <erna:ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth
      contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="2"
      id="Fact_ca8f450cf4004a03a96f29f1f8b744fd"
      unitRef="U004">0.02</erna:ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth>
    <erna:ObligationToPayLiquidatedDamagesPercentage
      contextRef="c20220930_InvestmentTypeAxis_PIPEInvestorMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_e23d721f8ea84fe5aedb2bc5a2b18526"
      unitRef="U004">0.12</erna:ObligationToPayLiquidatedDamagesPercentage>
    <erna:ConsecutiveCalendarDays
      contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember"
      id="Fact_a5b5e7f58eb5418997b1f417324f39dc">P10D</erna:ConsecutiveCalendarDays>
    <erna:ConsecutiveCalendarDays
      contextRef="c20220101to20220930_InvestmentTypeAxis_PIPEInvestorMember"
      id="Fact_b8be767f29e74a29bb58dfca91799404">P10D</erna:ConsecutiveCalendarDays>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="c20220331_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_13148b4372194414b3a7d1fe2b181421"
      unitRef="U002">200000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="c20220601to20220630_InvestmentTypeAxis_PIPEInvestorMember"
      decimals="-5"
      id="Fact_f5d6300dea254c1383a88d873a05ef7c"
      unitRef="U002">200000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassAMember"
      decimals="0"
      id="Fact_3663e2cbc3c24d699eb3559e030e94bd"
      unitRef="U001">87000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember"
      decimals="0"
      id="Fact_eea066cc77e14d44b3f2a90851f0258b"
      unitRef="U001">1114000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassBMember"
      decimals="0"
      id="Fact_bf409077e40242dcb0c3b37535429efb"
      unitRef="U001">15000000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember"
      decimals="0"
      id="Fact_f892f1cf8d3243c796d808dd9dff8bb9"
      unitRef="U001">126000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_15e0508e6cb442ada157199a74f0e02e"
      unitRef="U001">10000000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_d69f9773d1f84fa8bc8913a70cfea8f8"
      unitRef="U001">84000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e78959963c61408f9520dea24cb405df"
      unitRef="U001">630000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d5f7b1c555304023aeac81080a790e48"
      unitRef="U001">31000</us-gaap:ConversionOfStockSharesConverted1>
    <erna:ClassOfWarrantOrRightIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_8eee233b891f4970b9e8cb33c99ac872"
      unitRef="U001">10500000</erna:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_c9744f4bb41f49c9a49f43f71d2755f6"
      unitRef="U001">591000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <erna:StockIssuedDuringPeriodSharesAcquisitions1
      contextRef="c20210325to20210325"
      decimals="0"
      id="Fact_f0add22f4d7d4d7ea3de994a62d3b6a5"
      unitRef="U001">53000</erna:StockIssuedDuringPeriodSharesAcquisitions1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20220101to20220930"
      id="Text_8268f62872184c44b547e4e59daca28d">
&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); text-align: justify;"&gt;13)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;EARNINGS PER SHARE&lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period
          including the weighted average effect of the Pre-Funded Warrants the Company issued in connection with the PIPE Transaction, the exercise of which requires little or no consideration for the delivery of shares of common stock. The Company
          determined that the exercise of the Pre-Funded Warrants requires nominal consideration for the delivery of shares of common stock, and as such, has considered the 68,000 shares underlying the Pre-Funded Warrants to be outstanding effective on March 9, 2022 for the purposes of calculating basic EPS. Diluted net loss per share is calculated by
          dividing net loss by the weighted-average number of common shares outstanding (including the weighted average effect of the Pre-Funded Warrants) plus dilutive securities. Stock options, RSUs, warrants and other convertible securities are
          considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. Diluted net loss per share is the same as basic net loss per share in periods where the
          effect of potentially dilutive shares of common stock are antidilutive. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table presents the amount of stock options, RSUs, warrants and convertible preferred stock that were excluded from the computation of diluted net loss per
          common share for the three and nine months ended September 30, 2022 and 2021, as their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;Three and Nine months ended September 30,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; text-align: center;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;362&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;180&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;15&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;11&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;343&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Preferred stock converted into common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Total potential common shares excluded from computation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;722&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;193&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220309_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="0"
      id="Fact_16ac43b550844f6d8782bd901074b552"
      unitRef="U001">68000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20220101to20220930"
      id="Text_f95b70294eaa41198c37dcff691de5a5">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table presents the amount of stock options, RSUs, warrants and convertible preferred stock that were excluded from the computation of diluted net loss per
          common share for the three and nine months ended September 30, 2022 and 2021, as their effect was anti-dilutive:&lt;/span&gt;
&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;Three and Nine months ended September 30,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; text-align: center;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;362&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;180&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;15&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;11&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;343&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Preferred stock converted into common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Total potential common shares excluded from computation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;722&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;193&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-style: normal; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_5317fd874d4141afbec1f431718c158d"
      unitRef="U001">362000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_3de5dc1889a04f9fa4616361e042d164"
      unitRef="U001">362000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_fd62192fbb8047ab8b2a89e4ce660ff3"
      unitRef="U001">180000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_df4a468051c04051ae1111bfcd353116"
      unitRef="U001">180000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_4cfec09352ef49feb6f26e9014dfda4f"
      unitRef="U001">15000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_1af926a4fb154e6db7664bc6beb83ad1"
      unitRef="U001">15000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_51600cfa4e2740619ce6d107eedd0d49"
      unitRef="U001">11000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_2e9896fe49814a5fa5204f52f055a91b"
      unitRef="U001">11000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="-3"
      id="Fact_3826f425d24349358510e828d60b1a46"
      unitRef="U001">343000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="-3"
      id="Fact_2327c210992844d5954a701ff8b94677"
      unitRef="U001">343000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="-3"
      id="Fact_37b13f0a9b6a4d359ac064407830cc12"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="-3"
      id="Fact_367b4c0b8d644babb8723814461fe48d"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact_d830d3c215bf4584842fd59224f6faaa"
      unitRef="U001">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220701to20220930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact_2ac63eb8355a47379d2a2cc4a670d901"
      unitRef="U001">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210701to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact_a7da759bc54f4bac8331f656d4bb0f76"
      unitRef="U001">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact_26e309eb933c4b50bf848602c5455bef"
      unitRef="U001">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220701to20220930"
      decimals="-3"
      id="Fact_39ea060b135c4a19ab9e06da2fb7a6d3"
      unitRef="U001">722000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220930"
      decimals="-3"
      id="Fact_1b119c7cd5454ed88f86b2ff0fc33024"
      unitRef="U001">722000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210930"
      decimals="-3"
      id="Fact_a3022a96399c4a61b4d5447edae7d51a"
      unitRef="U001">193000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210701to20210930"
      decimals="-3"
      id="Fact_16711c14f46d4c049261ec27a9734dd4"
      unitRef="U001">193000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="c20220101to20220930"
      id="Text_71749bfdf5ce4d45be3204a3fb4fa9d8">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;14)&lt;br/&gt;
          &lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
            &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
     &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; September 2022, the Financial Accounting Standard Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2022-04,&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;Liabilities&#x2014;Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier
        Finance Program Obligations&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(&#x201c;ASU












        2022-04&#x201d;). ASU 2022-04 requires a buyer that uses supplier finance programs to make annual disclosures about the program&#x2019;s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and
        associated roll-forward information. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is
        effective for fiscal years beginning after December 15, 2023. The Company does not expect a material impact on its financial statements as a result of adopting this amendment.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In June 2022, the FASB issued ASU No. 2022-03,&#160;Fair Value Measurement (Topic 820): Fair Value Measurement
        of Equity Securities&#160;Subject to Contractual Sale Restrictions&#160;(&#x201c;ASU 2022-03&#x201d;). The FASB issued ASU 2022-03 to (1) clarify the&#160;guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual
        restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity related securities subject to contractual sale restrictions that are measured at
        fair value in accordance with Topic 820. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair
        value. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years with early adoption permitted. The Company is evaluating when to adopt the amendments in ASU 2022-02. The Company
        does not expect a material impact as a result of adopting this amendment.&lt;/span&gt;  &lt;/div&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20220101to20220930"
      id="Text_ded1775e458c4616b485ea8de8a75a66">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; September 2022, the Financial Accounting Standard Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2022-04,&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;Liabilities&#x2014;Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier
        Finance Program Obligations&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(&#x201c;ASU












        2022-04&#x201d;). ASU 2022-04 requires a buyer that uses supplier finance programs to make annual disclosures about the program&#x2019;s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and
        associated roll-forward information. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is
        effective for fiscal years beginning after December 15, 2023. The Company does not expect a material impact on its financial statements as a result of adopting this amendment.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In June 2022, the FASB issued ASU No. 2022-03,&#160;Fair Value Measurement (Topic 820): Fair Value Measurement
        of Equity Securities&#160;Subject to Contractual Sale Restrictions&#160;(&#x201c;ASU 2022-03&#x201d;). The FASB issued ASU 2022-03 to (1) clarify the&#160;guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual
        restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity related securities subject to contractual sale restrictions that are measured at
        fair value in accordance with Topic 820. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair
        value. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years with early adoption permitted. The Company is evaluating when to adopt the amendments in ASU 2022-02. The Company
        does not expect a material impact as a result of adopting this amendment.&lt;/span&gt;  &lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20220101to20220930"
      id="Text_677b4506c14f4d87b7c706a033b5aa24">
&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;15)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;SUBSEQUENT EVENTS&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Facility Sublease&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;On October 18, 2022, the Company entered into the Sublease with E.R. Squibb &amp;amp; Sons, L.L.C., a Delaware
            limited liability company and subsidiary of Bristol-Myers Squibb Company (&#x201c;Sublessor&#x201d;), for office, laboratory and research and development space (the &#x201c;Premises&#x201d;). The Premises consists of approximately 45,500 square feet on the ninth floor of the building currently under construction located at 250 Water Street, Somerville, Massachusetts 02141.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal; text-indent: 36pt;"&gt;The Sublease rent commences on the date that is the earlier of (i) the date that the Company commences
            business operations from the Premises and (ii) the date that is the one-year anniversary of the later to occur of (A) October 18, 2022 and (B) the date that Sublessor obtains the primary landlord&#x2019;s consent for the Sublease (such applicable
            date, the &#x201c;Rent Commencement Date&#x201d;). The Sublease has a term of 10 years from the Rent Commencement Date (the &#x201c;Term&#x201d;), subject to a
            five-year extension in accordance with the terms of the Sublease.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; text-indent: 36pt;"&gt;Pursuant to the Sublease, within &lt;span style="-sec-ix-hidden:Fact_8744bc3fa0f34851947cbc5afae0d9dc"&gt;two&lt;/span&gt; business days following receipt of the primary landlord&#x2019;s consent to the Sublease, the Company will pay Sublessor a security deposit in the form of a letter of credit
            in the amount of approximately $4.1 million. Provided there are no events of default by the Company under the Sublease, the letter of
            credit will be reduced on an incremental basis throughout the Term. Pursuant to the Sublease, the Company has agreed to pay base rent of approximately $0.5
            million per month during the first year of the Term, increasing on an incremental basis each subsequent year of the Term, as well as traditional lease expenses including, certain taxes, operating expenses and utilities.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: italic; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman'; text-indent: 36pt;"&gt;Exacis Option Agreement (Related Party Transaction)&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal; text-indent: 36pt;"&gt;On October 8, 2022, the Company entered into an option agreement (the &#x201c;Option Agreement&#x201d;) with Exacis
            Biotherapeutics, Inc., a Delaware corporation (&#x201c;Exacis&#x201d;), pursuant to which Exacis granted the Company the option to negotiate and enter into an exclusive worldwide license to certain of the technology licensed by Exacis for the treatment of
            cancer in humans (the &#x201c;Option&#x201d;). The Option Agreement provides that the Company will pay Exacis a fee of $0.3 million for the Option,
            which would be creditable against the fees or purchase price payable under any such license if entered into by the Company in accordance with Option Agreement. The Option Agreement provides for certain payments upon the execution of a
            definitive license agreement, which would become payable only upon execution, and in accordance with the terms, of the applicable license agreement, if any.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: normal;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; text-indent: 36pt;"&gt;The Option Agreement has been deemed a related party transaction, as one of the Company&#x2019;s Board members, Dr. Gregory
            Fiore, is the Chief Executive Officer of Exacis.&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; Additionally, the Company&#x2019;s Interim Chief Executive Office, Dr. Matthew Angel, is &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Chairman of Exacis&#x2019; scientific advisory board. Dr. Angel is also the Chairman and Chief Executive Officer of Factor, which is &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;the majority shareholder&lt;/span&gt; of Exacis.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; text-indent: 36pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_23939bef93e44a27bbc33c7d6574a975"
      unitRef="U005">45500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_f379b196274b4fb88d5b348804b0abe9">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_9b210ebebc25489b8a5d7c097b7a371f">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LineOfCredit
      contextRef="c20221018_PledgingPurposeAxis_LetterOfCreditMember_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_f12b20ca06e3479b899839a43bac4028"
      unitRef="U002">4100000</us-gaap:LineOfCredit>
    <erna:OperatingLeasesMonthlyBaseRent
      contextRef="c20221018to20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_44e4cbcadd814bf2a4bcfbfbcddb06dd"
      unitRef="U002">500000</erna:OperatingLeasesMonthlyBaseRent>
    <erna:OptionFee
      contextRef="c20221008to20221008_RelatedPartyTransactionsByRelatedPartyAxis_ExacisBiotherapeuticsIncMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_0799c2f47f7c404fae5a8fd48c246d1c"
      unitRef="U002">300000</erna:OptionFee>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M*(OEKL<Z:319N&;;DJE-%L.=T4N@P3/+.:'LQ]E/9"J\3$%16>EQI8F,(IC
M4RV]UQ/RO7/J. .2P))QQ<-,D 3*.M^JM!;",1P8JQT8PST2+(W\(%Z0Z2::
MR=#*OL?"/3]:QV4\K"U7;;,8[HFVM4ENW[PECQ>BN67C0H_CZ<W8ND.(![8E
MK(T5.\A8;?=CBH5M7I4PU]H7\7L4OUCWTB=X5%O.VC6Q@US3O7%YQ<F*V6OB
M6W K)Z[8Q'D,R\1JR\0.LDQF(0\K'[!+"ZGL@Q&N\RCC+O<\ 3(@XA>"5MYC
M.">W=D[N0<YI&O$P)-=9"J]3:ZO=H].T&8R'M<6K[9*+NYT2[Q8FVH7IE;^
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MSQQ/3PZ &Y_IKRYS"!:$9^/X2&HZD^?:39XM-4F:;:5Z8'XB.>[;D@/ P.0
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MFN*##-(D8/]&"/T:F#N_?N*C?U!+ P04    "  5A&Y5O%0CRDD1  !.N@
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M/'FZRK=KKGQ/I2[3+WGW%L^7/ZT/GS^07JQ+EERGM"2B)8R6<)?>%866Q/1
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M?^GYI#VDGOY?K[,0O!_8U$VE-O-<!F_B"G48H#0&I7%/;?Y6^W\U(B4<H6X
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MBZ T!J7Q4+66Y$C72.1(#U7;2.T/T8CD]*KE]/2'A)W_%)[X]A&B/\0\]N#
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M!Y?F!H.T=L,!EUCC;O.X6<A9;!YNE]\[76CJCMVMXIU/1YTBC4H0"VTJA+4
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MK5<K'#)6\4+]YV>3%Y$\1,Z-CGWVY'90P:[RQB\^=K77M9A ,DP&<-B/-=<
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M970Q,2YX;6RM6EMSVSBR?N>O0'D\4W:5+.MBV5)N5;*3S&8K<7SBS.[#J?,
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MEAQ(W? ]'?2O&F!-N3=!X9+HBFP+9XFZ6>>0HED!U62-Q*/,K]M]W1"TV\8
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MA.VK_N#-FG]=GQOO3<%O5QCIE:4#^)Y^H:H_D(#FSRW>_1]02P,$%     @
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M ?P^=RYV7]C ^AWAR?\!4$L#!!0    ( !6$;E6+(.LE; 8  "X0   9
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M0+:23I$?_RF+R3C&N; <\A54&QM$WA"[Q<"Y\K+G,/*%[8-.+3=7_*!%(@!
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M.RCK@-_W4IK3P@9H?RK,_@%02P,$%     @ %81N55D]@GOW%P  &$<  !D
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M'>CNU@J&U%DX!/9:NYX>^(=("K\U($@O&V/H6+4!QM!:<K[MRN($<BLOU:%
M:0V#P JBRU9V34""G<U7DW>40."DW+!?OC7-$J:PQ0-L-:;U4+/1#:R@*S4L
M?]\*28L3$K;YFJ\T (11 LQ6;F&:AC "Y]6;#3REJPA\0$T]9QT3BY$K?*SS
MWSO0R5"5$^X)XKZ#F99E)_A#1K'^^.[R1 0%P )*$A;R060_90E4 >XL&[U>
M,T:9?%759;WDLX>N"<:)8SR^MHRSZH>SZ0.D)F5)R.AT24A &S_\*RF2)&5
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M\.DQ4GGR+D.(?(RML7>0*_AL$<FD*/1^"Q0TO7@#ALGQB[HLZVT O)#6$1D
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M[_R 5%#_PCD0W&TR>)@J"U*U4^+5PPT[#^=#4A94]6X940_?>F=J/Z)0X/Z
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MUJK"?5P+CK2D!7B_5,K&+W1 \Y\ SOX'4$L#!!0    ( !6$;E4BRD:0?P0
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M6H#S*XVNU3^T07LUG_P-4$L#!!0    ( !6$;E5;]=#*3@4  #,-   9
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M(BUMZ$IJJNE_[!Q%>4RG @]5KNR)4 AW2%-6IM\TUIK-IK'N]]"NA!BYU3^
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M:O80.6*'B!>(^#ZB> ]1!(" 2,K2+B9X;*5DPNX,J)2[-JDM5%2#"*$&O"+
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MYY8(9?S=</IM2 L\WA_8;UWNF,N&:IA+_IEE)A_[0Y]DL*45-X]R_QZ:?)S
M5'+M_I-][=L+?9)6VLBB :."@HEZI2]-'8X PY\!X@80.]UU(*?RAAHZ&2FY
M)\IZ(YO=N%0=&L4Q89NR-@J_,L29R70^?_RXN"&++P^+N_5B3:9W-^3^Z?WB
MD:R6T]ERM7Q:HO7M$]UPT.]&@<&@%AJD38!9'2#^28 K\D$*DVNR$!ED_\8'
M*+95'!\4S^*SA&LH+TD2=D@<QO$9OJ2M0.+XDM^KP-?I1AN%/Z)OIVI0A^B>
M#F$'ZUJ7-(6QCY.C03V#/_GSCZ@?_G4F@6Z;0/<<^V2:IJJ"C"Q><%(UZ%/Z
MSC*<UG>@A8:6I!)'41LTR2TQ.9"MY#C33.S(6R;0(BM-1:;?77O8(P/%!E3;
M*'(#:6.)G"7R#@%26=@(U$ZI]\:+.H,PPK7?Z[<N5A15:4Z0'V?N&>^2$F\&
MTXKSDD'BQ7'<(G8@0%'N #3#P6&V>_8&>,5$G0AC)(/(>Y+&^OXG8Q21=.(D
M=*+B[A4YTZQ>VZS>V6;=8^$463&Z89P9=KI;9RE.=ZOFY:^\O]<N[__MFE=*
MV9*74KG[%%E7++6%(K< Y'[#V>ZHASU;M@MO*72EJ$@!<9RE/PA*+EA5:&]X
M-?3B[J"IO73ZTR;&<1YO2-SI=X=V1>^51/T&5/%K'8B($!GC>N&Y^GC=H?T[
MCG@4R>GN7UG=&.Y4KX.C>[8 M7.OB:UT)4Q]Y;;6]L&:UO?TJWO]VGV@:L>$
M)ARV" TO!]AS5;\@]<'(TMW:&VGP#7#;'!]=4-8!OV^E-(>##= ^XY-_ %!+
M P04    "  5A&Y5%+/U^/H$  #Y#@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6R]5VUOXC@0_NY?8;'752M!R LOH:5(]&7W5J>^J-#=#Z?[8,A
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M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R-5=]OVS@,?O=?0?B
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M/]T!EA.O*B"?;R@5[Q=J&ZO:21W_!%!+ P04    "  5A&Y5%9Q.#L4$  !
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M[FN7_9[I'NG4T6O@# ='W3SWM0*R^AX:1P)TT$S3=H:]=K] .:ISGRT0K"5
MOQ&@_U,!(CFSH9S+_XVLV.2BA86"9.NJZB>"X$YUE-ASWX60,*_?H:'CV.:1
MU%W=7-<Y2IP ,K0Y$*RE]*!1>J!4>I$O.7[*<2:0_UQ\?KW%Z1*SSDI'B3I7
M74B8!PGS(6$!)&P.!&MERK#)E*&R2+[#.Q2$$4F*.OD&RX7[3^KB(62V0,(\
M2)@/"0L@87,@6"M;3&._)6"H*R^&0T172,)3PN4JZE_5RN]*33LW74!I'BC-
M!Z4%->VPAK$=QS@J8>903MO)<+ _9"J30:ZE!2-1485';ZR8U(2S$P"2YH'2
M?%!:4-,.2Q;;?*T_D,^V_M9>?^O_E1ER5KC!0F!63!4SAF.B+D'4?L[.$DB:
M!TKS06D!*&T.16MGTWZ[SE3OUYU=BIB@>W2@- ^4YH/2 E#:'(K6SIK]3IVI
MWJK;SS-1.<]T)@KDCM8,E.:!TGQ06F"^WKSK>@D!^:P20#\XKTHQ6Y='D1Q%
M-,]$M???M#;'G=/RD.^H_<J\G)D=[9YYZ5>'F7M\=;9Z&[(UR3A*\$JZ,B[Z
MLOQBU7%E=2/HMCPM6U(A:%I>;G 88U9TD+^O*!4O-X6#YM!X\A]02P,$%
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MWV=KJ02F_]]U:#*Q;KV8K@GG,J$>3 Q<]!+$/1C37W^Q^];O=:#:%'-;$JM
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MBP%06@BE<12M&4M3,W#IFH'5<@*:91T5:"T!2N-N>\:[+_&9 H%+%P@.7%)
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MY;]CO"@;J.H+)7C\3"5.7J$2 [^AL?]L+9;]')D#^%$DN 7(M)V<?BMRI\'
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MR,,WG,.)%GGYW60E-'9P>;@%3+@T-^#O:R'TTXGY%%-_29O]!U!+ P04
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M^*%H=D",XX_]CO]E=$7ELIN9WY/Z29T_$M");5 :AJ+9,3'C!/$I6.("'2<
MI26@- Q%LS>)F7&"09?);EF-%[.-%%+YF*Q\0%2%3'Y6?3%E3ZF0SFGN@7.:
M.]K/5OZ:=-X<!CHR $6KH]#?V66KO.)#M;U9H&H=0;VY=/OK=@OU1;5Q>._W
M)'R+ZXW0!E/OR[XF_"%3GU%.EPJIVX8>XO56Y_I$LG6UE_>>2<F*ZG!%R8)R
M?8'Z^Y(Q^7*B;[#=<#[]%U!+ P04    "  5A&Y519_J-?<#  !?%0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RMF.]OXC88Q_\5*SM-=U)%?@$M
M'2 !R3:FE3*X;B].>V&2!X@NB3/;P)VT/_[L)(2DE[IE<U^4./'W8_O[Q,YC
M#T^$?F9[ (Z^)''*1L:>\^S>-%FPAP2S#LD@%4^VA":8BR+=F2RC@,-<E,2F
M8UE],\%1:HR'^;TE'0_)@<=1"DN*V"%),/TZA9B<1H9MG&^LHMV>RQOF>)CA
M':R!/V5+*DIF10FC!%(6D111V(Z,B7WOVZX4Y#7^C.#$:M=(#F5#R&=9F(<C
MPY(]@A@"+A%8_!QA!G$L2:(?_Y10HVI3"NO79_K/^>#%8#:8P8S$?T4AWX^,
M.P.%L,6'F*_(Z5<H!]23O(#$+/^/3F5=RT#!@7&2E&+1@R1*BU_\I32B)G"[
M+PB<4N \$SC."P*W%+AO%71+0?>M@EXIR(=N%F//C?,PQ^,A)2=$96U!DQ>Y
M^[E:^!6E\D59<RJ>1D+'QP_^ZA=_=8.\^7KYN)Y_G#\NT&3AH<GLCZ=Y6?ZX
MFBS6DYF\7M^@>7H$QL6[PE&4H@4188XXH/<><!S%[,/0Y*)?DFX&91]F11^<
M%_K@H@>2\CU#?AI"V*+WU/K!:WI?K;<=!< 4AE:N.F=7IXZ2^-LA[B"[?X,<
MR['1T]I#[]]]0%.":?@ R09HFTEJY!JR#G*M'.F<D6U>Z<'X:HP'@<#8S0$J
MC'.KU]'-N>X+W,O+Q="GR89Q*E:2OUOZ-RTXW7:.7%[O688#&!EB_61 CV",
M?_S![EL_M5FO$^;IA/F:8(U@=*M@=%7T6C#: J#47AN  M;/8?+;=ASW[RS+
M&IK'NK-OJN5_7\NV\K^J7L.-7N5&3^G&>:43*^!BUD&?BHG<^FXJ0==:HQ/F
MZ83YFF"-:/2K:/0U+11]G<'0"?-TPGQ-L$8P;JM@W"JGQN,I!<KV488RH(&(
MB4@QVT)14&RK-C6MCM-KSM^9LJUK/=8)\S7!&A[?51[?J9>?@UQN$-FBC4PC
M$ .Q0T#_OI)43 MHK^:X^\QN9;/7VJT3YFN"->P>5'8/_L>W;_#J)Z;P5MG&
MM=[JA/F:8 UO;>NRZ;"4[OY.& .&Q$8Q4OJLQER[>)>T>M@<^_LLHZ7:H"6X
M?DN]GB+/L&M;,ON_9!IBLHN[T8&AY1Z+/7( !QX%.&9R3Q:H,Q)UBU<;J9/F
M::7YNFC-V#F7V#F:\I(2I"LD.FF>5IJOB]8,R65+:2LW2:W9"=I\+2=3:VC<
MMD3E]GFBHF[W:L^U[AMUT0K/S=H!4P)TEY_L,1200\J+LZ;J;G5Z.,G/S,Q+
M]>+H\0'3790R%,-62*6K!J+%:5Y1X"3+CZLVA'.2Y)=[P"%064$\WQ+"SP79
M0'6F.OX&4$L#!!0    ( !6$;E6CRA=<B <  #Y=   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;+6<7T_;2!3%O\HHNUJU$B6QG03H0B2:^;.L@$50
MVH=J'X9D"%8=.SMV0E?:#[^VXV8RQ)G$Z/!2XB3W=VWF=.[X<#VGSXG^GCXI
ME9$?TRA.SUI/63;[V&ZGHR<UE>EA,E-Q_LECHJ<RRP_UI)W.M)+C,F@:M?U.
MI]^>RC!N#4[+]V[TX#299U$8JQM-TOET*O6_GU24/)^UO-;/-V[#R5-6O-$>
MG,[D1-VI['YVH_.C]HHR#J<J3L,D)EH]GK7.O8^BZQ<!Y3>^A.HY77M-BDMY
M2)+OQ<'%^*S5*<Y(16J4%0B9_UBHH8JB@I2?QS\5M+7*602NO_Y)Y^7%YQ?S
M(%,U3**OX3A[.FL=M\A8/<IYE-TFSW^HZH)Z!6^41&GY+WFNOMMID=$\S9)I
M%9R?P32,ES_EC^H7L1;@=;<$^%6 OV] 4 4$^P9TJX#NO@&]*J"W;T"_"NCO
M&W!4!1R5@[7\[99#0V4F!Z<Z>2:Z^'9.*UZ4XUM&YR,2QH44[S*=?QKF<=F
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MK4I?/JSV@TD&8FT2YVP#/>E^_-E)2%B1^%"[[1>('<_,,^/Q\X '*RY^R A
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MQRT_DTBM/.1#E8<T*$^_@]N*52L/V?TOR/]R?.G+M_Z =#=N!A(0\_S^0Z+
M_,$K+@FJV>J.95S<+-3+BPL:O7>ZBR2*8:9-O:.N3E\4=Q[%0/$LOV>8<J5X
MDC]&0$,09H%^/^-<K0<F0'7S-/H/4$L#!!0    ( !6$;E5[DMUV3@0  /\5
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;*V876_B.!2&_XJ57:U:
M:89\0$+;!:1"LMJ1IIJJJ+L7J[UPPP&L2>*,;4J[VA\_MA/20%,7*M] G/A]
M;+_GQ(X]VE+VG:\!!'K*LX*/G;40Y97K\G0-.>8]6D(AGRPIR[&01;9R><D
M+[0HS]S \R(WQZ1P)B-][Y9-1G0C,E+ +4-\D^>8/4\AH]NQXSN[&W=DM1;J
MACL9E7@%<Q#WY2V3);>A+$@.!2>T0 R68^?:OTK\@1+H&G\1V/+6-5)#>:#T
MNRI\68P=3_4(,DB%0F#Y]P@SR#)%DOWX44.=IDTE;%_OZ'_HP<O!/& .,YK]
M319B/78N'+2 )=YDXHYN_X1Z0*'BI33C^A=MJ[JA;#'=<$'S6BS+.2FJ?_Q4
M&]$2!-$;@J 6!,<*^K6@?R@(WA ,:L'@6$%8"_30W6KLVK@8"SP9,;I%3-66
M-'6AW==JZ1<I5*+,!9-/B=2)R=?D>I[,/Z%O)3 L2+%"7T'ZCLYB$)AD_'SD
M"MF,JNRF-7):(8,WD'UT0PNQYB@I%K#HT,_,^DN#WI7#:\88[,8X#8S .90]
MU/<^H< + G0_C]'9K^=H*7[[Q1]>_-[50<N\^'B>O^-U8!(SY@:S'O+"_6X9
M[.LW*=+7W/X;W(/4X.B?ZP<NF'S%_^U*C@HVZ(:I>>^*ESB%L2,G-@[L$9R)
M-"[R.@-A$Q;;A"668'L1&301&9CHK8AD^F7%<HE _YLR<%H!0PU4B\?C))1K
MR<A];+M]3*78V+537;0$VW,Q;%P,C2Y6$YT EG<99M9& <KU)-65M!^7QD;I
MJ>9:@NV9&S7F1L913I6W# J!SF2RRO5_(Y,4+2D5Y^]DJI%[ZOQ1P2Y;&1WU
M^N%!1MML,;$$VS-]V)@^-)I^"RR5ELL//$27B!0ITRE."OTM585#?IP!3M?H
M&3#KLK]JP?=:EGD]KW\P4QQ5*S;V]E1C+<'VC+UHC+TP&IL\"5 ?(_5\^]:<
M88:$VO/.&>.CPM@H/-5A2[ ]AR\;AR^-8_Q2$$%PAG)I\(9!KE-UB>C!2G?W
M[1YASD%TN3$U-G'JU%'!HE:&^T,O\EZMAS8;32S!]D+@>R][ <]&$#*"'T@F
MJT)G%,R-G!J&FA:^&X>Z8CM@%]'K>HFM[NU[W-IO^6:/\Q(3MK/6G,\UJCVD
MPT^VCBJ?A\.@PYYW68FYYQ]U)GAQ)C Z,Z-Y3H1V1E!4;EBZ5MD&/S:D5'<[
M'3(B3\XUF[38*BVI:>WXA5X[S/NNOVSN?.-.97)?X)PR0?[;K6YKFBT0R4M&
M'_4,T)V95G=Y5FFQ55I2T\(C?7_9POGF/=P<T@TCXADMH*2<=&>WS;W6S"HM
MMDI+:EH[NZ/^:Y?=UD%7#FRE3Q@Y2NFF$-5Y4'.W.<6\UF=W!_=G_E5<G46^
M8*JCT1O,5J3@\EU82J37&\K(L^JTL2H(6NKCM <J!,WUY1KP IBJ()^K/<ZN
MH!IHSGPG/P%02P,$%     @ %81N57C_V^\' P  A H  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&ULK59=;YLP%/TK%JNF3FK+-W19@I0$IDUJMZII
MNX=I#PXXP2I@9CM)]^]G Z$)<6FT]278YIQS?>YUS!UN"'UD*4(</.59P49:
MRGDYT'46IRB'[(*4J!!O%H3FD(LI7>JLI @F%2G/=,LP/#V'N-""8;5V0X,A
M6?$,%^B& K;*<TC_3%!&-B/-U+8+MWB9<KF@!\,2+M$,\?ORAHJ9WJHD.$<%
MPZ0 %"U&VM@<1+[$5X 'C#9L9PRDDSDACW+R-1EIAMP0RE#,I0(4CS6:HBR3
M0F(;OQM-K0TIB;OCK?KGRKOP,H<,34GV R<\'6F7&DC0 JXR?DLV7U#CQY5Z
M,<E8]0LV-=:W-!"O&"=Y0Q8[R'%1/^%3DX<=@M!1$ZR&8'4)S@L$NR'8QT9P
M&H)S; 2W(536]=I[E;@0<A@,*=D *M%"30ZJ[%=LD2]<R',RXU2\Q8+'@ZMH
M/(MF9^";.)+?2T0AQ\427"&1>Q ]B=/($ .G(>(09^P#. ?WLQ"<GGP )P 7
MX"XE*P:+A UU+C8C)?6X"3RI ULO!+;!-2EXRD!4)"A1\,-^_L<>OBZ2T&;"
MVF9B8O4*SE!Y 6SC#%B&92GV,SV>;JKL_%_TZ)^C[R7#;H^%7>G9+^CU' ?P
M<SQGG(I_^"]5U6M=1ZTK;[T!*V&,1IJXUABB:Z0%[]^9GO%)E?*W% O?4BQZ
M([&]XCAM<9P^]>"Y,%E5&%071E6-6LBKA.0G8QV8CCW4U[M)5F N_7U,>(AQ
M?&\?$QUB7,-L,7M.W=:IV^MTMIK7%G$1DUSIL!9P=Z*>6V;'X1&84('Q.IF*
M5!A+[=!K'7J]#A\@Q5"8?+V4WD%PS^CX5$ Z+@\1IMEUJ<!X:I-^:]+O-7E'
M.,Q>=^@K#J+5L:C ^!U,>(AQK>YA/<0XKMMQJ>]\5G-$EU4_PT!,5@6OK])V
MM6V9QE6GT%F?F(.IJ5@/18M5=T3/\G5_=@WI$A=,Y&PA0AD7OB@'K7N>>L))
M67W4YX2+%J$:IJ)-1%0"Q/L%(7P[D0':QC/X"U!+ P04    "  5A&Y58+;M
M<LD$  "P&P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RUF6V/XC80
MQ[^*E9ZJ.VG9) XDL 4DEJ3J27NZU=+MO:CZP@L&K$OBU#;+;3]]G0<2\H"/
M7-TW"TD\?X]_,PXSZ^F1LJ]\C[$ WZ(PYC-C+T1R9YI\O<<1XK<TP;%\LJ4L
M0D)>LIW)$X;1)C.*0A-:EFM&B,3&?)K=>V3S*3V(D,3XD0%^B"+$WNYQ2(\S
MPS9.-Y[(;B_2&^9\FJ =7F'QG#PR>666*AL2X9@3&@.&MS-C8=\%]C@UR$;\
M0?"1GWT'Z5)>*/V:7GS<S PK]0B'>"U2"20_7O$2AV&J)/WXNQ URCE3P_/O
M)_5?L\7+Q;P@CI<T_$(V8C\SQ@;8X"TZA.*)'G_#Q8)&J=Z:ACS["X[%6,L
MZP,7-"J,I0<1B?-/]*T <68@=;H-8&$ KS5P"@.G:3"\8# L#(;7&HP*@VSI
M9K[V#)R/!)I/&3T"EHZ6:NF7C'YF+7F1.$V4E6#R*9%V8OX0+%;!Z@9\3C!#
M@L0[\( E=Y!ES(!N!P=YL> <"PY0O $/!+V0D B".7CO8X%(R#^  7A>^>#]
MNP_@'2 Q^'U/#UR.YE-32!_3F<QUX<]][@^\X(\#/M%8[#D(X@W>=-@OU?83
MA;TIV92 X G0/50*KG!R"QSK!D +PBY__INY?[VYW6$>J,U]O);F=I=Y#893
M9HN3Z3D7]!I9<I-G!OAS\<(%DWO^KZZ YY+#;LGT17C'$[3&,T.^Z3AFK]B8
M__R3[5J_=-'6*>;K% LTB=7B,BSC,E2IG\4ES'?OYV> LDU[ ^[QCL2Q?-85
M&Z5LW]CD8FXFEOY O<[AR/6FYNLY<YTS!IK$:LQ')?.1DOG'6+X%40@B2?S
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M_(6_*QVV )*G&>!4 .=80+<"=/<![CL MP*XQP)Z%:!W+,"K %ZA?2E6H70
M!?0'C&X 4]:232V*=!5H*3 FJK#F@LFG6.*$?_MP,9T]CL/Y',S">3B:C;^"
MCS#+/X,@_![>/4[OPX=O8/00@"^/C\&/V[L[<!8@ 7'*S\$%>)H'X.S#.?@
M3, 3R! 'F( G@@7_) _E^EM"5QR2F ],(>-57LVHBNVFC,UY)[8NN*=$)!R$
M)$9Q WZLQU]I\*;4J1;+>17KQM$2_KLB'="U/@''<IRF>/3P.<JU\.!XN-T
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M5,@!I5@F<JI%3!G(YPM*Q>M&.:CG9/\/4$L#!!0    ( !6$;E42EZB^$ 0
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MNM$PM;4</LG4_[X43'XETDY,9O-;M)S?3>^G7S[=?D;37^_G\\7\\Q=T$8+
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M9RA[8\7A6?$@:*Z/DU94")KJVRU@.4>J!O+[FE+Q\J!.J*HCS,D_4$L#!!0
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MWVRX2(C2JV+KRKT $A=!"7-]SQN[":&I$TR+;?<BF/),,9K"O4 R2Q(BOM\
MX\>9@YW'#1_I=J?R#6XPW9,MK$!]VM\+O>;6E)@FD$K*4R1@,W.N\56(+_*
M8H^_*!SEV3+*3V7-^9=\Y2Z>.5Y^1, @4CF"Z(\#S(&QG*2/XVL%=>HQ\\#S
MY4?ZV^+D]<FLB80Y9W_36.UFSH6#8MB0C*F/_/@G5"<TRGD19[+XCX[EON-+
M!T695#RI@O41)#0M/\FW2L19@.\_$^!7 ?Z3@,'PF8!!%3#XV1&&5<"P,%.>
M2N$A)(H$4\&/2.1[:UJ^4,@LHO7ITS2_[BLE]+=4QZE@_F&QN'M8W"X?5NAZ
M&:+YA^7#W?+=[7)^=[OJH?>P)0PMB%(@)'H=@B*4R3?H%:(I6E#&]+634U?I
M(\EY;E2->E..ZC\SZG6V[2-OU$.^Y_OHTRI$KU^]:<',S9@0HC[")08_8M -
M)R)>0+(&T8(,S<BWL*Z/#+<?F:L5UY[]VK-?< ?/<)LB/U^OI1+ZGO^GS5U)
M&K:3\D1P)?<D@IFC9[H$<0 G^/TW//;^:#-H$Q9:@C4,#FJ# Q,]>$\5W9(B
M64A0BH'./JJ'2,*S5+5I+'&XO-)Y_CL$N.]/W<.Y'N.87?58@C7T#&L]0Z.>
M)3_HY)E)/6=5W$>?RPG0>G\905WO+YNPT!*L(7!4"QQ9FZ$CFP9MPD)+L(;!
M<6UP;+P%0]A &I-4220)TU4$V@N>4 DQ(EM=@DB%]DQ_*KK9M%DUTKM:M0D+
MQS^F$J\_JE-)P]:DMC4QVKH'$>D,IHLKQ#<(OF94=15F'*"K,)NPL(1AKR',
MFWB-/]PN\*(6>/%_,A[Z5Q<F*4VRQ)@$C>RN[FS"0DNPAM/+VNFEM21X:=.@
M35AH"=8PB+U31>V9"Q4N)8JXGK7I%M+H>P_%)-'37&=%GNDNI(<.A&706C4;
MR5V=6J6%%6U\7DYY[3,8GW4?V.CJG9[#:0S".%7-C,Y6;-)"6[2FOU-7@>VU
M%=AJ7V&5%MJB-36>6@ML[BU^M7(QXSNK;>E<SLN-2ME+=!OXU&Y@<[]AH7PQ
MC]#9VK!;S5%9?(F6 Y]Z#FPLR(-EEF>]W&!2Y#]$Q)KJ*5RTN7N2 M/EC/F%
MQHUYB,X:2]KHS.+@J;.7:#+PJ<O YC;CAV?&3U9\9FQG3U8;#%NTIM)3*X(G
M]AXC5KL.J[30%JVI\=208'-'\BN5G]5^I*(U:S7OZ32VVFBX9^^@\U\,%D1L
M]2, ,=AHO->?Z*0ARI?PY8KB^^*U])HKQ9-B<0=$S^M\!_W]AG/UN)*_Z:Y_
M"@G^ U!+ P04    "  5A&Y5CO:,*KX%  ".-   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6RMFVUOVCH<Q;^*Q9VN-FDK27AJ=ULD2IXJC:X:V[TO
MIOO"$ /6DI@YAF[2/OQU0AH("[X@G;YH2<CYV6F._#<^^/99R&_9BC%%?B1Q
MFMVU5DJMW[?;V7S%$II=B35+]3L+(1.J]*%<MK.U9#0J1$G<=BRKWTXH3UO#
MV^+<DQS>BHV*><J>),DV24+ESWL6B^>[EMUZ.?&)+U<J/]$>WJ[IDDV9^K)^
MDOJH75$BGK TXR(EDBWN6B/[?>@4@N**OSE[S@Y>D_Q69D)\RP\>HKN6E?>(
MQ6RN<@35?[9LS.(X)^E^?"^AK:K-7'CX^H7N%S>O;V9&,S86\3\\4JN[UG6+
M1&Q!-['Z))Y#5MY0+^?-19P5O\ES>:W5(O--ID12BG4/$I[N_M(?Y3_B0&!W
M3PB<4N"<*^B4@LZY@FXIZ!X+>B<$O5+0.[>%?BGHGRL8E(+!N8+K4G!=/-W=
MXRB>I4L5'=Y*\4QD?K6FY2\*0Q1J_0AYFGMWJJ1^EVN=&HX_3B8/GR?>X^<I
M&3VZ9/SQ\?/#8^ ]CA^\Z5OR@<]SGZ9+,EI*QK1I549>NTQ1'F=OR#OR9>J2
MUZ_>D%>$IV3"XU@;,KMM*]VUO('VO.R&M^N&<Z(;-V0B4K7*B)=&+*KKV_J6
MJOMR7N[KWC$"1VMY13K66^)8CMW0G_$9<KMW4NZ>(^^<E'MF^92MJ\X[#7+?
M+/\X5UINGY0'Y\N;.A^><>].OTE>>Y*=RJ&=@M<]P7L46SVR;3)M1A5=D:\3
MELR8_)?\(A/Z@R>;I#K5T-=[(SLO#.^S-9VSNY8>^3,FMZPU_/,/NV_]U>09
M),Q%PCPDS$?" B0L!,%J/NQ6/NP6],X)'S8.A5]'LTQ)78 ;S==%F@\)<Y$P
M#PGSD;  "0M!L)KY>I7Y>L9!4%=6IN<"*2-K^K.P7I/?C(Q+_8:$N4B8MX/U
M"U@^-]\.>[K0; ]=A&PO0,)"$*SFHG[EHK[11;LA3,C,6#*-C$M=A(2Y2)B'
MA/E(6("$A2!8S6^#RF\#=,D<(,V'A+E(F(>$^4A8@(2%(%C-?->5^:[_YW-#
M^DZRQ2:-Z"QF1*R+M9(%8TVV,Z(NM1T2YNY@MG-0[:RK7KW<><@6?20L0,)"
M$*QFIYO*3C=&.SVD7'$:D[@8TUANI,8YV,UODY-N_6&-C>U<:@\DS$/"?"0L
M0,)"$*QF(]O:+[A91B.-$K%)%9'L^X9+1I3(I_1$+ @_TV%F_J6#54D[-.S1
M9-J%-NA!:3Z4%D!I(8I6-]K!RJY]CM'$+.9+JECT8C6>5A:C+].R1I\9\1?[
M#$ESH30/2O.AM !*"TM:<WFJ^\S9^\PQ^RR*>#ZWTD-7/F0U&N[$4O*]&7VQ
MQY T%TKSH#0?2@M*6FV2Z1Q/,D-4FW6;[6, VYP#_+YX07X17T@VIYDR+FB8
MP1>;#)H"0&D>E.9#:0&4%J)H=3/NLP ;'@;8T#0 2G.A- ]*\Z&T $H+4;2Z
M"_>A@&U.!<ZLO$T9\+T9?;$=H6D!E.9!:7Y)J]7*SG&M#*!MABA:W6;[U, V
MQP9Y C_FBIF++#0V@-)<*,V#TGPH+8#20A2M[KM]>F##XP,;FA] :2Z4YD%I
M/I060&DABE9WX3Y&L,TYPA.3VH:*+EF^2"?9EJ6;Q@S!S+G8>] 4 4KS2EJ^
MOG4ZE/"A;0906HBBU3VUSQ)L<YCP)>5;)C.NBH7?J=BH%?%C(7E$S446N0X^
MAM)<*,V#TGPH+8#20A2M_C79?1SA6.@BZT #""C-A=(\*,V'T@(H+431ZB[<
M9Q6..:LX*K+B)XWUV*@_PN;9?:,'H>$$E.9":5Y).RJVUL"J_1Q_ 0[:AP!*
M"U&TG=?:!YL?$B:7Q4:8C,SS\&NW#Z(Z6VVV&15;3-K[RW<[=294+GF:D9@M
MM-2Z&NC/W7*W^65WH,2ZV$HQ$TJ)I'BY8C1B,K] O[\00KT<Y U46Y"&_P%0
M2P,$%     @ %81N52^A](X! P  T P  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&ULQ9==;]HP%(;_BI5)TR9-Y(-/=1")DFYC$A25;KNH=F'" :(F
M<6H[4/[]CIT0D2UD0XJT&[ =O^^Q'\?'SO# ^+/8 4CR&H6Q&!D[*9,;TQ3^
M#B(J6BR!&)]L&(^HQ"K?FB+A0-=:%(6F8UD],Z)!;+A#W;;@[I"E,@QB6' B
MTBBB_'@+(3N,#-LX-3P$VYU4#:8[3.@6EB"_)0N.-;-P60<1Q")@,>&P&1EC
M^\8;J/ZZP_< #N*L3-1,5HP]J\IT/3(L-2 (P9?*@>+?'B80ALH(A_&2>QI%
M2"4\+Y_</^FYXUQ65,"$A3^"M=R-C(%!UK"A:2@?V.$+Y//I*C^?A4+_DD/6
MMV\9Q$^%9%$NQA%$09S]T]><PYG [EP0.+G ^5=!.Q>T?Q>T+P@ZN:"CR613
MT1P\*JD[Y.Q N.J-;JJ@86HU3C^(U;(O)<>G >JD.[F?S::/L[OYXY*,YQZ9
MW,\?I_//=_/)]&[Y@3RP(PWED8RW' !76PKRS@-)@U"\'YH2!Z!L3#\/=IL%
M<RX$FU'>(H[S@3B68U?()_7RKVE\DMN#"KGWM^A'8ME:[935)D(KR#D%.4?;
M=2[83>,]X/+P/QF1IQE$*^ _JPC5FJI-?B,2ZL/(P%TL@._!<-^^L7O6QRI>
M39IY#9F58+8+F&WMWKX L^(]>QJOA.28%RHQMIO$V*29UY!9"6.GP-BI?2<7
MP'V$A_F:L WA.50./F!R)?"2TI!(A@U[B%,09,-91 0-=?=5*M!.B"K<65C;
MTG'54;)WK9;5&9K[<XZU@[N68T-F)8[=@F/W"HX)/>IMC46Z7@?JO$*.)[IX
M>&TY$T)SK(17&^O:=[5),Z];N:QVL:PE>+T"7J\6'A[!(5TQ3J]/CK7&UY)J
MTLQKR*P$M%\ [3>;'/M-8FS2S&O(K(1Q4& <_)_D6!OV6MR#RBW9*V=:KZ&0
M&4?S[/JH[OIX3=L&L2 A;-#>:O4Q3?#L_IQ5)$OTC7+%)-Y/=7&'GQS 50=\
MOF%,GBKJDEI\Q+B_ %!+ P04    "  5A&Y56@@T),P"  !Y"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,BYX;6RM5EMOFS 4_BL6DZ96:LLU;981I 28
M6DUIHM)M#]4>'#@)J("9[23MOY]M"$LZ&D5;7O#M?-^YX7/L;@A]9BD 1R]%
M7K*AEG)>#72=Q2D4F%V1"DIQLB"TP%PLZ5)G%06<*%"1ZY9A7.L%SDK-<]7>
MC'HN6?$\*V%&$5L5!::O8\C)9JB9VG;C(5NF7&[HGEOA)43 OU4S*E9ZRY)D
M!90L(R6BL!AJ(W,0]J2\$OB>P8;MS)'T9$[(LUS<)4/-D 9!#C&7#%@,:_ A
MSR61,.-7PZFU*B5P=[YE_Z)\%[[,,0.?Y#^RA*=#K:^A!!9XE?,'LKF%QA]E
M8$QRIKYHT\@:&HI7C).B 0L+BJRL1_S2Q&$'('BZ 58#L-X"G'< =@.PC]7@
M- #G6 V]!J!<UVO?5> "S+'G4K)!5$H+-CE1T5=H$:^LE/])Q*DXS02.>]'C
MU/]Z.1Y%88#\Z606WD>CQ[OI_06*.(F?T;12^1S)?&;\%9T%P'&6LW-TB5B*
M*;#MD)7H,24KALN$N3H7MDD->MS8,:[ML-ZQPT834O*4H;!,(.G !X?QGP[@
M=1&3-C#6-C!CZR!A!-45LHT+9!F6U6&/?SS<['+G_[2'_ZQ]+QAV^Y?8BL]Y
MCV_G7V#H:0+%'.C/KBP?Y)%%;\ J',-0$U6- 5V#YGW\8%X;G[M"?$JRX)1D
MX8G(]I+AM,EP%+M]*!F7LCHFR">%Z!@,JTOZ-)HS3D7I[<R,<\K,G)(L."59
M>"*RO<STVLSTCK@FI+DF2XI++G)T)BIC72//N_)24_84I>SJ:\_L]UU]O1ON
M#AEK7R3X6\3JW^S+A%VJC%:F=EG?Z24%T*5JX@S%9%7RNF"TN^T[8:3:XYO]
ML3GPS8[]0+PKZF? '_KZ43+!=)F)P.6P$*J,JQMA*:T;?;W@I%*=;$ZXZ(MJ
MFHJW$5 I(,X7A/#M0BIH7UO>;U!+ P04    "  5A&Y5&9-=Q5 #  " "P
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M[*?=[+J,G,F2QC"TL$Y($$NP@H\?>@/G:Y?U_T3V(A&G;2).=[$'QOZRMG^
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M( :?"83'_S8P@S@6)#Z.GP54*WT*P^KU"_VS#)X'L_ HS'#\3Q2P<*0--!3
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MBN_-A=@(</P] 6X3X&X'#/<$>$V MQ7@CO8$^$V ?^PA#9N X;$!HR9@=&S
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MDAOQ/4J6B76RAIW=66G0S#Z4%D)I%$IC4!I'T4P]ZG2_-WRER1H>=-$!E!9
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MSX.51=HCDDS'G)T03ZT5+3W(TI5YJP '<?ID+2575P/E)Z=XMOC\Z?.')7K
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M&JCK6Z9>R44C[:#<<S/]'U!+ P04    "  5A&Y55YM3@J,$   Z'P  &0
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MH\BJ460M4&0M4&0M4&0M_E/69VN7?QP_///6U-TAGPW_=IJ] 5!+ 0(4 Q0
M   ( !6$;E4'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ %81N530;S$7M    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %81N59E<
MG",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    "  5A&Y5W.9*"AH&   /(   &               @($,
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %81N59Q
MNJ5C!@  _AL  !@              ("!7 X  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( !6$;E5ANB*D+ ,  %4+   8
M  " @?44  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  5
MA&Y5ITI3?$$&  !%'   &               @(%7&   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ %81N5<B'B*=U @  [@<  !@
M         ("!SAX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( !6$;E6\5"/*21$  $ZZ   8              " @7DA  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  5A&Y599S E) "   1"
M&               @('X,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ %81N5;K0-(\X"@  %S   !@              ("!OC4  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !6$;E7OY#07T L
M %8?   8              " @2Q   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  5A&Y5&X,GHFX'   ($@  &0              @($R
M3   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !6$;E7U
MS%')K1   ,4N   9              " @==3  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ %81N59G[']9G"0  "QD  !D
M     ("!NV0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !6$;E6#E_40D ,  #8(   9              "
M@962  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ %81N
M55D]@GOW%P  &$<  !D              ("!7)8  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  5A&Y5A 4N4T0,   C)@  &0
M        @(&*K@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( !6$;E4JO@E6]PH  ! @   9              " @06[  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ %81N52+*1I!_!   I@L
M !D              ("!,\8  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  5A&Y56_70RDX%   S#0  &0              @('IR@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !6$;E7\D9)@
M)@8  &<.   9              " @6[0  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ %81N57+:OP87!P  .Q(  !D
M ("!R]8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  5
MA&Y5U5T@;5T%   9#0  &0              @($9W@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !6$;E6'B_U'8@8  #(/   9
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M970S,"YX;6Q02P$"% ,4    "  5A&Y5M"D7W T#  "Y!@  &0
M    @(%T^P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M !6$;E7/FQN;% 0  %45   9              " @;C^  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ %81N516<3@[%!   0!X  !D
M             ("! P,! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  5A&Y5E>$^ED<$  #&$@  &0              @('_!P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !6$;E7;;B/.&@D
M -97   9              " @7T, 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ %81N5?A[AM#U!   51,  !D              ("!
MSA4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  5A&Y5
MX31OK_<'  !\/@  &0              @('Z&@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( !6$;E5%G^HU]P,  %\5   9
M      " @2@C 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ %81N5:/*%UR(!P  /ET  !D              ("!5B<! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  5A&Y527(P%3H$  "%$@
M&0              @($5+P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( !6$;E5[DMUV3@0  /\5   9              " @88S 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ %81N57C_V^\'
M P  A H  !D              ("!"S@! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  5A&Y58+;M<LD$  "P&P  &0
M@(%).P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !6$
M;E5@0DUTDP,  "X.   9              " @4E  0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ %81N50IBF(^C P  ,P\  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( !6$;E6.]HPJO@4  (XT   9
M  " @0); 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M%81N52^A](X! P  T P  !D              ("!]V ! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  5A&Y56@@T),P"  !Y"0  &0
M            @($O9 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( !6$;E49DUW%4 ,  ( +   9              " @3)G 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ %81N51P^GEN+"
M_%,  !D              ("!N6H! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  5A&Y5<8$PCK\"  !8"0  &0              @(%[
M<P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !6$;E6&
MAQ^2M (  ' '   9              " @7%V 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ %81N55+]]C$U!@  _BX  !D
M     ("!7'D! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !6$;E6&0638L 0  '\C   9              "
M@:J6 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ %81N
M55>;4X*C!   .A\  !D              ("!D9L! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    "  5A&Y5>(3QG#L#  #L$P  #0
M        @ %KH $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !6$;E67BKL<
MP    !,"   +              "  =&C 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( !6$;E7R?U4E,P4  #<J   /              "  ;JD 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  5A&Y5)V75I0P"  "$)0  &@
M    @ $:J@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  5A&Y5[M7M&.8!  #U)   $P              @ %>K $ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     1P!' &@3  !UK@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>234</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>020100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>030100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060200 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LiquidityAndCapitalResources</Role>
      <ShortName>LIQUIDITY AND CAPITAL RESOURCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060500 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060600 - Disclosure - IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill</Role>
      <ShortName>IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060700 - Disclosure - CEO SEPARATION AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CeoSeparationAgreement</Role>
      <ShortName>CEO SEPARATION AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>060800 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>060900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061100 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061200 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061300 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/EarningsPerShare</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>061400 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/RecentAccountingPronouncements</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>061500 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>070100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>071400 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eternatx.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080500 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eternatx.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>080900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eternatx.com/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081100 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eternatx.com/role/StockbasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>081300 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/EarningsPerShareTables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eternatx.com/role/EarningsPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090200 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LiquidityAndCapitalResourcesDetails</Role>
      <ShortName>LIQUIDITY AND CAPITAL RESOURCES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/LiquidityAndCapitalResources</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090302 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090304 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Disposition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Disposition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090306 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090308 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Investment in NoveCite (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails</Role>
      <ShortName>MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Investment in NoveCite (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS, Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS, Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090402 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS, Changes in Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS, Changes in Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090500 - Disclosure - LEASES, Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LeasesOperatingLeaseDetails</Role>
      <ShortName>LEASES, Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090502 - Disclosure - LEASES, Net Operating Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails</Role>
      <ShortName>LEASES, Net Operating Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090504 - Disclosure - LEASES, Operating Lease Right-of-use Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails</Role>
      <ShortName>LEASES, Operating Lease Right-of-use Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090506 - Disclosure - LEASES, Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES, Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090600 - Disclosure - IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails</Role>
      <ShortName>IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090700 - Disclosure - CEO SEPARATION AGREEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CeoSeparationAgreementDetails</Role>
      <ShortName>CEO SEPARATION AGREEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/CeoSeparationAgreement</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090800 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES, Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES, Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>091002 - Disclosure - COMMITMENTS AND CONTINGENCIES, Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES, Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>091004 - Disclosure - COMMITMENTS AND CONTINGENCIES, Royalty Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES, Royalty Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>091100 - Disclosure - STOCK-BASED COMPENSATION, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>091102 - Disclosure - STOCK-BASED COMPENSATION, Weighted-Average Assumptions Used for Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Weighted-Average Assumptions Used for Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>091104 - Disclosure - STOCK-BASED COMPENSATION, Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>091106 - Disclosure - STOCK-BASED COMPENSATION, RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationRsusDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>091108 - Disclosure - STOCK-BASED COMPENSATION, Number of RSUs Vested and Settled (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Number of RSUs Vested and Settled (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>091110 - Disclosure - STOCK-BASED COMPENSATION, Summary of RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Summary of RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>091112 - Disclosure - STOCK-BASED COMPENSATION, Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>091114 - Disclosure - STOCK-BASED COMPENSATION, Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION, Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>091200 - Disclosure - STOCKHOLDERS' EQUITY, Private Placement of Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Private Placement of Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>091202 - Disclosure - STOCKHOLDERS' EQUITY, Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/StockholdersEquityMergerDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>091300 - Disclosure - EARNINGS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/EarningsPerShareDetails</Role>
      <ShortName>EARNINGS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/EarningsPerShareTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="brhc10043851_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>091500 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://eternatx.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: erna:AggregateCalendarDays, erna:TermToPaySecurityDeposit, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  brhc10043851_10q.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="brhc10043851_10q.htm">brhc10043851_10q.htm</File>
    <File>brhc10043851_ex10-3.htm</File>
    <File>brhc10043851_ex31-1.htm</File>
    <File>brhc10043851_ex31-2.htm</File>
    <File>brhc10043851_ex32-1.htm</File>
    <File>brhc10043851_ex32-2.htm</File>
    <File>erna-20220930.xsd</File>
    <File>erna-20220930_cal.xml</File>
    <File>erna-20220930_def.xml</File>
    <File>erna-20220930_lab.xml</File>
    <File>erna-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image00001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="739">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10043851_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 234,
   "dts": {
    "calculationLink": {
     "local": [
      "erna-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "erna-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc10043851_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "erna-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "erna-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "erna-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 599,
   "entityCount": 1,
   "hidden": {
    "http://eternatx.com/20220930": 2,
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 137,
   "keyStandard": 250,
   "memberCustom": 30,
   "memberStandard": 29,
   "nsprefix": "erna",
   "nsuri": "http://eternatx.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://eternatx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:LiquidityAndCapitalResourcesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES",
     "role": "http://eternatx.com/role/LiquidityAndCapitalResources",
     "shortName": "LIQUIDITY AND CAPITAL RESOURCES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:LiquidityAndCapitalResourcesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "role": "http://eternatx.com/role/FairValueOfFinancialInstruments",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:LesseeOperatingAndFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - LEASES",
     "role": "http://eternatx.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:LesseeOperatingAndFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - IN-PROCESS RESEARCH & DEVELOPMENT AND GOODWILL",
     "role": "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill",
     "shortName": "IN-PROCESS RESEARCH & DEVELOPMENT AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:ChiefExecutiveOfficerSeparationAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - CEO SEPARATION AGREEMENT",
     "role": "http://eternatx.com/role/CeoSeparationAgreement",
     "shortName": "CEO SEPARATION AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:ChiefExecutiveOfficerSeparationAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://eternatx.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES",
     "role": "http://eternatx.com/role/AccruedExpensesAndOtherLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://eternatx.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://eternatx.com/role/StockbasedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://eternatx.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061300 - Disclosure - EARNINGS PER SHARE",
     "role": "http://eternatx.com/role/EarningsPerShare",
     "shortName": "EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061400 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://eternatx.com/role/RecentAccountingPronouncements",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061500 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://eternatx.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)",
     "role": "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071400 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies)",
     "role": "http://eternatx.com/role/RecentAccountingPronouncementsPolicies",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS (Tables)",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://eternatx.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - LEASES (Tables)",
     "role": "http://eternatx.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "role": "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081100 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://eternatx.com/role/StockbasedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "erna:ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081300 - Disclosure - EARNINGS PER SHARE (Tables)",
     "role": "http://eternatx.com/role/EarningsPerShareTables",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20221017",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "role": "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20221017",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)",
     "role": "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
     "shortName": "LIQUIDITY AND CAPITAL RESOURCES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20221018_SubsequentEventTypeAxis_SubsequentEventMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Merger (Details)",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090302 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090304 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Disposition (Details)",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Disposition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210101to20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090306 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Acquisition (Details)",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090308 - Disclosure - MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Investment in NoveCite (Details)",
     "role": "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
     "shortName": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS, Investment in NoveCite (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210716to20210716_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NoveCiteINCMember",
      "decimals": "INF",
      "lang": null,
      "name": "erna:NumberOfBoardSeats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS, Liabilities Measured at Fair Value (Details)",
     "role": "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS, Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "erna:OverSubscriptionAmountReceived",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090402 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS, Changes in Warrant Liabilities (Details)",
     "role": "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS, Changes in Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "erna:OperatingLeaseArea",
      "reportCount": 1,
      "unitRef": "U005",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - LEASES, Operating Lease (Details)",
     "role": "http://eternatx.com/role/LeasesOperatingLeaseDetails",
     "shortName": "LEASES, Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": "2",
      "lang": null,
      "name": "erna:BaseRentPerSquareFoot",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090502 - Disclosure - LEASES, Net Operating Lease Expenses (Details)",
     "role": "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails",
     "shortName": "LEASES, Net Operating Lease Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090504 - Disclosure - LEASES, Operating Lease Right-of-use Assets and Liabilities (Details)",
     "role": "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails",
     "shortName": "LEASES, Operating Lease Right-of-use Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": "-3",
      "lang": null,
      "name": "erna:RemeasurementOfOperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090506 - Disclosure - LEASES, Maturities of Operating Lease Liabilities (Details)",
     "role": "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "LEASES, Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - IN-PROCESS RESEARCH & DEVELOPMENT AND GOODWILL (Details)",
     "role": "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails",
     "shortName": "IN-PROCESS RESEARCH & DEVELOPMENT AND GOODWILL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - CEO SEPARATION AGREEMENT (Details)",
     "role": "http://eternatx.com/role/CeoSeparationAgreementDetails",
     "shortName": "CEO SEPARATION AGREEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220524to20220524_TitleOfIndividualAxis_ChiefExecutiveOfficerMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsForPostemploymentBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://eternatx.com/role/RelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220909to20220909_RelatedPartyTransactionsByRelatedPartyAxis_FactorBioscienceIncMember",
      "decimals": "-5",
      "lang": null,
      "name": "erna:AgreedWaivePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "role": "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220805to20220805",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - COMMITMENTS AND CONTINGENCIES, Legal Matters (Details)",
     "role": "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES, Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220805to20220805",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "erna:MilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091002 - Disclosure - COMMITMENTS AND CONTINGENCIES, Licensing Agreements (Details)",
     "role": "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES, Licensing Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "erna:MilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091004 - Disclosure - COMMITMENTS AND CONTINGENCIES, Royalty Agreements (Details)",
     "role": "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES, Royalty Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "erna:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - STOCK-BASED COMPENSATION, Stock Option Activity (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
     "shortName": "STOCK-BASED COMPENSATION, Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091102 - Disclosure - STOCK-BASED COMPENSATION, Weighted-Average Assumptions Used for Stock Options Granted (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails",
     "shortName": "STOCK-BASED COMPENSATION, Weighted-Average Assumptions Used for Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091104 - Disclosure - STOCK-BASED COMPENSATION, Summary of Stock Options (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION, Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091106 - Disclosure - STOCK-BASED COMPENSATION, RSUs (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationRsusDetails",
     "shortName": "STOCK-BASED COMPENSATION, RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091108 - Disclosure - STOCK-BASED COMPENSATION, Number of RSUs Vested and Settled (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails",
     "shortName": "STOCK-BASED COMPENSATION, Number of RSUs Vested and Settled (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091110 - Disclosure - STOCK-BASED COMPENSATION, Summary of RSUs (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
     "shortName": "STOCK-BASED COMPENSATION, Summary of RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930_AwardTypeAxis_Two022PerformanceBasedRestrictedStockUnitsMember",
      "decimals": "INF",
      "lang": null,
      "name": "erna:NumberOfPerformanceGoalsAreSubjectToAchieve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U008",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091112 - Disclosure - STOCK-BASED COMPENSATION, Restricted Stock (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
     "shortName": "STOCK-BASED COMPENSATION, Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091114 - Disclosure - STOCK-BASED COMPENSATION, Stock-Based Compensation Expense (Details)",
     "role": "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION, Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY",
     "role": "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091200 - Disclosure - STOCKHOLDERS' EQUITY, Private Placement of Equity (Details)",
     "role": "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Private Placement of Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember",
      "decimals": "4",
      "lang": null,
      "name": "erna:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210325to20210325",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "erna:StockIssuedDuringPeriodSharesAcquisitions1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091202 - Disclosure - STOCKHOLDERS' EQUITY, Merger (Details)",
     "role": "http://eternatx.com/role/StockholdersEquityMergerDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20210325to20210325",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "erna:StockIssuedDuringPeriodSharesAcquisitions1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091300 - Disclosure - EARNINGS PER SHARE (Details)",
     "role": "http://eternatx.com/role/EarningsPerShareDetails",
     "shortName": "EARNINGS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220701to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091500 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://eternatx.com/role/SubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20221018_RelatedPartyTransactionsByRelatedPartyAxis_ERSquibbSonsLLCMember_SubsequentEventTypeAxis_SubsequentEventMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (Parenthetical)",
     "role": "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "role": "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10043851_10q.htm",
      "contextRef": "c20220101to20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "erna_AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for accrual of fractional shares to be paid in connection with reverse stock split.",
        "label": "Accrual for Fractional Shares to be Paid in Connection with Reverse Stock Split",
        "negatedLabel": "Accrual for fractional shares to be paid in connection with reverse stock split"
       }
      }
     },
     "localname": "AccrualForFractionalSharesToBePaidInConnectionWithReverseStockSplit",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AccruedGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued general and administrative expenses.",
        "label": "Accrued General and Administrative Expenses",
        "terseLabel": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued research and development expenses.",
        "label": "Accrued Research and Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AcquisitionAgreementNonCompetitivePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Acquisition Agreement contains non-competition and non-solicitation provisions pursuant to which the Seller has agreed not to engage in certain competitive activities for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquisition Agreement, Non Competitive Period",
        "terseLabel": "Non-compete period"
       }
      }
     },
     "localname": "AcquisitionAgreementNonCompetitivePeriod",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_AdditionalFeesObligatedToPay": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity is obligated to pay additional fees to Licensors.",
        "label": "Additional Fees Obligated to Pay",
        "terseLabel": "Amount require to pay of initial license fees"
       }
      }
     },
     "localname": "AdditionalFeesObligatedToPay",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in redemption of temporary equity as the result of a triggering event associated with the temporary equity.",
        "label": "Adjustments to Additional Paid in Capital, Elimination Historical Member Equity",
        "terseLabel": "Elimination of Brooklyn's historical members' equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AggregateCalendarDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered in specified aggregate calendar days (which need not be consecutive calendar days) during any 12-month period for resale in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Aggregate Calendar Days",
        "terseLabel": "Aggregate calendar days"
       }
      }
     },
     "localname": "AggregateCalendarDays",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_AgreedWaivePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount agreed to waive payment as per waiver agreement.",
        "label": "Agreed Waive Payment",
        "terseLabel": "Agreed waive payment"
       }
      }
     },
     "localname": "AgreedWaivePayment",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AmountObligatedToPayInYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity is obligated to pay additional fees to the Licensors in first year.",
        "label": "Amount Obligated to Pay in Year One",
        "terseLabel": "Additional fees obligated to pay in 2021"
       }
      }
     },
     "localname": "AmountObligatedToPayInYearOne",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AmountObligatedToPayInYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity is obligated to pay additional fees to the Licensors in second year.",
        "label": "Amount Obligated to Pay in Year Two",
        "terseLabel": "Additional fees obligated to pay in 2022"
       }
      }
     },
     "localname": "AmountObligatedToPayInYearTwo",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AmountRequireToPayInitialLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount require to pay out of the total initial license fees.",
        "label": "Amount Require to Pay Initial License Fees",
        "terseLabel": "Amount obligated to pay in license agreement"
       }
      }
     },
     "localname": "AmountRequireToPayInitialLicenseFees",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AssetAcquisitionFairValueOfConsiderationPaid": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fair value of consideration paid in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Fair Value of Consideration Paid",
        "totalLabel": "Total fair value of consideration paid"
       }
      }
     },
     "localname": "AssetAcquisitionFairValueOfConsiderationPaid",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_AssetAcquisitionRestrictedSharesSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered with restrictions to be paid in asset acquisition.",
        "label": "Asset Acquisition, Restricted Shares, Share Price",
        "terseLabel": "Restricted shares, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionRestrictedSharesSharePrice",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "erna_AssetAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in asset acquisition.",
        "label": "Asset Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionSharePrice",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "erna_AssetAcquisitionUnrestrictedSharesSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered without any restrictions to be paid in asset acquisition.",
        "label": "Asset Acquisition, Unrestricted Shares, Share Price",
        "terseLabel": "Unrestricted shares, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionUnrestrictedSharesSharePrice",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "erna_BaseRentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent expense per square foot for leased asset.",
        "label": "Base Rent per Square Foot",
        "terseLabel": "Base rent (per square foot)"
       }
      }
     },
     "localname": "BaseRentPerSquareFoot",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "erna_BeneficialHoldersContractualCommitmentsToInvest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual commitment made by beneficial holders to invest in the entity.",
        "label": "Beneficial Holders Contractual Commitments To Invest",
        "terseLabel": "Beneficial holders contractual commitments to invest"
       }
      }
     },
     "localname": "BeneficialHoldersContractualCommitmentsToInvest",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of software development costs recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Software Development Costs",
        "terseLabel": "Software development costs"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_CEOSEPARATIONAGREEMENTAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO SEPARATION AGREEMENT [Abstract]"
       }
      }
     },
     "localname": "CEOSEPARATIONAGREEMENTAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "xbrltype": "stringItemType"
    },
    "erna_CashPaidDuringThePeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid During the Period for [Abstract]",
        "terseLabel": "Cash paid during the period for:"
       }
      }
     },
     "localname": "CashPaidDuringThePeriodForAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_CashPaidForFractionalSharesInConnectionWithReverseStockSplit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fractional shares in connection with reverse stock split.",
        "label": "Cash Paid for Fractional Shares in Connection with Reverse Stock Split",
        "verboseLabel": "Amount paid for fractional share in connection with reverse stock split"
       }
      }
     },
     "localname": "CashPaidForFractionalSharesInConnectionWithReverseStockSplit",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chair of the board of directors, former chief executive officer and president.",
        "label": "Chair of the Board of Directors, Former Chief Executive Officer and President [Member]",
        "terseLabel": "Chair of the Board of Directors, Former Chief Executive Officer and President [Member]"
       }
      }
     },
     "localname": "ChairOfTheBoardOfDirectorsFormerChiefExecutiveOfficerAndPresidentMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ChiefExecutiveOfficerAndPresidentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer and president.",
        "label": "Chief Executive Officer and President [Member]",
        "terseLabel": "Dr. Federoff [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerAndPresidentMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ChiefExecutiveOfficerSeparationAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to chief executive officer separation agreement.",
        "label": "Chief Executive Officer Separation Agreement [Text Block]",
        "terseLabel": "CEO SEPARATION AGREEMENT"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerSeparationAgreementTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_CitiusPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Citius Pharmaceuticals, Inc. Ownership interest.",
        "label": "Citius Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "CitiusPharmaceuticalsIncMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Exercised",
        "verboseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued into which the class of warrant or right may be converted.",
        "label": "Class of Warrant or Right, Issued",
        "terseLabel": "Number of rights options issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of securities that would be issuable upon the exercise of warrants or rights.",
        "label": "Class of Warrant or Right Percent of Securities that Would be Issuable Upon Exercise of Warrants or Rights",
        "terseLabel": "Percentage of warrants exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_ClassOfWarrantOrRightsExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants or rights exercisable term, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Class of Warrant or Rights Exercisable Term",
        "terseLabel": "Warrant exercisable term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExercisableTerm",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_CollaboratorRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative royalty arrangement in licensing deal with the company.",
        "label": "Collaborator Royalty Agreement [Member]",
        "terseLabel": "Collaborator Royalty Agreement [Member]"
       }
      }
     },
     "localname": "CollaboratorRoyaltyAgreementMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_CommonStockToBeRetainedByNTNSharesStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock to be retained by NTN stockholders during the period pursuant to acquisitions.",
        "label": "Common Stock to be Retained by NTN, Shares, Stockholders",
        "terseLabel": "Common stock to be retained by NTN stockholders (in shares)"
       }
      }
     },
     "localname": "CommonStockToBeRetainedByNTNSharesStockholders",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_CommonStockToBeRetainedByNTNValueStockholders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock to be retained by NTN stockholders during the period.",
        "label": "Common Stock to be Retained by NTN, Value, Stockholders",
        "terseLabel": "Common stock to be retained by NTN stockholders"
       }
      }
     },
     "localname": "CommonStockToBeRetainedByNTNValueStockholders",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_CommonStockWithheldToCoverTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of common stock withheld to cover the withholding taxes.",
        "label": "Common Stock Withheld to Cover Taxes",
        "negatedLabel": "Common stock withheld to cover taxes (in shares)"
       }
      }
     },
     "localname": "CommonStockWithheldToCoverTaxes",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_CommonUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than provided to common units, representing ownership interest in a corporation.",
        "label": "Common Units [Member]",
        "verboseLabel": "Common [Member]"
       }
      }
     },
     "localname": "CommonUnitsMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_CommonWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A common warrant represents the right to purchase a company's stock at a specific price and at a specific date.",
        "label": "Common Warrants [Member]",
        "terseLabel": "Common Warrants [Member]"
       }
      }
     },
     "localname": "CommonWarrantsMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ConsecutiveCalendarDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event the PIPE Investor is not permitted to use the registration statement to resell the securities registered in specified consecutive calendar days for resale, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Consecutive Calendar Days",
        "terseLabel": "Consecutive calendar days"
       }
      }
     },
     "localname": "ConsecutiveCalendarDays",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_ConversionOfWarrantLiabilityToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The conversion of warrant liability to equity in non-cash investing and financing activities.",
        "label": "Conversion of Warrant Liability to Equity",
        "terseLabel": "Conversion of warrant liability to equity"
       }
      }
     },
     "localname": "ConversionOfWarrantLiabilityToEquity",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_CurrentPortionOfLicenseFeeObligation": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of License Fee Obligation",
        "label": "Current portion of License Fee Obligation"
       }
      }
     },
     "localname": "CurrentPortionOfLicenseFeeObligation",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deposit paid which will be applied to the last month of the first work order.",
        "label": "Deposit Paid to be Applied to Last Month of First Work Order",
        "terseLabel": "Deposit paid to be applied to last month of first work order"
       }
      }
     },
     "localname": "DepositPaidToBeAppliedToLastMonthOfFirstWorkOrder",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Detailed information about Liquidity and Capital Resources [Abstract]",
        "verboseLabel": "Liquidity and Capital Resources [Abstract]"
       }
      }
     },
     "localname": "DetailedInformationAboutLiquidityAndCapitalResourcesAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_DheshGovenderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dhesh Govender, a former short-term consultant of the entity",
        "label": "Dhesh Govender [Member]",
        "terseLabel": "Govender [Member]"
       }
      }
     },
     "localname": "DheshGovenderMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as Lease liability attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Lease liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiability",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as Obligations under finance leases attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Obligations under finance leases",
        "terseLabel": "Obligations under finance leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received from assume advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Assume Advance/Loans",
        "terseLabel": "Assume advance/loans"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromCash",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received from escrow deposits in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Escrow",
        "terseLabel": "Escrow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received from interest on advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Interest on Advance/Loans",
        "terseLabel": "Interest on advance/loans"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as software development cost attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Software development costs",
        "negatedLabel": "Software development costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of the business disposal including legal, accounting, and other costs incurred to consummate the business disposition.",
        "label": "Disposal Group, Including Discontinued Operation, Transaction Costs",
        "negatedLabel": "Transaction costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_DispositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposition [Abstract]"
       }
      }
     },
     "localname": "DispositionAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_ERSquibbSonsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Delaware limited liability company (\"Sublessor\"), for office, laboratory and research and development space (the \"Premises\").",
        "label": "E.R. Squibb &amp; Sons, L.L.C. [Member]",
        "terseLabel": "E.R. Squibb &amp; Sons, L.L.C. [Member]"
       }
      }
     },
     "localname": "ERSquibbSonsLLCMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_EachLockUpAgreementExtendsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Each Lock-up Agreement Extends Term",
        "terseLabel": "Each lock-up agreement extend term"
       }
      }
     },
     "localname": "EachLockUpAgreementExtendsTerm",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of the employee of the entity, appointed to the position.",
        "label": "Employee [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_EscrowShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares have been placed in escrow shares.",
        "label": "Escrow Shares",
        "terseLabel": "Escrow shares (in shares)"
       }
      }
     },
     "localname": "EscrowShares",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_ExacisBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Delaware corporation the company entered into Option Agreement.",
        "label": "Exacis Biotherapeutics, Inc. [Member]",
        "terseLabel": "Exacis Biotherapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "ExacisBiotherapeuticsIncMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ExacisOptionAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exacis Option Agreement [Abstract]",
        "terseLabel": "Exacis Option Agreement [Abstract]"
       }
      }
     },
     "localname": "ExacisOptionAgreementAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_FacilitySubleaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Sublease [Abstract]",
        "terseLabel": "Facility Sublease [Abstract]"
       }
      }
     },
     "localname": "FacilitySubleaseAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_FactorBioscienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A corporation the company entered into agreement to provide the Company with MRNA cell engineering research support services, including access to certain facilities, equipment, materials and training, and the Company.",
        "label": "Factor Bioscience Inc. [Member]",
        "terseLabel": "Factor Bioscience Inc. [Member]"
       }
      }
     },
     "localname": "FactorBioscienceIncMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the fees incurred in connection with the common stock issued to Lincoln Park to the entity.",
        "label": "Fees Incurred in Connection With the Common Stock Issued to Lincoln Park",
        "negatedLabel": "Fees incurred in connection with the common stock issued to Lincoln Park"
       }
      }
     },
     "localname": "FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_GainLossOnDisposalOfFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of fixed assets.",
        "label": "Gain (Loss) on Disposal of Fixed Assets",
        "terseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDisposalOfFixedAssets",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_GainLossOnForgivenessOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on forgiveness of PPP loan.",
        "label": "Gain (Loss) on Forgiveness of Paycheck Protection Program Loan",
        "negatedLabel": "Gain on forgiveness of PPP loan"
       }
      }
     },
     "localname": "GainLossOnForgivenessOfPaycheckProtectionProgramLoan",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_GainOnTerminationOfLease": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain on termination of lease before expiration of lease term.",
        "label": "Gain on Termination of Lease",
        "negatedLabel": "Gain on lease termination"
       }
      }
     },
     "localname": "GainOnTerminationOfLease",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the operating lease liabilities.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InitialLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial license fees required to pay including non-refundable fee.",
        "label": "Initial License Fees",
        "terseLabel": "Initial license fees"
       }
      }
     },
     "localname": "InitialLicenseFees",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InitialMeasurementOfFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of initial measurement of finance lease liabilities in noncash financing activities.",
        "label": "Initial Measurement of Finance Lease Liabilities",
        "terseLabel": "Initial measurement of finance lease liabilities"
       }
      }
     },
     "localname": "InitialMeasurementOfFinanceLeaseLiabilities",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InitialMeasurementOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of initial measurement of operating lease liabilities in noncash financing activities.",
        "label": "Initial Measurement of Operating Lease Liabilities",
        "terseLabel": "Initial measurement of operating lease liabilities"
       }
      }
     },
     "localname": "InitialMeasurementOfOperatingLeaseLiabilities",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/LeasesOperatingLeaseDetails",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InitialMeasurementOfOperatingLeaseROUAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of initial measurement of operating lease ROU assets.",
        "label": "Initial Measurement of Operating Lease ROU Assets",
        "terseLabel": "Initial measurement of operating lease ROU assets"
       }
      }
     },
     "localname": "InitialMeasurementOfOperatingLeaseROUAssets",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InitialMeasurementOfRightOfUseAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of Initial measurement of ROU assets and liabilities in noncash financing activities.",
        "label": "Initial Measurement of Right-of-Use Assets and Liabilities",
        "terseLabel": "Initial measurement of ROU assets, net of tenant improvement allowance"
       }
      }
     },
     "localname": "InitialMeasurementOfRightOfUseAssetsAndLiabilities",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InsurancePolicyPremiums": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for insurance policy premiums.",
        "label": "Insurance Policy Premiums",
        "terseLabel": "Insurance policy premiums"
       }
      }
     },
     "localname": "InsurancePolicyPremiums",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_InterimChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of interim chief executive officer.",
        "label": "Interim Chief Executive Officer [Member]",
        "terseLabel": "Dr. Matthew Angel [Member]"
       }
      }
     },
     "localname": "InterimChiefExecutiveOfficerMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_InvestorRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement other than collaborative applicable to investor royalty.",
        "label": "Investor Royalty Agreement [Member]",
        "terseLabel": "Investor Royalty Agreement [Member]"
       }
      }
     },
     "localname": "InvestorRoyaltyAgreementMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_IssuanceOfCommonStockForAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The issuance of common stock for asset acquisition in noncash financing activities.",
        "label": "Issuance of Common Stock for Asset Acquisition",
        "terseLabel": "Issuance of common Stock for Novellus acquisition"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForAssetAcquisition",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_IssuanceOfCommonStockForSeriesAPreferredStockDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of issuance of common stock for Series A preferred stock dividend in non-cash investing and financing activities.",
        "label": "Issuance of Common Stock for Series A Preferred Stock Dividend",
        "verboseLabel": "Issuance of common stock for Series A preferred stock dividend"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForSeriesAPreferredStockDividend",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_IssuanceOfCommonStockFromExerciseOfPreFundedWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash flows from issuance of common stock from exercise of pre-funded warrants.",
        "label": "Issuance of Common Stock from Exercise of Pre-funded Warrants",
        "negatedLabel": "Issuance of common stock from exercise of pre-funded warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonStockFromExerciseOfPreFundedWarrants",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_LIQUIDITYANDCAPITALRESOURCESAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY AND CAPITAL RESOURCES [Abstract]"
       }
      }
     },
     "localname": "LIQUIDITYANDCAPITALRESOURCESAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "xbrltype": "stringItemType"
    },
    "erna_LegalMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Matters [Abstract]",
        "terseLabel": "Legal Matters [Abstract]"
       }
      }
     },
     "localname": "LegalMattersAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_LesseeCommitmentToPurchaseProperty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property for which lessee committed to purchase.",
        "label": "Lessee, Commitment to Purchase Property",
        "terseLabel": "Commitment to purchase equipment"
       }
      }
     },
     "localname": "LesseeCommitmentToPurchaseProperty",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_LesseeOperatingAndFinanceLeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of lessee's finance and operating lease and maturity analysis of finance and operating lease liability.",
        "label": "Lessee Operating and Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Lessee Operating Lease Weighted Average Remaining Lease Term And Discount Rate Abstract [Abstract]",
        "terseLabel": "Weighted Average Remaining Lease Term and Discount Rate [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_LicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Abstract]",
        "terseLabel": "Licensing Agreements [Abstract]"
       }
      }
     },
     "localname": "LicensingAgreementsAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_LiquidityAndCapitalResourcesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.",
        "label": "Liquidity And Capital Resources [Text Block]",
        "terseLabel": "LIQUIDITY AND CAPITAL RESOURCES"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResources"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_LockUpPeriodForRestrictedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period in which shares are locked-up, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Lock-up Period for Restricted Shares",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "LockUpPeriodForRestrictedShares",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_LongTermPortionOfLicenseFeeObligation": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term portion of License Fee Obligation",
        "label": "Long-term portion of License Fee Obligation"
       }
      }
     },
     "localname": "LongTermPortionOfLicenseFeeObligation",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_LossContingencyDamagesSoughtExpectedEquityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of equity promised to the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Expected Equity Percentage",
        "terseLabel": "Percentage of equity promised against plaintiff"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtExpectedEquityPercentage",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_LossContingencyDamagesSoughtExpectedSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The monetary amount of salary promised to the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Expected Salary",
        "terseLabel": "Defendants salary promised against plaintiff"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtExpectedSalary",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_LossContingencyNonRefundableOptionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Non-refundable option fee in licensing agreement.",
        "label": "Loss Contingency, Non-refundable Option Fee",
        "terseLabel": "Non-refundable option fee"
       }
      }
     },
     "localname": "LossContingencyNonRefundableOptionFee",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_LossContingencyNumberOfArbitrationPanel": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number member in arbitration panel pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, Number of Arbitration Panel Member",
        "terseLabel": "Number of member arbitration panel"
       }
      }
     },
     "localname": "LossContingencyNumberOfArbitrationPanel",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "erna_LossContingencyPercentageOfRoyaltyPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payable from one party to another in licensing agreement.",
        "label": "Loss contingency, Percentage of Royalty Payable",
        "terseLabel": "Percentage of royalty payable"
       }
      }
     },
     "localname": "LossContingencyPercentageOfRoyaltyPayable",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_LossOnNonControllingInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss on non-controlling investment.",
        "label": "Loss on Non-controlling Investment",
        "negatedLabel": "Loss on non-controlling investment",
        "terseLabel": "Loss on non-controlling investment"
       }
      }
     },
     "localname": "LossOnNonControllingInvestment",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_MasterServiceAgreementInitialFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount agreed to pay an initial fee under Master Services Agreement (or \"MSA\").",
        "label": "Master Service Agreement, Initial Fees Payable",
        "terseLabel": "Master services agreement, initial fees payable"
       }
      }
     },
     "localname": "MasterServiceAgreementInitialFeesPayable",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_MembershipEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity membership interest in entity.",
        "label": "Membership Equity [Member]",
        "terseLabel": "Membership Equity [Member]"
       }
      }
     },
     "localname": "MembershipEquityMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_MergerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Abstract]"
       }
      }
     },
     "localname": "MergerAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_MilestoneOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions based on milestones.",
        "label": "Milestone Options [Member]",
        "terseLabel": "Milestone Options [Member]"
       }
      }
     },
     "localname": "MilestoneOptionsMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestones upfront payment on licenses.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_MonthlyMasterServicesAgreementFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The monthly master service agreement (\"MSA\") fees payable to related party.",
        "label": "Monthly Master Services Agreement Fees Payable",
        "terseLabel": "Monthly master services agreement fees payable initial 12-month"
       }
      }
     },
     "localname": "MonthlyMasterServicesAgreementFeesPayable",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_NTNBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the disposal group.",
        "label": "NTN Business [Member]",
        "terseLabel": "NTN Business [Member]"
       }
      }
     },
     "localname": "NTNBusinessMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NTNBuzztimeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of acquiree entity.",
        "label": "NTN Buzztime, Inc [Member]",
        "terseLabel": "NTN Buzztime, Inc [Member]"
       }
      }
     },
     "localname": "NTNBuzztimeIncMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NewFacilityLeaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Facility Lease [Abstract]"
       }
      }
     },
     "localname": "NewFacilityLeaseAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of preferred stock issued in a reverse merger transaction in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Preferred Shares Issued in Connection with Reverse Merger",
        "terseLabel": "Series A preferred stock retained in business combination"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_NoticePeriodForFirstTerminationOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Company may terminate the first work under the MSA on or after the second anniversary of the date of the MSA, subject to providing Factor with prior notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Notice Period for First Termination of Contract",
        "terseLabel": "Notice period for first termination of contract"
       }
      }
     },
     "localname": "NoticePeriodForFirstTerminationOfContract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_NoticePeriodForSupersedingTerminationProvisions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Master Services Agreement (or \"MSA\") contains customary confidentiality provisions and representations and warranties of the parties, and the Master Services Agreement (or \"MSA\") may be terminated by ether party prior notice, subject to any superseding termination provisions contained in a particular work order, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Notice Period for Superseding Termination Provisions",
        "terseLabel": "Notice period for superseding termination provisions"
       }
      }
     },
     "localname": "NoticePeriodForSupersedingTerminationProvisions",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_NoveCiteINCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "NoveCite, INC. [Member]",
        "terseLabel": "NoveCite, INC. [Member]"
       }
      }
     },
     "localname": "NoveCiteINCMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NoveCiteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "NoveCite [Member]",
        "terseLabel": "NoveCite [Member]"
       }
      }
     },
     "localname": "NoveCiteMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NovellusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "Novellus, Inc. [Member]"
       }
      }
     },
     "localname": "NovellusIncMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NovellusLtdAndFactorBioscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of companies involved in licensing agreement.",
        "label": "Novellus Ltd. and Factor Bioscience [Member]",
        "terseLabel": "Licensors [Member]"
       }
      }
     },
     "localname": "NovellusLtdAndFactorBioscienceMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NovellusTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "Novellus Therapeutics Limited [Member]",
        "terseLabel": "Novellus, Ltd. [Member]"
       }
      }
     },
     "localname": "NovellusTherapeuticsLimitedMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_NumberOfAwardsVestedAndSettledAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Awards Vested and Settled [Abstract]",
        "terseLabel": "Number of RSUs Vested and Settled [Abstract]"
       }
      }
     },
     "localname": "NumberOfAwardsVestedAndSettledAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_NumberOfBoardSeats": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members of the company's management holds board seats on board of directors.",
        "label": "Number of Board Seats",
        "terseLabel": "Number of board seats"
       }
      }
     },
     "localname": "NumberOfBoardSeats",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "erna_NumberOfMonthlyInstallmentsForFeesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equal monthly installments for initial fees payable.",
        "label": "Number of Monthly Installments for Fees Payable",
        "terseLabel": "Number of monthly installments for fees payable"
       }
      }
     },
     "localname": "NumberOfMonthlyInstallmentsForFeesPayable",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "erna_NumberOfPerformanceGoalsAreSubjectToAchieve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of performance goals are subject to achieve under 2022 performance based restricted stock units.",
        "label": "Number of Performance Goals are Subject to Achieve",
        "terseLabel": "Number of performance goals are subject to achieve"
       }
      }
     },
     "localname": "NumberOfPerformanceGoalsAreSubjectToAchieve",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "erna_NumberOfSharesConsideredAsFractionalInReverseStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares considered as fractional in reverse stock split.",
        "label": "Number of Shares Considered as Fractional in Reverse Stock",
        "terseLabel": "Number of fractional shares considered in reverse stock split (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesConsideredAsFractionalInReverseStock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents obligated to maintain under merger agreement on balance sheet at the effective time of the merger.",
        "label": "Obligated to Maintain Cash and Cash Equivalents Under Merger Agreement",
        "terseLabel": "Cash and cash equivalents obligated to have under merger agreement"
       }
      }
     },
     "localname": "ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_ObligationToPayLiquidatedDamagesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pursuant to the registration rights agreement, obligation to pay the PIPE Investor liquidated damages percentage of aggregate payment on Subscription Amount.",
        "label": "Obligation to Pay Liquidated Damages Percentage",
        "terseLabel": "Obligated to pay liquidated damages percentage"
       }
      }
     },
     "localname": "ObligationToPayLiquidatedDamagesPercentage",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pursuant to the registration rights agreement, obligation to pay the PIPE Investor liquidated damages equal to the Subscription Amount per month.",
        "label": "Obligation to Pay Liquidated Damages Percentage on Subscription Amount per Month",
        "terseLabel": "Obligation to pay liquidated damages per month"
       }
      }
     },
     "localname": "ObligationToPayLiquidatedDamagesPercentageOnSubscriptionAmountPerMonth",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_OperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased property under operating lease.",
        "label": "Operating Lease Area",
        "terseLabel": "Operating lease area"
       }
      }
     },
     "localname": "OperatingLeaseArea",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "erna_OperatingLeaseAssestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Asset [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseAssestAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating lease right-of-use assets and liabilities.",
        "label": "Operating Lease Right-of-use Assets and Liabilities [Table Text Block]",
        "terseLabel": "Operating Lease Right-of-use Assets and Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_OperatingLeasesMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rental expense payable per month for operating leases.",
        "label": "Operating Leases, Monthly Base Rent",
        "terseLabel": "Monthly base rent payable"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyBaseRent",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_OptionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of option fee in licensing agreement.",
        "label": "Option Fee",
        "terseLabel": "Option fee"
       }
      }
     },
     "localname": "OptionFee",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_OverSubscriptionAmountReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over-subscription amount received in PIPE (Private Investment in Public Equity) transaction.",
        "label": "Over-Subscription Amount Received",
        "terseLabel": "Over-subscription amount received"
       }
      }
     },
     "localname": "OverSubscriptionAmountReceived",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_PIPEInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private investment in public equity, often called a PIPE deal, involves the selling of publicly traded common shares or some form of preferred stock or convertible security to private investors. It is an allocation of shares in a public company not through a public offering in a stock exchange. PIPE deals are part of the primary market. In the U.S., a PIPE offering may be registered with the Securities and Exchange Commission on a registration statement or may be completed as an unregistered private placement.",
        "label": "PIPE Investor [Member]",
        "terseLabel": "PIPE Investor [Member]"
       }
      }
     },
     "localname": "PIPEInvestorMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_PaymentToOfficerBaseSalary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflows for payment of annual base salary for a period of twelve months after the expiration of the applicable revocation period.",
        "label": "Payment to Officer Base Salary",
        "terseLabel": "Payment of annual base salary"
       }
      }
     },
     "localname": "PaymentToOfficerBaseSalary",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_PaymentsOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for payment of paycheck protection program loans.",
        "label": "Payments of Paycheck Protection Program Loan",
        "negatedLabel": "Repayment of NTN's PPP loan"
       }
      }
     },
     "localname": "PaymentsOfPaycheckProtectionProgramLoan",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_PaymentsToAcquireProductiveAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.",
        "label": "Cash paid, net",
        "negatedLabel": "Purchase of Novellus, net of common stock issue and cash acquired",
        "terseLabel": "Cash paid, net"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssetsNet",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_PercentageBaseRentIncreaseOnEachAnniversary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of base rent increase on each anniversary.",
        "label": "Percentage, Base Rent Increase on each Anniversary",
        "terseLabel": "Percentage of increase in base rent on each year"
       }
      }
     },
     "localname": "PercentageBaseRentIncreaseOnEachAnniversary",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PercentageOfAdditionalRightsOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional right offering made by the entity for unit holders.",
        "label": "Percentage of Additional Rights Offering",
        "terseLabel": "Percentage of additional rights offering"
       }
      }
     },
     "localname": "PercentageOfAdditionalRightsOffering",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PercentageOfCommonStockSubjectToLockUpAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of shares of common stock subject to the lock-up agreement",
        "label": "Percentage of Common Stock Subject to Lock-up Agreement",
        "terseLabel": "Percentage of common stock subject to the lock-up agreement"
       }
      }
     },
     "localname": "PercentageOfCommonStockSubjectToLockUpAgreement",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PercentageOfDiscountOnFairValueOfRestrictedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of discount on restricted shares, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models.",
        "label": "Percentage of Discount on Fair Value of Restricted Shares",
        "terseLabel": "Percentage of discount on fair value restricted shares"
       }
      }
     },
     "localname": "PercentageOfDiscountOnFairValueOfRestrictedShares",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional royalty payable on gross sales by the entity.",
        "label": "Percentage of Payment Of Additional Royalty On Gross Sales",
        "terseLabel": "Percentage of payment of additional royalty on gross sales"
       }
      }
     },
     "localname": "PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue from receives any revenue involving the original cell line included in the licensed technology, then Novellus, Ltd shall remit to NoveCite.",
        "label": "Percentage of Revenue",
        "terseLabel": "Percentage of revenue"
       }
      }
     },
     "localname": "PercentageOfRevenue",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty receive equal to revenues generated from disposition of business.",
        "label": "Percentage of Royalty Receive Equal to Revenues from Sale of Business",
        "terseLabel": "Percentage of royalty receive equal to revenues from sale of business"
       }
      }
     },
     "localname": "PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "erna_PerformanceBasedStockOptionGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.",
        "label": "Performance-Based Stock Option Grant [Member]",
        "terseLabel": "Milestone Grant [Member]"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionGrantMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price.",
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_PrincipalPaymentsOnOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal payments on operating lease liabilities.",
        "label": "Principal payments on operating lease liabilities",
        "negatedLabel": "Principal payments on operating lease liabilities"
       }
      }
     },
     "localname": "PrincipalPaymentsOnOperatingLeaseLiabilities",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_PrivatePlacementOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement of Equity [Abstract]",
        "terseLabel": "Private Placement of Equity [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementOfEquityAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_ProFormaFairValueAdjustmentToAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment to acquisition-date assets reported in proforma information.",
        "label": "Pro Forma Fair Value Adjustment to Assets [Member]",
        "terseLabel": "Fair Value Adjustment to Assets [Member]"
       }
      }
     },
     "localname": "ProFormaFairValueAdjustmentToAssetsMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ProceedsFromDispositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Disposition [Abstract]",
        "terseLabel": "Proceeds from sale [Abstract]"
       }
      }
     },
     "localname": "ProceedsFromDispositionAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_ProceedsFromIssuanceOfCommonStockToLincolnPark": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the proceeds from issuance of common stock to Lincoln Park to the entity.",
        "label": "Proceeds From Issuance of Common Stock to Lincoln Park",
        "terseLabel": "Proceeds from issuance of common stock to Lincoln Park"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockToLincolnPark",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_ProceedsFromSaleOfRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of rights during the period.",
        "label": "Proceeds From Sale Of Rights",
        "terseLabel": "Proceeds from right offering"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRights",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_PurchasePriceAllocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price allocation of acquisition-date assets and liability assumed.",
        "label": "Purchase Price Allocation [Member]"
       }
      }
     },
     "localname": "PurchasePriceAllocationMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_ReimburseCostsIncurredOrPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount reimburse for costs already incurred or paid.",
        "label": "Reimburse Costs Incurred or Paid",
        "terseLabel": "Reimburse costs incurred or paid"
       }
      }
     },
     "localname": "ReimburseCostsIncurredOrPaid",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_RelatedPartyTransactionPeriodicFeesPaymentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of required periodic fees payment.",
        "label": "Related Party Transaction, Periodic Fees Payment, Amount",
        "terseLabel": "Monthly installment fees amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionPeriodicFeesPaymentAmount",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_RemeasurementOfOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of remeasurement of operating lease right-of-use asset.",
        "label": "Remeasurement of Operating Lease Right-of-use Asset",
        "terseLabel": "Remeasurement of ROU asset"
       }
      }
     },
     "localname": "RemeasurementOfOperatingLeaseRightOfUseAsset",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_ResearchAndDevelopmentInProcessAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process, Asset Acquisition",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "In-process R&amp;D acquired in Novellus asset acquisition"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessAssetAcquisition",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_ReverseStockSplitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock-Split [Abstract]",
        "terseLabel": "Reverse Stock-Split [Abstract]",
        "verboseLabel": "Reverse Stock-Split [Abstract]"
       }
      }
     },
     "localname": "ReverseStockSplitAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the reverse stock split during the period.",
        "label": "Reverse Stock Split [Policy Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_RoyaltyAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreements [Abstract]",
        "terseLabel": "Royalty Agreements [Abstract]"
       }
      }
     },
     "localname": "RoyaltyAgreementsAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number RSUs vested and settled.",
        "label": "Schedule of Restricted Stock Units Vested and Settled [Table Text Block]",
        "terseLabel": "RSUs Vested and Settled"
       }
      }
     },
     "localname": "ScheduleOfRestrictedStockUnitsVestedAndSettledTableTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_SeparationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Separation Agreement [Abstract]",
        "terseLabel": "Separation Agreement [Abstract]"
       }
      }
     },
     "localname": "SeparationAgreementAbstract",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "erna_SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of severance benefit, would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period.",
        "label": "Severance Benefit Receivable Based on Performance Restricted Stock Units",
        "terseLabel": "Severance benefit receivable based on performance restricted stock"
       }
      }
     },
     "localname": "SeveranceBenefitReceivableBasedOnPerformanceRestrictedStockUnits",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of extended post-termination exercise period under the share-based compensation arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Extended Post-Termination, Exercise Period",
        "terseLabel": "Exercise period of extended post-termination"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPostTerminationExercisePeriod",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of performance goals not achieved under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Performance Goal not Achieved",
        "terseLabel": "Number of performance goals not achieved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceGoalNotAchieved",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "erna_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of monthly installments for vesting of remaining shares in share-based compensation arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment, Number of Monthly Installments for Vesting of Remaining Shares",
        "terseLabel": "Number of monthly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "erna_ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option granted during the year.",
        "label": "Share-Based Payment Arrangement, Option, Grants in Period [Table Text Block]",
        "terseLabel": "Stock Option Granted"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionGrantsInPeriodTableTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the equity options or other equity instruments granted during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Grant in Period [Table Text Block]",
        "terseLabel": "RSU Granted"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementRestrictedStockUnitGrantInPeriodTableTextBlock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "erna_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares Forfeiture of unvested restricted stock during the period.",
        "label": "Shares Issued, Shares, Forfeiture of unvested restricted stock",
        "negatedLabel": "Forfeiture of unvested restricted stock (in shares)"
       }
      }
     },
     "localname": "SharesIssuedSharesForfeitureOfUnvestedRestrictedStock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodRestrictedSharesAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued with restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Restricted Shares, Acquisitions",
        "terseLabel": "Restricted shares, issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRestrictedSharesAcquisitions",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 3.0,
       "parentTag": "erna_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued with restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Restricted Shares, Value, Acquisitions",
        "terseLabel": "Restricted shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRestrictedSharesValueAcquisitions",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodSharesAcquisitions1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions1",
        "terseLabel": "Issuance of common stock for business combination (in shares)",
        "verboseLabel": "Stock issued, shares, acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions1",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodSharesAcquisitions2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions2",
        "terseLabel": "Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions2",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including exercise of pre-funded warrants.",
        "label": "Stock Issued During Period Shares Exercise of Pre-funded Warrants",
        "terseLabel": "Issuance of common stock from exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodSharesInLieuOfDividends": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period in lieu of dividends to be paid.",
        "label": "Stock Issued During Period, Shares, in Lieu of Dividends",
        "terseLabel": "Issuance of common stock in lieu of cash dividend to Series A preferred stockholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesInLieuOfDividends",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the shares of new stock issued of preferred stock during the period.",
        "label": "Stock Issued During Period, Shares, New Issues of Preferred Stock, Retained by Stockholders",
        "terseLabel": "Series A preferred stock retained in business combination (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodSharesPrivateOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been issued in private offering during the period.",
        "label": "Stock Issued During Period, Shares, Private Offering",
        "terseLabel": "Issuance of common stock in connection with private offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPrivateOffering",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodSharesStockPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been issued in a stock purchase agreement during the period.",
        "label": "Stock Issued During Period, Shares, Stock Purchase Agreement",
        "terseLabel": "Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPurchaseAgreement",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Unrestricted Shares, Acquisitions",
        "terseLabel": "Unrestricted shares, issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodUnrestrictedSharesAcquisitions",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "erna_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "erna_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued without any restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Unrestricted Shares, Value, Acquisitions",
        "terseLabel": "Unrestricted shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueAcquisitions1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions1",
        "terseLabel": "Issuance of common stock for business combination"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions1",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueAcquisitions2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions2",
        "terseLabel": "Issuance of common stock in connection with the acquisition of Novellus, Inc."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions2",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.",
        "label": "Stock Issued During Period Value Exercise of Pre-funded Warrants",
        "terseLabel": "Issuance of common stock from exercise of pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Forfeiture of unvested restricted stock during the period.",
        "label": "Stock Issued During Period, Value, Forfeiture of Unvested Restricted Stock",
        "terseLabel": "Forfeiture of unvested restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueInLieuOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period in Lieu of Dividends to be paid.",
        "label": "Stock Issued During Period, Value, in Lieu of Dividends",
        "terseLabel": "Issuance of common stock in lieu of cash dividend to Series A preferred stockholders"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueInLieuOfDividends",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued of preferred stock during the period.",
        "label": "Stock Issued During Period, Value, New Issues of Preferred Stock, Retained by Stockholders",
        "terseLabel": "Series A preferred stock retained in business combination"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValuePrivateOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been issued in private offering during the period.",
        "label": "Stock Issued During Period, Value, Private Offering",
        "terseLabel": "Issuance of common stock in connection with private offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePrivateOffering",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to rights offering membership units during the period.",
        "label": "Stock Issued During Period, Value, Rights Offering Membership Units",
        "terseLabel": "Brooklyn rights offerings membership units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRightsOfferingMembershipUnits",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_StockIssuedDuringPeriodValueStockPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been issued in a stock purchase agreement during the period.",
        "label": "Stock Issued During Period, Value, Stock Purchase Agreement",
        "terseLabel": "Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPurchaseAgreement",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_TermToPaySecurityDeposit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term to pay, sub lessor a security deposit primary landlord's consent to the Sublease in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term to Pay Security Deposit",
        "terseLabel": "Term to pay security deposit"
       }
      }
     },
     "localname": "TermToPaySecurityDeposit",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_TimeBasedStockOptionGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on time basis.",
        "label": "Time-Based Stock Option Grant [Member]",
        "terseLabel": "Time-Based Grant [Member]"
       }
      }
     },
     "localname": "TimeBasedStockOptionGrantMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_TransactionFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees incurred related to PIPE transaction.",
        "label": "Transaction Fees Payable",
        "terseLabel": "Transaction fees"
       }
      }
     },
     "localname": "TransactionFeesPayable",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_Two022PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of awards.",
        "label": "2022 Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "2022 PSUs [Member]"
       }
      }
     },
     "localname": "Two022PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_UnamortizedLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unamortized leasehold improvements.",
        "label": "Unamortized Leasehold Improvements",
        "terseLabel": "Unamortized leasehold improvements"
       }
      }
     },
     "localname": "UnamortizedLeaseholdImprovements",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_UniversityOfSouthFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal entity involved in litigation.",
        "label": "University of South Florida [Member]",
        "terseLabel": "University of South Florida [Member]"
       }
      }
     },
     "localname": "UniversityOfSouthFloridaMember",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "erna_VariableRateTransactionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pursuant to the Purchase Agreement, the Company is prohibited from issuing equity in variable rate transactions for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Variable Rate Transactions Period",
        "terseLabel": "Variable rate transaction period"
       }
      }
     },
     "localname": "VariableRateTransactionsPeriod",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "erna_WarrantLiabilitiesExpense": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to warrant liabilities.",
        "label": "Warrant Liabilities Expense",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Gain on lease warrant liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesExpense",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_WriteOffOfOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of operating lease liability due to lease termination.",
        "label": "Write- off of Operating Lease Liability",
        "negatedLabel": "Write off of operating lease liability due to lease termination"
       }
      }
     },
     "localname": "WriteOffOfOperatingLeaseLiability",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "erna_WriteOffOfOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of operating lease right-of-use asset due to lease termination.",
        "label": "Write-off of Operating Lease Right-of-use Asset",
        "negatedLabel": "Write off of ROU asset due to lease termination"
       }
      }
     },
     "localname": "WriteOffOfOperatingLeaseRightOfUseAsset",
     "nsuri": "http://eternatx.com/20220930",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Dr. Federoff's [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r183",
      "r185",
      "r186",
      "r187",
      "r202",
      "r211",
      "r250",
      "r253",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r453",
      "r454",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r183",
      "r185",
      "r186",
      "r187",
      "r202",
      "r211",
      "r250",
      "r253",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r453",
      "r454",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r169",
      "r183",
      "r185",
      "r186",
      "r187",
      "r202",
      "r211",
      "r239",
      "r250",
      "r253",
      "r282",
      "r283",
      "r284",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r453",
      "r454",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r169",
      "r183",
      "r185",
      "r186",
      "r187",
      "r202",
      "r211",
      "r239",
      "r250",
      "r253",
      "r282",
      "r283",
      "r284",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r453",
      "r454",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r95",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r95",
      "r100",
      "r181",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r95",
      "r100",
      "r181",
      "r251",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r136",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Expenses [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Legal expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r293",
      "r294",
      "r295",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r255",
      "r296",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r225",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedLabel": "Accrual for fractional shares to be paid in cash in connection with reverse stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation expense recognized",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total potential common shares excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of premises"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Fair Value of Asset Acquired"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r24",
      "r81",
      "r127",
      "r130",
      "r134",
      "r142",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r329",
      "r331",
      "r351",
      "r391",
      "r393",
      "r431",
      "r443"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r18",
      "r35",
      "r81",
      "r142",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r329",
      "r331",
      "r351",
      "r391",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value of assets sold [Abstract]"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails",
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r249",
      "r252",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r249",
      "r252",
      "r310",
      "r311",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Purchase price",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of common stock issued in exchange of membership interests (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of outstanding common stock received by members and financial adviser"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Closing price of common stock (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement [Abstract]",
        "terseLabel": "Description of Business [Abstract]",
        "verboseLabel": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable, accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Net assets acquired, excluding goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r20",
      "r393",
      "r463",
      "r464"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "erna_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r73",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r355"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r79",
      "r81",
      "r106",
      "r107",
      "r108",
      "r111",
      "r113",
      "r122",
      "r123",
      "r124",
      "r142",
      "r191",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r209",
      "r210",
      "r214",
      "r218",
      "r225",
      "r351",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r235",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Number of rights options converted (in shares)",
        "terseLabel": "Warrants to be outstanding (in shares)",
        "verboseLabel": "Warrants exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityMergerDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r188",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]",
        "verboseLabel": "Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B [Member]",
        "verboseLabel": "Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation.",
        "label": "Common Class C [Member]",
        "terseLabel": "Common Class C [Member]",
        "verboseLabel": "Class C [Member]"
       }
      }
     },
     "localname": "CommonClassCMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Number of shares of common stock owned by Brooklyn stockholders immediately before the Merger (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.005 par value, 100,000 shares authorized at September 30, 2022 and December 31, 2021; 2,942 and 2,601 issued and outstanding at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of shares converted to common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Preferred Stock Converted into Common Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customers [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r71",
      "r125"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Warrant Liabilities [Member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Warrant liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r258",
      "r259",
      "r288",
      "r289",
      "r290",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "negatedLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "negatedLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r162",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets",
        "negatedLabel": "Prepaids and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r3",
      "r4",
      "r11",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r71",
      "r161",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Total loss on sale of assets"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r249",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r233",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedLabel": "Cash dividends to Series A preferred stockholders"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS PER SHARE [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r51",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r103",
      "r106",
      "r111",
      "r112",
      "r113",
      "r118",
      "r119",
      "r337",
      "r338",
      "r438",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r51",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r106",
      "r111",
      "r112",
      "r113",
      "r118",
      "r119",
      "r337",
      "r338",
      "r438",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive Securities [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails",
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r83",
      "r84",
      "r85",
      "r89",
      "r97",
      "r99",
      "r121",
      "r143",
      "r225",
      "r233",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r336",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r380",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage",
        "terseLabel": "Percentage of total outstanding equity interests"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r53",
      "r54",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Losses on investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r21",
      "r128",
      "r140"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Investment in non-controlling interest",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r342",
      "r343",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r343",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r203",
      "r240",
      "r241",
      "r246",
      "r248",
      "r343",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r240",
      "r241",
      "r246",
      "r248",
      "r343",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r343",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Changes in Fair Value of Warrant Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair value at March 9, 2022 (issuance date)",
        "terseLabel": "Warrants fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance lease liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease liabilities, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r368",
      "r373"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r156",
      "r158",
      "r411",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r153",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Loss on sale of NTN assets",
        "negatedLabel": "Loss on sale of NTN assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r22",
      "r146",
      "r148",
      "r150",
      "r152",
      "r393",
      "r430"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "IN-PROCESS RESEARCH &amp; DEVELOPMENT AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r71",
      "r147",
      "r149",
      "r151",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfOngoingProject": {
     "auth_ref": [
      "r71",
      "r160"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned.",
        "label": "Impairment of Ongoing Project",
        "terseLabel": "Impairment of in-process research and development",
        "verboseLabel": "Non-cash impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfOngoingProject",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r127",
      "r129",
      "r132",
      "r133",
      "r135",
      "r428",
      "r436",
      "r439",
      "r451"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r249",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r13",
      "r14",
      "r15",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r165",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r98",
      "r99",
      "r126",
      "r300",
      "r306",
      "r307",
      "r452"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r65",
      "r67",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r376",
      "r378"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Lease Expense [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Net Operating Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Extended lease term",
        "terseLabel": "Extension term of sublease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term",
        "terseLabel": "Term of sublease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r81",
      "r131",
      "r142",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r330",
      "r331",
      "r332",
      "r351",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r81",
      "r142",
      "r351",
      "r393",
      "r434",
      "r447"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r40",
      "r81",
      "r142",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r330",
      "r331",
      "r332",
      "r351",
      "r391",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities transferred upon sale [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r25",
      "r433",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Letter of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r180",
      "r182",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Liquidated damages payment"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r180",
      "r182",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss contingency, damages sought, value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r183",
      "r185",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Estimated contingent loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r16",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "MERGER, DISPOSITION AND ACQUISITION TRANSACTIONS"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Ownership percentage by Citius"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r15",
      "r44",
      "r45",
      "r48",
      "r50",
      "r72",
      "r81",
      "r88",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r109",
      "r127",
      "r129",
      "r132",
      "r133",
      "r135",
      "r142",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r338",
      "r351",
      "r437",
      "r449"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r103",
      "r104",
      "r110",
      "r113",
      "r127",
      "r129",
      "r132",
      "r133",
      "r135"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r86",
      "r87",
      "r90",
      "r91",
      "r100",
      "r101",
      "r102",
      "r138",
      "r139",
      "r144",
      "r145",
      "r303",
      "r304",
      "r305",
      "r335",
      "r339",
      "r340",
      "r341",
      "r352",
      "r353",
      "r354",
      "r363",
      "r364",
      "r379",
      "r381",
      "r412",
      "r413",
      "r414",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/RecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.",
        "label": "Noncash Merger Related Costs",
        "terseLabel": "Transaction costs - shares to Financial Advisor",
        "verboseLabel": "Transaction costs"
       }
      }
     },
     "localname": "NoncashMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Axis]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Domain]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r127",
      "r129",
      "r132",
      "r133",
      "r135"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r370",
      "r378"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Impairment of right-of-use asset",
        "negatedLabel": "Impairment of ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/LeasesOperatingLeaseDetails",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "periodEndLabel": "Operating lease liabilities, Ending",
        "periodStartLabel": "Operating lease liabilities, Beginning"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "periodEndLabel": "Current portion",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Less non-current portion",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use assets - operating leases",
        "periodEndLabel": "Operating lease ROU assets, Ending",
        "periodStartLabel": "Operating lease ROU assets, Beginning"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization of operating lease ROU assets",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r375",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r374",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r17",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "OtherExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other liabilities.",
        "label": "Other Liabilities [Table Text Block]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26",
      "r432",
      "r444"
     ],
     "calculation": {
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountAcquisitions": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the different classes of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.",
        "label": "Partners' Capital Account, Acquisitions",
        "terseLabel": "Issuance of common stock to Brooklyn members"
       }
      }
     },
     "localname": "PartnersCapitalAccountAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountUnitsAcquisitions": {
     "auth_ref": [
      "r233",
      "r319",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the number of units for each class of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.",
        "label": "Partners' Capital Account, Units, Acquisitions",
        "terseLabel": "Issuance of common stock to Brooklyn members (in shares)"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnitsAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForPostemploymentBenefits": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflows for payments of postemployment benefits (such as severance pay and health insurance benefits) recognized during the period. Postemployment benefits are benefits paid to employees after employment but before retirement.",
        "label": "Payments for Postemployment Benefits",
        "terseLabel": "Severance benefit",
        "verboseLabel": "Lump sum cash severance paid"
       }
      }
     },
     "localname": "PaymentsForPostemploymentBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "negatedLabel": "Dividends paid to Series A preferred stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payroll tax remitted on net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Less amount of cash paid for NoveCite investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r61",
      "r321",
      "r322",
      "r323"
     ],
     "calculation": {
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 0.0,
       "parentTag": "erna_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PledgingPurposeAxis": {
     "auth_ref": [
      "r329",
      "r331",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Axis]"
       }
      }
     },
     "localname": "PledgingPurposeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgingPurposeDomain": {
     "auth_ref": [
      "r329",
      "r331",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Domain]"
       }
      }
     },
     "localname": "PledgingPurposeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r104",
      "r114"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Series A preferred stock dividend"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsShares": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Cash dividends to Series A preferred stockholders (in shares)"
       }
      }
     },
     "localname": "PreferredStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r79",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred stock, liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r28",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r28",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.005 par value, 1,000 shares authorized, 156 designated and outstanding of Series A convertible preferred stock at September 30, 2022 and December 31, 2021, $156 liquidation preference"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from the sale of NTN assets, net of cash disposed"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock and warrants in connection with private offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Aggregate exercise price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Proceeds from sale of members' equity"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from the sales of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.",
        "label": "Proceeds from Sales of Assets, Investing Activities",
        "verboseLabel": "Purchase of NTN, net of cash acquired"
       }
      }
     },
     "localname": "ProceedsFromSalesOfAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Sale of rights, title and interest in and to the assets relating to the business"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r292"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from the exercise of stock options",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "negatedLabel": "Exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r163",
      "r393",
      "r440",
      "r448"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r247",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/RelatedPartyTransactionsDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r247",
      "r384",
      "r388",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://eternatx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/RelatedPartyTransactionsDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r382",
      "r383",
      "r385",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r20",
      "r78",
      "r429",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Common Shares [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSU [Member]",
        "terseLabel": "Restricted Common Units [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails",
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails",
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r233",
      "r393",
      "r446",
      "r458",
      "r462"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r89",
      "r97",
      "r99",
      "r143",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r336",
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Computation of Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r310",
      "r311",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Changes in Warrant Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r13",
      "r14",
      "r15",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposition Details"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Tangible and Intangible Assets Acquired and Liabilities Assumed, Based on Estimated Fair Values"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r254",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails",
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used for Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r79",
      "r122",
      "r123",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r218",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r27",
      "r28",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Restricted stock units vesting period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Unvested restricted common stock forfeited (in shares)",
        "terseLabel": "Number of RSUs cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs Granted (in shares)",
        "verboseLabel": "Number of RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Unvested restricted stock outstanding (in shares)",
        "terseLabel": "Number of stock units awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-Based Compensation Abstract [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "RSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weightage-Average Assumptions Used for Stock Options Granted [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Weighted average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Weighted average risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails",
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Stock options exercised, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of stock option awards granted (in shares)",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Stock option outstanding (in shares)",
        "terseLabel": "Number of stock option awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails",
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails",
      "http://eternatx.com/role/StockbasedCompensationRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on one-year Anniversary [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "terseLabel": "Stock-Based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price (in dollars per share)",
        "terseLabel": "Stock price (in dollars per share)",
        "verboseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails",
      "http://eternatx.com/role/InprocessResearchDevelopmentAndGoodwillDetails",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Number of accelerated vesting stock option (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Warrant expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CeoSeparationAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Incremental fair value of stock options recognized"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Number of shares issued in merger agreement (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r79",
      "r81",
      "r106",
      "r107",
      "r108",
      "r111",
      "r113",
      "r122",
      "r123",
      "r124",
      "r142",
      "r191",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r209",
      "r210",
      "r214",
      "r218",
      "r225",
      "r351",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r46",
      "r47",
      "r48",
      "r83",
      "r84",
      "r85",
      "r89",
      "r97",
      "r99",
      "r121",
      "r143",
      "r225",
      "r233",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r336",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r380",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockholdersEquityMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r121",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock for business combination"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r28",
      "r29",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Acquisition of common stock (in shares)",
        "verboseLabel": "Issuance of common stock to Financial Advisor upon consummation of merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Number of common stock issued as compensation for services (in shares)",
        "terseLabel": "Lock-up agreements shares received in acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r225",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Restricted stock replaced during the period (in shares)",
        "terseLabel": "Issuance of common stock from vested restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockbasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r28",
      "r29",
      "r225",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationNumberOfRsusVestedAndSettledDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r225",
      "r233",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance of common stock from the exercise of stock options (in shares)",
        "verboseLabel": "Stock option exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r42",
      "r225",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock to Financial Advisor upon consummation of merger",
        "verboseLabel": "Acquisition agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r28",
      "r29",
      "r225",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Fair value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r28",
      "r29",
      "r225",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Issuance of common stock from vested restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r225",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance of common stock from the exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Gross proceeds received",
        "terseLabel": "Aggregate gross purchase price"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/FairValueOfFinancialInstrumentsChangesInWarrantLiabilitiesDetails",
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Private placement (in shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r81",
      "r137",
      "r142",
      "r351",
      "r393"
     ],
     "calculation": {
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY [Abstract]",
        "verboseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r210",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r233",
      "r236",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stock conversion ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical",
      "http://eternatx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r372",
      "r378"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r362",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/RelatedPartyTransactionsDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r362",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r362",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/RelatedPartyTransactionsDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r362",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfStockholdersAndMembersEquityParenthetical",
      "http://eternatx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://eternatx.com/role/RelatedPartyTransactionsDetails",
      "http://eternatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r394",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://eternatx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r371",
      "r378"
     ],
     "calculation": {
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants outstanding weighted average contractual life"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/StockholdersEquityPrivatePlacementOfEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r105",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r103",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://eternatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=66006417&loc=d3e8580-128490"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=66023778&loc=d3e9298-128500"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=66023778&loc=d3e9334-128500"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=66023778&loc=d3e9337-128500"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r486": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r487": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r488": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r489": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001140361-22-041399-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-041399-xbrl.zip
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MRT\'IU$_->\^NC/3=>"(_-M/!ZGZEK[+!NJ\LT-]-QRK^<@C^>PDZ7-/_73
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M=O;-#E*ZB^%U,;RV\F;G7:_%N]X4W6?JYG7617/6XT8* *Y&WTZN=Y[N>^O
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M9JPOVRK2KV:$DK$U2'I@]&A%TD\U?6L1LQE$F!3<#?N3DK([C11E]72+@]^
MP==A4 V,V&%3139]M0!L*^I!-QBB7O:IA2D#0449G&E:;Z+JA;IGO;.LUYE
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MC2N_\W,4.\9_<?X<<;63>P6.LD75ET/R==;Z+/<L"K( &%$N9#Y$#./ 110
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M-J)D,?WK:[5&U5C.$GZV!RS&1AMG22%9+:?3:-!/X^?32!;9&WE$8BD%U2C
M$"GJ \ #B:F'E+D*7Z&A$_NVISCZ8OMD#<)/JL>^,AL/K::C)WP_?WTE[0T7
M4<%R@.'._D\'X&#,RRL]>O,4OF/?SH?+._GAF?/H[G/"H<(<^Q*[!KQ<A)DD
MFFN)M(95T!U9<#<_LX6C&B'> K.C+4(WC:T&1C-1L@@:%@7L^_UDV+G9.3^^
M.;X]=H;)BK$SS:#.972\VDR]S2BMJ$^K*:Q.2S6 82=2QBI)AO]<A'T%"O@%
M,:"!YWG,4P!#++FKI.LIGQJ33$*&*L63$2'.K0A57RCG-.NI\RD.OZA#YW80
M&E$&9*'E6L\4+#/,AX,_-1^OXKOH:[\P [Z4TJ<4*T  IBZD@G),B8%O0A0$
M58S/6]9W/H7J/IH=Y6'%CF6(=Q5?&X5N,*]H.TB/^5(K$$A(L"L!!0* P.=8
M FT^T#ILAU,SPZ91/V15J=1RR,W7U:;E?<@^R\7N]2)V'=F%VO\O?)JQ_UQ%
M")&2P"#P,9 ^IT(:=X?XDBL@@BHR1B& H#,/,@4XG&UK(#S%1ES")]9SU#<E
MLN1K<]GH0I5TYD(^6X8='<N/:S0*7I*DDFC3:P(TWRV42(OQ)[%B,S+(E/ ,
MS+M$*Q\3$E#%&0F(!AYW"6>L@@Q",!=D_WXQOE]$AJC7#U%_/B*$ ':Y[_IN
M(! 6B%/F!0$)N$"NJS"N@@<D@,9IH+1J0.@5P8Q)M.9__A(8/?A#8O"TIY[L
MD(8!L4-KH?<&UGYSC._)3+_E@K79%6S%U1<DG)4MQN(\#(><7_O"XM ,^<B(
M%DL'!F<6W!?&HIS<ZF7IH$=#VW9R/1/3L&\M]/=.EJZ17<G"GE8MC_)!OCX8
M,RG[>:$_7XTA.WED]NOYY X[#Y"00V?TU_?#=T@EAH[3F-[], W'O2K<'SYJ
M^GX=X9'<\C"O^&P^J/A"W;/>59PSEHJ5G T#NCY64E*N%,&!$5*"&: 80D"5
MI)Y702X^QE'T1^^Y[YP_/@[Z43$<>%@Q'E@E^%TC$[Z.X:;(@8WGLB\L.*??
M<M;*F.\P,W7-%S:T$%A?CB[I,#%X[-@%5(-:VD9?^_?*:&1K;SL]EJ2S*C#.
M%MJJ9YJLAG#5%[#&B#S95C8,+5L1<IX&<3*P,>8T<DR++ 8 X'?\>VL?V366
M$Y&^[X+("TPPM,B\FTW1@^,LO)FEVT666NF-URVA'7RX"]->%A%33#SDB^4O
M.-#-&K[.D#N*4U.'-;PMI(A99N\DSX]&#794V P5+H=K;)D\J&\YFCL&^HP:
M,U<F^%@3@6KTD1?.\.N\OLIK[@NMM:%>>0:09SA3C(T%6$M/>P'3 :8*4@8]
MY*) 2:$P<%4%BRP_P,2,(!)_'#K_[1Z[+C',&SM?6&^@[+*_DVT>V*6%J]:1
M> A:MQEF%>BK7( X@:Z@&F.M_8":3Y[Q2*5TN2%ZE87WF\N3CG9K$,^S(<K-
M.DU0<.QAX/E*8,DU=14%W"Y&!D2+H(*(S@6(+9Z.8L/&@W(N62+9GTY6%L.Q
M*=@J=2XN3M<;CEPM]%2:E%IN5K\B(K7"T\_[TJ[,*8<_&Y]#F0E\M#GL7Q^4
MW4&7&>B%/)'OP/?. TNRI"/IL%YOZ(58B__/06CM?6/F<S5L8)XY-OF1$\7#
MS+6AX5_P%T:\8YT!>]MFKCG2W#6&C&WZ%"NA,K,&0"=+.4V<[Z)XF@*&39QD
M8+1K\A#9S)51RE;ZP-+9@?QHA?#E'-*O;'I46:+5C^_L#S]DKQD._?O#S(_[
M#N93PPU;FF[P?YF!VY]E3<UO;>>'C[,)DTG6W6QLQK=SJ.M(]IP<+UN/.1W$
ML?EUGF1I$3,U3GE2U(@>T\+'GJN4AQ7S M\/N-9$<.02)*KLO_BGW2@W+3K.
M__R%FH?^X%Q&^4>\6MK:F-VJI;R5\:]!H&4TJX7%+0T-^1[#-#5T5SU#QCCJ
M6[#M/3O* .^S$UKHM#M1ORA#M93EK#$C 9-G%#W@FX%IB8V%$>E97+E1]X->
MOD9^>W3G?&>GRO\!(GB<MS<=#;.LK">;E55!.E82B%ENS[L_YEZ5?+^4-\\G
MT_+)S,J050N\R27&F&GM*9]C$A#&*,3*L)TD2.E*UEH9;PYE<HH]%G%?QL5E
M/UB!GX89B451R)^W9HFHA=T-2S&GQV*#O4P(P^ZQW5:=D3RVP%9ZU8;DCDIO
M)*8/YN,0&RU+BNC13,ZS17_S-(-]=D/?O7,?1U_3A]'=8Z,,U+1 2*6S:%O4
MSU;2;(P?NC\LZFEV&_PP:K:TP<)^CAM:3!\V7M#I4<NPGXNU\4^.X$BY%37:
M<:WAK1<"5$,3D=HXUDQH:O7H[WRTJ^+^S-J#8-!=Y/.72\ J=O!$O5R4LU9-
M'@$F+^0!O(!6>%7_H'2R7G[1Z^;KI*&96GVB7M?_&3NF4J]K#+.LAZDK; B(
M3PT)[Z/XN>BT,8F,>PTU-+8DTCZ#%! N FR^"!>])B,XKZ61,8H8OM#Z;Y=E
MFF3M_OIKI=-KK73>+E)P&Y/2):R8=?CC( G[*BDZ-$)H( ,50,]#F& <2$]+
MP1 C0OK<77'38F,;>#>(#*_+[7D-Q[_B/6MC^+-R(ZVM[#[J[L]9;T_SSA9]
M):HI !@0+S!LSUS*C=N$B/*D2SB"%;(^U[)K<MW!L'/]@A=ATWU*?9]0EWGY
MF6]O5$X_RESS0:*R5J8S^3[KDLU_QHFQ[^H]VY=_#<VKK6O3-V9T9*'V2YAD
M*JS/^B)D/6M,V@TWIO'T]-A*99+%,G%LFFN8;>I>'I JQA&&+N<DNO8=^[[4
M]=A4N*8^YS1Y,"[1V(W\SA N<PWSC6HO.U[?'SO_-&[.,LUC7S O@90P[6+-
M)104!\*N+0GN8Q( #R$75,C(>ZT$S@08O%<1;]Y_&T<N&@TH3W/ZHH=,I4^\
M+4W)>")9A. R^I)7'  @KSAP."_TTHD&:29]5H"'?/$YSJO*S0=;LZ7!;%DA
MJZ*<7$U^7(1J08FO/>@%"F*/,&.J$-^8)KYV$5+$+6$48/X<.+:2578MJ^9F
MV%J$9@Z3GP[.+S\;=]^H&I4Y_L6B"_W!XY&,LMPDV_C@ SRD&!X".-[!,!K.
MAWS=,IL;47&1LSQ2\:IH[0P?/!5Y-:=<&7'S>$(Q$6R4&@;Q,7E*"YCT]&8.
MGNMDQ7)8<Q6OBN6PYFIEO;H<5MER7?4268MG9%C+XN/-]>=K=J\^QHK]83.2
MQQ$FT5,LSNR;A_'C\[%E@:'AE7%QL%P(2^2^[$7CESR9*T?<7CIBVHSM/>M]
M9<])B?U7(,N(/2P%LNDL2]T:7G,G4P^+,S\*B)7,_.A6<0+L7%:6BO\Z.KJ^
MN;(^K!UPGEA]HQ*5_O7B].:OX*]__>O1T3QEIK\7O^7F5?Y]+37F?F09KMV=
M?+PXN_I\>G5Y=W9Y=VNL63.RD[YXB&(S@!_?L2&1EJPNV\7+A5'Y4>$+^RI;
MK6+TLE$TO:"D9B9HV4N7OG-& Y;&[_-\R96>5/Z<K=M:..'H,M]UD8?D'7M^
MQ<R$EXV"U?7_M)5:%-$9CV51WX/@&'G;VGE\3!?U?7%.7*Z;JHXMTRVO32"?
MD1@+C$M'6^)6KL*+E!R[>'D*#JPZ_FF3=R7R7I_<W#GGV4H2 #\XG\\O3RY/
MST\N'&/C7=W\>F++^C1#_)8P[AM)60.LO(%ZYZEZ=,#QAJ'E#0/X/(Y%9%MX
M\\R3[P9]-I!AJF3)IKN.]2JPWJ)=)BXVKB<*AKM,6C(-KV/.=@S1V*,/L761
M_V+,PT]GE[=GG\R'VZN+\T\G=V>?/IY<G-@47NLCVM";^93IMVPIZ2/K,;MY
MYO9!*</U+/.$YPL39BO]GY087LV#!\#:N/4+QRAD7.O<OE(['WP 6P#>K92-
M#7.]+5*]D.L+.&_8_>I)Y3O8)OF&J7FTRIB^'_;5*%\L#WDOD([&!:)Q5H>=
MLM@>9?$&>V<B.;=W5Z=_^^7JXM/9S>W)Y:=?SW[]:#Z=_?VWBI)SFJTB)':1
M(8L /QCW1<7)<*]Y)A;Y*0KC2V=_#L+TN8J<S2^N;4KP6J*)4*>)6NM"3$3J
MZO/IR>TOGR^N_G%;58A8\N!\[D5?)^IGCY0.>6GS_@8XO5-$FU!$EU=W9U89
MS5ER-ODM-0]*(V>!,)5Y[_N@#KP=5@=92 EN.J3T=L_D5]9G]SE+?@H3,<BJ
M41O<-FP]N36NS#-IDF'[29_UGI,PTQ$3)K=2D.?;V#8W*AGT9KV8[58(D.X,
M^K\UJ(J:DH#6#',B*G^W65NA/9O[BS*<;;[V\F\''XJW,JZ?W%29T/0B>_A9
MXISP:)".-K?>A,D?^Z ',&R9!;4NZ<";U@^U\+W!\S2.>HGAZ^LX$DI:3C[.
M7(?L>L;PDSO-<O0\0QY\<,H8;$L!>0_,\;8ML;<++->S*-:ZI?7)VOK5W2]G
M-\VNJZ_+4-RQ!<[6KL"W9I@3I6D'#(R2S(I1YMHQV]O?!L=_@1+%&U2B:V/!
MDYTPR3+N.C'L95T(QZ:O1_&6.]5E[->%61N.,[5CC--\#0U;_]8OE!Z]9;U\
M^\-P9:Y0<,AZ'K\E68F^(<2V 5_W3U:V/MRT=O1&Q_8P+<VRV.AO3[9:D.J'
M45S@[@[/:^71UAB)S8:&6C/,:7['AM]_M6O&MTPK ^*%H&B'V!N0AG7Q.=D9
MQ":&@Z^R[<V%$P<ZC*Z5*UL#7AGO>GN&T9[A\+-O#R$/]R,_83/LWZ+0:R'-
M\OSGRY.[WV[.#C[<FJ?F1X1L.;AY]5 W_W>V_$FVK]19LKNUV2W:RS;0SKX^
MW\><O;]D1VRUN0WF]@-.'163/;!012)<4%/S%?O*G9*-Y7,[_<>;QK.=XO.3
MNVC+^2MWF)=M*B]2I?B..7+\HICI\=1PZHJK5*/2^'";"0S,;1AW[K)MS[-E
M;NW2[SB+;4;*JF^+=Z8/;*AT\-Q;]ZV>GOQFUY1.;O[IV(P^Y^;LYY.;3^>7
M/SN?KV[^83X>75Q=_<U^M]LSSG[-M[(O)G$='5U4H&?F.(NE"J"F.BQWMD#Q
MWP?9L?&]9R<O4FT/O;!G()E&1W_/*J&PL)^,2JL:>_@KB^51+XK^R$XM&><Y
MCNNP)L-ZQ<H\(YP4_S%2-2P8=!V'7VQ)H4)X[\+\<Y_74KY1UN8N<N&XQC@E
MMLIRUH_KVXN;D^$KOS\<5RV'_DE)M?))D7)T:/O''O-$YN]LN^$#IYM/GFP#
MC^.G@[.*M= 7OJ;8>/228SO?"V9U>"">*EZ*52_+-DVCXBSI@57EMN*U:7-H
M&F79>(>V5DSFQ/2%.K3EJY(G,YH\H!H]68+;JC9F',6S]TI?YD0#"\*V[.-]
M*)RG'NOGCTEM(=;\G>;E ^7<J_XP_R][HQR8B6%?6-AC/.S9P&[V<JV5K8AM
M?B?8DX4HIV_#NI.OZMN3L@F&UD+)2H49]H^?G30V5[,W%X=O.S<IY/44Y87
M7IQ:9J:+,YO$:V@;3EP]1^25L(U(#'MM@#$K.'9H6]HW#5MD711IGNIXZ"@C
MGN81MK?F84JPQ,Z*':R9A7_E3&1>FV6&69X8#BG,=ZWD)\U\-1B<94_FZ67F
M?;8E5[U0Z7RZC6X9/#YESYJ: &U4WRB/<SQNIV3<D5&S_9%D9T>R)7G=<#86
M\WQ<R5R9YKXQ\,*G;(@SMT0TZ,G9BR/.F+D\G(VYZ[9.NR'M7'/+:;,7LQGY
M,M^/1*D_YBY."#-SXY$]SU[Z&O9Z<]>F!F>)D(0&9UEL&<">#&>)<>R<]^U)
M<1GC'19)8^N@%>8_@T>CABT<1E.L86B8\7$NR@5V+LJP;3$AA!S5U,LD,1>-
M,&=2/BS.F;-@E$4T#/K8<E-&\O[-QN^<@@Y;&4^$L1@\VM)9PC*S%93%P#\G
M8\6A%X;-GRTKA_9HO>QUHT/U#&%,?X;38EYU:&=%AA8>K(A)=1\KVXO"&0UQ
MF/R1"\/ ]#"V?)Q!<?:(C!,-B-CZ@&:H ]8;@>'DP?:E9@ZR,P(RF9+&>4F4
M^:;CZ-$\)TK4B+9YX3I+PR5S8 &B./8G9OVA@643G2_<YAU\M';*L(-9@<*^
MP0 ^2-7X^(G1Z(6:*("\3XM&+E4BS$/ROEZ;%SOGA\YP(7S$Q<4EY!$O#SGN
MI-^W\S1O ?SMW<EX)Y ]ZW"X!6AN^W76I6(GIJ I8ST9&9[*..%K?M[(<*Z-
MH6('GOV;E6B<T:_VR6.U:4N\A9F\'4X <RQ+F>UA?GQV.E<8[94F5ZUU[Q88
M?^TP!F\R+R77BH/X?E)GT\"O4-9\&]B9[H79'OVA7EHL$98/TZ7VY8B(QBAA
M?Y@[5AR3&2?$OL=NKQD?J?'B$X^=?ZAL#!-K)C^'@PTLWC%C0)AQ91SWR/XP
M39^>C&]D5?SAT)BQ%^47@[#,G@"G\ZJ$"=/*,=AIO,^\!F@R L_,HK76Z+'E
M4O64.L63.0SH]=C70\NE,LIF-+.#[5OR]PU!Q@Q&VH42%CY:J)F2'MX;VL9#
M9#20]&A40VJ?8#WFR0P9,5.VQQ:L!D_V4C(N=)KUU\J(54;9*2&+:6<A5FE;
M;C5K/I0]0]&BO6.?/+(VQ6@GR+SZF!RB-WYSF0W6">RJG?O'T"S\HB8'Q$S1
M9TC"7">\55(+UO+ +F+'BB5&G(S<3%DZ$]O4&78IP_5'@RW'SB_15WL@SZ%S
M'QJ^R:M]ENNS0^<Y&MAC<*PJMU(36]T<3:OA,MO6NEWV?!T9YBZ;$=!I&^#0
M:*DOJA<]/8Z,G5P[&9M<1&;2CYU_3MYL!FE/WU')2TA7'/]8?V52/BY<FM'G
MJYV&9WO4T* _<BF8>,@(.#0"E:S:S1RK,HMII>&-NE"P?R:F5J:/OP[[FK/2
M:\1RQ4!1(P'OJ[YS90R=K+RL/]RD; 8U.J79VCRV>FP^Y*6'?%M2G9D)ZS.G
M>#._]UN_9\W8C"&&9O;7,#?M+"<,:\D6;@R50]%8S$]F*]A\520RC<91A:QO
M(YMN; XMZO)A\5V3IXRGX>+B=.Y9+\R1;6_/$OKZ$%E^BK[:<(^QUI-0AE;?
MVH2NK">YQIM^=R$V<CISHL_(^5*C*Y/Y&MX:3.S8>'3-D';11-BWAVDRZ=M,
MV*,X 8=9?>)>;S!B ?OCT:7I*;TPOF!:IL'J9^NY0I@5H^UUEHNM'/?^'!E#
M*SXHJ<:Z#0L:BU8T:EO3:.>JQIO6-;9I9>/EM8UYV:J@QA97$S:?2ZL)YVN0
M<FWU@@M+E@V_:8%ML'0U9685IQ'>6K1HM"A;@9 L46&TJ6*Q_3X-(OFU+T;-
ML/YLG?_LK H;TQN6+!_MCCJ>5!R=9M>2;5*S<S,-C=7&4C()M;@G;Y^/\NK,
MNSK:\@R&; +**Y>OL4KU<HD?:89/M]>?+\(DS1"W_G,%D6?[MORDI7J$>:WT
MMZ%:2^%E_YN=*B?;:[?2T4CY*02O.Y&\9)I7-V++J^3,9NN,9*"^0XQ6MD-+
M-=+<:2SU/+:*HJLU/^+L[NSF\L2Q>W!/KL]^NSL_O35*9CYP7CK XND"HS,(
M7BCXNN T@M?.U3 L5WSH^.5.\>U3DSK5A^(7V\?+TS/G]I>SL[O;F;[6PC+?
MG5N'/AK8R@IVG3B/$T_.<V&/]MBI[YOAK.5'.DS5EW[)Z5GQS:N>ZY"/>5$'
MFM5X%6/(I0Z1T&DZK_'FP:E,VTU0^DOV=NL*6L=[/)+R[-$X^IIGCX)")BEX
M\<R_I6^J1M:%J;Y?'PP''5G:9$KP:\R:ZFB5DB$O#&"%CL*##U/5#F>[^KK^
ME_1IGOTV/\UOXX<=('UQE7MW*/^"]50;0#E#2"Z>9/+#=/_JX\E%\U76AP63
MN GVG#GK9>A,#<][J=+7N8T#6><*>GJQ;S.CA^WR2+D%_G8JO<S3&Z#16UFH
MI=S2%&.4'#JPC8RQ#M2K:=JGSU$\HH5%F?P<09J?HGE[>S9)6:^;.DLDHSDA
MR-1'^:)0@;^;9K^-J(EF)W5Z NM"T,:FL;4"NTPZ09")Y^DP1=QXB"I-WM<I
MIQW[=%*X0U(X"JKX=A-IR6KUZ>G9V>?/S0HK2QZ:TJ3#?:T+B3.,*+T\]D:L
MWR5<LWK'5B?0P8?_7@,REM3!&PV/-CR\\C/+!\G1/6-/[RW?31UA+R6#2% H
M ^Q[?J!<CTN(@X#YOH*B[ C[[.#ZXLGDL'@R^1$:'TR.EAQ,#M A)'CN5/+-
MF/^5F&^-CF(GQ)T05Q1BU]6F+QAIA0(,)&-84PU\R5 @ Q:4"#$ $(&:A-@[
MI '9%R%>MW72I F25QR*E5#A%[N8M'%S9+-PM=XHVQR<-(T9&;5OQL1.+E4Z
M=!@+2*(XPCX)?"IH@#F$5#+7IX1[E%+@0;]1<X!"KWTPTD*%WXG)QL5$@0!R
MQ0-7^1CZ+% 84P@8]10G H)&%:X7M-!DWB*56A[HWTP4X#I63RR4>>&)9+C)
M:KAO?BJ:MW'=O/*L;=CU6+K4N8ZNO]*OJ*WO]</CD&'/<GX]Z<L,+T\R'IW'
M20JQ='U(?<@\+"7D%!D89) RB*CT6;/1A4//A^U#RA7EJ(T&2(<%'1:LC 4>
M0DP:'T(QAK$4F 488"(0E( B34I<BSJ#%(<N]?<:"W8B< ']O(I<9(MUM<Q
MZKRR!J%F$:APP'SN*4T) C@@DKD,,/-'2 ]12FBS!@8Y#$@++8P66@R=<&Q
M. B3'@ZPJQ@U?WN <RJ!*T3@!4#Z08EPU*EQ@T/?VZUXWIYD)ES'MASDL&:F
M+1R2578Y=/HJW;B2;;&3T5X78H,.0LY)USW63XU_<#9BIDLU%24@ $$6$ T(
MP)@@&@!/:LBY"QF0#2MQ WCM ZDM"P=T0KE[0ND!3V$9X,#8#)AICRD)-95$
M$*2%PKK9)0[?W1>AW F_?&@YW%@V/XKT458(-[-*G:-A<6E;[:JG6*(Z3WVG
MG9&K$;4O++$SCKC2OR4J<U(*^ *E)P*N.=/*PYHI3A D$OF>I(&O@J#AI0$*
M.L>]DY4MD16)!-=( N@AB*E/&:*06,DAD/F*X$9U,3PD7@M#YUND<C?DQ_\<
M1=(>+;!Q?=OY!]OD'XS8IH _@2 & YC1TS# Q$,4>0IBUV,00$VX:M9!/W1Q
M"Q.>.A>]$\$UBB"CP&AUY:/ B"%2+  2,*0"E_E4(UYB+M=J NR1".Z20W[>
M/WJ*(V&+A<<J42P6#\-C4\85VS=N'70>1H-(<M[/#L,SPG 1?E'RO)^R_GW(
M>[F+D9Q]&Q8B+T$<:!0]I BYB!OI1R# ,@#8IYQH"3U=J]+7X3<EC_ZMXNC@
MPU'[@*:%"KV3FG9*#7*)0$ AA;#"V,<T4)[&*H"<,"R0UZB>)H>4MC!POD7*
M^$6CKU#W; G3E=3..>]_44EJ-:X]:\/0YR@[A2WJ]6QDW)Y#:#3TYK5QU0EH
MK].PJ1J JSD0BWKY,C#9M;KT^5>5/D1RPE!) 7^T[Q$&J$$>3^# :&2I.)0^
M$\@'/N8ERW8UNNI>4 (^+6"*#56P[(1N3X1. 8T4UMK8R0I+2J@' $+(9QH*
MKG#)-I=Z4]O=,J7? K[8JOJARW8(OD+GYQOL6Y*?WG!ER3IVYI@>#7>V3)OK
MFX:45_2R@<7"R>::RZ@OYO?7 ,4U!E)JCV!,)<.<<Z8!EHPH)6"CFC\ M'U^
MQX8KO7:2V4EF)IG"1;8H#PH"#V*E90 XE=0%*B N%%HV:A[@H,PHWS')W+B!
M@#=00F!J,UQ;C8QE$],JE!OMKI71P![\L5+?7P,K;:AAMMD9J+*QJ8BD/G61
MP,0''L5"40YP +7RD1M0E[C-EB>"[F$K*Q2M*');80%UL-'!1GVPH10!4!(5
M8$ Q<P.F7>@'Q)=:N<93:K9<$P*'!+:P/N(:86,MYEF5(PRF\RZZ1=O-+=JN
M';-;J/4Z=MA*=FC3FO1K_,I7'_]R<7[R\?SB_.[\[-8YN?SDW-Y=G?[MEZN+
M3V<WM__SEP "_P?G[.^_G=_]<_-^:'MMQZW/=VW1E+41U;=Q'CO6ZU*,WWCH
M4"]D/.R%::CJ/7FHLZSVQ[+JV*%CAYD.;;.A71%!3X2P9[$GSA-[;L4Q#-NH
MCG<CJKJYD.F0!Z]S%IRO)2>EALC5T*<>PH0C2K@T'P+*!0JXWW"AQ4- 6IC7
MWODEG51OMU0CQ! $*!!N0+ +?281@9![0 A A6XZ<=4G+5P7Z5R^"@9+/%"3
M0RLV;K!T]GVS(&*I?3'Q[TO*,'M <@+M(3@2<V+K.OD(: ,6KO*8;G;7"3HT
MEDG[<*2%)D G)QN6$QD@(* 00GL>UIX,M$UF4@&5A#.CA1O6MQ"W,$M[BY3J
MA@($5],%%(NAUL/1*0@;U\';[UZT=]FC?K":KCPWPJSG$LU.#4[Y% G&/0M5
MW ^TKT" H $LZC5[@A-&+4RW[+S^3BPW+I9*4\R9QY5/,69(!! S:$LU*^1Z
M2I849ZES2TD;LZ!WQ&U_6Y&)SV&?]85JLYW0G@WM+=JU_MJMZ4-Z+T,+S'A
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MS561:7>TH+5[<-YR<'R;L'3%GJ\38<<5CX9AUR*RXL 'E%/((!:8"<*A3R#
M5&&L "P_P+F!U('@$+EXRY!UJ[;@=9C084)E3&"N]E#@$:@1-KX19\!#5/.
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MU@Y9.V3=1V3UI8]]0EUDH!3[D'"((01:2<J9QX/2NLXO)#%L%EE!H)F22D,
M*/8TY"!09GA,<<@8]$N.9VMT,,0[]KMX0+OJ9;PEAEVMB&=+(MW_R,IF*NDP
M,U9VK_(P=^)$@S1)6=\.;OMBWE4IT'Y5N-Z1-*K3ZA"+ND\D'W'_2<[\EX-'
MKN(K/=1_F?)(KB:24#RG'"A;G,,-)/0P)HA1X&G!D3WBTUQ<==\*>.5.OE<-
M;VY<<^%_30D&G$-?",R8^_^S]Z[-C=U(GO?[C=COP''/3'1'2-VX)("$QUL1
MY7)YV[-NE]>NGHU]-9$ $BZ-5:26E.SV\^D?'%(J2U64*(J4"%)9=EW$ZSE
M_G]( )D)]*E6M-97[P/!NNOE#[TY<Q1A69SBQP\\?N;:UH?+^]5Y[O_8=J&M
MT'93VJ[$44F,V=;L*"B@H&,([-DX$X(.)JY[J,R3LO8>0TD;/5)6%H:\1] Y
MDT,'A9&YJE1YW;JV#Z=M:]!]GX8(5X6KPM5[HR=FP\:KP($M0&S^K.48&UX2
M9&B(77.-N2\O5C$KQUJ'!E8HU1'H .U6BZ^FN+CN;L##N8INV<E#PE7AJG#U
M,+F:0PA.)W:^*HBZIE@Y^IJ'P#-;>=TZ/WUQ->F(.:M".7KPU$CJLT:K4\DF
M:[>D;MFCW)PY4GI9GO%SY^J2]>^K?_WW_]:>&/)6/SPWR.>C!92K!KO^DF4W
MGGDX\7P0T= \5Z^X=A>_:_MA)SK-/W&XWV8$IY>/_4+3$QH6M&\\>G7VT]6#
MIWS>+FW>8*W%?W_\YI*XT?[/\S)3\X?/IS2>#08WO'S,GS3ZXA-^;33[_7/5
M'5WHW+SWKKIP_AW-=B>+\^6O;NZD">'DPZ5=>_[RHSX\7TYF9Z?TV_#(Z<F8
M1_\T.GE_-IDVB0[-=3JA\\OK_NS%7,#SQ?HA>GT1ME[HG$;OZ!<>)>;QB.;5
MR;C,CR2GT]/AE2>3,KMN1V>- D,7EZ%@U)3K*>?S$8UN]/;QC//QR3^.WYV4
MUJB?+]CGVW361!UU:NQ3)GE=30RN1JR*C?[LA3YN7WMLU!=_&3[K1?OP)I\9
M7Y;O;O=Y<C[B6MOWG;0+?I//)PU,(QU:6S;/[,]7;UMFJ/>PY6NZN&[:&QNN
M_;-MOP:+6&6]QTU ='[1VO>6YS.=??S4E8F#4K?;]V1Z]JY9\><C\Y&MJW7-
M_*1,?EU\SA*+;Q>3?CYIGS5\X.Q\.OF9CR]!MX$BSM^=Y)_'/)O=H8IU5;.4
M5V_?-77D/'G?K.BW87]K/#EO_;H037OO.?\TI28)FIZ/)G5T_J[I8!C2RG".
M81G^-:\@2'/]G(QIG-MW-3-J#\SK_?WYXP7ICZU0#.]Y&MYH3<,X99K.78EW
M'[9NSR=G5V/DY2-7[L3"HQWE4YHU/^K+'[[_^OOFU'TY9?KY9?OCIN=\_6NN
M7!2E_N73]W\]:=J8?O;BTRM=[1A\_%D+!W-Q,3=&D36,'3\Y[_&&L=ZT_>8C
M7HX5JR[_K%W><1K:ZIAJN_C/VZ#X*_TVNZ5!/YZ&?/%N>O5)E].=ZU:YI!\7
M\Z#YL]>;?_3N\J;F;LE5)M^B;.G2)+_+ISYK5K7J%N_LYK\RE:&;/[JM;04D
MW*_73L[;Y^?!H6RNRG28'?SA[<LOOWW]YNM7;[Y[^_J[MS\V";V=E["<U(_G
M@:/1JV'2T?#[Q5_HEL(;2QKH4P%^[#'<^/GZ3PL_>_'S)K/0T:=-^W'WOKCZ
MOLWFN_?]IJOON<536J+U)4>P?O;B]=O7/WSW<O3VKZ]_>/G]Z[^__>;5CZ-O
MOGOUY[NI=]]/_]C.7S0C^>KU=S^^_FK4[&>8K/[X]LVK__77-]]^]?J''U]^
M]]7?7O_MR_:OU__[[\W"_NGX^.4XOVMNZ/&+N<%L=0[S-"-R6&M$_JA)991>
M-JFZ=4[5C.O'-]]^\]7+M\V^?GS;_OK; *31FZ]'U\WL7_^ 1H=_&S5S&XE)
MB4G=95*7/+HRF4M/I>'IF[?_]P:?1BN<&(&76-J=EO;U9#K,8MOO*2\6AL;#
M&]ZW_G@W&W%KQS+ZD<_:]'589[%JL<XR?^&P9'ME?W^\&--%:2U:_G2K*8[^
M>#)NWS.YF+5WS_[TJ1]V^SL_+-]<^J8OS\Y.^7B8CD]SLX;FH(_YU^%.;_-V
MA^7;N7>8^?3TLE?GT=?#SY>KK_.?[^D^W=LZ/[6[ S&Q^SN0-W&S=*Z1Z_F\
M>S[=P_G4EU\>KGW]U6L$;5^MQ=^*LW5<Z*7G%-POU/K67;@-[VO9)=W8MGCX
M-Z]10V?E81O7+LE_:@._DV#E1& K&PD?S28693Q'\SJ>RW:,+B_OP7VW%=N[
M_[;34BM=NHNT'3L1"WUT"_UPW.F'@V=NM]-=7J8H:,\4M.*;5]RSZ4XHHY>M
MJ09WADY'W]-).>Y2)R?CQQ")V/>ZW]RU*;_,^>+]Q2G=DG!W\-:R=>9?]5AW
M9KB=R<GR7;AK]MU=ASR]V2T)C[KQE,PZ.R?VQWY\^^)+'_YF"86>P;Z(L=PM
MT^_7C#OT"=;NYYZNI3^;>_E^<C$^?Y9^A#!,&"8,.P";$X8)P[:Z[$]G0]29
M&)08U'8,ZBNN)_E$""4&M26#>CLY2#X]]2K,542"?\AA*:M-XI&Z_YY+/%_2
M*8WSD,)R/OKWB]/?1GH1P?/89K/)243+TAR718AO%Q0/2\;>[L4OK5:U6:=L
MZURCA]W7W5G&=Z5)LTF:7?5LBX%@:DH%<J$ ":TJ84F:M%'>JO_\\2K7ZO7_
MNS@Y_^W5Y/W99#S$_K_\Q\GL/Z\=R?JW>4C;UNHXA&6UY??$%I_  1 V//CB
M__F3W+"#Y\*U(Y,7,KX&AIHCY<0 EC0@!E1>F<RH:[ 0,ST*&.XX6?GN Y67
MU47?$RL4*O35'T\S+^I"_W?X!9H2!U5<C)P J Q''U1%N5H7()LEI\I\)/]7
M0\CQFSJ7^ESZB^BYEQ]BYZY!8 4TEKUE.PZ%=E[ (>!X%'?B0)EQE\^@8G%,
M4<5AYA A8\BV0N6<&C2475+5?Y?0>+"S(<@09#P.,F0"<JW&6;:0H&15P$/"
M'(U2#KP&]LIR2 ^;@/P>F3P$)G\SOMQ^VBH?/!X9$,="*"'K%/>\IQ6'(]W)
MB5)C\S$<8:4 FG12P1MVG*JQU>$#%RI^X',Z&7.Y.LAH34!\.(!HQ?3#'@$>
M]HKFGP02 HE=^Q(F1!]"1)>L@U U.J4]9W!D0V6ZC1';6IP\"F%9F=0]L:P]
MWFA^LHWC^^P2+S?Q%]_,9A?#WO%0Z# O<J 753CK=/*^]>R\2.BT_34]R<,_
M%T\.AOGHD9_WAVZG..UU?7<KL!L,A\M7%]/FGWP_+QZ[6-#]X8.M+-91?J5I
M^9_3R6QV?7)5.5#R1;,!*)0HL:I07-"@O*:EDZL;QTOM9@-XYTLO>S5=$E'V
M(,K_H-,+OH\F<XHJ9;0^.@!V!J-7-B1OHG:FWN,\NR?9>ZTG_^!R_/_Q=/+9
MBV.1H\AQS^1X_S$2E2G)NYH@&$#4B(Y\(<*8D[%^Z1;H+7KL<3-4A"Q"WF<A
MWWM<3;%8<@0I4("@7:HU*)<#>E9%H^I5QS(@BXY%Q[_KV&8.U7B$F"W$-BX'
ME8C]<*()6N>7GI2WCG^\_:U!D:9(\UE($TWD#!@#0&QS5VBZM(BYM+FKTFC#
MIM+<<#=.-"F:?'::#%2:&"WYB*5)DB(5;NZNUQI2;?[P2DV*O#K;S;HC;7+_
M-[KX'SS-)[/YLV=3/JX7\Z+HS;*G-.YIJTOB"PXT+8*G8[I[U?#UI8V^J6WV
M_O7<0/_/I7U>!Z\F5SQQ<(R@*J-BXD@V>&]#Q(V=H4?:6_//.$1!8-'SQ>\;
M+.8NVOU8H50:%B5+2"6!LAJ3:SX:UEQ JXCK[#$\:;ZEH$)0T>/%[QLJUO$K
MT)F 45&(*4*T,9E@3/,PB#5C\*77?8Q]W(\4O@A?#H$O:[@B#%Q(:Q-T"4/5
MAQ@)<] 80_"8_>KU(MDF%;SL7J&"ES[QHD(,V1NTI U4]#'6&%C5$BB"BQM'
M'#]!8B<&*3,CX.CRX@\8'"X@V*S!<6*PG%.DZ(I)MJBHDNPM"RH$%8**.2IB
M1.^+PP11022(ID V56DD91+9Q]GR7N(GN.<K?LGVO',3?&[DQXEF7(9-\#,>
MS^8'/_>SO]TI/GL%X^KK.NZ@I;H=TL7:GC2H[&7YKXO9^> +S]Y.;IDRS_<D
MYH1Z=0U0/W!SGF?-B'[DZ2\GF1>#\P^<)S^-YY\R'Z>OUV4!79-RH7)50#XG
MK<DIEVV(V497^]C:[,IE%^4^9^7*."'6]@S'B>IM-KY6[T,$ZT,J-L:<;$Z&
M:INLR+Z32%XD?U"25[%Z'5$G[1%,CI@HZ9@J0J+J:9V,W%WM!4'8>8%/$;.(
MN0,Q&X.%2D&+R$#%D@TI64UHB_)4M>S/B'Q%OMW*U\)0#,,4ZVN B$2DT>7H
MD@^EA+0ZJU[&TSYW0Y8?&GFOC:%]V$CYCL]'IY-91XF!2]M[J5'=KQ-VC]=[
MGNW>RST^<&?[:6_RJ5?Y'OWVNO59]LQZ^^S=9ZC0NUVS-NY\,\Z3]_SMS7(+
M%2GI6C'IH>Y"FPF%V&9!.I-)41N]\9K& 6YW;7G [!9$XA@(=L0QZ$>/>V:]
M??;N,U3HPQP#CJ:XJGV(18,U3.S F-A^HPY1L^QOBD<A'H7PJA=>U4K% 5I%
M',$ZE;*W7))7Q0Y[/.O$8SS',JN"H [D*0CJ!$$K#G:\C4'!#54',E5LCA)'
MCBXD;KZ3*Y1T":L3>7HXW3$<6;WS3:VGQ]&3'_@H)!(2/1J)AG"6'+RUI2JP
M*245#9#VU:4VG\M;K*(K4'D 5'K:7X?6"D^V<WZCM=/DM-QO,_VS%U_2Z5"$
M=S:B\]$70_O>L(2KMZOY:W_DL_/YR#BRZHN_#"]^<;3R38/A7[ZXW[UYN,UB
M^Z-_N]11F5RD4[X'&3L$^P;7OZ) ^KQVWIN+\]DYC8?>O9X)WAS&8'UCL;;
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M!+6(M-O!-H8F1@U!JQQ E9)\-<K[8K)W6+ULSLG *9I\\H%3YZ 4Q#9B5JB
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M4RX1EXV**$B4KQ!(""0$NIM %<GHG!B]#I *)6<M&U)@C?*X5G:UQ"0+@81
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MI@9M@50J$ MB*E&A]29EE8M;789- JY%WZ+O7D=AA&1S8E5U88B)246E2_;
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M4;[H"F JH@FQ30!!^:A,"AM5'9,H=8&40&I_(74L.A&=B$[V9S WR85J0^6
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M*\J62 ),G#R7YYP\%PDHX5 (S5DCG.\3YC=H?I^N;_8D/- KT%Z![AL=7Z!
M 3<A"@U57$980$R!D(3(,(H0)Z%JC([VY0.] NT5:!<$OU>@KZY 3<0BJT3M
M0W"%.6>"\2@40G $K:JDC?.?^F**7H'V"K0+@M\KT%=7H)(("I!"4ECXB8WB
ML51A'*M(1")6J+4"[4M+>OWYAO5G!T[F#DZ-N3Y)^>5DG(_YT+%<O>L:)%1
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M"CY:]5XGP-6VRM[:.7.[*<%[HF.W:C'/T9(SUEE(Q8E5I %S+8ZYP!@8CD*
M(AD3"( B44,JSE903APWN6RO[IIMGR=[ >FX@$AD"&-420X,QICQR)T4FE!$
M$%"$MW3.L&ZFWSY*1F=!P*,0=V_Q@7USE*52YWG@NB/Q3-[Y_ JEO^E!.O(?
MVV/ \-1-Z[)KUR$MVFJ=CRO8&3M>FLOA;6I5[566_E\MQS7URID40J$HC!#
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M$381YP!A!4$DL,'([*S5%L =/6K8O^2*W10\/#F24%K^,HPP#P!4DH_2O",
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M+)-I58[]2=YI^=4:RW%Q&F-_NLWX_6?+M?6&*"*&U VP)MBB1B.I]8Q#@B
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M 8/4 $4@I9SOJK'#&]43G8%E3\->[9HQG%L&2?@@N-?<E<^X>AH7)/IR^5O
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M."*<*:X+WC"N:=$J5>]#K2]5^FTGMATQQH["QOKVQC&-1[X\<[&:^'%"^[E
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M(U!EG]!ILLV++Z?Z,GP-J+:_'!C[@C;89YNG1+J+BGU[:-IF*VAJB^2OVBH
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M F)19LD01ZDKEYFF*XD;-J:T[Q^B5A6B9@E0<P- ;<<Z P5Q":95CI+JW:,
MX/%HA"E2"*6SS)C+F_-J(2*34;J=%Q!NAK/!@#VVSV=3@Q4B2&U"]A5']$]\
MU(H3XH#;,O0=']@.-87+>.B(T -2D(XR7=IMG+=,TB"Z2Z0/&7IKXW'UQ$!,
M,01U/M1FDD1<K@&MKN]8W*+&^5N\LP))J0+;YQ[Q3=^G=N@%,K# S+2$*]#3
MKU9I1/N GUV%']T:PTE@7CBFVP#!">"MQNW2)RV 1R"<(D O3*8YT]\J%B49
MJA;(G5/$(TL7N,LS<!>$C_ZEBK@ 8N9(8-.!Y6(#/N9Z(E!,69(SAYFKP-T1
MQ'7\B^7.M 7>7AS6[V^W2@2Q3RH1I#WP6D6=[?U$G5^!)K<R=%;*-PT^%J$?
MD<-^8"7)4Y5!)W("# 0-3BVK0!RR!%ZC9Y*A]L+!6H?;T2LI1^-(@>6N7P"\
MY@>\#&X!GK6%7J,Y^Z>4)_%CIL-4F(L5>J;/@7];MD/-D ;"5%P2:ELLI+9/
MNJVW>(UJRP*#CC2K12=S7?-&Y:-Z'("E7,=.#:EA!<J(D4H^ Q5E\03BREP"
MN"K7TN=*T":]1X\-&@Z-= :Z4R%'4!=*I!YL((P\?IO"8V2"CNDL/@Q0)VNB
MMG/4 TC&!?ZE)28!E,Y!?9O(:51$;JL0P)^Q H1'TT5,,R:S!,7A%%>6Z7QS
MA_J7JT+3&,?Z CE^8 ]2J^+YF\NW_I &'M./;/0>6C\,93 (0#RV'(&_SD;P
M%:]I)A4,*W;Y%4M+R^=F8K3JN7%<#GCL$T8)Y9X3^DIYCB/]P 2=I6FR,C$M
MT]*X3<S -EOC=@5KSP&%?A&SY#%.!-#ZF_<*0? D69(6B)OOMJ9NSZ,EE3#Y
M&4 TS]6=<Q2,TTSA]@P; 8'@Z/ V.(719!@_20ELXFOEKUJL1P=#X!#*+T!-
M1(MT3?I *13P$E"*L@=GB VW:CR.L;'28Y3*'!6$$3[E9 *;&(VDB#*.5=MG
M%0!-KSZTNM JP\=>RO Y58EG'%D!:94S9/\T.4.?-2F.92;JR[R<9D>2YB+Q
MN8JUD$JKE%9E![4$HB'8*>>S2<;;M6\I>PLPG F\%9G$WMPJV??7<7(GDQ]@
M;E9U%,;= (Y96+9G4C?P6*!\D]@B"*GO,[-QH,<..LKG,<_X]G]_0^8IQ2U+
MID^5]@7IAZ?J+_KFJP'8@S<*9,"'F"7B1GW4@>,X26$/P,ZO!I%4G[(4J1_R
M1H'J()/+L;B%O4:(3'M4@RPWV$8/6G#=P#%R"6O3&L\6S#?36A8"YAH,@.#%
MJS0PLNC_5$MW (6A86&4P#!R:.C+2GC444]_A9&J;9 P$T-%<\U!/$0!J?>;
M*V9ZOQ?&)P9:R]+S#$ <.1:Y+E)3"+=02_"97^"1OT]*K>13]KQ[F8RJBK;%
M \_V)'$<1AT>^HPI#UF9"!UI>PV-!'=21DHD7J]\3 >PR&;MXRS3]H26ZVQJ
M (P MFLLBGFT[$9=:<32%'XW"_\'#N8^7@!+%1;$E HH-R#4HX[I PQD($@H
M+=#33+(JI-:"H-GX(0NH_<: 2\U&&X-I9/M@FK?<Q.,O&T@NS6!3J%?+N#AB
M3T98,0-4$H]JE]:4/3C&802$%&4O+3U\M7?&XTPLL%2P?P&R<]#34P.)!^P9
M6=/_$3M2I)\TLS$::"]30&5%_<0G3K+UZ%A&/DP[-81F\OKE("; JM"I$,4S
M,^*Z.+0.T2KSDYY4YF=KX-%6B9[4^CD4L%5] !Q'MP H^@ TE:MHYQ'&6ZO$
MAY8L&S_I,<)\FJZVOQZCX=!@XH>>@XAB5OZ(AUDFMI:=##T94URIMKKQF5E.
MGC&))G(8C36/&,.>C <Y+KPAHV]?+W5>TFS(,M&,/QH2"TB!BD$V/"1L!(P!
MU$Z6EY5F:B6KK&W)M QG$;"3@@E] 08U!J.P% I5 +QEP#.DTOXR4$F^QE,)
M)_7NPKA,8>WU;,1F!07N8IR#K-.@*37BQI#4.4HBX%=+2\HVI6N.,S=<U=FS
MM#^T<V7F^)EDKH[<^$:P%VZ>8?8.@5#$D&QJ#-B/FL(%))9D7I],9<GX[]+:
MLCWE*_\0Q2F/)&XU=S\8;U$Q(^:OY=[TU_I+Z]=W%0=5PZXSI\X#.B#3>8XG
M^G: P\-^47/+H0++%!*@$$_FGB4DD45TJF%0YM$$:$RUW^2I!,99W2<ZRCRF
MLS$?H/0&"&(E76[ C"9#62#:*CPXL)> MLJGI*\EG[*O+CUZ=:EE]N6E?7GI
M OT=K[R4MLIOIO9^U;Q.L,,&9?/-^\OA=!#/'@;&3K45=>G>4&:1Z1F%UL>R
ML?5H\JU)",,@%J9UH/5;T[O>YB446;^B^1)%E,5D,/(UC:8S4*D8Z&19)P^C
MKG!=9DO +=SA7E@"BMM5+.9AKT*]N+R[*G6*^W@2<<,WG;,\WWN)9R[23=%(
M!/<>1N-,L\HYX+O\*:@L8&+%",Q@K1F%3]G^1KA$;>-BCI?.B\-K\Y]7)FDL
M&L593+"F6I[I8H\IQE\9%I%43C=[8@E4G?$Q!3,\G$TSI0TD'&@S'#>%$5V6
M\,%B;"U7F+06]_;S[;?_8*/)KQ_?G54+*G-#NGCM?(L%3D1E]G"F(6>9N(7N
M%J5&*+6J54.F#&?JM^:)O3J\J2-QN@@'*!CL>NUWF"5Z8DT(:WX\M$+5*B>7
MTE-2J-H#KU6^+?UI\FVW2*#-G)F;LF>_RJH'TV&!Y?M<4B>PJ.\))D)IF<3Q
MF!_84C[7@]F%!-HSL.GFG+9@?II/3%A26N*[9#/#+1FGVC65>5XU48T+F9Q1
MP7SN4NE0V[8#1I3E>+[C.U2(YC;2W3D$:UT^YZ.&<B3*;.;U$N"BU$TP[:-(
M>#EPRK-IAQZ5(7/\@%-I4C]T*- "!0. ^:%TNITZM%/*<T53*T-?]33H$K6W
M@;KF."M _ONX</'+]>!W8!F^\EW3#B3EQ&:^:U,J7$7@&R"+3H/?\DESR#*'
M.?P+7C.'A%;R=@?FM^U Z4IAVI)*W_4<JCS"0BY=&Y@+#0F7XDC<?-_1WPHH
M%^).J\.96<PN ]YUG"S"KP(S8;F6HC:W%+!:4PC&0D=)PCW;=[CDSXUGMDRN
MTO'-<XQOKDNNPAC4;)+Y6&M85DW%FY<E[)(POTR^C2GTW+(YM_Q0$(M39G'?
MMW@H@Y!XS Q"UCBL]2 I]-OC&1S?FNSYP@9YS W1/&-M'I-<2!Q8#%'6NM_4
M>MK<-]IU#8>6&S"YY0,6X=:LN!K)_I@_XF9\#2_52?DW:@T=2*9"6PI" DFH
M&UI^("R?,M# A92^W=C"<_^\HVT,VVZ*80.7V 7E%X'3B/"^XU@$F&E@@Y(@
MA!<PQ5W8?TBL '2%5=4W^T=XLCUCM<V+514CB^A717]0AG5:31F[9S]@F0^R
MQ$XCP0J34$X?I<SB8A^&#,C@C@_B89[[?1V-QS(!$QVQ/@^IQ$(.TXMF[ETH
M<HOPTHY(M D_(--[,S<L;<9!5Z.@/'LVE3:<0@BJ@[)!J7-=&C2H#PO\^PVF
M20/TP21,<!#ULA7J$L$M&=K,)0%EOADZ >@KU Z(L$%S8=:"A_W()F.6PI\Y
M?Y!5+3.9BI]-9R9ICUF6L5K+H'NK,ZCB60HGE[[[I?3FUR70@1T!K6I=J/OF
M_>IW;C[ %J?^^@-A!SK 5O4VU'O. 9(C]"C9V);$:(SY<#6=+K<G:>A"?'H#
M#QH'R#0U6EC?=:3HOW)J/;17'5[CQ(WFD.^>)A9T&XVV&^^RJ9$XV07S<@C7
M@ZAY<W%4IXU_YN)U9>^0%@^^JGH@3P_=E_GG3@30SZO>RZ"T/UU=??IT?=V&
M#U\58;S3QLU\2D>K 4HE=/MA,MN#IQD1^R$QJX>@[03'_77;L0-!*;%"9A%*
M?:("6ZK0MZ@E32Y,^B*=1W885DK.?)_TLUEV)=9>\AYGZ/=5-3Q]VEBYM8CM
MY>CIP>#H [\+48<$E@LY<9W$HXH<JM;T"1EZIA<&W',I\7A@4>E8'A'$9HZE
MO(X+N7[X6#^0^Y7;F;\O1[)/&X=[B_/(%N?K!T^'+,G=DL#6=;8,/>F$H6MR
MQW*H%Q*F0DHHDXX2+&3ND7IXM16]MGOF]N*WMR]?9H!XR]C:MU[2;C>KEO0C
MPAM'A.?![SPB=XI0VLMD[TU@VIO$74QB6R=O/15(D+#$)LRG*C1]3AU'4->G
MIDN$Z+JI2\Y,Q^WE[?;\JY>T+V[;WNN^\/4,O7KE41]@_1GMN=[<?57F[J+<
MJZ38U[)X;H&8J\GC,N"4<JELQZ)*66'@2D]X-F/2\[UB/'97!:YOG3EV;^#V
M!NYK,G"_Z/X0#=T65-XL&LM.*]6HIXW-O?W;V[^OR?[=$-'=LKZ>2F%)YOHF
M#RGU ND3BTI7<L<4S!3VD0J\VXK=YOKNT^93AS9S^U#OWN0R18COU4:^KEG'
M98NA/C=J ^YO.HD3DTO[E-XBGF'IV$X0[-.66VD >P3U&@/]6]Z]['(L/LX;
MEGT>WV;=S1;E>76DJ&U9GK)L:2E)A<7 1">F%3B>Y8'Q'G3=1C=[&WUO''/O
MAOO\\_H9T>L*<^>?GE&BVVI $%T:$-0)5#AZI[I6XWSHSS/.IU38]/B-J-+%
M<SI(= /2LO7G9 8\FJ4RNQ0^5:EE'!MLJ+NMZ&DK:C;%$7:S-.\L,<:I=A.F
M>U!(.)!X%/%,;4RSEA784CX&N12-V5"W+AWC3!!XY22&-\*ZL$.];F>>#8XI
MYJ1DW>!2O?1HK,>Q8(=-W9 =N,?PJ=[QM'Q*<^/..3@J<R2F@R@1QK]F+,&6
MX' E"@]X677[]3:AZQJ9M!=VG''3(S;E%B'4#&40* EVL47<0-G2:6X8E3?/
ML)[5_&BEL+.V[FOBFQ?+75^.-)&5MIK'X?3S.'(PM '>TCR.E1T97AR<U6XP
M^AI VC@+"?V232_ \15Z]EE3&\2%-NH'.H56_?^=LNU)?9?MAXATY=",XT"]
M59-R9ZE)>4> =F(XL-S(/D>*0W/$5JVC'=K3XK.@OM1Z^S1;_S]KPM-E32??
M:GY19A0OCQG P3G9<,/ADQ$_CM,-S7P_Z>;NO\GI(!9S07GS.)9).H@F\VZ'
MU7:>E$@6A+[G"TX9XX&@4IEP_BX7/I-J57^^.SZ08C:4-ZKYK<O?2OD55EOJ
MNRBW/W^]VF=30[)B,%\9MD:(PH<(X'\[8/ DKG5M>,^9\7G,+\I!!]E%Q:R#
MZH'J8\@:48[RH4_K#^6W"% #0/$YGP71<!P?GFY94I^4J!PG8!([)5*+<I^&
M@KHL(%):(75"6ZXZEO+IV;!2O8V%K<ZG)';Q#)N&*X(Q:8ST.U;U9 ;6 '#,
MU$(]S#::#K,)#3C5T(BST6=K3,)L^L^-TG-,[R2KQ4,MR_94(*0OA:(2Z"(@
MM@HL.!#;=BQOBSX.AX2T6X7TYZ_7*^Q!W3(7P%UOF;ML#X9ZDFN*(,#^K,7+
M2U!GOP,T13'X]L*8DPM<8F#G;#WH-?,[E-=E9Z&GIN@9$]/'N/JVK"UOX270
M;I!R+@DFGT1Z"F5&1%7EOTJ=V:"SR[NK?#R)3>PS8_-DDDH8W-"[L( ;ZR/9
M?*^!IY:+WSACVO^(89T94_\G/'.FRT3T!1?9M_?UAN[8/#1!@T=D?8?1F5)M
M++JA:WXS2E41.."^9;G$Y]@R//3-,%32L<(PD"P,PY6#E ^*MH=HGS^?(8/H
M(U#1J S6660:NH '<#6[:PG1)4O&V3SAQ!C&:8JS4O)6[PFR?S64N@XH=X8A
MMNKG([X".$7FY,)D9<SA8+ID: K_T4<.]!-/\J3'=*GM<04W<#"L;NZ?OQ!]
M@?D0%UQ4\7;Y R_67D$>)7PVPH$V7.+O J?XH.S+R.X<+AJ?PS(F8& G0&BP
MZ"C!=UT8USFDLFG!VFF(4R-'@!P#9*N(GW=R,LUXL6WJKLVD[MZ;(W*M"W,K
M'/XF@<C^+<7?0-)^@=W>C#^"PAFG@ >5 )3P;>$2APE@Q80$S/>4X]N4F%P0
M+AL;DGNUAN1'0_,=FFXW9['H,SD@**7O6H''B(?YMJ#_<4DE59)X7N!Y;H-[
M<[&W>Q<YAKEFZ,E9,4\\ KW\J3:1$B@K(_NY=WS5&"8]+3333 YW. [89*[G
M@\(!R!VH,'"(JVQ36+XO&:CKIW<X&8<KV/=VK.AP\&? 9[CIT<"V)/5X&!!/
M*C>P?5.8EN)6DQ MX&]9Q+8Z"O_5,0$<1\[R26=+XA%G+>3G\%'R_!BLO(]_
M3943,= 0#J-[F#&<,@NBI6&TKC;0QJCG 9U-,UGU&*5Z^.LHFDX7)I;'^=1Z
MK1WF0\M4- :A%[&AD<XF(-ZFM:1EO2B0HC%V;:]*+#U7.1-;!<7'8Q!9LXD>
M\5:G>\Z21(OX+-2T5=BDXGOIGD>RWBVX6&K][X6_EAQH'=G*HA<L3RI8]D;M
MO+2-O:RSG)LY? []IO(<%O(;5LX'*"MN<,X%8#D:)>CT6QP/(#WN!F'H$<=4
MU)2<>8'# ],#EB>9339+F<WC 3Q?>5QP*@+?HJ$*?1X0!\.HK@-L50KK",W)
M:V-M-\.\:$[^\>[V^DN43N^?WZ$\7WF^D,SON)B2,XTG"V[&O/4Q?=<T0G9C
MAE+]G6PVC9O?N2D)M6E)UY>?OQG_O/SR^R?CYMJX_OSU\NO5Y\LOQN>O=_??
M?O\-Y^,^+UMX33)0X[B?U7[NS0C8 FOG<;XZ1VWGBM_\MA9+W//DWM<>-FD<
M^HM\$@7=YO_-,3/+7XGF0W7S64C9#"1ME#_&LZ$P0O0;<*FGQ$PQ'0<4CR*W
MYPS]#+K2"H=UZ:6"2L.,8<3": AZX1G:'&C%8YHHJ"?ZFES)+6;*C%CR'=.$
M&-)T!+(0W6J7U2R;0203S'UYPNPAN ]N M4&B"E*![FO9#YY)AI/9M,TV\$#
MK#K;U@#.$NZI0@!VJIW<N/9_S6+4&?7FM7^":>LJ7UNFST<(<^0ZQ>!B]+'D
M&XWR?"5\U3!^1&]?]?&S<1RF,OFAQ4.VP(O%65'S3=9&M_QR6)ILC$ENNHD>
ME6TT#HW==)/31TUS9:L6Z%Z690U?/>>P&@?[;+K)+0^K081OIU,UZCH+ND.F
M..UZ9$UZQ:+F5/T6-*A5!3^KU)3J(U>H66N+.58^H5$W*Z#AK]S<'#-.6I8V
MY7"=^!XWO!ZQ+'"]X->2R=1MTV8\V0DEUZ;S5_%3:_H_.7Y^P4S?U1 P#,OX
MG*D[103PG]D@T)!A' <8]SX4&ZU*9>D#Z*!"1Y*.5F?JF(XC9=H>JCJ,<UV-
MG]TQD@RM=NV%PG#216M46E&,6<6R^C=S<VOQ'9L%9_6Z>J+8XG<-W[26G8TS
MU3;=Y/6*SG-@WE@DL^FFI1J9$V4_Q]#N&PMM-MT4]$C_(MI]8T'$1L^4V:OW
M1J_>O[3J^S/LL5?O7]79;53OR2;U/G=VYKF) [:L\//A3&0)7_IM8#%H=5YG
MD<U]DD6^0E:Q6='_G\X,&>FG9RF1F-2=Z 2M["_MQDQ!T4< %Z];6 0^/(T
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MGC:&JMHM$,1W^-=L*-!:03$5Y<8+$S]0P,QWJL$+=*2EU/RQMSG*H2RU 3W
MBD5@Q: %)WAL(,W@.$ @+0  3P2,M:E>A@2^R:<EPE;0< [-7%K7;"Z-HF#O
M\>^%$C\ ,P\,%R/#&%A*CF0Y@61P?\P5Z7@,J),?/; %,-[TX>(FGLK%7.1K
M@GT"C.0XWZ, -5P;CXA^L"R-HW,@@^: \:04\0=-PJ5FJ@/),B,&#-[O0!
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M:5'J#'1<X%V@/50Z7]$5GK^Z2*+J@8)?[N_3MAOEMM/Z]GH<AE+TZ"TB:ZA
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MXB=>W"VK>BTW%XZ9@@U<"V[#1S$'T4Y$2U).X9Q7[0H4XD;LFW]6BWK+15W
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MF:>7&$ZM= KF"/.4JUP9F\+Z%9%#7LHD8[]EX)?7&Z3I=ZR]#$%I9&A,=XV
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MU\&'HJ08DT)DXG\Z-$04PA_S'-A+O$ZH>B(MM'9"Y(6/J>Y>BJ(@]'W7#(/
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M[ZPSN>['<1RR,'#<@+C [:$?6\2ES&*ZX]C4V*<.W!I4K&2=BI5>PKX:W#&
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M81@-U3EV6?'>@G$80(M%O=C[YAER9R>?/[[[^+<+X_SLLW'Q]Y//9]WY>@,
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M;@:[G.*P'6;@+.X2Q1]@+,,!49/.R.9*39.O<%0/@P-5\S$-)&(I]LFEB5<
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MKO,XG\DIC>,%*X^,E_8K7);$)(E1H2;EXS%@.NJ57W$T'[N9CKD8U_K2H0=
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MNK91Q#.63RI94@&Z'+QA# _!1:1U;05J80@U52]0P_)E-4<5' LY$HQLMD&
M[Q.VB-3$/^,BIQ)>I*V_@9^T]?)Z[6O*T\*2#CS<TIR2]W 6SC\)0$^NWN/S
ME_#@ITRE@.HCV)T@BJW(!WJ.W2P.P]2+'3<,33<V6<P'Y@4^C5*NJ=M'%4]^
M3N<EXL*+7RVSF^TAL^YJ]!J&<\LH0O TAI:6>\DZ$FY3N,.[^2T;X_H:T*,8
M@,AC'B>VYX91'#(O#1(S"N* .8$U-+)W7X".W ^P_\6O&9 @D6,/_+!O#D8D
M2IM^RBD"G0J3%.4J#']XDV2KZ)YU".]M N.MXGM6+\"WJ>O^,2L?15K5=ZHP
M'(R2K5%_J["@=8@+;@+CK0*#5B\R^!!&R<&3O[8G9,@H.9^7U9R)BEM=+1BI
MNHH6>: V<I1_.[K.4UCE9U*JPL!UX\3)F)F! NM9D1LD<>*QC'$SC=+DQ:^S
MVT)Q@]H>2=D=EN*,Q\4M>EQ+GO!\6E>BK+0!>KO5;:';?#PVINQ.,S!84]62
M\FE1Y3,C%R87WC$YW24^X)^3DJ?YK,W/Y,]547;72_^GY6[Z]W!JL -H7=T*
ML.S8-A-F^MQQP2 (HRAT(N8Z@$6N:0]U/R.%]'S,TRML[C,OX3!"EWQ/VU<O
MD8KG4_KP[5:+0Z]VXONKG/C'_=G6!B#UF,K6S\OB:X[-PJDPB2JP)H7!*8L?
MKR7E&<.:FOBNA1/"D=_'F?K2V[<M,$!@4HS6.I:5I6BF,U2O$U%,QN!+5I&9
M#!1_=:VZ J#9 3M=2%KZQLC O"HYGJ@@K(UK_\"Z6,;+"?NY;0!5'P!QKL=W
MKX4QI".=ZW(7*)2E:6BY<09\.TZR.(N3-(U-/QT8E$=()^H:GCPRM"U6F<=>
M#ZO:=RY1#$O$C!N$GI%J]9!Y6<W(PE4\"B]Y)' !< !^M@@Y.$NN*10I3C:P
M"*# +0=,@_^"W '$@VW X\(#@15D$_32U#T61D;"2W28&#/VC5<CY=R!/=0_
M1H_+?"8;L3R\C;=5]H1]R)[8)*U^J^P)NY<]L65ZU@X2'P_!J!_>S-/Q$-A;
M2=V#KW\Q0-L#?>9H5DS5SN0GJH.P"-VI(JK7G\_?GK,K_AIX[Q=,@5C6RE,O
MU.JM\+8H  -?]$H(^\OH]YU0.DM_M8]S%%AB0_T4XO4N)JSOI7OE@WX#.UQ0
M!-D_P11V>!0CR(ZHPOIG@XUO00]? -=^\=1?KLL:<T6#= E;(KN!"Q6MX^G;
M5KG<M3P9C>GI5,H--5:OB^C^O,8QE][WWSE+\;Y[1]O5%)SUKJ]NE_879ER7
MJ-K\]^7)Z_=GG]Z>?OIXB?5>P"JH1+"GFHI_,*2 *N]?_LP&Z;+;V7G9IX.?
M;2^GMJO8/*2@; +CK5)0[%X*R@,Z9(;TA8-#9K5#YNP;;+XR/HEV%2=H&8K&
M--*T,LBV,C2SZ]6#8]M6>1_V(>]C$QAOE?=A]_(^#L47!^W^^05Q[*UBQ/8A
M1KP)C+>*$=O;%X$>,LL>*[-,J[Y877P!=")[8;%&N=!R<KJ:1]V+6Q1JD'K2
MYA*O\P*=\6S*Y[,\J4;&NTG2JMD O"NG$@AUI858J<G^F6KN<M'85:I"5W")
M,^'PKT]$>6EBH_#S";\J9MCOEMR>=-KZK#1<M,*&8W#-XQ2,0VZ 8HI>4FKR
M)CVITA\[X\GU!&[IZD[]*,5(@MR)RCR;@7D\NQ$>^D[< #-N\.7&]1SNL!J
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M73BI1=IQW:7PVM>(S[O/__?(?I+ #KV9:A! >'U#1S+5=[=4AR^8NJ#4&[K
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MS6.ZVESD4PJ1Q1 -0)WA,VQBK90V#K*ON!/?RZ@+O+Z8DO8H1)K028A6FY^
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MW&EEUWTX0)MA+Z%^)SRVM0L<23.A:I%YE7]3+1.S%I"0MU+263;(^T:"Z-'
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M"JN3*M3J&S9\:V/98_5^N\]53^8XL7O3')"'ZJVOQHZV6YE14TR]QQK="M;
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MP98&!>ITU/11\?Z% K)19I4Z6$R.1/%V2^?%![B8KHV3HPJ:IP3/*_/JN)L
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M>-H$O0<6NX%?OP>AH:JKQ[5??X&;-9>RKBH]OS,S8P"\TP#N]2J*,^W,S!@
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M7L H.^/.O><^CW0ZJVYJ5VA8NZ+.+LYZ D1/J@QL"[#MUKI*Z0D1/:DRP"T
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M?]0D0!A0-YNV[8"ZN_5,IYVI>_!J2QS4+JLZ"J1QH@T!VX)/O:>I7^G\U4[
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M7O18=T+.(HXS4D)P$7[#A./ \+"O"D6"#9X(OLU/!-NH>  #^ #F>8&C7OS
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M]</&IN1)';'*I*2KC86HQ2U7V@D]P9H3M%L:J*U$TI8+&NF)FC1 ^_3T.-<
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M-CT>*YI1CI)/\Y(#?@DT#<L9(M(HFO(44L .60LLUQK7\4,U,XU(+[?3;BB
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MCMQ;/G*?=CCL[N3</;%6Z7LUG+[;>/KZ>V/H6W=Z-^JK_X$';F..P_;9F>F
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MKSJ)!9K8]<QY]%718)=(ET^#VL'RA"?[%+839#$N]8.D3EL%(F\?JH<35D=
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M"I<AL;FIAT$L3&RR>W324>1TQT'@]_'F:/;K^X\S#8"1 3#RF  C/PV D4[
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M-@VBRZC :C]CO7GC(;$,9GA([3Q[/I*-"<]@([-.(+P@BAM=O)E(:U+G3,3
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MJ^VQ(+ ?1*!4"%O[C/MRD^G&R;F''W#=8=$[B6G98$)PV8STLQDII0RAU<'
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M"7!14V1"ZXKNH)*8>9\OIN%BL!CRV,FWZ!DP!'!SD[O--Z@L;AR-3N!N4NA
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M'5)OLI:5*:[%K:W_UG:4W]IG3^2V2[;T&/2WJ 6[C4!.$]RVN0U^/AXDXP5
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ML[I;@.: $*.$K]170(&%([<O" D/!PD],^ATMD[W5:H?%+ %&,3;%P8,=,"
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M<UE-^K/BO<7+/%[F:[S,NR>6XYJ^UWDA5U"#?H RE.T0G.!8.SF=CV"S('9
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M,2TQ+FAT;>U96W/;N!5^[TS_ ZI,=^,929847];R9<;Q*E/-I+;7=CK;1Y
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MYTXUGU;CQ>ALG_X<$@;UWWS^#5!+ P04    "  5A&Y5_@ K F$'   &&@
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MFV# O)[SG?OA*+69./_Y)X!1R@CU(QQ;;@4['QV6_]7B+YT.?.8)DX91L&H
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M)BEGF*'6F(HMOV,P6RZQJ]8^H=U@/N(4,])_5U%5_G,'!L M[B9(9_]&<ZP
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M#"\M,<8?>:V?3@*RV7I\ ,5O:X:7GTXXKWL)E_^Y9?@]=#4!8=3#%2SAQ:>
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M&W8#GS:O'.YM. Z-A-J?,NK#1P<K#GL-3 U3"OSUV7 @_(_!P+X7BP./H9W
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M$75P7J6VHQF[XHE!V1PJQT%_O_LBXLW((W&Q[]9.K%K\HQ^?BA5*'^5X1J'
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MIL)2 ZG0$3EP.V"I:RBG"=*Q>"FYO%D%^K8"QC"EJSI1\1E'RIN2A-B\.T'
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M&N!\6^W_\RG0&SAKO$&__!]02P,$%     @ %81N51RDP_D;$@  /_H  !4
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M"M+,V-]GWK3J:].6#IXI!05'!>I3G>:"5>F#@]X:V)*QIH_0](GUM4-+EO^
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MI3KL'D2KN-!#03LT!+F8W@(]EF)4ZU,[3^*I0"O1?/6"64"X>"%Z:-<+>91
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M"_BQ.*)CY-1+@\[Q?=7C8<=NLS?C85/'6[>]<9<7#ZS/-BV<=))N"=X<HOS
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MN9_P<#33B@R[O*9;9K,7\L<CXOBG_P-02P,$%     @ %81N5=YKVF! 5P
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MV(Y<H,9CRZ[DJNW-\W=?YI%>ITFO46:W%K.X^I)8;_T20$>DK@P5U^6*Z_%
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MY!=;;E2ZLY2WIU&7=-ORZ;;_-H]\VYWT38H@XBG G+@5M*S;,K1C>]-I0\W
MK:"A( \WGY/OS(\CJ:AYF;DT;2,P:#QFX):R()33CFIB&F-B<0;#V5IZDIK:
MKZVIF;>-C,W/O:UE;@O9MQG;I(<,@TW%U*3:?*)62Q:1)_>)WP^AI%)]TU$Y
M$I.Q./GNHKT+4E2S,K]/+Z&%;DR1*E)VI##QG8=WN,2B6I%'0EVJAFY+"86D
MS$GG8YB<U\(^+G53C6I:*=K]#BJ7-E1CJZ@H974!0\,$NL;F[VZI7D8H3_.G
M@FIW/M'^/3HZ4:B6EE)*RL0L3H99:.VM>2^RJ.C>K."M=UETX[7NE"[T=:Y
M,\DU[I2+[_FX+Q%UR<,FZ)PJ"D$ RUJFP:"$3E1SCCG6'A:%DW<O6=VDDQ6>
M1Z-RUZ]J5I5;N,K9-83WHAI_OI;MC+, HA$,5D!# D_S*Z<30@E-^J:<LCJL
M?H8LO/?-@TSG(@N>BRQX/A<+TC51LN!Y* O8GDP7(@M>B"QX,1<+TC51LN"%
MI04K-[51G0*48Q;*]X%5!M\#-@I;#UF;##CX7D3> Y2"XDQB<TB"LEML\"B#
M-*V\;F(C<WE-UY4S>1AQ'2%,M 4E>;%E>271_D/S9X]%B:*8FM9$2,Q]1/Y
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MFJM;'U'-=@M8.32/5!O[8-QN;>$,0=S=K>.TMN%1O%W)W*2*73UFZ1-)M/4
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MH>\M<+G"ZW%WT,-J[F^H#TU;TU<OJ27I^H&W:^?+I>#E4G"OQ@Z/WBZI+Q<
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MX/L<(AZ!(\=&RUCP0$3UF>:(5\/6G3&R9#CP<<7G,$]4*;2*!4SQ:S/-;,Y
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M"!I&GT[2_LQ.G:LMV9T_IQM:WMW>PL4V2M%J@Q>ZYS!"";GX@T",2Q=7$.T
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MY_%JRT>P 0B[_7@L(1VFD8L,*$_[*)3K/$E?TJ2*LLMO<5:1!SWNMQ$">#T
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MQ_!;8.;@",XSQ[#8M'?X3IQ\5U1+GF1ZN/ ;S9-\^4>%75^2J@A5M3>T*K<
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M+N';<XYA6,*W9QNY>DIQJTOX]M()EO#M)7Q["=\.<-FYA&][!)\,Z&3 ]K9
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M'"]7Z"Y]VI9[Z4%<(=P2H+B(L@PDYZ^74;P=THY :XU?EYG!G%_PX+7=9FH
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MEP#MGWCM.#:9 28>TIVM,*'5OD%V XNC814NI1N9A 'JJ1JIKQ^>HC1F$9\
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M_8:XH29I?^V369 D+_0,O.=R.34G-4KCS=JSH?<P1'8BP6!H\.)%+Z7=J#+
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M%H<H>Q>E0)!OZ2W)%MSLO?](.\_2FXW5=_"/QEZ>(5+S;60.VSL'A!AXX_T
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M8%(>A/%ZF05))ILW@/!)%FN'ZQ=?HH>"#-WCQS"*Z*H-":OY=W8;*F'@&EM
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M6>6H[2K.,#V8]#(.HO06KS")O&04=X4'+%/KZ^X_3RS3/?X$D]@;MV,C;?^
M9Y@4]@XSQ$GU[&BBG@&ZA\T*Z8%J\)20V,S "2&5_[[1U.4LL-JS41DZ: ;X
M!#'E;##&U*.#?O+LB+:M>$)UN.E?1UP_DA'<T'>%0-X0<O1>D#=O UE[!ZCS
MYD\^ #NREWS@WBV ?J%G^&L$#E_>\>"5'7LOZD"\GG.4K^18(\OPC S.%A]R
M;"KW.+T*MO@BW@9AYQ*%85IX6=9$"V2<T;=K;>;3V 7M.&.HN15G$'V,ON0"
M[H^^&X0X41CIU_V2,**O4!A'3'UR'D?(:(+KZ4?BXF6<IM=1*2Z+(^9:>''$
M1 MD'-&W:RV.&+N@'4<,-4_NXHP$D0UY@N@]],$&TTO!O2O=>R!.%$?Z=;\D
MCN@K%,814Y_<Q)'G<(VC==J\@)DN*W=BA5*RB@<2R<&<%^JV,@Y769-36-XZ
MWPJU+J4HCI8XH>MK4[2K[AA/:9NG>+/&B7/NJA$0&W=5FX/"1DV>*73;A1G@
M>%=I9P#"V,BUD& G1M2OK<^W +TF1 E'F1"0<C1>G =)1 K1] 8G[)3EBW"S
M)T&+#69I<LF/9A8=IMZS=?'[&;<>2#I#>Y!U7#_3,FKVT3B9DE+AW9I*AL\8
M%?=?LKN3/#D!O2^@8I!>;O+:4%&=Z[U\\('^YT$:KA0D;\@(J%S( !.6:05_
MRT]FQ82!AW83NH#'1D<[NJ4LWF[I*(G*H'?HGHJA'\,(K>/-)DAR(?;T)[_(
MU^QH"<4Z_2(G$A.7T:6FSQ:"P"HLJ85>\"%55?D,D8?Y#>DGB#T_=H (2JC^
M"/&K;-(KC_3*(%OES@AE3?_R11T^U[G@4030=G^KJQ3C:D2CZO"GNA!=$Z>4
M$S %[FHWH6;KU8;)G6SRMI/Y]/9J<?5QB6[FMVCYU^GMW"\Z2&]0T^H!.26X
MMYXI]-K$C;4:HV.E-VBXM0;Z0F40$_)L/-@?0IJ5ASF&/*E -&=H-*=BK,VY
MC#&Y,F 6I3E=T@VHWDZ4F,R(F$]]Z,QQ>#"9L=UMXA>,V;SJ]8XNA7$O>U?*
ME:00RPUEA4@S*"T41J2\D+:=L(]1_KDO%Z^K>S4V[( 6)T1-&J20Z[4)&Z-J
M0UVFJDSU1L_I:X>/J-(8C!]7E4;I$W[&24!^0'E0Y4NU0VI;"HH93;U6PBG7
MA!8=."TGY4-4/?6-$((.Y=%!_.L+N-!LP&4"3Z=+&A07T]9>,"Y>.1800BG?
MHH9$'H@D0@LVZ*(RID,<N8Y)>:K9JG9]L!_<4?<]AT5:W</GD[ ICUD*.TXX
M]H]]F+U\PME3O%Y$SSC-Z&FOUU\C4JX\A3LRU%B1?P>/;80;MRLYI]]N*/=T
M+8%RT-"HE(M&NB;5 SHY7SQQS$ECC,0#NZ_%45T5#:Z:V1T3I,#C#5/38%@E
MXY':;Q\_D)^?;FZ.]UF:!1%["0LS?2B,R-<@RAQODQP/R**1C'4DNQKI<'V\
MQ<$F_"=>*]]VZ-M<FHQDS:W076S0?FI2VC9GO4+EA'Z&V6L,8=7&1WYKP$A)
M<[VNU2&[6).:\RHOW#%_1@80<41<Y+X4*95I<+@C T+4EE9X-O(-J"G':S?)
M'Z'JF2?O&<H[L<,@R6_.HTE+O,L%KCY_4EW[L V%E#1Q#3\N0Z 7?DN&U(YY
MRJFNJO<YGW#?P-?XQ76R0ZI. C G2DATPVV^D-OH"8_3.CY(Z8&B.'I'7^4C
M_FSHF*,<;+P&[!B-(W3!XVB,\"$(D]^#S9Z>I<1.>RCGSUX$.S#T&Q2_CDZ#
M@;Q1FX"L+K2MR;BDJ61"Y1 31(<W+;S9MF$ AKAO=S5)IFY;YYNN):?,RP]9
MH:>;'::N/^& =O3Z.KJE;S4E)(02@:LX2LI_TBWCZ648X46&M^U"QXKN-I]A
M=$-1'\(;*U$"T#&M@ )FKQ9[3HJCF?)#%VLG&Y>*Z81#I9I)U96SESU2](7J
M1\R +W$+E!^\$ <-2T$TA####9QP_CN-L><O5>2?;8(TG7X+A3%3)MN.@7Q9
MJ)C&TVXE1DD,:<4<8?M)]3EB#TCE0A[YPGYI3_/8K.H0 3MYS;AL$^MWRA[U
MF_,ZHFWNV'@G7J;<"G/ZO>VN;#[Y,%W<HM^GEY_GZ/H#^K"XFE[-%M-+M+A:
MWMU^_C2_NEOZ-PK0?*5=MY,$;%*\K*[6?JS5_AT]\]A"I=_0"UCE%WH]J/"9
M)[Y5]W6G;%?V!UN-JEY2LG]A37R)+&#H!J[1.\""K\^9">C:O.;W44=#T2NX
M]@Q QT>XEW[A7?(R8IJ\86S)Z(0[!1)DZ!!;7TG<E+Z@:A=PEB(I]XU86]_$
M\9Q']>=?0YP0V#R]7.)G@C[IY(=&H^XLB+01W'2(Q(RE>1&U1<T)$I6B^DI/
M)9*79=/??9LVT<$(?_Y$LP>%$RF2]H(9%:5%IR0M@@M=!OXCS)X^1_%]BA-V
MN\TBVNTS>ML-Z1(2BMA[(+>-D%--%BW2=-^Y$-2JC78(@+4!%3$@O;(28"PX
MJ!6/P.WFX>N9A2]2"'VB1$._GB"*?/1C2 39NX#K('-]JI%=6O"BGBT4"H(D
MI#EN3(7_/K[R'?:E$*MN.J']Z0^3/X(D">@VIX<J +SQ&PAUKX7@KO>V&7Z?
M5/"%F"Z@(DO+QL B2V'#4="5>F5:9.UP$L;K>22]EL"FIS;"KMINK=HZ09B,
M$>,'E/\4QQE[]=@ $'NUP0<3>J7F($*OQO?QE>9&M54.[F46))D3IMNJL#0,
M-[A^CQ_#B)Y3]L9X<!R^%LIWJRUO.'_F>@)%RT,G1#]KKLS7U*.O1#^J&T"Y
M!=0T45_.9T9.JJVZ+UXM2AUMJ#A[;:'BS)^!6=J=I^>^MMRKK60@)6EK(8H*
MK=F>7589-HUY<GV*Q2PO7IWN!R1%F-'J7W7T$*I1106%?:=DER^ILPC5"6C-
M>-;>'BT/$+;MM8.*/7M0@<B6AU:"EV5GM0*>51_J0?+^I5:K%6]*^!4EK;.)
M%UG' *P@&MLRS8W@=K^G+^^.*#=KRF0E;X]8V$+)TPY^4(>.-=.W2%H;%35>
M(_$DODC[7O'RB,G^05XSU>LCL)>L*"V G?6A96D0PDX%)Q2D'EVZ @\QU93A
M8(RY7C#-)Q/8/KE3[O'H&I+M@,V3A&)25[>5DE1H1HM#@M83]@DZ]>2<=)V>
MY7%%W@4"HG0;<6DBTNT+1\ZT.7*FS9$SBQPY&X<C9X,X<M;ER)G''&GWK((C
MG"Y0<^1,CR-G/G+D%VV._*+-D5\L<N27<3CRRR"._-+ER"\><Z3=LPJ.<+I
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M7FX45R?W'TCO)>=E\%%S7=&Q6ASGZ-#@MM#RJ @&V^EI;A8.OJ=O^!5UZ_@
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M]"5_ZGAN7]Z)L<%OWJ0 5[R.?(D^#P __1:V)QDD$GRPYQ*P4*<Z+0*]IMX
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MTL9=V<M<OGZX")_#-8[6Z0W1C),$KY=TQ)V?;4<^P*1GV2>"9-U#0RM/&VD
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M&> 82FUH",38Z"D70;0G42&$*JG7A2OAF D&6,Y&2P>WEL&&#.(>\M(Q/^:
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MZ-<518YM*-Z\<3>XW^ _,)UAP.OI,TZ"1WR+Z3T5[-7?B%VHM \VH&/TX1X
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MWEV=E1W87LS%I+F#LM=TWBR,UM6.[ISGQZ#":$.E45R+S[V_UQ$WQ*M1N_V
ME8*VBSO8G,-[[[)HC;]%.YPK%R)TK^6'Z;_V=+RN0D@/T^@VN9)2Y)P_1?SQ
M0I8:M,U$[#YM&^?=DDU J[7,@ERJ^VK#,\0<5@7/'*-<91XL5V)97\X7U#K-
MH.@>,&*$N5'VG*\HT/&@56 AJ\S#K4L<&Z+C"SJ1EE.8]<[G'1=91MN<CS^*
M)3=CF997],J >$1'*[PWJ T,>X)*[OR2)-0B8:>"'S%J%$%1NF[]^ZK8LDYS
M&Z6H+;2$53ESH_><Q=!&*D?I%.\[B5+?' [R=^JMU$\5;J%X(W]JZXVG"S1T
M00*_K]8$]V[I<_E@$4A5M0,9_(!M5#8*-;'8DYT1@4K2HGS71B$0.6EI"X!$
M:Q+2+U^C<1%40]TF?40.48I6,04JYZ8.?X^RF(64ON HQY<D[X9NM.]+?/;?
M^V*TJQ$4IQKE1JPJ9<[+QRAASQ'^P:X,GCF1F;ZUB.4'[J"W6[2%8+6>.5#\
M1\28AGI[I?*=_)F==Y[(;6D#/Y2DTFZ";;_\N7RTE$"&NF6(Q0=MH[15K(E0
MA3QT$X,=(%)J=FK?TZJ!7VS[:HX V3?P3$=]2L>Z2-<W\<.VR*\.15[0J2(=
MX>]PME-W28/%V[V4H3@,JK4&($=@2UL6R#>KJ#L[4K]%3Y@)X#6*'G$6/6"6
M HP'Y0]1@I)X,_/X;0V,OA-9-9[2K;22"D\;L#*+[\DFO1 M^NW ^H*KS8<X
M.;!4XORJ@D9ENZXX3KKT3%=I7T=ULP?JMZ-,&]UXA,;S/[H.+*_);CKY.[06
M.I9S,\A8F!&0MN^XO9NB5B\PI@X+ZA1Z-7P?Y?'*KDLPRYH[!)ULF.Y ;6V"
MSL!H>$178-!GV1'<,X'%=P,#T!KN!(9;W*H+4*NQZ !,]L'</\^*ANO3?]5N
M3__QWY?;&&\^_L"K UM^N=ILXA7.E!$!BY+R<QE+CG3>@;J"Q0WL[*B\TD;R
M_$/V*_J$US@CF\U/2XDHV+0L<6J"MM\8A)B76.D-!QOO6(2EC9&8.?W;.2^!
MJB)(EGEUZ-'$,?SA QG?&.A/59M4V5X@Y1*676'Y-88*>WB(634$!;*VHO,2
M"^%S\9RMFY_PK6<+612S;&7BVA9M+S'+E8YBHWTJ5_D:_8AWAYV2;"C?R1_<
M>>>!^Y8F*)BKE.I0W2][+A\MI'-7MP,9^'QM9+:*E4!4R$Z&NSC5XT[UKL1=
M^YT/[IJ:P'"G4*K%7:_LN7RT%-PIVX$,?+X.[IK%*MSU9:?"W=532F<=VWBO
MY *:M_(G]=YZH*^C"PI_:K4Z!*I*GU</%S)RZ]J$#'[(-A([!4LL*N4G1Z-B
M>Y_R71>)7EO\>C4 1^' ]CYUV28"%["]3]T.7?29M_>UBO60%V![WP#N;MC>
M5@7F>L_ESV@\]\!:I04*9UV%.HRURYW?%E$1YT6\BA+T%4?L'!G?#[T$M/5;
M@!@^7AME59$281T9J*:#N5I+J=:J!4]?0Q-JXBSF-IPPAL+M*NFYXDVSFP"@
MY@T]H%V%%2WOEM1C;1'T2-4:Q/@9%8!KT_.>W%28NUWA-,IB\HED>!7EFIR3
MQD+E 6Q-(0]0JE5"X=.H70=5@]!Y^6PA<\F!5B.VW[ASTEE9OL2Q2=O4D/Z>
MYGN\BC<Q7JMS# ^5ZP!;40X VSVMT/#6&1A"N%KNO'R]D+YXN!&)P_=60[TG
MTD6[1N=T@-_B]8$E!.F'N=FPJ0M^JU*M JBJW,9'E9=GC3<,YWS>==#[IZ=J
MQ7K1 B@\"/((+ *ZW<%XK76/X5NSR3H52L$YZ2X[.55O82I37<ZF+./CWRJ-
M8(YK4*[U2*U,8[1<@HL9FXM8?MWNG5:*XA7:];JF@O$=J^W5YG.ZCA_C]2%*
M5,D.3&7*9 ?J,AXP5FJ$@K%)N0[&>IES_HKE^:A?+@+1YI8CEA^ZDZU 5;Q$
MM$'7;(C^(RZV-SCA6:-8;/N.?$SI3WI6I[P9)ZWS@B%I2/\PVPKF.59FK7W*
M0IO:VQ8QVQJ+'ITGVC?I@(^:%6F]U\:^KU_G>/7K WG\MS6.A5O3/VJ/IO_X
M[TORB#--,D3ENW*_<?O=2%_KU0#"DW1*57ZB+GO.'RTF(;FZ'<C Y^MLZ&P6
M8YC4R(9'W >R.NSDS1<=.*A>R9_1?N4!MZ8B*+0I=.K UBMZ7C[AJ8KF!9KR
M^Q/S=VO#K%FJ1%E?<CJ0_=]#E!4X2YYO\)YDW0YNH%0'>KU2 "CLZ(0&I%K]
M$#954C5,J[=(O%X&9'5-2*R_MQK('8$NII7Z)NQ#LRC-8\8@C/C6%>OVK;UB
M$/UL1REXGZO6/]C_JL0:?7'U>E$HUS9DMY,V?'1-A]V1Z'7>2HWAD2XX\>>4
M.AGE*/$C_A 5T>4ARVB=.JBS*5J>ZS 6]4"]23$4\BULZ- _*'HN2J!&$<3*
M(%EHYE,=-BU,W%JB<Z+#(%6ZQ+#F\&YQ07URS?SR4Q)U$T4HW\F?V7GG@?26
M)BAHJY3JL-PO>UX]0NS9O%A5MP(9^'AM-+:*E?!3R$Y'.#[%^2I*_H&C[!-]
MT@UF#Y3JT(U>*0"VT=$)33;4ZH>XADJJIAKB+6*O$7^_#*JA:T-B_<'51*,C
MT.492GU3X_L:9S%9#R-<44Z)\58Y,)0WM(;!>=^ '=*[<CVLBP++0[NJ/95X
MUWQZ$^(;(FK,]W1.AWIA^F.ZIDQ&%Y-3ENF@O5,& .DMC= H5RD?0GA?ID:W
MA#5]R3CS0F)YZG8CEI]9C>A6\2Z:%;K"(_D+?H@20<P5B^R:M_+']=YZX+:C
M"PJQ:K4ZK*I*G_.'<GZSB/5S7:.0P2_9!F6G8 E'I?Q4\0IUY@G]VC;(PG77
M/&R\87#)65FTC"<L8PE9MSYL^G*J^$"]LJN6G IF-_@A9HMW:<'VZ2GAIB[2
M@EVWB#?\V@IA8:C4;8:C0J2$9?V*;T9= CHU#4;L/K *K>W2;=2J-$V%WDO,
M$MHFG],U_O'_XF<E?#5E6OCME?$&<$<C+(+5RLT05LF4&);O$'^)Z-LEH%C7
M;L3R,ZMPW"G>!K)2UU1(_A0G,L&@$L3]URW\-E][0[=6!HO:GEXS8#O%2ZRR
MQT@\7P)*%0U#AC^F"IMUR38LNQJF0N1=]./SFKI$O(E7?(>9 9X#95M8U9;U
M!JY&,RR*S4;,D#;)EOBF95"[T(+0/M3.Q+$Y5'Z@$6L[A5'W=$O**Y+M^15X
M).6'!2[)@8XASY=DK:;25A*=!6:C!, ZLT$_]'+SL*FA5><A#?7B<Z/DB3CF
MP>Z2E^41$UB"0]D!@HQJ,?6RM$&XNSH]:&>"O<5B3;Q>TE%'F(>*R4^A+^:S
M^5BC%&P?LEF_=DNR2>R\W(_07#E<1M!YL"F)_6=O>X!.HMK*;-0XV916U$)L
MD8K3!^9YO35$FZ+M":ZFJ/\\5ZD8>+IKLC$PZ]6+5I-?Z0I5&20*+6%X&&AA
MXM82RAFQ4JHS,39HGLHM;K<X22[);A^EZC"/JD#+!=H%O('?5 <+=X5F,\A[
M B6T^0LDWRP!S\I&(C:?587=9MDV8OM:IHSC9)=TU'@@F1JHRA*]:$ZC!$A
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M'8+KT<&C1+U%.H()8 ^8DL#:9J"D!$[V8<'?2TS0'$\:S+$WM!PE\BWR$DR
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MV9N: IPPHZ^+-6]8GK(L,Z(HHF5_%1O?>7%4EU_(="4H&C6C>Q X>C( 6S.
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ML!=IM2_RA.U89DG8J(H,[V)^+7*Y0V5!.;J["%)E954TN3[MJBRL3*S:4A0
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MRBC;')$TP&C9N(C8D4#7.W U$KN3!:!F"S(!!I+:P2(QO]3'BHX+P-Y!GY$
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M/$=0G5K X=-DPAD09Z\2$)KA<A0@0 ?*JT><W1[N\U46[_DDF2^>W<AC@AU
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M>L!BSC=IAXT-R!P=MO;\D'=6(^\$?2G6O[YNJ.FR9<!";?(5A8__.M 96[U
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MS=LE3N4=A&SX.T$IGGEP"XHW7;+L$(#S3:)M:08RH;:#26_8G1T1['0IMT/
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M;J2 ']G,<D<CQP!(>QNP9E5M!XZ3F%TQ<,PQ9]&X*B',,TU'R@NKT("K6@.
M6MEM@'[)@  '(EF<)? -MMO,R/>TY9QD(MITSO)Q\;^L\9_6^&^< .W=O[OS
MGR7^#0;@S/B?LMI12FNDC=]OKL4T#OPJHS7=X0K'/CK$6@RSF*FK&@<ECRW
M&& D769EAT0H#ZQJ [N&F\H*DJ6&#U?0HAA^F*#Z^8&<";4+H=TW=!;(H<Y1
MVWXA\-*O!66KJE"U:802#]V[3/9H;!<A_E\L.%)1#)4EXS#<6U)B9F$J)AD2
M.IN.3E(.."P21SL/E@ JB[)9_"= 75*=!6;'5?QA@Q:WRJ]?UG3U?<-R<:![
ML*9/G29%&[K!.4%W7 D?-G0KRZ_YC#^)5^+-\BWQ#_SXP(?_ %!+ P04
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M'O3[\?;A%9[&&;U.I>GU>8_&W1[G"2/9WST6=6__['!O7Q8I4=@-S/!R\G]
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M&>9>;N>&8@M76L(5EO-0$<JD @T:LQ%;,5^/)*17Y/J;'%X5^C=_'-K\4C7
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MV!2*-)%L4D6L#?M)$8.T--:U%U,TL(R2DVK8%/N@&2,++OKAJ+3P B91.\*
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MPU6^%M<>V]@4:;@+LLKQ?7KLFPXH&=H&1'Q:]X&C(*LB6/B<_76>2$P/2,G
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M!48U4Z0$R14EY@*P@G#)26V#H,HI+ 2SRL5.3-)Y?EL+IHQ>>C@G4\TF!8<
M1M=O!Y!D -.O\QU(JV]SV0^9-DQM4/AM6"S,/-U[/B:'+[37.VP3NFH2U6[B
M &NL6M4=R"G4A#9'6.<$-H93YV)3IND^KVT(1TC]"[33!*.8%/L1;?.O&+!7
MX!7$J!28=TE\CBHG, ;L*A=;,$GG>6T*V#+Z>^'9I'[ZYQCE NMI%R2,NZ]6
MZI[ BDC4O9B3:;O3:[LB(:S^O?<SV9[46[GVAS!$18+W=<$[Y4Z<E;JG<XGP
MZEYLR[3=Z;5MD1!6([O"+Y5M2< +>8_^3)8ON!<F-"(M[A.8B9+[8@C&=HG7
M0[T4IQ[,?_5W)Z*916W)6C?W$!RG8FM#3;G9]9#ZFW]#ZAQR3DV%8E<VDH,]
MWB_^Q>".R'(U8>SBZ/189MMFXW([XZ!@_1S#<N7^A#X'$*L()G4L%_F_5CS7
MEP2WN<HLM'I) :"<!QKA5??82%[.X]^DKM30/;)F:ZF[62==( %;&,(@_B\4
MXZ;A49N4PZP(8I) $I;W)[,G=)N\@FRPK=,KW:P-54L[#\MQ^E TLZIUZ0=F
M3'3CO_4LQ"J*2@F#^ &^[/)LO<7-&V:*52G2W/^7*N(\LC0D5X.37 6N'=1O
M4A0"$&4W6)F/ ;DW5+6XCQL!V2GA"(/,?7S(2:B("2;3*8YI/;GJYEY^4U-Y
MYY?\IDM^TVY^TQ;1DKQT<CEO$]Q'X!'W<KE9N CB( G!XPX $BYWFI1QKX0Q
MR@J,B8OWJHN"^%.*BD.&6<0%2?!.:/!Z$";D.:$#2"OY:#E/9ZZUUOYLM9YG
M1U+2O<Q;Z6S=:"_)C%(SF<EF1G*I]:S-Q7!"VLIDLK/1TKZW4]%VOUM;?HSM
M%"06M[OTT*SPF+"V6]$45T-GU/[,E@J9&H3=+IU'"H( [=;[FXMD[D4)LC1_
MS@VIX\9R+FF]3$2\Y-Q;<NXM.?>6G'M.AJ(L.?>6G'M+SKUEG:N[SC65JF_&
MQ:I.AC^_<J!,K\S!&=5L;D/6Z=BL-9OS@[4/3NB'$!R*CCNO1V$#=_T3WJQU
M]K7=PACBSL&=@<FB(LSQ .RF-F$<KRMR89R^2W.Q[$:D=S3E3%Y/+31'8J=*
MVDF]=%7./0/2$D0\TB2I*0 S-0*Y1J(V4WPKU6X5"2'DG1_H<:*=(:ARLC;&
M9+NX[^4=I:KNF!,T8>"B5:W:M3&H*<QUAOORJQGX=GF- W##ZXPA3%777"!N
M*G<MM%E3G.K&P2IZ):O1.Q0D_=6.<;[CX$WC>\90%ZIQ+MC3&N):B+6F:'B3
M#; 6\W5B?ACP>8\;"BS>9SP<I-0YUY!@-6:*J'$WMWGB38CR=H[*TMI<.]KC
M4"?FV2I C+'Y,\"I[I-1G*R'IO$;2K^<IF_+^?S4[3>+G[71;@)6:O9<2J5=
MNS&BD8KVG=4XC4VK,[EN5+16Y_BY1SG(R-5D,J.=<JX/,]U,PEM]6,GP_D!#
M3%G5MH:;3$,U)G\?AUZ=9IR;M]\4.YU]!Y7=!QI3,@JU-8P8;=/8G_LY<N0R
MT)MDJ;5S=RY_O(U1I)/Z?<Z19#)KNZG1--[?)9F6W2!']1'B8%+U^0>(5C[T
M^<:'T53F/DXV_8@L_0'$XJ0^<(:</M" $:C1UD 9-DLC%;>/ Z1);/:C_L@8
ML% ?$BT6'V@LL!1G:Q"TVN-SLF@%B8WLW8WLV#_J/MV]W3EM3ZZ29UEB'+AS
M/&CNF$KJZ'!4=5Z^W=?*%FKB6-$4N[K3QK-SW,#W7D$HDPF%*:9H23[^C$2&
MN_XI"9^[-<MB#(IZAR4*.N^:IK'MUCPSX;?7XRC;.N<L_E>55?8&)F5T#0BR
M,6-+BJW&.HO/]J.-)A4M6QU&@H9Z'-Y;BM!H\UU_P-#YJ(^0/I^/-B2X>K0Z
M!OHMLQ;0.^<*[JJ6ZP&\ OQ!?WPP&*D/D &CCS9"^)JT.D0&33.<A=:YX5%Z
M*X:OOXWT9K$9:GJV: P_VK"1TZS=51:KB?HIM6TGL1 XP P[5*2\8./KM&'5
MQJ]T!6^Z&>"D;IT<>MM-@%1SZI$"Z:CJSB:ZX![E]*.R "9W*,O624/. [,Z
M%QJ05;AX 6)MM:@#6*4JPX]PGU7"ICO:\QZ\/K>3G.FN_5 (M7E+5BZV]BQD
MGQWBZNQ3T-X-GDHQ=;+IX%,I<X-6YX65V=IX[@^SM'Y>'F:97$[=5XAJV4<^
M8J1>W)B.LC1OZ0?_==(-_J.E%W(K('__#/(=BJKW!LGX'OX*RJRJE,39)E@-
M]*7#:B[=L5I!S9XM1US++R(V^"0(>@67, >W]Y?T)T%8WYLG08;?K4VSDBI&
M8JFZ4R*?;_G QY"?YP]\&!G,2!'VK,?VU)M .D54M;^;FS%O'QJTTN/?1AS7
M&"\?IBB#.UNZH$RD/))VNI,!B0OR4"<_/A%#IFDFNS@NLJ<=WFL<0)'#$&\P
M]]AP1\S)3XJ^-1D*Z.T&K;.[ *E+2PD]'_!O)D<!7]<"^YHFXYTJ%QB#[ST@
MM+Y[T/$L:50[NL7'WS<7N$8829HTON::A0J+U<=<H$C,?N,7'O1*W'EW0+#S
M? B2%]H6?/![K;#6[[,VD6H\*5_:S:0;S.D:^CEX@_MB3VTJ]5O=V-XW:V.-
MID[$;WIW_+08D*'1*^BO$1H.!L0#'T4IC8'N%/)7(6.L,LNRC#?%+<[^ANJ6
M#Y2!:!.D^7O;R7_QWOY"L]C*!1M;J5#0MD:H>T(V 45"\WO!RUT T_46;THN
M4)!&),0L!2$NG=V@= _2RQT$V^LW$!;DK8WU=@M#D);O;X ,1ACR]&<!S7)M
MGA TQ=6>+69W-II*:SV#/FA!^<"@J9H]=_=JF"$D,8397<"OI)P7*,P_Z-RK
M.T<8F)P5JO;R$@%%%7>,9]9D2'OGWW12FW*V3N2O0!:F\$ +2&.?^',*L<_^
MJ85L:(%^RK#^FF ;O(.'#4A#,EY>^L?_RN68Y[C,<BX%)_$ZF7JF)Z<-8: 1
MI5[Z01ZS/G_?!'[,4?COVRPK0'15I#!YP6)!%#WN<,=U#'4_ZD*U7!-B(5_.
M(VCJ:D,7F@KUN>-<'(_*7X.X .J@9!;C8Y)2S'](BG1A&)&4ZO2]+:\@?483
M'+OUO?+E,-JD>,\E.$\>$C+.E-N$'F%(6EY=U/ JF.+I'_O6ZQY\+;^HF*Y!
M&0F[U2KC$>!TM#"%Q6K5I7^Y=IH8@>K-Q&JF[V\7*)^:'4'GDT>(X,BDO:[O
ML-2_4#9-_[9/AU]24-YVN"=W-_<'@ 6'KZ#":7]J4BS63%32Q3S"C*8NM"<Q
MZ>HT$K>Z/:55@ZCZ_0:ECR!]Q7.WTEZ165AFPT@I[!%.1^EEDJTCI5*-)*O3
MSG]!N+O#(GPY' ?;=7E9*GL"Z;X_(TH1-W.D@-@C9"G)K3V/"BJID?,W5Y!S
M<MBMMUBZ/=YND+'P6#S_"X3Y$^K)TH.29NE:Q\JE/0+;.,WHHD^YUAJ.OS@#
MQ^"=-"Q[0N4"@NQ[452$9+U096(>OA"H4J0!GE01G]"FK@-MB$E5U3A8G8DB
M9\SP7Q+RP'(*PQQHN_?E>/!7;B(>'F'1A)8,K^-$=3=H=289*T..A]%8E>'
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M@JS:\%1+THP_@F!PSL\F:-PZ% )702 41JJO:5S\?2*";C$'J</X5-S9R6%
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M7R[T.W,9>;G0OUSH7R[T+Q?ZSVHYLUSH=]*M.#AA60+X9TXP<!G$81&7_WQ
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MYER";A-_C"&DI#(+8T'4/L.AL_-?KJH=C<TU,M[5*A8IY6+5D/1CP%E!71;
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M-:4J]1.S33._BAO?\H\HPX]25AJ G;+G!4&V6B8$8:=2_1,-VS-M5ZC;_2&
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MYBW4X;].B,-__'/8O#?8GP:X-+5.&336Q"!=]P#B4J79#AZ>T'6"F_I^A4C
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M@-$3N@"KPR&& /_S#LM2BD6>RTRS_#>4_GM-VMX#I7;YXVU#Y?+>@G2LKLR
M5:,5UM[+82T_48Y'6&7RR>J$-)<$C,.DU,UZVP22]Y>?JN6:Y:=\.6_!J:L;
M0\M/^=I'/(TS!Q@?BP.IAL1"M038I.@59L1WR8>D;&DZ,,6ESP6>BGJ:!*3B
M-F@\<>-(T'_S0L4JB5J/5%R_D5 \< SV6X6_%S ER?(WU<,6ER@;;J]&<SKN
MM$9P\A;XYO1G:O\UHCWZC_2,SFK.=![ _7.!!QMI8':;A 5ITCHERZ,!DL6D
M1ZCR2#W&HK0&3(&-5V&-IE_.*_IJ>&+'=KVHG&I)]<A=^\Z+7J4?^+1;\0QV
MVABMNW.XF2$=<X[,A&7+A2[2+TPHU>KE'895&*8%><>QG.S)S8YUO@/I\"$U
M&[<9:A<;:579SB!F7620H#SENF%3VKZ^@-M1A.1Q.[S<2J(:8^5$*;JT(%F2
M<E5!6-+29N74+-*8LFD92%]IL9R2U*=-!Y_:AL#5#:E.T^C9YD5T35YY-IT-
M\:[+O%H '&_=4Z,[!52U:$PJ>_G+A9V"9(7KY2IG,2;3%).AO\LUV8&,Y ="
M?_KG5E!FY68S]E>Q.E,%4C6L[,6OH,K:"<&ORIV[",NK*,NK*,NK*,NK*'/W
MP/(JBI.3Y)CG2:2F1OX[(;Y=@6!.\P.?FGAWQW+#R16Q\DY*Y6]I^5<NB0.<
MF=I:FKZY)B"FM[G_J_$];!YC)RBD[^T).?3V'I>0[D*D+GCO]0A15>U](Z<*
M&VMMULV92B3N&>7@P2&5,MV!(RKC!XIT%*"!),EJ7+OJ4#?[$TA 6B8H6D5[
MF$ B%UE%\D$E6ZH+*W$IKX"EJ 1]:(DKLG9U8;JE@.P20';J]PQ<4\QY'-8C
M[A*@/(CM VB3HBW(2'Q:=<6,BR(!<1=*3&*O\"0GLCZHF/SU+P;P0J/<<,</
M=UZ\ 2P9OR*NC3N6I\W>.L^8[I^^,[:%(K):P6PR<ZNI6OD;E%9AW7<P)%,S
M'@GKYQB^E)W;]XTJ%&F<I%)%K(T487\@+:F[ X152>D(E6+NT+[N-LF*\M1R
M@V(8OF]2L(?%P/<CH*K5Q*1R&@]RLLE#@,G/WP>+^N+2ES8"*H8MM+^8D0&)
MG&SR(&'R&[&/&K<,9MB'.U3=P5"95Y3*U*J3+.,T2'3DEH>,)'<;[[J8,3"/
M11*E[RWI[U$5EDZW-!+D;9/#)7<:5HK2*AHA+F-_WU;IRRV8JP23E \(84NC
M/RV-NJ#,G(\<WCI+;NCT=LQLYH;/D-T_K-<X3)XJK.WN'&YSR 3>HS&AZEWM
M<ZKKW]P05N/E?8U+M-_#O'F%@URAQ_*!),2C^@Z\!/'G("<SH,5+&YP67L$L
MC!'>I0*&6TNK;.,A4BMK8VUPA\BMV5;#:+<Z^$3'70N=R*$,G\MC$AM7'Y.X
M1Z\@CHOL"2\+@@,H<AAF=Q"/'A!18UFEZ8\Y+(3T3EP_'(:NJDK*OEQXBE&5
MX.E:4M*K'<AVGW"[\<Q$#V_F4#1IH&@4CG:[6!J9CJ9RF<+YZL!MW>4]$4,*
M%DSWYAX,H5?D[XL@@IL:#^15.]JBH_][,^.>?I^UB53K2OG2;B;=FD[7T,\P
M@?MB3VTJ]5N3IK+[S9X1HZ@3\9O>,U G!F5RR&Y!?XW/<# @'O@H2CD:Y78A
M?Q4B88T9]D/:V)[*>WF!8R#9P&W&VL>R_&L\0H/GB2WO",/[P"-IVDHE,7GJ
MV=;%^U6P#UY ]HB*EUT94%V^01_$0?K.U;9,0:KV^07M#4M>SZ 1TO=&+:6:
MZ@14GKUK6SF9ME__7L#\?0/2D.CBA>^14F.A@+(A"Z_Q)M"(.>0-*_(WX(<G
M[Z]!7*A LT,O@<.:WDO0T60=C[":J^'3*8/6K'GB8I4^P_)F"$HV04*JY*%$
M5(J.%78I7Q C*;<6;MB\K;W5,-X8P;R.;GH$.5;-Z06*U=< 2Q4]H?)DO72/
M]"&G4[8!GEI9=^$W0@>2(%2K88JH(IN;T^&."DGM8@1[U;MV[ B=G>>I-<3;
M?.G=J^R^G\?0W_ /O0-[FG[%L1]*=5%5?JZ!'V4\+HES:=ZG6>(_EO@/+:DR
M$'[_@EY_B "L!,+_.,F!_ZC\:-=EQA_*Z0KC:]M[UOXZ?7.OV2G*:)^:=")C
MDXLQMB]?$OB*YS_,>[W%6ZQ\=Q.C%$8!]61%CKANL8C8V@Q!U3)2E*X[$;19
M$CLO8N7[8H4QIA 7PI0%](E'F0;F3+)V2:SEN$9)>@'7Y^+.4?@2K+<$ZRW!
M>A\U6*]I\ET>X87O#1Y>*+V *,/6BY5H6Z5(#R;\(HXC14%>%;#PV;J6_HJT
M^A(#FHF,X<<6!MH?'>YMI@RR_=IF,$6.J26&<XGAM!O#Z4#<D2#N\!'+7?JS
M'D.0!"E$E'4IEZ9Y[H1.,YL8=:U?DNP 0KB%(*(N-(5TQ]=;F'1SBW2#4A"2
M5X9I<PF?J"=,G\CBQ5)1+R!)T?H71QE\JXN+='[^VD3^N$3R:.]ID<:VK4$*
M.W^5*)Y89,R?[!S"X&4C_&,)^>\U<_:0_^"-'?)/^]:$_'>_.1?RSVDZ/^2_
M6]!?D[*$_#L0\N]C,)2O<?_#PW%6^+^8\AB@Q:&<+-CQ%.&[WCZ@]R#.W^MT
M&-P>D"A'#WCDE;,W6B4Z:1CY**V"WI!F5T8)@>15XIK/N!^]B9('L"V2B+1V
M?2#2WP !K/AE&#&TC#*>P4E*]#%08E7@FBOY-H$Y#.)30L!A_E86P3%UZY#
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M$L.YQ' N,9Q>>Y>6&$[MY>2O(".Y["C[$LJ76J6=+Q8;3=U,4+]U&VYS^<Z
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MG 6D8*VCMW@<,G4GBZ^"/;HH,I@ /+6&>#&<P;+WALM& 56M2":5*X*1?Z8
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M\"9%!X#7'OW "P%9$TO!)+,V0(6]@J2EZXY4%N/R:)/)T$LWTQW(,@#66(2
MO#5Y1\1] ND>SW\HH0T%^0+'E82X@-,04I98'DPRK/U]E( FW0-(P-<@)D)*
M (M"S4%5A]H[2+%E'8>G#E]KMY$8\R]IU1/:!.]UL,'[%<!K(-@W.B*R6E%L
M,J?1("F=/ S8#/4O#%DW)GCYUVS*^I:#\JDQ$YU/3J. (X6" >@PT4^99SSG
M8M<F99_Q]+:+WR\J^]3O4#GB6CDB8J<[74E2>1B(V-; ^+.G/G3A!A));]FX
M6_2[=CPKFZ&;9U15>H/52PK*AV58%WED:#LG5$Q:D\:"5'$#^H%A@]^/)N#X
MN[UP3RE%(K80O7!-'KMJB!_9>)Z:2F8TJ\!4?D@+N'I^TJ@8>\-RPVD%W]R=
M1>)447PM)8!)G"N5P906P313-'7]A?SG&4]L_^O_!U!+ P04    "  5A&Y5
M,].<_&$)   <"@  #@   &EM86=E,# P,#$N:G!GG91Y--1['\=_PXPQ0Q<9
M2],U9!U9HK*494+6+NY((UR&YI:8Y%IGLB91W$$(U])49+NRC#6:D<$@BDK1
MR#:4-5O1:"QS=<]S[W/.<YX_[O.\/^?]_>?].=_S>7T_YWSY;_D3@+B=E:T5
M  *! *_= OCO  M " P1@H"%A"!"4*B0,%P<#H?!X(COQ$3%91"RLC((:6FD
MG(H\<K_2]]+2"IH*2JIJZ@?5]\EKZ6BA=530ZNAOEX"@4"A<&"X)ATNBD=)(
M]/\L?BL@(0PX ]&"($5 0 (D* 'B=P#R  ""@/X4\"^!! 1WYX4*P^ BNPWU
MXH  2%!0 "P(@8#!NVG4;@Z )2![#^B:"4EBO:&*@8C#L6GWA97,:4PIIY<K
MRD?.!5V#P:5E9/<A5535T.H'C^KI&Q@>.VYQTM+*VL;6[K3S&9S+65<WPL_G
M+_A<]/4+#@D-(Y&OA,==CT^X<3,Q*3WC=F96]F\YN06%#XJ*2TK+?J^IK:MO
M:'S4U-S6WL'J[.I^VO-JX/6;P:&W[&'.Y-3[#],SLW/SJY\^KZU_X6Y\Y7WC
M @&"H+_T7[DD=KD$P&!!,/0;%TB ]*U! @PYH"NTUPP+]0Z45#P<*XPP3[M/
M8\*4CCBM2)T+>@F75C[*45G]AO8GV3\#N_9_D?T-]F^N84!4$+2[/$$)  /P
MBI/0]P3^]D'Z4$.U/GO)*YF!.O&D+]?^H^JK-UGH4@Y5_?5O*BDGCM_VBLFT
M/>5=$O4CUA(!_*==#*9B9'W')&@I[J.?1T?T>XF&5N?O,("UN8SEA5CW1JYB
M7^?DAX)<;U%_M6RX#*FU3\I:F=KJ<F?KZ,KB4E&40;(QX5)OI>=>+?\+YJ9,
M0/G@U7#=!2J=E^'N1+DT8Y(]>3)O6+G!33Z)CBM88"%O-YO<SB_.]@I[A+>5
MKXQJVCJ.&[W;/BXZ7"I2 G-_W*M!PU2$AIPFY^99LJ]<]%GW"W M?V+B@(L!
MS5)(;)8)Y6UKUO %)\QA2^?TJ)BVPF?TM/H*N>BUV,! X77,&(H/]#QV4W_X
MPUBFR8>9G8@"U%X1-\^%3]NX9Q4E>'<_7*"'JUT-4Z&GA@\<(BSBB#=S,1L6
M6Z<0+R)S464**6?Y0 (LU0IUE0^DWJL<*ZC0VV_X\8MVO,O1*3U?+3[0_S(>
M@77=OWN<@""<D=>#GGL'R]7>G"'G$(*W-,V86[."?8=:E/QXE;51)9&8%?;@
M(&NK_->Y2MS^T%NA9]26H\'19THFQN5M?U]()\=TY.IUQDXB*#U9K[J54T+D
MW(Y!]XPK1/M 4:XKA#:7X:IXM['V3EYG<I2/<9KG7.#!N  %PFO4%=ECZ]V+
M'B9WXQ8)&QD%Q453VQ9GANI>#>FPG\L&E5KWP>1#Q(TV70J=,F6;+!HK=A^E
MTY?Q'$\)'V04D5.9NN2+.=K:E<6X.E_ZHR6=\OC@N:=ZHZ:T[4P.MIR<UU-]
M4>OZ4%(%X]RER)Z2C:8)0I54^Y;+^5^[^, >U<Q,122EVR,%N& )QTB>VK1V
M]?#<TF)L'NQ>91J?'GE(T/3&?;W)^R7ZZJ"=1&X1M(BW]7:96$.7%X\DEIMM
MEW#&@5.F258;N?/K"KD<H\/WY]*Z%ZCLRM[6:-WJU:QLK>?I]O[!_FII))]?
M'I]OO!6*0U%OM(C]<H*SAH?XN56F!93ZXA&A30]5*,9!UK67Q_LI(4H-NK@=
ML=GC'M3&JOEAEZ295<20B@(]<ZKM:^*+Y>]U.\-]JAC':47=7TD>51LCDB1]
M8^)4^1T-SX85;D*=KUZ_N+T,=05V$LN4#F2,K,TT+G3WVT[*A0VT4^6:!O6R
M/ODO%HBA/1W"(:@'&;$_J<7M!*3BQ46"G 99SM36#IC@:N&7E!E.]^D>QG9-
M]4>KG4S3'NT'ZN\B\-,R89>Z!^G!D^X, ?M3'AL1!EN*EPM<Y0XYCW3)X U\
MH+%]AES#:4: Q9/ZUVL1&HNF$R/#/YG76*H;-Z<Q37=:UN5OM@:(^5VEQ!'1
M&"ZS4F3B(TD&#UKK]L__-4=S22DQ<9;U7F1;W;:SR*B(B.G?D;53M]NV&HVT
M&=1+=OK4S^$FN+M?Z[- \*YS1< HK_E2QW%>W 8!/+^AT37C.CBSP@=NAN34
MR>\UIP:P56_99%AOS^9[&41#[[^?F#+Z$M%2G<%A9>41&S2VCSU(X+$?I:N3
M:"HW/*-BONNDF:H1P_:LYG$^)-^FM9010Q4>O373[5(X Q][?]GPHVE]8<D^
M!^?;82V,D.4![.@PUX2:A*[<V[;[<WVGQ(H1-3:8]/AQGB0^PIZ_I,]X0YF6
MN153GP*;*MM7(08A[S^Q\O,1[7B?#\\QO(7$GYYJ4EFI =ZQ'B92A178KC0&
MY'Q$_G+''DF'(;I&A'^Y;U69!7+?*^$4]JE2Y2L^M>N"0X;&DMA(H]=K=X);
M>3\W'\UP+!&&/'*O06+K_#74\'DI4<'4A.;P3Q4!/[PQ19&3ECL\D77$93&\
M05[9'&U[%D]_F3J-*8;/V4;8;!HM#-".1+9PS=]PF8[0D5%[99UQMONS=Q_J
MZA]?G C>F0FXURI73G]1%X4Q&S@PL!9A4Z$Y*:\92!$+BG)L*HTTF-QSI",\
MR'.6BQTY>6($]+70E,)PWB;B"HKL4D=+Q^YTH7!5DB+V*ZR4NY,,?(>X\?2F
MLTUZZ 4(D&Q>^9*2 C7.Q>\CG^MB-1L.A%K=\>]XJN_M5='D8*V,T@BJIMM.
MNMM+@2T,CE^_JZF?%K0T6@,U.VGR8+J)I/J XZ!].NQD[DZ)K^@M7Q>8<:W?
M@?MG)X!J)YVS[RF T0!=A;/I*$(.Z[<:<+M05R]*R_GM2#Z-D XL.?KUKS0D
MAS0&+;AQ7-Y<EH''+;TKX<KP^ #O\\! ^<7---+RO"7,P;?/;XA]Y4H^)BE:
MADSL<"OT"S8+))09=F3C)&51CEP:TW2C_XE=57&DTDIQ=FC1Z%GW$8O0DI'M
M,I_/)./^.25Q6U2[U"S"Z<R\2N^SC_X]UY+0#Q,06$O@+P?R&MNW5><WYI$$
MQT(_#WM6W->()V-8)G>.NG9K=N=0G4<:.65X7I=KS[J'V[+I(](*&L\F#O?C
MG7.N5[_(:&Y>\X^V5@R1E_",;$Y-1*)K>US;E-1V(*]QE?&<"@-+E47O0T'C
MX9.$%JNMB&BI6DMUE_QL[=Y>Q^X?VP8H316DT08^H%.0I"%Y#UV0!/P3\]E_
M %!+ 0(4 Q0    ( !6$;E6 P=R\[WP" **V(  4              "  0
M  !B<FAC,3 P-#,X-3%?,3!Q+FAT;5!+ 0(4 Q0    ( !6$;E5SCP;LFKL
M #RE"  7              "  2%] @!B<FAC,3 P-#,X-3%?97@Q,"TS+FAT
M;5!+ 0(4 Q0    ( !6$;E5+9@&K;@<  /P9   7              "  ? X
M P!B<FAC,3 P-#,X-3%?97@S,2TQ+FAT;5!+ 0(4 Q0    ( !6$;E7^ "L"
M80<   8:   7              "  9-  P!B<FAC,3 P-#,X-3%?97@S,2TR
M+FAT;5!+ 0(4 Q0    ( !6$;E7$1G5\QP0  &(/   7              "
M 2E( P!B<FAC,3 P-#,X-3%?97@S,BTQ+FAT;5!+ 0(4 Q0    ( !6$;E4[
M'!02M00  &T/   7              "  25- P!B<FAC,3 P-#,X-3%?97@S
M,BTR+FAT;5!+ 0(4 Q0    ( !6$;E5[0PD=-!P  ,A# 0 1
M  "  0]2 P!E<FYA+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( !6$;E4<I,/Y
M&Q(  #_Z   5              "  7)N P!E<FYA+3(P,C(P.3,P7V-A;"YX
M;6Q02P$"% ,4    "  5A&Y5WFO:8$!7  "Q0P8 %0              @ '
M@ , 97)N82TR,#(R,#DS,%]D968N>&UL4$L! A0#%     @ %81N5:FJI4.
M^   ^L<. !4              ( !,]@# &5R;F$M,C R,C Y,S!?;&%B+GAM
M;%!+ 0(4 Q0    ( !6$;E7,] BW>7H  $+!"  5              "  >;0
M! !E<FYA+3(P,C(P.3,P7W!R92YX;6Q02P$"% ,4    "  5A&Y5,].<_&$)
M   <"@  #@              @ &22P4 :6UA9V4P,# P,2YJ<&=02P4&
/  P #  B P  'U4%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
